PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Capturing genes	SCIENCE			English	Article																		Roberts RW, 1997, P NATL ACAD SCI USA, V94, P12297, DOI 10.1073/pnas.94.23.12297	1	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2143	2143						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9432724				2022-12-24	WOS:A1997YM23500059
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Cell shocked	SCIENCE			English	Article																		Suzue K, 1997, P NATL ACAD SCI USA, V94, P13146, DOI 10.1073/pnas.94.24.13146; UDONO H, 1994, P NATL ACAD SCI USA, V91, P3077, DOI 10.1073/pnas.91.8.3077	2	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2143	&						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9432724				2022-12-24	WOS:A1997YM23500060
J	Korzus, E; Torchia, J; Rose, DW; Xu, L; Kurokawa, R; McInerney, EM; Mullen, TM; Glass, CK; Rosenfeld, MG				Korzus, E; Torchia, J; Rose, DW; Xu, L; Kurokawa, R; McInerney, EM; Mullen, TM; Glass, CK; Rosenfeld, MG			Transcription factor-specific requirements for coactivators and their acetyltransferase functions	SCIENCE			English	Article							YEAST PUTATIVE ADAPTERS; CREB-BINDING PROTEIN; HISTONE ACETYLTRANSFERASE; NUCLEAR RECEPTORS; CO-REPRESSOR; ACTIVATION; CBP; P300; IDENTIFICATION; COMPLEX	Different classes of mammalian transcription factors-nuclear receptors, cyclic adenosine 3',5'-monophosphate-regulated enhancer binding protein (CREB), and signal transducer and activator of transcription-1 (STAT-1)-functionally require distinct com ponents of the coactivator complex, including CREB-binding protein (CBP/p300), nuclear receptor coactivators (NCoAs), and p300/CBP-associated factor (p/CAF), based on their platform or assembly properties. Retinoic acid receptor, CREB, and STAT-1 also require different histone acetyltransferase (HAT) activities to activate transcription. Thus, transcription factor-specific differences in configuration and content of the coactivator complex dictate requirements for specific acetyltransferase activities, providing an explanation, at least in part, for the presence of multiple HAT components of the complex.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Rosenfeld, MG (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592; MULLEN, Tina-Marie/0000-0001-6150-8084				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bisotto S, 1996, J BIOL CHEM, V271, P17746, DOI 10.1074/jbc.271.30.17746; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Candau R, 1996, J BIOL CHEM, V271, P5237; Candau R, 1996, MOL CELL BIOL, V16, P593; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HONG M, 1997, MOL CELL BIOL, V17, P2735; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KORZUS E, UNPUB; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHERTY OD, 1997, CELL, V89, P349; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Moore DD, 1995, GLOB MOB SURV; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	54	542	551	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	1998	279	5351					703	707		10.1126/science.279.5351.703	http://dx.doi.org/10.1126/science.279.5351.703			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445475				2022-12-24	WOS:000071731500036
J	Chan, JM; Stampfer, MJ; Giovannucci, E; Gann, PH; Ma, J; Wilkinson, P; Hennekens, CH; Pollak, M				Chan, JM; Stampfer, MJ; Giovannucci, E; Gann, PH; Ma, J; Wilkinson, P; Hennekens, CH; Pollak, M			Plasma insulin-like growth factor I and prostate cancer risk: A prospective study	SCIENCE			English	Article							BODY-MASS INDEX; BINDING-PROTEINS; HORMONE; SEX; ADOLESCENTS; CHILDREN; ANTIGEN; CELLS; STAGE; AGE	Insulin-like growth factor-I (IGF-I) is a mitogen for prostate epithelial cells. To investigate associations between plasma IGF levels and prostate cancer risk, a nested case-control study within the Physicians' Health Study was conducted on prospectively collected plasma from 152 cases and 152 controls. A strong positive association was observed between IGF-I levels and prostate cancer risk. Men in the highest quartile of IGF-I levels had a relative risk of 4.3 (95 percent confidence interval 1.8 to 10.6) compared with men in the lowest quartile. This association was independent of baseline prostate-specific antigen levels. Identification of plasma IGF-I as a predictor of prostate cancer risk may have implications for risk reduction and treatment.	Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab, Boston, MA 02115 USA; Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Med,Canc Prevent Res Unit, Montreal, PQ H3T 1E2, Canada; McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Oncol,Canc Prevent Res Unit, Montreal, PQ H3T 1E2, Canada; Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Ambulatory Care & Prevent, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Northwestern University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Chan, JM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA.	jmlchan@hsph.harvard.edu	Wilkinson, Peter/AAK-6426-2020; Pollak, Michael/G-9094-2011	Wilkinson, Peter/0000-0002-1365-0470; Pollak, Michael/0000-0003-3047-0604; Chan, June/0000-0002-7620-569X	NATIONAL CANCER INSTITUTE [R01CA058684, T32CA009001, R01CA042182] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 09001-20, CA-42182, CA-58684] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersson SO, 1997, JNCI-J NATL CANCER I, V89, P385, DOI 10.1093/jnci/89.5.385; COHEN P, 1994, HORM METAB RES, V26, P81, DOI 10.1055/s-2007-1000777; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Gann PH, 1996, J NATL CANCER I, V88, P1118, DOI 10.1093/jnci/88.16.1118; Giovannucci E, 1997, P NATL ACAD SCI USA, V94, P3320, DOI 10.1073/pnas.94.7.3320; Giovannucci E, 1997, CANCER EPIDEM BIOMAR, V6, P557; GoodmanGruen D, 1997, AM J EPIDEMIOL, V145, P970, DOI 10.1093/oxfordjournals.aje.a009065; Hebert PR, 1997, CANCER CAUSE CONTROL, V8, P591, DOI 10.1023/A:1018442329319; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; Huynh H, 1996, CELL GROWTH DIFFER, V7, P1501; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; JUUL A, 1995, J CLIN ENDOCR METAB, V80, P2534, DOI 10.1210/jc.80.8.2534; JUUL A, 1994, J CLIN ENDOCR METAB, V78, P744, DOI 10.1210/jc.78.3.744; LASSARRE C, 1991, PEDIATR RES, V29, P219, DOI 10.1203/00006450-199103000-00001; LAVECCHIA C, 1990, INT J CANCER, V45, P275, DOI 10.1002/ijc.2910450212; Mantzoros CS, 1997, BRIT J CANCER, V76, P1115, DOI 10.1038/bjc.1997.520; POLLAK M, 1990, J NATL CANCER I, V82, P1693, DOI 10.1093/jnci/82.21.1693; Pollak MN, 1998, P SOC EXP BIOL MED, V217, P143; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Rechler MM, 1997, ENDOCRINOLOGY, V138, P2645, DOI 10.1210/en.138.7.2645; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P82; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; TIBLJIN G, 1995, EPIDEMIOLOGY, V6, P423; ZARANDI M, 1994, P NATL ACAD SCI USA, V91, P12298, DOI 10.1073/pnas.91.25.12298	28	1640	1729	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					563	566		10.1126/science.279.5350.563	http://dx.doi.org/10.1126/science.279.5350.563			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438850				2022-12-24	WOS:000071616000047
J	Kodish, E; Wiesner, GL; Mehlman, M; Murray, T				Kodish, E; Wiesner, GL; Mehlman, M; Murray, T			Genetic testing for cancer risk - How to reconcile the conflicts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OVARIAN-CANCER; BREAST-CANCER; BRCA1; MUTATIONS		Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Human Genet, Cleveland, OH USA; Case Western Reserve Univ, Sch Med, Law Med Ctr, Cleveland, OH USA; Case Western Reserve Univ, Sch Med, Ctr Biomed Eth, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Law, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Law, Ctr Human Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Law, Law Med Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Law, Ctr Biomed Eth, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Kodish, E (corresponding author), Rainbow Babies & Childrens Hosp, 11100 Euclid Ave,RBC 310, Cleveland, OH 44106 USA.							BAKER SG, 1995, J NATL CANCER I, V87, P1137, DOI 10.1093/jnci/87.15.1137; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; COLLINS FS, 1994, JAMA-J AM MED ASSOC, V271, P785, DOI 10.1001/jama.1994.03510340075038; Geller G, 1997, JAMA-J AM MED ASSOC, V277, P1467, DOI 10.1001/jama.277.18.1467; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; Khoury MJ, 1996, AM J PUBLIC HEALTH, V86, P1717, DOI 10.2105/AJPH.86.12.1717; KING MC, 1992, NAT GENET, V2, P89, DOI 10.1038/ng1092-89; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; Lerman C, 1996, Oncology (Williston Park), V10, P191; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; Mehlman MJ, 1996, AM J HUM GENET, V58, P393; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Peters J A, 1996, Oncology (Williston Park), V10, P159; RICCARDI VA, 1996, HUMAN GENOME PROJECT, P21; Rimer Barbara K., 1997, P619; ROTHSTEIN MA, 1995, MONOGRAPH NCI, V17, P87; Rubin SC, 1996, NEW ENGL J MED, V335, P1413, DOI 10.1056/NEJM199611073351901; Schrag D, 1997, NEW ENGL J MED, V336, P1465, DOI 10.1056/NEJM199705153362022; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; *US DEP HHS, 1997, UND GEN TEST	25	26	26	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					179	181		10.1001/jama.279.3.179	http://dx.doi.org/10.1001/jama.279.3.179			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR124	9438721				2022-12-24	WOS:000071460700001
J	McCall, K; Steller, H				McCall, K; Steller, H			Requirement for DCP-1 caspase during Drosophila oogenesis	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; NUCLEAR LAMIN ISOFORMS; NONMUSCLE MYOSIN-II; DNA FRAGMENTATION; EGG CHAMBER; APOPTOSIS; GENE; INTERCONVERSION; EMBRYOGENESIS; DEGRADATION	Caspases, a class of cysteine proteases, are an essential component of the apoptotic cell death program. During Drosophila oogenesis, nurse cells transfer their cytoplasmic contents to developing oocytes and then die. Loss of function for the dcp-l gene, which encodes a caspase, caused female sterility by inhibiting this transfer. dcp-1(-) nurse cells were defective in the cytoskeletal reorganization and nuclear breakdown that normally accompany this process. The dcp-1(-) phenotype suggests that the cytoskeletal and nuclear events in the nurse cells make use of the machinery normally associated with apoptosis and that apoptosis of the nurse cells is a necessary event for oocyte development.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Steller, H (corresponding author), MIT, Dept Biol, 31 Ames St,68-430, Cambridge, MA 02139 USA.							ABRAMS JM, 1993, DEVELOPMENT, V117, P29; ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CANT K, 1994, J CELL BIOL, V125, P369, DOI 10.1083/jcb.125.2.369; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chou TB, 1996, GENETICS, V144, P1673; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; COOLEY L, 1994, SCIENCE, V266, P590, DOI 10.1126/science.7939713; COTTER TG, 1992, CANCER RES, V52, P997; DeFelici M, 1997, CELL DEATH DIFFER, V4, P169, DOI 10.1038/sj.cdd.4400237; Edwards KA, 1996, DEVELOPMENT, V122, P1499; FOLEY KM, UNPUB; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIORGI F, 1976, J EMBRYOL EXP MORPH, V35, P521; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; GUTZEIT HO, 1986, J CELL SCI, V80, P159; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JEWELL SA, 1982, SCIENCE, V217, P1257, DOI 10.1126/science.7112127; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; King R. C., 1970, OVARIAN DEV DROSOPHI; KNOWLES BA, 1994, TRENDS GENET, V10, P235, DOI 10.1016/0168-9525(94)90170-8; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Moir RD, 1995, INT REV CYTOL, V162B, P141; NEAMATI N, 1995, J IMMUNOL, V154, P3788; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; OKADA E, 1959, J EMBRYOL EXP MORPH, V7, P583; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; RIEMER D, 1995, J CELL SCI, V108, P3189; RUBY JR, 1969, J MORPHOL, V127, P307, DOI 10.1002/jmor.1051270304; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SMITH DE, 1989, J CELL BIOL, V108, P255, DOI 10.1083/jcb.108.2.255; SMITH DE, 1987, J CELL BIOL, V105, P771, DOI 10.1083/jcb.105.2.771; Song Z., UNPUB; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Spradling A.C., 1993, DEV DROSOPHILA MELAN, VI, P1; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TOURMENTE S, 1990, BIOL CELL, V68, P119, DOI 10.1016/0248-4900(90)90296-F; VERHEYEN E, 1994, METHOD CELL BIOL, V44, P545, DOI 10.1016/S0091-679X(08)60931-0; WHEATLEY S, 1995, DEVELOPMENT, V121, P1937; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; ZAMBONI L, 1968, J CELL BIOL, V36, P276, DOI 10.1083/jcb.36.1.276; [No title captured]	53	142	145	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					230	234		10.1126/science.279.5348.230	http://dx.doi.org/10.1126/science.279.5348.230			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422696				2022-12-24	WOS:000071408100043
J	Stelfox, HT; Chua, G; O'Rourke, K; Detsky, AS				Stelfox, HT; Chua, G; O'Rourke, K; Detsky, AS			Conflict of interest in the debate over calcium-channel antagonists	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; GASTROINTESTINAL HEMORRHAGE; ARTERY DISEASE; BLOCKERS; NIFEDIPINE; HYPERTENSION; MORTALITY; RISK; SAFE	Background Physicians' financial relationships with the pharmaceutical industry are controversial because such relationships may pose a conflict of interest. It is unknown to what extent industry support of medical education and research influences the opinions and behavior of clinicians and researchers. The recent debate over the safety of calcium-channel antagonists provided an opportunity to examine the effect of financial conflicts of interest. Methods We searched the English-language medical literature published from March 1995 through September 1996 for articles examining the controversy about the safety of calcium-channel antagonists. Articles were reviewed and classified as being supportive, neutral, or critical with respect to the use of calcium-channel antagonists. The authors of the articles were asked about their financial relationships with bath manufacturers of calcium-channel antagonists and manufacturers of competing products (i.e., beta-blockers, angiotensin-converting-enzyme inhibitors, diuretics, and nitrates). We examined the authors' published positions on the safety of calcium-channel antagonists according to their financial relationships with pharmaceutical companies. Results Authors who supported the use of calcium-channel antagonists were significantly more likely than neutral or critical authors to have financial relationships with manufacturers of calcium-channel antagonists (96 percent, vs. 60 percent and 37 percent, respectively; P<0.001). Supportive authors were also more likely than neutral or critical authors to have financial relationships with any pharmaceutical manufacturer, irrespective of the product (100 percent, vs. 67 percent and 43 percent, respectively; P<0.001). Conclusions Our results demonstrate a strong association between authors' published positions on the safety of calcium-channel antagonists and their financial relationships with pharmaceutical manufacturers. The medical profession needs to develop a more effective policy on conflict of interest. We support complete disclosure of relationships with pharmaceutical manufacturers for clinicians and researchers who write articles examining pharmaceutical products. (C) 1998, Massachusetts Medical Society.	Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Hlth Adm, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Toronto Hosp, Dept Med, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Detsky, AS (corresponding author), Mt Sinai Hosp, Dept Med, Rm 427,600 Univ Ave, Toronto, ON M5G 1X5, Canada.			Stelfox, Henry/0000-0003-1231-1490				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Angeli M, 1996, NEW ENGL J MED, V335, P1055, DOI 10.1056/NEJM199610033351410; AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; Barlow, 1972, STAT INFERENCE ORDER; Barnett AA, 1996, LANCET, V347, P313; Blandino DA, 1996, JAMA-J AM MED ASSOC, V275, P516; BROWN MJ, 1995, LANCET, V346, P768; Buring JE, 1996, JAMA-J AM MED ASSOC, V275, P517, DOI 10.1001/jama.1996.03530310021017; BURING JE, 1995, JAMA-J AM MED ASSOC, V274, P654, DOI 10.1001/jama.274.8.654; CHREN MM, 1994, JAMA-J AM MED ASSOC, V271, P684, DOI 10.1001/jama.271.9.684; Cooper RS, 1996, JAMA-J AM MED ASSOC, V275, P515, DOI 10.1001/jama.1996.03530310021014; COOPER RS, 1995, LANCET, V346, P961; Cox DR., 1989, ANAL BINARY DATA; Dargie HJ, 1996, LANCET, V348, P488, DOI 10.1016/S0140-6736(05)64663-6; DARGIE HJ, 1996, LANCET, V348, P694; ELLIOTT HL, 1995, LANCET, V346, P1421, DOI 10.1016/S0140-6736(95)92433-7; EPSTEIN M, 1995, ARCH INTERN MED, V155, P2150, DOI 10.1001/archinte.155.20.2150; FAGAN TC, 1995, ARCH INTERN MED, V155, P2145, DOI 10.1001/archinte.155.20.2145; Feeman WE, 1996, JAMA-J AM MED ASSOC, V275, P515, DOI 10.1001/jama.1996.03530310021013; FERRARI D, 1996, AM J CARDIOL, V77, pD22; Frohlich E D, 1995, J La State Med Soc, V147, P343; Frohlich ED, 1996, HYPERTENSION, V27, P317, DOI 10.1161/01.HYP.27.3.317; Furberg CD, 1996, CIRCULATION, V93, P1475; FURBERG CD, 1995, J AM GERIATR SOC, V43, P1309, DOI 10.1111/j.1532-5415.1995.tb07411.x; FURBERG CD, 1995, ARCH INTERN MED, V155, P2157, DOI 10.1001/archinte.155.20.2157; Furberg CD, 1996, EUR HEART J, V17, P1142; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; Furberg CD, 1996, CIRCULATION, V93, P1473; Furberg CD, 1996, CIRCULATION, V93, P1474; Ghali WA, 1996, ANN INTERN MED, V125, P518, DOI 10.7326/0003-4819-125-6-199609150-00029; GIFFORD RW, 1995, CLEV CLIN J MED, V62, P348, DOI 10.3949/ccjm.62.6.348; GOODMAN S, 1996, UPDATE CALCIUM ANTAG; Gordon RD, 1996, LANCET, V347, P1056, DOI 10.1016/S0140-6736(96)90269-X; HABIB GB, 1995, CHEST, V108, P3, DOI 10.1378/chest.108.1.3; Hardell L, 1996, LANCET, V348, P542, DOI 10.1016/S0140-6736(05)64695-8; HORTON R, 1995, LANCET, V346, P891, DOI 10.1016/S0140-6736(95)92717-4; HORTON R, 1995, LANCET, V346, P770; HORTON R, 1995, LANCET, V346, P586, DOI 10.1016/S0140-6736(95)91429-3; Kaplan NM, 1996, JAMA-J AM MED ASSOC, V275, P518, DOI 10.1001/jama.1996.03530310023019; Kaplan NM, 1996, LANCET, V348, P541, DOI 10.1016/S0140-6736(96)24034-6; Kaplan NM, 1996, AM J CARDIOL, V77, P81, DOI 10.1016/S0002-9149(97)89139-4; KLONER RA, 1995, CIRCULATION, V92, P1074, DOI 10.1161/01.CIR.92.5.1074; LICHTLEN PR, 1995, LANCET, V346, P962; Lichtlen PR, 1996, CIRCULATION, V93, P1472; Lip GYH, 1996, LANCET, V347, P1761; LUCAS BD, 1995, ANN PHARMACOTHER, V29, P629, DOI 10.1177/106002809502900615; MacCarthy EP, 1996, JAMA-J AM MED ASSOC, V275, P518, DOI 10.1001/jama.1996.03530310023020; MACDONALD G, 1995, LANCET, V346, P768; Mancia G, 1996, J HYPERTENS, V14, P13; Marwick C, 1996, JAMA-J AM MED ASSOC, V275, P423, DOI 10.1001/jama.275.6.423; MARWICK C, 1996, JAMA-J AM MED ASSOC, V275, P1638; MCKINNEY WP, 1990, JAMA-J AM MED ASSOC, V264, P1693, DOI 10.1001/jama.264.13.1693; Mehta JL, 1996, CIRCULATION, V93, P1472; MESSERLI FH, 1995, ANN INTERN MED, V123, P888, DOI 10.7326/0003-4819-123-11-199512010-00015; MESSERLI FH, 1995, LANCET, V346, P767, DOI 10.1016/S0140-6736(95)91526-5; Messerli FH, 1996, ANN INTERN MED, V125, P519, DOI 10.7326/0003-4819-125-6-199609150-00031; Messerli FH, 1996, J AM COLL CARDIOL, V28, P12, DOI 10.1016/0735-1097(96)00171-4; Messerli Franz H., 1996, Journal of the American College of Cardiology, V27, p319A; MONGE JC, 1996, SAFETY ANTIHYPERTENS; OPIE LH, 1995, CIRCULATION, V92, P1068, DOI 10.1161/01.CIR.92.5.1068; OPIE LH, 1995, LANCET, V346, P961; ORLOWSKI JP, 1992, CHEST, V102, P270, DOI 10.1378/chest.102.1.270; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; Pahor M, 1996, LANCET, V348, P541, DOI 10.1016/S0140-6736(05)64694-6; Parmley WW, 1996, J AM COLL CARDIOL, V27, P1820; Parmley WW, 1996, J AM COLL CARDIOL, V27, P510, DOI 10.1016/0735-1097(95)00601-X; PHILLIPS BG, 1995, AM J HEALTH-SYST PH, V52, P1460, DOI 10.1093/ajhp/52.13.1460; Pilotto A, 1996, LANCET, V347, P1761; PooleWilson PA, 1996, EUR HEART J, V17, P1131; POOLEWILSON PA, 1995, LANCET, V346, P769; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; Psaty BM, 1996, LANCET, V347, P1761, DOI 10.1016/S0140-6736(96)90837-5; Psaty BM, 1996, JAMA-J AM MED ASSOC, V275, P516, DOI 10.1001/jama.1996.03530310021016; Psaty BM, 1996, JAMA-J AM MED ASSOC, V275, P518, DOI 10.1001/jama.1996.03530310023021; Rafflenbeul W, 1996, EUR HEART J, V17, P1147; RAFFLENBEUL W, 1996, CIRCULATION, V493, P1473; Ryden L, 1996, EUR HEART J, V17, P1; SCHUBERT T, 1995, LANCET, V346, P961, DOI 10.1016/S0140-6736(95)91580-X; Smith G N, 1996, J Fam Pract, V42, P30; *STAT SCI, 1995, S PLUS GUID STAT MAT; Stryer DB, 1996, JAMA-J AM MED ASSOC, V275, P517, DOI 10.1001/jama.275.7.517; Tierney WM, 1996, ANN INTERN MED, V125, P519, DOI 10.7326/0003-4819-125-6-199609150-00030; Tijssen JGP, 1996, EUR HEART J, V17, P1152; Walker AM, 1996, LANCET, V348, P489, DOI 10.1016/S0140-6736(05)64664-8; Walker AM, 1996, AM J CARDIOL, V78, P380; YUSUF S, 1995, CIRCULATION, V92, P1079, DOI 10.1161/01.CIR.92.5.1079; 1996, LANCET, V348, P487	89	441	457	1	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	1998	338	2					101	106		10.1056/NEJM199801083380206	http://dx.doi.org/10.1056/NEJM199801083380206			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ039	9420342	Bronze			2022-12-24	WOS:000071341300006
J	Weiss, HB; Friedman, DI; Coben, JH				Weiss, HB; Friedman, DI; Coben, JH			Incidence of dog bite injuries treated in emergency departments	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Pennsylvania-Public-Health-Association Annual Meeting	OCT   01, 1996	PITTSBURGH, PENNSYLVANIA	Penn Public Hlth Assoc			CHILDREN	Context.-Dog bites that result in injuries occur frequently, but how frequently dog bite injuries necessitate medical attention at a hospital or hospital admission is unknown. Objective.-To describe the incidence and characteristics of dog bite injuries treated in US emergency departments (EDs). Design.-Emergency department survey from the National Center for Health Statistics National Hospital Ambulatory Medical Care Survey for 1992 to 1994. Patients.-National probability sample of patients visiting EDs. Main Outcome Measure.-Incidence of dog bites treated in EDs, defined as a cause of injury recorded as the E-code E906.0. Results.-The 3-year annualized, adjusted, and weighted estimate of new dog bite-related injury visits to US EDs was 333 687, a rate of 12.9 per 10 000 persons (95% confidence interval [CI], 10.5-15.4). This represents approximately 914 new dog bite injuries requiring ED visits per day. The median age of patients bitten was 15 years, with children, especially boys aged 5 to 9 years, having the highest incidence rate (60.7 per 10 000 persons for boys aged 5 to 9 years). Children seen in EDs were more likely than older persons to be bitten on the face, neck, and head (73% vs 30%). We estimated that for each US dog bite fatality there are about 670 hospitalizations and 16000 ED visits. Conclusions.-Dog bite injuries are an important source of injury in the US population, especially among children. Improved surveillance and prevention of dog bite-related injuries, particularly among children, are needed.	Univ Pittsburgh, Ctr Injury Res & Control, Dept Emergency Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Weiss, HB (corresponding author), Allegheny Univ Hlth Sci, Ctr Violence & Injury Control, Dept Emergency Med, 1 Allegheny Ctr,Suite 510,320 E North Ave, Pittsburgh, PA 15212 USA.		Weiss, Hank/D-1052-2010		PHS HHS [MCH-424002-01-0] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGHABABIAN RV, 1980, ANN EMERG MED, V9, P79, DOI 10.1016/S0196-0644(80)80335-0; AVNER JR, 1991, PEDIATRICS, V88, P55; BECK AM, 1975, PUBLIC HEALTH REP, V90, P262; BECK AM, 1985, PUBLIC HEALTH REP, V100, P315; BROGAN TV, 1995, PEDIATRICS, V96, P947; BURT CW, 1995, ADV DATA VITAL HLTH, V261; CHIN Y, 1982, PEDIATRICS, V69, P119; DAVIS SJM, 1978, NATURE, V276, P608, DOI 10.1038/276608a0; GERSHMAN KA, 1994, PEDIATRICS, V93, P913; KIZER KW, 1979, JACEP-J AM COLL EMER, V8, P134, DOI 10.1016/S0361-1124(79)80339-1; LANGLEY J, 1992, NEW ZEAL MED J, V105, P33; MCCAIG LF, 1994, ADV DATA VITAL HLTH, V245; PEEL MM, 1993, PATHOLOGY, V25, P379, DOI 10.3109/00313029309090863; Pickney LE, 1982, PEDIATRICS, V69, P193; Sacks J J, 1996, Inj Prev, V2, P52, DOI 10.1136/ip.2.1.52; SACKS JJ, 1989, JAMA-J AM MED ASSOC, V262, P1489, DOI 10.1001/jama.262.11.1489; Sacks JJ, 1996, PEDIATRICS, V97, P891; Scarcella J V, 1969, Ohio State Med J, V65, P25; SOKOL AB, 1971, CLIN PEDIATR, V10, P336, DOI 10.1177/000992287101000616; STUSSMAN BJ, 1996, ADV DATA VITAL HLTH, V271; *US CONS PROD SAF, 1992, 009207 US CONS PROD; WISE JK, 1994, J AM VET MED ASSOC, V204, P1166; 1996, CONSUMER PRODUCT SUM, V1, P5	23	274	285	0	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					51	53		10.1001/jama.279.1.51	http://dx.doi.org/10.1001/jama.279.1.51			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424044	Bronze			2022-12-24	WOS:000071295100035
J	Gradia, S; Acharya, S; Fishel, R				Gradia, S; Acharya, S; Fishel, R			The human mismatch recognition complex hMSH2-hMSH6 functions as a novel molecular switch	CELL			English	Article							NONPOLYPOSIS COLON-CANCER; HUMAN MSH2 PROTEIN; HETERODUPLEX REPAIR; SIGNAL-TRANSDUCTION; BINDING-PROTEINS; NUCLEAR EXTRACTS; RAS SUPERFAMILY; TUMOR-CELLS; DNA; HETERODIMER	The mechanism of DNA mismatch repair has been modeled upon biochemical studies of the E. coli DNA adenine methylation-instructed pathway where the initial recognition of mismatched nucleotides is performed by the MutS protein. MutS homologs (MSH) have been identified based on a highly conserved region containing a Walker-A adenine nucleotide binding motif. Here we show that adenine nucleotide binding and hydrolysis by the human mismatch recognition complex hMSH2-hMSH6 functions as a novel molecular switch. The hMSH2-hMSH6 complex is ON (binds mismatched nucleotides) in the ADP-bound form and OFF in the ATP-bound form. These results suggest a new model for the function of MutS proteins during mismatch repair in which the switch determines the timing of downstream events.	Thomas Jefferson Univ, Kimmel Canc Ctr, Genet & Mol Biol Program, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Fishel, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Genet & Mol Biol Program, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA.				NATIONAL CANCER INSTITUTE [R01CA067007, R01CA056542] Funding Source: NIH RePORTER; NCI NIH HHS [CA56542, R01 CA067007, CA67007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Alani E, 1997, MOL CELL BIOL, V17, P2436, DOI 10.1128/MCB.17.5.2436; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Biswas I, 1997, J BIOL CHEM, V272, P13355, DOI 10.1074/jbc.272.20.13355; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHI NW, 1994, J BIOL CHEM, V269, P29984; Dixon M., 1979, ENZYMES, Vthird; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FISHEL RA, 1988, P NATL ACAD SCI USA, V85, P36, DOI 10.1073/pnas.85.1.36; GLAZER PM, 1987, MOL CELL BIOL, V7, P218, DOI 10.1128/MCB.7.1.218; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; Jiang W, 1997, J BIOL CHEM, V272, P7626, DOI 10.1074/jbc.272.12.7626; Laalami S, 1996, BIOCHIMIE, V78, P577, DOI 10.1016/S0300-9084(96)80004-6; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Meyers M, 1997, CANCER RES, V57, P206; MILLER LK, 1976, P NATL ACAD SCI USA, V73, P3073, DOI 10.1073/pnas.73.9.3073; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1989, J BIOL CHEM, V264, P6597; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; SPIEGEL AM, 1987, MOL CELL ENDOCRINOL, V49, P1, DOI 10.1016/0303-7207(87)90058-X; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WIESMULLER L, 1994, CELL SIGNAL, V6, P247, DOI 10.1016/0898-6568(94)90030-2; WILSON TM, 1995, CANCER RES, V55, P5146; WOODWARDGRAVES KL, 1996, J BIOL CHEM, V271, P13629; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994; YU X, 1992, J MOL BIOL, V225, P193, DOI 10.1016/0022-2836(92)91036-O	49	300	307	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	1997	91	7					995	1005		10.1016/S0092-8674(00)80490-0	http://dx.doi.org/10.1016/S0092-8674(00)80490-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428522	Bronze			2022-12-24	WOS:000071281400016
J	Martin, KC; Casadio, A; Zhu, HX; E, YP; Rose, JC; Chen, M; Bailey, CH; Kandel, ER				Martin, KC; Casadio, A; Zhu, HX; E, YP; Rose, JC; Chen, M; Bailey, CH; Kandel, ER			Synapse-specific, long-form facilitation of Aplysia sensory to motor synapses: A function for local protein synthesis in memory storage	CELL			English	Article							TERM FACILITATION; HETEROSYNAPTIC FACILITATION; STRUCTURAL-CHANGES; MESSENGER-RNA; CELL-CULTURE; NEURONS; DENDRITES; SENSITIZATION; LOCALIZATION; HABITUATION	The requirement for transcription during long-lasting synaptic plasticity has raised the question of whether the cellular unit of synaptic plasticity is the soma and its nucleus or the synapse. To address this question, we cultured a single bifurcated Apylsia sensory neuron making synapses with two spatially separated motor neurons. By perfusing serotonin onto the synapses made onto one motor neuron, we found that a single axonal branch can undergo long-term branch-specific facilitation. This branch-specific facilitation depends on CREB-mediated transcription and involves the growth of new synaptic connections exclusively at the treated branch. Branch-specific long-term facilitation requires local protein synthesis in the presynaptic but not the postsynaptic cell. In fact, presynaptic sensory neuron axons deprived of their cell bodies are capable of protein synthesis, and this protein synthesis is stimulated 3-fold by exposure to serotonin.	Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Kandel, ER (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, Howard Hughes Med Inst, 722 W 168th St, New York, NY 10032 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32099] Funding Source: Medline; NIMH NIH HHS [MH37134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; BAILEY CH, 1992, NEURON, V9, P749, DOI 10.1016/0896-6273(92)90037-E; BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P2373, DOI 10.1073/pnas.85.7.2373; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRUNET JF, 1991, SCIENCE, V252, P856, DOI 10.1126/science.1840700; CLARK GA, 1993, P NATL ACAD SCI USA, V90, P11411, DOI 10.1073/pnas.90.23.11411; CLARK GA, 1984, P NATL ACAD SCI-BIOL, V81, P2577, DOI 10.1073/pnas.81.8.2577; Crino PB, 1996, NEURON, V17, P1173, DOI 10.1016/S0896-6273(00)80248-2; Crispino M, 1997, J NEUROSCI, V17, P7694; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; EMPTAGE NJ, 1993, SCIENCE, V262, P253, DOI 10.1126/science.8211146; FATT P, 1951, J PHYSIOL-LONDON, V115, P320, DOI 10.1113/jphysiol.1951.sp004675; FEIG S, 1993, J NEUROSCI, V13, P1010; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; GHIRARDI M, 1995, NEURON, V14, P413, DOI 10.1016/0896-6273(95)90297-X; GLANZMAN DL, 1989, NEURON, V3, P441, DOI 10.1016/0896-6273(89)90203-1; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; Mayford M, 1996, P NATL ACAD SCI USA, V93, P13250, DOI 10.1073/pnas.93.23.13250; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; Nestler E. J., 1984, PROTEIN PHOSPHORYLAT; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; RAYPORT SG, 1986, J NEUROSCI, V6, P759; ROBISON GA, 1968, ANNU REV BIOCHEM, V37, P149, DOI 10.1146/annurev.bi.37.070168.001053; SCHACHER S, 1983, J NEUROSCI, V3, P2403; SCHELLER RH, 1982, CELL, V28, P707, DOI 10.1016/0092-8674(82)90050-2; Schuman EM, 1997, NEURON, V18, P339, DOI 10.1016/S0896-6273(00)81234-9; Sossin WS, 1996, TRENDS NEUROSCI, V19, P215; Steward O, 1997, NEURON, V18, P9, DOI 10.1016/S0896-6273(01)80041-6; STIRPE F, 1980, J BIOL CHEM, V255, P6947; TRUDEAU LE, 1995, J NEUROSCI, V15, P1275; VanMinnen J, 1997, NEUROSCIENCE, V80, P1; WEILER IJ, 1993, P NATL ACAD SCI USA, V90, P7168, DOI 10.1073/pnas.90.15.7168; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	42	580	594	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					927	938		10.1016/S0092-8674(00)80484-5	http://dx.doi.org/10.1016/S0092-8674(00)80484-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428516	hybrid			2022-12-24	WOS:000071281400010
J	Ozaki, M; Sasner, M; Yano, R; Lu, HS; Buonanno, A				Ozaki, M; Sasner, M; Yano, R; Lu, HS; Buonanno, A			Neuregulin-beta induces expression of an NMDA-receptor subunit	NATURE			English	Article							NEU DIFFERENTIATION FACTOR; ACETYLCHOLINE-RECEPTOR; DEVELOPING CEREBELLUM; GENE-EXPRESSION; MESSENGER-RNAS; SINGLE-CHANNEL; GRANULE CELLS; MUSCLE; ERBB3; SYNAPSES	Neuregulins (also known as ARLA, NDF, heregulin, GGF) are a family of widely expressed growth and differentiation factors. Neuregulins secreted from motor neurons accumulate at maturing neuromuscular junctions, where they stimulate transcription of genes encoding specific acetylcholine receptors. How these factors function at central synapses, however, is unknown. In the maturing cerebellum, neuregulins are concentrated in glutamatergic messy fibres that innervate granule cells in the internal granule-cell layer(1). We have analysed the effects of neuregulins on the expression of genes encoding NMDA (N-methyl-D-aspartate) receptors in the cerebellum, because receptor composition changes dramatically as expression of the receptor NR2C subunit is specifically induced in neurons in the internal granule-cell layer during synaptogenesis. Here we report that addition of a neuregulin-beta isoform to cultured cerebellar slices specifically increases the expression of NR2C messenger RNAs by at least 100-fold; effects are only minor with a neuregulin-alpha isoform. This stimulation of NR2C expression requires synaptic activity by NMDA receptors, as well as neuregulin-beta. Addition of the NMDA-receptor-channel blocker AP-5 prevents upregulation of the NR2C subunit by neuregulin, whereas an AMPA/kainate-receptor antagonist does not. Consistent with these effects of neuregulin, we find that granule cells express its receptors ErbB2 and ErbB4 before the NR2C subunit of the NMDA receptor. Our results indicate that neuregulins regulate the composition of neurotransmitter receptors in maturing synapses in the brain, in a manner analogous to the neuromuscular junction.	NIH,MOL NEUROBIOL UNIT,LDN,BETHESDA,MD 20892; RIKEN,FRONTIER RES PROGRAM,LAB CELLULAR INFORMAT PROC,WAKO,SAITAMA 35101,JAPAN; AMGEN INC,DEPT PROT STRUCT,THOUSAND OAKS,CA 91320	National Institutes of Health (NIH) - USA; RIKEN; Amgen				Sasner, Michael/0000-0002-6612-6111				AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; ANGERER LM, 1981, NUCLEIC ACIDS RES, V9, P2819, DOI 10.1093/nar/9.12.2819; AUDINAT E, 1994, EUR J NEUROSCI, V6, P1792, DOI 10.1111/j.1460-9568.1994.tb00572.x; BUONANNO A, 1995, SOC NEUR ABSTR, V21; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carroll SL, 1997, J NEUROSCI, V17, P1642; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; FARRANT M, 1994, NATURE, V368, P335, DOI 10.1038/368335a0; Feldmeyer D, 1996, J NEUROCYTOL, V25, P857, DOI 10.1007/BF02284847; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Kadotani H, 1996, J NEUROSCI, V16, P7859; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; LEVI G, 1982, BRAIN RES, V239, P425, DOI 10.1016/0006-8993(82)90520-0; LU HS, 1995, J BIOL CHEM, V270, P4784, DOI 10.1074/jbc.270.9.4784; LU HS, 1995, J BIOL CHEM, V270, P4775, DOI 10.1074/jbc.270.9.4775; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; Sandrock AW, 1997, SCIENCE, V276, P599, DOI 10.1126/science.276.5312.599; SANDROCK AW, 1995, J NEUROSCI, V15, P6124; Shahar A, 1989, DISSECTION TISSUE CU, V1, P203; STERN P, 1992, P ROY SOC B-BIOL SCI, V250, P271, DOI 10.1098/rspb.1992.0159; Takahashi T, 1996, J NEUROSCI, V16, P4376; TANAKA M, 1994, BRAIN RES, V641, P319, DOI 10.1016/0006-8993(94)90161-9; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027	30	219	226	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 25	1997	390	6661					691	694		10.1038/37795	http://dx.doi.org/10.1038/37795			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM508	9414162				2022-12-24	WOS:A1997YM50800033
J	Blader, P; Rastegar, S; Fischer, N; Strahle, U				Blader, P; Rastegar, S; Fischer, N; Strahle, U			Cleavage of the BMP-4 antagonist chordin by zebrafish tolloid	SCIENCE			English	Article							BONE MORPHOGENETIC PROTEIN-1; DROSOPHILA-MELANOGASTER; PATTERN-FORMATION; LARVAL CUTICLE; ZYGOTIC LOCI; SPEMANN ORGANIZER; XENOPUS CHORDIN; C-PROTEINASE; BETA FAMILY; GENE	Dorsoventral patterning of vertebrate and Drosophila embryos requires bone morphogenetic proteins (BMPs) and antagonists of BMP activity. The Drosophila gene tolloid encodes a metalloprotease similar to BMP-1 that interacts genetically with decapentaplegic, the Drosophila homolog of vertebrate BMP-2/4. Zebrafish embryos overexpressing a zebrafish homolog of tolloid were shown to resemble loss-of-function mutations in chordino, the zebrafish homolog of the Xenopus BMP-4 antagonist Chordin. Furthermore, Chordin was degraded by COS cells expressing Tolloid. These data suggest that Tolloid antagonizes Chordin activity by proteolytically cleaving Chordin, A conserved function for zebrafish and Drosophila Tolloid during embryogenesis is proposed.	UNIV STRASBOURG 1,INSERM,CNRS,INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Rastegar, Sepand/E-2324-2015; Straehle, Uwe/K-7054-2013	Rastegar, Sepand/0000-0003-4411-5646; Blader, Patrick/0000-0003-3299-6108				BLADER P, UNPUB; BOURGUET W, 1995, PROTEIN EXPRES PURIF, V6, P604, DOI 10.1006/prep.1995.1079; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALE L, 1992, DEVELOPMENT, V115, P573; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hammerschmidt M, 1996, GENE DEV, V10, P2452, DOI 10.1101/gad.10.19.2452; Hammerschmidt M, 1996, DEVELOPMENT, V123, P95; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; JOLY JS, 1993, DEVELOPMENT, V119, P1261; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KRAUSS S, 1991, DEVELOPMENT, V113, P1193; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Mullins MC, 1996, DEVELOPMENT, V123, P81; Neave B, 1997, MECH DEVELOP, V62, P183, DOI 10.1016/S0925-4773(97)00659-X; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; PUSCHEL AW, 1992, MECH DEVELOP, V38, P197, DOI 10.1016/0925-4773(92)90053-M; Sarras MP, 1996, BIOESSAYS, V18, P439, DOI 10.1002/bies.950180604; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; WAKIMOTO BT, 1984, DEV BIOL, V102, P147, DOI 10.1016/0012-1606(84)90182-9; Westerfield M, 1995, ZEBRAFISH BOOK; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; ZUSMAN SB, 1985, DEV BIOL, V111, P359, DOI 10.1016/0012-1606(85)90490-7	42	162	174	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1937	1940		10.1126/science.278.5345.1937	http://dx.doi.org/10.1126/science.278.5345.1937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395394				2022-12-24	WOS:A1997YL00200032
J	Fetz, EE				Fetz, EE			Neuroscience - Temporal coding in neural populations?	SCIENCE			English	Editorial Material							COOPERATIVE FIRING ACTIVITY; PRIMATE MOTOR CORTEX; MOVEMENT; NEURONS; DIRECTION; DYNAMICS				Fetz, EE (corresponding author), UNIV WASHINGTON,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195, USA.							ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; ABELES M, 1993, BRAIN THEORY, P149; Abeles M., 1991, CORTICONICS; Aertsen A, 1996, J PHYSIOLOGY-PARIS, V90, P243, DOI 10.1016/S0928-4257(97)81432-5; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; Buszaki G, 1994, TEMPORAL CODING BRAI; Davis J., 1994, LARGE SCALE NEURONAL; FERSTER D, 1995, SCIENCE, V270, P756, DOI 10.1126/science.270.5237.756; FETZ EE, 1992, BEHAV BRAIN SCI, V15, P679; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GERSTEIN GL, 1985, J NEUROSCI, V5, P881; GERSTEIN GL, 1985, J NEUROPHYSIOL, V54, P1513, DOI 10.1152/jn.1985.54.6.1513; Lindsey BG, 1997, J NEUROPHYSIOL, V78, P1714, DOI 10.1152/jn.1997.78.3.1714; Murthy VN, 1996, J NEUROPHYSIOL, V76, P3968, DOI 10.1152/jn.1996.76.6.3968; RIECKE F, 1997, SPIKES; RIEHLE A, 1950, SCIENCE, V278; Roelfsema PR, 1996, J COGNITIVE NEUROSCI, V8, P603, DOI 10.1162/jocn.1996.8.6.603; Salinas E, 1994, J Comput Neurosci, V1, P89, DOI 10.1007/BF00962720; SANES JN, 1993, P NATL ACAD SCI USA, V90, P4470, DOI 10.1073/pnas.90.10.4470; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; SINGER W, 1993, ANN REV PHYSL, V55, P201; Taira M, 1996, EXP BRAIN RES, V109, P367; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0; ZHANG K, IN PRESS J NEUROPHYS	25	47	50	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1901	1902		10.1126/science.278.5345.1901	http://dx.doi.org/10.1126/science.278.5345.1901			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9417639				2022-12-24	WOS:A1997YL00200021
J	Krishnan, V; Pereira, FA; Qiu, Y; Chen, CH; Beachy, PA; Tsai, SY; Tsai, MJ				Krishnan, V; Pereira, FA; Qiu, Y; Chen, CH; Beachy, PA; Tsai, SY; Tsai, MJ			Mediation of Sonic Hedgehog induced expression of COUP-TFII by a protein phosphatase	SCIENCE			English	Article							TERMINAL CLEAVAGE PRODUCT; MOTOR-NEURON INDUCTION; FLOOR PLATE; KINASE-A; GENE; RECEPTOR; NOTOCHORD; HOMOLOG; TUBE	A Sonic hedgehog (Shh) response element was identified in the chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) promoter that binds to a factor distinct from Gli, a gene known to mediate Shh signaling. Although this binding activity is specifically stimulated by Shh-N (amino-terminal signaling domain), it can also be unmasked with protein phosphatase treatment in the mouse cell line P19, and induction by Shh-N can be blocked by phosphatase inhibitors. Thus, Shh-N signaling may result in dephosphorylation of a target factor that is required for activation of COUP-TFII-, Islet1-, and Gli response element-dependent gene expression. This finding identifies another step in the Shh-N signaling pathway.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205	Baylor College of Medicine; Howard Hughes Medical Institute; Johns Hopkins University				Pereira, Fred/0000-0003-2100-0280				Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; CHEN CH, COMMUNICATION; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Concordet JP, 1996, DEVELOPMENT, V122, P2835; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; Krishnan V, 1997, MOL ENDOCRINOL, V11, P1458, DOI 10.1210/me.11.10.1458; LUTZ B, 1994, DEVELOPMENT, V120, P25, DOI 10.1242/dev.120.1.25; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MONSOROBURQ AH, 1995, MECH DEVELOP, V53, P157, DOI 10.1016/0925-4773(95)00426-2; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229	24	123	129	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1947	1950		10.1126/science.278.5345.1947	http://dx.doi.org/10.1126/science.278.5345.1947			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395397				2022-12-24	WOS:A1997YL00200035
J	Hess, RF; Dakin, SC				Hess, RF; Dakin, SC			Absence of contour linking in peripheral vision	NATURE			English	Article							VISUAL-CORTEX; INTEGRATION; SYSTEM	Human foveal vision is subserved initially by groups of spatial, temporal and orientational 'filters', the outputs of which are combined to define perceptual objects, Although a great deal is known about the filtering properties of individual cortical cells, relatively little is known about the nature of this 'linking' process. One recent approach(1) has shown that the process can be thought of in terms of an association field whose strength is determined conjointly by the orientation and distance of the object. Here we describe a fundamental difference in this feature-linking process in central and peripheral parts of the visual field, which provides insight into the ways that foveal and peripheral visual perception differ(2,3). In the fovea, performance can be explained only by intercellular Linking operations whereas in the periphery intracellular filtering will suffice. This difference represents a substantial economy in cortical neuronal processing of peripheral visual information and may allow a recent theory of intercellular binding to be tested(4-7).			Hess, RF (corresponding author), MCGILL UNIV,DEPT OPHTHALMOL,MONTREAL,PQ H3A 1A1,CANADA.		Dakin, Steven C/B-7610-2008; Hess, Robert F/A-5624-2008	Dakin, Steven C/0000-0002-3548-9104; 				Aubert H., 1857, ARCHIV F UR OPHTHALM, V3, P1; ENGEL AK, 1992, TRENDS NEUROSCI, V15, P218, DOI 10.1016/0166-2236(92)90039-B; FIELD DJ, 1993, VISION RES, V33, P173, DOI 10.1016/0042-6989(93)90156-Q; GILBERT CD, 1989, J NEUROSCI, V9, P2432; KREITER AK, 1994, EUROPEAN J NEUROSC S, V7, P153; PHILLIPS G, 1983, J OPT SOC AM, V62, P226; SCHNEIDER GE, 1969, SCIENCE, V163, P895, DOI 10.1126/science.163.3870.895; TSO DY, 1988, J NEUROSCI, V8, P1712; von der Malsburg Ch., 1983, SYNERGETICS BRAIN, P238; VONDERMALSBURG C, 1988, NEUROBIOLOGY NEOCORT, P69; Wang YZ, 1996, VISION RES, V36, P1737, DOI 10.1016/0042-6989(95)00249-9; Watt R., 1991, UNDERSTANDING VISION; WATT RJ, 1985, VISION RES, V25, P1661, DOI 10.1016/0042-6989(85)90138-5	13	125	125	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					602	604		10.1038/37593	http://dx.doi.org/10.1038/37593			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403687				2022-12-24	WOS:A1997YK85300047
J	Chow, CW; Rincon, M; Cavanagh, J; Dickens, M; Davis, RJ				Chow, CW; Rincon, M; Cavanagh, J; Dickens, M; Davis, RJ			Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway	SCIENCE			English	Article							KINASE; FAMILY; MORPHOGENESIS; CALCINEURIN; ACTIVATION; DROSOPHILA; INDUCTION; RECEPTOR; DOMAIN; MEMBER	The nuclear factor of activated T cells (NFAT) group of transcription factors is retained in the cytoplasm of quiescent cells, NFAT activation is mediated in part, by induced nuclear import, This process requires calcium-dependent dephosphorylation of NFAT caused by the phosphatase calcineurin, The c-Jun amino-terminal kinase (JNK) phosphorylates NFAT4 on two sites, Mutational removal of the JNK phosphorylation sites caused constitutive nuclear localization of NFAT4, in contrast, JNK activation in calcineurin-stimulated cells caused nuclear exclusion of NFAT4. These findings show that the nuclear accumulation of NFAT4 promoted by calcineurin is opposed by the JNK signal transduction pathway.	UNIV MASSACHUSETTS, SCH MED,HOWARD HUGHES MED INST,PROGRAM MOL MED, DEPT BIOCHEM & MOL BIOL, WORCESTER, MA 01605 USA; UNIV VERMONT, DEPT MED, PROGRAM IMMUNOBIOL, BURLINGTON, VT 05405 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Vermont			Dickens, Martin/B-2001-2012		NCI NIH HHS [CA58396, CA65831] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHOW CW, UNPUB; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAO A, 1995, J LEUKOCYTE BIOL, V57, P536, DOI 10.1002/jlb.57.4.536; RAPP UR, 1994, ONCOGENE, V9, P3493; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004	28	297	305	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 28	1997	278	5343					1638	1641		10.1126/science.278.5343.1638	http://dx.doi.org/10.1126/science.278.5343.1638			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374467				2022-12-24	WOS:A1997YJ87400046
J	Su, XZ; Kirkman, LA; Fujioka, H; Wellems, TE				Su, XZ; Kirkman, LA; Fujioka, H; Wellems, TE			Complex polymorphisms in an similar to 330 kDa protein are linked to chloroquine-resistant P-falciparum in Southeast Asia and Africa	CELL			English	Article							PARASITE PLASMODIUM-FALCIPARUM; INFECTED HUMAN-ERYTHROCYTES; DRUG-RESISTANCE; CROSS-RESISTANCE; PFMDR1 GENE; MALARIA; INVITRO; AMPLIFICATION; PYRIMETHAMINE; SENSITIVITY	Chloroquine resistance in a P. falciparum cross maps as a Mendelian trait to a 36 kb segment of chromosome 7. This segment harbors cg2, a gene encoding a unique similar to 330 kDa protein with complex polymorphisms. A specific set of polymorphisms in 20 chloroquine-resistant parasites from Asia and Africa, in contrast with numerous differences in 21 sensitive parasites, suggests selection of a cg2 allele originating in Indochina over 40 years ago. One chloroquine-sensitive clone exhibited this allele, suggesting another resistance component. South American parasites have cg2 polymorphisms consistent with a separate origin of resistance. CG2 protein is found at the parasite periphery, a site of chloroquine transport, and in association with hemozoin of the digestive vacuole, where chloroquine inhibits heme polymerization.	NIAID, NIH, BETHESDA, MD 20892 USA; CASE WESTERN RESERVE UNIV, INST PATHOL, CLEVELAND, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Case Western Reserve University				Su, Xinzhuan/0000-0003-3246-3248	NIAID NIH HHS [AI-35827] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035827] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKAWA M, 1990, ADV PARASIT, V29, P151, DOI 10.1016/S0065-308X(08)60106-2; Allen M J, 1994, PCR Methods Appl, V4, P71; BABIKER HA, 1994, PARASITOLOGY, V109, P413, DOI 10.1017/S0031182000080665; BARNES DA, 1992, EMBO J, V11, P3067, DOI 10.1002/j.1460-2075.1992.tb05378.x; BAYOUMI RAL, 1993, T ROY SOC TROP MED H, V87, P454, DOI 10.1016/0035-9203(93)90034-N; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; BRAY PG, 1994, MOL BIOCHEM PARASIT, V63, P87, DOI 10.1016/0166-6851(94)90011-6; BRAY PG, 1992, BIOCHEM PHARMACOL, V44, P1317, DOI 10.1016/0006-2952(92)90532-N; BRAY PG, 1992, BIOCHEM PHARMACOL, V43, P1219, DOI 10.1016/0006-2952(92)90495-5; COWMAN AF, 1994, P NATL ACAD SCI USA, V91, P1143, DOI 10.1073/pnas.91.3.1143; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; CREEDON KA, 1994, J BIOL CHEM, V269, P16364; De DY, 1996, AM J TROP MED HYG, V55, P579, DOI 10.4269/ajtmh.1996.55.579; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLAN SA, 1993, MOL BIOCHEM PARASIT, V61, P137, DOI 10.1016/0166-6851(93)90166-U; DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0; EGAN TJ, 1994, FEBS LETT, V352, P54, DOI 10.1016/0014-5793(94)00921-X; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FITCH CD, 1970, SCIENCE, V169, P289, DOI 10.1126/science.169.3942.289; FITCH CD, 1983, CIBA F SYMP, V94, P222; FITCH CD, 1969, P NATL ACAD SCI USA, V64, P1181, DOI 10.1073/pnas.64.4.1181; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FOOTE SJ, 1990, P NATL ACAD SCI USA, V87, P3014, DOI 10.1073/pnas.87.8.3014; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; FREESE JA, 1991, B WORLD HEALTH ORGAN, V69, P707; Galfre G, 1981, Methods Enzymol, V73, P3; GEARY TG, 1983, J PARASITOL, V69, P97, DOI 10.2307/3281283; GINSBURG H, 1991, BIOCHEM PHARMACOL, V41, P1463, DOI 10.1016/0006-2952(91)90562-J; Hawley SR, 1996, ANTIMICROB AGENTS CH, V40, P2345, DOI 10.1128/AAC.40.10.2345; Kirkman LA, 1996, EXP PARASITOL, V83, P147, DOI 10.1006/expr.1996.0058; Kotecka BM, 1997, ANTIMICROB AGENTS CH, V41, P1369, DOI 10.1128/AAC.41.6.1369; KROGSTAD DJ, 1992, BIOCHEM PHARMACOL, V43, P57, DOI 10.1016/0006-2952(92)90661-2; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830; Liang H, 1997, MOL BIOCHEM PARASIT, V84, P241, DOI 10.1016/S0166-6851(96)02791-0; Loureiro LF, 1996, ANN TROP MED PARASIT, V90, P223, DOI 10.1080/00034983.1996.11813048; MARTIN SK, 1987, SCIENCE, V235, P899, DOI 10.1126/science.3544220; MARTINEY JA, 1995, J BIOL CHEM, V270, P22393, DOI 10.1074/jbc.270.38.22393; PAYNE D, 1987, PARASITOL TODAY, V3, P241, DOI 10.1016/0169-4758(87)90147-5; PETERS W, 1989, LANCET, V2, P334, DOI 10.1016/S0140-6736(89)90522-9; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; PETERSON DS, 1990, P NATL ACAD SCI USA, V87, P3018, DOI 10.1073/pnas.87.8.3018; PETERSON DS, 1995, P NATL ACAD SCI USA, V92, P7100, DOI 10.1073/pnas.92.15.7100; Ridley RG, 1996, ANTIMICROB AGENTS CH, V40, P1846, DOI 10.1128/AAC.40.8.1846; ROBSON KJH, 1990, P ROY SOC B-BIOL SCI, V242, P205, DOI 10.1098/rspb.1990.0126; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Sanchez CP, 1997, J BIOL CHEM, V272, P2652, DOI 10.1074/jbc.272.5.2652; SAUL A, 1988, MOL BIOCHEM PARASIT, V27, P35, DOI 10.1016/0166-6851(88)90022-9; SIXSMITH DG, 1984, AM J TROP MED HYG, V33, P772, DOI 10.4269/ajtmh.1984.33.772; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; Su XZ, 1996, NUCLEIC ACIDS RES, V24, P1574, DOI 10.1093/nar/24.8.1574; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Sullivan DJ, 1996, P NATL ACAD SCI USA, V93, P11865, DOI 10.1073/pnas.93.21.11865; TRIGLIA T, 1991, MOL CELL BIOL, V11, P5244, DOI 10.1128/MCB.11.10.5244; VERDIER F, 1985, ANTIMICROB AGENTS CH, V27, P561, DOI 10.1128/AAC.27.4.561; vonSeidlein L, 1997, T ROY SOC TROP MED H, V91, P450, DOI 10.1016/S0035-9203(97)90281-9; WALKERJONAH A, 1992, MOL BIOCHEM PARASIT, V51, P313, DOI 10.1016/0166-6851(92)90081-T; WELLEMS TE, 1991, P NATL ACAD SCI USA, V88, P3382, DOI 10.1073/pnas.88.8.3382; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0; WHITE NJ, 1992, J ANTIMICROB CHEMOTH, V30, P571, DOI 10.1093/jac/30.5.571; WILSON CM, 1989, SCIENCE, V244, P1184, DOI 10.1126/science.2658061; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x; YAYON A, 1985, P NATL ACAD SCI USA, V82, P2784, DOI 10.1073/pnas.82.9.2784	64	297	311	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 28	1997	91	5					593	603		10.1016/S0092-8674(00)80447-X	http://dx.doi.org/10.1016/S0092-8674(00)80447-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393853	Bronze			2022-12-24	WOS:A1997YH96000007
J	Furberg, CD; Psaty, BM				Furberg, CD; Psaty, BM			JNC VI: Timing is everything	LANCET			English	Editorial Material									UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Furberg, CD (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27109, USA.							Byington RP, 1997, LANCET, V350, P1075, DOI 10.1016/S0140-6736(05)70455-4; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; Garber AM, 1997, CIRCULATION, V95, P1642; Giatras I, 1997, ANN INTERN MED, V127, P337, DOI 10.7326/0003-4819-127-5-199709010-00001; *JOINT NAT COMM DE, IN PRESS ARCH INTERN; Kaplan NM, 1996, JAMA-J AM MED ASSOC, V275, P1577, DOI 10.1001/jama.275.20.1577; PEARCE KA, 1997, IN PRESS AM J HYPERT; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; TATTI P, 1997, CIRCULATION S, V96	10	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1413	1414		10.1016/S0140-6736(05)64202-X	http://dx.doi.org/10.1016/S0140-6736(05)64202-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371160				2022-12-24	WOS:A1997YF95300003
J	Scott, G; Goldberg, D; Weir, M; Cameron, S; Peutherer, J; Carrington, D; Follett, E; Leadbetter, G; Scoular, A				Scott, G; Goldberg, D; Weir, M; Cameron, S; Peutherer, J; Carrington, D; Follett, E; Leadbetter, G; Scoular, A			Prevalence of HIV-1 infection among heterosexual men and women attending genitourinary clinics in Scotland: unlinked anonymous testing	BRITISH MEDICAL JOURNAL			English	Article									RUCHILL HOSP,SCOTTISH CTR INFECT & ENVIRONM HLTH,GLASGOW G20 9NB,LANARK,SCOTLAND; ROYAL FREE HOSP,DEPT GENITOURINARY MED,LONDON NW3 2QG,ENGLAND; RUCHILL HOSP,REG VIRUS LAB,GLASGOW G20 9NB,LANARK,SCOTLAND; UNIV EDINBURGH,DEPT MICROBIOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT VIROL,LONDON SW17 0RE,ENGLAND; ROYAL INFIRM,DEPT GENITOURINARY MED,GLASGOW G4 0SF,LANARK,SCOTLAND; ROYAL INFIRM,DEPT GENITOURINARY MED,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Edinburgh; St Georges University London; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh								ARTENSTEIN AW, 1995, LANCET, V346, P1197, DOI 10.1016/S0140-6736(95)92900-2; Goldberg D, 1996, SCOT MED J, V41, P131, DOI 10.1177/003693309604100501; MacDonagh SE, 1996, BRIT MED J, V313, P532; *U COLL MIDDL SCH, 1993, DIS REP CDR REV, V3, pR1; *UK HLTH DEP, 1995, HIV AIDS HLTH PROM E	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 15	1997	315	7118					1281	1282		10.1136/bmj.315.7118.1281	http://dx.doi.org/10.1136/bmj.315.7118.1281			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390056	Green Published			2022-12-24	WOS:A1997YG64500023
J	Yarnold, J				Yarnold, J			Benefits of post-mastectomy radiotherapy	LANCET			English	Editorial Material							BREAST-CANCER; TRIALS				Yarnold, J (corresponding author), INST CANC RES,DEPT RADIOTHERAPY,SUTTON SM2 5PT,SURREY,ENGLAND.			Yarnold, John/0000-0002-9010-1854				AUQUIER A, 1992, EUR J CANCER, V28A, P433, DOI 10.1016/S0959-8049(05)80070-X; CUZICK J, 1987, CANCER TREAT REP, V71, P15; *EARL BREAST CANC, 1995, NEW ENGL J MED, V333, P1444; *EARL BREAST CANC, 1996, NEW ENGL J MED, V334, P1003; FISHER B, 1980, CANCER-AM CANCER SOC, V46, P1009, DOI 10.1002/1097-0142(19800815)46:4+<1009::AID-CNCR2820461326>3.0.CO;2-H; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; Ragaz J, 1997, NEW ENGL J MED, V337, P956, DOI 10.1056/NEJM199710023371402	7	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1415	1416		10.1016/S0140-6736(05)64204-3	http://dx.doi.org/10.1016/S0140-6736(05)64204-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371162				2022-12-24	WOS:A1997YF95300005
J	Haigney, E; Morgan, R; King, D; Spencer, B				Haigney, E; Morgan, R; King, D; Spencer, B			Breast examinations in older women: questionnaire survey of attitudes of patients and doctors	BRITISH MEDICAL JOURNAL			English	Article									WIRRAL HOSP,DEPT MED ELDERLY,WIRRAL L49 5PE,MERSEYSIDE,ENGLAND; ROYAL LIVERPOOL UNIV HOSP,LIVERPOOL L14 3LB,MERSEYSIDE,ENGLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool								ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; AMSTERDAM E, 1987, J SURG ONCOL, V180, P183; Ries LAB, 1989, NIH PUBLICATION; SHELDON T, 1996, EFFECTIVE HLTH CARE, V2, P1	4	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1058	1059		10.1136/bmj.315.7115.1058	http://dx.doi.org/10.1136/bmj.315.7115.1058			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366734	Green Published			2022-12-24	WOS:A1997YD44500024
J	DeRisi, JL; Iyer, VR; Brown, PO				DeRisi, JL; Iyer, VR; Brown, PO			Exploring the metabolic and genetic control of gene expression on a genomic scale	SCIENCE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATOR; MESSENGER-RNAS; ENCODING GENE; PROTEIN; COMPLEX; GLUCOSE; PATHWAY; CARBON; HYBRIDIZATION	DNA microarrays containing virtually every gene of Saccharomyces cerevisiae were used to carry out a comprehensive investigation of the temporal program of gene expression accompanying the metabolic shift from fermentation to respiration. The expression profiles observed for genes with known metabolic functions pointed to features of the metabolic reprogramming that occur during the diauxic shift, and the expression patterns of many previously uncharacterized genes provided clues to their possible functions. The same DNA microarrays were also used to identify genes whose expression was affected by deletion of the transcriptional co-repressor TUP1 or overexpression of the transcriptional activator YAP1. These results demonstrate the feasibility and utility of this approach to genomewide exploration of gene expression patterns.	STANFORD UNIV,HOWARD HUGHES MED INST,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University					NHGRI NIH HHS [HG00450, T32 HG00044] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R21HG000450, R01HG000450, T32HG000044] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; DeRisi J, 1996, NAT GENET, V14, P457; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FERNANDEZ M, 1994, MOL GEN GENET, V242, P727; Fondrat C, 1996, COMPUT APPL BIOSCI, V12, P363; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GUTIERREZ A, 1994, APPL ENVIRON MICROB, V60, P1783; HARTIG A, 1992, NUCLEIC ACIDS RES, V20, P5677, DOI 10.1093/nar/20.21.5677; HASELBECK RJ, 1993, J BIOL CHEM, V268, P12116; HERRERO P, 1995, YEAST, V11, P137, DOI 10.1002/yea.320110205; HIRATA D, 1994, MOL GEN GENET, V242, P250, DOI 10.1007/BF00280413; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, P193; KOWALSKI LR, 1995, MOLMICROBIOL, V115, P341; KRATZER S, 1995, GENE, V161, P75, DOI 10.1016/0378-1119(95)00289-I; LASHKARI D, IN PRESS P NATL ACAD; Lesage P, 1996, MOL CELL BIOL, V16, P1921, DOI 10.1128/mcb.16.5.1921; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MARTINEZ PM, 1996, EMBO J, V15, P2227; MOORE PA, 1991, MOL CELL BIOL, V11, P5330, DOI 10.1128/MCB.11.10.5330; MUHEIM A, 1991, EUR J BIOCHEM, V195, P369, DOI 10.1111/j.1432-1033.1991.tb15715.x; NEUMANSILBERBERG FS, 1995, MOL CELL BIOL, V15, P3187; OH D, 1990, MOL CELL BIOL, V10, P1415, DOI 10.1128/MCB.10.4.1415; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; Parrou JL, 1997, MICROBIOL-UK, V143, P1891, DOI 10.1099/00221287-143-6-1891; PLANTA RJ, 1988, TRENDS GENET, V4, P64, DOI 10.1016/0168-9525(88)90042-X; PRAEKELT UM, 1990, MOL GEN GENET, V223, P97, DOI 10.1007/BF00315801; ROSENKRANTZ M, 1994, MOL MICROBIOL, V13, P119, DOI 10.1111/j.1365-2958.1994.tb00407.x; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHOLER A, 1994, MOL CELL BIOL, V14, P3613, DOI 10.1128/MCB.14.6.3613; SCHOLER A, 1993, CURR GENET, V23, P375, DOI 10.1007/BF00312621; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VARELA JCS, 1995, MOL CELL BIOL, V15, P6232; VISWANATHAN M, 1994, GENE, V148, P149, DOI 10.1016/0378-1119(94)90249-6; VNDENBERG MA, 1996, J BIOL CHEM, V271, P28953; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; Wotton D, 1996, J BIOL CHEM, V271, P2717, DOI 10.1074/jbc.271.5.2717; Yin ZK, 1996, MOL MICROBIOL, V20, P751, DOI 10.1111/j.1365-2958.1996.tb02514.x	41	3448	3688	2	257	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					680	686		10.1126/science.278.5338.680	http://dx.doi.org/10.1126/science.278.5338.680			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381177				2022-12-24	WOS:A1997YC32300053
J	Ahmad, W; Haque, WFU; Brancolini, V; Tsou, HC; Haque, SU; Lam, H; Aita, VM; Owen, J; deBlaquiere, M; Frank, J; Cserhalmi-Friedman, PB; Leask, A; McGrath, JA; Peacocke, M; Ahmad, M; Ott, J; Christiano, AM				Ahmad, W; Haque, WFU; Brancolini, V; Tsou, HC; Haque, SU; Lam, H; Aita, VM; Owen, J; deBlaquiere, M; Frank, J; Cserhalmi-Friedman, PB; Leask, A; McGrath, JA; Peacocke, M; Ahmad, M; Ott, J; Christiano, AM			Alopecia universalis associated with a mutation in the human hairless gene	SCIENCE			English	Article							GROWTH CYCLE; NUDE LOCUS; MOUSE; EXPRESSION; MICE; MECHANISMS; FOLLICLE; PROTEIN; RAT	There are several forms of hereditary human hair loss, known collectively as alopecias, the molecular bases of which are entirely unknown. A kindred with a rare, recessively inherited type of alopecia universalis was used to search for a locus by homozygosity mapping, and linkage was established in a B-centimorgan interval on chromosome 8p12 (the logarithm of the odds favoring linkage score was 6.19). The human homolog of a murine gene, hairless, was localized in this interval by radiation hybrid mapping, and a missense mutation was found in affected individuals. Human hairless encodes a putative single zinc finger transcription factor protein with restricted expression in the brain and skin.	Columbia Univ, Dept Dermatol, New York, NY 10032 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Quaid I Azam Univ, Dept Biol Sci, Islamabad, Pakistan; Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA; Res Genet Inc, Huntsville, AL 35801 USA; Fibrogen Inc, San Francisco, CA 94080 USA; St Thomas Hosp, Inst Dermatol, London SE1 7EH, England	Columbia University; Columbia University; Quaid I Azam University; Rockefeller University; FibroGen; Guy's & St Thomas' NHS Foundation Trust	Christiano, AM (corresponding author), Columbia Univ, Dept Dermatol, 630 W 168 St,VC-15-526, New York, NY 10032 USA.	amc65@columbia.edu	McGrath, John/N-3529-2019; Ahmad, Wasim/GSD-8904-2022; Leask, Andrew/G-5217-2015; Leask, Andy/ABH-9433-2020; Ahmad, Wasim/E-9713-2015; McGrath, John/D-6824-2012	Brancolini, Valeria/0000-0003-0871-537X; McGrath, John/0000-0002-3708-9964	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR044535] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG-00008] Funding Source: Medline; NIAMS NIH HHS [P30AR44535] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BERGFELD WF, 1995, AM J MED, V98, pS95, DOI 10.1016/S0002-9343(99)80065-5; BROOKE HC, 1924, J HERED, V15, P173; CACHONGONZALEZ MB, 1994, P NATL ACAD SCI USA, V91, P7717, DOI 10.1073/pnas.91.16.7717; Engelkamp D, 1996, CURR OPIN GENET DEV, V6, P334, DOI 10.1016/S0959-437X(96)80011-6; GALLAGHER CH, 1984, J INVEST DERMATOL, V83, P169, DOI 10.1111/1523-1747.ep12263512; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HOOG C, 1991, MOL REPROD DEV, V30, P173, DOI 10.1002/mrd.1080300302; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; Latchman DS, 1996, NEW ENGL J MED, V334, P28, DOI 10.1056/NEJM199601043340108; MORRISSEY PJ, 1980, J IMMUNOL, V125, P1558; MULLER HK, 1980, BRIT J DERMATOL, V102, P609, DOI 10.1111/j.1365-2133.1980.tb07664.x; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; ROOK A, 1991, DIS HAIR SCALP, P136; Rosenquist TA, 1996, DEV DYNAM, V205, P379, DOI 10.1002/(SICI)1097-0177(199604)205:4<379::AID-AJA2>3.0.CO;2-F; Sambrook JFE, 1989, MOL CLONING LAB MANU; Schaffer AA, 1996, HUM HERED, V46, P226, DOI 10.1159/000154358; Schuddekopf K, 1996, P NATL ACAD SCI USA, V93, P9661, DOI 10.1073/pnas.93.18.9661; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; SEMENZA GL, 1994, HUM MUTAT, V3, P180, DOI 10.1002/humu.1380030304; SHEFFIELD VC, 1995, CURR OPIN GENET DEV, V5, P335, DOI 10.1016/0959-437X(95)80048-4; STOYE JP, 1988, CELL, V54, P383, DOI 10.1016/0092-8674(88)90201-2; Thompson CC, 1996, J NEUROSCI, V16, P7832; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	27	322	352	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	1998	279	5351					720	724		10.1126/science.279.5351.720	http://dx.doi.org/10.1126/science.279.5351.720			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445480				2022-12-24	WOS:000071731500041
J	Crameri, A; Raillard, SA; Bermudez, E; Stemmer, WPC				Crameri, A; Raillard, SA; Bermudez, E; Stemmer, WPC			DNA shuffling of a family of genes from diverse species accelerates directed evolution	NATURE			English	Article							BETA-LACTAMASE; MOLECULAR EVOLUTION; IN-VITRO; SEQUENCE; RECOMBINATION; PROTEIN; PLASMID	DNA shuffling is a powerful process for directed evolution, which generates diversity by recombination(1,2), combining useful mutations from individual genes. Libraries of chimaeric genes can be generated by random frag;mentation of a pool of related genes, followed by reassembly of the fragments in a self-priming polymerase reaction. Template switching causes crossovers in areas of sequence homology. Our previous studies used single genes and random point mutations as the source of diversity(3-6). An alternative source of diversity is naturally occurring homologous genes, which provide 'functional diversity.' To evaluate whether natural diversity could accelerate the evolution process, we compared the efficiency of obtaining moxalactamase activity from four cephalosporinase genes evolved separately with that from a mixed pool of the four genes. A single cycle of shuffling yielded eightfold improvements from the four separately evolved genes, versus a 270- to 540-fold improvement from the four genes shuffled together, a 50-fold increase per cycle of shuffling. The best clone contained eight segments from three of the four genes as well as 33 amino-acid point mutations, Molecular breeding by shuffling can efficiently mix sequences from different species, unlike traditional breeding techniques, The power of family shuffling may arise from sparse sampling of a larger portion of sequence space.	Maxygen Inc, Santa Clara, CA 95051 USA		Stemmer, WPC (corresponding author), Maxygen Inc, 3410 Cent Expressway, Santa Clara, CA 95051 USA.							Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Crameri A, 1997, NAT BIOTECHNOL, V15, P436, DOI 10.1038/nbt0597-436; Eigen M, 1992, STEPS LIFE PERSPECTI; GALLENI M, 1988, BIOCHEM J, V250, P753, DOI 10.1042/bj2500753; Kauffman S. A., 1993, ORIGINS ORDER; LEIZA MG, 1994, ANTIMICROB AGENTS CH, V38, P2150; LINDBERG F, 1986, EUR J BIOCHEM, V156, P441, DOI 10.1111/j.1432-1033.1986.tb09601.x; LOBKOVSKY E, 1993, P NATL ACAD SCI USA, V90, P11257, DOI 10.1073/pnas.90.23.11257; Moore JC, 1996, NAT BIOTECHNOL, V14, P458, DOI 10.1038/nbt0496-458; SEOANE A, 1992, ANTIMICROB AGENTS CH, V36, P1049, DOI 10.1128/AAC.36.5.1049; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4; STEMMER WPC, 1995, BIO-TECHNOL, V13, P549, DOI 10.1038/nbt0695-549; Zhang JH, 1997, P NATL ACAD SCI USA, V94, P4504, DOI 10.1073/pnas.94.9.4504; Zhao HM, 1997, NUCLEIC ACIDS RES, V25, P1307, DOI 10.1093/nar/25.6.1307	16	618	1129	6	133	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					288	291		10.1038/34663	http://dx.doi.org/10.1038/34663			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440693				2022-12-24	WOS:000071484400052
J	Crick, F; Koch, C				Crick, F; Koch, C			Constraints on cortical and thalamic projections: The no-strong-loops hypothesis	NATURE			English	Article							LATERAL GENICULATE NEURONS; PRIMARY VISUAL-CORTEX; INDETERMINATE ORGANIZATION; SQUIRREL-MONKEY; STRIATE CORTEX; CONNECTIONS; PULVINAR; SYSTEM; TERMINATIONS; NETWORKS	The many distinct cortical areas of the macaque monkey visual system can be arranged hierarchically, but not in a unique way, We suggest that the connections between these cortical areas never form strong, directed loops. For connections between the visual cortex and particular thalamic nuclei, we predict that certain types of connections will not be found, If strong, directed loops were to exist, we suggest that the cortex would go into uncontrolled oscillations.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; CALTECH, Computat & Neural Syst Program, Pasadena, CA 91125 USA	Salk Institute; California Institute of Technology	Crick, F (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Koch, Christof/0000-0001-6482-8067				BAKER FH, 1977, EXP BRAIN RES, V29, P433; BOURASSA J, 1995, NEUROSCIENCE, V66, P253, DOI 10.1016/0306-4522(95)00009-8; CALLWAY EM, IN PRESS ANN REV NEU; CRICK F, 1995, NATURE, V375, P121, DOI 10.1038/375121a0; DOUGLAS RJ, 1995, SCIENCE, V269, P891; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Guillery R W, 1971, Vision Res, VSuppl 3, P211; Guillery RW, 1995, J ANAT, V187, P583; Gutierrez C, 1995, J COMP NEUROL, V363, P545, DOI 10.1002/cne.903630404; HENDRY SHC, 1994, SCIENCE, V264, P575, DOI 10.1126/science.8160015; Hilgetag CC, 1996, SCIENCE, V271, P776, DOI 10.1126/science.271.5250.776; HIRSCH MW, 1989, NEURAL NETWORKS, V2, P331, DOI 10.1016/0893-6080(89)90018-X; Jones EG, 1985, THALAMUS; KALIL RE, 1970, J NEUROPHYSIOL, V33, P459, DOI 10.1152/jn.1970.33.3.459; KUAN CM, 1994, NEURAL COMPUT, V6, P420, DOI 10.1162/neco.1994.6.3.420; LEVITT JB, 1995, EXP BRAIN RES, V104, P419; Lisman JE, 1997, TRENDS NEUROSCI, V20, P38, DOI 10.1016/S0166-2236(96)10070-9; MATHERS LH, 1972, J COMP NEUROL, V146, P43, DOI 10.1002/cne.901460104; MATHERS LH, 1972, J COMP NEUROL, V146, P15, DOI 10.1002/cne.901460103; MIGNARD M, 1991, SCIENCE, V251, P1249, DOI 10.1126/science.1848727; OJIMA H, 1994, CEREB CORTEX, V4, P646, DOI 10.1093/cercor/4.6.646; PETERS A, 1994, CEREB CORTEX, V4, P215, DOI 10.1093/cercor/4.3.215; Robinson D. F., 1980, DIGRAPHS THEORY TECH; ROBINSON DL, IN PRESS THALAMUS, V2; ROCKLAND KS, 1994, NEUROREPORT, V5, P1865, DOI 10.1097/00001756-199410000-00006; Rockland KS, 1996, J COMP NEUROL, V368, P57, DOI 10.1002/(SICI)1096-9861(19960422)368:1<57::AID-CNE5>3.0.CO;2-J; ROCKLAND KS, 1979, BRAIN RES, V179, P3, DOI 10.1016/0006-8993(79)90485-2; ROCKLAND KS, IN PRESS J COMP NEUR; SALIN PA, 1995, PHYSIOL REV, V75, P107, DOI 10.1152/physrev.1995.75.1.107; SANDELL JH, 1982, J NEUROPHYSIOL, V48, P38, DOI 10.1152/jn.1982.48.1.38; Sherman SM, 1996, J NEUROPHYSIOL, V76, P1367, DOI 10.1152/jn.1996.76.3.1367; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; VanEssen DC, 1996, SCIENCE, V271, P777; WEBSTER MJ, 1994, CEREB CORTEX, V4, P470, DOI 10.1093/cercor/4.5.470	34	232	235	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					245	250		10.1038/34584	http://dx.doi.org/10.1038/34584			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440687				2022-12-24	WOS:000071484400039
J	Huang, HJ; Liao, J; Cohen, SN				Huang, HJ; Liao, J; Cohen, SN			Poly(A)- and poly(U)-specific RNA 3 ' tail shortening by E-coli ribonuclease E	NATURE			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; ANTISENSE RNAI; DEGRADATION; REPLICATION; PROTEINS; CLEAVES; BINDING; COMPLEX; ENZYME	Ribonuclease (RNase) E is an extensively studied enzyme from Escherichia coli whose site-specific endoribonuclease activity on single-stranded RNA has a central role in the processing of ribosomal RNA, the degradation of messenger RNA and the control of replication of ColE1-type plasmids (for recent reviews, see refs 1-3). Here we report a previously undetected activity of RNase E: the ability to shorten 3' poly(A)- and poly(U)-homopolymer tails on RNA molecules. This activity, which leaves a 6-nucleotide adenylate or a 1-nucleotide uridylate remnant on primary transcripts, resides in the amino-terminal region of RNase E and does not require other protein cofactors. Addition of a 3'-terminal phosphate group prevents both removal of the poly(A) tail and endonucleolytic cleavage within primary transcripts, but has no effect on the cleavage of transcripts with tails that have already been truncated. The ability of RNase E to shorten poly(A) tails, together with the effect of tail length on endonucleolytic cleavage within primary transcripts, suggests a mechanism by which RNase E may exercise overall control over RNA decay.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Cohen, SN (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.							Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; ClaverieMartin F, 1997, J BIOL CHEM, V272, P13823, DOI 10.1074/jbc.272.21.13823; Coburn GA, 1996, J BIOL CHEM, V271, P1048, DOI 10.1074/jbc.271.2.1048; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; Cohen SN, 1997, MOL MICROBIOL, V23, P1099, DOI 10.1111/j.1365-2958.1997.tb02593.x; EHRETSMANN CP, 1992, FASEB J, V6, P318; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; HELMERCITTERICH M, 1988, EMBO J, V7, P557, DOI 10.1002/j.1460-2075.1988.tb02845.x; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JACOBSON A, 1996, COLD SPRING HARBOR M, V30, P451; Kaberdin VR, 1996, J BIOL CHEM, V271, P13103, DOI 10.1074/jbc.271.22.13103; Kido M, 1996, J BACTERIOL, V178, P3917, DOI 10.1128/jb.178.13.3917-3925.1996; KLEE CB, 1968, J BIOL CHEM, V243, P923; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LITTAUER UZ, 1982, ENZYMES, V15, P517; McDowall KJ, 1996, J MOL BIOL, V255, P349, DOI 10.1006/jmbi.1996.0027; MELEFORS O, 1993, CONTROL MESSENGER RN, P53; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; NOSSAL NG, 1968, J BIOL CHEM, V243, P913; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; RAZZELL WE, 1959, J BIOL CHEM, V234, P2105; Sarkar N, 1996, MICROBIOL-UK, V142, P3125, DOI 10.1099/13500872-142-11-3125; SINGER MF, 1965, BIOCHEMISTRY-US, V4, P1319, DOI 10.1021/bi00883a016; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756	28	68	70	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					99	102		10.1038/34219	http://dx.doi.org/10.1038/34219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422514				2022-12-24	WOS:000071326100058
J	Simmonds, RE; Ireland, H; Lane, DA; Zoller, B; de Frutos, PG; Dahlback, B				Simmonds, RE; Ireland, H; Lane, DA; Zoller, B; de Frutos, PG; Dahlback, B			Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect	ANNALS OF INTERNAL MEDICINE			English	Article						protein S deficiency; thrombophlebitis; heterozygote; mutation; hereditary diseases	C4B-BINDING PROTEIN; C DEFICIENCY; PLASMA-LEVELS; FACTOR-X; THROMBOPHILIA; ORGANIZATION; COMPLEX; DISEASE; OUTPATIENTS; RESISTANCE	Background: Protein S is an important regulatory protein of the coagulation cascade. The risk for venous thrombosis associated with protein S deficiency has been uncertain because all previous risk estimates used phenotypic evaluation alone, which can be ambiguous. Objective: To quantitate the risk for thrombosis associated with a characterized protein S gene mutation that causes a Gly295-->Val substitution and protein S deficiency. Design: Retrospective study of a single extended family. Setting: University hospital referral center. Participants: A 122-member protein S-deficient family, in which 44 members had a recently characterized gene defect. Measurements: Comprehensive history of thrombosis, history of exposure to acquired risk factors for thrombosis, levels of total and free protein S antigen, and genotype for the mutation causing the Gly295-->Val substitution. Results: Kaplan-Meier analysis of thrombosis-free survival showed that the probability of remaining free of thrombosis at 30 years of age is 0.5 (95% CI, 0.33 to 0.66) for carriers of the Gly295-->Val mutation compared with 0.97 (CI, 0.93 to 1.0) for normal family members (P < 0.001). In a multivariate Cox regression model that included smoking and obesity, the mutation was a strong independent risk factor for thrombosis (hazard ratio, 11.5 [CI, 4.33 to 30.6]; P < 0.001). For free (but not total) protein S antigen levels, the distributions of persons with and persons without the mutation did not overlap. Conclusions: Protein S deficiency, as defined by the presence of a causative gene mutation or a reduced level of free protein S antigen; is a strong independent risk factor for venous thrombosis in a clinically affected family.	Charing Cross Hosp, Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Haematol, London W6 8RP, England; Univ Lund Hosp, Dept Internal Med, S-22185 Lund, Sweden; Lund Univ, Dept Clin Chem, S-20502 Malmo, Sweden	Imperial College London; Lund University; Skane University Hospital; Lund University	Simmonds, RE (corresponding author), Charing Cross Hosp, Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Haematol, St Dunstans Rd, London W6 8RP, England.		Ireland, Helen A/B-9868-2008; Zöller, Bengt/M-3217-2019; de Frutos, Pablo García/B-8594-2011; Zöller, Bengt/H-8856-2012; Simmonds, Rachel E/M-7122-2016	Ireland, Helen A/0000-0002-7980-548X; Zöller, Bengt/0000-0002-8250-5613; de Frutos, Pablo García/0000-0003-1547-1190; Zöller, Bengt/0000-0002-8250-5613; Simmonds, Rachel E/0000-0003-4843-8266; Lane, David/0000-0003-4283-3695; Dahlback, Bjorn/0000-0003-1546-0328				ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; BENTAL O, 1989, THROMB HAEMOSTASIS, V61, P50; COX DR, 1972, J R STAT SOC B, V34, P187; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1995, THROMB RES, V77, P1, DOI 10.1016/0049-3848(94)00138-4; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; EDENBRANDT CM, 1990, BIOCHEMISTRY-US, V29, P7861, DOI 10.1021/bi00486a012; ENGESSER L, 1987, ANN INTERN MED, V106, P677, DOI 10.7326/0003-4819-106-5-677; FAIONI EM, 1993, THROMB HAEMOSTASIS, V70, P1067; Gandrille S, 1997, THROMB HAEMOSTASIS, V77, P1201; GLADSON CL, 1988, THROMB HAEMOSTASIS, V59, P18; GRIFFIN JH, 1992, BLOOD, V79, P3203; HACKENG TM, 1994, J BIOL CHEM, V269, P21051; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HENKENS CMA, 1995, THROMB HAEMOSTASIS, V74, P1271; Hille ETM, 1997, BLOOD, V89, P1963, DOI 10.1182/blood.V89.6.1963; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOPPELMAN SJ, 1995, BLOOD, V86, P1062; KOSTER T, 1995, BLOOD, V85, P2756, DOI 10.1182/blood.V85.10.2756.bloodjournal85102756; MAHASANDANA C, 1990, LANCET, V335, P61, DOI 10.1016/0140-6736(90)90201-F; MALM J, 1992, THROMB HAEMOSTASIS, V68, P7; MALM J, 1988, BRIT J HAEMATOL, V68, P437, DOI 10.1111/j.1365-2141.1988.tb04232.x; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; PABINGER I, 1994, THROMB HAEMOSTASIS, V71, P441; ROSENDAAL FR, 1991, LANCET, V337, P260, DOI 10.1016/0140-6736(91)90867-O; Rosendaal FR, 1997, THROMB HAEMOSTASIS, V78, P1; SCHMIDEL DK, 1990, BIOCHEMISTRY-US, V29, P7845, DOI 10.1021/bi00486a010; SCHWARZ HP, 1984, BLOOD, V64, P1297; SCOTT BD, 1991, AM HEART J, V122, P76, DOI 10.1016/0002-8703(91)90761-6; Simmonds RE, 1996, BLOOD, V88, P4195; Simmonds RE, 1997, BLOOD, V89, P4364, DOI 10.1182/blood.V89.12.4364; TABERNERO MD, 1991, AM J HEMATOL, V36, P249, DOI 10.1002/ajh.2830360405; VANAMSTEL HKP, 1990, BIOCHEMISTRY-US, V29, P7853, DOI 10.1021/bi00486a011; VANBOVEN HH, 1994, BLOOD, V84, P4209, DOI 10.1182/blood.V84.12.4209.bloodjournal84124209; vanBoven HH, 1997, THROMB HAEMOSTASIS, V77, P452; ZOLLER B, 1993, THROMB HAEMOSTASIS, V69, P1256; ZOLLER B, 1995, BLOOD, V85, P3524, DOI 10.1182/blood.V85.12.3524.bloodjournal85123524; ZOLLER B, 1995, BLOOD, V85, P3518, DOI 10.1182/blood.V85.12.3518.bloodjournal85123518	38	76	77	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					8	+		10.7326/0003-4819-128-1-199801010-00002	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424998				2022-12-24	WOS:000071158000002
J	Hay, JA; Maldonado, L; Weingarten, SR; Ellrodt, AG				Hay, JA; Maldonado, L; Weingarten, SR; Ellrodt, AG			Prospective evaluation of a clinical guideline recommending hospital length of stay in upper gastrointestinal tract hemorrhage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED TRIAL; EARLY ENDOSCOPY; SCORING SYSTEM; PEPTIC-ULCERS; MORTALITY; SIGNS; POPULATION	Context.-Upper gastrointestinal tract hemorrhage (UGIH) is a common and potentially life-threatening disorder. Resource utilization can vary without adverse effect on patient outcome. Clinical practice guidelines are a potential solution to reduce variation in practice while improving patient outcomes. Objective.-To validate prospectively the safety, acceptability, and impact of a clinical practice guideline defining the medically appropriate length of stay (LOS) for patients hospitalized with UGIH. Design.-Prospective, controlled time-series study with an alternate-month design. Outcome surveyors and patients were blinded to study group allocation. Guideline.-A retrospectively validated scoring system using 4 independent variables: hemodynamics, time from bleeding, comorbidity, and esophagogastroduodenoscopy (EGD) findings to predict risk of adverse events. The quantitative risk for the low-risk subset was 0.6% (95% confidence interval [CI], 0.0%-2.0%) for subsequent complications and 0% (95% CI, 0.0%-0.9%) for life-threatening complications from this retrospective evaluation. Setting.-A 1000-bed, not-for-profit, university-affiliate teaching hospital. Patients.-Consecutive adult patients hospitalized for acute UGIH. Intervention.-Concurrent feedback of guideline recommendation (same-day hospital discharge) to physicians caring for patients at low risk for complication. No risk information was provided during control months. Results.-Seventy percent (209/299) of UGIH patients achieved low-risk status according to the guideline and were therefore potentially suitable for early discharge from the hospital. Providing real-time quantitative risk information (intervention group only) was associated with an increase in guideline compliance from 30% to 70% (P<.001) and a decrease in mean (SD) LOS from 4.6 (3.5) days to 2.9 (1.3) days (mean reduction of 1.7 days per patient; P<.001). No differences in complications, patient health status, or patient satisfaction were found when measured 1 month after discharge. An independent variable predicting decreased hospital LOS for low-risk UGIH patients was early EGD. Conclusions.-Implementation of the clinical practice guideline safely reduced hospital LOS for selected low-risk patients with acute UGIH. Further prospective validation in other settings is warranted.	Healthcare Partners Med Grp, Pasadena, CA 91105 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Med, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Hlth Serv Res, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Hay, JA (corresponding author), Healthcare Partners Med Grp, 55 E Calif Blvd, Pasadena, CA 91105 USA.							BORDLEY DR, 1985, JAMA-J AM MED ASSOC, V253, P3282, DOI 10.1001/jama.253.22.3282; BORNMAN PC, 1985, BRIT MED J, V291, P245, DOI 10.1136/bmj.291.6490.245; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CARSTENSEN HE, 1980, SCAND J GASTROENTERO, V15, P103, DOI 10.3109/00365528009181439; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; COOK DJ, 1992, GASTROENTEROLOGY, V102, P139, DOI 10.1016/0016-5085(92)91793-4; Cooper GS, 1996, GASTROENTEROLOGY, V111, P385, DOI 10.1053/gast.1996.v111.pm8690203; Dixon W.J, 1990, BMDP STAT SOFTWARE; EVERETT S, 1996, GUT               S1, V39, pA4; FLEISCHER D, 1983, GASTROENTEROLOGY, V84, P538; FLEISCHER DE, 1990, J CLIN GASTROENTE S2, V12, P41; GILBERT DA, 1990, GASTROINTEST ENDOSC, V36, P8; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; HALL WH, 1989, JAMA-J AM MED ASSOC, V262, P1369; Hay JA, 1996, AM J MED, V100, P313, DOI 10.1016/S0002-9343(97)89490-9; HAY JA, 1995, AM J GASTROENTEROL, V90, P1661; LAINE L, 1987, NEW ENGL J MED, V316, P1613, DOI 10.1056/NEJM198706253162601; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; MCMAHON LF, 1989, MED CARE, V27, P623, DOI 10.1097/00005650-198906000-00005; MORGAN AG, 1977, BRIT MED J, V2, P237, DOI 10.1136/bmj.2.6081.237; *NAT CTR HLTH STAT, 1991, VIT HLTH STAT, V13; *NIH CONS DEV PAN, 1990, GASTROINTEST ENDOS S, V36, P31; OSHITA Y, 1986, ENDOSCOPY, V18, P11, DOI 10.1055/s-2007-1018419; PANES J, 1987, LANCET, V2, P1292; PETERSON WL, 1981, NEW ENGL J MED, V304, P925, DOI 10.1056/NEJM198104163041601; PIMPL W, 1987, ENDOSCOPY, V19, P101, DOI 10.1055/s-2007-1013010; PROVENZALE D, 1987, AM J MED SCI, V294, P26, DOI 10.1097/00000441-198707000-00004; RICHTER JM, 1991, J CLIN GASTROENTEROL, V13, P268, DOI 10.1097/00004836-199106000-00005; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; ROCKALL TA, 1995, LANCET, V346, P346, DOI 10.1016/S0140-6736(95)92227-X; SAEED ZA, 1995, GASTROINTEST ENDOSC, V41, P561, DOI 10.1016/S0016-5107(95)70191-5; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706	34	136	137	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	1997	278	24					2151	2156		10.1001/jama.278.24.2151	http://dx.doi.org/10.1001/jama.278.24.2151			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM043	9417008				2022-12-24	WOS:000071022200030
J	Martin, LA; Vile, R; Lemoine, NR; Sikora, K; Pandha, HS				Martin, LA; Vile, R; Lemoine, NR; Sikora, K; Pandha, HS			Genetic prodrug activation therapy	LANCET			English	Editorial Material									Hammersmith Hosp, Imperial Coll Sch Med, Imperial Canc Res Fund, London W12 0NN, England	Cancer Research UK; Imperial College London	Martin, LA (corresponding author), Hammersmith Hosp, Imperial Coll Sch Med, Imperial Canc Res Fund, London W12 0NN, England.							Cosset FL, 1996, GENE THER, V3, P946; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; HARRIS JD, 1994, GENE THER, V1, P170; HUBER BE, 1991, P NATL ACAD SCI USA, V88, P8039, DOI 10.1073/pnas.88.18.8039; Martin LA, 1996, CANCER METAST REV, V15, P301, DOI 10.1007/BF00046344; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; Ring CJA, 1997, GENE THER, V4, P1045, DOI 10.1038/sj.gt.3300510; VILE RG, 1993, CANCER RES, V53, P3860	8	5	5	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1793	1794		10.1016/S0140-6736(05)63633-1	http://dx.doi.org/10.1016/S0140-6736(05)63633-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428248				2022-12-24	WOS:000071102500005
J	Ferrer, M; Alonso, J; Morera, J; Marrades, RM; Khalaf, A; Aguar, MC; Plaza, V; Prieto, L; Anto, JM				Ferrer, M; Alonso, J; Morera, J; Marrades, RM; Khalaf, A; Aguar, MC; Plaza, V; Prieto, L; Anto, JM		Quality Life Chronic Obstructive Pulm Dis Stud	Chronic obstructive pulmonary disease stage and health-related quality of life	ANNALS OF INTERNAL MEDICINE			English	Article							GEORGE RESPIRATORY QUESTIONNAIRE; SPANISH VERSION; OF-LIFE; MANAGEMENT; ADAPTATION; VALIDITY; OUTCOMES; PROFILE	Background: The American Thoracic Society recently recommended that chronic obstructive pulmonary disease be staged on the basis of the percentage of predicted FEV1. Objective: To examine 1) the relation between the American Thoracic Society system for staging chronic obstructive pulmonary disease and health-related quality of life and 2) the effect of self-reported comorbid conditions on health-related quality of life. Design: Cross-sectional study. Setting: Outpatient clinics of respiratory departments of four hospitals and one primary health care center in Spain. Patients: 321 consecutive male patients with chronic obstructive pulmonary disease. Measurements: Functional respiratory impairment, FEV1, respiratory symptoms, and health-related quality of life. Respiratory symptoms and health-related quality of life were measured by using the Spanish version of the St. George's Respiratory Questionnaire and the Nottingham Health Profile. Results: Patient scores on the St. George's Respiratory Questionnaire were moderately to strongly associated with disease staging (r = 0.27 to 0.51). Compared with reference values, values for health-related quality of life for patients with stage I disease were substantially higher on the St. George's Respiratory Questionnaire (6 and 34; P < 0.001) and values for impairment were significantly greater in stage I patients with comorbid conditions (19 and 36; P = 0.001). At least one concomitant chronic condition was found in 84% of study patients. Comorbid conditions only partly influenced the observed pattern of deterioration of health-related quality of life with worsening stages of disease. Conclusion: Staging criteria for chronic obstructive pulmonary disease based on percentage of predicted FEV1 separated groups of patients with varying degrees of impair ment in health-related quality of life. Contrary to expectations, even patients with mild disease showed substantially compromised health-related quality of life. Comorbid conditions influenced the relation between chronic obstructive pulmonary disease and health-related quality of life.	Hosp Badalona Germans Trias & Pujol, Dept Pneumol, E-08915 Badalona, Spain; Hosp Mar, Inst Municipal Invest Med, Hosp Clin & Prov, Barcelona, Spain; Hosp Vic, Barcelona, Spain; Hosp Magdalena, Dept Pneumol, E-12004 Castellon de La Plana, Spain	Hospital Germans Trias i Pujol; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; University of Barcelona; Hospital Clinic de Barcelona	Anto, JM (corresponding author), Hosp Mar, Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, Carrer Doctor Aiguader 80, E-08003 Barcelona, Spain.		MArrades, Ramón M/AFU-6757-2022; Ferrer, Montse/A-5510-2010; Alonso, Jordi/A-5514-2010; Anto, J M/H-2676-2014	Ferrer, Montse/0000-0001-9867-7391; Alonso, Jordi/0000-0001-8627-9636; Anto, J M/0000-0002-4736-8529; Plaza, Vicente/0000-0003-2567-5496				ALONSO J, 1995, MED CLIN-BARCELONA, V104, P771; ALONSO J, 1990, AM J PUBLIC HEALTH, V80, P704, DOI 10.2105/AJPH.80.6.704; ALONSO J, 1994, QUAL LIFE RES, V3, P385, DOI 10.1007/BF00435390; ALONSO J, 1992, MED CARE, V30, pMS125, DOI 10.1097/00005650-199205001-00011; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; ARINO EC, 1988, ANN MED BARCELONA, V74, P231; Brooks SM, 1982, ATS NEWS, V8, P12; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; CURTIS JR, 1994, THORAX, V49, P162, DOI 10.1136/thx.49.2.162; Domingo Salvany A, 1989, Gac Sanit, V3, P320; FEINSTEIN AR, 1970, J CHRON DIS, V23, P455, DOI 10.1016/0021-9681(70)90054-8; Ferrer M, 1996, EUR RESPIR J, V9, P1160, DOI 10.1183/09031936.96.09061160; *GRUP TRAB SEPAR P, 1985, NORM ESP FORZ; JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Ketelaars CAJ, 1996, THORAX, V51, P39, DOI 10.1136/thx.51.1.39; MAHLER DA, 1987, CLIN CHEST MED, V8, P215; MCSWEENY AJ, 1982, ARCH INTERN MED, V142, P473, DOI 10.1001/archinte.142.3.473; Okubadejo AA, 1996, THORAX, V51, P44, DOI 10.1136/thx.51.1.44; PRIGATANO GP, 1984, ARCH INTERN MED, V144, P1613, DOI 10.1001/archinte.144.8.1613; ROCA J, 1986, B EUR PHYSIOPATH RES, V22, P217; *SAS I, 1989, SAS STAT US GUID VER; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; Ware J.E., 1993, LINC RI QUAL METR IN	26	288	298	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1072	1079		10.7326/0003-4819-127-12-199712150-00003	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412309				2022-12-24	WOS:000070936600003
J	Burn, J; Dennis, M; Bamford, J; Sandercock, P; Wade, D; Warlow, C				Burn, J; Dennis, M; Bamford, J; Sandercock, P; Wade, D; Warlow, C			Epileptic seizures after a first stroke: the Oxfordshire community stroke project	BRITISH MEDICAL JOURNAL			English	Article							ACUTE CEREBROVASCULAR-DISEASE; CEREBRAL INFARCTION; INTRACEREBRAL HEMORRHAGE; POPULATION; CLASSIFICATION; DEMOGRAPHY; FREQUENCY; ONSET	Objective: To describe the immediate and long term risk of epileptic seizures after a first ever stroke. Design: Cohort study following up stroke survivors for 2 to 6.5 years; comparison with age specific incidence rates of epileptic seizures in the general population. Setting: Community based stroke register. Subjects: 675 patients with a first stroke, followed up for a minimum of 2 years. Main outcome measures: Occurrence of single and recurrent seizures. Results: 52 patients had one or more post stroke seizures; in 25 the seizures were recurrent The 5 year actuarial risk of a post stroke seizure in survivors (excluding 19 patients with a history of epilepsy and 3 patients in whom the seizure occurred shortly before death from another cause) was 11.5% (95% confidence interval 4.8% to 18.2%). The relative risk of seizures, in comparison with the general population, was estimated at 35.2 in the first year after stroke and 19.0 in year 2. The risk of seizures was increased in survivors of subarachnoid and intracerebral haemorrhage (hazard ratio for intracranial haemorrhage v cerebral infarction 10.2 (3.7 to 27.9)), The risk of seizures after ischaemic stroke was substantial only in patients presenting with severe strokes due to total anterior circulation infarction. Only 9 of 295 patients (3%) independent one month after stroke suffered a seizure between 1 month and 5 years (actuarial risk 4.2% (0.1% to 8.3%)). Conclusion: Stroke patients hare about an 11.5% risk of single or recurrent seizures in the first 5 years after a stroke, Patients with more severe strokes or haemorrhagic strokes are at higher risk.	Southampton Gen Hosp, Rehabil Res Unit, Southampton SO9 4XY, Hants, England; Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland; St James Univ Hosp, Dept Neurol, Leeds LS9 7TF, W Yorkshire, England; Rivermead Rehabil Ctr, Oxford OX1 4XD, England	University of Southampton; University of Edinburgh; Saint James's University Hospital	Burn, J (corresponding author), Southampton Gen Hosp, Rehabil Res Unit, Southampton SO9 4XY, Hants, England.		sandercock, peter/GQI-3167-2022; Bamford, John/ABE-6218-2021; Ritter, Stefanie L/D-9312-2012	sandercock, peter/0000-0001-8484-0135; Wade, Derick/0000-0002-1188-8442				ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Aring CD, 1935, ARCH INTERN MED, V56, P435, DOI 10.1001/archinte.1935.00170010023002; AVRAHAMI E, 1988, J NEUROL, V235, P472, DOI 10.1007/BF00314250; BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BAMFORD JM, 1988, STROKE, V19, P1074, DOI 10.1161/01.STR.19.9.1074; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; BAQUIS GD, 1985, STROKE, V16, P444, DOI 10.1161/01.STR.16.3.444; BAROLIN GS, 1971, FORTSCHR NEUROL P I, V39, P199; DAVALOS A, 1988, J NEUROL NEUROSUR PS, V51, P1464, DOI 10.1136/jnnp.51.11.1464; DECAROLIS P, 1984, J NEUROL NEUROSUR PS, V47, P1345, DOI 10.1136/jnnp.47.12.1345; DODGE PR, 1954, BRAIN, V77, P610, DOI 10.1093/brain/77.4.610; EVANS JH, 1963, NEUROLOGY, V13, P207, DOI 10.1212/WNL.13.3.207; FAUGHT E, 1984, EPILEPSIA, V25, P666; FRENCH JD, 1956, ARCH NEURO PSYCHIATR, V75, P260, DOI 10.1001/archneurpsyc.1956.02330210040005; Gardner M. J., 1989, STAT CONFIDENCE; GOODRIDGE DMG, 1983, BMJ-BRIT MED J, V287, P641, DOI 10.1136/bmj.287.6393.641; GUPTA SR, 1988, STROKE, V19, P1477, DOI 10.1161/01.STR.19.12.1477; HALL G C, 1988, Pharmaceutical Medicine (London), V2, P345; HAUSER WA, 1984, EPILEPSIA, V25, P666; Jennet B, 1975, EPILEPSY NONMISSILE; KASE CS, 1989, STROKE, V20, P850, DOI 10.1161/01.STR.20.7.850; KILPATRICK CJ, 1990, ARCH NEUROL-CHICAGO, V47, P157, DOI 10.1001/archneur.1990.00530020053014; MOSKOWITZ E, 1972, ARCH PHYS MED REHAB, V53, P167; OLSEN TS, 1987, NEUROLOGY, V37, P1209, DOI 10.1212/WNL.37.7.1209; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; REITH J, 1996, EUR J N EUROL S2, V3, P93; ROBERTS MA, 1982, AGE AGEING, V11, P24, DOI 10.1093/ageing/11.1.24; ROBERTS RC, 1988, EPILEPSIA, V29, P190, DOI 10.1111/j.1528-1157.1988.tb04418.x; ROPPER AH, 1988, NEUROLOGY, V38, P1500, DOI 10.1212/WNL.38.9.1500-a; SHINTON RA, 1988, J NEUROL NEUROSUR PS, V51, P273, DOI 10.1136/jnnp.51.2.273; SHINTON RA, 1987, LANCET, V1, P11; So EL, 1996, NEUROLOGY, V46, P350, DOI 10.1212/WNL.46.2.350; STARKEY IR, 1987, LANCET, V1, P742; SUNG CY, 1989, J NEUROL NEUROSUR PS, V52, P1273, DOI 10.1136/jnnp.52.11.1273; TALLIS R, 1991, AGE AGEING, V20, P442, DOI 10.1093/ageing/20.6.442; VIITANEN M, 1988, EUR NEUROL, V28, P227, DOI 10.1159/000116272	39	274	286	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 13	1997	315	7122					1582	1587		10.1136/bmj.315.7122.1582	http://dx.doi.org/10.1136/bmj.315.7122.1582			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437276	Green Published			2022-12-24	WOS:000071021900023
J	Ordway, JM; TallaksenGreene, S; Gutekunst, CA; Bernstein, EM; Cearley, JA; Wiener, HW; Dure, LS; Lindsey, R; Hersch, SM; Jope, RS; Albin, RL; Detloff, PJ				Ordway, JM; TallaksenGreene, S; Gutekunst, CA; Bernstein, EM; Cearley, JA; Wiener, HW; Dure, LS; Lindsey, R; Hersch, SM; Jope, RS; Albin, RL; Detloff, PJ			Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse	CELL			English	Article							LESCH-NYHAN SYNDROME; HUNTINGTONS-DISEASE; IN-VITRO; MODEL; POLYGLUTAMINE; DEFICIENCY; PATHOGENESIS; EXPANSION; CELLS; MICE	The mutations responsible for several human neurodegenerative disorders are expansions of translated CAG repeats beyond a normal size range. To address the role of repeat context, we have introduced a 146-unit CAG repeat into the mouse hypoxanthine phosphoribosyltransferase gene (Hprt). Mutant mice express a form of the HPRT protein that contains a long polyglutamine repeat. These mice develop a phenotype similar to the human translated CAG repeat disorders. Repeat containing mice show a late onset neurological phenotype that progresses to premature death. Neuronal intranuclear inclusions are present in affected mice. Our results show that CAG repeats do not need to be located within one of the classic repeat disorder genes to have a neurotoxic effect.	UNIV ALABAMA,DEPT BIOCHEM & MOL GENET,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PSYCHIAT & BEHAV NEUROBIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT ORAL BIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PEDIAT NEUROL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT COMPARAT MED,BIRMINGHAM,AL 35294; UNIV MICHIGAN,DEPT NEUROL,ANN ARBOR,MI 48104; EMORY UNIV,DEPT NEUROL,ATLANTA,GA 30329	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Michigan System; University of Michigan; Emory University			Longo, Kenneth A/A-5631-2010; Dure, Leon/B-3243-2008		NIA NIH HHS [AG06569, AG08671] Funding Source: Medline; NINDS NIH HHS [NS34492] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG006569] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHA JHJ, 1994, LIFE SCI, V54, P1459, DOI 10.1016/0024-3205(94)90012-4; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DUNNETT SB, 1989, BRAIN RES, V501, P401, DOI 10.1016/0006-8993(89)90659-8; FINGER S, 1988, J NEUROL SCI, V86, P203, DOI 10.1016/0022-510X(88)90099-8; Gusella JF, 1996, COLD SPRING HARB SYM, V61, P615; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; JINNAH HA, 1993, J NEUROCHEM, V60, P2036, DOI 10.1111/j.1471-4159.1993.tb03488.x; JINNAH HA, 1994, J NEUROSCI, V14, P1164; JINNAH HA, 1991, BEHAV NEUROSCI, V105, P1004, DOI 10.1037/0735-7044.105.6.1004; KAZEMIESFARJANI P, 1995, HUM MOL GENET, V4, P523, DOI 10.1093/hmg/4.4.523; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nasir J, 1996, HUM MOL GENET, V5, P1431, DOI 10.1093/hmg/5.Supplement_1.1431; Ordway JM, 1996, BIOTECHNIQUES, V21, P609; Orr HT, 1996, COLD SPRING HARB SYM, V61, P649; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; QUARREL O, 1991, HUNTINGTONS DISEASE, P37; REDDY RS, 1997, CURR OPIN CELL BIOL, V9, P364; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Ruppert SML, 1996, HYBRIDOMA, V15, P55, DOI 10.1089/hyb.1996.15.55; Saudou F, 1996, COLD SPRING HARB SYM, V61, P639; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SKINNER PJ, 1997, ATAXIN 1 EXPANDED GL; STRITTMATTER WJ, 1997, COLD SPRING HARB SYM, V61, P597; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WILLIAMSON DJ, 1992, J INHERIT METAB DIS, V15, P665, DOI 10.1007/BF01799622; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62; Zoghbi HY, 1996, NAT GENET, V14, P237, DOI 10.1038/ng1196-237	33	301	305	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					753	763		10.1016/S0092-8674(00)80464-X	http://dx.doi.org/10.1016/S0092-8674(00)80464-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413985	Bronze			2022-12-24	WOS:A1997YL43900007
J	Vaughan, CW; Ingram, SL; Connor, MA; Christie, MJ				Vaughan, CW; Ingram, SL; Connor, MA; Christie, MJ			How opioids inhibit GABA-mediated neurotransmission	NATURE			English	Article							ARACHIDONIC-ACID METABOLITES; HIPPOCAMPUS IN-VITRO; LIPOXYGENASE METABOLITES; PRESYNAPTIC INHIBITION; PROTEIN-KINASE; RAT; CELLS; CHANNELS; NOCICEPTION; ACTIVATION	The midbrain region periaqueductal grey (FAG) is rich in opioid receptors and endogenous opioids and is a major target of analgesic action in the central nervous system(1). It has been proposed that the analgesic effect of opioids on the FAG works by suppressing the inhibitory influence of the neurotransmitter GABA (gamma-aminobutyric acid) on neurons that form part of a descending antinociceptive pathway(2). Opioids inhibit GABA-mediated (GABAergic) synaptic transmission in the FAG and other brain regions by reducing the probability of presynaptic neurotransmitter release(3,4), but the mechanisms involved remain uncertain. Here we report that opioid inhibition of GABAergic synaptic currents in the FAG is controlled by a presynaptic voltage-dependent potassium conductance, Opioid receptors of the mu type in GABAergic presynaptic terminals are specifically coupled to this potassium conductance by a pathway involving phospholipase A(2), arachidonic acid and 12-lipoxygenase. Furthermore, opioid inhibition of GABAergic synaptic transmission is potentiated by inhibitors of the enzymes cyclooxygenase and 5-lipoxygenase, presumably because more arachidonic acid is available for conversion to IZ-lipoxygenase products, These mechanisms account for the analgesic action of cyclooxygenase inhibitors in the PAG(5) and their synergism with opioids(6).			Vaughan, CW (corresponding author), UNIV SYDNEY,DEPT PHARMACOL,SYDNEY,NSW 2006,AUSTRALIA.		Christie, MacDonald J/F-4724-2013; Connor, Mark/A-4197-2008	Christie, MacDonald J/0000-0002-0622-609X; Connor, Mark/0000-0003-2538-2001; Vaughan, Christopher/0000-0003-4314-7689				BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BLACKWELL GJ, 1983, BRIT MED BULL, V39, P260, DOI 10.1093/oxfordjournals.bmb.a071830; CAPOGNA M, 1995, J NEUROSCI, V15, P1249; CAPOGNA M, 1993, J PHYSIOL-LONDON, V470, P539, DOI 10.1113/jphysiol.1993.sp019874; Duerson K, 1996, NEUROPHARMACOLOGY, V35, P949, DOI 10.1016/0028-3908(96)00131-1; EVANS JF, 1991, MOL PHARMACOL, V40, P22; Fukuda K, 1996, J NEUROCHEM, V67, P1309; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; KURACHI Y, 1989, PFLUG ARCH EUR J PHY, V414, P102, DOI 10.1007/BF00585635; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; MAVES TJ, 1994, ANESTHESIOLOGY, V80, P1094, DOI 10.1097/00000542-199405000-00018; NORTH RA, 1993, OPIOIDS, V1, P773; PIOMELLI D, 1990, TRENDS PHARMACOL SCI, V11, P367, DOI 10.1016/0165-6147(90)90182-8; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; SCHWEITZER P, 1990, NATURE, V346, P464, DOI 10.1038/346464a0; SHAPIRO MS, 1994, J NEUROSCI, V14, P7109; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; Simmons ML, 1996, MOL PHARMACOL, V50, P80; TORTORICI V, 1995, EUR J NEUROSCI, V7, P1857, DOI 10.1111/j.1460-9568.1995.tb00706.x; Vaughan CW, 1997, J PHYSIOL-LONDON, V498, P463, DOI 10.1113/jphysiol.1997.sp021872; Vaughan CW, 1997, J NEUROSCI, V17, P996; WIMPEY TL, 1991, NEURON, V6, P281, DOI 10.1016/0896-6273(91)90363-5	22	400	415	1	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					611	614		10.1038/37610	http://dx.doi.org/10.1038/37610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403690				2022-12-24	WOS:A1997YK85300050
J	Golombek, MP; Cook, RA; Economou, T; Folkner, WM; Haldemann, AFC; Kallemeyn, PH; Knudsen, JM; Manning, RM; Moore, HJ; Parker, TJ; Rieder, R; Schofield, JT; Smith, PH; Vaughan, RM				Golombek, MP; Cook, RA; Economou, T; Folkner, WM; Haldemann, AFC; Kallemeyn, PH; Knudsen, JM; Manning, RM; Moore, HJ; Parker, TJ; Rieder, R; Schofield, JT; Smith, PH; Vaughan, RM			Overview of the Mars Pathfinder Mission and assessment of landing site predictions	SCIENCE			English	Article							THERMAL INERTIA; PHYSICAL-PROPERTIES; ALBEDO	Chemical analyses returned by Mars Pathfinder indicate that some rocks may be high in silica, implying differentiated parent materials. Rounded pebbles and cobbles and a possible conglomerate suggest fluvial processes that imply liquid water in equilibrium with the atmosphere and thus a warmer and wetter past. The moment of inertia indicates a central metallic core of 1300 to 2000 kilometers in radius. Composite airborne dust particles appear magnetized by freeze-dried maghemite stain or cement that may have been leached from crustal materials by an active hydrologic cycle. Remote-sensing data at a scale of generally greater than similar to 1 kilometer and an Earth analog correctly predicted a rocky plain safe for landing and roving with a variety of rocks deposited by catastrophic floods that are relatively dust-free.	UNIV CHICAGO, ENRICO FERMI INST, CHICAGO, IL 60637 USA; UNIV COPENHAGEN, NIELS BOHR INST, DK-1168 COPENHAGEN, DENMARK; US GEOL SURVEY, ASTROGEOL TEAM, MENLO PK, CA 94025 USA; MAX PLANCK INST CHEM, D-55128 MAINZ, GERMANY; UNIV ARIZONA, LUNAR & PLANETARY LAB, TUCSON, AZ 85721 USA	University of Chicago; University of Copenhagen; Niels Bohr Institute; United States Department of the Interior; United States Geological Survey; Max Planck Society; University of Arizona	Golombek, MP (corresponding author), CALTECH, JET PROP LAB, 4800 OAK GROVE DR, PASADENA, CA 91109 USA.		Haldemann, Albert F C/I-9224-2012	Haldemann, Albert F C/0000-0003-3741-8841				Baker V.R., 1992, CHANNELS VALLEY NETW, P493; BAKER VR, 1972, 144 GEOL SOC AM, P73; Christensen, 1992, MARS, P686; CHRISTENSEN PR, 1986, ICARUS, V68, P217, DOI 10.1016/0019-1035(86)90020-5; CHRISTENSEN PR, 1982, J GEOPHYS RES, V87, P9985, DOI 10.1029/JB087iB12p09985; CHRISTENSEN PR, 1986, J GEOPHYS RES-SOLID, V91, P3533, DOI 10.1029/JB091iB03p03533; Edgett KS, 1997, J GEOPHYS RES-PLANET, V102, P4107, DOI 10.1029/96JE02825; Farmer C. B., 1977, Journal of Geophysical Research, V82, P4225, DOI 10.1029/JS082i028p04225; FOLKNER WM, 1997, SCIENCE, V278, P1748; Golombek M, 1997, J GEOPHYS RES-PLANET, V102, P4117, DOI 10.1029/96JE03319; Golombek MP, 1997, J GEOPHYS RES-PLANET, V102, P3967, DOI 10.1029/96JE03318; Golombek MP, 1997, J GEOPHYS RES-PLANET, V102, P3953, DOI 10.1029/96JE02805; GOLOMBEK MP, 1995, MARS PATHFINDER LA 1, V2, P63; GOLOMBEK MP, 1994, MARS PATHFINDER LA 2, P47; GUINNESS EA, 1987, J GEOPHYS RES E S, V575; HABERLE RM, 1991, ICARUS, V90, P187, DOI 10.1016/0019-1035(91)90100-8; Haldeman AFC, 1997, J GEOPHYS RES-PLANET, V102, P4097, DOI 10.1029/96JE03321; Harmon JK, 1997, J GEOPHYS RES-PLANET, V102, P4081, DOI 10.1029/96JE01953; HAYASHI JN, 1995, J GEOPHYS RES-PLANET, V100, P5277, DOI 10.1029/94JE02449; HOWINGTONKRAUS E, 1995, MARS PATHF LAND SI 2, V2, P38; HVIID SF, 1997, SCIENCE, V278, P1767; Kieffer H. H., 1977, Journal of Geophysical Research, V82, P4249, DOI 10.1029/JS082i028p04249; Komatsu G, 1997, J GEOPHYS RES-PLANET, V102, P4151, DOI 10.1029/96JE02564; KONOPLIV AS, 1995, JPL PUBL, P73; Longhi J., 1992, MARS, V1, P184, DOI [10.2307/j.ctt207g59v.10, DOI 10.2307/J.CTT207G59V.10]; MCSWEEN HY, 1985, REV GEOPHYS, V23, P391, DOI 10.1029/RG023i004p00391; Mitchell JK., 1972, P 3 LUNAR SCI C, P3235; OLHOEFT GR, 1975, EARTH PLANET SC LETT, V24, P394, DOI 10.1016/0012-821X(75)90146-6; PALLUCONI FD, 1981, ICARUS, V45, P415, DOI 10.1016/0019-1035(81)90044-0; PLESKOT LK, 1981, ICARUS, V45, P179, DOI 10.1016/0019-1035(81)90013-0; Pollack J. B., 1977, Journal of Geophysical Research, V82, P4479, DOI 10.1029/JS082i028p04479; POLLACK JB, 1979, J GEOPHYS RES, V84, P2929, DOI 10.1029/JB084iB06p02929; Rice JW, 1997, J GEOPHYS RES-PLANET, V102, P4185, DOI 10.1029/96JE02824; RIEDER R, 1997, SCIENCE, V278, P1770; *ROV TEAM, 1997, SCIENCE, V278, P1764; Schofield JT, 1997, SCIENCE, V278, P1752, DOI 10.1126/science.278.5344.1752; SMITH PH, 1997, SCIENCE, V278, P1757; SPENCER DA, 1995, 95379 AM ASTR SOC AM; THOMPSON TW, 1989, P LUN PLAN SCI C, V19, P409; Yoder CF, 1997, J GEOPHYS RES-PLANET, V102, P4065, DOI 10.1029/96JE03642; Zurek R.W., 1992, MARS, P835; [No title captured]	42	187	194	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1743	1748		10.1126/science.278.5344.1743	http://dx.doi.org/10.1126/science.278.5344.1743			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388167				2022-12-24	WOS:A1997YJ90100033
J	Schofield, JT; Barnes, JR; Crisp, D; Haberle, RM; Larsen, S; Magalhaes, JA; Murphy, JR; Seiff, A; Wilson, G				Schofield, JT; Barnes, JR; Crisp, D; Haberle, RM; Larsen, S; Magalhaes, JA; Murphy, JR; Seiff, A; Wilson, G			The Mars Pathfinder atmospheric structure investigation meteorology (ASI/MET) experiment	SCIENCE			English	Article							MARTIAN ATMOSPHERE; BOUNDARY-LAYER; THERMAL TIDES; DUST STORMS; DEVILS; MODEL	The Mars Pathfinder atmospheric structure investigation/meteorology (ASI/MET) experiment measured the vertical density, pressure, and temperature structure of the martian atmosphere from the surface to 160 km, and monitored surface meteorology and climate for 83 sols (1 sol = 1 martian day = 24.7 hours). The atmospheric structure and the weather record are similar to those observed by the Viking 1 lander (VL-1) at the same latitude, altitude, and season 21 years ago, but there are differences related to diurnal effects and the surface properties of the landing site. These include a cold nighttime upper atmosphere; atmospheric temperatures that are 10 to 12 degrees kelvin warmer near the surface; light slope-controlled winds; and dust devils, identified by their pressure, wind, and temperature signatures. The results are consistent with the warm, moderately dusty atmosphere seen by VL-1.	OREGON STATE UNIV,COLL OCEAN & ATMOSPHER SCI,CORVALLIS,OR 97331; NASA,AMES RES CTR,MOFFETT FIELD,CA 94035; RISO NATL LAB,DK-4000 ROSKILDE,DENMARK; SAN JOSE STATE UNIV FDN,SAN JOSE,CA; ARIZONA STATE UNIV,TEMPE,AZ	Oregon State University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Technical University of Denmark; California State University System; San Jose State University; Arizona State University; Arizona State University-Tempe	Schofield, JT (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.		Crisp, David/F-6642-2017	Crisp, David/0000-0002-4573-9998				CLANCY R, UNPUB; Clancy RT, 1996, ICARUS, V122, P36, DOI 10.1006/icar.1996.0108; Folkner W. M., COMMUNICATION; Folkner WM, 1997, SCIENCE, V278, P1749, DOI 10.1126/science.278.5344.1749; GIERASCH P, 1968, PLANET SPACE SCI, V16, P615, DOI 10.1016/0032-0633(68)90102-5; Golombek MP, 1997, SCIENCE, V278, P1743, DOI 10.1126/science.278.5344.1743; HABERLE RM, 1993, J ATMOS SCI, V50, P1544, DOI 10.1175/1520-0469(1993)050<1544:ABLMFM>2.0.CO;2; Haberle RM, 1997, J GEOPHYS RES-PLANET, V102, P13301, DOI 10.1029/97JE01334; Hess S. L., 1977, Journal of Geophysical Research, V82, P4559, DOI 10.1029/JS082i028p04559; JAKOSKY BM, IN PRESS ICARUS; JAMES PB, 1992, MARS, P934; LOPEZPUERTAS M, 1995, ICARUS, V114, P113, DOI 10.1006/icar.1995.1047; MAGALHAES JA, 1995, ICARUS, V113, P277, DOI 10.1006/icar.1995.1024; MURPHY JR, 1990, J GEOPHYS RES-SOLID, V95, P14555, DOI 10.1029/JB095iB09p14555; Nier A. O., 1977, Journal of Geophysical Research, V82, P4341, DOI 10.1126/science.194.4271.1298; Rivell T, 1997, J SPACECRAFT ROCKETS, V34, P265, DOI 10.2514/2.3211; RYAN JA, 1983, J GEOPHYS RES-OCEANS, V88, P1005, DOI 10.1029/JC088iC15p11005; Seiff A, 1997, J GEOPHYS RES-PLANET, V102, P4045, DOI 10.1029/96JE03320; Seiff A., 1977, Journal of Geophysical Research, V82, P4364, DOI 10.1029/JS082i028p04364; SHARMAN RD, 1980, J ATMOS SCI, V37, P1994, DOI 10.1175/1520-0469(1980)037<1994:MAPPFV>2.0.CO;2; Smith PH, 1997, SCIENCE, V278, P1758, DOI 10.1126/science.278.5344.1758; THOMAS P, 1985, SCIENCE, V230, P175, DOI 10.1126/science.230.4722.175; TILLMAN JE, 1994, J ATMOS SCI, V51, P1709, DOI 10.1175/1520-0469(1994)051<1709:TBLOMF>2.0.CO;2; TILLMAN JE, 1988, J GEOPHYS RES-ATMOS, V93, P9433, DOI 10.1029/JD093iD08p09433; TILLMAN JE, 1993, J GEOPHYS RES-PLANET, V98, P10963, DOI 10.1029/93JE01084; Wilson RJ, 1996, J ATMOS SCI, V53, P1290, DOI 10.1175/1520-0469(1996)053<1290:CMSOTT>2.0.CO;2; WOLFF MJ, IN PRESS B AM ASTRON; Zurek R.W., 1992, MARS, P835; ZUREK RW, 1981, SCIENCE, V213, P437, DOI 10.1126/science.213.4506.437	29	340	343	2	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1752	1758		10.1126/science.278.5344.1752	http://dx.doi.org/10.1126/science.278.5344.1752			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388169				2022-12-24	WOS:A1997YJ90100035
J	Frey, M				Frey, M			Risks and prevention of Dupuytren's contracture	LANCET			English	Editorial Material											Frey, M (corresponding author), UNIV VIENNA,SCH MED,DEPT SURG,PLAST & RECONSTRUCT SURG SECT,WAEHRINGER GUERTEL 18,A-1090 VIENNA,AUSTRIA.							Burge P, 1997, J BONE JOINT SURG BR, V79B, P206, DOI 10.1302/0301-620X.79B2.6990; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; Sinha A, 1997, J BONE JOINT SURG BR, V79B, P211, DOI 10.1302/0301-620X.79B2.6670	3	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1568	1568		10.1016/S0140-6736(05)64010-X	http://dx.doi.org/10.1016/S0140-6736(05)64010-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393334				2022-12-24	WOS:A1997YH98600006
J	Duan, D; Winter, C; Cowley, S; Hume, JR; Horowitz, B				Duan, D; Winter, C; Cowley, S; Hume, JR; Horowitz, B			Molecular identification of a volume-regulated chloride channel	NATURE			English	Article							RESISTANCE P-GLYCOPROTEIN; CL CURRENTS; PROTEIN; CELLS; EXPRESSION; MYOCYTES; ELECTROPHYSIOLOGY; CLONING	A volume-regulated chloride current (I-Cl.vol) is ubiquitously present in mammalian cells, and is required for the regulation of electrical activity cell volume, intracellular pH, immunological responses, cell proliferation and differentiation. However, the molecule responsible for I-Cl.vol has yet to be determined(1-3). Although three putative chloride channel proteins expressed from cloned genes (P-glycoprotein(4), pI(Cln), (ref. 5) and ClC-2 (ref. 6)) have been proposed to be the molecular equivalent of I-Cl.vol, neither P-glycoprotein nor pI(Cln), is thought to be a chloride channel or part thereof(7,8), and the properties of expressed ClC-2 channels differ from native I-Cl.vol (refs. 3, 6). Here we report that functional expression in NIH/3T3 cells of a cardiac clone of another member of the CIC family, ClC-3, results in a large basally active chloride conductance, which is strongly modulated by cell volume and exhibits many properties identical to those of I-Cl.vol in native cells(1-3,9-13). A mutation of asparagine to lysine at position 579 at the end of the transmembrane domains of ClC-3 abolishes the outward rectification and changes the anion selectivity from I- > Cl- to Cl- > I- but leaves swelling activation intact. Because ClC-3 is a channel protein belonging to a large gene family of chloride channels(3,14), these results indicate that ClC-3 encodes I-Cl.vol in many native mammalian cells.	UNIV NEVADA,SCH MED,DEPT CELL BIOL & PHYSIOL,RENO,NV 89557	Nevada System of Higher Education (NSHE); University of Nevada Reno								BORSANI G, 1995, GENOMICS, V27, P131, DOI 10.1006/geno.1995.1015; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUAN D, 1995, CIRC RES, V77, P379, DOI 10.1161/01.RES.77.2.379; Duan D, 1997, CIRC RES, V80, P103, DOI 10.1161/01.RES.80.1.103; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P266; FORENZ C, 1996, P NATL ACAD SCI USA, V93, P13362; GRIMDER S, 1992, NATURE, V360, P759; GSCHWENTNER M, 1995, PFLUG ARCH EUR J PHY, V430, P464, DOI 10.1007/BF00373882; HAMILL OP, 1981, PFLUGERS ARCH, V422, P143; HARDY SP, 1995, EMBO J, V14, P68, DOI 10.1002/j.1460-2075.1995.tb06976.x; Jentsch TJ, 1996, CURR OPIN NEUROBIOL, V6, P303, DOI 10.1016/S0959-4388(96)80112-7; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KAWASAKI M, 1995, NEURON, V14, P1285, DOI 10.1016/0896-6273(95)90275-9; KAWASAKI M, 1994, NEURON, V12, P597, DOI 10.1016/0896-6273(94)90215-1; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; LUCKIE DB, 1994, AM J PHYSIOL, V267, pC650, DOI 10.1152/ajpcell.1994.267.2.C650; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; Meyer K, 1996, J GEN PHYSIOL, V108, P177, DOI 10.1085/jgp.108.3.177; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; Nilius B, 1996, GEN PHARMACOL-VASC S, V27, P1131, DOI 10.1016/S0306-3623(96)00061-4; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; Shuba LM, 1996, J PHYSIOL-LONDON, V491, P69, DOI 10.1113/jphysiol.1996.sp021197; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANDENBERG JI, 1994, J GEN PHYSIOL, V104, P997, DOI 10.1085/jgp.104.6.997; Vogalis F, 1996, AM J PHYSIOL-GASTR L, V271, pG629, DOI 10.1152/ajpgi.1996.271.4.G629	30	401	444	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					417	421		10.1038/37151	http://dx.doi.org/10.1038/37151			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389484				2022-12-24	WOS:A1997YH54900068
J	Ellrodt, G; Cook, DJ; Lee, J; Cho, M; Hunt, D; Weingarten, S				Ellrodt, G; Cook, DJ; Lee, J; Cho, M; Hunt, D; Weingarten, S			Evidence-based disease management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-PRACTICE GUIDELINES; DEPENDENT DIABETES-MELLITUS; MEDICAL LITERATURE; USERS GUIDES; INTERVENTIONAL TRIAL; COST-EFFECTIVENESS; CRITICAL PATHWAYS; PRIMARY-CARE; RECOMMENDATIONS; DECISION	Disease management is an approach to patient care that emphasizes coordinated, comprehensive care along the continuum of disease and across health care delivery systems, Evidence-based medicine is an approach to practice and teaching that integrates pathophysiological rationale, caregiver experience, and patient preferences with valid and current clinical research evidence, Using diabetes mellitus as an example, we describe the importance of evidence-based medicine to the development of disease management programs, We present a method for developing and implementing evidence-based clinical guidelines, clinical pathways, and algorithms and describe the creation of systems to measure and report processes and outcomes that could drive quality improvement in diabetes care, Multidisciplinary teams are ideally suited to develop, lead, and implement evidence-based disease management programs, since they play an essential role in the preventive, diagnostic, and therapeutic decisions for patients with diabetes throughout the course of their disease.	UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, SCH MED, DIV GEN INTERNAL MED, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, SCH MED, HLTH SERV RES FELLOWSHIP PROGRAM, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, SCH MED, DEPT MED, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, SCH MED, DEPT PHARM, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR,SCH MED,HLTH SERV RES, DEPT MED, LOS ANGELES, CA 90048 USA; MCMASTER UNIV, FAC HLTH SCI, DEPT MED, DIV GEN INTERNAL MED, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, FAC HLTH SCI, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON L8N 3Z5, CANADA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; McMaster University; McMaster University								ALBERTI KGMM, 1994, DIABETIC MED, V11, P899, DOI 10.1111/j.1464-5491.1994.tb00376.x; Aucott JN, 1996, J GEN INTERN MED, V11, P139, DOI 10.1007/BF02600265; BARONDESS JA, 1993, ANN INTERN MED, V119, P153, DOI 10.7326/0003-4819-119-2-199307150-00010; BLANK LL, 1992, ANN INTERN MED, V117, P778; BROWMAN GP, 1995, J CLIN ONCOL, V13, P502, DOI 10.1200/JCO.1995.13.2.502; CLARK CM, 1995, NEW ENGL J MED, V332, P1210, DOI 10.1056/NEJM199505043321807; COOK DJ, 1995, CHEST, V108, pS227, DOI 10.1378/chest.108.4_Supplement.227S; COOK DJ, 1995, CAN MED ASSOC J, V153, P755; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; DEIGNAN M, 1995, PATIENT FOCUSED CARE; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; ECKMAN MH, 1995, JAMA-J AM MED ASSOC, V273, P712, DOI 10.1001/jama.273.9.712; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P287, DOI 10.1001/jama.263.2.287; ELLRODT AG, 1995, ANN INTERN MED, V122, P277, DOI 10.7326/0003-4819-122-4-199502150-00007; ELLRODT AG, 1995, PATIENT FOCUSED CARE; Epstein RS, 1996, ANN INTERN MED, V124, P832, DOI 10.7326/0003-4819-124-9-199605010-00008; Fang E, 1996, ARCH FAM MED, V5, P528, DOI 10.1001/archfami.5.9.528; FELD MJ, 1990, CLIN PRACTICE GUIDEL; FITZGERALD JF, 1994, ARCH INTERN MED, V154, P1721, DOI 10.1001/archinte.154.15.1721; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; Grimshaw J, 1995, Qual Health Care, V4, P55, DOI 10.1136/qshc.4.1.55; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GUYAT GH, 1993, JAMA-J AM MED ASSOC, V270, P2096, DOI 10.1001/jama.270.17.2096; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; Harris JM, 1996, ANN INTERN MED, V124, P838, DOI 10.7326/0003-4819-124-9-199605010-00009; HAYNES RB, 1994, J AM MED INFORM ASSN, V1, P447, DOI 10.1136/jamia.1994.95153434; Hayward RSA, 1996, J GEN INTERN MED, V11, P176, DOI 10.1007/BF02600272; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; Hiss RG, 1996, ANN INTERN MED, V124, P180, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00021; Javitt JC, 1996, ANN INTERN MED, V124, P164, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00017; KASISKE BL, 1993, ANN INTERN MED, V118, P129, DOI 10.7326/0003-4819-118-2-199301150-00009; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; LARSEN RA, 1989, INFECT CONT HOSP EP, V10, P316, DOI 10.2307/30146474; LavizzoMourey R, 1996, ANN INTERN MED, V124, P919, DOI 10.7326/0003-4819-124-10-199605150-00010; Lee TH, 1996, J GEN INTERN MED, V11, P174, DOI 10.1007/BF02600271; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LUMSDON K, 1995, HOSP HEALTH NETWORK, V69, P34; MEYER LC, 1993, CASE MANAGER, V4, P54; Mulrow CD, 1996, J GEN INTERN MED, V11, P185, DOI 10.1007/BF02600275; NANNIPIERI M, 1995, DIABETES CARE, V18, P1, DOI 10.2337/diacare.18.1.1; NATHAN DM, 1993, NEW ENGL J MED, V328, P1676, DOI 10.1056/NEJM199306103282306; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; NOBLE J, 1994, J GEN INTERN MED, V9, pS31, DOI 10.1007/BF02598116; OBrien BJ, 1997, JAMA-J AM MED ASSOC, V277, P1802; OXMAN AD, 1994, CAN MED ASSOC J, V150, P1417; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; OXMAN AD, 1994, CAN MED ASSOC J, V150, P1971; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; OXMAN AD, 1994, CAN MED ASSOC J, V150, P1249; OXMAN AD, 1994, CAN MED ASSOC J, V150, P1793; OXMAN AD, 1994, CAN MED ASSOC J, V150, P1575; PEARSON SD, 1995, ANN INTERN MED, V123, P941, DOI 10.7326/0003-4819-123-12-199512150-00008; PETERS AL, 1991, ANN INTERN MED, V115, P45, DOI 10.7326/0003-4819-115-1-45; Quickel KE, 1996, ANN INTERN MED, V124, P160, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00016; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Sackett D. L., 1995, EVIDENCE BASED MED, V1, P5; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; SCHOENBAUM SC, 1995, AGENCY HLTH CARE POL; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIEGEL JE, 1992, J AM SOC NEPHROL, V3, pS111; SINGER DE, 1992, ANN INTERN MED, V116, P683; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; TAN MH, 1992, CAN MED ASSOC J, V147, P697; The Boston Consulting Group, 1995, PROM DIS MAN; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; TINKER LF, 1994, J AM DIET ASSOC, V94, P507, DOI 10.1016/0002-8223(94)90212-7; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; WEINGARTEN SR, IN PRESS AM REV RESP; WILCZYNSKI NL, 1994, P ANN S COMP APPL ME, V17, P601; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630; Yandell B, 1995, Qual Manag Health Care, V3, P55	74	273	276	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	1997	278	20					1687	1692		10.1001/jama.278.20.1687	http://dx.doi.org/10.1001/jama.278.20.1687			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG859	9388089				2022-12-24	WOS:A1997YG85900031
J	Klenerman, P; Hengartner, H; Zinkernagel, RM				Klenerman, P; Hengartner, H; Zinkernagel, RM			A non-retroviral RNA virus persists in DNA form	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; T-CELL MEMORY; IMMUNOLOGICAL MEMORY; INFECTION; SEQUENCE; ANTIGEN; ESCAPE; ASSAY	Infection of adult mice with lymphocytic choriomeningitis virus (LCMV), a non-cytopathic segmented RNA virus, leads initially to generalized infection, followed by clearance and subsequent lifelong immunity. Indirect evidence has suggested that viral antigens may persist in lymphoid tissues during the phase of immunological memory, but viral genomic RNA has not been detected in previous studies(1,2). During a search for persistent virus in the spleen, we identified LCMV-specific sequences present as DNA by polymerase chain reaction (PCR) in mice over 200 days after infection. In vivo and in vitro studies revealed that reverse transcription of viral RNA into complementary DNA occurred after acute infection of cells of its natural hosts, mouse and hamster, but not of other species and could be inhibited in vitro by azidothymidine (AZT), indicating that this was mediated by endogenous reverse transcriptase activity. These findings reveal a surprising and new pathway of interaction between exogenous RNA viruses and endogenous retroviral, and perhaps other host components, that results in the persistence of virally determined DNA. We speculate that the latter may function in vivo as a form of DNA vaccine.	UNIV ZURICH HOSP,INST EXPT IMMUNOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital				klenerman, paul/0000-0003-4307-9161				Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; Coffin J, 1993, REVERSE TRANSCRIPTAS, P445; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; KAGI D, 1994, NATURE, V369, P91; Kundig TM, 1996, P NATL ACAD SCI USA, V93, P9716, DOI 10.1073/pnas.93.18.9716; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LEHMANNG.F, 1967, NATURE, V213, P770, DOI 10.1038/213770a0; LEHMANNGRUBE F, 1971, VIROL MONOGR, V10, P28; Loewer Roswitha, 1996, Proceedings of the National Academy of Sciences of the United States of America, V93, P5177; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; OLDSTONE MB, 1971, SCIENCE, V174, P843, DOI 10.1126/science.174.4011.843; OLDSTONE MBA, 1982, NATURE, V300, P360, DOI 10.1038/300360a0; Oxenius A, 1995, EUR J IMMUNOL, V25, P3402, DOI 10.1002/eji.1830251230; PEASE LR, 1980, NATURE, V286, P398, DOI 10.1038/286398a0; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; Planz O, 1997, P NATL ACAD SCI USA, V94, P6874, DOI 10.1073/pnas.94.13.6874; Planz O, 1996, NATURE, V382, P726, DOI 10.1038/382726a0; PYRA H, 1994, P NATL ACAD SCI USA, V91, P1544, DOI 10.1073/pnas.91.4.1544; RAWLS WE, 1976, J GEN VIROL, V33, P421, DOI 10.1099/0022-1317-33-3-421; ROMANOWSKI V, 1985, VIRUS RES, V3, P101, DOI 10.1016/0168-1702(85)90001-2; Salvato MS, 1993, ARENAVIRIDAE, P133; SILVER J, 1993, NUCLEIC ACIDS RES, V21, P3593, DOI 10.1093/nar/21.15.3593; SKYULEV Y, 1996, IMMUNITY, V4, P565; SLIFKA MK, 1995, J VIROL, V69, P1895, DOI 10.1128/JVI.69.3.1895-1902.1995; SMITH MS, 1987, J VIROL, V61, P3769, DOI 10.1128/JVI.61.12.3769-3773.1987; WIENER AM, 1986, ANNU REV BIOCHEM, V55, P631; YOKOYAMA M, 1995, J VIROL, V69, P2684, DOI 10.1128/JVI.69.4.2684-2688.1995; ZHDANOV VM, 1975, NATURE, V256, P471, DOI 10.1038/256471a0; Zinkernagel RM, 1996, ANNU REV IMMUNOL, V14, P333, DOI 10.1146/annurev.immunol.14.1.333	30	142	145	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					298	301		10.1038/36876	http://dx.doi.org/10.1038/36876			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384383				2022-12-24	WOS:A1997YG66700066
J	RayCoquard, I; Philip, T; Lehmann, M; Fervers, B; Farsi, F; Chauvin, F				RayCoquard, I; Philip, T; Lehmann, M; Fervers, B; Farsi, F; Chauvin, F			Impact of a clinical guidelines program for breast and colon cancer in a French cancer center	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLORECTAL-CARCINOMA; RADIATION-THERAPY; RANDOMIZED TRIAL; ADJUVANT THERAPY; FOLLOW-UP; FLUOROURACIL; CHEMOTHERAPY; WOMEN; METASTASES; MEDICINE	Context.-Between 1993 and 1994, the 80 physicians in the French comprehensive cancer center, Leon Berard, developed and implemented a Clinical Practice Guidelines (CPGs) project based on an analysis of the literature and a consensus of intrainstitutional experts. Objective.-The aims of this project are to assist community-based oncologists in their decision making and to minimize inappropriate variation in practices. A study was designed to assess the impact of CPGs on management of breast and colon cancer. Design.-A ''before-after'' study, using institutional computerized records of patients with breast or colon cancer. Setting.-Records for 100 women with localized breast cancer were randomly selected from those available in 1993 and 1995, and those for all patients newly referred with colon cancer in 1993 and 1995 (77 and 81 patients, respectively). Medical decisions on these records were analyzed to assess their compliance with the CPGs. (A systematic search of the literature was performed to determine the scientific evidence for noncompliant decisions.) Results.-Of 375 available medical decisions, 350 were assessable. The compliance rate with CPGs for breast cancer was significantly higher in 1995 compared with 1993, 54% (54/99; 95% confidence interval [CI]; 44%-64%) vs 19% (18/95; 95% CI, 11%-27%) (P<.001), The compliance rate for colon cancer was also significantly higher in 1995 than in 1993, 70% (62/88; 95% CI, 60%-80%) vs 50% (34/68; 95% CI, 38%-62%) (P=.009), In 1993, 42% (40/95; 95% CI, 32%-52%) of medical decisions for breast cancer and in 1995, 68% (67/99; 95% CI, 59%-77%) conformed with the CPGs or were judged to be based on ''scientific evidence.'' In 1993, 71% (48/68; 95% CI, 60%-81%) of medical decisions for colon cancer, and in 1995 81% (71/88; 95% CI, 73%-89%) conformed with the CPGs or were judged to be based on scientific evidence. Conclusions.-Compliance rates were significantly higher in 1995 for both cancers. The development and implementation of CPGs for cancer management seem to result in significant changes in medical practice, although a causal relationship between changes and CPGs is not demonstrated in this study.	FEDERAT NATL CTR LUTTE CONTRE CANC, PARIS, FRANCE		RayCoquard, I (corresponding author), CTR LEON BERARD, 28 RUE LAENNEC, F-69008 LYON, FRANCE.		Fervers, Béatrice/AAD-1847-2022	Fervers, Béatrice/0000-0003-3498-6499				A Donabedian, 1982, CRITERIA STANDARDS Q, VII; ALLEE PE, 1989, INT J RADIAT ONCOL, V17, P1171, DOI 10.1016/0360-3016(89)90522-1; ASLER VB, 1954, ANN SURG, V139, P846; BEKRADA M, 1994, B CANC, V6, P562; BROWMAN GP, 1995, J CLIN ONCOL, V13, P502, DOI 10.1200/JCO.1995.13.2.502; BUDD GT, 1987, J CLIN ONCOL, V5, P272, DOI 10.1200/JCO.1987.5.2.272; CALLE R, 1980, B CANCER, V67, P313; COBURN MC, 1994, J AM COLL SURGEONS, V179, P65; Coombes RC, 1996, J CLIN ONCOL, V14, P35, DOI 10.1200/JCO.1996.14.1.35; *EARL BREAST CANC, 1992, LANCET, V339, P1; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2239, DOI 10.1001/jama.263.16.2239; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P1446, DOI 10.1001/jama.265.11.1446; FARROW DC, 1992, NEW ENGL J MED, V326, P1097, DOI 10.1056/NEJM199204233261701; *FED NAT CTR LUTT, 1995, STAND OPT REC PRIS C, P110; Field MJ, 1990, CLIN PRACTICE GUIDEL, P38; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GRILLI R, 1994, MED CARE, V32, P202, DOI 10.1097/00005650-199403000-00002; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HAYWARD RSA, 1993, CAN MED ASSOC J, V148, P507; HUGUES K, 1991, P AN M AM SOC CLIN, V10, P145; HURTELOUP P, 1988, J CLIN ONCOL, V6, P679; JAGER W, 1991, J TUMOR MARKER ONCOL, V6, P56; JAKESZ R, 1994, CHIRURG, V65, P497; LAGIOS MD, 1982, CANCER-AM CANCER SOC, V50, P1309, DOI 10.1002/1097-0142(19821001)50:7<1309::AID-CNCR2820500716>3.0.CO;2-#; LIVRAGHI T, 1991, RADIOLOGY, V179, P709, DOI 10.1148/radiology.179.3.2027979; MARGOLESE RG, 1989, ARCH SURG-CHICAGO, V124, P548; MARGOLIS CZ, 1983, JAMA-J AM MED ASSOC, V249, P627, DOI 10.1001/jama.249.5.627; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; ROUGIER P, 1992, J CLIN ONCOL, V10, P1112, DOI 10.1200/JCO.1992.10.7.1112; ROUGIER P, 1992, P AM SOC CLIN ONCOL, V111, P63; RUTQVIST LE, 1993, RADIOTHER ONCOL, V26, P104, DOI 10.1016/0167-8140(93)90090-U; SACKETT DL, 1989, CHEST, V95, pS2, DOI 10.1378/chest.95.2.2S; SCHAAKEKONING C, 1985, INT J RADIAT ONCOL, V11, P1759, DOI 10.1016/0360-3016(85)90028-8; SCHEITHAUER W, 1993, BRIT MED J, V306, P752, DOI 10.1136/bmj.306.6880.752; SCHOLL SM, 1994, EUR J CANCER, V30A, P645, DOI 10.1016/0959-8049(94)90537-1; SHERMAN DM, 1978, CANCER, V41, P2013, DOI 10.1002/1097-0142(197805)41:5<2013::AID-CNCR2820410549>3.0.CO;2-T; SUNSHINE JA, 1985, AM J SURG, V150, P44, DOI 10.1016/0002-9610(85)90008-X; *UN INT CONTR CANC, 1988, UICC TNM CLASS TUM M, P99; VERONESI U, 1993, NEW ENGL J MED, V328, P1587, DOI 10.1056/NEJM199306033282202; WAZER DE, 1994, CANCER, V74, P878, DOI 10.1002/1097-0142(19940801)74:3<878::AID-CNCR2820740314>3.0.CO;2-4; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946; WOOLF SH, 1993, ARCH INTERN MED, V153, P2646, DOI 10.1001/archinte.153.23.2646; ZANIBONI A, 1993, P AN M AM SOC CLIN, V12, P191	45	91	91	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	1997	278	19					1591	1595		10.1001/jama.278.19.1591	http://dx.doi.org/10.1001/jama.278.19.1591			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF407	9370505				2022-12-24	WOS:A1997YF40700040
J	Marcellin, P; Boyer, N; Gervais, A; Martinot, M; Pouteau, M; Castelnau, C; Kilani, A; Areias, J; Auperin, A; Benhamou, JP; Degott, C; Erlinger, S				Marcellin, P; Boyer, N; Gervais, A; Martinot, M; Pouteau, M; Castelnau, C; Kilani, A; Areias, J; Auperin, A; Benhamou, JP; Degott, C; Erlinger, S			Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy	ANNALS OF INTERNAL MEDICINE			English	Article						RNA, viral; hepatitis C-like viruses; hepatitis C; interferon-alpha; aminotransferases	NON-B-HEPATITIS; CHRONIC NON-A; CHRONIC ACTIVE HEPATITIS; CONTROLLED TRIAL; FOLLOW-UP; VIRUS-RNA; ALFA-2B; CIRRHOSIS; PLACEBO; SYSTEM	Background: Less than 20% of patients with chronic hepatitis C have a sustained response to interferon-alpha therapy. The long-term benefit of interferon-alpha with regard to hepatic viral clearance and histologic improvement remains unknown. Objective: To determine the long-term biochemical, virologic, and histologic outcomes in patients with chronic hepatitis C who have a sustained response to interferon-alpha therapy. Design: Prospective cohort study. Setting: University hospital. Patients: 80 patients who had chronic hepatitis C, had a sustained biochemical and virologic response to interferon-alpha therapy, and were followed for at least 12 months. Measurements: Serum hepatitis C virus (HCV) RNA detected by polymerase chain reaction (PCR); HCV genotyping determined by line probe assay; liver histologic studies; liver HCV RNA detected by PCR on frozen liver tissue samples (in 27 patients); and repeated measurements of serum alanine aminotransferase (ALT) levels. Liver biopsy was done before treatment in all 80 patients, and at least one biopsy was done in 69 patients 1 to 6 years after treatment. Results: The 80 patients had follow-up 1 to 7.6 years (mean +/- SD, 4.0 +/- 2.0 years) after interferon-alpha treatment. The follow-up period was 1, 2, 3, 4, 5, 6, and more than 6 years in 11, 13, 14, 18, 10, 12, and 2 patients, respectively, after the end of therapy. During the entire follow-up period, 93% (95% CI, 84% to 97%) of patients had persistently normal serum ALT levels. Serum HCV RNA remained undetectable in 96% (CI, 89% to 99%) of patients, A comparison of liver histologic findings before and 1 to 6.2 years after interferon-alpha treatment showed a clear improvement in 94% (CI, 83% to 99%) of patients, In 62% of patients, the last biopsy done showed normal or nearly normal histologic findings. Liver HCV RNA was detectable before treatment in all 13 patients tested and was undetectable 1 to 5 years after treatment in all 27 patients tested. Conclusions: In patients with chronic hepatitis C who have persistently normal serum ALT levels and no detectable serum HCV RNA 6 months after interferon-alpha therapy, a long-term sustained biochemical and virologic response is generally seen. This response is associated with an absence of detectable intrahepatic HCV RNA and marked histologic improvement.	HOP BEAUJON, UNITE RECH PHYSIOPATHOL HEPAT, INSERM U24, F-92118 CLICHY, FRANCE; HOP BEAUJON, SERV ANAT & CYTOL PATHOL, F-92118 CLICHY, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Marcellin, P (corresponding author), HOP BEAUJON, SERV HEPATOL, 100 BLVD GEN LECLERC, F-92118 CLICHY, FRANCE.		Yang, Chen/G-1379-2010					Bacon B. R., 1995, Hepatology, V22, p152A; Benhamou J. P., 1995, Hepatology, V22, p151A; BHATTACHERJEE V, 1995, J GEN VIROL, V76, P1737, DOI 10.1099/0022-1317-76-7-1737; CAUSSE X, 1991, GASTROENTEROLOGY, V101, P497, DOI 10.1016/0016-5085(91)90030-O; Chemello L, 1996, ANN INTERN MED, V124, P1058, DOI 10.7326/0003-4819-124-12-199606150-00005; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DIMARTINO V, 1995, HEPATOLOGY, V22, P1216; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; MARCELLIN P, 1995, GASTROENTEROLOGY, V109, P156, DOI 10.1016/0016-5085(95)90281-3; MARCELLIN P, 1991, HEPATOLOGY, V13, P393, DOI 10.1002/hep.1840130302; MARCELLIN P, 1994, LIVER, V14, P302; MARCELLIN P, 1994, HEPATOLOGY, V20, pA154; MARTINOTPEIGNOUX M, 1992, J INFECT DIS, V165, P595, DOI 10.1093/infdis/165.3.595; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; REICHARD O, 1995, HEPATOLOGY, V21, P918, DOI 10.1016/0270-9139(95)90234-1; SARACCO G, 1993, HEPATOLOGY, V18, P1300, DOI 10.1002/hep.1840180603; SHINDO M, 1995, ANN INTERN MED, V122, P586, DOI 10.7326/0003-4819-122-8-199504150-00005; SHINDO M, 1992, HEPATOLOGY, V15, P1013, DOI 10.1002/hep.1840150607; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; Urdea M S, 1991, Nucleic Acids Symp Ser, P197; YOUNG KKY, 1993, J CLIN MICROBIOL, V31, P882, DOI 10.1128/JCM.31.4.882-886.1993	28	480	490	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					875	+		10.7326/0003-4819-127-10-199711150-00003	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382365				2022-12-24	WOS:A1997YF54500003
J	Xu, XP; Rijcken, B; Schouten, JP; Weiss, ST				Xu, XP; Rijcken, B; Schouten, JP; Weiss, ST			Airways responsiveness and development and remission of chronic respiratory symptoms in adults	LANCET			English	Article							RANDOM-POPULATION SAMPLE; BRONCHIAL RESPONSIVENESS; PULMONARY-FUNCTION; ASTHMA; INFLAMMATION; EPIDEMIOLOGY; EOSINOPHILS; HISTAMINE; COMMUNITY; SMOKING	Background Many patients with chronic obstructive lung disease show increased airways responsiveness to histamine. We investigated the hypothesis that increased airways responsiveness predicts the development and remission of chronic respiratory symptoms. Methods We used data from 24-year follow-up (1965-90) of 2684 participants in a cohort study in Vlagtwedde and Vlaardingen, Netherlands. Increased airways responsiveness was defined as a PC10 value (concentration of histamine for which challenge led to a 10% fall in forced expiratory volume in 1 s) of less than 8 mg/mL. Information on respiratory symptoms was collected by means of a standard questionnaire every 3 years. Logistic regression was used to control for age, area of residence, cigarette smoking status, and sex. Findings Participants with increased airways responsiveness (1281 observations) were more likely than those without increased airways responsiveness (5801 observations) to develop the following symptoms during any 3-year follow-up interval: chronic cough (odds ratio 1.9 [95% CI 1.2-2.9]), chronic phlegm (2.0 [1.3-3.0]), dyspnoea (2.3 [1.5-3.5]), asthmatic attacks (3.7 [2.2-6.1]), and persistent wheeze (2.7 [1.7-4.4]). The estimate of the odds ratio for the development of any of the six symptoms was 1.7 (1.2-2.3). Participants with increased airways responsiveness were less likely than those without this characteristic to show remission of these respiratory symptoms. The estimate of the odds ratio for the remission of any of the six symptoms was 0.42 (0.28-0.61). Interpretation These prospective analyses show that increased airways responsiveness is positively associated with the development of chronic. respiratory symptoms and negatively associated with the remission of these symptoms in adults.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH, BOSTON, MA 02115 USA; UNIV GRONINGEN, UNIV HOSP GRONINGEN, DEPT EPIDEMIOL, GRONINGEN, NETHERLANDS	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; University of Groningen					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL049460] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49460] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BURNEY PGJ, 1987, THORAX, V42, P38, DOI 10.1136/thx.42.1.38; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; FREW AJ, 1992, AM REV RESPIR DIS, V146, P878, DOI 10.1164/ajrccm/146.4.878; HELSING KJ, 1979, AM REV RESPIR DIS, V120, P1221; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; LEFKOPOULOU M, 1989, J AM STAT ASSOC, V84, P810, DOI 10.2307/2289671; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; ORIE NGM, 1961, BRONCHITIS INT S, P44; PHAM QT, 1984, BRIT J IND MED, V41, P267; RIJCKEN B, 1988, AM REV RESPIR DIS, V137, P826, DOI 10.1164/ajrccm/137.4.826; RIJCKEN B, 1987, AM REV RESPIR DIS, V136, P62, DOI 10.1164/ajrccm/136.1.62; RIJCKEN B, 1989, AM REV RESPIR DIS, V140, P615, DOI 10.1164/ajrccm/140.3.615; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; VANDERLE.R, 1972, INT J EPIDEMIOL, V1, P47, DOI 10.1093/ije/1.1.47; VANDERLENDE R, 1972, SCAND J RESPIR DIS, V53, P218; VANDERLENDE R, 1981, CLIN RES PROC, V17, P775; VANDERLENDE R, 1969, EPIDEMIOLOGY CHRONIC; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; XU X, 1994, EUR RESPIR J, V7, P1056; XU X, 1991, American Review of Respiratory Disease, V143, pA90; XU XP, 1995, CHEST, V108, P656, DOI 10.1378/chest.108.3.656; XU XP, 1995, AM J EPIDEMIOL, V141, P554, DOI 10.1093/oxfordjournals.aje.a117471	27	94	99	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 15	1997	350	9089					1431	1434		10.1016/S0140-6736(97)10041-1	http://dx.doi.org/10.1016/S0140-6736(97)10041-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371166				2022-12-24	WOS:A1997YF95300009
J	Dove, SK; Cooke, FT; Douglas, MR; Sayers, LG; Parker, PJ; Michell, RH				Dove, SK; Cooke, FT; Douglas, MR; Sayers, LG; Parker, PJ; Michell, RH			Osmotic stress activates phosphatidylinositol-3,5-bisphosphate synthesis	NATURE			English	Article							INOSITOL PHOSPHATE ISOMERS; LIQUID-CHROMATOGRAPHY; CELLS; PHOSPHATIDYLINOSITOL(3,4,5)-TRISPHOSPHATE; POLYPHOSPHOINOSITIDE; TRISPHOSPHATE; PURIFICATION; METABOLISM; PATHWAY; YEAST	Inositol phospholipids play multiple roles in cell signalling systems. Two widespread eukaryotic phosphoinositide-based signal transduction mechanisms, phosphoinositidase C-catalysed phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P-2) hydrolysis and 3-OH kinase-catalysed PtdIns(4,5)P-2 phosphorylation, make the second messengers inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) sn-1,2-diacylglycerol and PtdIns(3,4,5)P-3 (refs 1-7). In addition, PtdIns(4,5)P-2 and PtdIns3P have been implicated in exocytosis and membrane trafficking(8). We now show that when the yeasts Saccharomyces cerevisiae and Schizosaccharomyces pombe are hyperosmotically stressed, they rapidly synthesize phosphatidylinositol-3,5-bisphosphate (PtdIns(3,5)P-2) by a process that involves activation of a PtdIns3P 5-OH kinase. This PtdIns(3,5)P-2 accumulation only occurs in yeasts that have an active vps34-encoded PtdIns 3-OH kinase, showing that this latter kinase makes the PtdIns3P needed for PtdIns(3,5)P-2 synthesis and indicating that PtdIns(3,5)P-2 may have a role in sorting vesicular proteins. PtdIns(3,5)P-2 is also present in mammalian and plant cells: in monkey Cos-7 cells, its labelling is inversely related to the external osmotic pressure. The stimulation of a PtdIns3P 5-OH kinase-catalysed synthesis of PtdIns(3,5)P-2, a molecule that might be a new type of phosphoinositide 'second messenger', thus appears to be central to a widespread and previously uncharacterized regulatory pathway.	UNIV BIRMINGHAM,DEPT BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT RHEUMATOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	University of Birmingham; University of Birmingham; Cancer Research UK	Dove, SK (corresponding author), UNIV BIRMINGHAM,CTR CLIN RES IMMUNOL & SIGNALLING,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Parker, Peter j/D-5192-2013; Michell, Robert H/AAT-4974-2020	Michell, Robert H/0000-0001-9422-9858; parker, peter/0000-0002-6218-2933				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BARKER CJ, 1995, BIOCHEM J, V306, P557, DOI 10.1042/bj3060557; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CREBA JA, 1983, BIOCHEM J, V212, P733, DOI 10.1042/bj2120733; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DOUGHNEY C, 1988, BIOCHEM J, V251, P927, DOI 10.1042/bj2510927; EINSPAHR KJ, 1988, J BIOL CHEM, V263, P5775; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; Jenkinson S, 1995, Methods Mol Biol, V41, P151; LETCHER AJ, 1990, METHODS INOSITIDE RE, P31; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; WREGGETT KA, 1989, BIOCHEM J, V262, P997, DOI 10.1042/bj2620997; WurglerMurphy SM, 1997, TRENDS BIOCHEM SCI, V22, P172, DOI 10.1016/S0968-0004(97)01036-0; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525	27	380	390	0	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					187	192		10.1038/36613	http://dx.doi.org/10.1038/36613			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367158				2022-12-24	WOS:A1997YF49400058
J	Macfarlane, J; Holmes, W; Macfarlane, R; Britten, N				Macfarlane, J; Holmes, W; Macfarlane, R; Britten, N			Influence of patients' expectations on antibiotic management of acute lower respiratory tract illness in general practice: questionnaire study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE BRONCHITIS; PRIMARY-CARE; CONSULTATION; COMMUNITY	Objective: To assess patients' views and expectations when they consult their general practitioner with acute lower respiratory symptoms and the influence these have on management. Design: General practitioners studied consecutive, previously well adults and recorded clinical data, the certainty regarding their prescribing decision, and the influence of non-clinical factors on that decision. Patients completed a questionnaire at home after the consultation. Setting: 76 doctors from suburban, inner city, and rural practices. Subjects: 1014 eligible patients entered; 787 (78%) returned the questionnaire. Main outcome measures: The views of the patient, the views of and antibiotic prescription by the doctor. Results: Most patients thought that their symptoms were caused by an infection (662) and that antibiotics would help (656) and had both wanted (564) and expected (561) such a prescription. 146 requested an antibiotic, 587 received one. Of the 643 patients who thought they had an infection, 582 wanted an antibiotic and thought it would help. Severity of symptoms did not relate to wanting antibiotics. For those prescribed antibiotics, their doctor thought they were definitely indicated in only 116 cases and not indicated in 126. Patient pressure most commonly influenced the decision to prescribe even when the doctor thought antibiotics were not indicated. Doctors considered antibiotics definitely indicated in only 1% of the group in whom patient pressure influenced the prescribing decision. Patients who did not receive an antibiotic that they wanted were much more likely to express dissatisfaction. Dissatisfied patients reconsulted for the same symptoms twice as often as satisfied patients. Conclusion: Patients presenting with acute lower respiratory symptoms often believe that infection is the problem and antibiotics the answer. Patients' expectations have a significant influence on prescribing, even when their doctor judges that antibiotics are not indicated.	SHERRINGTON PK MED PRACTICE, NOTTINGHAM NG5 2EJ, ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, DEPT GEN PRACTICE, LONDON SE11 6SP, ENGLAND	University of London; King's College London	Macfarlane, J (corresponding author), CITY HOSP NOTTINGHAM, RESP INFECT UNIT, HUCKNALL RD, NOTTINGHAM NG5 1PB, ENGLAND.							Armstrong D, 1996, BRIT MED J, V312, P949; *AUD COMM, 1994, PRESCR IMPR MOR RAT; BAIN DJG, 1983, BRIT MED J, V287, P1269, DOI 10.1136/bmj.287.6401.1269; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; BRITTEN N, 1995, BRIT MED J, V310, P1084, DOI 10.1136/bmj.310.6987.1084; BRITTEN N, 1996, THESIS U LONDON; CARTWRIGHT A, 1981, GENERAL PRACTICE REV; Davey PG, 1996, BRIT MED J, V312, P613, DOI 10.1136/bmj.312.7031.613; HOLMES WF, IN PRESS BR J GEN PR; Howie J G, 1973, J R Coll Gen Pract, V23, P895; HOWIE JGR, 1991, BRIT J GEN PRACT, V41, P48; HOWIE JGR, 1978, BRIT MED J, V2, P1342, DOI 10.1136/bmj.2.6148.1342; HOWIE JGR, 1974, BRIT MED J, V2, P540, DOI 10.1136/bmj.2.5918.540; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Macfarlane J, 1997, RESP MED, V91, P427, DOI 10.1016/S0954-6111(97)90258-4; Macfarlane JT, 1997, BRIT J GEN PRACT, V47, P719; MOLSTAD S, 1994, FAM PRACT, V11, P282, DOI 10.1093/fampra/11.3.282; MONTO A S, 1971, American Journal of Epidemiology, V94, P269; MORRELL DC, 1986, BMJ-BRIT MED J, V292, P870, DOI 10.1136/bmj.292.6524.870; Nicholson KG, 1996, BMJ-BRIT MED J, V313, P1119, DOI 10.1136/bmj.313.7065.1119; ORR PH, 1993, J FAM PRACTICE, V36, P507; RAPAPORT J, 1979, J R COLL GEN PRACT, V29, P468; VENKATESAN P, 1995, THORAX, V50, P481, DOI 10.1136/thx.50.5.481; VERHEIJ TJM, 1989, FAM PRACT, V6, P66, DOI 10.1093/fampra/6.1.66; VIRJI A, 1991, FAM PRACT, V8, P314, DOI 10.1093/fampra/8.4.314; WEBB S, 1994, BRIT J GEN PRACT, V44, P165	26	336	346	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 8	1997	315	7117					1211	1214		10.1136/bmj.315.7117.1211	http://dx.doi.org/10.1136/bmj.315.7117.1211			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393228	Green Published			2022-12-24	WOS:A1997YF25200027
J	Hajduk, PJ; Meadows, RP; Fesik, SW				Hajduk, PJ; Meadows, RP; Fesik, SW			Drug design - Discovering high-affinity ligands for proteins	SCIENCE			English	Editorial Material											Hajduk, PJ (corresponding author), ABBOTT LABS,DIV PHARMACEUT DISCOVERY,ABBOTT PK,IL 60064, USA.							BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P61, DOI 10.1007/BF00124387; ECKER DJ, 1995, BIO-TECHNOL, V13, P351, DOI 10.1038/nbt0495-351; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Hajduk PJ, 1997, J MED CHEM, V40, P3144, DOI 10.1021/jm9703404; HAJDUK PJ, IN PRESS J AM CHEM S; HAJDUK PJ, 1997, IN PRESS J AM CHEM S, V119, P5818; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078; OLEJNICZAK ET, 1997, IN PRESS J AM CHEM S, V119, P5828; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; VERLINDE CLMJ, 1992, J COMPUT AID MOL DES, V6, P131, DOI 10.1007/BF00129424	12	172	182	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					497	&		10.1126/science.278.5337.497	http://dx.doi.org/10.1126/science.278.5337.497			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9381145				2022-12-24	WOS:A1997YB35500054
J	Kim, JJ; Krupa, DJ; Thompson, RF				Kim, JJ; Krupa, DJ; Thompson, RF			Inhibitory cerebello-olivary projections and blocking effect in classical conditioning	SCIENCE			English	Article							NICTITATING-MEMBRANE RESPONSE; INFERIOR OLIVE; US LOCUS; LESIONS; RABBIT; RAT; ACQUISITION; EYEBLINK; STIMULI; CAT	The behavioral phenomenon of blocking indicates that the informational relationship between the conditioned stimulus and the unconditioned stimulus is essential in classical conditioning. The eyeblink conditioning paradigm is used to describe a neural mechanism that mediates blocking, Disrupting inhibition of the inferior olive, a structure that conveys unconditioned stimulus information (airpuff) to the cerebellum prevented blocking in rabbits. Recordings of cerebellar neuronal activity show that the inferior olive input to the cerebellum becomes suppressed as learning occurs. These results suggest that the inferior olive becomes functionally inhibited by the cerebellum during conditioning, and that this negative feedback process might be the neural mechanism mediating blocking.	Univ So Calif, Neurosci Program, Los Angeles, CA 90089 USA	University of Southern California	Kim, JJ (corresponding author), Yale Univ, Dept Psychol, 2 Hillhouse Ave, New Haven, CT 06520 USA.	jeansok.kim@yale.edu			ACF HHS [AF05142] Funding Source: Medline	ACF HHS		ANDERSON G, 1988, BRAIN RES, V472, P450; ANGAUT P, 1987, NEUROSCI LETT, V83, P227, DOI 10.1016/0304-3940(87)90090-5; ANGAUT P, 1989, BRAIN RES, V479, P361, DOI 10.1016/0006-8993(89)91641-7; Angaut P, 1996, NEUROSCI RES, V26, P345, DOI 10.1016/S0168-0102(96)01116-9; Betts SL, 1996, ANIM LEARN BEHAV, V24, P459, DOI 10.3758/BF03199017; DICKINSON A, 1979, J EXP PSYCHOL ANIM B, V5, P162, DOI 10.1037/0097-7403.5.2.162; DONEGAN NH, 1989, COMPUTATIONAL MODELS, P108; FREDETTE BJ, 1991, ANAT EMBRYOL, V184, P225, DOI 10.1007/BF01673258; GIBSON AR, 1987, J COMP NEUROL, V260, P362, DOI 10.1002/cne.902600304; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; HAWKINS RD, 1984, PSYCHOL REV, V91, P375, DOI 10.1037/0033-295X.91.3.375; Hesslow G, 1996, EXP BRAIN RES, V110, P36; Kamin L. J., 1968, MIAMI S PREDICTION B, P9; Katz DB, 1997, LEARN MEMORY, V4, P88, DOI 10.1101/lm.4.1.88; Kim JJ, 1997, TRENDS NEUROSCI, V20, P177, DOI 10.1016/S0166-2236(96)10081-3; MACKINTOSH NJ, 1975, PSYCHOL REV, V82, P276, DOI 10.1037/h0076778; MARCHANT HG, 1973, J EXP PSYCHOL, V101, P155; MAUK MD, 1986, P NATL ACAD SCI USA, V83, P5349, DOI 10.1073/pnas.83.14.5349; MCCORMICK DA, 1985, BRAIN RES, V359, P120, DOI 10.1016/0006-8993(85)91419-2; MOORE JW, 1997, LEARN MEM COLD SPRIN, V3, P116; RESCORLA RA, 1988, ANNU REV NEUROSCI, V11, P329, DOI 10.1146/annurev.ne.11.030188.001553; Rescorla RA, 1972, CLASSICAL CONDITION, P64, DOI DOI 10.1101/GR.110528.110; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; SCHULTZ W, 1993, J NEUROSCI, V13, P900; SEARS LL, 1991, BRAIN RES, V545, P114, DOI 10.1016/0006-8993(91)91276-7; STICKNEY KJ, 1983, ANIM LEARN BEHAV, V11, P60, DOI 10.3758/BF03212308; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519; TURKER KS, 1984, BRAIN RES BULL, V13, P229, DOI 10.1016/0361-9230(84)90121-7; TURKER KS, 1986, BRAIN RES, V363, P376; VONEIDA TJ, 1990, J NEUROSCI, V10, P3583; Wagner A.R., 1981, P5; WAGNER AR, 1989, PSYCHOL LEARN MOTIV, V23, P157; YEO CH, 1991, ANN NY ACAD SCI, V627, P292; YEO CH, 1986, EXP BRAIN RES, V63, P81	34	155	157	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	1998	279	5350					570	573		10.1126/science.279.5350.570	http://dx.doi.org/10.1126/science.279.5350.570			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YT527	9438852				2022-12-24	WOS:000071616000049
J	Iacoviello, L; Di Castelnuovo, A; de Knijff, P; D'Orazio, A; Amore, C; Arboretti, R; Kluft, C; Donati, MB				Iacoviello, L; Di Castelnuovo, A; de Knijff, P; D'Orazio, A; Amore, C; Arboretti, R; Kluft, C; Donati, MB			Polymorphism in the coagulation factor VII gene and the risk of myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ISCHEMIC-HEART-DISEASE; REPEAT POLYMORPHISM; HEMOSTATIC FUNCTION; HEALTHY-MEN; F7; IDENTIFICATION; FIBRINOGEN; MUTATION; ANTIGEN; REGION	Background High blood levels of coagulation factor VII are associated with a risk of ischemic vascular disease. Although factor VI levels may be genetically determined, the relation between genetic polymorphisms of factor VII, factor VII blood levels, and the risk of myocardial infarction has not been established. Methods We performed a case-control study of 165 patients with familiar myocardial infarction (mean [+/-SD] age, 55+/-9 years) and 225 controls without a personal or family history of cardiovascular disease (mean age, 56+/-8 years). The polymorphisms involving R353Q and hypervariable region 4 of the factor VI gene were studied. Factor VII clotting activity and antigen levels were also measured. Results Patients with the QQ or H7H7 genotype had a decreased risk of myocardia[ infarction (odds ratios, 0.08 [95 percent confidence interval, 0.01 to 0.9] and 0.22 [95 percent confidence interval, 0.08 to 0.63], respectively). For the R353Q polymorphism, the RR genotype was associated with the highest risk, followed by the RQ genotype and then by the QQ genotype (P<0.001). For the polymorphism involving hypervariable region 4, the combined H7H5 and H6H5 genotypes were associated with the highest risk, followed in descending order by the H6H6, H6H7, and H7H7 genotypes (P<0.001). Patients with the OQ or H7H7 genotype had lower levels of both factor VI[ antigen and factor VII clotting activity than those with the RR or H6H6 genotype. Patients with the fewest level of factor VII clotting activity had a lower risk of myocardial infarction than those with the highest level (odds ratio, 0.13; 95 percent confidence interval, 0.05 to 0.34). Conclusions Our findings suggest that certain polymorphisms of the factor VII gene may influence the risk of myocardial infarction. It is possible that this effect may be mediated by alterations in factor VII levels. (C) 1998. Massachusetts Medical Society.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud,Dept Vasc Med & Pharm, Angela Valenti Lab Thrombosis Pharmacol, Unit Genet Vasc Risk Factors, I-66030 Santa Maria Imbaro, Italy; Ist Ric Farmacol Mario Negri, Dept Clin Pharmacol & Epidemiol, Lab Drug Epidemiol, I-66030 Santa Maria Imbaro, Italy; Leiden Univ, Gaubius Lab, Leiden, Netherlands; Leiden Univ, Dept Human Genet, Ctr Genet Med, NL-2300 RA Leiden, Netherlands	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	Iacoviello, L (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud,Dept Vasc Med & Pharm, Angela Valenti Lab Thrombosis Pharmacol, Unit Genet Vasc Risk Factors, I-66030 Santa Maria Imbaro, Italy.		Arboretti, Rosa/AAY-6499-2020; Donati, Maria Benedetta/K-6606-2016; Siani, Alfonso/B-7925-2015; Iacoviello, Licia/K-4676-2016; Di Castelnuovo, Augusto Filippo/AAC-2436-2022; de Knijff, Peter/Y-2519-2018; Iacoviello, Licia/AGX-7071-2022	Donati, Maria Benedetta/0000-0003-1747-5443; Iacoviello, Licia/0000-0003-0514-5885; Di Castelnuovo, Augusto Filippo/0000-0001-9767-7998; de Knijff, Peter/0000-0002-0899-771X; Iacoviello, Licia/0000-0003-0514-5885; ARBORETTI GIANCRISTOFARO, ROSA/0000-0003-1263-0440				[Anonymous], 1990, LANCET, V336, P65; BALLEISEN L, 1985, THROMB HAEMOSTASIS, V54, P475; BERNARDI F, 1993, HUM GENET, V92, P446, DOI 10.1007/BF00216448; Bernardi F, 1996, ARTERIOSCL THROM VAS, V16, P72; CORTELLARO M, 1992, ARTERIOSCLER THROMB, V12, P1063, DOI 10.1161/01.ATV.12.9.1063; DEKNIJFF P, 1994, HUM MOL GENET, V3, P384; deMaat MPM, 1997, ARTERIOSCL THROM VAS, V17, P1918, DOI 10.1161/01.ATV.17.10.1918; DICASTELNUOVO A, 1997, THROMB HAEMOST S, V77, P390; GREEN F, 1991, ARTERIOSCLER THROMB, V11, P540, DOI 10.1161/01.ATV.11.3.540; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P1392; Heywood DM, 1997, STROKE, V28, P816, DOI 10.1161/01.STR.28.4.816; HOFFMAN CJ, 1992, ARTERIOSCLER THROMB, V12, P267, DOI 10.1161/01.ATV.12.3.267; HUMPHRIES SE, 1994, ARTERIOSCLER THROMB, V14, P193, DOI 10.1161/01.ATV.14.2.193; Lane A, 1996, ATHEROSCLEROSIS, V119, P119, DOI 10.1016/0021-9150(95)05638-6; MARCHETTI G, 1992, HUM GENET, V89, P497; MARCHETTI G, 1991, NUCLEIC ACIDS RES, V19, P4570, DOI 10.1093/nar/19.16.4570-a; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; Pollak ES, 1996, J BIOL CHEM, V271, P1738, DOI 10.1074/jbc.271.3.1738; RONCAGLIONI MC, 1992, CIRCULATION, V85, P2065, DOI 10.1161/01.CIR.85.6.2065; *SAS I, 1989, SAS STAT US GUID VER; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; TERWILLINGER JD, 1994, HDB HUMAN GENETIC LI, P278; VAZIRI ND, 1992, AM J MED, V93, P651, DOI 10.1016/0002-9343(92)90198-K; Wang XL, 1997, ARTERIOSCL THROM VAS, V17, P246, DOI 10.1161/01.ATV.17.2.246; ZOLLER B, 1994, J CLIN INVEST, V94, P2521, DOI 10.1172/JCI117623; 1989, INT J EPIDEMIOL S1, V18, pS1	28	264	277	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 8	1998	338	2					79	85		10.1056/NEJM199801083380202	http://dx.doi.org/10.1056/NEJM199801083380202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ039	9420338				2022-12-24	WOS:000071341300002
J	Leeuw, T; Wu, CL; Schrag, JD; Whiteway, M; Thomas, DY; Leberer, E				Leeuw, T; Wu, CL; Schrag, JD; Whiteway, M; Thomas, DY; Leberer, E			Interaction of a G-protein beta-subunit with a conserved sequence in Ste20/PAK family protein kinases	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PHEROMONE RESPONSE; GAMMA-SUBUNITS; YEAST; PHOSPHORYLATION; ASSOCIATION; FAR1	Serine/threonine protein kinases of the Ste20/PAK family have been implicated in the signalling from heterotrimeric G proteins to mitogen-activated protein (MAP) kinase cascades(1,2). in the yeast Saccharomyces cerevisiae, Ste20 is involved in transmitting the mating-pheromone signal from the beta gamma-subunits (encoded by the STE4 and STE18 genes, respectively) of a heterotrimeric G protein to a downstream MAP kinase cascade(1). We have identified a binding site for the G-protein beta-subunit (G beta) in the non-catalytic carboxy-terminal regions of Ste20 and its mammalian homologues, the p21-activated protein kinases (PAKs). Association of G beta with this site in Ste20 was regulated by binding of pheromone to the receptor. Mutations in G beta and Ste20 that prevented this association blocked activation of the MAP kinase cascade. Considering the high degree of structural and functional conservation of Ste20/PAK family members and G-protein subunits, our results provide a possible model for a role of these kinases in G beta gamma-mediated signal transduction in organisms ranging from yeast to mammals.	Natl Res Council Canada, Biotechnol Res Inst, Eukaryot Genet Grp, Montreal, PQ H4P 2R2, Canada; Natl Res Council Canada, Biotechnol Res Inst, Macromol Struct Grp, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2B2, Canada	National Research Council Canada; National Research Council Canada; McGill University; McGill University; McGill University	Leberer, E (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Eukaryot Genet Grp, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	Ekkehard.Leberer@nrc.ca	Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; CHANG F, 1992, MOL BIOL CELL, V3, P445, DOI 10.1091/mbc.3.4.445; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SIKORSKI RS, 1989, GENETICS, V122, P19; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787	20	179	180	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 8	1998	391	6663					191	195		10.1038/34448	http://dx.doi.org/10.1038/34448			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428767				2022-12-24	WOS:000071380900055
J	McDonagh, TA; Robb, SD; Murdoch, DR; Morton, JJ; Ford, I; Morrison, CE; Tunstall-Pedoe, H; McMurray, JJV; Dargie, HJ				McDonagh, TA; Robb, SD; Murdoch, DR; Morton, JJ; Ford, I; Morrison, CE; Tunstall-Pedoe, H; McMurray, JJV; Dargie, HJ			Biochemical detection of left-ventricular systolic dysfunction	LANCET			English	Article							BRAIN NATRIURETIC PEPTIDE; ACUTE MYOCARDIAL-INFARCTION; HEART-FAILURE; IN-VITRO; ECHOCARDIOGRAPHY; COMMUNITY; INDICATOR; ACCURACY	Background In previous studies on the use of natriuretic peptides to detect left-ventricular systolic dysfunction, a higher rate of cardiac disorders in the control groups than in the study groups could have led to bias. We investigated the effectiveness of plasma N-terminal atrial natriuretic peptide (NT-ANP) and brain natriuretic peptide (BNP) concentrations to show left-ventricular systolic dysfunction in a random sample of the general population. Methods We randomly selected 2000 participants aged 25-74 years from family physicians' lists in Glasgow, UK. We sent all participants questionnaires, 1653 respondents underwent echocardiography and electrocardiography. We took a left-ventricular ejection fraction of 30% or less to show left-ventricular systolic dysfunction. NT-ANP and BNP were measured in plasma by RIAs. Findings 1252 participants had analysable electrocardiograms and echocardiograms, completed available blood samples. Median and BNP were significantly higher in participants with left-ventricular systolic dysfunction (2.8 ng/mL [IQR 1.8-4.6] and 24.0 pg/mL [18.0-33.0]) than in those without (1.3 ng/mL [0.9-1.8] and 7.7 pg/mL [3.4-13.0]; each p<0.001). Among participants with left-ventricular systolic dysfunction, both symptomatic and asymptomatic subgroups had raised NT-ANP and BNP concentrations, A BNP concentration of 17.9 pg/mL or more gave a sensitivity of 77% and specificity of 87% in all participants, and 92% and 72% in participants aged 55 years or older, NT-ANP Interpretation Measurement of BNP could be a cost-effective method of screening for left-ventricular systolic dysfunction in the general population, especially if its use were targeted to individuals at high risk.	Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, MRC, Clin Res Initiat Heart Failure, Glasgow G12 8QQ, Lanark, Scotland; Glasgow Royal Infirm, Scottish Monica Project, Glasgow, Lanark, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow	McDonagh, TA (corresponding author), Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland.		Ford, Ian/ABE-6145-2020; mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975				CHOY AMJ, 1994, BRIT HEART J, V72, P16; DAVIDSON NC, 1995, CIRCULATION, V91, P1276; DAVIS M, 1994, LANCET, V343, P40; FAHEY MT, 1995, AM J EPIDEMIOL, V141, P680, DOI 10.1093/oxfordjournals.aje.a117485; FRANCIS GS, 1990, CIRCULATION, V82, P1724, DOI 10.1161/01.CIR.82.5.1724; GLENBOTSKI CC, 1988, J BIOL CHEM, V263, P16073; HALL C, 1995, CIRCULATION, V91, P911; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HEUBLEIN D M, 1989, Journal of the American College of Cardiology, V13, p9A; Jacobsen SJ, 1996, ARCH INTERN MED, V156, P2462, DOI 10.1001/archinte.156.21.2462; LAND CC, 1991, J HYPERTENS, V9, P779; LERMAN A, 1993, LANCET, V341, P1105, DOI 10.1016/0140-6736(93)93125-K; McDonagh TA, 1997, LANCET, V350, P829, DOI 10.1016/S0140-6736(97)03033-X; MCKEE PA, 1971, NEW ENGL J MED, V285, P781; MOTWANI JG, 1993, LANCET, V341, P1109, DOI 10.1016/0140-6736(93)93126-L; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; Omland T, 1996, CIRCULATION, V93, P1963, DOI 10.1161/01.CIR.93.11.1963; Omland T, 1996, HEART, V76, P232, DOI 10.1136/hrt.76.3.232; ROSE GA, WHO MONOGRAPH SERIES, V56; SCHILLER NB, 1979, CIRCULATION, V60, P547, DOI 10.1161/01.CIR.60.3.547; SUNDSFJORD JA, 1988, J CLIN ENDOCR METAB, V66, P605, DOI 10.1210/jcem-66-3-605; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; SWETS JA, 1991, MED DECIS MAKING, V11, P9, DOI 10.1177/0272989X9101100102; WEI CM, 1993, CIRCULATION, V88, P1004, DOI 10.1161/01.CIR.88.3.1004; WHEELDON NM, 1993, Q J MED, V86, P17; YAMAMOTO K, 1996, J AM COLL CARDIOL A, V69, P723; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	27	801	862	2	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					9	13		10.1016/S0140-6736(97)03034-1	http://dx.doi.org/10.1016/S0140-6736(97)03034-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433422				2022-12-24	WOS:000071253100009
J	Majeti, R; Bilwes, AM; Noel, JP; Hunter, T; Weiss, A				Majeti, R; Bilwes, AM; Noel, JP; Hunter, T; Weiss, A			Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; CD45; PHOSPHORYLATION; KINASES; MATURATION; ACTIVATION; EXPRESSION; MICE	The function and regulation of the receptorlike transmembrane protein tyrosine phosphatases (RPTPs) are not well understood. Ligand-induced dimerization inhibited the function of the epidermal growth factor receptor (EGFR)-RPTP CD45 chimera (EGFR-CD45) in T cell signal transduction. Properties of mutated EGFR-CD45 chimeras supported a general model for the regulation of RPTPs, derived from the crystal structure of the RPTP alpha membrane-proximal phosphatase domain, The phosphatase domain apparently forms a symmetrical dimer in which the catalytic site of one molecule is blocked by specific contacts with a wedge from the other.	Univ Calif San Francisco, Dept Microbiol & Immunol, Biomed Sci Grad Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Biomed Sci Grad Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Salk Institute; Salk Institute	Weiss, A (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, Biomed Sci Grad Program, San Francisco, CA 94143 USA.		Noel, Joseph P/A-9459-2009	Bilwes Crane, Alexandrine/0000-0001-9922-0692				Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DESAI DM, 1994, EMBO J, V13, P4002, DOI 10.1002/j.1460-2075.1994.tb06716.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LEDBETTER JA, 1991, J IMMUNOL, V146, P1577; MARVEL J, 1991, EUR J IMMUNOL, V21, P195, DOI 10.1002/eji.1830210129; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MITTLER RS, 1994, J IMMUNOL, V153, P84; MOUREY RJ, 1994, CURR OPIN GENET DEV, V4, P31, DOI 10.1016/0959-437X(94)90088-4; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	23	211	220	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					88	91		10.1126/science.279.5347.88	http://dx.doi.org/10.1126/science.279.5347.88			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417031				2022-12-24	WOS:000071323900046
J	Harlow, T				Harlow, T			Do overweight people remove their shoes before being weighed by a doctor? Consecutive study of patients in general practice	BRITISH MEDICAL JOURNAL			English	Article									Coll Surg, Cullompton EX15 1TG, Devon, England		Harlow, T (corresponding author), Coll Surg, Cullompton EX15 1TG, Devon, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1663	1663		10.1136/bmj.315.7123.1663	http://dx.doi.org/10.1136/bmj.315.7123.1663			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448534	Green Published			2022-12-24	WOS:000071149400018
J	IkeshimaKataoka, H; Skeath, JB; Nabeshima, Y; Doe, CQ; Matsuzaki, F				IkeshimaKataoka, H; Skeath, JB; Nabeshima, Y; Doe, CQ; Matsuzaki, F			Miranda directs Prospero to a daughter cell during Drosophila asymmetric divisions	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; GANGLION MOTHER CELLS; GENE; PROTEIN; NUMB; EXPRESSION; FATES; SEGREGATION; MARKERS	Asymmetric cell division is a general process used in many developmental contexts to create two differently fated cells from a single progenitor cell. Intrinsic mechanisms like the asymmetric transmission of tell-fate determinants during cell division, and extrinsic cell-interaction mechanisms, can mediate asymmetric divisions(1-3). During embryonic development of the Drosophila central nervous system, neural stem cells called neuroblasts divide asymmetrically to produce another multipotent neuroblast and a ganglion mother cell (GMC) of more restricted developmental potential. Intrinsic mechanisms promote asymmetric division of neuroblasts: for example, the transcription factor Prospero localizes to the basal cell cortex of mitotic neuroblasts and then segregates exclusively into the GMC, which buds off from the basal side of the neuroblast(4-6). In the GMC, Prospero translocates to the nucleus, where it establishes differential gene expression between sibling cells. Here we report the identification of a gene, miranda, which encodes a new protein that co-localizes with Prospero in mitotic neuroblasts, tethers Prospero to the basal cortex of mitotic neuroblasts, directing Prospero into the GMC, and releases Prospero from the cell cortex within GMCs. miranda thus creates intrinsic differences between sibling cells by mediating the asymmetric segregation of a transcription factor into only one daughter cell during neural stem-cell division.	NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DEPT MOL GENET,KODAIRA,TOKYO 187,JAPAN; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; UNIV ILLINOIS,HOWARD HUGHES MED INST,URBANA,IL 61801; UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801	National Center for Neurology & Psychiatry - Japan; Washington University (WUSTL); Howard Hughes Medical Institute; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign								BRAND AH, 1993, DEVELOPMENT, V118, P401; BROADUS J, 1995, MECH DEVELOP, V53, P393, DOI 10.1016/0925-4773(95)00454-8; CamposOrtega JA, 1996, NEURON, V17, P1, DOI 10.1016/S0896-6273(00)80274-3; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DOE CQ, 1992, DEVELOPMENT, V116, P855; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; JAN YN, 1995, NEURON, V14, P1; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Lin HF, 1997, TRENDS GENET, V13, P33, DOI 10.1016/S0168-9525(96)10050-0; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; OTOUSA JE, 1989, J NEUROGENET, V6, P41, DOI 10.3109/01677068909107099; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPANA EP, 1995, DEVELOPMENT, V121, P3489; UEMERA T, 1989, CELL, V5, P349; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; VINCENT JP, 1994, DEV BIOL, V164, P328, DOI 10.1006/dbio.1994.1203	23	258	262	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					625	629		10.1038/37641	http://dx.doi.org/10.1038/37641			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403694				2022-12-24	WOS:A1997YK85300054
J	Welch, HG; Black, WC				Welch, HG; Black, WC			Using autopsy series to estimate the disease ''reservoir'' for ductal carcinoma in situ of the breast: How much more breast cancer can we find?	ANNALS OF INTERNAL MEDICINE			English	Review							IN-SITU; EPIDEMIOLOGIC NECROPSY; LESIONS; MAMMOGRAPHY; PREVALENCE; WOMEN; RADIOLOGISTS; VARIABILITY; THERAPY; BENIGN	Purpose: To determine how many cases of breast cancer might be found if women not known to have the disease were thoroughly examined (the disease ''reservoir''). Data Sources: MEDLINE search from 1966 to the present. Study Selection: Hospital-based and forensic autopsy series examining women not known to have had breast cancer during life. Data Extraction: Observed prevalence of occult invasive breast cancer or ductal carcinoma in situ (DCIS) in which the number of women who were given a diagnosis was the numerator and the number of women examined was the denominator. For each autopsy series, we attempted to ascertain the level of scrutiny (sampling method, number of slides examined) given to the pathologic specimens. Data Synthesis: Among seven autopsy series of women not known to have had breast cancer during life, the median prevalence of invasive breast cancer was 1.3% (range, 0% to 1.8%) and the median prevalence of DCIS was 8.9% (range, 0% to 14.7%). Prevalences were higher among women likely to have been screened (that is, women 40 to 70 years of age). The mean number of slides examined per breast ranged from 9 to 275; series that reported higher levels of scrutiny tended to discover more cases of cancer. Conclusions: A substantial reservoir of DCIS is undetected during life. How hard pathologists look for the disease and, perhaps, their threshold for making the diagnosis are potentially important factors in determining how many cases of DCIS are diagnosed. The latter has important implications for what it means to have the disease.	DARTMOUTH COLL SCH MED, CTR EVALUAT CLIN SCI, HANOVER, NH 03755 USA; DARTMOUTH HITCHCOCK MED CTR, LEBANON, NH 03766 USA	Dartmouth College; Dartmouth College	Welch, HG (corresponding author), DEPT VET AFFAIRS MED CTR, VA OUTCOMES GRP 111B, WHITE RIVER JCT, VT 05009 USA.							ALPERS CE, 1985, HUM PATHOL, V16, P796, DOI 10.1016/S0046-8177(85)80251-3; BARTOW SA, 1987, CANCER, V60, P2751, DOI 10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M; Beam CA, 1996, ARCH INTERN MED, V156, P209, DOI 10.1001/archinte.156.2.209; BHATHAL PS, 1985, BRIT J CANCER, V51, P271, DOI 10.1038/bjc.1985.39; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; CHAN CK, 1989, INT J EPIDEMIOL, V18, P315, DOI 10.1093/ije/18.2.315; ELMORE JG, 1994, NEW ENGL J MED, V331, P1493, DOI 10.1056/NEJM199412013312206; Ernster VL, 1996, JAMA-J AM MED ASSOC, V275, P913, DOI 10.1001/jama.275.12.913; FEUER EJ, 1992, AM J EPIDEMIOL, V136, P1423, DOI 10.1093/oxfordjournals.aje.a116463; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; Foucar E, 1996, LANCET, V347, P707, DOI 10.1016/S0140-6736(96)90073-2; HARRIS JR, 1992, NEW ENGL J MED, V327, P390, DOI 10.1056/NEJM199208063270606; JATOI I, 1995, SURGERY, V118, P118, DOI 10.1016/S0039-6060(05)80019-4; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; KETCHAM AS, 1990, CANCER, V65, P387, DOI 10.1002/1097-0142(19900201)65:3<387::AID-CNCR2820650302>3.0.CO;2-Y; KRAMER WM, 1973, CANCER, V31, P130, DOI 10.1002/1097-0142(197301)31:1<130::AID-CNCR2820310117>3.0.CO;2-N; MCFARLANE MJ, 1987, JAMA-J AM MED ASSOC, V258, P331, DOI 10.1001/jama.258.3.331; NIELSEN M, 1984, CANCER-AM CANCER SOC, V54, P612, DOI 10.1002/1097-0142(1984)54:4<612::AID-CNCR2820540403>3.0.CO;2-B; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; POLLEI SR, 1987, RADIOLOGY, V163, P459, DOI 10.1148/radiology.163.2.3562827; ROSAI J, 1991, AM J SURG PATHOL, V15, P209, DOI 10.1097/00000478-199103000-00001; SCHNITT SJ, 1992, AM J SURG PATHOL, V16, P1133, DOI 10.1097/00000478-199212000-00001; Schwartz G F, 1994, Oncology (Williston Park), V8, P21; SEIDMAN H, 1985, CA-CANCER J CLIN, V35, P36, DOI 10.3322/canjclin.35.1.36; SHAPIRO S, 1991, J NATL CANCER I, V83, P1522, DOI 10.1093/jnci/83.21.1522; SIMONOVIS NJ, 1991, AM J EPIDEMIOL, V133, P922, DOI 10.1093/oxfordjournals.aje.a115971; STACEYCLEAR A, 1992, LANCET, V340, P991; WELLINGS SR, 1975, J NATL CANCER I, V55, P231; WHITE E, 1990, J NATL CANCER I, V82, P1546, DOI 10.1093/jnci/82.19.1546	31	231	234	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					1023	1028		10.7326/0003-4819-127-11-199712010-00014	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00014			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412284				2022-12-24	WOS:A1997YJ08000010
J	Muzio, M; Ni, J; Feng, P; Dixit, VM				Muzio, M; Ni, J; Feng, P; Dixit, VM			IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling	SCIENCE			English	Article							INTERLEUKIN-1 RECEPTOR; DORSOVENTRAL SIGNAL; DROSOPHILA EMBRYO; DEATH DOMAIN; KINASE; ACTIVATION; TUBE; TRANSDUCTION; EXPRESSION; PROTEINS	The interleukin-1 receptor (IL-1R) signaling pathway leads to nuclear factor kappa B (NF-kappa B) activation in mammals and is similar to the Toll pathway in Drosophila: the IL-1R-associated kinase (IRAK) is homologous to Pelle. Two additional proximal mediators were identified that are required for IL-1R-induced NF-kappa B activation: IRAK-2, a Pelle family member, and MyD88, a death domain-containing adapter molecule. Both associate with the IL-IR signaling complex. Dominant negative forms of either attenuate IL-1R-mediated NF-kappa B activation. Therefore, IRAK-2 and MyD88 may provide additional therapeutic targets for inhibiting IL-1-induced inflammation.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; HUMAN GENOME SCI,ROCKVILLE,MD 20850	University of Michigan System; University of Michigan; GlaxoSmithKline; Human Genome Sciences Inc			Muzio, Marta/J-9360-2018; dixit, vishva m/A-4496-2012	Muzio, Marta/0000-0002-7761-759X; dixit, vishva m/0000-0001-6983-0326				Bonnert TP, 1997, FEBS LETT, V402, P81, DOI 10.1016/S0014-5793(96)01506-2; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Eriksson A, 1995, CYTOKINE, V7, P649; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hardiman G, 1996, ONCOGENE, V13, P2467; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; HULTMARK D, 1994, BIOCHEM BIOPH RES CO, V199, P144, DOI 10.1006/bbrc.1994.1206; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; LETSOU A, 1993, EMBO J, V12, P3449, DOI 10.1002/j.1460-2075.1993.tb06019.x; LORD KA, 1990, ONCOGENE, V5, P1095; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; MEDZHITOV R, 1997, NATURE, V38, P394; Norris JL, 1996, GENE DEV, V10, P862, DOI 10.1101/gad.10.7.862; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; Singh R, 1997, J CLIN INVEST, V100, P419, DOI 10.1172/JCI119549; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727	27	946	1022	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1612	1615		10.1126/science.278.5343.1612	http://dx.doi.org/10.1126/science.278.5343.1612			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374458				2022-12-24	WOS:A1997YJ87400037
J	VanderHeiden, MG; Chandel, NS; Williamson, EK; Schumacker, PT; Thompson, CB				VanderHeiden, MG; Chandel, NS; Williamson, EK; Schumacker, PT; Thompson, CB			Bcl-x(L) regulates the membrane potential and volume homeostasis of mitochondria	CELL			English	Article							CYTOCHROME-C-OXIDASE; CELL-DEATH; APOPTOSIS; OXYGEN; HEPATOCYTES; DNA	Mitochondrial physiology is disrupted in either apoptosis or necrosis. Here, we report that a wide variety of apoptotic and necrotic stimuli induce progressive mitochondrial swelling and outer mitochondrial membrane rupture. Discontinuity of the outer mitochondrial membrane results in cytochrome c redistribution from the intermembrane space to the cytosol followed by subsequent inner mitochondrial membrane depolarization. The mitochondrial membrane protein Bcl-x(L) can inhibit these changes in cells treated with apoptotic stimuli. In addition, Bcl-x(L)-expressing cells adapt to growth factor withdrawal or staurosporine treatment by maintaining a decreased mitochondrial membrane potential. Bcl-x(L) expression also prevents mitochondrial swelling in response to agents that inhibit oxidative phosphorylation. These data suggest that Bcl-x(L) promotes cell survival by regulating the electrical and osmotic homeostasis of mitochondria.	UNIV CHICAGO,COMM IMMUNOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOL GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago	VanderHeiden, MG (corresponding author), UNIV CHICAGO,GWEN KNAPP CTR,CHICAGO,IL 60637, USA.			Schumacker, Paul T/0000-0001-9591-2034				ADAMS V, 1991, BIOCHEM MED METAB B, V45, P271, DOI 10.1016/0885-4505(91)90032-G; ALLMAN R, 1990, CYTOMETRY, V11, P822, DOI 10.1002/cyto.990110708; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Chandel NS, 1996, J BIOL CHEM, V271, P18672, DOI 10.1074/jbc.271.31.18672; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; DECKER RS, 1980, AM J PATHOL, V98, P425; DEJONG D, 1994, CANCER RES, V54, P256; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEMASTERS JJ, 1987, NATURE, V325, P78, DOI 10.1038/325078a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, CANCER RES, V56, P2033; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; PETIT JM, 1992, EUR J BIOCHEM, V209, P267, DOI 10.1111/j.1432-1033.1992.tb17285.x; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SCHUMACKER PT, 1993, AM J PHYSIOL, V265, pL395, DOI 10.1152/ajplung.1993.265.4.L395; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wilson AJ, 1993, PROCEDURES ELECT MIC; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	34	1186	1197	1	72	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					627	637		10.1016/S0092-8674(00)80450-X	http://dx.doi.org/10.1016/S0092-8674(00)80450-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393856	Bronze			2022-12-24	WOS:A1997YH96000010
J	Naylor, CD; Sermer, M; Chen, EL; Farine, D				Naylor, CD; Sermer, M; Chen, EL; Farine, D			Selective screening for gestational diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TOLERANCE TEST VALUE; GLUCOSE-TOLERANCE; PERINATAL MORBIDITY; RISK-FACTORS; PREGNANCY; CRITERIA; WOMEN; DELIVERY; IMPACT; WEIGHT	Background The usual approach to detecting gestational diabetes mellitus is to screen all pregnant women by measuring their plasma glucose after a 50-g oral glucose load at 24 to 28 weeks' gestation. Women are referred for an oral glucose-tolerance test if the plasma glucose concentration one hour later is greater than or equal to 140 mg per deciliter (7.8 mmol per liter). We hypothesized that the efficiency of screening could be enhanced by considering women's risks of gestational diabetes on the basis of their clinical characteristics. Methods We studied 3131 pregnant women who underwent both the screening and the diagnostic tests. We randomly selected data on half the women and used them to derive new screening strategies. We categorized each woman's risk of gestational diabetes mellitus on the basis of her age, body-mass index before pregnancy, and race. We developed strategies that entailed no screening for low-risk women, usual care for intermediate-risk women, and universal screening with lower thresholds - plasma glucose values of 130 mg per deciliter (7.2 mmol per liter) or 128 mg per deciliter (7.1 mmol per liter) - for high-risk women. The strategies were validated with data on the other half of the women. Results The new strategies allowed a 34.6 percent reduction in the number of screening tests performed (95 percent confidence interval, 32.3 to 37.0 percent) and detected 81.2 to 82.6 percent of the women with gestational diabetes as compared with the 78.3 percent detected through usual care. The percentage of false positive screening tests was significantly reduced, from 19.9 percent with usual care to 16.0 percent (P = 0.02) or 15.4 percent (P < 0.001) with the new strategies, depending on the threshold values for high-risk women. Conclusions Consideration of women's clinical characteristics allows efficient selective screening for gestational diabetes. (C) 1997, Massachusetts Medical Society.	UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA; TORONTO HOSP,DEPT OBSTET & GYNECOL,TORONTO,ON M5T 2S8,CANADA; MT SINAI HOSP,DEPT OBSTET & GYNECOL,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT OBSTET & GYNECOL,TORONTO,ON,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Naylor, CD (corresponding author), SUNNYBROOK HLTH SCI CTR,INST CLIN EVALUAT SCI,CLIN EPIDEMIOL UNIT,G106,2075 BAYVIEW AVE,N YORK,ON M4N 3M5,CANADA.							*AM DIAB ASS, 1987, AM J OBSTET GYNECOL, V156, P488; BERKOWITZ GS, 1992, AM J EPIDEMIOL, V135, P965, DOI 10.1093/oxfordjournals.aje.a116408; *CAN TASK FORC PER, 1992, CMAJ, V147, P435; CARPENTER MW, 1982, AM J OBSTET GYNECOL, V144, P768, DOI 10.1016/0002-9378(82)90349-0; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; COUSTAN DR, 1986, AM J OBSTET GYNECOL, V154, P1031, DOI 10.1016/0002-9378(86)90744-1; COUSTAN DR, 1989, OBSTET GYNECOL, V73, P557; COUSTAN DR, 1984, AM J OBSTET GYNECOL, V150, P836, DOI 10.1016/0002-9378(84)90459-9; COUSTAN DR, 1985, CLIN OBSTET GYNECOL, V28, P507, DOI 10.1097/00003081-198528030-00006; DIETRICH ML, 1987, AM J OBSTET GYNECOL, V156, P1403, DOI 10.1016/0002-9378(87)90007-X; DORNHORST A, 1992, DIABETIC MED, V9, P820, DOI 10.1111/j.1464-5491.1992.tb01900.x; *EXP COMM DIAGN CL, 1997, DIABETES CARE S1, V20, pS1183; GABBE SG, 1986, NEW ENGL J MED, V315, P1025, DOI 10.1056/NEJM198610163151609; GABBE SG, 1977, AM J OBSTET GYNECOL, V127, P465, DOI 10.1016/0002-9378(77)90436-7; GREEN JR, 1990, AM J OBSTET GYNECOL, V163, P86, DOI 10.1016/S0002-9378(11)90675-9; KITZMILLER JL, 1978, AM J OBSTET GYNECOL, V131, P560, DOI 10.1016/0002-9378(78)90120-5; LANGER O, 1987, AM J OBSTET GYNECOL, V157, P758, DOI 10.1016/S0002-9378(87)80045-5; LINDSAY MK, 1989, OBSTET GYNECOL, V73, P103; MAGEE MS, 1993, JAMA-J AM MED ASSOC, V269, P609, DOI 10.1001/jama.269.5.609; MARQUETTE GP, 1985, OBSTET GYNECOL, V66, P181; METZGER BE, 1991, DIABETES, V40, P197, DOI 10.2337/diab.40.2.S197; NAHUM GG, 1993, OBSTET GYNECOL, V81, P517; *NAT DIAB DAT GROU, 1979, DIABETES, V28, P1039; Naylor CD, 1996, JAMA-J AM MED ASSOC, V275, P1165, DOI 10.1001/jama.275.15.1165; OSULLIVAN JB, 1973, AM J OBSTET GYNECOL, V116, P895; OSULLIVAN JB, 1980, DIABETES CARE, V3, P437, DOI 10.2337/diacare.3.3.437; OWEN J, 1995, AM J OBSTET GYNECOL, V172, P615, DOI 10.1016/0002-9378(95)90581-2; Peters RK, 1996, LANCET, V347, P227, DOI 10.1016/S0140-6736(96)90405-5; *PREV SERV TASK FO, 1996, GUID CLIN PREV SERV, P193; SERMER M, 1995, AM J OBSTET GYNECOL, V173, P146, DOI 10.1016/0002-9378(95)90183-3; SERMER M, 1994, AM J OBSTET GYNECOL, V171, P607, DOI 10.1016/0002-9378(94)90072-8; Tu JV, 1997, J CLIN EPIDEMIOL, V50, P743, DOI 10.1016/S0895-4356(97)89028-2; WALKINSHAW SA, 1995, PREGNANCY CHILDBIRTH; WALKINSHAW SA, 1997, PREGNANCY CHILDBIRTH; WEEKS JW, 1994, AM J OBSTET GYNECOL, V171, P1003, DOI 10.1016/0002-9378(94)90023-X; Widness J A, 1985, Diabetes, V34 Suppl 2, P61; 1985, DIABETES S2, V34, P123	37	178	186	1	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 27	1997	337	22					1591	1596		10.1056/NEJM199711273372204	http://dx.doi.org/10.1056/NEJM199711273372204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH521	9371855				2022-12-24	WOS:A1997YH52100004
J	Zazopoulos, E; Lalli, E; Stocco, DM; SassoneCorsi, P				Zazopoulos, E; Lalli, E; Stocco, DM; SassoneCorsi, P			DNA binding and transcriptional repression by DAX-1 blocks steroidogenesis	NATURE			English	Article							ACUTE REGULATORY PROTEIN; ADRENAL HYPOPLASIA CONGENITA; STAR GENE; EXPRESSION; CELLS; SUPERFAMILY; MOTIF; HMG1; CREM	Mutations in the DAX-1 gene are responsible for congenital X-linked adrenal hypoplasia, a disease that is associated with hypogonadotropic hypogonadism(1,2). DAX-1 expression is tissue-specific and is finely regulated throughout development(3-5), suggesting that it has a role in both adrenal and gonadal function. DAX-1 is an unusual member of the nuclear-receptor superfamily of transcription factors which contains no canonical zinc-finger or any other known DNA-binding motif(1). Binding sites for DAX-1 are found in the promoters of the dax-1 and StAR (for steroidogenic acute regulatory protein) genes. Here we show that DAX-1 binds DNA and acts as a powerful transcriptional repressor of StAR gene expression, leading to a drastic decrease in steroid production. We provide in vitro and in vivo evidence that DAX-1 binds to DNA hairpin structures. Our results establish DAX-1 as the first member of the nuclear receptor superfamily with novel DNA-binding features and reveal that it has regulatory properties critical to the understanding of its physiological functions.	CNRS, INSERM, ULP, INST GENET & BIOL MOL & CELLULAIRE, F-67404 ILLKIRCH GRAFFENSTADEN, STRASBOURG, FRANCE; TEXAS TECH UNIV, HLTH SCI CTR, DEPT BIOCHEM & CELL BIOL, LUBBOCK, TX 79430 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center			Lalli, Enzo/F-7052-2013	Lalli, Enzo/0000-0002-0584-5681	Fondazione Telethon Funding Source: Custom	Fondazione Telethon(Fondazione Telethon)		BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Ikeda Y, 1996, MOL ENDOCRINOL, V10, P1261, DOI 10.1210/me.10.10.1261; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; LALLI E, IN PRESS MOL ENDOCRI; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; Schimmer B P, 1979, Methods Enzymol, V58, P570; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; Tamai KT, 1996, MOL ENDOCRINOL, V10, P1561, DOI 10.1210/me.10.12.1561; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; Werner MH, 1996, SCIENCE, V271, P778, DOI 10.1126/science.271.5250.778; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0	25	344	354	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	1997	390	6657					311	315		10.1038/36899	http://dx.doi.org/10.1038/36899			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384387				2022-12-24	WOS:A1997YG66700070
J	Kigotho, AW				Kigotho, AW			HIV-1 statistics bring good news for Uganda	LANCET			English	News Item																			0	3	3	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1456	1456		10.1016/S0140-6736(05)64230-4	http://dx.doi.org/10.1016/S0140-6736(05)64230-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371180				2022-12-24	WOS:A1997YF95300037
J	Kaplan, KB; Hyman, AA; Sorger, PK				Kaplan, KB; Hyman, AA; Sorger, PK			Regulating the yeast kinetochore by ubiquitin-dependent degradation and skp1p-mediated phosphorylation	CELL			English	Article							SACCHAROMYCES-CEREVISIAE KINETOCHORE; BUDDING YEAST; CHROMOSOME SEGREGATION; IN-VITRO; CENTROMERE; PROTEIN; BINDING; CYCLE; PROTEOLYSIS; COMPLEX	In S. cerevisiae, the four-protein Cbf3 complex binds to the essential CDEIII region of centromeric DNA to initiate kinetochore assembly. We report the reconstitution of Cbf3p from recombinant proteins and an analysis of its p58(Ctf13) and p23(Skp1) subunits. p23(Skp1) has both G1- and G2-specific functions in yeast and binds to p58(Ctf13) and to the essential Cdc4p component of the ubiquitin conjugating complex Scul(Cdc4). We show that the function of p23(Skp1) in Cbf3p is to activate p58(Ctf13) by phosphorylation. p58(Ctf13) is an unstable protein that is targeted to the proteosome, probably by Scul(Cdc4)-mediated ubiquitination. Thus, p58 appears to be activated by phosphorylation in a p23(Skp1)-dependent step and degraded by the proteosome in a ubiquitin-dependent step. We propose that coupled activation and destruction link the assembly of Cbf3p to the duplication of centromeres in S phase.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY	Massachusetts Institute of Technology (MIT); European Molecular Biology Laboratory (EMBL)			Hyman, Anthony A/B-3917-2017; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; Sorger, Peter/0000-0002-3364-1838	NIGMS NIH HHS [GM51464] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051464] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; COHENFIX O, 1996, GENE DEV, V15, P3071; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; GAUDET A, 1987, MOL CELL BIOL, V7, P68, DOI 10.1128/MCB.7.1.68; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hyman AA, 1995, ANNU REV CELL DEV BI, V11, P471, DOI 10.1146/annurev.cb.11.110195.002351; JIANG W, 1993, COLD SPRING HARB SYM, V58, P669, DOI 10.1101/SQB.1993.058.01.074; KAPLAN KB, 1997, PROTEIN FUNCTION PRA, P245; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LECHNER J, 1994, EMBO J, V13, P5203, DOI 10.1002/j.1460-2075.1994.tb06851.x; MCGREW J, 1986, MOL CELL BIOL, V6, P530, DOI 10.1128/MCB.6.2.530; NG R, 1987, MOL CELL BIOL, V7, P4522, DOI 10.1128/MCB.7.12.4522; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SORGER PK, 1994, J CELL BIOL, V127, P995, DOI 10.1083/jcb.127.4.995; Sorger PK, 1995, P NATL ACAD SCI USA, V92, P12026, DOI 10.1073/pnas.92.26.12026; Stemmann O, 1996, EMBO J, V15, P3611, DOI 10.1002/j.1460-2075.1996.tb00730.x; STRUNNIKOV AV, 1995, J CELL BIOL, V128, P749, DOI 10.1083/jcb.128.5.749; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	31	133	135	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					491	500		10.1016/S0092-8674(00)80435-3	http://dx.doi.org/10.1016/S0092-8674(00)80435-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390558	Bronze			2022-12-24	WOS:A1997YG49200010
J	Mitchell, P; Petfalski, E; Shevchenko, A; Mann, M; Tollervey, D				Mitchell, P; Petfalski, E; Shevchenko, A; Mann, M; Tollervey, D			The exosome: A conserved eukaryotic RNA processing complex containing multiple 3'->5' exoribonucleases	CELL			English	Article							DOUBLE-STRANDED-RNA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; POLYACRYLAMIDE GELS; ANTIVIRAL SYSTEM; RIBOSOMAL-RNA; IN-VIVO; YEAST; PROTEINS	We identified a complex in S. cerevisiae, the ''exosome,'' consisting of the five essential proteins Rrp4p, Rrp41p, Rrp42p, Rrp43p, and Rrp44p (Dis3p). Remarkably, four of these proteins are homologous to characterized bacterial 3'-->5' exoribonucleases; Rrp44p is homologous to RNase II, while Rrp41p, Rrp42p, and Rrp43p are related to RNase PH. Recombinant Rrp4p, Rrp44p, and Rrp41p are 3'-->5' exoribonucleases in vitro that have distributive, processive, and phosphorolytic activities, respectively. All components of the exosome are required for 3' processing of the 5.8S rRNA. Human Rrp4p is found in a comparably sized complex, and expression of the hRRP4 gene in yeast complements the rrp4-1 mutation. We conclude that the exosome constitutes a highly conserved eukaryotic RNA processing complex.	EUROPEAN MOL BIOL LAB,EMBL,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Tollervey, David/AAR-6662-2020; Mann, Matthias/A-3454-2013	Tollervey, David/0000-0003-2894-2772; Mann, Matthias/0000-0003-1292-4799; Mitchell, Phil/0000-0002-3178-0439				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BELTRAME M, 1992, EMBO J, V11, P1531, DOI 10.1002/j.1460-2075.1992.tb05198.x; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; Brown CE, 1996, MOL CELL BIOL, V16, P5744; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; DEUTSCHER MP, 1991, P NATL ACAD SCI USA, V88, P3277, DOI 10.1073/pnas.88.8.3277; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DMOCHOWSKA A, 1995, CURR GENET, V28, P108, DOI 10.1007/BF00315775; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; INGOLIA TD, 1982, MOL CELL BIOL, V2, P1388, DOI 10.1128/MCB.2.11.1388; KASAI T, 1977, J BIOL CHEM, V252, P8950; KELLY KO, 1992, J BIOL CHEM, V267, P17153; KROGH A, 1994, J MOL BIOL, V235, P1501, DOI 10.1006/jmbi.1994.1104; Lafontaine D, 1996, NUCLEIC ACIDS RES, V24, P3469, DOI 10.1093/nar/24.17.3469; Laggerbauer B, 1996, NUCLEIC ACIDS RES, V24, P868, DOI 10.1093/nar/24.5.868; LAING S, 1996, MOL CELL BIOL, V16, P5139; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI ZW, 1995, P NATL ACAD SCI USA, V92, P6883, DOI 10.1073/pnas.92.15.6883; Li ZW, 1996, J BIOL CHEM, V271, P1133, DOI 10.1074/jbc.271.2.1133; LI ZW, 1994, J BIOL CHEM, V269, P6064; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Margossian SP, 1996, CELL, V84, P199, DOI 10.1016/S0092-8674(00)80975-7; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MASISON DC, 1995, MOL CELL BIOL, V15, P2763; MIAN S, 1997, NUCLEIC ACIDS RES, V25, P3187; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; MIN JJ, 1993, J BIOL CHEM, V268, P7350; Mitchell P, 1996, GENE DEV, V10, P502, DOI 10.1101/gad.10.4.502; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; RIDLEY SP, 1984, MOL CELL BIOL, V4, P761, DOI 10.1128/MCB.4.4.761; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THIERRY A, 1990, YEAST, V6, P521, DOI 10.1002/yea.320060609; TOBE T, 1992, J BACTERIOL, V174, P6359, DOI 10.1128/JB.174.20.6359-6367.1992; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; VOLCKAERT G, 1977, ANAL BIOCHEM, V83, P222, DOI 10.1016/0003-2697(77)90530-9; WIDNER WR, 1993, MOL CELL BIOL, V13, P4331, DOI 10.1128/MCB.13.7.4331; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Zhou ZH, 1997, J BACTERIOL, V179, P4391, DOI 10.1128/jb.179.13.4391-4395.1997	48	744	757	0	83	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					457	466		10.1016/S0092-8674(00)80432-8	http://dx.doi.org/10.1016/S0092-8674(00)80432-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390555	Bronze			2022-12-24	WOS:A1997YG49200007
J	Lahn, BT; Page, DC				Lahn, BT; Page, DC			Functional coherence of the human Y chromosome	SCIENCE			English	Article							ESCAPES X-INACTIVATION; SEX-DETERMINING REGION; AMINO-ACID-SEQUENCE; FAT-FACETS GENE; TURNER SYNDROME; MOLECULAR-CLONING; PROTEIN GENE; DROSOPHILA; EXPRESSION; MOUSE	A systematic search of the nonrecombining region or the human Y chromosome (NRY) identified 12 novel genes or families, 10 with full-length complementary DNA sequences. All 12 genes, and six of eight NRY genes or families previously isolated by less systematic means, fell into two classes. Genes in the first group were expressed in many organs; these housekeeping genes have X homologs that escape X inactivation. The second group, consisting of Y-chromosomal gene families expressed specifically in testes, may account for infertility among men with Y deletions. The coherence of the NRY's gene content contrasts with the apparently haphazard content of most eukaryotic chromosomes.	MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lahn, BT (corresponding author), MIT,HOWARD HUGHES MED INST,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							Affara N, 1996, CYTOGENET CELL GENET, V73, P33; AGULNIK AI, 1994, HUM MOL GENET, V3, P873, DOI 10.1093/hmg/3.6.873; AGULNIK AI, 1994, HUM MOL GENET, V3, P879, DOI 10.1093/hmg/3.6.879; ARNEMANN J, 1991, GENOMICS, V11, P108, DOI 10.1016/0888-7543(91)90107-P; Boynton ZL, 1996, J BACTERIOL, V178, P3015, DOI 10.1128/jb.178.11.3015-3024.1996; Bull J. J., 1983, EVOLUTION SEX DETERM; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; COOKE HJ, 1985, NATURE, V317, P687, DOI 10.1038/317687a0; Delbridge ML, 1997, NAT GENET, V15, P131, DOI 10.1038/ng0297-131; DEVER TE, 1994, J BIOL CHEM, V269, P3212; FERGUSON-SMITH M A, 1965, J Med Genet, V2, P142, DOI 10.1136/jmg.2.2.142; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; Fisher RA, 1931, BIOL REV BIOL P CAMB, V6, P345, DOI 10.1111/j.1469-185X.1931.tb01030.x; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; FORD CE, 1959, LANCET, V1, P711; FREIJE D, 1992, SCIENCE, V258, P1784, DOI 10.1126/science.1465614; GONDO H, 1987, J IMMUNOL, V139, P3840; GRAVES JAM, 1995, BIOESSAYS, V17, P311, DOI 10.1002/bies.950170407; Graves JAM, 1996, ANNU REV GENET, V30, P233, DOI 10.1146/annurev.genet.30.1.233; Greenfield A, 1996, NAT GENET, V14, P474, DOI 10.1038/ng1296-474; Hendriks W, 1995, J CELL BIOCHEM, V59, P418, DOI 10.1002/jcb.240590403; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HO MF, 1994, CELL, V77, P869, DOI 10.1016/0092-8674(94)90136-8; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; JACOBS PA, 1959, NATURE, V183, P302, DOI 10.1038/183302a0; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; Jones MH, 1996, HUM MOL GENET, V5, P1695, DOI 10.1093/hmg/5.11.1695; JUST W, 1992, HUM GENET, V89, P240; KANAZAWA M, 1993, ENZYME PROTEIN, V47, P9, DOI 10.1159/000468650; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; LUOH SW, 1995, GENOMICS, V29, P353, DOI 10.1006/geno.1995.9994; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; Madireddi MT, 1996, CELL, V87, P75, DOI 10.1016/S0092-8674(00)81324-0; MANZ E, 1993, GENOMICS, V17, P726, DOI 10.1006/geno.1993.1393; Mumm S, 1997, GENOME RES, V7, P307, DOI 10.1101/gr.7.4.307; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PALOSAARI PM, 1991, J BIOL CHEM, V266, P10750; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; Pryor JL, 1997, NEW ENGL J MED, V336, P534, DOI 10.1056/NEJM199702203360802; Rao E, 1997, NAT GENET, V16, P54, DOI 10.1038/ng0597-54; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Rice WR, 1996, BIOSCIENCE, V46, P331, DOI 10.2307/1312947; SAFER D, 1991, J BIOL CHEM, V266, P4029; SALIDO EC, 1992, AM J HUM GENET, V50, P303; SALO P, 1995, HUM GENET, V95, P283, DOI 10.1007/BF00225194; SALO P, 1995, GENE CHROMOSOME CANC, V14, P210, DOI 10.1002/gcc.2870140309; Saxena R, 1996, NAT GENET, V14, P292, DOI 10.1038/ng1196-292; SCHMITZ A, 1992, APPL ENVIRON MICROB, V58, P4068, DOI 10.1128/AEM.58.12.4068-4071.1992; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SCHWARTZ A, IN PRESS HUM MOL GEN; SEBOUN E, 1986, COLS SPRING HARBOR S, V1, P237; SHARMA V, 1992, J BACTERIOL, V174, P5057, DOI 10.1128/JB.174.15.5057-5062.1992; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SIMMLER MC, 1985, NATURE, V317, P692, DOI 10.1038/317692a0; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STEN C, 1957, AM J HUM GENET, V9, P147; Stokes DG, 1996, P NATL ACAD SCI USA, V93, P7137, DOI 10.1073/pnas.93.14.7137; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; TSUCHIYA K, 1995, AM J HUM GENET, V57, P1400; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; Vogt PH, 1996, HUM MOL GENET, V5, P933, DOI 10.1093/hmg/5.7.933; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769; WATANABE M, 1993, NAT GENET, V4, P268, DOI 10.1038/ng0793-268; ZINN AR, 1993, TRENDS GENET, V9, P90, DOI 10.1016/0168-9525(93)90230-F	68	665	706	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					675	680		10.1126/science.278.5338.675	http://dx.doi.org/10.1126/science.278.5338.675			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381176				2022-12-24	WOS:A1997YC32300052
J	Davies, SW; Beardsall, K; Turmaine, M; DiFiglia, M; Aronin, N; Bates, GP				Davies, SW; Beardsall, K; Turmaine, M; DiFiglia, M; Aronin, N; Bates, GP			Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?	LANCET			English	Article							SPINOCEREBELLAR ATAXIA TYPE-2; BULBAR MUSCULAR-ATROPHY; ANDROGEN RECEPTOR GENE; CAG REPEAT; HYALINE INCLUSIONS; DISEASE; DEGENERATION; CLONING	Neuronal intranuclear inclusions have been found in the brain of a transgenic mouse model of Huntington's disease and in necropsy brain tissue of patients with Huntington's disease, We suggest that neuronal intranuclear inclusions are the common neuropathology for all inherited diseases caused by expansion of polyglutamine repeats, We also suggest that patients with a pathological diagnosis of neuronal intranuclear hyaline inclusion disease may also have polyglutamine repeat expansions.	UCL, Dept Anat & Dev Biol, London WC1E 6JJ, England; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA; Univ Med & Dent New Jersey, Guys Hosp, Div Med & Mol Genet, London, England	University of London; University College London; Harvard University; Harvard Medical School; Massachusetts General Hospital; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Davies, SW (corresponding author), UCL, Dept Anat & Dev Biol, Rockefeller Bldg, London WC1E 6JJ, England.		Bates, Gillian P/E-1146-2012	Bates, Gillian P/0000-0002-4041-6305				[Anonymous], ADV NEUROL; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; Bates GP, 1997, HUM MOL GENET, V6, P1633, DOI 10.1093/hmg/6.10.1633; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; GILLES D, 1997, NAT GENET, V17, P65; Heintz N, 1997, NAT GENET, V16, P325, DOI 10.1038/ng0897-325; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; JANOTA I, 1979, NEUROPATH APPL NEURO, V5, P311, DOI 10.1111/j.1365-2990.1979.tb00630.x; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LINDENBERG R, 1968, ACTA NEUROPATHOL, V10, P54, DOI 10.1007/BF00690510; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MUNOZGARCIA D, 1986, NEUROLOGY, V36, P785, DOI 10.1212/WNL.36.6.785; NAKAMURA M, 1993, ANN NEUROL, V34, P261; NAKAMURA Y, 1994, RHODIUM EX, V6, P14; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PARKER JC, 1983, J NEUROPATH EXP NEUR, V42, P352, DOI 10.1097/00005072-198305000-00149; PATEL H, 1985, J NEUROL SCI, V67, P57, DOI 10.1016/0022-510X(85)90022-X; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; ROBITAILLE Y, 1997, BRAIN PATHOL, V7, P877; Ross CA, 1997, BRAIN PATHOL, V7, P1003, DOI 10.1111/j.1750-3639.1997.tb00898.x; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Sathasivam K, 1997, HUM GENET, V99, P692, DOI 10.1007/s004390050432; SCHALLING M, 1993, NAT GENET, V4, P136; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SCHUFFLER MD, 1978, GASTROENTEROLOGY, V75, P889; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; SLOANE AE, 1994, PEDIATR NEUROL, V10, P61, DOI 10.1016/0887-8994(94)90070-1; SOFFER D, 1985, ACTA NEUROPATHOL, V65, P322, DOI 10.1007/BF00687016; SUNG JH, 1980, J NEUROPATH EXP NEUR, V39, P107, DOI 10.1097/00005072-198003000-00001; SUNG JH, 1980, ACTA NEUROPATHOL, V50, P115, DOI 10.1007/BF00692861; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; YOUNG AB, 1977, HUNTINGTONS DIS OTHE; ZHUCHENKO S, 1997, NAT GENET, V15, P622	39	146	148	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					131	133		10.1016/S0140-6736(97)08360-8	http://dx.doi.org/10.1016/S0140-6736(97)08360-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439509				2022-12-24	WOS:000071591900045
J	Salisbury, DM				Salisbury, DM			Association between oral poliovaccine and Guillain-Barre syndrome?	LANCET			English	Editorial Material							CAMPAIGN		Dept Hlth, London SE1 8UG, England		Salisbury, DM (corresponding author), Dept Hlth, London SE1 8UG, England.							daSilveira CM, 1997, LANCET, V349, P14, DOI 10.1016/S0140-6736(96)07408-9; Howson CP, 1991, ADVERSE EFFECTS PERT; Hughes R, 1996, BRIT MED J, V312, P1475; KINNUNEN E, 1989, NEUROLOGY, V39, P1034, DOI 10.1212/WNL.39.8.1034; Kinnunen E, 1998, AM J EPIDEMIOL, V147, P69; Olive JA, 1997, J INFECT DIS, V175, pS160, DOI 10.1093/infdis/175.Supplement_1.S160; Stratton K.R., 1994, ADVERSE EVENTS ASS C; UHARI M, 1989, LANCET, V2, P440	8	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					79	80		10.1016/S0140-6736(05)78156-3	http://dx.doi.org/10.1016/S0140-6736(05)78156-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439487				2022-12-24	WOS:000071591900004
J	Gow, AJ; Stamler, JS				Gow, AJ; Stamler, JS			Reactions between nitric oxide and haemoglobin under physiological conditions	NATURE			English	Article							HEMOGLOBIN; NO; BLOOD; NITROSYLATION; BINDING; CELLS	The tenet of high-affinity nitric oxide (NO) binding to a haemoglobin (Hb) has shaped our view of haem proteins and of small diffusible signaling molecules. Specifically, NO binds rapidly to haem iron in Hb (k approximate to 10(7) M-1 s(-1)) (refs 1, 2) and once bound, the NO activity is largely irretrievable (K-d approximate to 10(-5) s(-1)) (refs 3-10); the binding is purportedly so tight as to be unaffected by O-2 or CO. However, these general principles do not consider the allosteric state of Hb or the nature of the allosteric effector,and they mostly derive from the functional behaviour of fully nitrosylated Hb, whereas Hb is only partially nitrosylated in vivo(11-16). Here we show that oxygen drives the conversion of nitrosylhaemoglobin in the 'tense' T (or partially nitrosylated, deoxy) structure to S-nitrosohaemoglobin in the 'relaxed' R (or ligand-bound, oxy) structure. In the absence of oxygen, nitroxyl anion(NO-) is liberated in a reaction producing methaemoglobin. The yields of both S-nitrosohaemoglobin and methaemoeglobin are dependent on the NO/Hb ratio. These newly discovered reactions elucidate mechanisms underlying NO function in the respiratory cycle, and provide insight into the aetiology of S-nitrosothiols, methaemoglobin and its related valency hybrids. Mechanistic re-examination of NO interactions with other haem proteins containing allosteric-site thiols may be warranted.	Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst, Durham, NC 27710 USA; Univ Penn, Inst Environm Med, Philadelphia, PA 19104 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; University of Pennsylvania	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA.		Gow, Andrew/N-8566-2013; Gow, Andrew/AAR-2309-2020	Gow, Andrew/0000-0003-0876-5158; Gow, Andrew/0000-0003-0876-5158; Stamler, Jonathan/0000-0002-6866-1572				ADDISON AW, 1986, BIOCHEMISTRY-US, V25, P4104, DOI 10.1021/bi00362a018; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, V32, P272; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; GIBSON QH, 1957, J PHYSIOL-LONDON, V136, P507, DOI 10.1113/jphysiol.1957.sp005777; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; HALL DM, 1994, J APPL PHYSIOL, V77, P548, DOI 10.1152/jappl.1994.77.2.548; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kagan VE, 1996, NATURE, V383, P30, DOI 10.1038/383030b0; KHARITONOV VG, 1996, METHODS NITRIC OXIDE, P39; KOSAKA H, 1994, AM J PHYSIOL, V266, pC1400, DOI 10.1152/ajpcell.1994.266.5.C1400; KRUSZYNA R, 1988, TOXICOL APPL PHARM, V94, P458, DOI 10.1016/0041-008X(88)90286-4; KRUSZYNA R, 1987, J PHARMACOL EXP THER, V241, P307; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; MARLETTA M A, 1990, Biofactors, V2, P219; MOORE EG, 1976, J BIOL CHEM, V251, P2788; Motterlini R, 1996, TRANSFUS MED REV, V10, P77, DOI 10.1016/S0887-7963(96)80084-8; Perutz MF, 1996, NATURE, V380, P205, DOI 10.1038/380205b0; PERUTZ MF, 1987, MOL BASIS BLOOD DISE, P127; RIGGS A, 1961, J BIOL CHEM, V236, P1948; RIGGS AF, 1956, J GEN PHYSIOL, V39, P585, DOI 10.1085/jgp.39.4.585; SHARMA VS, 1978, J BIOL CHEM, V253, P6467; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TAKETA F, 1978, J BIOL CHEM, V253, P5448; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; WESTENBERGER U, 1990, FREE RADICAL RES COM, V11, P167, DOI 10.3109/10715769009109680	30	490	508	0	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 8	1998	391	6663					169	173		10.1038/34402	http://dx.doi.org/10.1038/34402			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428761				2022-12-24	WOS:000071380900049
J	Hosenpud, JD; Bennett, LE; Keck, BM; Edwards, EB; Novick, RJ				Hosenpud, JD; Bennett, LE; Keck, BM; Edwards, EB; Novick, RJ			Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease	LANCET			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; REDUCTION SURGERY APPROPRIATE; QUALITY-OF-LIFE; EMPHYSEMA; RECIPIENTS; PROGNOSIS	Background Although certain forms of end-stage lung disease are debilitating, whether the associated mortality rate exceeds that of transplantation is unclear. We undertook analysis to clarify the survival benefit of lung transplantation for various types of end-stage lung disease. Methods We analysed data for all patients listed for transplantation in the USA for emphysema, cystic fibrosis, or interstitial pulmonary fibrosis in the years 1992-94. The numbers of patients entered on the waiting list, posttransplantation, died waiting, and currently waiting were: emphysema group 1274, 843, 143, and 165; cystic fibrosis group 664, 318, 193, and 59; interstitial pulmonary fibrosis group 481, 230, 160, and 48, A time-dependent non-proportional hazard analysis was used to assess the risk of mortality after transplantation relative to that for patients an the waiting list. Findings The dearest survival benefit from lung transplantation occurred in the cystic fibrosis group, The relative risks of transplantation compared with waiting were 0.87, 0.61, and 0.61 at 1 month, 6 months, and 1 year (p=0.008), respectively. For interstitial pulmonary fibrosis, the corresponding relative risks were 2.09, 0.71, and 0.67 (p=0.09). No survival benefit was apparent in the emphysema group, The risks of transplantation relative to waiting were 2.76, 1.12, and 1.10 at 1 month, 6 months, and 1 year, respectively, and the relative risk did not decrease to below 1.0 during 2 years of follow-up. Interpretation These findings suggest that lung transplantation does not confer a survival benefit in patients with end-stage emphysema by 2 years of follow-up, Other benefits not accounted for in this analysis such as improved quality of life, however, may justify lung transplantation for these patients.	Int Soc Heart & Lung Transplantat Thorac Registry, Joint United Network Organ Sharing, Richmond, VA USA	United Network for Organ Sharing	Hosenpud, JD (corresponding author), Med Coll Wisconsin, Div Cardiovasc Med, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.		Bennett, Louise/AAA-8266-2020	Bennett, Louise/0000-0001-9421-4410				[Anonymous], 1980, Ann Intern Med, V93, P391; [Anonymous], 1983, ANN INTERN MED, V99, P612, DOI 10.7326/0003-4819-99-5-612; ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P14, DOI 10.1164/arrd.1986.133.1.14; ANTHONISEN NR, 1989, AM REV RESPIR DIS, V140, pS95, DOI 10.1164/ajrccm/140.3_Pt_2.S95; COOPER JD, 1995, J THORAC CARDIOV SUR, V109, P106, DOI 10.1016/S0022-5223(95)70426-4; Cooper JD, 1996, AM J RESP CRIT CARE, V153, P1201, DOI 10.1164/ajrccm.153.4.8616541; COX DR, 1984, ANAL SURVIVAL DATA, P137; GROSS CR, 1995, CHEST, V108, P1587, DOI 10.1378/chest.108.6.1587; Hosenpud JD, 1996, J HEART LUNG TRANSPL, V15, P655; Lynch JP, 1996, MED CLIN N AM, V80, P657, DOI 10.1016/S0025-7125(05)70459-4; Make BJ, 1996, AM J RESP CRIT CARE, V153, P1205, DOI 10.1164/ajrccm.153.4.8616542; Naunheim KS, 1996, ANN THORAC SURG, V62, P601, DOI 10.1016/0003-4975(96)00428-6; ONOFRIO JM, 1992, MED CLIN N AM, V76, P1207, DOI 10.1016/S0025-7125(16)30319-4; PORT FK, 1993, JAMA-J AM MED ASSOC, V270, P1339, DOI 10.1001/jama.270.11.1339; RAMSEY SD, 1995, J HEART LUNG TRANSPL, V14, P870; RAMSEY SD, 1995, CHEST, V108, P1594, DOI 10.1378/chest.108.6.1594; SUNDARESAN S, 1995, ANN THORAC SURG, V60, P1341, DOI 10.1016/0003-4975(95)00751-6; ZENATI M, 1995, ANN THORAC SURG, V59, P1581, DOI 10.1016/0003-4975(95)00082-V	18	351	352	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 3	1998	351	9095					24	27		10.1016/S0140-6736(97)06405-2	http://dx.doi.org/10.1016/S0140-6736(97)06405-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433425				2022-12-24	WOS:000071253100012
J	Chen, R; Amoui, M; Zhang, ZH; Mardon, G				Chen, R; Amoui, M; Zhang, ZH; Mardon, G			Dachshund and eyes absent proteins form a complex and function synergistically to induce ectopic eye development in Drosophila	CELL			English	Article							HOMEOBOX-CONTAINING GENE; VISUAL-SYSTEM; EYELESS GENE; ENCODES; DIFFERENTIATION; MORPHOGENESIS; ANIRIDIA; DPP; MELANOGASTER; PROPAGATION	The eyeless, dachshund, and eyes absent genes encode conserved, nuclear proteins that are essential for eye development in Drosophila. Misexpression of eyeless or dachshund is also sufficient to induce the formation of ectopic compound eyes. Here we show that the dachshund and eyes absent genes act synergistically to induce ectopic retinal development and positively regulate the expression of each other. Moreover, we show that the Dachshund and Eyes Absent proteins can physically interact through conserved domains, suggesting a molecular basis for the genetic synergy observed and that a similar complex may function in mammals. We propose that a conserved regulatory network, rather than a linear hierarchy, controls retinal specification and involves multiple protein complexes that function during distinct steps of eye development.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA; Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Mardon, G (corresponding author), Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011232] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY11232-01, EY07001] Funding Source: Medline; NICHD NIH HHS [P30 HD24064] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BEVERLEY SM, 1984, J MOL EVOL, V21, P1, DOI 10.1007/BF02100622; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BONINI NM, 1995, CURR OPIN GENET DEV, V5, P507, DOI 10.1016/0959-437X(95)90056-M; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; Chanut F, 1997, DEVELOPMENT, V124, P559; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Freund C, 1996, HUM MOL GENET, V5, P1471, DOI 10.1093/hmg/5.Supplement_1.1471; Glardon S, 1997, DEVELOPMENT, V124, P817; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HARPER JW, 1993, CELL, V75, P805; HEBERLEIN U, 1995, CELL, V81, P987, DOI 10.1016/S0092-8674(05)80003-0; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEBERLEIN U, 1995, NATURE, V373, P709, DOI 10.1038/373709a0; HILL RE, 1992, NATURE, V355, P750, DOI 10.1038/355750a0; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MARDON G, 1994, DEVELOPMENT, V120, P3473; MOSES K, 1989, NATURE, V340, P531, DOI 10.1038/340531a0; MOSES K, 1991, GENE DEV, V5, P583, DOI 10.1101/gad.5.4.583; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Oliver G, 1995, DEVELOPMENT, V121, P4045; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; Pignoni F, 1997, DEVELOPMENT, V124, P271; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; Shen WP, 1997, DEVELOPMENT, V124, P45; STAEHLINGHAMPTON K, 1994, DEV BIOL, V164, P502, DOI 10.1006/dbio.1994.1219; THAKER HM, 1992, GENETICS, V131, P883; Tomarev SI, 1997, P NATL ACAD SCI USA, V94, P2421, DOI 10.1073/pnas.94.6.2421; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TREISMAN JE, 1995, DEVELOPMENT, V121, P3519; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; Wolff Tanya, 1993, P1277; Xu PX, 1997, DEVELOPMENT, V124, P219; Zimmerman JE, 1997, GENOME RES, V7, P128, DOI 10.1101/gr.7.2.128	44	314	323	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					893	903		10.1016/S0092-8674(00)80481-X	http://dx.doi.org/10.1016/S0092-8674(00)80481-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428513	Bronze			2022-12-24	WOS:000071281400007
J	Yaffe, MB; Rittinger, K; Volinia, S; Caron, PR; Aitken, A; Leffers, H; Gamblin, SJ; Smerdon, SJ; Cantley, LC				Yaffe, MB; Rittinger, K; Volinia, S; Caron, PR; Aitken, A; Leffers, H; Gamblin, SJ; Smerdon, SJ; Cantley, LC			The structural basis for 14-3-3 : phosphopeptide binding specificity	CELL			English	Article							PROTEIN-KINASE-C; BIOSPECIFIC INTERACTION ANALYSIS; MULTIPLE SIGNALING PATHWAYS; MIDDLE TUMOR-ANTIGEN; 14-3-3 PROTEIN; T-CELLS; 14-3-3-PROTEINS; ASSOCIATION; INHIBITION; ACTIVATION	The 14-3-3 family of proteins mediates signal transduction by binding to phosphoserine-containing proteins. Using phosphoserine-oriented peptide libraries to probe all mammalian and yeast 14-3-3s, we identified two different binding motifs, RSXpSXP and RXY/FXpSXP, present in nearly all known 14-3-3 binding proteins. The crystal structure of 14-3-3 zeta complexed with the phosphoserine motif in polyoma middle-T was determined to 2.6 Angstrom resolution. The bound peptide is in an extended conformation, with a tight turn created by the pS +2 Pro in a cia conformation. Sites of peptide-protein interaction in the complex rationalize the peptide library results. Finally, we show that the 14-3-3 dimer binds tightly to single molecules containing tandem repeats of phosphoserine motifs, implicating bidentate association as a signaling mechanism with molecules such as Raf, BAD, and CbI.	Beth Israel Deaconess Med Ctr, Dept Med, Div Signal Transduct, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Vertex Pharmaceut, Cambridge, MA 02139 USA; Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England; Rigshosp, Dept Growth, DK-2100 Copenhagen, Denmark; Rigshosp, Reprod Sect GR5064, DK-2100 Copenhagen, Denmark	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Vertex Pharmaceuticals; MRC National Institute for Medical Research; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Yaffe, MB (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Signal Transduct, HIM 1018,330 Brookline Ave, Boston, MA 02215 USA.		Cantley, Lewis C/D-1800-2014; Volinia, Stefano/AAA-9264-2019; Volinia, Stefano/A-3029-2010; Rittinger, Katrin/D-2586-2014; Rittinger, Katrin/N-3344-2019	Cantley, Lewis C/0000-0002-1298-7653; Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893; Rittinger, Katrin/0000-0002-7698-4435; Rittinger, Katrin/0000-0002-7698-4435; Smerdon, Stephen/0000-0001-5688-8465; Gamblin, Steve/0000-0001-5331-639X	NIGMS NIH HHS [GM56203, R01 GM056203] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, MOL CELL BIOCHEM, V149, P41, DOI 10.1007/BF01076562; AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; Craparo A, 1997, J BIOL CHEM, V272, P11663; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JONES DHA, 1995, J MOL BIOL, V245, P375, DOI 10.1006/jmbi.1994.0031; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONSSON U, 1993, ANN BIOL CLIN-PARIS, V51, P19; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Meller N, 1996, MOL CELL BIOL, V16, P5782; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rommel C, 1996, ONCOGENE, V12, P609; Schulz G. E., 1979, PRINCIPLES PROTEIN S; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; WheelerJones CPD, 1996, BIOCHEM J, V315, P41, DOI 10.1042/bj3150041; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	1320	1378	9	101	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	1997	91	7					961	971		10.1016/S0092-8674(00)80487-0	http://dx.doi.org/10.1016/S0092-8674(00)80487-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428519	Bronze			2022-12-24	WOS:000071281400013
J	Tappero, JW; Koehler, JE				Tappero, JW; Koehler, JE			Bacillary angiomatosis or Kaposi's sarcoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Centers for Disease Control & Prevention - USA; University of California System; University of California San Francisco	Tappero, JW (corresponding author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.								0	9	9	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 25	1997	337	26					1888	1888		10.1056/NEJM199712253372605	http://dx.doi.org/10.1056/NEJM199712253372605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN051	9407156				2022-12-24	WOS:000071128200005
J	Hanlon, VM				Hanlon, VM			Damascus Road	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	1997	278	24					2137	2138						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM043	9416996				2022-12-24	WOS:000071022200013
J	Debbie, JG; Trimarchi, CV				Debbie, JG; Trimarchi, CV			Prophylaxis for suspected exposure to bat rabies	LANCET			English	Editorial Material							EPIDEMIOLOGY		New York State Dept Hlth, Albany, NY 12201 USA	State University of New York (SUNY) System	Debbie, JG (corresponding author), New York State Dept Hlth, Albany, NY 12201 USA.							*CDC, 1997, MMWR-MORBID MORTAL W, V46, P770; CHILDS JE, 1994, EPIDEMIOL INFECT, V113, P501, DOI 10.1017/S0950268800068515; Feder HM, 1997, LANCET, V350, P1300, DOI 10.1016/S0140-6736(05)62479-8; LAFON M, 1986, LANCET, V2, P515; SCATTERDAY JE, 1954, VET MED, V49, P133; Smith JS, 1996, CLIN MICROBIOL REV, V9, P166, DOI 10.1128/CMR.9.2.166; Whitby JE, 1996, VET REC, V139, P491, DOI 10.1136/vr.139.20.491; *WHO, 1992, WHO TECH REP SER, V824, P21	8	5	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1790	1791		10.1016/S0140-6736(97)22051-9	http://dx.doi.org/10.1016/S0140-6736(97)22051-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428245				2022-12-24	WOS:000071102500002
J	Levine, S; Kaiser, L; Leferovich, J; Tikunov, B				Levine, S; Kaiser, L; Leferovich, J; Tikunov, B			Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOSIN HEAVY-CHAIN; HUMAN SKELETAL-MUSCLE; MYOFIBRILLAR PROTEIN-TURNOVER; FIBER TYPES; ELECTROPHORETIC SEPARATION; SINGLE FIBERS; SLOW MYOSIN; NORMAL MEN; FATIGUE; EXERCISE	Background In patients with severe chronic obstructive pulmonary disease, the diaphragm undergoes physiologic adaptations characterized by an increase in energy expenditure and relative resistance to fatigue. We hypothesized that these physiologic characteristics would be associated with structural adaptations consisting of an increased proportion of less-fatigable slow-twitch muscle fibers and slow isoforms of myofibrillar proteins. Methods We obtained biopsy specimens of the diaphragm from 6 patients with severe chronic obstructive pulmonary disease (mean [+/-SE] forced expiratory volume in one second, 33+/-4 percent of the predicted value; residual volume, 259+/-25 percent of the predicted value) and 10 control subjects. The proportions of the various isoforms of myosin heavy chains, myosin light chains, troponin, and tropomyosin were determined by sodium dodecyl sulfate-polyacrylamide-gel electrophoresis. We also used immunocytochemical techniques to determine the proportions of the various types of muscle fibers. Results The diaphragm-biopsy specimens from the patients had higher percentages of slow myosin heavy chain I (64+/-3 vs. 45+/-2 percent, P<0.001), and lower percentages of fast myosin heavy chains IIa (29+/-3 vs. 39+/-2 percent, P=0.01) and IIb (8+/-1 vs. 17+/-1 percent, P<0.001) than the diaphragms of the controls. Similar differences were noted when immunohistochemical techniques were used to compare the percentages of these fiber types in the two groups. In addition, the patients had higher percentages of the slow isoforms of myosin light chains, troponins, and tropomyosin, whereas the controls had higher percentages of the fast isoforms of these proteins. Conclusions Severe chronic obstructive pulmonary disease increases the slow-twitch characteristics of the muscle fibers in the diaphragm, an adaptation that increases resistance to fatigue. (C) 1997, Massachusetts Medical Society.	ALLEGHENY UNIV HLTH SCI,VET AFFAIRS MED CTR,CRIT CARE DIV,PHILADELPHIA,PA 19104; UNIV PENN,PENN MUSCLE INST,PHILADELPHIA,PA 19104; UNIV PENN,DIV THORAC SURG,PHILADELPHIA,PA 19104	Drexel University; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Pennsylvania	Levine, S (corresponding author), ALLEGHENY UNIV HLTH SCI,VET AFFAIRS MED CTR,DIV PULM,UNIV & WOODLAND AVES,PHILADELPHIA,PA 19104, USA.		Kaiser, Larry/L-7940-2019					AUBIER M, 1981, J APPL PHYSIOL, V50, P538, DOI 10.1152/jappl.1981.50.3.538; BATES PC, 1983, BIOCHEM J, V214, P593, DOI 10.1042/bj2140593; BAUMANN H, 1987, PFLUG ARCH EUR J PHY, V409, P349, DOI 10.1007/BF00583788; BELLEMARE F, 1987, J APPL PHYSIOL, V62, P1307, DOI 10.1152/jappl.1987.62.3.1307; BELLEMARE F, 1983, J APPL PHYSIOL, V55, P8, DOI 10.1152/jappl.1983.55.1.8; BILLETER R, 1981, EUR J BIOCHEM, V116, P389, DOI 10.1111/j.1432-1033.1981.tb05347.x; DHOOT GK, 1979, NATURE, V278, P714, DOI 10.1038/278714a0; EDWARDS RHT, 1977, J PHYSIOL-LONDON, V272, P769, DOI 10.1113/jphysiol.1977.sp012072; GRANDMONTLEBLANC A, 1977, CAN J BIOCHEM CELL B, V55, P949, DOI 10.1139/o77-142; GREASER ML, 1971, J BIOL CHEM, V246, P4226; HAVERBERG LN, 1975, BIOCHEM J, V152, P503, DOI 10.1042/bj1520503; HOWALD H, 1985, PFLUG ARCH EUR J PHY, V403, P369, DOI 10.1007/BF00589248; HUGHES SM, 1993, DEV BIOL, V158, P183, DOI 10.1006/dbio.1993.1178; JAKOBSSON P, 1990, EUR RESPIR J, V3, P192; JOHNSON BD, 1993, J PHYSIOL-LONDON, V460, P385, DOI 10.1113/jphysiol.1993.sp019477; KANNER RE, 1984, CLIN PULMONARY FUNCT; KELSEN SG, 1996, PULMONARY REHABILITA, V91, P117; KLITGAARD H, 1990, PFLUG ARCH EUR J PHY, V416, P470, DOI 10.1007/BF00370757; KLITGAARD H, 1990, ACTA PHYSIOL SCAND, V140, P55, DOI 10.1111/j.1748-1716.1990.tb08975.x; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFRAMBOISE WA, 1990, BIOCHIM BIOPHYS ACTA, V1035, P109, DOI 10.1016/0304-4165(90)90181-U; LARSSON L, 1985, MUSCLE NERVE, V8, P714, DOI 10.1002/mus.880080815; LARSSON L, 1991, AM J PHYSIOL, V261, pC93, DOI 10.1152/ajpcell.1991.261.1.C93; LARSSON L, 1993, J PHYSIOL-LONDON, V472, P595, DOI 10.1113/jphysiol.1993.sp019964; LEFEROVICH JM, 1995, J NEUROSCI, V15, P596; LEVINE S, 1988, J APPL PHYSIOL, V64, P672, DOI 10.1152/jappl.1988.64.2.672; Levine S, 1996, AM J PHYSIOL-CELL PH, V271, pC1480, DOI 10.1152/ajpcell.1996.271.5.C1480; MADOR MJ, 1993, AM REV RESPIR DIS, V148, P1571, DOI 10.1164/ajrccm/148.6_Pt_1.1571; MANCINI DM, 1992, CIRCULATION, V86, P909, DOI 10.1161/01.CIR.86.3.909; MOXHAM J, 1981, THORAX, V36, P164, DOI 10.1136/thx.36.3.164; NARUSAWA M, 1987, J CELL BIOL, V104, P447, DOI 10.1083/jcb.104.3.447; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; POLKEY MI, 1995, AM J RESP CRIT CARE, V152, P959, DOI 10.1164/ajrccm.152.3.7663810; ROUSSOS CS, 1977, J APPL PHYSIOL, V43, P189, DOI 10.1152/jappl.1977.43.2.189; SANCHEZ J, 1985, B EUR PHYSIOPATH RES, V21, P351; SANCHEZ J, 1982, B EUR PHYSIOPATH RES, V18, P901; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; SMERDU V, 1994, AM J PHYSIOL-CELL PH, V267, pC1723, DOI 10.1152/ajpcell.1994.267.6.C1723; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; TALMADGE RJ, 1993, J APPL PHYSIOL, V75, P2337, DOI 10.1152/jappl.1993.75.5.2337; Tikunov BA, 1996, J MOL CELL CARDIOL, V28, P2537, DOI 10.1006/jmcc.1996.0245; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed	44	252	263	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 18	1997	337	25					1799	1806		10.1056/NEJM199712183372503	http://dx.doi.org/10.1056/NEJM199712183372503			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL855	9400036				2022-12-24	WOS:A1997YL85500003
J	Lazaridis, T; Karplus, M				Lazaridis, T; Karplus, M			''New view'' of protein folding reconciled with the old through multiple unfolding simulations	SCIENCE			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; NUCLEATION-CONDENSATION MECHANISM; CHYMOTRYPSIN INHIBITOR-2; TRANSITION-STATE; ENERGY; PRINCIPLES	Twenty-four molecular dynamics trajectories of chymotrypsin inhibitor 2 provide a direct demonstration of the diversity of unfolding pathways. Comparison with experiments suggests that the transition state region for folding and unfolding occurs early with only 25 percent of the native contacts and that the root-mean-square deviations between contributing structures can be as large as 15 angstroms. Nevertheless, a statistically preferred unfolding pathway emerges from the simulations; disruption of tertiary interactions between the helix and a two-stranded portion of the beta sheet is the primary unfolding event. The results suggest a synthesis of the ''new'' and the classical view of protein folding with a preferred pathway on a funnel-like average energy surface.	HARVARD UNIV,DEPT CHEM & BIOL CHEM,CAMBRIDGE,MA 02138; UNIV STRASBOURG 1,INST LE BEL,ISIS,LAB CHIM BIOPHYS,F-67000 STRASBOURG,FRANCE	Harvard University; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ALONSO DOV, 1995, J MOL BIOL, V247, P501, DOI 10.1006/jmbi.1994.0156; BALDWIN RL, 1994, NATURE, V369, P183, DOI 10.1038/369183a0; BOCZKO EM, 1995, SCIENCE, V269, P393, DOI 10.1126/science.7618103; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRYNGELSON JD, 1989, J PHYS CHEM-US, V93, P6902, DOI 10.1021/j100356a007; CAFLISCH A, 1995, J MOL BIOL, V252, P672, DOI 10.1006/jmbi.1995.0528; CHAKRABARTTY A, 1994, PROTEIN SCI, V3, P843; DILL KA, 1995, PROTEIN SCI, V4, P561; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; Fersht AR, 1997, CURR OPIN STRUC BIOL, V7, P3, DOI 10.1016/S0959-440X(97)80002-4; Guo ZY, 1997, P NATL ACAD SCI USA, V94, P10161, DOI 10.1073/pnas.94.19.10161; ITZHAKI LS, 1995, J MOL BIOL, V254, P260, DOI 10.1006/jmbi.1995.0616; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; KARPLUS M, 1995, CURR OPIN STRUC BIOL, V5, P58, DOI 10.1016/0959-440X(95)80010-X; Karplus Martin, 1992, P127; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; Li AJ, 1996, J MOL BIOL, V257, P412, DOI 10.1006/jmbi.1996.0172; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Neira JL, 1996, FOLD DES, V1, P189, DOI 10.1016/S1359-0278(96)00031-4; Neria E, 1996, J CHEM PHYS, V105, P1902, DOI 10.1063/1.472061; Nolting B, 1997, P NATL ACAD SCI USA, V94, P826, DOI 10.1073/pnas.94.3.826; ONUCHIC JN, 1995, P NATL ACAD SCI USA, V92, P3626, DOI 10.1073/pnas.92.8.3626; Onuchic JN, 1996, FOLD DES, V1, P441, DOI 10.1016/S1359-0278(96)00060-0; PRIVALOV PL, 1993, J MOL BIOL, V232, P660, DOI 10.1006/jmbi.1993.1417; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; SCHOEMAKER BA, 1997, P NATL ACAD SCI USA, V94, P777; SHAKHNOVICH EI, 1989, BIOPHYS CHEM, V34, P187, DOI 10.1016/0301-4622(89)80058-4; Thirumalai D, 1996, ACCOUNTS CHEM RES, V29, P433, DOI 10.1021/ar9500933	28	486	490	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1928	1931		10.1126/science.278.5345.1928	http://dx.doi.org/10.1126/science.278.5345.1928			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395391				2022-12-24	WOS:A1997YL00200029
J	Biederer, T; Volkwein, C; Sommer, T				Biederer, T; Volkwein, C; Sommer, T			Role of Cue1p in ubiquitination and degradation at the ER surface	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM; PROTEASOME PATHWAY; PROTEIN; COMPLEX; TRANSLOCATION; SEC61P; ENZYME	Endoplasmic reticulum (ER) degradation of aberrant proteins is mediated by the ubiquitin-proteasome pathway. Here, a membrane-bound component of the ubiquitin system, Cue1p, was identified. It was shown to recruit the soluble ubiquitin-conjugating enzyme Ubc7p to the ER membrane. In the absence of Cue1p, unassembled and thus cytosolically mislocalized Ubc7p was unable to participate in ER degradation or in the turnover of soluble non-ER proteins. Moreover, ubiquitination by Cue1p-assembled Ubc7p and Ubc6p was a prerequisite for retrograde transport of lumenal substrates out of the ER, which suggests that ubiquitination is mechanistically integrated into the ER degradation process.	MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Biederer, Thomas/AAZ-6133-2021	Biederer, Thomas/0000-0003-0912-1514				Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Papworth C.B., 1996, STRATEGIES, V9, P3, DOI DOI 10.1080/08924562.1996.11000299; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SCHWARTZ AL, 1992, P NATL ACAD SCI USA, V89, P5542, DOI 10.1073/pnas.89.12.5542; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WOLF DH, 1975, J BACTERIOL, V123, P1150, DOI 10.1128/JB.123.3.1150-1156.1975	22	312	314	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1806	1809		10.1126/science.278.5344.1806	http://dx.doi.org/10.1126/science.278.5344.1806			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388185				2022-12-24	WOS:A1997YJ90100051
J	DeAngelis, PL; Jing, W; Graves, MV; Burbank, DE; VanEtten, JL				DeAngelis, PL; Jing, W; Graves, MV; Burbank, DE; VanEtten, JL			Hyaluronan synthase of chlorella virus PBCV-1	SCIENCE			English	Article							STREPTOCOCCUS-PYOGENES; SEQUENCE; PROTEIN; ALGA	Sequence analysis of the 330-kilobase genome of the virus PBCV-1 that infects a chlorella-like green algae revealed an open reading frame, A98R, with similarity to several hyaluronan synthases. Hyaluronan is an essential polysaccharide found in higher animals as well as in a few pathogenic bacteria. Expression of the A98R gene product in Escherichia coli indicated that the recombinant protein is an authentic hyaluronan synthase. A98R is expressed early in PBCV-1 infection and hyaluronan is produced in infected algae. These results demonstrate that a virus can encode an enzyme capable of synthesizing a carbohydrate polymer and that hyaluronan exists outside of animals and their pathogens.	UNIV NEBRASKA,DEPT PLANT PATHOL,LINCOLN,NE 68583	University of Nebraska System; University of Nebraska Lincoln	DeAngelis, PL (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,940 STANTON L YOUNG BLVD,OKLAHOMA CITY,OK 73104, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056497, R01GM032441] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM32441, R01-GM56497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBANK DE, 1983, SCIENCE, V219, P994; CARTER GR, 1953, AM J VET RES, V14, P475; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; DEANGELIS PL, 1994, BIOCHEM BIOPH RES CO, V199, P1, DOI 10.1006/bbrc.1994.1184; DeAngelis PL, 1996, BIOCHEMISTRY-US, V35, P9768, DOI 10.1021/bi960154k; DEANGELIS PL, UNPUB; GRAVES M, UNPUB; HARMON BG, 1991, AM J VET RES, V52, P1507; Kass EH, 1944, J EXP MED, V79, P319, DOI 10.1084/jem.79.3.319; KNUDSON CB, 1993, FASEB J, V7, P1234; LANDSTEIN D, UNPUB; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; MOFFATT BA, 1986, J MOL BIOL, V189, P113; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; PUMMILL PE, UNPUB; QUINN RW, 1957, BIOCHEM J, V95, P290; Reisser W., 1992, ALGAE SYMBIOSES; ROHOZINSKI J, 1989, VIROLOGY, V168, P363, DOI 10.1016/0042-6822(89)90277-8; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SKRDLA MP, 1984, VIROLOGY, V135, P308, DOI 10.1016/0042-6822(84)90188-0; TENGBLAD A, 1980, BIOCHEM J, V185, P101, DOI 10.1042/bj1850101; VANETTEN JL, 1991, MICROBIOL REV, V55, P586, DOI 10.1128/MMBR.55.4.586-620.1991; VANETTEN JL, 1995, MOL CELLS, V5, P99; VANETTEN JL, 1985, VIROLOGY, V140, P135, DOI 10.1016/0042-6822(85)90452-0; WANG IN, 1993, P NATL ACAD SCI USA, V90, P3840, DOI 10.1073/pnas.90.9.3840; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; YAMADA T, 1991, APPL ENVIRON MICROB, V57, P3433, DOI 10.1128/AEM.57.12.3433-3437.1991; ZHANG YP, 1994, VIROLOGY, V202, P1079, DOI 10.1006/viro.1994.1444	34	96	112	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1800	1803		10.1126/science.278.5344.1800	http://dx.doi.org/10.1126/science.278.5344.1800			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388183	Green Published			2022-12-24	WOS:A1997YJ90100049
J	Palkova, Z; Janderova, B; Gabriel, J; Zikanova, B; Pospisek, M; Forstova, J				Palkova, Z; Janderova, B; Gabriel, J; Zikanova, B; Pospisek, M; Forstova, J			Ammonia mediates communication between yeast colonies	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; RAS PROTEINS; LOCALIZATION; EXPRESSION; GROWTH	Under certain growth conditions unicellular organisms behave as highly organized multicellular structures. For example, the fruiting bodies of myxobacteria(1) and of the slime mould Dictyostelium discoideum(2) form structures composed of non-dividing motile cells. Although non-motile, yeasts can create organized structures, colonies in which cells communicate and act in a coordinated fashion. Colony morphologies are characteristic for different species and strains. Here we describe that, in addition to short-range intracolony cell-cell communication, yeasts exhibit long-distance signals between neighbouring colonies. The volatile alkaline compound ammonia, transmitted by yeast colonies in pulses, has been identified as a substance mediating the intercolony signal. The first alkaline pulse produced by neighbouring colonies is non-directed and is followed by acidification of the medium. The second pulse seems to be enhanced and is oriented towards the neighbour colony. Ammonia signalling results in growth inhibition of the facing parts of both colonies. This phenomenon is observed in different yeast genera. The presence of amino acids in the medium is required for ammonia production, Colonies derived from the yeast Saccharomyces cerevisiae shr3 mutant, defective in localization of amino-acid permeases(3), do not produce detectable amounts of ammonia and do not exhibit asymmetric growth inhibition.	ACAD SCI CZECH REPUBL,INST MICROBIOL,CR-14220 PRAGUE 4,CZECH REPUBLIC	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Palkova, Z (corresponding author), CHARLES UNIV,DEPT GENET & MICROBIOL,VINICNA 5,PRAGUE 12844 2,CZECH REPUBLIC.		Zikánová, Blanka/P-9993-2017; Pospisek, Martin/A-9100-2008; Gabriel, Jiri/H-2473-2014; Palkova, Zdena/M-8692-2014; Forstova, Jitka/L-7328-2017	Zikánová, Blanka/0000-0002-2599-4713; Palkova, Zdena/0000-0002-0864-8042; Gabriel, Jiri/0000-0001-9341-3434; Forstova, Jitka/0000-0003-0219-506X; Pospisek, Martin/0000-0002-9490-8911				CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; GROSS JD, 1994, MICROBIOL REV, V58, P330, DOI 10.1128/MMBR.58.3.330-351.1994; KOCKOVAKRATOCHV.A, 1990, YEASTS YEAST LIKE OR; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; MARAZ A, 1979, PROTOPLASTS APPLICAT, P35; MARINI AM, 1994, EMBO J, V13, P3456, DOI 10.1002/j.1460-2075.1994.tb06651.x; MITCHELL AP, 1986, NATURE, V319, P738, DOI 10.1038/319738a0; SCHAAP P, 1995, DEV BIOL, V168, P179, DOI 10.1006/dbio.1995.1070; Serrano R, 1991, MOL CELLULAR BIOL YE, P523; SHIMKETS LJ, 1990, MICROBIOL REV, V54, P473, DOI 10.1128/MMBR.54.4.473-501.1990; SUOMALAINEN H, 1967, J I BREWING, V73, P477; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WRIGHT RM, 1993, CURR GENET, V23, P388, DOI 10.1007/BF00312623	15	170	177	1	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					532	536		10.1038/37398	http://dx.doi.org/10.1038/37398			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394006				2022-12-24	WOS:A1997YJ86500058
J	Hamblin, R; Harrison, A; Boyle, S				Hamblin, R; Harrison, A; Boyle, S			The supertanker's not for turning	LANCET			English	Editorial Material											Hamblin, R (corresponding author), KINGS FUND, LONDON W1M 0AN, ENGLAND.							APPLEBY J, 1994, HLTH SERVICE J, V104, P36; Dixon J, 1997, BRIT MED J, V314, P86, DOI 10.1136/bmj.314.7074.86; NEWTON JN, 1995, BRIT MED J, V311, P783, DOI 10.1136/bmj.311.7008.783; *NHS EX, 1997, EX LETT, V97, P42	4	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1493	1494		10.1016/S0140-6736(05)63937-2	http://dx.doi.org/10.1016/S0140-6736(05)63937-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388394				2022-12-24	WOS:A1997YH11500005
J	Endres, MJ; Jaffer, S; Haggarty, B; Turner, JD; Doranz, BJ; OBrien, PJ; Kolson, DL; Hoxie, JA				Endres, MJ; Jaffer, S; Haggarty, B; Turner, JD; Doranz, BJ; OBrien, PJ; Kolson, DL; Hoxie, JA			Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CYTOPLASMIC DOMAIN; REPLICATION; EXPRESSION	Retroviral vectors containing CD4 and an appropriate chemokine receptor were evaluated for the ability to transduce cells infected with human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV). These CD4-chemokine receptor pseudotypes were able to target HIV- and SIV-infected cell lines and monocyte-derived macrophages in a manner that corresponded to the specificity of the viral envelope glycoprotein for its CD4-chemokine receptor complex. This approach could offer a way to deliver antiviral genes directly to HIV-infected cells in vivo and could provide an additional treatment strategy in conjunction with existing antiviral therapies.	UNIV PENN,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	Endres, MJ (corresponding author), UNIV PENN,DEPT MED,DIV HEMATOL ONCOL,PHILADELPHIA,PA 19104, USA.		O'Brien, Peter J/B-5182-2013; Good (formerly Turner), Julie/I-8305-2018	O'Brien, Peter J/0000-0003-4127-2718; 	NHLBI NIH HHS [HL 07439] Funding Source: Medline; NIAID NIH HHS [AI33854, AI40880] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033854, R01AI040880] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLIET JW, IN PRESS J VIROL; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; COLLMAN R, 1989, J EXP MED, V170, P1149, DOI 10.1084/jem.170.4.1149; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; ENDRES M, UNPUB; Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; LABRANCHE CC, 1995, J VIROL, V69, P5217, DOI 10.1128/JVI.69.9.5217-5227.1995; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; Mebatsion T, 1997, CELL, V90, P841, DOI 10.1016/S0092-8674(00)80349-9; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nolan GP, 1997, CELL, V90, P821, DOI 10.1016/S0092-8674(00)80345-1; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Sauter MM, 1996, J CELL BIOL, V132, P795, DOI 10.1083/jcb.132.5.795; Schnell MJ, 1997, CELL, V90, P849, DOI 10.1016/S0092-8674(00)80350-5	22	59	66	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1462	1464		10.1126/science.278.5342.1462	http://dx.doi.org/10.1126/science.278.5342.1462			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367958				2022-12-24	WOS:A1997YG85800044
J	Kunst, F; Ogasawara, N; Moszer, I; Albertini, AM; Alloni, G; Azevedo, V; Bertero, MG; Bessieres, P; Bolotin, A; Borchert, S; Borriss, R; Boursier, L; Brans, A; Braun, M; Brignell, SC; Bron, S; Brouillet, S; Bruschi, CV; Caldwell, B; Capuano, V; Carter, NM; Choi, SK; Codani, JJ; Connerton, IF; Cummings, NJ; Daniel, RA; Denizot, F; Devine, KM; Dusterhoft, A; Ehrlich, SD; Emmerson, PT; Entian, KD; Errington, J; Fabret, C; Ferrari, E; Foulger, D; Fritz, C; Fujita, M; Fujita, Y; Fuma, S; Galizzi, A; Galleron, N; Ghim, SY; Glaser, P; Goffeau, A; Golightly, EJ; Grandi, G; Guiseppi, G; Guy, BJ; Haga, K; Haiech, J; Harwood, CR; Henaut, A; Hilbert, H; Holsappel, S; Hosono, S; Hullo, MF; Itaya, M; Jones, L; Joris, B; Karamata, D; Kasahara, Y; KlaerrBlanchard, M; Klein, C; Kobayashi, Y; Koetter, P; Koningstein, G; Krogh, S; Kumano, M; Kurita, K; Lapidus, A; Lardinois, S; Lauber, J; Lazarevic, V; Lee, SM; Levine, A; Liu, H; Masuda, S; Mauel, C; Medigue, C; Medina, N; Mellado, RP; Mizuno, M; Moestl, D; Nakai, S; Noback, M; Noone, D; OReilly, M; Ogawa, K; Ogiwara, A; Oudega, B; Park, SH; Parro, V; Pohl, TM; Portetelle, D; Porwollik, S; Prescott, AM; Presecan, E; Pujic, P; Purnelle, B; Rapoport, G; Rey, M; Reynolds, S; Rieger, M; Rivolta, C; Rocha, E; Roche, B; Rose, M; Sadaie, Y; Sato, T; Scanlan, E; Schleich, S; Schroeter, R; Scoffone, F; Sekiguchi, J; Sekowska, A; Seror, SJ; Serror, P; Shin, BS; Soldo, B; Sorokin, A; Tacconi, E; Takagi, T; Takahashi, H; Takemaru, K; Takeuchi, M; Tamakoshi, A; Tanaka, T; Terpstra, P; Tognoni, A; Tosato, V; Uchiyama, S; Vandenbol, M; Vannier, F; Vassarotti, A; Viari, A; Wambutt, R; Wedler, E; Wedler, H; Weitzenegger, T; Winters, P; Wipat, A; Yamamoto, H; Yamane, K; Yasumoto, K; Yata, K; Yoshida, K; Yoshikawa, HF; Zumstein, E; Yoshikawa, H; Danchin, A				Kunst, F; Ogasawara, N; Moszer, I; Albertini, AM; Alloni, G; Azevedo, V; Bertero, MG; Bessieres, P; Bolotin, A; Borchert, S; Borriss, R; Boursier, L; Brans, A; Braun, M; Brignell, SC; Bron, S; Brouillet, S; Bruschi, CV; Caldwell, B; Capuano, V; Carter, NM; Choi, SK; Codani, JJ; Connerton, IF; Cummings, NJ; Daniel, RA; Denizot, F; Devine, KM; Dusterhoft, A; Ehrlich, SD; Emmerson, PT; Entian, KD; Errington, J; Fabret, C; Ferrari, E; Foulger, D; Fritz, C; Fujita, M; Fujita, Y; Fuma, S; Galizzi, A; Galleron, N; Ghim, SY; Glaser, P; Goffeau, A; Golightly, EJ; Grandi, G; Guiseppi, G; Guy, BJ; Haga, K; Haiech, J; Harwood, CR; Henaut, A; Hilbert, H; Holsappel, S; Hosono, S; Hullo, MF; Itaya, M; Jones, L; Joris, B; Karamata, D; Kasahara, Y; KlaerrBlanchard, M; Klein, C; Kobayashi, Y; Koetter, P; Koningstein, G; Krogh, S; Kumano, M; Kurita, K; Lapidus, A; Lardinois, S; Lauber, J; Lazarevic, V; Lee, SM; Levine, A; Liu, H; Masuda, S; Mauel, C; Medigue, C; Medina, N; Mellado, RP; Mizuno, M; Moestl, D; Nakai, S; Noback, M; Noone, D; OReilly, M; Ogawa, K; Ogiwara, A; Oudega, B; Park, SH; Parro, V; Pohl, TM; Portetelle, D; Porwollik, S; Prescott, AM; Presecan, E; Pujic, P; Purnelle, B; Rapoport, G; Rey, M; Reynolds, S; Rieger, M; Rivolta, C; Rocha, E; Roche, B; Rose, M; Sadaie, Y; Sato, T; Scanlan, E; Schleich, S; Schroeter, R; Scoffone, F; Sekiguchi, J; Sekowska, A; Seror, SJ; Serror, P; Shin, BS; Soldo, B; Sorokin, A; Tacconi, E; Takagi, T; Takahashi, H; Takemaru, K; Takeuchi, M; Tamakoshi, A; Tanaka, T; Terpstra, P; Tognoni, A; Tosato, V; Uchiyama, S; Vandenbol, M; Vannier, F; Vassarotti, A; Viari, A; Wambutt, R; Wedler, E; Wedler, H; Weitzenegger, T; Winters, P; Wipat, A; Yamamoto, H; Yamane, K; Yasumoto, K; Yata, K; Yoshida, K; Yoshikawa, HF; Zumstein, E; Yoshikawa, H; Danchin, A			The complete genome sequence of the Gram-positive bacterium Bacillus subtilis	NATURE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; DNA-SEQUENCES; REPLICATION; TERMINATORS; COMPETENCE; PROJECT; STRANDS; REGION; ACIDS	Bacillus subtilis Is the best-characterized member of the Gram-positive bacteria. Its genome of 4,214,810 base pairs comprises 4,100 protein-coding genes. Of these protein-coding genes, 53% are represented once, while a quarter of the genome corresponds to several gene families that have been greatly expanded by gene duplication, the largest family containing 77 putative ATP-binding transport proteins. In addition, a large proportion of the genetic capacity is devoted to the utilization of a variety of carbon sources, including many plant-derived molecules. The identification of five signal peptidase genes, as well as several genes for components of the secretion apparatus, is important given the capacity of Bacillus strains to secrete large amounts of industrially important enzymes. Many of the genes are involved in the synthesis of secondary metabolites, Including antibiotics, that are more typically associated with Streptomyces species. The genome contains at least ten prophages or remnants of prophages, indicating that bacteriophage Infection has played an important evolutionary role in horizontal gene transfer, in particular In the propagation of bacterial pathogenesis.	NARA INST SCI & TECHNOL, GRAD SCH BIOL SCI, NARA 63001, JAPAN; INST PASTEUR, UNITE REGULAT EXPRESS GENET, F-75724 PARIS 15, FRANCE; UNIV PAVIA, DIPARTIMENTO GENET & MICROBIOL, I-27100 PAVIA, ITALY; INRA, F-78352 JOUY EN JOSAS, FRANCE; UNIV FRANKFURT, INST MIKROBIOL, D-60439 FRANKFURT, GERMANY; HUMBOLDT UNIV BERLIN, INST GENET & MIKROBIOL, D-10115 BERLIN, GERMANY; UNIV LIEGE, CTR INGN PROT, INST CHIM B6, B-4000 LIEGE, BELGIUM; QIAGEN GMBH, D-40724 HILDEN, GERMANY; UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT MICROBIOL IMMUNOL & VIROL SCI, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND; UNIV GRONINGEN, DEPT GENET, NL-9751 NN HAREN, NETHERLANDS; UNIV PARIS 06, ATELIER BIOINFORMAT, F-75005 PARIS, FRANCE; INT CTR GENET ENGN & BIOTECHNOL, AREA SCI PK, I-34012 TRIESTE, ITALY; GENENCOR INT, PALO ALTO, CA 94304 USA; KRIBB, APPL MICROBIOL RES DIV, BACTERIAL MOL GENET RES UNIT, TAEJON 305600, SOUTH KOREA; INST NATL RECH INFORMAT & AUTOMAT, F-78153 LE CHESNAY, FRANCE; INST FOOD RES, READING LAB, DEPT FOOD MACROMOL SCI, READING RG6 6BZ, BERKS, ENGLAND; UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, OXFORD OX1 3RE, ENGLAND; CNRS, CHIM BACTERIENNE LAB, F-13402 MARSEILLE 09, FRANCE; TRINITY COLL DUBLIN, DEPT GENET, DUBLIN, IRELAND; UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT BIOCHEM & GENET, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND; NATL INST GENET, CTR RADIOISOTOPE, MISHIMA, SHIZUOKA 411, JAPAN; FUKUYAMA UNIV, FAC ENGN, DEPT BIOTECHNOL, HIROSHIMA 72902, JAPAN; UNIV TSUKUBA, INST BIOL SCI, TSUKUBA, IBARAKI 305, JAPAN; UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, FAC SCI AGRON, B-1348 LOUVAIN, BELGIUM; NOVO NORDISK BIOTECH, DAVIS, CA 95616 USA; ENIRICERCHE SPA, I-20097 SAN DONATO MILANESE, MILAN, ITALY; UNIV TOKYO, INST MOL & CELLULAR BIOL, BUNKYO KU, TOKYO 113, JAPAN; UNIV VERSAILLES, LAB GENOME & INFORMAT, F-78035 VERSAILLES, FRANCE; TOKYO UNIV AGR & TECHNOL, FAC AGR, FUCHU, TOKYO 183, JAPAN; MITSUBISHI KASEI INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN; INST PASTEUR, SERV INFORMAT SCI, F-75724 PARIS 15, FRANCE; UNIV LAUSANNE, INST GENET & BIOL MICROBIENNES, CH-1005 LAUSANNE, SWITZERLAND; FREE UNIV AMSTERDAM, FAC BIOL, DEPT MOL MICROBIOL, MBW BCA, NL-1081 HV AMSTERDAM, NETHERLANDS; CHONGJU UNIV, COLL SCI & ENGN, CHONJU, SOUTH KOREA; UNIV PARIS 11, INST GENET & MICROBIOL, CNRS, URA 2225, F-91405 ORSAY, FRANCE; CSIC, CTR NACL BIOTECNOL, E-28049 MADRID, SPAIN; NATL INST BASIC BIOL, OKAZAKI, AICHI 444, JAPAN; GESELL ANAL TECH & CONSULTING MBH, D-78467 CONSTANCE, GERMANY; FAC AGRON, DEPT MICROBIOL, B-5030 GEMBLOUX, BELGIUM; BMF, BIOTECH RES, D-69434 HIRSCHHORN, GERMANY; SHINSHU UNIV, FAC TEXT SCI & TECHNOL, DEPT APPL BIOL, UEDA, NAGANO 386, JAPAN; UNIV TOKYO, INST MED SCI, CTR HUMAN GENOME, MINATO KU, TOKYO 108, JAPAN; TOKAI UNIV, SCH MARINE SCI & TECHNOL, DEPT MARINE SCI, SHIZUOKA 424, JAPAN; COMMISS EUROPEAN COMMUNITIES, DG XII E 1, SDME 878, B-1049 BRUSSELS, BELGIUM; AGOWA GMBH, D-12489 BERLIN, GERMANY	Nara Institute of Science & Technology; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Pavia; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Goethe University Frankfurt; Humboldt University of Berlin; University of Liege; QIAGEN GmbH; Newcastle University - UK; University of Groningen; UDICE-French Research Universities; Sorbonne Universite; International Center for Genetic Engineering & Biotechnology (ICGEB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of Oxford; Centre National de la Recherche Scientifique (CNRS); Trinity College Dublin; Newcastle University - UK; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Fukuyama University; University of Tsukuba; Universite Catholique Louvain; Novo Nordisk; Eni SpA; University of Tokyo; UDICE-French Research Universities; Universite Paris Saclay; Tokyo University of Agriculture & Technology; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Lausanne; Vrije Universiteit Amsterdam; Cheongju University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Shinshu University; University of Tokyo; Tokai University	Kunst, F (corresponding author), INST PASTEUR, UNITE BIOCHIM MICROBIENNE, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE.		Levine, Alex/A-6867-2008; Ogasawara, Naotake/B-7971-2011; Bolotine, Alexandre/AAW-1156-2020; Pujic, Petar/ACY-1850-2022; Glaser, Philippe/O-2641-2015; Ehrlich, S./Y-2423-2019; Parro, Victor/K-3788-2014; TAKEUCHI, Michio/H-6592-2013; Lapidus, Alla L/I-4348-2013; Choi, Soo-Keun/AAF-2432-2019; Daniel, Richard A./I-2850-2019; Entian, Karl-Dieter/D-3080-2011; haiech, jacques J/F-2890-2010; Pupin, Maude/I-7437-2015; Harwood, Colin/AGF-0120-2022; Azevedo, Vasco/B-1556-2019; Sekiguchi, Junichi/F-9963-2010; Sorokin, Alexei/AAV-4666-2020; Errington, Jeff/G-1832-2011; Borriss, Rainer/C-5026-2012; Rocha, Eduardo/B-7009-2009; Azevedo, Vasco A.C/F-4315-2011; Rocha, Eduardo/A-4727-2008; Serror, Pascale/ABA-1314-2021; Mellado, Rafael P/D-2680-2009; Yoshida, Ken-ichi/R-8863-2016; Kasahara, Yasuhiro/C-8620-2012	Bolotine, Alexandre/0000-0002-5878-8270; Pujic, Petar/0000-0003-1957-8534; Glaser, Philippe/0000-0003-4156-2782; Ehrlich, S./0000-0002-7563-4046; Lapidus, Alla L/0000-0003-0427-8731; Daniel, Richard A./0000-0002-6483-5897; Pupin, Maude/0000-0003-3197-0715; Azevedo, Vasco/0000-0002-4775-2280; Sorokin, Alexei/0000-0002-8653-9896; Errington, Jeff/0000-0002-6977-9388; Borriss, Rainer/0000-0003-3726-1004; Rocha, Eduardo/0000-0001-7704-822X; Azevedo, Vasco A.C/0000-0002-4775-2280; Serror, Pascale/0000-0002-8446-9011; Yoshida, Ken-ichi/0000-0002-3383-4664; Brans, Alain/0000-0003-4001-2762; Choi, Soo-Keun/0000-0001-7757-4748; Grandi, Guido/0000-0001-9724-2185; Harwood, Colin/0000-0002-3624-0001; Jones, Louis/0000-0002-3080-9770; Wipat, Anil/0000-0001-7310-4191; haiech, jacques/0000-0003-2908-8053; Parro, Victor/0000-0003-3738-0724; Capuano, Veronique/0000-0001-8738-0947; Rivolta, Carlo/0000-0002-0733-9950; Lazarevic, Vladimir/0000-0002-6839-2536; Connerton, Ian/0000-0001-8652-8938; Danchin, Antoine/0000-0002-6350-5001; Fujita, Masaya/0000-0003-0060-5328; Bertero, Michela/0000-0002-2012-6706				ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; AZEVEDO V, 1993, P NATL ACAD SCI USA, V90, P6047, DOI 10.1073/pnas.90.13.6047; Billoud B, 1996, NUCLEIC ACIDS RES, V24, P1395, DOI 10.1093/nar/24.8.1395; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BORODOVSKY M, 1993, COMPUT CHEM, V17, P123, DOI 10.1016/0097-8485(93)85004-V; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURGE C, 1992, P NATL ACAD SCI USA, V89, P1358, DOI 10.1073/pnas.89.4.1358; BURKHOLDER PR, 1947, AM J BOT, V34, P345, DOI 10.2307/2437147; CARAFA YD, 1990, J MOL BIOL, V216, P835, DOI 10.1016/S0022-2836(99)80005-9; Danchin A, 1997, DNA Res, V4, P9, DOI 10.1093/dnares/4.1.9; DANIEL RA, 1994, J MOL BIOL, V235, P209, DOI 10.1016/S0022-2836(05)80027-0; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; FICHANT GA, 1991, J MOL BIOL, V220, P659, DOI 10.1016/0022-2836(91)90108-I; FICHANT GA, 1995, NUCLEIC ACIDS RES, V23, P2900; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRANKS AH, 1995, MOL MICROBIOL, V17, P13, DOI 10.1111/j.1365-2958.1995.mmi_17010013.x; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GLASER P, 1993, MOL MICROBIOL, V10, P371, DOI 10.1111/j.1365-2958.1993.tb01963.x; Glemet E, 1997, COMPUT APPL BIOSCI, V13, P137; Goffeau A, 1997, NATURE, V387, P5, DOI DOI 10.1038/387005B0.PUBMED:9169864; HARWOOD CR, 1992, TRENDS BIOTECHNOL, V10, P247, DOI 10.1016/0167-7799(92)90233-L; HENAUT A, 1996, ESCHERICHIA COLI SAL, P2047; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; ITAYA M, 1993, J BACTERIOL, V175, P741, DOI 10.1128/JB.175.3.741-749.1993; Kaneko T, 1996, DNA Res, V3, P109; KARLIN S, 1992, NUCLEIC ACIDS RES, V20, P1363, DOI 10.1093/nar/20.6.1363; Kasahara Y, 1997, DNA Res, V4, P155, DOI 10.1093/dnares/4.2.155; Krogh S, 1996, MICROBIOL-UK, V142, P2031, DOI 10.1099/13500872-142-8-2031; Kunst F., 1995, MICROBIOLOGY, V389, P84; LANDES C, 1992, NUCLEIC ACIDS RES, V20, P3631, DOI 10.1093/nar/20.14.3631; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; Luttinger A, 1996, MOL MICROBIOL, V19, P343, DOI 10.1046/j.1365-2958.1996.380907.x; MEDIGUE C, 1995, GENE, V165, pGC37, DOI 10.1016/0378-1119(95)00636-K; Mizuno T, 1997, DNA Res, V4, P161, DOI 10.1093/dnares/4.2.161; Moszer I, 1996, MICROBIOL-UK, V142, P2987, DOI 10.1099/13500872-142-11-2987; MOSZER I, 1995, MICROBIOL-SGM, V141, P261, DOI 10.1099/13500872-141-2-261; NUSSINOV R, 1981, J MOL EVOL, V17, P237, DOI 10.1007/BF01732761; Ogasawara N, 1994, DNA Res, V1, P1, DOI 10.1093/dnares/1.1.1; Ogasawara N, 1996, MICROBIOL-UK, V142, P2993, DOI 10.1099/13500872-142-11-2993; Perego M, 1996, MOL MICROBIOL, V19, P1151, DOI 10.1111/j.1365-2958.1996.tb02460.x; Presecan E, 1997, MICROBIOL-SGM, V143, P3313, DOI 10.1099/00221287-143-10-3313; Solomon JM, 1996, TRENDS GENET, V12, P150, DOI 10.1016/0168-9525(96)10014-7; Sorokin A, 1996, GENOME RES, V6, P448, DOI 10.1101/gr.6.5.448; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; SUUTARI M, 1992, BIOCHIM BIOPHYS ACTA, V1126, P119, DOI 10.1016/0005-2760(92)90281-Y; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; WU LJ, 1994, SCIENCE, V264, P572, DOI 10.1126/science.8160014	49	3018	7446	20	564	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	1997	390	6657					249	256		10.1038/36786	http://dx.doi.org/10.1038/36786			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384377	Green Accepted, Green Submitted, hybrid			2022-12-24	WOS:A1997YG66700052
J	Kim, WR; Poterucha, JJ; Hermans, JE; Therneau, TM; Dickson, ER; Evans, RW; Gross, JB				Kim, WR; Poterucha, JJ; Hermans, JE; Therneau, TM; Dickson, ER; Evans, RW; Gross, JB			Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C	ANNALS OF INTERNAL MEDICINE			English	Article						cost-benefit analysis; hepatitis C; interferon-alpha; age factors; quality-adjusted life-years	NON-B-HEPATITIS; TERM FOLLOW-UP; CHRONIC NON-A; CONTROLLED TRIAL; HEPATOCELLULAR-CARCINOMA; NATURAL-HISTORY; POSTTRANSFUSION HEPATITIS; VIRUS GENOTYPES; LIVER-DISEASE; UNITED-STATES	Background: Interferon-alpha is effective in only a small number of patients with chronic hepatitis C, although prolonged treatment may increase the response rate. There is concern that the expense of interferon-alpha therapy may not be justified by the low response rates and uncertain long-term benefit. Objective: To compare clinical and economic outcomes after 6 months and 12 months of interferon-alpha therapy for chronic hepatitis C. Design: A Markov model depicting the natural progression of chronic hepatitis C. On the basis of this model, a simulated trial compared no therapy with 6 and 12 months of interferon-alpha therapy at standard doses (3 million U three times weekly). Patients: Four age-specific cohorts (30, 40, 50, and 60 years of age) with chronic hepatitis C. Measurements: Number of deaths from liver disease, total costs, and cumulative quality-adjusted life-years (QALYs). Results: Six and 12 months of interferon-alpha treatment gained 0.25 QALYs at an incremental cost of $1000 and 0.37 QALYs at an incremental cost of $1900, respectively. Thus, although 6 months of interferon-alpha therapy was less efficacious than 12 months of therapy, it was more cost-effective ($4000 per QALY gained compared with $5000 per QALY gained). Nonetheless, in patients younger than 60 years of age, both 6 and 12 months of therapy compared favorably with other established medical interventions, such as screening mammography and cholesterol reduction programs. Important variables affecting the cost-effectiveness of interferon-alpha treatment included the cost and efficacy of interferon-alpha, the cost of treatment for decompensated cirrhosis, and quality of life in patients with chronic hepatitis C. Conclusion: From the standpoint of cost-effectiveness, interferon-alpha therapy for 6 or 12 months may be justified in patients with chronic hepatitis C. The possible exception is patients older than 60 years of age.	MAYO CLIN & MAYO FDN, DIV GASTROENTEROL & HEPATOL W19, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, BIOSTAT SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, SECT HLTH SERV EVALUAT, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic				Kim, W. Ray/0000-0002-3030-860X	NIDDK NIH HHS [DK34238] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034238] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; Ampurdanes S, 1996, J HEPATOL, V25, P827, DOI 10.1016/S0168-8278(96)80285-6; AVORN J, 1984, NEW ENGL J MED, V310, P1294, DOI 10.1056/NEJM198405173102005; Belle S H, 1995, Clin Transpl, P19; BENNETT WG, 1995, HEPATOLOGY, V22, P735; BROWN DM, 1994, DIGESTIVE DIS US EPI; Cane EJ, 1996, NEW ENGL J MED, V334, P815, DOI 10.1056/NEJM199603283341302; *CDCP HEP BRANCH, 1997, 1997 HEP C FACT SHEE; CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1016/0270-9139(95)90286-4; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; DAVIS GL, 1994, CLIN THER, V16, P334; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; Dusheiko GM, 1995, HEPATOLOGY, V22, P1863, DOI 10.1016/0270-9139(95)90216-3; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; Evans R W, 1995, Liver Transpl Surg, V1, P61, DOI 10.1002/lt.500010114; Fattovich G, 1997, GASTROENTEROLOGY, V112, P463, DOI 10.1053/gast.1997.v112.pm9024300; Friedlander L, 1996, DIGEST DIS SCI, V41, P1678, DOI 10.1007/BF02087924; GINES P, 1987, HEPATOLOGY, V7, P122, DOI 10.1002/hep.1840070124; Hoofnagle JH, 1996, NEW ENGL J MED, V334, P1470, DOI 10.1056/NEJM199605303342210; Kim W R, 1995, Clin Transpl, P315; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KIYOSAWA K, 1994, INTERVIROLOGY, V37, P101, DOI 10.1159/000150363; KORETZ RL, 1990, HEPATOLOGY, V12, P880; LAPUMA J, 1990, JAMA-J AM MED ASSOC, V263, P2917, DOI 10.1001/jama.263.21.2917; LINDFORS KK, 1995, JAMA-J AM MED ASSOC, V274, P881, DOI 10.1001/jama.274.11.881; MARCELLIN P, 1995, GASTROENTEROLOGY, V109, P156, DOI 10.1016/0016-5085(95)90281-3; MARCELLIN P, 1991, HEPATOLOGY, V13, P393, DOI 10.1002/hep.1840130302; *NAT CTR HLTH STAT, 1994, VIT STAT US A, V2; Petitti DB, 1994, METAANALYSIS DECISIO, P119; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; SAEZROYUELA F, 1991, HEPATOLOGY, V13, P327, DOI 10.1002/hep.1840130220; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; SILINI E, 1995, HEPATOLOGY, V21, P285, DOI 10.1016/0270-9139(95)90082-9; TAKAHASHI M, 1993, AM J GASTROENTEROL, V88, P240; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; Torrance GW, 1987, METHODS EC EVALUATIO; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; VAQUER P, 1994, LIVER, V14, P265; WEJSTAL R, 1991, LIVER, V11, P143; Wong LL, 1997, ARCH INTERN MED, V157, P1429, DOI 10.1001/archinte.157.13.1429; YANO M, 1993, GUT, V34, pS13, DOI 10.1136/gut.34.2_Suppl.S13; YOUSUF M, 1992, SCAND J GASTROENTERO, V27, P812, DOI 10.3109/00365529209011189; Zein NN, 1996, ANN INTERN MED, V125, P634, DOI 10.7326/0003-4819-125-8-199610150-00002; 1995, DRUG TOPICS RED BOOK	49	151	151	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					866	+		10.7326/0003-4819-127-10-199711150-00002	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382364				2022-12-24	WOS:A1997YF54500002
J	Swanton, C; Mann, DJ; Fleckenstein, B; Neipel, F; Peters, G; Jones, N				Swanton, C; Mann, DJ; Fleckenstein, B; Neipel, F; Peters, G; Jones, N			Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins	NATURE			English	Article							DEPENDENT KINASES; KAPOSIS-SARCOMA; DNA-SEQUENCES; IDENTIFICATION; TRANSITION; CANCER; P27	The passage of mammalian cells through the restriction point into the S phase of the cell cycle is regulated by the activities of Cdk4 and Cdk6 complexed with the D-type cyclins and by cyclin E/Cdk2 (refs 1-3). The activities of these holoenzymes are constrained by CDK inhibitory proteins(4,5). The importance of the restriction point is illustrated by its deregulation in many tumour cells(6,7) and upon infection with DNA tumour viruses(8). Here we describe the properties of cyclins encoded by two herpesviruses, herpesvirus saimiri (HVS) which can transform blood lymphocytes(9) and induce malignancies of lymphoid origin in New World primates(9,10) and human herpesvirus 8 (HHV8) implicated as a causative agent of Kaposi's sarcoma and body cavity lymphomas(11,12). Both viral cyclins form active kinase complexes with Cdk6 that are resistant to inhibition by the CDK inhibitors p16(Ink4a), p21(Cip1) and p27(Kip1). Furthermore, ectopic expression of a viral cyclin prevents G1 arrest imposed by each inhibitor and stimulates cell-cycle progression in quiescent fibroblasts. These results suggest a new mechanism for deregulation of the cell cycle and indicate that the viral cyclins may contribute to the oncogenic nature of these viruses.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; UNIV ERLANGEN NURNBERG,INST KLIN & MOL VIROL,D-8520 ERLANGEN,GERMANY	Cancer Research UK; University of Erlangen Nuremberg				Swanton, Charles/0000-0002-4299-3018				BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; FLECKENSTEIN B, 1982, HERPESVIRUSES, V1, P252; HALL M, 1995, ONCOGENE, V11, P1581; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; JUNG JU, 1994, MOL CELL BIOL, V14, P7235, DOI 10.1128/MCB.14.11.7235; KATO J, 1993, GENE DEV, V7, P331; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	25	273	282	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					184	187		10.1038/36606	http://dx.doi.org/10.1038/36606			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367157				2022-12-24	WOS:A1997YF49400057
J	Butler, RN				Butler, RN			Population aging and health	BRITISH MEDICAL JOURNAL			English	Article											Butler, RN (corresponding author), MT SINAI MED CTR,INT LONGEV CTR US,NEW YORK,NY 10029, USA.							BRINSTOCK RH, IN PRESS LIFE OLDER; HOBBS FB, 1996, CURRENT POPULATION R, P23; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593	3	81	81	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1082	1084		10.1136/bmj.315.7115.1082	http://dx.doi.org/10.1136/bmj.315.7115.1082			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366742	Green Published			2022-12-24	WOS:A1997YD44500033
J	RiesgoEscovar, JR; Hafen, E				RiesgoEscovar, JR; Hafen, E			Common and distinct roles of DFos and DJun during Drosophila development	SCIENCE			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; C-FOS; GENE-EXPRESSION; NULL MUTATION; AP-1 COMPLEX; CELL FATE; HOMOLOG; TRANSCRIPTION; MORPHOGENESIS; PATHWAYS	The Drosophila homolog of c-Jun regulates epithelial cell shape changes during the process of dorsal closure in mid-embryogenesis. Here, mutations in the DFos gene are described. In dorsal closure, DFos cooperates with DJun by regulating the expression of dpp; Dpp acts as a relay signal that triggers cell shape changes and DFos expression in neighboring cells. In addition to the joint requirement of DFos and DJun during dorsal closure, DFos functions independently of DJun during early stages of embryogenesis. These findings demonstrate common and distinct roles of DFos and DJun during embryogenesis and suggest a conserved link between AP-1 (activating protein-1) and TGF-beta (transforming growth factor-beta) signaling during epithelial cell shape changes.	UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich								BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BLENZ M, 1996, SEMIN CELL DEV BIOL, V7, P113; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; FEHON RG, 1994, DEVELOPMENT, V120, P545; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Heitzler P, 1996, GENETICS, V143, P1271; Hou XS, 1997, GENE DEV, V11, P1728, DOI 10.1101/gad.11.13.1728; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; JURGENS G, 1984, ROUX ARCH DEVEL BIOL, V193, P183; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kockel L, 1997, GENE DEV, V11, P1748, DOI 10.1101/gad.11.13.1748; LINDSEY DL, 1992, GENETICS BIOL DROSOP; LIU ZG, 1997, CURR OPIN CELL BIOL, V9, P240; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PERKINS KK, 1990, GENE DEV, V4, P822, DOI 10.1101/gad.4.5.822; PERKINS KK, 1988, EMBO J, V7, P4265, DOI 10.1002/j.1460-2075.1988.tb03324.x; RAY RP, 1991, DEVELOPMENT, V113, P35; Riese J, 1997, DEVELOPMENT, V124, P3353; RIESGOESCOVAR J, UNPUB; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; Rusch J, 1997, DEVELOPMENT, V124, P303; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; TATEI K, 1995, MECH DEVELOP, V51, P157, DOI 10.1016/0925-4773(95)00349-5; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZHANG K, 1990, P NATL ACAD SCI USA, V87, P6281, DOI 10.1073/pnas.87.16.6281	35	122	125	2	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					669	672		10.1126/science.278.5338.669	http://dx.doi.org/10.1126/science.278.5338.669			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381174				2022-12-24	WOS:A1997YC32300050
J	Kurokawa, R; Kalafus, D; Ogliastro, MH; Kioussi, C; Xu, L; Torchia, J; Rosenfeld, MG; Glass, CK				Kurokawa, R; Kalafus, D; Ogliastro, MH; Kioussi, C; Xu, L; Torchia, J; Rosenfeld, MG; Glass, CK			Differential use of CREB binding protein coactivator complexes	SCIENCE			English	Article							TRANSCRIPTIONAL COACTIVATOR; NUCLEAR RECEPTORS; P300; CBP; ACTIVATION; E1A	CREB binding protein (CBP) functions as an essential coactivator of transcription factors that are inhibited by the adenovirus early gene product E1A. Transcriptional activation by the signal transducer and activator of transcription-1 (STAT1) protein requires the C/H3 domain in CBP, which is the primary target of E1A inhibition, Here it was found that the C/H3 domain is not required for retinoid acid receptor (RAR) function, nor is it involved in E1A inhibition, Instead, E1A inhibits RAR function by preventing the assembly of CBP-nuclear receptor coactivator complexes, revealing differences in required CBP domains for transcriptional activation by RAR and STAT1.	Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Glass, CK (corresponding author), Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592; Kioussi, Chrissa/0000-0001-8226-9908				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, UNPUB; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; NEVINS JR, 1992, SCIENCE, V258, P442; ONATE SA, 1995, SCIENCE, V270, P1354; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	32	189	190	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	1998	279	5351					700	703		10.1126/science.279.5351.700	http://dx.doi.org/10.1126/science.279.5351.700			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445474				2022-12-24	WOS:000071731500035
J	Han, JW; Luby-Phelps, K; Das, B; Shu, XD; Xia, Y; Mosteller, RD; Krishna, UM; Falck, JR; White, MA; Broek, D				Han, JW; Luby-Phelps, K; Das, B; Shu, XD; Xia, Y; Mosteller, RD; Krishna, UM; Falck, JR; White, MA; Broek, D			Role of substrates and products of PI3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav	SCIENCE			English	Article							PROTEIN; TRANSFORMATION; EFFECTORS; EXCHANGE; DISTINCT; DOMAIN; DBL	Mitogen stimulation of cytoskeletal changes and c-jun amino-terminal kinases is mediated by Rac small guanine nucleotide-binding proteins, Vav, a guanosine diphosphate (GDP)-guanosine triphosphate (GTP) exchange factor for Rac that stimulates the exchange of bound GDP for GTP, bound to and was directly controlled by substrates and products of phosphoinositide (PI) 3-kinase, The PI 3-kinase substrate phosphatidylinositol-4,5-bisphosphate inhibited activation of Vav by the tyrosine kinase Lck, whereas the product phosphatidylinositol-3,4,5-trisphosphate enhanced phosphorylation and activation of Vav by Lck. Control of Vav in response to mitogens by the products of PI 3-kinase suggests a mechanism for Ras-dependent activation of Rac.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of Southern California; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Broek, D (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA.	broek@zygote.hsc.usc.edu		Falck, John/0000-0002-9219-7845; Luby-Phelps, Katherine/0000-0002-8378-1409	NATIONAL CANCER INSTITUTE [R01CA071443, R01CA050261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER; NCI NIH HHS [CA71443, CA50261] Funding Source: Medline; NIGMS NIH HHS [GM31278] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSTELO XR, 1994, ONCOGENE, V9, P2405; Collins TL, 1997, IMMUNOL TODAY, V18, P221; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Han J., UNPUB; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; RAAB M, 1994, MOL CELL BIOL, V14, P2862, DOI 10.1128/MCB.14.5.2862; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; REDDY KK, 1995, J ORG CHEM, V60, P3385, DOI 10.1021/jo00116a023; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6	23	687	697	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	1998	279	5350					558	560		10.1126/science.279.5350.558	http://dx.doi.org/10.1126/science.279.5350.558			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438848				2022-12-24	WOS:000071616000045
J	Glinka, A; Wu, W; Delius, H; Monaghan, AP; Blumenstock, C; Niehrs, C				Glinka, A; Wu, W; Delius, H; Monaghan, AP; Blumenstock, C; Niehrs, C			Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction	NATURE			English	Article							HOMEOBOX GENE; XENOPUS-EMBRYOS; SPEMANN ORGANIZER; WNT GENES; EXPRESSION; MESODERM; HOMOLOG; LAEVIS; RECEPTOR; SEQUENCE	The Spemann organizer in amphibian embryos is a tissue with potent head-inducing activity, the molecular nature of which is unresolved. Here we describe dickkopf-1 (dkk-1), which encodes Dkk-1, a secreted inducer of Spemann's organizer in Xenopus and a member of a new protein family. Injections of mRNA and antibody Indicate that dkk-1 is sufficient and necessary to cause head induction. dkk-1 is a potent antagonist of Wnt signalling, suggesting that dkk genes encode a family of secreted Wnt inhibitors.	Deutsch Krebsforschungszentrum, Div Mol Embryol, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Appl Tumorvirol, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Mol Biol Cell 1, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Niehrs, C (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Embryol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.							BallyCuif L, 1997, BIOESSAYS, V19, P127, DOI 10.1002/bies.950190207; BANVILLE D, 1985, NUCLEIC ACIDS RES, V13, P5407, DOI 10.1093/nar/13.15.5407; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BLITZ IL, 1995, DEVELOPMENT, V121, P993; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Carnac G, 1996, DEVELOPMENT, V122, P3055; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; CUI YZ, 1995, DEVELOPMENT, V121, P2177; Devoto SH, 1996, DEVELOPMENT, V122, P3371; Fagotto F, 1997, DEVELOPMENT, V124, P453; GAMMIL LS, 1996, DEVELOPMENT, V124, P471; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; GERHART J, 1991, BOD MAR LAB, P57; Glinka A, 1996, MECH DEVELOP, V60, P221, DOI 10.1016/S0925-4773(96)00624-7; Glinka A, 1997, NATURE, V389, P517, DOI 10.1038/39092; GOOD PJ, 1989, NUCLEIC ACIDS RES, V17, P8000, DOI 10.1093/nar/17.19.8000; HARDY S, 1991, EUR J BIOCHEM, V202, P431, DOI 10.1111/j.1432-1033.1991.tb16392.x; Harlow E, 1988, ANTIBODIES LAB MANUA; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; Itoh K, 1995, DEVELOPMENT, V121, P3979; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; Lemaire P, 1996, TRENDS GENET, V12, P525, DOI 10.1016/S0168-9525(97)81401-1; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; MEIER VS, 1989, NUCLEIC ACIDS RES, V17, P795, DOI 10.1093/nar/17.2.795; MONAGHAN AP, 1995, DEVELOPMENT, V121, P839; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PANNESE M, 1995, DEVELOPMENT, V121, P707; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PIERCE SB, 1995, DEVELOPMENT, V121, P755; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	46	1302	1409	2	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					357	362		10.1038/34848	http://dx.doi.org/10.1038/34848			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450748				2022-12-24	WOS:000071604200044
J	Carson, JL; Duff, A; Berlin, JA; Lawrence, VA; Poses, RM; Huber, EC; O'Hara, DA; Noveck, H; Strom, BL				Carson, JL; Duff, A; Berlin, JA; Lawrence, VA; Poses, RM; Huber, EC; O'Hara, DA; Noveck, H; Strom, BL			Perioperative blood transfusion and postoperative mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORBIDITY; DISEASE; SYSTEM; RISK	Context.-The risks of blood transfusion have been studied extensively but the benefits and the hemoglobin concentration at which patients should receive a transfusion have not. Objective.-To determine the effect of perioperative transfusion on 30- and 90-day postoperative mortality. Design.-Retrospective cohort study. Setting.-A total of 20 US hospitals between 1983 and 1993. Participants.-A total of 8787 consecutive hip fracture patients, aged 60 years or older, who underwent surgical repair. Main Outcome Measures.-Primary outcome was 30-day postoperative mortality; secondary outcome was 90-day postoperative mortality. The "trigger" hemoglobin level was defined as the lowest hemoglobin level prior to the first transfusion during the time period or, for patients in the nontranfused group, as the lowest hemoglobin level during the time period. Results.-Overall 30-day mortality was 4.6% (n=402; 95% confidence interval [CI], 4.1%-5.0%); overall 90-day mortality was 9.0% (n=788; 95% CI, 8.4%-9.6%). A total of 42% of patients (n=3699) received a postoperative transfusion. Among patients with trigger hemoglobin levels between 80 and 100 g/L (8.0 and 10.0 g/dL), 55.6% received a transfusion, while 90.5% of patients with hemoglobin levels less than 80 g/L (8.0 g/dL) received postoperative transfusions. Postoperative transfusion did not influence 30- or 90-day mortality after adjusting for trigger hemoglobin level, cardiovascular disease, and other risk factors for death: for 30-day mortality, the adjusted odds ratio (OR) was 0.96 (95% CI, 0.74-1.26); for 90-day mortality, the adjusted hazard ratio was 1.08 (95% CI, 0.90-1.29). Similarly, 30-day mortality after surgery did not differ between those who received a preoperative transfusion and those who did not (adjusted OR, 1.23; 95% CI, 0.81-1.89). Conclusions.-Perioperative transfusion in patients with hemoglobin levels 80 g/L (8.0 g/dL) or higher did not appear to influence the risk of 30- or 90-day mortality in this elderly population, At hemoglobin concentrations of less than 80 g/L (8.0 g/dL), 90.5% of patients received a transfusion, precluding further analysis of the association of transfusion and mortality.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Internal Med, Dept Med, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Internal Med, Dept Anesthesia, New Brunswick, NJ 08903 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA; S Texas Vet Hlth Care Syst, Audie Murphy Div, Div Gen Med, San Antonio, TX USA; Univ Texas, Dept Med, San Antonio, TX 78285 USA; Brown Univ, Sch Med, Dept Med, Div Gen Internal Med, Providence, RI 02912 USA; Brown Univ, Mem Hosp Rhode Isl, Pawtucket, RI 02860 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Gen Internal Med, Richmond, VA 23298 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; Brown University; Brown University; Virginia Commonwealth University	Carson, JL (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Internal Med, Dept Med, 125 Paterson St, New Brunswick, NJ 08903 USA.	carson@umdnj.edu			AHRQ HHS [1R01HS07322] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON HT, 1978, SURGERY, V84, P8; BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700; BLAIR SD, 1986, BRIT J SURG, V73, P783, DOI 10.1002/bjs.1800731007; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P142; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DRIPPS RD, 1961, JAMA-J AM MED ASSOC, V178, P261, DOI 10.1001/jama.1961.03040420001001; FEINBERG SE, 1977, ANAL CROSS CLASSIFIE, P9; Geha A S, 1978, World J Surg, V2, P645; GOODNOUGH LT, 1991, JAMA-J AM MED ASSOC, V265, P86, DOI 10.1001/jama.265.1.86; HAGL S, 1977, BASIC RES CARDIOL, V72, P344, DOI 10.1007/BF02023594; HERBERT PC, 1995, JAMA-J AM MED ASSOC, V273, P1439; JOHNSON RG, 1992, J THORAC CARDIOV SUR, V104, P307; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LUNN JN, 1970, BRIT MED J, V3, P71, DOI 10.1136/bmj.3.5714.71; MANTEL N, 1959, J NATL CANCER I, V22, P719; Rawstron R E, 1970, Aust N Z J Surg, V39, P425, DOI 10.1111/j.1445-2197.1970.tb05389.x; SAS Institute Inc, 1990, SAS STAT US GUID VER, V4; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; SECHZER PH, 1963, ANESTHESIOLOGY, V24, P779, DOI 10.1097/00000542-196311000-00005; TOPLEY E, 1956, BR J CLIN PRACT, V1, P770; WEISEL RD, 1992, J THORAC CARDIOVASC, V104, P308; WILKERSON DK, 1988, SURGERY, V103, P665; YOSHIKAWA H, 1973, AM J CARDIOL, V32, P670, DOI 10.1016/S0002-9149(73)80061-X	27	297	306	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					199	205		10.1001/jama.279.3.199	http://dx.doi.org/10.1001/jama.279.3.199			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR124	9438739	Bronze			2022-12-24	WOS:000071460700029
J	De Koninck, P; Schulman, H				De Koninck, P; Schulman, H			Sensitivity of CaM kinase II to the frequency of Ca2+ oscillations	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; SYNAPTIC PLASTICITY; HIPPOCAMPAL SLICES; CALMODULIN KINASE; AUTOPHOSPHORYLATION; EXPRESSION; MECHANISM; MEMORY; ACTIVATION	The transduction of many cellular stimuli results in oscillations in the intracellular concentration of calcium ions (Ca2+). Although information is thought to be encoded in the frequency of such oscillations, no frequency decoder has been identified. Rapid superfusion of immobilized Ca2+ - and calmodulin-dependent protein kinase II (CaM kinase II) in vitro showed that the enzyme can decode the frequency of Ca2+ spikes into distinct amounts of kinase activity. The frequency response of CaM kinase II was modulated by several factors, including the amplitude and duration of individual spikes as well as the subunit composition and previous state of activation of the kinase. These features should provide specificity in the activation of this multifunctional enzyme by distinct cellular stimuli and may underlie its pivotal role in activity-dependent forms of synaptic plasticity.	Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University	Schulman, H (corresponding author), Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040600, R01GM030179, R37GM030179] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30179, GM40600] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BROCKE L, 1995, J NEUROSCI, V15, P6797; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Deisseroth K, 1995, CURR BIOL, V5, P1334, DOI 10.1016/S0960-9822(95)00262-4; DEKONINCK P, UNPUB; Dosemeci A, 1996, BIOPHYS J, V70, P2493, DOI 10.1016/S0006-3495(96)79821-1; ESTEP RP, 1989, CURR TOP CELL REGUL, V31, P161; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; LUBYPHELPS K, 1995, J BIOL CHEM, V270, P21532, DOI 10.1074/jbc.270.37.21532; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAYER P, 1994, BIOCHEM J, V298, P757, DOI 10.1042/bj2980757; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.biophys.20.1.153; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MICHELSON S, 1994, J THEOR BIOL, V171, P281, DOI 10.1006/jtbi.1994.1231; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Skene J H, 1990, Neurosci Res Suppl, V13, pS112, DOI 10.1016/0921-8696(90)90040-A; SODERLING TR, 1995, ADV SEC MESS PHOSPH, V30, P175	37	1004	1019	4	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					227	230		10.1126/science.279.5348.227	http://dx.doi.org/10.1126/science.279.5348.227			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422695				2022-12-24	WOS:000071408100042
J	Xu, L; Eu, JP; Meissner, G; Stamler, JS				Xu, L; Eu, JP; Meissner, G; Stamler, JS			Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation	SCIENCE			English	Article							FROG SKELETAL-MUSCLE; PROTEIN-KINASE-C; NITRIC-OXIDE; SARCOPLASMIC-RETICULUM; FUNCTIONAL CONSEQUENCES; CA-2+ RELEASE; CA2+ RELEASE; OXIDATION; SULFHYDRYLS; MECHANISM	Several ion channels are reportedly redox responsive, but the molecular basis for the changes in activity is not known. The mechanism of nitric oxide action on the cardiac calcium release channel (ryanodine receptor) (CRC) in canines was explored. This tetrameric channel contains similar to 84 free thiols and is S-nitrosylated in vivo. S-Nitrosylation of up to 12 sites (3 per CRC subunit) led to progressive channel activation that was reversed by denitrosylation. In contrast, oxidation of 20 to 24 thiols per CRC (5 or 6 per subunit) had no effect on channel function. Oxidation of additional thiols (or of another class of thiols) produced irreversible activation. The CRC thus appears to be regulated by poly-S-nitrosylation (multiple covalent attachments), whereas oxidation can lead to loss of control. These results reveal that ion channels can differentiate nitrosative from oxidative signals and indicate that: the CRC is regulated by posttranslational chemical modification(s) of sulfurs.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Physiol, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med,Div Pulm, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med,Div Cardiovasc Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Cell Biol, Durham, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Meissner, G (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.			Stamler, Jonathan/0000-0002-6866-1572	NHLBI NIH HHS [HL59130, HL52529, HL-27430] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052529, R01HL059130, P01HL027430] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMSON JJ, 1983, P NATL ACAD SCI-BIOL, V80, P1526, DOI 10.1073/pnas.80.6.1526; ABRAMSON JJ, 1988, MOL CELL BIOCHEM, V82, P81; ABRAMSON JJ, 1989, J BIOENERG BIOMEMBR, V21, P283, DOI 10.1007/BF00812073; Aghdasi B, 1997, J BIOL CHEM, V272, P25462, DOI 10.1074/jbc.272.41.25462; ALLISON WS, 1976, ACCOUNTS CHEM RES, V9, P293, DOI 10.1021/ar50104a003; AOKI T, 1985, CAN J PHYSIOL PHARM, V63, P1070, DOI 10.1139/y85-175; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; CHIAMVIMONVAT N, 1995, CIRC RES, V76, P325, DOI 10.1161/01.RES.76.3.325; DOU YM, 1994, J BIOL CHEM, V269, P20410; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; Feelisch M., 1996, METHODS NITRIC OXIDE, P71; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; GATH I, IN PRESS NITRIC OXID; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HUTCHISON KA, 1991, J BIOL CHEM, V266, P10505; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P246; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P76; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; LEE HB, 1994, J BIOL CHEM, V269, P13305; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; Meszaros LG, 1996, FEBS LETT, V380, P49, DOI 10.1016/0014-5793(96)00003-8; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; OBA T, 1985, PFLUG ARCH EUR J PHY, V405, P354, DOI 10.1007/BF00595688; OBA T, 1992, BIOPHYS J, V63, P1416, DOI 10.1016/S0006-3495(92)81704-6; OTSU K, 1990, J BIOL CHEM, V265, P13472; Pinsky DJ, 1997, CIRC RES, V81, P372, DOI 10.1161/01.RES.81.3.372; PRABHU SD, 1990, ARCH BIOCHEM BIOPHYS, V282, P275, DOI 10.1016/0003-9861(90)90117-H; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, J BIOL CHEM, V266, P4244; Reid MB, 1996, NEWS PHYSIOL SCI, V11, P114, DOI 10.1152/physiologyonline.1996.11.3.114; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; Sheu FS, 1996, J BIOL CHEM, V271, P22407, DOI 10.1074/jbc.271.37.22407; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STAMLER JS, 1996, METHODS NITRIC OXIDE, P521; Stoyanovsky D, 1997, CELL CALCIUM, V21, P19, DOI 10.1016/S0143-4160(97)90093-2; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; WIER WG, 1990, ANNU REV PHYSIOL, V52, P467; XU L, 1993, CARDIOVASC RES, V27, P1815, DOI 10.1093/cvr/27.10.1815; Xu L, 1996, CIRC RES, V79, P1100, DOI 10.1161/01.RES.79.6.1100	55	810	832	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 9	1998	279	5348					234	237		10.1126/science.279.5348.234	http://dx.doi.org/10.1126/science.279.5348.234			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422697				2022-12-24	WOS:000071408100044
J	Nightingale, SL				Nightingale, SL			Irradiation of meat approved for pathogen control	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					9	9		10.1001/jama.279.1.9	http://dx.doi.org/10.1001/jama.279.1.9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424027				2022-12-24	WOS:000071295100005
J	Banner, AS				Banner, AS			Non-steroidal anti-inflammatory therapy for bronchial asthma	LANCET			English	Editorial Material									Vet Affairs Med Ctr, Manchester, NH 03104 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University	Banner, AS (corresponding author), Vet Affairs Med Ctr, Manchester, NH 03104 USA.							ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; BARNES PJ, 1993, ANNU REV MED, V44, P229, DOI 10.1146/annurev.me.44.020193.001305; ERZURUM SC, 1991, ANN INTERN MED, V114, P353, DOI 10.7326/0003-4819-114-5-353; FISH JE, 1997, AM J RESP CARE MED, V156; HILL MR, 1990, CLIN PHARMACOL THER, V48, P390, DOI 10.1038/clpt.1990.167; KANE GC, 1994, CLIN PULM MED, V1, P69; MAZER BD, 1991, J ALLERGY CLIN IMMUN, V87, P976, DOI 10.1016/0091-6749(91)90420-S; Spahn JD, 1996, ALLERGY ASTHMA PROC, V17, P341, DOI 10.2500/108854196778606365; SPAHN JD, 1995, AM J RESP CRIT CARE, V151, P1709, DOI 10.1164/ajrccm.151.6.7767511; Spahn JD, 1997, J ASTHMA, V34, P177, DOI 10.3109/02770909709068188	10	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					5	7		10.1016/S0140-6736(05)78098-3	http://dx.doi.org/10.1016/S0140-6736(05)78098-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433419				2022-12-24	WOS:000071253100005
J	Bielinsky, AK; Gerbi, SA				Bielinsky, AK; Gerbi, SA			Discrete start sites for DNA synthesis in the yeast ARS1 origin	SCIENCE			English	Article							REPLICATION ORIGINS; RECOGNITION COMPLEX; S-PHASE; SIMIAN VIRUS-40; CELL-CYCLE; INITIATION; ORC; CHROMOSOMES; CEREVISIAE; SEQUENCE	Sites of DNA synthesis initiation have been detected at the nucleotide level in a yeast origin of bidirectional replication with the use of replication initiation point mapping. The ARS1 origin of Saccharomyces cerevisiae showed a transition from discontinuous to continuous DNA synthesis in an 18-base pair region (nucleotides 828 to 845) from within element B1 toward B2, adjacent to the binding site for the origin recognition complex, the putative initiator protein.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Div Biol & Med, Providence, RI 02912 USA	Brown University	Gerbi, SA (corresponding author), Brown Univ, Dept Mol Biol Cell Biol & Biochem, Div Biol & Med, Providence, RI 02912 USA.			Bielinsky, Anja/0000-0003-1783-619X	NIGMS NIH HHS [GM 35929] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035929] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1977, BIOCHEMISTRY-US, V16, P4990, DOI 10.1021/bi00642a009; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLUMENTHAL AB, 1977, CELL, V12, P183, DOI 10.1016/0092-8674(77)90196-9; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1991, BIOESSAYS, V13, P317, DOI 10.1002/bies.950130702; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; FANGMAN WL, 1983, CELL, V32, P831, DOI 10.1016/0092-8674(83)90069-7; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; HAY RT, 1982, CELL, V28, P767, DOI 10.1016/0092-8674(82)90056-3; HENDRICKSON EA, 1987, EMBO J, V6, P2011, DOI 10.1002/j.1460-2075.1987.tb02465.x; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; LASKEY RA, 1989, SCIENCE, V246, P609, DOI 10.1126/science.2683076; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Lin S, 1997, MOL CELL BIOL, V17, P5473, DOI 10.1128/MCB.17.9.5473; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; NETHANEL T, 1988, J VIROL, V62, P2867, DOI 10.1128/JVI.62.8.2867-2873.1988; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; RADDING CM, 1966, J MOL BIOL, V18, P235, DOI 10.1016/S0022-2836(66)80243-7; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; YAMAGUCHI M, 1985, MOL CELL BIOL, V5, P1170, DOI 10.1128/MCB.5.5.1170; ZAKIAN VA, 1979, CELL, V17, P923, DOI 10.1016/0092-8674(79)90332-5	30	124	126	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					95	98		10.1126/science.279.5347.95	http://dx.doi.org/10.1126/science.279.5347.95			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417033				2022-12-24	WOS:000071323900048
J	Rozwarski, DA; Grant, GA; Barton, DHR; Jacobs, WR; Sacchettini, JC				Rozwarski, DA; Grant, GA; Barton, DHR; Jacobs, WR; Sacchettini, JC			Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis	SCIENCE			English	Article							CATALASE-PEROXIDASE GENE; MYCOLIC ACID SYNTHESIS; RESISTANT STRAINS; DRUG-RESISTANCE; ENOYL REDUCTASE; OXIDATION; KATG; MUTATIONS; DNA; IDENTIFICATION	The preferred antitubercular drug isoniazid specifically targets a long-chain enoyl-acyl carrier protein reductase (InhA), an enzyme essential for mycolic acid biosynthesis in Mycobacterium tuberculosis. Despite the widespread use of this drug for more than 40 years, its precise mode of action has remained obscure. Data from x-ray crystallography and mass spectrometry reveal that the mechanism of isoniazid action against InhA is covalent attachment of the activated form of the drug to the nicotinamide ring of nicotinamide adenine dinucleotide bound within the active site of InhA.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Washington University (WUSTL)	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.			Jacobs, William/0000-0003-3321-3080	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI036849] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-36849] Funding Source: Medline; NIGMS NIH HHS [GM-45859] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldock C, 1996, SCIENCE, V274, P2107, DOI 10.1126/science.274.5295.2107; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Basso LA, 1996, J AM CHEM SOC, V118, P11301, DOI 10.1021/ja962035y; Blanchard JS, 1996, ANNU REV BIOCHEM, V65, P215, DOI 10.1146/annurev.bi.65.070196.001243; BLOOM BR, 1994, TUBERCULOSIS PATHOGE; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; BRUNGER AT, 1992, XPLOR VERSOIN 3 1 SY; COCKERILL FR, 1995, J INFECT DIS, V171, P240, DOI 10.1093/infdis/171.1.240; COLE ST, 1995, EUR RESPIR J, V8, pS701; DAVIDSON LA, 1979, ANTIMICROB AGENTS CH, V16, P104, DOI 10.1128/AAC.16.1.104; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; DROBNIEWSKI FA, 1995, J MED MICROBIOL, V43, P85, DOI 10.1099/00222615-43-2-85; Heym B, 1996, CURR TOP MICROBIOL, V215, P49; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; HEYM B, 1994, LANCET, V344, P293, DOI 10.1016/S0140-6736(94)91338-2; HILLAR A, 1995, ARCH BIOCHEM BIOPHYS, V323, P438, DOI 10.1006/abbi.1995.0065; ITO K, 1992, BIOCHEMISTRY-US, V31, P11606, DOI 10.1021/bi00161a046; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; KAPUR V, 1995, ARCH PATHOL LAB MED, V119, P131; Lee RE, 1996, CURR TOP MICROBIOL, V215, P1; LEWIN E, 1955, AM REV TUBERC PULM, V71, P732; Magliozzo RS, 1996, J AM CHEM SOC, V118, P11303, DOI 10.1021/ja962047j; Magliozzo RS, 1997, J BIOL CHEM, V272, P8867; Mdluli K, 1996, J INFECT DIS, V174, P1085, DOI 10.1093/infdis/174.5.1085; MUSSER JH, COMMUNICATION; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; OBRIEN RJ, 1993, LUNG BIOL HLTH DISEA, V66, P207; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAOLETTI F, 1990, CHEM-BIOL INTERACT, V76, P3, DOI 10.1016/0009-2797(90)90030-Q; PORTER JDH, 1994, ANNU REV PUBL HEALTH, V15, P303; QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035; Quemard A, 1996, J AM CHEM SOC, V118, P1561, DOI 10.1021/ja950998b; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; ROUSE DA, 1995, ANTIMICROB AGENTS CH, V39, P2472, DOI 10.1128/AAC.39.11.2472; Sacchettini JC, 1996, RES MICROBIOL, V147, P36, DOI 10.1016/0923-2508(96)80201-4; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P399, DOI 10.1128/AAC.27.3.399; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P404, DOI 10.1128/AAC.27.3.404; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P408, DOI 10.1128/AAC.27.3.408; SINHA BK, 1983, J BIOL CHEM, V258, P796; STOECKLE MY, 1993, J INFECT DIS, V168, P1063, DOI 10.1093/infdis/168.4.1063; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; Telenti A, 1997, J CLIN MICROBIOL, V35, P719, DOI 10.1128/JCM.35.3.719-723.1997; WANG L, 1975, ANTIMICROB AGENTS CH, V16, P308; Wheeler PR, 1996, BIOCHEM J, V318, P451, DOI 10.1042/bj3180451; WINDER F G, 1970, Journal of General Microbiology, V63, P41; WINDER FG, 1959, BIOCHEM J, V73, P500, DOI 10.1042/bj0730500; YOUNG DB, 1995, ANNU REV MICROBIOL, V49, P641, DOI 10.1146/annurev.mi.49.100195.003233; YOUNG DB, 1994, CURR BIOL, V4, P351, DOI 10.1016/S0960-9822(00)00077-4; Zabinski RF, 1997, J AM CHEM SOC, V119, P2331, DOI 10.1021/ja9639731; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; ZHANG Y, 1994, J ANTIMICROB CHEMOTH, V34, P313, DOI 10.1093/jac/34.3.313; ZHANG Y, 1993, MOL MICROBIOL, V8, P521, DOI 10.1111/j.1365-2958.1993.tb01596.x	53	573	593	2	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					98	102		10.1126/science.279.5347.98	http://dx.doi.org/10.1126/science.279.5347.98			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417034				2022-12-24	WOS:000071323900049
J	Jiang, CY; Ting, AT; Seed, B				Jiang, CY; Ting, AT; Seed, B			PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; PROLIFERATOR-ACTIVATED RECEPTORS; ADIPOCYTE DIFFERENTIATION; RHEUMATOID-ARTHRITIS; 3T3-L1 CELLS; FACTOR-ALPHA; EXPRESSION; LIGAND; J(2); BETA	The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a member of the nuclear receptor family of transcription factors, a large and diverse group of proteins that mediate ligand-dependent transcriptional activation and repression(1,2). Expression of PPAR-gamma is an early and pivotal event in the differentiation of adipocytes(3-6). Several agents that promote differentiation of fibroblast lines into adipocytes have been shown to be PPAR-gamma agonists(7-10), including several prostanoids, of which 15-deoxy-Delta(12,14)-prostaglandin J(2) is the most potent(8,9), as well as members of a new class of oral antidiabetic agents, the thiazolidinediones(7), and a variety of non-steroidal anti-inflammatory drugs (NSAIDs)(10). Here we show that PPAR-gamma agonists suppress monocyte elaboration of inflammatory cytokines at agonist concentrations similar to those found to be effective for the promotion of adipogenesis. Inhibition of cytokine production may help to explain the incremental therapeutic benefit of NSAIDs observed in the treatment of rheumatoid arthritis at plasma drug concentrations substantially higher than are required to inhibit prostaglandin G/H synthase (cyclooxygenase).	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Seed, B (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.							BERG M, 1994, CYTOKINE, V6, P425, DOI 10.1016/1043-4666(94)90067-1; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brennan FM, 1996, CURR OPIN IMMUNOL, V8, P872, DOI 10.1016/S0952-7915(96)80018-5; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Firestein GS, 1997, NEW ENGL J MED, V337, P195, DOI 10.1056/NEJM199707173370310; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Greene M. E., 1995, Gene Expression, V4, P281; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; LAU CS, 1993, BRIT J RHEUMATOL, V32, P982; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARSHALL MK, 1994, ENDOCRINOLOGY, V135, P141, DOI 10.1210/en.135.1.141; MCEVOY GK, 1997, AHFS 97 DRUG INFORMA; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; PATTON JS, 1986, P NATL ACAD SCI USA, V83, P8313, DOI 10.1073/pnas.83.21.8313; SZALKOWSKI D, 1995, ENDOCRINOLOGY, V136, P1474, DOI 10.1210/en.136.4.1474; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	28	2551	2706	3	133	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					82	86		10.1038/34184	http://dx.doi.org/10.1038/34184			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422509				2022-12-24	WOS:000071326100053
J	Barrett, K; Leptin, M; Settleman, J				Barrett, K; Leptin, M; Settleman, J			The rho GTPase and a putative RhoGEF mediate a signaling pathway for the cell shape changes in Drosophila gastrulation	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; ACTIN STRESS FIBERS; BINDING PROTEIN-RHO; GENE; CDC42; RAS; ENCODES; EMBRYO; DOMAIN; TRANSFORMATION	The Rho GTPases mediate actin rearrangements that are likely to be required for the numerous cell shape changes in a developing embryo. In a genetic screen for Rho signaling pathway components in Drosophila, we identified a gene, DRhoGEF2, that encodes a predicted Rho-specific guanine nucleotide exchange factor. Embryos lacking DRhoGEF2 fail to gastrulate due to a defect in cell shape changes required for tissue invagination, and expression of a dominant-negative Rho GTPase in early embryos results in similar defects. Evidence is also presented that DRhoGEF2 mediates these specific cell shape changes in response to the extracellular ligand, Fog. Together, these results establish a Rho-mediated signaling pathway that is essential for the major morphogenetic events in Drosophila gastrulation.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Univ Cologne, Inst Genet, D-5000 Cologne, Germany	Harvard University; Massachusetts General Hospital; Harvard University; University of Cologne	Settleman, J (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA.							BRONNER G, 1991, MECH DEVELOP, V35, P205, DOI 10.1016/0925-4773(91)90019-3; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHOU TB, 1993, DEVELOPMENT, V119, P1359; COSTA M, 1994, CELL, V76, P1075, DOI 10.1016/0092-8674(94)90384-0; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dutartre H, 1996, J CELL SCI, V109, P367; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; HARDEN N, 1995, DEVELOPMENT, V121, P903; HARIHARAN IK, 1995, EMBO J, V14, P292, DOI 10.1002/j.1460-2075.1995.tb07003.x; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAY BA, 1994, DEVELOPMENT, V120, P2121; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; HUANG KP, 1989, TRENDS NEUROSCI, V12, P425, DOI 10.1016/0166-2236(89)90091-X; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LEPTIN M, 1990, DEVELOPMENT, V110, P73; Leptin M, 1995, ANNU REV CELL DEV BI, V11, P189; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PATEL NH, 1994, DROSOPHILA MELANOGAS, P445; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; SULLIVAN W, 1995, CURR OPIN CELL BIOL, V7, P18, DOI 10.1016/0955-0674(95)80040-9; SWEETON D, 1991, DEVELOPMENT, V112, P775; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMAS GH, 1994, DEVELOPMENT, V120, P2039; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; Werner LA, 1997, GENE, V187, P107, DOI 10.1016/S0378-1119(96)00732-9; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; YOUNG PE, 1991, DEVELOPMENT, V111, P1; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	57	306	309	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					905	915		10.1016/S0092-8674(00)80482-1	http://dx.doi.org/10.1016/S0092-8674(00)80482-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428514	Bronze			2022-12-24	WOS:000071281400008
J	Levchenko, I; Smith, CK; Walsh, NP; Sauer, RT; Baker, TA				Levchenko, I; Smith, CK; Walsh, NP; Sauer, RT; Baker, TA			PDZ-like domains mediate binding specificity in the Clp/Hsp100 family of chaperones and protease regulatory subunits	CELL			English	Article							BACTERIOPHAGE-MU REPRESSOR; DEPENDENT CLP PROTEASE; HEAT-SHOCK PROTEIN; ESCHERICHIA-COLI; TRANSPOSASE TETRAMER; MOLECULAR CHAPERONE; SERINE-PROTEASE; MESSENGER-RNA; HSP104; COMPONENT	ClpX, a molecular chaperone and the regulatory subunit of the ClpXP protease, is shown to contain tandem modular domains that bind to the C-terminal sequences of target proteins in a manner that parallels functional specificity Nuclear magnetic resonance studies show that these C-terminal sequences are displayed as disordered peptides on the surface of otherwise folded proteins. The ClpX substrate-binding domains are homologous to sequences in other Clp/Hsp100 proteins and are related more distantly to PDZ domains, which also mediate C-terminal specific protein-protein interactions. Conservation of these binding domains indicates that the mode of substrate recognition characterized here for ClpX will be a conserved feature among Clp/Hsp100 family members and a distinguishing characteristic between this chaperone family and the Hsp70 chaperones.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Baker, TA (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Sauer, Robert/0000-0002-1719-5399	NIAID NIH HHS [AI-16892] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016892] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CAMPBELL ID, 1975, FEBS LETT, V57, P96, DOI 10.1016/0014-5793(75)80160-8; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Domian IJ, 1997, CELL, V90, P415, DOI 10.1016/S0092-8674(00)80502-4; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Frank EG, 1996, P NATL ACAD SCI USA, V93, P10291, DOI 10.1073/pnas.93.19.10291; GEUSKENS V, 1992, EMBO J, V11, P5121, DOI 10.1002/j.1460-2075.1992.tb05619.x; GEUSKENS V, 1991, J BACTERIOL, V173, P6578, DOI 10.1128/jb.173.20.6578-6585.1991; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; Laachouch JE, 1996, EMBO J, V15, P437, DOI 10.1002/j.1460-2075.1996.tb00374.x; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 1997, GENE DEV, V11, P1561, DOI 10.1101/gad.11.12.1561; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; MILLA ME, 1993, PROTEIN SCI, V2, P2198, DOI 10.1002/pro.5560021219; NAKAI H, 1995, J BIOL CHEM, V270, P19591, DOI 10.1074/jbc.270.33.19591; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Ponting CP, 1997, PROTEIN SCI, V6, P464; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; SKELTON NJ, 1993, J MAGN RESON SER B, V102, P253, DOI 10.1006/jmrb.1993.1095; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WEISS MA, 1987, BIOCHEMISTRY-US, V26, P890, DOI 10.1021/bi00377a033; Welty DJ, 1997, J MOL BIOL, V272, P31, DOI 10.1006/jmbi.1997.1193; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WOJTKOWIAK D, 1993, J BIOL CHEM, V268, P22609	47	102	105	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	1997	91	7					939	947		10.1016/S0092-8674(00)80485-7	http://dx.doi.org/10.1016/S0092-8674(00)80485-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428517	Bronze			2022-12-24	WOS:000071281400011
J	Beasley, BW				Beasley, BW			Whispering through the keyhole	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material													Beasley, Brent/AAE-9466-2021	Beasley, Brent/0000-0002-0997-9636					0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2061	2061		10.1001/jama.278.23.2061	http://dx.doi.org/10.1001/jama.278.23.2061			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403410				2022-12-24	WOS:A1997YK98700019
J	Brancati, FL; Whelton, PK; Randall, BL; Neaton, JD; Stamler, J; Klag, MJ				Brancati, FL; Whelton, PK; Randall, BL; Neaton, JD; Stamler, J; Klag, MJ			Risk of end-stage renal disease in diabetes mellitus - A prospective cohort study of men screened for MRFIT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	56th Scientific Session of the American-Diabetes-Association	JUN 08-11, 1996	SAN FRANCISCO, CA	Amer Diabet Assoc			FACTOR INTERVENTION TRIAL; RACIAL-DIFFERENCES; EXCESS INCIDENCE; BLOOD-PRESSURE; AMERICANS; FAILURE; INDIANS; RACE	Context.-Diabetes is a frequent cause of end-stage renal disease (ESRD). However, the degree of risk is uncertain. Objective.-To determine the relative risk (RR) of ESRD related to diabetes in the United States. Design.-Nonconcurrent prospective cohort study. Participants.-A total of 332 544 men aged 35 to 57 years from 18 US cities screened in 1973 to 1975 for participation in the Multiple Risk Factor Intervention Trial (MRFIT). Main Exposure.-Diabetes mellitus defined by self-reported use of medication for diabetes at baseline. Main Outcome.-Incident ESRD through 1990 assessed from a national ESRD registry and by surveillance for death from renal disease. Results.-Over an average follow-up of 16 years, there were 136 cases of ESRD in 5147 diabetic men and 678 cases in 327 397 nondiabetic men. Age-adjusted incidence of all-cause ESRD in the diabetic men was 199.8 per 100 000 person-years compared with 13.7 per 100 000 person years in their nondiabetic counterparts (RR, 12.7; 95% confidence interval [CI], 10.5-15.4). Diabetic men were also at higher risk for ESRD ascribed to causes other than diabetes (RR=4.3; 95% CI, 3.2-5.9). With simultaneous adjustment for age, ethnicity, income, blood pressure, serum cholesterol level, and history of myocardial infarction, diabetic men remained at higher risk for ail-cause ESRD (RR, 9.0; 95% CI, 7.4-11.0), ESRD ascribed to diabetes (RR, 92.3; 95% CI, 64.6-131.9), and ESRD ascribed to nondiabetic causes (RR, 3.0; 95% CI, 2.2-4.1). Conclusions.-Diabetes mellitus is a strong independent risk factor for ESRD, even for ESRD ascribed to causes other than diabetes. Improvements in the prevention and control of diabetes should produce substantial reductions in ESRD incidence.	JOHNS HOPKINS MED INST,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT EPIDEMIOL,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21205; UNIV MINNESOTA,SCH PUBL HLTH,DIV BIOSTAT,MINNEAPOLIS,MN 55455; NORTHWESTERN UNIV,SCH MED,DEPT PREVENT MED,CHICAGO,IL	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Minnesota System; University of Minnesota Twin Cities; Northwestern University					NHLBI NIH HHS [R01 HL28715] Funding Source: Medline; NIDDK NIH HHS [R01 DK41837] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028715] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041837] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1977, Journal of Chronic Diseases, V30, P261; BRANCATI FL, 1992, JAMA-J AM MED ASSOC, V268, P3079, DOI 10.1001/jama.268.21.3079; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; COX DR, 1972, J R STAT SOC B, V34, P187; DISCHINGER P, 1986, CONTROL CLIN TRIALS, V7, pS137; DYCK RF, 1994, CAN MED ASSOC J, V150, P203; Eggers P W, 1984, Health Care Financ Rev, V5, P69; FERTIG BJ, 1995, NIH PUBLICATION, P519; *HLTH CAR FIN ADM, 1987, HCFA PUBL; HUMPHREY LL, 1989, ANN INTERN MED, V111, P788, DOI 10.7326/0003-4819-111-10-788; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPPEL DF, 1986, AM J KIDNEY DIS, V8, P234, DOI 10.1016/S0272-6386(86)80031-2; Kenny S.J., 1995, NIH PUBLICATION, P47; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; Krolewski M, 1996, KIDNEY INT, V50, P2041, DOI 10.1038/ki.1996.527; LEE ET, 1994, DIABETES, V43, P572, DOI 10.2337/diabetes.43.4.572; MEGILL DM, 1988, WESTERN J MED, V149, P178; *MULT RISK FACT IN, 1982, JAMA-J AM MED ASSOC, V248, P1465; *NAT HEART LUNG I, 1974, DHEW PUBL; NEATON JD, 1988, CONTROL CLIN TRIALS, V8, P415; NELSON RG, 1988, DIABETOLOGIA, V31, P730, DOI 10.1007/BF00274774; Nelson RG, 1995, DIABETES AM, V2, P349; NEWMAN JM, 1990, AM J PUBLIC HEALTH, V80, P318, DOI 10.2105/AJPH.80.3.318; PASINSKI R, 1987, ARCH INTERN MED, V147, P1093, DOI 10.1001/archinte.147.6.1093; PERNEGER TV, 1995, AM J KIDNEY DIS, V25, P722, DOI 10.1016/0272-6386(95)90548-0; PERNEGER TV, 1995, AM J EPIDEMIOL, V141, P10, DOI 10.1093/oxfordjournals.aje.a117338; Prevention CfDCa, 1992, MMWR-MORBID MORTAL W, V41, P845; PUGH JA, 1988, AM J EPIDEMIOL, V127, P135, DOI 10.1093/oxfordjournals.aje.a114773; ROSTAND SG, 1982, NEW ENGL J MED, V306, P1276, DOI 10.1056/NEJM198205273062106; SHERWIN R, 1981, PREV MED, V10, P402, DOI 10.1016/0091-7435(81)90058-X; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STEPHENS GW, 1990, AM J KIDNEY DIS, V15, P562, DOI 10.1016/S0272-6386(12)80527-0; SUGIMOTO T, 1984, AM J PUBLIC HEALTH, V74, P14, DOI 10.2105/AJPH.74.1.14; *US DEP HHS, 1988, INT CLASS DIS 9 REV; *US REN DAT SYST, 1995, USRDS 1995 ANN DAT R, P25; WELLER JM, 1985, AM J NEPHROL, V5, P84, DOI 10.1159/000166912; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270	37	218	222	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2069	2074		10.1001/jama.278.23.2069	http://dx.doi.org/10.1001/jama.278.23.2069			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403420				2022-12-24	WOS:A1997YK98700035
J	Gee, MA; Heuser, JE; Vallee, RB				Gee, MA; Heuser, JE; Vallee, RB			An extended microtubule-binding structure within the dynein motor domain	NATURE			English	Article							BETA-HEAVY CHAIN; CRYSTAL-STRUCTURE; RETROGRADE TRANSPORT; CYTOPLASMIC DYNEIN; DICTYOSTELIUM; PROTEINS; CLEAVAGE; SEQUENCE; MAP-1C; MYOSIN	Flagellar dynein was discovered over 30 years ago as the first motor protein capable of generating force along microtubules(1). A cytoplasmic form of dynein has also been identified which is involved in mitosis and a wide range of other intracellular movement(2) (reviewed in ref. 3). Rapid progress has been made on understanding the mechanism of force production by kinesins and myosins(4-8). In contrast, progress in understanding the dyneins has been limited by their great size (relative molecular mass 1,000K-2,000K) and subunit complexity. We now report evidence that the entire carboxy-terminal two-thirds of the 532K force-producing heavy chain subunit is required for ATP-binding activity. We further identify a microtubule-binding domain, which, surprisingly, lies well downstream of the entire ATPase region and is predicted to form a hairpin-like stalk Direct ultrastructural analysis of a recombinant fragment confirms this model, and suggests that the mechanism for dynein force production differs substantially from that of other motor proteins.	WORCESTER FDN BIOMED RES, SHREWSBURY, MA 01545 USA; UNIV MASSACHUSETTS, MED CTR, WORCESTER, MA 01655 USA; WASHINGTON UNIV, ST LOUIS, MO 63110 USA	Worcester Foundation for Biomedical Research; University of Massachusetts System; University of Massachusetts Worcester; Washington University (WUSTL)			Heuser, John/H-5940-2012					AMOS LA, 1989, J CELL SCI, V93, P19; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; GIBBONS IR, 1965, SCIENCE, V149, P424, DOI 10.1126/science.149.3682.424; GIBBONS IR, 1991, NATURE, V352, P640, DOI 10.1038/352640a0; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; GOODENOUGH UW, 1982, J CELL BIOL, V95, P798, DOI 10.1083/jcb.95.3.798; HAIMO LT, 1979, P NATL ACAD SCI USA, V76, P5759, DOI 10.1073/pnas.76.11.5759; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KOONCE MP, 1992, J CELL BIOL, V119, P1597, DOI 10.1083/jcb.119.6.1597; Koonce MP, 1996, MOL BIOL CELL, V7, P935, DOI 10.1091/mbc.7.6.935; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mazumdar M, 1996, P NATL ACAD SCI USA, V93, P6552, DOI 10.1073/pnas.93.13.6552; MIKAMI A, 1993, NEURON, V10, P787, DOI 10.1016/0896-6273(93)90195-W; MITCHELL DR, 1994, J CELL SCI, V107, P635; OGAWA K, 1991, NATURE, V352, P643, DOI 10.1038/352643a0; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PORTER ME, 1989, ANNU REV CELL BIOL, V5, P119; PORTER ME, 1994, J CELL BIOL, V126, P1495, DOI 10.1083/jcb.126.6.1495; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Ruppel KM, 1996, ANNU REV CELL DEV BI, V12, P543, DOI 10.1146/annurev.cellbio.12.1.543; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SMITH EF, 1992, SCIENCE, V257, P1557, DOI 10.1126/science.1387971; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; STEUER ER, 1988, CELL MOTIL CYTOSKEL, V11, P200; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	30	256	261	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 11	1997	390	6660					636	639		10.1038/37663	http://dx.doi.org/10.1038/37663			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403697				2022-12-24	WOS:A1997YK85300057
J	Keely, PJ; Westwick, JK; Whitehead, IP; Der, CJ; Parise, LV				Keely, PJ; Westwick, JK; Whitehead, IP; Der, CJ; Parise, LV			Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K	NATURE			English	Article							NUCLEOTIDE EXCHANGE FACTORS; ACTIVATED PROTEIN-KINASE; GTP-BINDING PROTEIN; STRUCTURAL SIMILARITIES; ACTIN POLYMERIZATION; EXPRESSION CLONING; RHO; FAMILY; PATHWAY; PHOSPHORYLATION	Transformation of mammary epithelial cells into invasive carcinoma results in alterations in their integrin-mediated responses to the extracellular matrix, including a loss of normal epithelial polarization and differentiation, and a switch to a more motile, invasive phenotype, Changes in the actin cytoskeleton associated with this switch suggest that the small GTPases Cdc42 and Rac, which regulate actin organization(1,2), might modulate motility and invasion, However, the role of Cdc42 and Rad in epithelial cells, especially with respect to integrin-mediated events, has not been well characterized, Here we show that activation of Cdc42 and Rad disrupts the normal polarization of mammary epithelial cells in a collagenous matrix, and promotes motility and invasion. This motility does not require the activationof PAK, JNK, p70 S6 kinase, or Rho, but instead requires phosphatidylinositol-3-OH kinase (PI(3)K). Further, direct PI(3)K activation is sufficient to disrupt epithelial polarization and induce cell motility and invasion. PI(3)K inhibition also disrupts actin structures, suggesting that activation of PI(3)K by Cdc42 and Rad alters actin organization, leading to increased motility and invasiveness.	UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	Keely, PJ (corresponding author), UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,DEPT PHARMACOL,CHAPEL HILL,NC 27599, USA.			Der, Channing/0000-0002-7751-2747				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Collard JG, 1996, INT J ONCOL, V8, P131; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KEELY PJ, 1995, J CELL SCI, V108, P595; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SANTORO SA, 1994, METHOD ENZYMOL, V245, P147; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; YAN MH, 1994, NATURE, V372, P798; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	29	628	639	2	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					632	636		10.1038/37656	http://dx.doi.org/10.1038/37656			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403696				2022-12-24	WOS:A1997YK85300056
J	Quill, TE; Dresser, R; Brock, DW				Quill, TE; Dresser, R; Brock, DW			The rule of double effect - A critique of its role in end-of-life decision making	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PHYSICIAN-ASSISTED SUICIDE; EUTHANASIA; PAIN; VIEWS; DEATH		UNIV ROCHESTER, SCH MED, ROCHESTER, NY 14607 USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; BROWN UNIV, PROVIDENCE, RI 02912 USA	University of Rochester; Case Western Reserve University; Brown University								*ABIM, 1996, ED RES DOC; Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; Alpers A, 1997, JAMA-J AM MED ASSOC, V277, P1705, DOI 10.1001/jama.277.21.1705; Annas GJ, 1996, NEW ENGL J MED, V335, P683, DOI 10.1056/NEJM199608293350924; [Anonymous], 1992, ANN INTERN MED, V117, P947; [Anonymous], 1985, MOD PEN COD COMM, P229; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BROCK DW, 1997, MED ETHICS, P363; BRODY H, 1993, J CLIN ETHIC, V4, P112; Cantor NL, 1996, KENNEDY INST ETHIC J, V6, P107; Cherny N I, 1994, J Palliat Care, V10, P31; *COUNC ETH JUD AFF, 1992, JAMA-J AM MED ASSOC, V276, P2229; Donagan Alan, 1977, ETHICS; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; FOLEY KM, 1995, PAIN FORUM, V4, P163; Fried C., 1978, RIGHT WRONG; GARCIA JLA, 1995, ENCY BIOETHICS, V2, P636; Graber MA, 1996, J GEN INTERN MED, V11, P71, DOI 10.1007/BF02599581; GRANFIELD D, 1971, ABORTION DECISION, P126; *HAST CTR, 1987, GUID TERM LIF SUST T; HILL CS, 1995, JAMA-J AM MED ASSOC, V274, P1881, DOI 10.1001/jama.274.23.1881; JOHNPAUL II, 1995, CATH C MARCH 30, P189; KASS LR, 1993, HASTINGS CENT REP, V23, P34, DOI 10.2307/3562279; Kenny A., 1973, ANATOMY SOUL; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KUHSE H, 1987, SANCTITYY LIFE DOCRI; Mangan J.T., 1949, THEOL STUD, V10, P41, DOI [DOI 10.1177/004056394901000102, 10.1177/004056394901000102]; MARQUIS DB, 1991, J MED PHILOS, V16, P515, DOI 10.1093/jmp/16.5.515; MEISEL A, 1995, RIGHT DIE; Nagel Thomas., 1986, VIEW NOWHERE; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912; Pellegrino E D, 1992, J Clin Ethics, V3, P95; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; QUILL TE, IN PRESS JAMA; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; *SUPPORT PRINC INV, 1996, JAMA-J AM MED ASSOC, V275, P1232, DOI DOI 10.1001/JAMA.1995.03530200027032; TROUG RD, 1991, NEW ENGL J MED, V327, P1678; Ventafridda V, 1990, J Palliat Care, V6, P7; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949	41	229	235	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 11	1997	337	24					1768	1771		10.1056/NEJM199712113372413	http://dx.doi.org/10.1056/NEJM199712113372413			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YK653	9392707				2022-12-24	WOS:A1997YK65300013
J	Busettini, C; Masson, GS; Miles, FA				Busettini, C; Masson, GS; Miles, FA			Radial optic flow induces vergence eye movements with ultra-short latencies	NATURE			English	Article							OCULAR-FOLLOWING RESPONSES; SUPERIOR TEMPORAL AREA; MACAQUE MONKEY; EXPANSION CONTRACTION; ROTATION CELLS; SELF-MOTION; DORSAL PART; MST NEURONS; DEPENDENCE; DIRECTION	An observer moving forwards through the environment experiences a radial pattern of image motion on each retina, Such patterns of optic now are a potential source of information about the observer's rate of progress(1), direction of heading(2) and time to reach objects that lie ahead(3). As the viewing distance changes there must be changes in the vergence angle between the two eyes so that both foveas remain aligned on the object of interest in the scene ahead. Here we show that radial optic flow can elicit appropriately directed (horizontal) vergence eye movements with ultra-short latencies (roughly 80 ms) in human subjects. Centrifugal flow, signalling forwards motion, increases the vergence angle, whereas centripetal now decreases the vergence angle. These vergence eye movements are still evident when the observer's view of the flow pattern is restricted to the temporal hemifield of one eye, indicating that these responses do not result from anisotropies in motion processing but from a mechanism that senses the radial pattern of now. We hypothesize that flow-induced vergence is but one of a family of rapid ocular reflexes, mediated by the medial superior temporal cortex, compensating for translational disturbance of the observer.	NEI, SENSORIMOTOR RES LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)			MASSON, Guillaume S/G-4615-2012	MASSON, Guillaume S/0000-0001-9227-0777				Busettini C, 1996, NATURE, V380, P342, DOI 10.1038/380342a0; Busettini C, 1996, J NEUROPHYSIOL, V75, P1392, DOI 10.1152/jn.1996.75.4.1392; BUSETTINI C, 1994, EXP BRAIN RES, V100, P484, DOI 10.1007/BF02738407; Busettini C., 1994, Society for Neuroscience Abstracts, V20, P1403; Cohen Gal A., 1996, Society for Neuroscience Abstracts, V22, P964; Collewijn H, 1990, Rev Oculomot Res, V4, P213; CornilleauPeres V, 1996, TRENDS NEUROSCI, V19, P196, DOI 10.1016/S0166-2236(96)10025-4; DEJONG BM, 1994, BRAIN, V117, P1039; DUFFY CJ, 1991, J NEUROPHYSIOL, V65, P1329, DOI 10.1152/jn.1991.65.6.1329; DUFFY CJ, 1995, J NEUROSCI, V15, P5192; ENRIGHT JT, 1987, PERCEPTION, V16, P731, DOI 10.1068/p160731; ERKELENS CJ, 1986, J PHYSIOL-LONDON, V379, P145, DOI 10.1113/jphysiol.1986.sp016245; FUCHS AF, 1966, J APPL PHYSIOL, V21, P1068, DOI 10.1152/jappl.1966.21.3.1068; GELLMAN RS, 1990, VISUAL NEUROSCI, V5, P107, DOI 10.1017/S0952523800000158; KAWANO K, 1994, J NEUROPHYSIOL, V71, P2305, DOI 10.1152/jn.1994.71.6.2305; KAWANO K, 1997, PARIETAL LOBE CONTRI, P185; Lappe M, 1996, J NEUROSCI, V16, P6265; LEE DN, 1980, PHILOS T R SOC B, V290, P169, DOI 10.1098/rstb.1980.0089; LEE DN, 1976, PERCEPTION, V5, P437, DOI 10.1068/p050437; MASSON GS, 1997, NATURE, V389, P293; MILES FA, 1995, STUD VIS INFORM PROC, V6, P47; MILES FA, 1986, J NEUROPHYSIOL, V56, P1321, DOI 10.1152/jn.1986.56.5.1321; Prokop T, 1997, EXP BRAIN RES, V114, P63, DOI 10.1007/PL00005624; SAITO H, 1986, J NEUROSCI, V6, P145; Takemura A., 1997, Society for Neuroscience Abstracts, V23, P1557; Takeuchi T, 1997, VISION RES, V37, P2083, DOI 10.1016/S0042-6989(96)00225-8; TANAKA K, 1989, J NEUROPHYSIOL, V62, P642, DOI 10.1152/jn.1989.62.3.642; TANAKA K, 1989, J NEUROPHYSIOL, V62, P626, DOI 10.1152/jn.1989.62.3.626; Ungerleider LG., 1982, ANAL VISUAL BEHAV, P549; WARREN WH, 1988, NATURE, V336, P162, DOI 10.1038/336162a0	30	71	72	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					512	515		10.1038/37359	http://dx.doi.org/10.1038/37359			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394000				2022-12-24	WOS:A1997YJ86500052
J	Rees, G; Frith, CD; Lavie, N				Rees, G; Frith, CD; Lavie, N			Modulating irrelevant motion perception by varying attentional load in an unrelated task	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; MONKEY VISUAL-CORTEX; AREA MT; SUPERIOR COLLICULUS; MACAQUE; MECHANISMS; SEGREGATION; PATHWAYS; FMRI	Lavie's theory of attention proposes that the processing load in a relevant task determines the extent to which irrelevant distracters are processed. This theory was tested by asking participants in a study to perform linguistic tasks of low or high load while ignoring irrelevant visual motion in the periphery of the display. Although task and distracter were unrelated, both functional imaging of motion-related activity in cortical area V5 and psychophysical measures of the motion aftereffect showed reduced motion processing during high load in the linguistic task. These findings fulfill the prediction that perception of irrelevant distracters depends on the relevant processing load.	UNIV LONDON UNIV COLL,DEPT PSYCHOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London	Rees, G (corresponding author), INST NEUROL,WELLCOME DEPT COGNIT NEUROL,12 QUEEN SQ,LONDON WC1N 3BG,ENGLAND.		Frith, Chris D/A-2171-2009; Rees, Geraint/C-1493-2008	Frith, Chris D/0000-0002-8665-0690; Rees, Geraint/0000-0002-9623-7007	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Broadbent D. E., 1958, PERCEPTION COMMUNICA; Buchel C, 1997, CEREB CORTEX, V7, P768, DOI 10.1093/cercor/7.8.768; CHAUDHURI A, 1991, NATURE, V344, P641; CORBETTA M, 1991, J NEUROSCI, V11, P2383; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.neuro.18.1.193; DESIMONE R, 1989, Society for Neuroscience Abstracts, V15, P162; DESIMONE R, 1990, COLD SPRING HARB SYM, V55, P963; Friston K.J., 1994, HUMAN BRAIN MAPPING, V2, P211, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; FRISTON KJ, 1995, NEUROIMAGE, V2, P157, DOI 10.1006/nimg.1995.1018; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; FRISTON KJ, 1995, HUMAN BRAIN MAPPING, V2, P165; Gibson J. J., 1950, PERCEPTION VISUAL WO; GIBSON JJ, 1977, SCAND J PSYCHOL, V18, P161, DOI 10.1111/j.1467-9450.1977.tb00272.x; GIRARD P, 1989, J NEUROPHYSIOL, V62, P1287, DOI 10.1152/jn.1989.62.6.1287; GROSS CG, 1991, NEUROPSYCHOLOGIA, V29, P497, DOI 10.1016/0028-3932(91)90007-U; Kahneman D., 1984, VARIETIES ATTENTION, P29; LAVIE N, 1995, J EXP PSYCHOL HUMAN, V21, P451, DOI 10.1037/0096-1523.21.3.451; LAVIE N, 1994, PERCEPT PSYCHOPHYS, V56, P182; MOTTER BC, 1981, J NEUROSCI, V1, P3, DOI 10.1523/JNEUROSCI.01-01-00003.1981; Neill W. Trammell, 1995, P207, DOI 10.1016/B978-012208930-5/50008-8; OCraven KM, 1997, NEURON, V18, P591, DOI 10.1016/S0896-6273(00)80300-1; RODMAN HR, 1990, J NEUROSCI, V10, P1154; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; Shipp S, 1995, J ANAT, V187, P547; SHIPP S, 1985, NATURE, V315, P322, DOI 10.1038/315322a0; SHULMAN GL, 1991, J EXP PSYCHOL HUMAN, V17, P726, DOI 10.1037/0096-1523.17.3.726; Talairach J., 1988, COPLANAR STEREOTAXIC; TOOTELL RBH, 1995, NATURE, V375, P139, DOI 10.1038/375139a0; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; TRELSMAN AM, 1969, PSYCHOL REV, V76, P282; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0; UNGERLEIDER LG, 1984, J COMP NEUROL, V223, P368, DOI 10.1002/cne.902230304; WATSON JDG, 1993, CEREB CORTEX, V3, P79, DOI 10.1093/cercor/3.2.79; ZEKI S, 1991, J NEUROSCI, V11, P641	34	458	469	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1616	1619		10.1126/science.278.5343.1616	http://dx.doi.org/10.1126/science.278.5343.1616			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YJ874	9374459				2022-12-24	WOS:A1997YJ87400038
J	Stanner, SA; Bulmer, K; Andres, C; Lantseva, OE; Borodina, V; Poteen, VV; Yudkin, JS				Stanner, SA; Bulmer, K; Andres, C; Lantseva, OE; Borodina, V; Poteen, VV; Yudkin, JS			Does malnutrition in utero determine diabetes and coronary heart disease in adulthood? Results from the Leningrad siege study, a cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; BLOOD-PRESSURE; FETAL GROWTH; BIRTH-WEIGHT; NONDIABETIC SUBJECTS; IN-UTERO; INSULIN; LIFE; MEN; HYPERTENSION	Objective: To investigate the relation between decreased maternal food intake and risk factors for coronary heart disease in adult life. Design: Cross sectional study. Subjects: 169 subjects exposed to malnutrition in utero (intrauterine group) during the siege of Leningrad (now St Petersburg) in 1941-4; 192 subjects born in Leningrad just before rationing began, before the siege (infant group); and 188 subjects born concurrently with the first two groups but outside the area of the siege (unexposed group). Setting: Ott Institute of Obstetrics and Gynaecology, St Petersburg. Main outcome measures: Development of risk factors for coronary heart disease and diabetes mellitus-obesity, blood pressure, glucose tolerance, insulin concentrations, lipids, albumin excretion rate, and clotting factors. Results: There was no difference between the subjects exposed to starvation in utero and those starved during infant life in: (a) glucose tolerance (mean fasting glucose: intrauterine group 5.2 (95% confidence interval 5.1 to 5.3), Infant group 5.3 (5.1 to 5.5), P = 0.94; mean 2 hour glucose: intrauterine group 6.1 (5.8 to 6.4), infant group 6.0 (5.7 to 6.3), P = 0.99); (b) insulin concentration; (c) blood pressure; (d) lipid concentration; or (e) coagulation factors. Concentrations of von Willebrand factor were raised in the intrauterine group (156.5 (79.1 to 309.5)) compared with the infant group (127.6 (63.9 to 254.8); P < 0.001), and female subjects in the intrauterine group had a stronger interaction between obesity and both systolic (P = 0.01) and diastolic (P = 0.04) blood pressure than in the infant group. Short adult stature was associated with raised concentrations of glucose and insulin 2 hours after a glucose load-independently of siege exposure. Subjects in the unexposed group had non-systematic differences in subscapular to triceps skinfold ratio, diastolic blood pressure, and clotting factors compared with the exposed groups. Conclusions: Intrauterine malnutrition tvas not associated with glucose intolerance, dyslipidaemia, hypertension, or cardiovascular disease in adulthood. Subjects exposed to malnutrition showed evidence of endothelial dysfunction and a stronger influence of obesity on blood pressure.	RUSSIAN ACAD MED SCI, OTT INST OBSTET & GYNAECOL, ST PETERSBURG, RUSSIA	Russian Academy of Medical Sciences; Ott Institute of Obstetrics, Gynecology & Reproductology	Stanner, SA (corresponding author), UCL, SCH MED, DEPT MED, LONDON N19 3UA, ENGLAND.		Yudkin, John S/C-1988-2008					ANTONOV AN, 1947, J PEDIATR, V30, P250, DOI 10.1016/S0022-3476(47)80160-X; Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1991, J ROY COLL PHYS LOND, V25, P129; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARKER DJP, 1995, PLACENTA, V16, P317, DOI 10.1016/0143-4004(95)90118-3; BARKER DJP, 1982, FETAL INFANT ORIGINS; BENNETT KA, 1986, HUM BIOL, V58, P751; BROWN DC, 1991, DIABETOLOGIA, V34, P531, DOI 10.1007/BF00403292; Campbell DM, 1996, BRIT J OBSTET GYNAEC, V103, P273, DOI 10.1111/j.1471-0528.1996.tb09718.x; EMANUEL I, 1992, BRIT J OBSTET GYNAEC, V99, P67, DOI 10.1111/j.1471-0528.1992.tb14396.x; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; Godfrey K, 1996, BRIT MED J, V312, P410, DOI 10.1136/bmj.312.7028.410; GOULD MM, 1993, BMJ-BRIT MED J, V306, P240, DOI 10.1136/bmj.306.6872.240; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Kramer MS, 1996, LANCET, V348, P1254, DOI 10.1016/S0140-6736(05)65750-9; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Leon DA, 1996, BRIT MED J, V312, P401, DOI 10.1136/bmj.312.7028.401; MARMOT MG, 1984, LANCET, V1, P1003; Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2; MARTYN CN, 1995, BRIT HEART J, V73, P116; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; MOHAMEDALI V, 1995, DIABETOLOGIA, V38, P1110; Office of Population Censuses and Surveys, 1980, CLASS OCC; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PAVLOV DV, 1965, LENINGRAD 1941 BLOCK; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; Robbins DC, 1996, DIABETES, V45, P242, DOI 10.2337/diabetes.45.2.242; ROBINSON S, 1992, DIABETOLOGIA, V35, P444, DOI 10.1007/BF02342441; ROSE GA, 1988, WHO MONOGRAPH SERIES, V56; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3; Stein Z., 1975, FAMINE HUM DEV DUTCH; SWENNE I, 1987, DIABETES, V36, P454, DOI 10.2337/diabetes.36.4.454; WADSWORTH MEJ, 1985, BRIT MED J, V291, P1534, DOI 10.1136/bmj.291.6508.1534; WALKER M, 1989, INT J EPIDEMIOL, V18, P602, DOI 10.1093/ije/18.3.602; WEINKOVE C, 1974, S AFR MED J, V48, P1888; *WHO STUD GROUP, 1985, WHO TECH REP SER, V727, P9	41	330	339	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 22	1997	315	7119					1342	1348		10.1136/bmj.315.7119.1342	http://dx.doi.org/10.1136/bmj.315.7119.1342			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402775	Green Published			2022-12-24	WOS:A1997YJ21800022
J	AuBuchon, JP; Birkmeyer, JD; Busch, MP				AuBuchon, JP; Birkmeyer, JD; Busch, MP			Safety of the blood supply in the United States: Opportunities and controversies	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS IMMUNE GLOBULIN; COST-EFFECTIVENESS ANALYSIS; DETERGENT-TREATED PLASMA; FRESH-FROZEN PLASMA; RISK; INFECTION; TRANSFUSION; HEALTH	The risk for viral transmission by transfusion has been reduced dramatically through improved techniques for selecting and testing blood donors. Initiatives to further improve the safety of the blood supply, including more stringent donor qualifications, additional testing for infectious disease markers, viral inactivation processes, and refinement of transfusion decisions, are possible. However, because the risk for viral transmission by allogeneic transfusion is already low, additional measures will have limited yield and poor cost-effectiveness. Furthermore, unexpected side effects of some of these ''improvements'' may reduce the safety of the blood supply by introducing new risks. Cost-effectiveness analyses of blood safety initiatives have highlighted such successes as the introduction of virus-specific assays for screening donated blood and have identified other interventions that have poor cost-effectiveness estimates. They have also quantitated the threshold level at which the risks of an intervention outweigh its benefits. These analyses have had little effect on decisions about blood safety, possibly because of overwhelming fear of AIDS and difficulties in applying cost-effectiveness estimates to a politically and emotionally charged issue. Future interventions for improving blood supply safety must be evaluated thoroughly and chosen carefully so that the intended goals are met. Communication with the public should be undertaken so that the public understands that some of the desired measures may result in inefficient allocation of health care resources.	DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT PATHOL & MED, LEBANON, NH 03756 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT SURG, LEBANON, NH 03756 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT COMMUNITY & FAMILY MED, LEBANON, NH 03756 USA; UNIV CALIF SAN FRANCISCO, DEPT LAB MED, SAN FRANCISCO, CA 94118 USA	Dartmouth College; Dartmouth College; Dartmouth College; University of California System; University of California San Francisco	AuBuchon, JP (corresponding author), DARTMOUTH COLL, HITCHCOCK MED CTR, DEPT PATHOL, 1 MED CTR DR, LEBANON, NH 03756 USA.				NHLBI NIH HHS [N01-HB-47114] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB047114] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, JAMA, V274, P1374; Au Buchon J. P., 1996, Transfusion (Bethesda), V36, p43S; AUBUCHON JP, 1994, JAMA-J AM MED ASSOC, V272, P1210, DOI 10.1001/jama.272.15.1210; AuBuchon JP, 1997, TRANSFUSION, V37, P45, DOI 10.1046/j.1537-2995.1997.37197176950.x; BASKETT TF, 1990, CAN MED ASSOC J, V142, P337; BenHur E, 1996, AIDS, V10, P1183, DOI 10.1097/00002030-199609000-00002; BIRKMEYER JD, 1993, TRANSFUSION, V33, P544, DOI 10.1046/j.1537-2995.1993.33793325048.x; BIRKMEYER JD, 1994, ANN THORAC SURG, V57, P161, DOI 10.1016/0003-4975(94)90386-7; Bresee JS, 1996, JAMA-J AM MED ASSOC, V276, P1563, DOI 10.1001/jama.276.19.1563; Busch M., 1996, Transfusion (Bethesda), V36, p59S; Busch MP, 1995, TRANSFUSION, V35, P903, DOI 10.1046/j.1537-2995.1995.351196110893.x; BUSCH MP, 1991, TRANSFUSION, V31, P4, DOI 10.1046/j.1537-2995.1991.31191096183.x; BUSCH MP, 1995, MOL GENETICS DIAGNOS; COHEN BJ, 1990, J VIROL METHODS, V30, P233, DOI 10.1016/0166-0934(90)90065-N; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; Elixhauser A, 1991, Int J Technol Assess Health Care, V7, P604; ETCHASON J, 1995, NEW ENGL J MED, V332, P719, DOI 10.1056/NEJM199503163321106; Evans RW, 1996, TRANSFUSION, V36, P671, DOI 10.1046/j.1537-2995.1996.36896374368.x; EVANS RW, 1986, SURG CLIN N AM, V66, P603; FOWLER FJ, 1995, MED DECIS MAKING, V15, P195, DOI 10.1177/0272989X9501500301; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HOROWITZ B, 1992, BLOOD, V79, P826; HUX JE, 1994, J GEN INTERN MED, V9, P195, DOI 10.1007/BF02600123; Kleinman S, 1996, CLIN PRACTICE TRANSF; Korelitz JJ, 1996, TRANSFUSION, V36, P203, DOI 10.1046/j.1537-2995.1996.36396182135.x; Korelitz JJ, 1996, TRANSFUSION, V36, P232, DOI 10.1046/j.1537-2995.1996.36396182141.x; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; Lefrere JJ, 1996, TRANSFUSION, V36, P394, DOI 10.1046/j.1537-2995.1996.36596282581.x; Leveton Lauren B., 1995, HIV BLOOD SUPPLY ANA, P49; LINDEN JV, 1992, TRANSFUSION, V32, P601, DOI 10.1046/j.1537-2995.1992.32792391030.x; Lynch TJ, 1996, TRANSFUSION, V36, P770, DOI 10.1046/j.1537-2995.1996.36996420751.x; MINTZ PD, 1992, AM J CLIN PATHOL, V98, P150, DOI 10.1093/ajcp/98.2.150; MORGAN MG, 1993, SCI AM, V269, P32, DOI 10.1038/scientificamerican0793-32; NELSON KE, 1995, INFECT DIS TESTING B; NORMANN A, 1992, LANCET, V340, P1232, DOI 10.1016/0140-6736(92)92938-C; POPOVSKY MA, 1995, TRANSFUSION, V35, P734, DOI 10.1046/j.1537-2995.1995.35996029156.x; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; SCHNEIDERMAN LJ, 1992, AM J PUBLIC HEALTH, V82, P584, DOI 10.2105/AJPH.82.4.584; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Shilts R., 1987, BAND PLAYED POLITICS; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; Stehling LC, 1996, ANESTHESIOLOGY, V84, P732; VAMVAKAS EC, 1994, TRANSFUSION, V34, P471, DOI 10.1046/j.1537-2995.1994.34694295060.x; WALLACE EL, 1995, TRANSFUSION, V35, P802, DOI 10.1046/j.1537-2995.1995.351096026360.x; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; WILLIAMSON LM, 1995, VOX SANG, V69, P159, DOI 10.1111/j.1423-0410.1995.tb02590.x	49	124	128	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					904	909		10.7326/0003-4819-127-10-199711150-00009	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382369				2022-12-24	WOS:A1997YF54500007
J	Burkey, Y; Black, M; Reeve, H				Burkey, Y; Black, M; Reeve, H			Patients' views on their discharge from follow up in outpatient clinics: qualitative study	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To discover the views of patients about their discharge from outpatient clinics, to detect any change in these perceptions over time, and explore how the discharge process might be improved for the patient. Design: A qualitative study comprising in-depth or semistructured interviews with patients 2 weeks and 3 months after discharge from an outpatient clinic. Subjects: 45 patients who had attended outpatient clinics on three or more occasions. Setting: Five general medical outpatient clinics from a Manchester provider trust. Main outcome measures: Aspects of the discharge consultation valued by patients included confidence that the doctor knew and understood their case; clarity of the discharge process; an explanation of the reasons for discharge; information about treatment, future care, and the mechanism for re-referral; and being seen by doctors who sought their views and allowed time for questions and reflection. Conclusions: Patients' views about their discharge changed over time and varied in relation to several factors, which included patients' perceptions of the discharge process, patients' expectations, the way in which the outpatient clinics were organised, and patients' relationships with, and confidence in, their general practitioners.	UNIV MANCHESTER,NATL PRIMARY CARE RES & DEV CTR,MANCHESTER M13 9PL,LANCS,ENGLAND; UNIV SALFORD,PUBL HLTH RES & RESOURCE CTR,SALFORD M5 4QA,LANCS,ENGLAND; UNIV MANCHESTER,RUSHOLME HLTH CTR,DEPT GEN PRACTICE,MANCHESTER M14 5NP,LANCS,ENGLAND	University of Manchester; University of Salford; University of Manchester								Burkey Y, 1997, FAM PRACT, V14, P29, DOI 10.1093/fampra/14.1.29; *DEP HLTH, 1995, OUTP WARD ATT ENGL F; FAULKNER A, 1993, EVALUATION DELIVERY; Fitzpatrick R., 1984, EXPERIENCE ILLNESS, P154; Horder J P, 1985, Health Trends, V17, P64; Lester J P, 1980, J R Coll Gen Pract, V30, P230; Reeve H, 1997, FAM PRACT, V14, P24, DOI 10.1093/fampra/14.1.24; Shaw C D, 1981, Health Trends, V13, P107; Stacey M, 1994, RES PEOPLES HLTH, P85; SZASZ TS, 1956, ARCH INTERN MED, V97, P585, DOI 10.1001/archinte.1956.00250230079008	10	29	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1138	1141						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE615	9374889				2022-12-24	WOS:A1997YE61500028
J	MacKie, RM; Hunter, D; Hunter, JAA; Rankin, R; Evans, A; McLaren, K; Fallowfield, M; Hutcheon, A; Morris, A				MacKie, RM; Hunter, D; Hunter, JAA; Rankin, R; Evans, A; McLaren, K; Fallowfield, M; Hutcheon, A; Morris, A			Cutaneous malignant melanoma in Scotland: incidence, survival, and mortality, 1979-94	BRITISH MEDICAL JOURNAL			English	Article							TRENDS	Objective: To determine the changing incidence of and mortality from cutaneous malignant melanoma in Scotland from 1979 to 1994. Design: Detailed registration of clinical and pathological features, surgical and other treatment, and follow up of all cases of cutaneous malignant melanoma diagnosed from 1979 to 1994 and registered with specialist database for Scotland. Setting: Scotland. Subjects: 6288 patients with invasive primary cutaneous malignant melanoma diagnosed between 1 January 1979 and 31 December 1994. Results: The annual age standardised incidence of cutaneous malignant melanoma rose significantly from 3.5 to 7.8 per 100 000 per year in men and from 6.8 to 12.3 per 100 000 per year in women (P < 0.001 for both). World standardised rates increased from 2.7 to 6.0 per 100 000 per year in men and 4.6 to 8.50 per 100 000 in women. The incidence of melanoma continued to increase significantly in men of all ages during the study but the rate stabilised in women after 1986. Mortality from cutaneous malignant melanoma was 1.3 per million per annum in men in 1979, rising to 2.3 per million per annum in 1994 (P < 0.01); it was 2.4 per million per annum in women in 1979, falling to 1.9 per million per annum in 1994 (P = 0.09). The underlying mortality trends showed a continuing rise for men but a downward trend for women that was not significant (P = 0.09). In men, melanoma free survival was 69% at 5 years and 61% at 10 years; in women the corresponding rates were 82% and 75%. Younger patients had higher survival rates, which were not entirely explained by thinner rumours. Over the 15 year period, survival rates improved by 12% overall, only partly owing to thinner tumours. Conclusions: In Scotland the incidence of melanoma in women has stabilised, while mortality associated with melanoma in women shows a downward trend.	RUCHILL HOSP,CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,LANARK,SCOTLAND; UNIV EDINBURGH,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; RAIGMORE HOSP,INVERNESS IV8 3UJ,SCOTLAND; NINEWELLS HOSP,DUNDEE DD2 1UB,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,GLASGOW G11 6NJ,LANARK,SCOTLAND; ABERDEEN ROYAL INFIRM,ABERDEEN AB9 2ZB,SCOTLAND; TAYSIDE HLTH BOARD,DUNDEE DD1 9NL,SCOTLAND	University of Edinburgh; University of Dundee; University of Glasgow; University of Aberdeen	MacKie, RM (corresponding author), UNIV GLASGOW,DEPT DERMATOL,ROBERTSON BLDG,GLASGOW G12 8QQ,LANARK,SCOTLAND.							Balzi D, 1997, CANCER CAUSE CONTROL, V8, P85, DOI 10.1023/A:1018491323442; BRAHME EM, 1994, CANCER, V73, P2324; BURTON RC, 1994, MELANOMA RES, V4, P107, DOI 10.1097/00008390-199404000-00005; BURTON RC, 1993, INT J CANCER, V55, P765, DOI 10.1002/ijc.2910550512; Giles GG, 1996, BMJ-BRIT MED J, V312, P1121; MACKIE R, 1992, LANCET, V339, P971, DOI 10.1016/0140-6736(92)91539-K; MACKIE RM, 1985, LANCET, V2, P859; MACKIE RM, 1992, BRIT MED J, V304, P1012, DOI 10.1136/bmj.304.6833.1012; MELIA J, 1995, BRIT J CANCER, V72, P224, DOI 10.1038/bjc.1995.307; *OFF POP CENS SURV, 1995, MORT STAT CAUS E DH2; *OFF POP CENS SURV, 1994, CANC STAT REG EN MB1; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; ROUSH GC, 1992, CANCER-AM CANCER SOC, V69, P1714, DOI 10.1002/1097-0142(19920401)69:7&lt;1714::AID-CNCR2820690712&gt;3.0.CO;2-Z; SCOTTO J, 1991, INT J CANCER, V49, P490, DOI 10.1002/ijc.2910490403; STREETLY A, 1995, INT J EPIDEMIOL, V24, P897, DOI 10.1093/ije/24.5.897	15	128	128	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1117	1121						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE615	9374883	Green Published			2022-12-24	WOS:A1997YE61500019
J	Campbell, JJ; Hedrick, J; Zlotnik, A; Siani, MA; Thompson, DA; Butcher, EC				Campbell, JJ; Hedrick, J; Zlotnik, A; Siani, MA; Thompson, DA; Butcher, EC			Chemokines and the arrest of lymphocytes rolling under flow conditions	SCIENCE			English	Article							T-CELL ADHESION; ENDOTHELIAL-CELLS; CHEMOATTRACTANT; MOLECULES; PROTEINS; MIP-1-BETA; MIGRATION; INTEGRINS; RECEPTOR; MEMORY	Circulating lymphocytes are recruited from the blood to the tissue by railing along the endothelium until being stopped by a signaling event linked to the G(i) alpha subunit of a heterotrimeric GTP-binding protein; that event then triggers rapid integrin-dependent adhesion. Four chemokines are now shown to induce such adhesion tb intercellular adhesion molecule-1 and to induce arrest of rolling cells within 1 second under flow conditions similar to those of blood. SDF-1 (also called PBSF), 6-C-kine (also called Exodus-2), and MIP-3 beta (also called ELC or Exodus-3) induced adhesion of most circulating lymphocytes, including most CD4(+) T cells; and MIP-3 alpha (also called LARC or Exodus-1) triggered adhesion of memory, but not nai ve, CD4(+) T cells. Thus, chemokines can regulate the arrest of lymphocyte subsets under flawing conditions, which may allow them to control lymphocyte-endothelial cell recognition and lymphocyte recruitment in vivo.	Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Ctr Digest Dis, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol & Med, Palo Alto, CA 94304 USA; DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunol, Palo Alto, CA 94304 USA; Gryphon Sci, San Francisco, CA 94080 USA	Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Campbell, JJ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA.		Zlotnik, Albert/C-3791-2011	Campbell, James/0000-0003-4252-5182; Thompson, Darren/0000-0002-3725-7112	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037734, R37GM037734] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA090302] Funding Source: Medline; NIDDK NIH HHS [DK38707] Funding Source: Medline; NIGMS NIH HHS [GM37734] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; BARGATZE R, 1994, THESIS MONTANA STATE; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Campbell JJ, 1997, EUR J IMMUNOL, V27, P2571, DOI 10.1002/eji.1830271016; CARLOS TM, 1994, BLOOD, V84, P2068; Carr MW, 1996, IMMUNITY, V4, P179, DOI 10.1016/S1074-7613(00)80682-2; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Hedrick JA, 1997, J IMMUNOL, V159, P1589; Hieshima K, 1997, J IMMUNOL, V159, P1140; Hieshima K, 1997, J BIOL CHEM, V272, P5846, DOI 10.1074/jbc.272.9.5846; HONDA S, 1994, J IMMUNOL, V152, P4026; Hromas R, 1997, BLOOD, V89, P3315; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; IMHOF BA, 1995, ADV IMMUNOL, V58, P345, DOI 10.1016/S0065-2776(08)60623-9; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; Lloyd AR, 1996, J IMMUNOL, V156, P932; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; NIELSON CP, 1990, J ALLERGY CLIN IMMUN, V86, P801, DOI 10.1016/S0091-6749(05)80186-1; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Rossi DL, 1997, J IMMUNOL, V158, P1033; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WARNOCK RA, IN PRESS J EXP MED; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803	41	792	822	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	1998	279	5349					381	384		10.1126/science.279.5349.381	http://dx.doi.org/10.1126/science.279.5349.381			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430588				2022-12-24	WOS:000071570800046
J	Bezzi, P; Carmignoto, G; Pasti, L; Vesce, S; Rossi, D; Rizzini, BL; Pozzan, T; Volterra, A				Bezzi, P; Carmignoto, G; Pasti, L; Vesce, S; Rossi, D; Rizzini, BL; Pozzan, T; Volterra, A			Prostaglandins stimulate calcium-dependent glutamate release in astrocytes	NATURE			English	Article							ARACHIDONIC-ACID; SYNAPTIC TRANSMISSION; GLIAL-CELLS; HIPPOCAMPAL; NEURONS; CULTURES; INHIBITION; RECEPTORS; RESPONSES; TETANUS	Astrocytes in the brain form an intimately associated network with neurons. They respond to neuronal activity and synaptically released glutamate by raising intracellular calcium concentration ([Ca2+](i))(1,2), which could represent the start of back-signalling to neurons(3-5). Here we show that coactivation of the AMPA/kainate and metabotropic glutamate receptors (mGluRs) on astrocytes stimulates these cells to release glutamate through a Ca2+-dependent process mediated by prostaglandins. Pharmacological inhibition of prostaglandin synthesis prevents glutamate release, whereas application of prostaglandins (in particular PGE(2)) mimics and occludes the releasing action of GluR agonists. PGE(2) promotes Ca2+-dependent glutamate release from cultured astrocytes and also from acute brain slices under conditions that suppress neuronal exocytotic release. When applied to the CA1 hippocampal region, PGE(2) induces increases in [Ca2+](i) both in astrocytes and in neurons. The [Ca2+](i) increase in neurons is mediated by glutamate released from astrocytes, because it is abolished by GluR antagonists. Our results reveal a new pathway of regulated transmitter release from astrocytes and outline the existence of an integrated glutamatergic cross-talk between neurons and astrocytes in situ that may play critical roles in synaptic plasticity and in neurotoxicity.	Univ Milan, Inst Pharmacol Sci, I-20133 Milan, Italy; Univ Padua, Dept Expt Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Ctr Study Biomembranes, I-35121 Padua, Italy	University of Milan; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Volterra, A (corresponding author), Univ Milan, Inst Pharmacol Sci, Via Balzaretti 9, I-20133 Milan, Italy.		Bezzi, Paola/AAP-2440-2020; Rossi, Daniela Maria/AAA-3401-2021; Carmignoto, Giorgio/A-8375-2018	Rossi, Daniela Maria/0000-0002-3346-1327; Carmignoto, Giorgio/0000-0003-3063-6774; Volterra, Andrea/0000-0003-1069-1602	Telethon [586, 845] Funding Source: Medline	Telethon(Fondazione Telethon)		BARAN H, 1987, BRAIN RES, V404, P107, DOI 10.1016/0006-8993(87)91360-6; CALABRESI P, 1989, NEUROSCIENCE, V30, P663, DOI 10.1016/0306-4522(89)90159-0; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CollacoMoraes Y, 1996, J CEREBR BLOOD F MET, V16, P1366, DOI 10.1097/00004647-199611000-00035; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; DUMUIS A, 1990, NATURE, V347, P182, DOI 10.1038/347182a0; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; ERIKSSON PS, 1992, NEUROSCI LETT, V143, P195, DOI 10.1016/0304-3940(92)90264-8; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HASSINGER TD, 1995, J NEUROBIOL, V28, P159, DOI 10.1002/neu.480280204; Jeftinija SD, 1997, BRAIN RES, V750, P41, DOI 10.1016/S0006-8993(96)00610-5; JEFTINIJA SD, 1996, J NEUROCHEM, V66, P674; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; Mennerick S, 1996, J NEUROSCI, V16, P55; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; OBanion MK, 1996, J NEUROCHEM, V66, P2532; OOMAGARI K, 1991, EUR J NEUROSCI, V3, P928, DOI 10.1111/j.1460-9568.1991.tb00028.x; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pasti L, 1997, J NEUROSCI, V17, P7817; PIOMELLI D, 1994, CRIT REV NEUROBIOL, V8, P65; Porter JT, 1996, J NEUROSCI, V16, P5073; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Steinhauser C, 1996, TRENDS NEUROSCI, V19, P339, DOI 10.1016/0166-2236(96)10043-6; STELLA N, 1994, J NEUROSCI, V14, P568; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Vesce S, 1997, FEBS LETT, V411, P107, DOI 10.1016/S0014-5793(97)00674-1; Volterra A, 1996, EUR J NEUROSCI, V8, P2019, DOI 10.1111/j.1460-9568.1996.tb01345.x	29	929	963	1	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					281	285		10.1038/34651	http://dx.doi.org/10.1038/34651			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440691				2022-12-24	WOS:000071484400050
J	Boccaccio, C; Ando, M; Tamagnone, L; Bardelli, A; Michieli, P; Battistini, C; Comoglio, PM				Boccaccio, C; Ando, M; Tamagnone, L; Bardelli, A; Michieli, P; Battistini, C; Comoglio, PM			Induction of epithelial tubules by growth factor HGF depends on the STAT pathway	NATURE			English	Article							SCATTER FACTOR-RECEPTOR; C-FOS PROMOTER; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; MET RECEPTOR; PROTEIN; EXPRESSION; CELLS; TRANSFORMATION; MORPHOGENESIS	Hepatocyte growth factor (HGF) induces a three-phase response leading-to the formation of branched tubular structures in epithelial cells(1,2). The HGF receptor tyrosine kinase works through a Src homology (SH2) docking site that can activate several signalling pathways(3). The first phase of the response (scattering), which results from cytoskeletal reorganization, loss of intercellular junctions and cell migration(4), is depdent on phosphatidylinositol-3-OH kinase and Rac activation(5,6). The second phase (growth) requires stimulation of the Ras-MAP kinase cascade(7). Here we show that the third phase (tubulogenesis) is dependent on the STAT pathway. HGF stimulates recruitment of Stat-3 to the receptor, tyrosine phosphorylation, nuclear translocation and binding to the specific promoter element SIE. Electroporation of a tyrosine-phosphorylated peptide, which interferes with both the association of STAT to the receptor and STAT dimerization, inhibits tubule formation in vitro without affecting either HGF-induced 'scattering' or growth. The same result is obtained using a specific 'decoy' oligonucleotide that prevents STAT from binding to DNA and affecting the expression of genes involved in cell-cycle regulation (c-fos and waf-1). Activation of signal transducers that directly control transcription is therefore required for morphogenesis.	Univ Turin, Sch Med, Inst Canc Res, I-10060 Candiolo, Italy; Pharmacia & Upjohn Inc, Preclin Res, I-20014 Nerviano, Italy	University of Turin; Pfizer	Boccaccio, C (corresponding author), Univ Turin, Sch Med, Inst Canc Res, Str Prov 142, I-10060 Candiolo, Italy.	cboccaccio@hal.ircc.polito.it	Tamagnone, Luca/J-8948-2018; Michieli, Paolo/A-2588-2011; Battistini, Carlo/AAJ-1193-2020; Boccaccio, Carla/AHE-7875-2022; BARDELLI, Alberto/J-9721-2018	Tamagnone, Luca/0000-0002-2884-7946; Michieli, Paolo/0000-0002-3093-8871; Boccaccio, Carla/0000-0003-2620-9083; BARDELLI, Alberto/0000-0003-1647-5070; Comoglio, Paolo/0000-0002-7056-5328				BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gambarotta G, 1996, ONCOGENE, V13, P1911; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; IHLE JN, 1996, CELL, V84, P221; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1995, ONCOGENE, V10, P1631; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RAPTIS LH, 1995, BIOTECHNIQUES, V18, P104; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STOCKER M, 1987, NATURE, V327, P239; TEKEDA K, 1997, P NATL ACAD SCI USA, V94, P3801; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0	30	436	457	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					285	288		10.1038/34657	http://dx.doi.org/10.1038/34657			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440692				2022-12-24	WOS:000071484400051
J	van Veen, HW; Callaghan, R; Soceneantu, L; Sardini, A; Konings, WN; Higgins, CF				van Veen, HW; Callaghan, R; Soceneantu, L; Sardini, A; Konings, WN; Higgins, CF			A bacterial antibiotic-resistance gene that complements the human multidrug-resistance P-glycoprotein gene	NATURE			English	Article							DRUG TRANSPORT; CELLS; BINDING; MDR1; VINBLASTINE; MEMBRANE; PROTEIN	Bacteria have developed many fascinating antibiotic-resistance mechanisms(1,2). A protein in Lactococcus lactis, LmrA, mediates antibiotic resistance by extruding amphiphilic compounds from the inner leaflet of the cytoplasmic membrane(3,4). Unlike other known bacterial multidrug-resistance proteins, LmrA is an ATP-binding cassette (ABC) transporter(5). The human multidrug-resistance P-glycoprotein(6), encoded by the MDR1 gene, is also an ABC transporter, overexpression of which is one of the principal causes of resistance of human cancers to chemotherapy(7,8). We expressed ImrA in human lung fibroblast cells. Surprisingly, LmrA was targeted to the plasma membrane and conferred typical multidrug resistance on these human cells. The pharmacological characteristics of LmrA and P-glycoprotein-expressing lung fibroblasts were very similar, and the affinities of both proteins for vinblastine and magnesium-ATP were indistinguishable. Blockers of P-glycoprotein-mediated multidrug resistance also inhibited LmrA-dependent drug resistance. Kinetic analysis of drug dissociation from LmrA expressed in plasma membranes of insect cells revealed the presence of two allosterically linked drug-binding sites indistinguishable from those of P-glycoprotein. These findings have implications for the reversal of antibiotic resistance in pathogenic microorganisms. Taken together, they demonstrate that bacterial LmrA and human P-glycopiotein are functionally interchangeable and that this type of multidrug-resistance efflux pump is conserved from bacteria to man.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands; Univ Oxford, John Radcliffe Hosp, Inst Mol Med,Nuffield Dept Clin Biochem, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England; Univ Oxford, John Radcliffe Hosp, Inst Mol Med,Nuffield Dept Clin Biochem, Canc Res Campaign,Drug Resistance Grp, Oxford OX3 9DS, England; Univ London Kings Coll, Dept Physiol, London WC2R 2LS, England	University of Groningen; Cancer Research UK; University of Oxford; University of Oxford; University of London; King's College London	van Veen, HW (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.		Callaghan, Richard/B-7032-2012; Callaghan, Richard/ABG-1638-2020; Konings, Wilhelmus N./C-7063-2013; van Veen, Hendrik W./A-4162-2008	Callaghan, Richard/0000-0001-6136-3532; Callaghan, Richard/0000-0001-6136-3532; van Veen, Hendrik W./0000-0002-9658-8077				Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; CALLAGHAN R, 1993, J BIOL CHEM, V268, P16059; CANOGAUCI DF, 1987, BIOCHEM PHARMACOL, V36, P2115, DOI 10.1016/0006-2952(87)90139-0; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; Ferry D. R, 1994, NEW MOL TARGETS CANC, P177; FERRY DR, 1992, BIOCHEM BIOPH RES CO, V188, P440, DOI 10.1016/0006-291X(92)92404-L; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; Goodfellow HR, 1996, J BIOL CHEM, V271, P13668, DOI 10.1074/jbc.271.23.13668; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; Kostenis E, 1996, TRENDS PHARMACOL SCI, V17, P280, DOI 10.1016/0165-6147(96)10034-1; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEVER JE, 1977, J BIOL CHEM, V252, P1990; MALKHANDI J, 1994, EUR J PHARM-MOLEC PH, V288, P105, DOI 10.1016/0922-4106(94)90015-9; Martin C, 1997, BRIT J PHARMACOL, V122, P765, DOI 10.1038/sj.bjp.0701429; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ruetz S, 1997, BIOCHEMISTRY-US, V36, P8180, DOI 10.1021/bi970564o; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Shao YM, 1997, BBA-MOL BASIS DIS, V1360, P30, DOI 10.1016/S0925-4439(96)00065-8; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; TAMAI I, 1991, J BIOL CHEM, V266, P16796; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; vanVeen HW, 1997, BIOL CHEM, V378, P769; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213	29	213	217	2	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					291	295		10.1038/34669	http://dx.doi.org/10.1038/34669			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440694				2022-12-24	WOS:000071484400053
J	Gannon, PJ; Holloway, RL; Broadfield, DC; Braun, AR				Gannon, PJ; Holloway, RL; Broadfield, DC; Braun, AR			Asymmetry of chimpanzee planum temporale: Humanlike pattern of Wernicke's brain language area homolog	SCIENCE			English	Article							CEREBRAL LATERALIZATION; BIOLOGICAL MECHANISMS; RHESUS-MONKEYS; ASSOCIATIONS; HYPOTHESIS; PATHOLOGY; PROGRAM; ORGANIZATION; REGION	The anatomic pattern and left hemisphere size predominance of the planum temporale, a language area of the human brain, are also present in chimpanzees (Pan troglodytes). The left planum temperate was significantly larger in 94 percent (17 of 18) of chimpanzee brains examined. It is widely accepted that the planum temporale is a key component of Wernicke's receptive language area, which is also implicated in human communication-related disorders such as schizophrenia and in normal variations such as musical talent. However, anatomic hemispheric asymmetry of this cerebrocortical site is clearly not unique to humans, as is currently thought. The evolutionary origin of human language may have been founded on this basal anatomic substrate, which was already lateralized to the left hemisphere in the common ancestor of chimpanzees and humans 8 million years ago.	CUNY Mt Sinai Sch Med, Dept Otolaryngol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA; Columbia Univ, Dept Anthropol, New York, NY 10027 USA; CUNY, Dept Anthropol, New York, NY 10036 USA; Natl Inst Deafness & Other Commun Disorders, Bethesda, MD 20892 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University; City University of New York (CUNY) System; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Gannon, PJ (corresponding author), CUNY Mt Sinai Sch Med, Dept Otolaryngol, Box 1189,5th Ave & 100th St, New York, NY 10029 USA.	P_Gannon@smtplink.mssm.edu						ANNETT M, 1992, NEUROPSYCHOLOGIA, V30, P951, DOI 10.1016/0028-3932(92)90048-Q; Bailey P, 1950, ISOCORTEX CHIMPANZEE; Binder JR, 1996, BRAIN, V119, P1239, DOI 10.1093/brain/119.4.1239; Calvert GA, 1997, SCIENCE, V276, P593, DOI 10.1126/science.276.5312.593; Crow TJ, 1997, TRENDS NEUROSCI, V20, P339; DDEWAAL F, 1997, DISCOVER, V18, P50; DEACON TW, 1992, EVOLUTION HUMAN LANG, V11, P49; FALK D, 1986, FOLIA PRIMATOL, V46, P98, DOI 10.1159/000156242; FOUNDAS AL, 1994, NEUROPSYCHOLOGIA, V32, P1225, DOI 10.1016/0028-3932(94)90104-X; FOUNDAS AL, 1995, ARCH NEUROL-CHICAGO, V52, P501, DOI 10.1001/archneur.1995.00540290091023; GALABURDA A, 1980, J COMP NEUROL, V190, P597, DOI 10.1002/cne.901900312; GALABURDA AM, 1993, ARCH NEUROL-CHICAGO, V50, P457, DOI 10.1001/archneur.1993.00540050011007; GALABURDA AM, 1978, ARCH NEUROL-CHICAGO, V35, P812, DOI 10.1001/archneur.1978.00500360036007; GALLUP GG, 1970, SCIENCE, V167, P86, DOI 10.1126/science.167.3914.86; GANNON PJ, 1995, THESIS CITY U NEW YO; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P428, DOI 10.1001/archneur.1985.04060050026008; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P521, DOI 10.1001/archneur.1985.04060060019009; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P634, DOI 10.1001/archneur.1985.04060070024012; GESCHWIND N, 1968, SCIENCE, V161, P186, DOI 10.1126/science.161.3837.186; Goodall J, 1986, CHIMPANZEES GOMBE, DOI DOI 10.1002/AJPA.1330730313; GREENFIELD PM, 1993, J CHILD LANG, V20, P1, DOI 10.1017/S0305000900009090; HABIB M, 1995, BRAIN LANG, V48, P238, DOI 10.1006/brln.1995.1011; Harasty J, 1997, ARCH NEUROL-CHICAGO, V54, P171, DOI 10.1001/archneur.1997.00550140045011; HEILBRONER PL, 1988, AM J PHYS ANTHROPOL, V76, P39, DOI 10.1002/ajpa.1330760105; Hickok G, 1996, NATURE, V381, P699, DOI 10.1038/381699a0; HOLLOWAY RL, 1980, AM J PHYS ANTHROPOL, V53, P285, DOI 10.1002/ajpa.1330530213; Just MA, 1996, SCIENCE, V274, P114, DOI 10.1126/science.274.5284.114; KIOYASHI H, 1997, NATURE, V387, P767; LEMAY M, 1975, BRAIN BEHAV EVOLUT, V11, P48, DOI 10.1159/000123623; LEMAY M, 1976, ANN NY ACAD SCI, V280, P349, DOI 10.1111/j.1749-6632.1976.tb25499.x; Lynch MP, 1996, BEHAV BRAIN SCI, V19, P788, DOI 10.1017/S0140525X00044071; Ojemann G A, 1993, Adv Neurol, V63, P155; OJEMANN GA, 1991, J NEUROSCI, V11, P2281; PETTY RG, 1995, AM J PSYCHIAT, V152, P715; PFEIFER RA, 1936, HDB NEUROLOGIE, V6, P533; Poizner H., 1987, LANGUAGE, DOI [10.2307/414579, DOI 10.2307/414579]; ROSSI A, 1994, BRAIN LANG, V47, P89, DOI 10.1006/brln.1994.1043; SAVAGERUMBAUGH ES, 1993, MONOGR SOC RES CHILD, V58, pR5; SCHLAUG G, 1995, SCIENCE, V267, P699, DOI 10.1126/science.7839149; STEINMETZ H, 1991, ANN NEUROL, V29, P315, DOI 10.1002/ana.410290314; STEINMETZ H, 1989, J COMPUT ASSIST TOMO, V13, P996, DOI 10.1097/00004728-198911000-00011; STEKIIS HD, 1979, NEUROBIOLOGY SOCIAL; STEKLIS HD, COMMUNICATION; TOBIAS PV, 1987, J HUM EVOL, V16, P741, DOI 10.1016/0047-2484(87)90022-4; Vauclair J, 1997, TRENDS COGN SCI, V1, P35, DOI 10.1016/S1364-6613(97)01004-8; von Economo C, 1930, Z GESAMTE NEUROL PSY, V130, P678; WITELSON SF, 1973, BRAIN, V96, P641, DOI 10.1093/brain/96.3.641; WITELSON SF, 1991, PSYCHONEUROENDOCRINO, V16, P131, DOI 10.1016/0306-4530(91)90075-5; YENIKOMSHIAN GH, 1976, SCIENCE, V192, P387, DOI 10.1126/science.816005; [No title captured]	50	339	343	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 9	1998	279	5348					220	222		10.1126/science.279.5348.220	http://dx.doi.org/10.1126/science.279.5348.220			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YQ636	9422693				2022-12-24	WOS:000071408100040
J	van Leeuwen, FW; de Kleijn, DPV; van den Hurk, HH; Neubauer, A; Sonnemans, MAF; Sluijs, JA; Koycu, S; Ramdjielal, RDJ; Salehi, A; Martens, GJM; Grosveld, FG; Burbach, JPH; Hol, EM				van Leeuwen, FW; de Kleijn, DPV; van den Hurk, HH; Neubauer, A; Sonnemans, MAF; Sluijs, JA; Koycu, S; Ramdjielal, RDJ; Salehi, A; Martens, GJM; Grosveld, FG; Burbach, JPH; Hol, EM			Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients	SCIENCE			English	Article							PAIRED HELICAL FILAMENTS; HUMAN-BRAIN; DOWNS-SYNDROME; DISEASE; GENE; MUTATIONS; IDENTIFICATION; TRANSCRIPTS; DESTRUCTION; PEPTIDES	The cerebral cortex of Alzheimer's and Down syndrome patients is characterized by the presence of protein deposits in neurofibrillary tangles, neuritic plaques, and neuropil threads. These structures were shown to contain forms of beta amyloid precursor protein and ubiquitin-B that are aberrant(+1 proteins) in the carboxyl terminus. The +1 proteins were not found in young control patients, whereas the presence of ubiquitin-B+1 in elderly control patients may indicate early stages of neurodegeneration. The two species of +1 proteins displayed cellular colocalization, suggesting a common origin, operating at the transcriptional level or by posttranscriptional editing of RNA. This type of transcript mutation is likely an important factor in the widely occurring nonfamilial early- and late-onset forms of Alzheimer's disease.	Netherlands Inst Brain Res, Grad Sch Neurosci, NL-1105 AZ Amsterdam, Netherlands; Univ Nijmegen, Dept Mol Anim Physiol, NL-6525 ED Nijmegen, Netherlands; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; Rudolf Magnus Inst Neurosci, NL-3584 CG Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Radboud University Nijmegen; Erasmus University Rotterdam; Utrecht University; Utrecht University Medical Center	van Leeuwen, FW (corresponding author), Netherlands Inst Brain Res, Grad Sch Neurosci, Meibergdreef 33, NL-1105 AZ Amsterdam, Netherlands.		Salehi, Ahmad/A-1148-2007; Martens, Gerard JM/D-1925-2010; Hol, Elly M/F-1891-2013; Salehi, Ahmad/H-2746-2019; Hol, Elly/J-2025-2019	Salehi, Ahmad/0000-0001-8257-3280; Hol, Elly M/0000-0001-5604-2603; Salehi, Ahmad/0000-0001-8257-3280; Hol, Elly/0000-0001-5604-2603				ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ALIKHAN Z, 1992, NEUROSCI LETT, V139, P24, DOI 10.1016/0304-3940(92)90849-3; BAKER RT, 1987, NUCLEIC ACIDS RES, V15, P443, DOI 10.1093/nar/15.2.443; Braak H, 1996, J NEURAL TRANSM, V103, P455, DOI 10.1007/BF01276421; EVANS DAP, 1994, P NATL ACAD SCI USA, V91, P6059, DOI 10.1073/pnas.91.13.6059; Glisic S, 1996, TRENDS GENET, V12, P391, DOI 10.1016/S0168-9525(96)90094-3; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Harrison PJ, 1996, NEURODEGENERATION, V5, P409, DOI 10.1006/neur.1996.0055; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Jicha GA, 1997, J NEUROSCI RES, V48, P128, DOI 10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E; JIN LW, 1994, J NEUROSCI, V14, P5461; Johnston JA, 1996, MOL BRAIN RES, V43, P85, DOI 10.1016/S0169-328X(96)00161-1; KWAK S, 1991, NEUROSCI LETT, V128, P21, DOI 10.1016/0304-3940(91)90751-E; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; OYAMA F, 1994, J NEUROCHEM, V62, P1062; PERRY G, 1989, J NEUROCHEM, V52, P1523, DOI 10.1111/j.1471-4159.1989.tb09203.x; PHILIPPE B, 1993, NEUROREPORT, V5, P289, DOI 10.1097/00001756-199312000-00027; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; Simpson L, 1996, ANNU REV NEUROSCI, V19, P27, DOI 10.1146/annurev.ne.19.030196.000331; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; STRACHAN T, 1997, HUMAN MOL GENETICS; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Terry Robert D., 1994, P179; VANBROECKHOVEN CL, 1995, EUR NEUROL, V35, P8, DOI 10.1159/000117083; VANLEEUWEN F, 1989, P NATL ACAD SCI USA, V86, P6417, DOI 10.1073/pnas.86.16.6417; VANLEEUWEN FXR, UNPUB; WEST MJ, 1994, LANCET, V344, P769, DOI 10.1016/S0140-6736(94)92338-8; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	31	465	478	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					242	247		10.1126/science.279.5348.242	http://dx.doi.org/10.1126/science.279.5348.242			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422699				2022-12-24	WOS:000071408100046
J	Kippelen, B; Marder, SR; Hendrickx, E; Maldonado, JL; Guillemet, G; Volodin, BL; Steele, DD; Enami, Y; Sandalphon; Yao, YJ; Wang, JF; Rockel, H; Erskine, L; Peyghambarian, N				Kippelen, B; Marder, SR; Hendrickx, E; Maldonado, JL; Guillemet, G; Volodin, BL; Steele, DD; Enami, Y; Sandalphon; Yao, YJ; Wang, JF; Rockel, H; Erskine, L; Peyghambarian, N			Infrared photorefractive polymers and their applications for imaging	SCIENCE			English	Article							STATE; GAIN	Photorefractive polymers with high diffraction efficiency in the visible and near-infrared regions of the electromagnetic spectrum have been developed, These polymers, which have a large dynamic range because of their high orientational birefringence, incorporate a dye designed to have a large dipole moment and a high linear polarizability anisotropy, Such polymers have enabled demonstrations of imaging through scattering media, using a holographic time-gating technique at a wavelength that is compatible with the transparency of biological tissues and with the emission of low-cost semiconductor laser diodes.	Univ Arizona, Ctr Opt Sci, Tucson, AZ 85721 USA; CALTECH, Beckman Inst, Pasadena, CA 91125 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	University of Arizona; California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Kippelen, B (corresponding author), Univ Arizona, Ctr Opt Sci, Tucson, AZ 85721 USA.		Maldonado, Jose-Luis/L-6884-2017; Kippelen, Bernard/I-4058-2013; Enami, Yasufumi/E-4273-2016; Marder, Seth/GRR-9990-2022	Maldonado, Jose-Luis/0000-0003-3601-7464; Kippelen, Bernard/0000-0002-8417-7051; Enami, Yasufumi/0000-0002-0303-2695; 				ABRAMSON NH, 1989, APPL OPTICS, V28, P1834, DOI 10.1364/AO.28.001834; ASHKIN A, 1966, APPL PHYS LETT, V9, P72, DOI 10.1063/1.1754607; DONCKERS MCJM, 1993, OPT LETT, V18, P1044, DOI 10.1364/OL.18.001044; DUCHARME S, 1991, PHYS REV LETT, V66, P1846, DOI 10.1103/PhysRevLett.66.1846; Gayen S. K., 1996, OPT PHOTONICS NEWS, V7, P16; GrunnetJepsen A, 1997, SCIENCE, V277, P549, DOI 10.1126/science.277.5325.549; GUNTER P, 1988, PHOTOREFRACTIVE MAT, V1; GUNTER P, 1989, PHOTOREFRACTIVE MAT, V2; Hendrickx E, 1997, APPL PHYS LETT, V71, P1159, DOI 10.1063/1.119612; Huignard J. P., 1988, PHOTOREFRACTIVE MAT; HYDE SCW, 1995, OPT LETT, V20, P1331, DOI 10.1364/OL.20.001331; Kippelen B, 1997, J AM CHEM SOC, V119, P4559, DOI 10.1021/ja9643477; Kippelen B, 1996, APPL PHYS LETT, V68, P1748, DOI 10.1063/1.116653; KIPPELEN B, 1997, NONLINEAR OPTICS ORG, P465; KOGELNIK H, 1969, AT&T TECH J, V48, P2909, DOI 10.1002/j.1538-7305.1969.tb01198.x; KUZYK MG, 1990, J OPT SOC AM B, V7, P842, DOI 10.1364/JOSAB.7.000842; LIPHARDT M, 1994, SCIENCE, V263, P367, DOI 10.1126/science.263.5145.367; Lundquist PM, 1996, SCIENCE, V274, P1182, DOI 10.1126/science.274.5290.1182; MEERHOLZ K, 1994, NATURE, V371, P497, DOI 10.1038/371497a0; MOERNER WE, 1994, J OPT SOC AM B, V11, P320, DOI 10.1364/JOSAB.11.000320; MOERNER WE, 1994, CHEM REV, V94, P127, DOI 10.1021/cr00025a005; OUDAR JL, 1977, J CHEM PHYS, V66, P2664, DOI 10.1063/1.434213; SINGER KD, 1987, J OPT SOC AM B, V4, P968, DOI 10.1364/JOSAB.4.000968; STEELE DD, IN PRESS OPT LETT; Volodin BL, 1996, NATURE, V383, P58, DOI 10.1038/383058a0; WILLIAMS DJ, 1987, NONLINEAR OPTICAL PR, V1; WU JW, 1991, J OPT SOC AM B, V8, P142, DOI 10.1364/JOSAB.8.000142; Zhang Y, 1996, ADV MATER, V8, P111, DOI 10.1002/adma.19960080203	28	235	243	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					54	57		10.1126/science.279.5347.54	http://dx.doi.org/10.1126/science.279.5347.54			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417020				2022-12-24	WOS:000071323900035
J	Escalante, CR; Yie, JM; Thanos, D; Aggarwal, AK				Escalante, CR; Yie, JM; Thanos, D; Aggarwal, AK			Structure of IRF-1 with bound DNA reveals determinants of interferon regulation	NATURE			English	Article							CRYSTAL-STRUCTURE; TRANSCRIPTION FACTORS; PROTEINS; RECOGNITION; COMPLEX; BINDING; IFN; EXPRESSION; DOMAIN; GENES	The family of interferon regulatory factor (IRF) transcription factors is important in the regulation of interferons in response to infection by virus and in the regulation of interferon-inducible genes(1,2). The IRF family is characterized by a unique 'tryptophan cluster' DNA-binding region. Here we report the crystal structure of the IRF-1 region bound to the natural positive regulatory domain I (PRD I) DNA element from the interferon-beta promoter(1). The structure provides the first three-dimensional view of a member of the growing IRF family, revealing a new helix-turn-helix motif that latches onto DNA through three of the five conserved tryptophans. The moth selects a short GAAA core sequence through an obliquely angled recognition helix, with an accompanying bending of the DNA axis in the direction of the protein. Together, these features suggest a basis for the occurrence of GAAA repeats within IRF response elements and provide clues to the assembly of the higher-order interferon-beta enhancesome.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University	Aggarwal, AK (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, Box 1677,1425 Madison Ave, New York, NY 10029 USA.		Thanos, Dimitris/AAE-5720-2019					AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Escalante CR, 1997, FEBS LETT, V414, P219, DOI 10.1016/S0014-5793(97)00996-4; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FUREY W, 1993, PHASES PROGRAM PACKA; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAWAKAMI T, 1995, FEBS LETT, V358, P225, DOI 10.1016/0014-5793(94)01426-2; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1993; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; UEGAKI K, 1995, FEBS LETT, V359, P184, DOI 10.1016/0014-5793(95)00040-G; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315	30	308	321	2	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					103	106		10.1038/34224	http://dx.doi.org/10.1038/34224			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422515				2022-12-24	WOS:000071326100059
J	Bender, M; Imam, FB; Talbot, WS; Ganetzky, B; Hogness, DS				Bender, M; Imam, FB; Talbot, WS; Ganetzky, B; Hogness, DS			Drosophila ecdysone receptor mutations reveal functional differences among receptor isoforms	CELL			English	Article							SINGLE-BASE CHANGES; INDUCIBLE GENE; EARLY PUFF; ENCODES 2; METAMORPHOSIS; SUPERFAMILY; TRANSCRIPTION; MELANOGASTER; PROTEINS; E74	The steroid hormone ecdysone directs Drosophila metamorphosis via three heterodimeric receptors that differ according to which of three ecdysone receptor isoforms encoded by the EcR gene (EcR-A, EcR-B1, or EcR-B2) is activated by the orphan nuclear receptor USP. We have identified and molecularly mapped two classes of EcR mutations: those specific to EcR-B1 that uncouple metamorphosis, and embryonic-lethal mutations that map to common sequences encoding the DNA-and ligand-binding domains. In the larval salivary gland, loss of EcR-B1 results in loss of activation of ecdysone-induced genes. Comparable transgenic expression of EcR-B1, EcR-B2, and EcR-A in these mutant glands results, respectively, in full, partial, and no repair of that loss.	STANFORD UNIV,MED CTR,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT BIOCHEM,STANFORD,CA 94305; UNIV GEORGIA,DEPT GENET,ATHENS,GA 30602; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706	Stanford University; Stanford University; University System of Georgia; University of Georgia; University of Wisconsin System; University of Wisconsin Madison				Imam, Farhad/0000-0003-2854-2568	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043100, R01GM053681] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53681, GM43100] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andres A.J., 1994, DROSOPHILA MELANOGAS, P565; ANDRES AJ, 1995, DEVELOPMENT, V121, P2667; ANDRES AJ, 1993, DEV BIOL, V160, P388, DOI 10.1006/dbio.1993.1315; ASHBURNER M, 1974, DEV BIOL, V39, P141, DOI 10.1016/S0012-1606(74)80016-3; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BELYAEVA ES, 1981, CHROMOSOMA, V84, P207, DOI 10.1007/BF00399132; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; Crossgrove K, 1996, DEV BIOL, V180, P745, DOI 10.1006/dbio.1996.0343; DAI JD, 1991, DEV BIOL, V144, P309, DOI 10.1016/0012-1606(91)90424-2; DIBELLO PR, 1991, GENETICS, V129, P385; FLETCHER JC, 1995, DEVELOPMENT, V121, P1411; Fristrom Dianne, 1993, P843; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; JIANG C, 1997, IN PRESS DEVELOPMENT; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOELLE MR, 1992, THESIS STANFORD U ST; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; MADHAVAN MM, 1980, J EMBRYOL EXP MORPH, V60, P1; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCPHAUL MJ, 1993, J CLIN ENDOCR METAB, V76, P17, DOI 10.1210/jc.76.1.17; MUNROE S, 1995, THESIS STANFORD U ST; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; REFETOFF S, 1994, ENDOCR REV, V15, P336; Riddiford Lynn M., 1993, P899; ROBINOW S, 1993, DEVELOPMENT, V119, P1251; Russell S., 1996, METAMORPHOSIS CELL B, P109, DOI [10.1016/B978-012283245-1/50005-1, DOI 10.1016/B978-012283245-1/50005-1]; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEGRAVES WA, 1988, THESIS STANFORD U ST; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; Skaer Helen, 1993, P941; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; UMESS LD, 1995, EMBO J, V14, P6239; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F	38	226	232	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					777	788		10.1016/S0092-8674(00)80466-3	http://dx.doi.org/10.1016/S0092-8674(00)80466-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413987	hybrid			2022-12-24	WOS:A1997YL43900009
J	Darji, A; Guzman, CA; Gerstel, B; Wachholz, P; Timmis, KN; Wehland, J; Chakraborty, T; Weiss, S				Darji, A; Guzman, CA; Gerstel, B; Wachholz, P; Timmis, KN; Wehland, J; Chakraborty, T; Weiss, S			Oral somatic transgene vaccination using attenuated S-typhimurium	CELL			English	Article							COMPLEX CLASS-I; SALMONELLA-TYPHIMURIUM; LISTERIA-MONOCYTOGENES; ESCHERICHIA-COLI; T-CELLS; BETA-GALACTOSIDASE; IMMUNE-RESPONSES; BACTERIAL-DNA; LYMPHOCYTE-T; ANTIGEN	An attenuated strain of S. typhimurium has been used as a vehicle for oral genetic immunization. Eukaryotic expression vectors containing truncated genes of ActA and listeriolysin-two virulence factors of Listeria monocytogenes-have been used to transform S. typhimurium aroA. Multiple or even single oral immunizations with such transformants induced excellent cellular and humoral responses. In addition, protective immunity was induced with listeriolysin transformants. The quality of the responses suggested a transfer of plasmid DNA from the bacterial carrier to the host. Such transfer was unequivocally shown in vitro with primary peritoneal macrophages. We describe a highly versatile system for antigen delivery, identification of protective antigens for vaccination, and efficient generation of antibodies against the product of open reading frames present on virtually any DNA segment.	GESELL BIOTECHNOL FORSCH MBH,NATL RES CTR BIOTECHNOL,DIV MICROBIOL,D-38124 BRAUNSCHWEIG,GERMANY; UNIV GIESSEN,INST MED MICROBIOL,D-35392 GIESSEN,GERMANY	Gesellschaft fur Biotechnologische Forschung mbH; Justus Liebig University Giessen	Darji, A (corresponding author), GESELL BIOTECHNOL FORSCH MBH,NATL RES CTR BIOTECHNOL,DIV CELL BIOL & IMMUNOL,MASCHERODER WEG 1,D-38124 BRAUNSCHWEIG,GERMANY.							[Anonymous], 1982, MOL CLONING LAB MANU; BROOKS AG, 1993, J IMMUNOL, V150, P3690; BROWN A, 1987, J INFECT DIS, V155, P86, DOI 10.1093/infdis/155.1.86; CHAKRABORTY T, 1992, J BACTERIOL, V174, P568, DOI 10.1128/jb.174.2.568-574.1992; Chatfield SN, 1994, MODERN VACCINOLOGY, P55; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Condon C, 1996, NAT MED, V2, P1122, DOI 10.1038/nm1096-1122; Courvalin P, 1995, CR ACAD SCI III-VIE, V318, P1207; Darji A, 1995, J BIOTECHNOL, V43, P205, DOI 10.1016/0168-1656(95)00138-7; DARJI A, 1995, EUR J IMMUNOL, V25, P2967, DOI 10.1002/eji.1830251038; Darji A, 1997, EUR J IMMUNOL, V27, P1353, DOI 10.1002/eji.1830270609; DESOUSA CR, 1995, J EXP MED, V182, P841; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; FAIRWEATHER NF, 1990, RES MICROBIOL, V141, P769, DOI 10.1016/0923-2508(90)90109-4; FLYNN JL, 1990, MOL MICROBIOL, V4, P2111, DOI 10.1111/j.1365-2958.1990.tb00572.x; Fox BC, 1997, AM J VET RES, V58, P265; Geissler M, 1997, J IMMUNOL, V158, P1231; GERMANIER R, 1975, J INFECT DIS, V131, P553, DOI 10.1093/infdis/131.5.553; GUZMAN CA, 1991, INFECT IMMUN, V59, P4391; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARTY JT, 1992, J EXP MED, V175, P1531, DOI 10.1084/jem.175.6.1531; Hassan JO, 1996, INFECT IMMUN, V64, P938, DOI 10.1128/IAI.64.3.938-944.1996; Hess J, 1996, P NATL ACAD SCI USA, V93, P1458, DOI 10.1073/pnas.93.4.1458; HOLTEL A, 1992, NUCLEIC ACIDS RES, V20, P1755, DOI 10.1093/nar/20.7.1755; JARAQUEMADA D, 1990, J EXP MED, V172, P947, DOI 10.1084/jem.172.3.947; Kim JJ, 1997, J IMMUNOL, V158, P816; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MENGAUD J, 1988, INFECT IMMUN, V56, P766, DOI 10.1128/IAI.56.4.766-772.1988; MESSINA JP, 1991, J IMMUNOL, V147, P1759; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; NEWTON SMC, 1989, SCIENCE, V244, P70, DOI 10.1126/science.2468182; Norbury CC, 1995, IMMUNITY, V3, P783, DOI 10.1016/1074-7613(95)90067-5; OCALLAGHAN D, 1990, MOL GEN GENET, V223, P156, DOI 10.1007/BF00315809; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; RAMMENSEE HG, 1989, IMMUNOGENETICS, V30, P296, DOI 10.1007/BF02421334; ROBERTS M, 1994, NOVEL DELIVERY SYSTE, P27; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; Siebers A, 1996, TRENDS MICROBIOL, V4, P22, DOI 10.1016/0966-842X(96)81501-0; SIZEMORE DR, 1995, SCIENCE, V270, P299, DOI 10.1126/science.270.5234.299; Steinbach G, 1996, VET MICROBIOL, V48, P199, DOI 10.1016/0378-1135(95)00134-4; Tian JD, 1996, NAT MED, V2, P1348, DOI 10.1038/nm1296-1348; TURNER SJ, 1993, INFECT IMMUN, V61, P5374, DOI 10.1128/IAI.61.12.5374-5380.1993; WALKER MJ, 1992, INFECT IMMUN, V60, P4260, DOI 10.1128/IAI.60.10.4260-4268.1992; WILES MV, 1993, METHOD ENZYMOL, V225, P900; XIANG ZQ, 1995, IMMUNITY, V2, P129, DOI 10.1016/S1074-7613(95)80001-8; YAMAMOTO S, 1992, J IMMUNOL, V148, P4072; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	50	346	414	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					765	775		10.1016/S0092-8674(00)80465-1	http://dx.doi.org/10.1016/S0092-8674(00)80465-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413986	Bronze			2022-12-24	WOS:A1997YL43900008
J	Gong, XH; Li, E; Klier, G; Huang, QL; Wu, Y; Lei, H; Kumar, NM; Horwitz, J; Gilula, NB				Gong, XH; Li, E; Klier, G; Huang, QL; Wu, Y; Lei, H; Kumar, NM; Horwitz, J; Gilula, NB			Disruption of alpha(3) connexin gene leads to proteolysis and cataractogenesis in mice	CELL			English	Article							GAP JUNCTION PROTEIN; TRANSGENIC MICE; RAT LENS; STRUCTURAL ORGANIZATION; BETA-GALACTOSIDASE; MAMMALIAN LENS; CHICK LENS; CALPAIN-II; MOUSE; CRYSTALLIN	Gap junction channels formed by alpha(3) (Cx46) and alpha(8) (Cx50) connexin provide pathways for communication between the fiber cells in the normal transparent lens. To determine the specific role of alpha(3) connexin in vivo, the alpha(3) connexin gene was disrupted in mice. Although the absence of alpha(3) connexin had no obvious influence on the early stages of lens formation and the differentiation of lens fibers, mice homozygous for the disrupted alpha(3) gene developed nuclear cataracts that were associated with the proteolysis of crystallins. This study establishes the importance of gap junctions in maintaining normal lens transparency by providing a cell-cell signaling pathway or structural component for the proper organization of lens membrane and cytoplasmic proteins.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; HARVARD UNIV, MGH, SCH MED, CARDIOVASC RES CTR, CHARLESTOWN, MA 02129 USA; UNIV CALIF LOS ANGELES, JULES STEIN EYE INST, LOS ANGELES, CA 90095 USA	Scripps Research Institute; Harvard University; University of California System; University of California Los Angeles					NATIONAL EYE INSTITUTE [R37EY003897, R01EY011093] Funding Source: NIH RePORTER; NEI NIH HHS [EY11093, R37EY3897] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AlGhoul KJ, 1996, EXP EYE RES, V62, P237, DOI 10.1006/exer.1996.0029; Bassnett S, 1997, J CELL BIOL, V137, P37, DOI 10.1083/jcb.137.1.37; BLOEMENDAL H, 1981, MOL CELLULAR BIOL EY, P85; Bond J, 1996, INVEST OPHTH VIS SCI, V37, P1557; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; BRAKENHOFF RH, 1994, HUM MOL GENET, V3, P279, DOI 10.1093/hmg/3.2.279; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; CAPUTO A, 1994, NAT STRUCT BIOL, V1, P364, DOI 10.1038/nsb0694-364; CHAUDUN E, 1994, J CELL PHYSIOL, V158, P354, DOI 10.1002/jcp.1041580218; COSTELLO MJ, 1989, INVEST OPHTH VIS SCI, V30, P975; DAVID LL, 1986, EXP EYE RES, V42, P227, DOI 10.1016/0014-4835(86)90057-6; DUNCAN G, 1994, PROG RETIN EYE RES, V13, P623, DOI 10.1016/1350-9462(94)90025-6; Dunia I, 1996, J CELL BIOL, V132, P701, DOI 10.1083/jcb.132.4.701; EVANS CW, 1993, EUR J CELL BIOL, V60, P243; Goodenough D.A., 1992, Seminars in Cell Biology, V3, P49; GORING DR, 1987, SCIENCE, V235, P456, DOI 10.1126/science.3099390; Harding JJ, 1984, EYE B, V1b, P207; JAHNGENHODGE J, 1992, EXP EYE RES, V55, P897, DOI 10.1016/0014-4835(92)90016-L; JARVIS LJ, 1993, INVEST OPHTH VIS SCI, V34, P613; JIANG JX, 1995, DEV BIOL, V168, P649, DOI 10.1006/dbio.1995.1109; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI WC, 1995, J CELL BIOL, V130, P169, DOI 10.1083/jcb.130.1.169; Lin JS, 1997, EUR J CELL BIOL, V73, P141; LO WK, 1987, CURR EYE RES, V6, P433, DOI 10.3109/02713688709025199; Mackay D, 1997, AM J HUM GENET, V60, P1474, DOI 10.1086/515468; Mathias RT, 1997, PHYSIOL REV, V77, P21, DOI 10.1152/physrev.1997.77.1.21; Mitton KP, 1996, J BIOL CHEM, V271, P31803, DOI 10.1074/jbc.271.50.31803; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; Rae JL, 1996, J MEMBRANE BIOL, V150, P89, DOI 10.1007/s002329900033; Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5; RISEK B, 1994, DEV BIOL, V164, P183, DOI 10.1006/dbio.1994.1190; ROBINSON KR, 1983, CURR EYE RES, V2, P843, DOI 10.3109/02713688209020020; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SHEARER TR, 1992, CURR EYE RES, V11, P357, DOI 10.3109/02713689209001789; Shiels A, 1996, NAT GENET, V12, P212, DOI 10.1038/ng0296-212; SIEZEN RJ, 1988, J MOL BIOL, V199, P475, DOI 10.1016/0022-2836(88)90619-5; SPECTOR A, 1985, OCULAR LENS STRUCTUR, P405; Srivastava OP, 1996, EXP EYE RES, V62, P593, DOI 10.1006/exer.1996.0070; TAKEMOTO L, 1994, EXP EYE RES, V59, P239, DOI 10.1006/exer.1994.1103; TRUSCOTT RJW, 1990, INVEST OPHTH VIS SCI, V31, P2405; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WHITE TW, 1992, MOL BIOL CELL, V3, P711, DOI 10.1091/mbc.3.7.711; Wride MA, 1996, DIFFERENTIATION, V61, P77, DOI 10.1046/j.1432-0436.1996.6120077.x; YANCEY SB, 1992, DEVELOPMENT, V114, P203; YOSHIDA H, 1986, INVEST OPHTH VIS SCI, V27, P1269; YOSHIDA H, 1985, CURR EYE RES, V4, P983, DOI 10.3109/02713689509000005; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255	52	344	354	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					833	843		10.1016/S0092-8674(00)80471-7	http://dx.doi.org/10.1016/S0092-8674(00)80471-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413992	Bronze			2022-12-24	WOS:A1997YL43900014
J	Liu, C; Weaver, DR; Strogatz, SH; Reppert, SM				Liu, C; Weaver, DR; Strogatz, SH; Reppert, SM			Cellular construction of a circadian clock: Period determination in the suprachiasmatic nuclei	CELL			English	Article							IN-VITRO; NEURONS; HAMSTER; OSCILLATORS; ELECTRODES; MUSCIMOL; EXPRESS; RHYTHM; SYSTEM; PHASE	The circadian clock in the suprachiasmatic nuclei is composed of multiple, single-cell circadian oscillators (clock cells). We now test the hypothesis that the circadian period in behavior is determined by the mean period that arises from the coupling of clock cells with diverse circadian periods. For these studies, we monitored firing rate rhythms of individual suprachiasmatic nuclei neurons on fixed multielectrode plates and exploited the altered circadian periods expressed by heterozygous and homozygous tau mutant hamsters. The results show that circadian period in the whole animal is determined by averaging widely dispersed periods of individual clock cells. The data also demonstrate that the tau mutation affects circadian function in a cell-autonomous manner.	MASSACHUSETTS GEN HOSP,SERV PEDIAT,LAB DEV CHRONOBIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114; CORNELL UNIV,DEPT THEORET & APPL MECH,CTR APPL MATH,ITHACA,NY 14853	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Cornell University			Strogatz, Steven H/A-1641-2014	Strogatz, Steven H/0000-0003-2923-3118; Weaver, David/0000-0001-7941-6719				CARD JP, 1984, NEUROSCIENCE, V13, P415, DOI 10.1016/0306-4522(84)90240-9; DAVIES IR, 1994, NEUROREPORT, V5, P2165, DOI 10.1097/00001756-199410270-00044; DAVIS FC, 1983, AM J PHYSIOL, V244, pR93, DOI 10.1152/ajpregu.1983.244.1.R93; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; ERMENTROUT GB, 1984, SIAM J MATH ANAL, V15, P215, DOI 10.1137/0515019; ERMENTROUT GB, 1991, J MATH BIOL, V29, P195, DOI 10.1007/BF00160535; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein D.C., 1991, SUPRACHIASMATIC NUCL; MASON R, 1991, BRAIN RES, V552, P53, DOI 10.1016/0006-8993(91)90659-J; MEISTER M, 1994, J NEUROSCI METH, V51, P95, DOI 10.1016/0165-0270(94)90030-2; OKAMURA H, 1989, NEUROSCI LETT, V102, P131, DOI 10.1016/0304-3940(89)90067-0; PINE J, 1980, J NEUROSCI METH, V2, P19, DOI 10.1016/0165-0270(80)90042-4; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; REGEHR WG, 1989, J NEUROSCI METH, V30, P91, DOI 10.1016/0165-0270(89)90055-1; Reppert SM, 1997, CELL, V89, P487, DOI 10.1016/S0092-8674(00)80229-9; REPPERT SM, 1986, J NEUROSCI, V6, P2724; SMITH RD, 1989, J COMP PHYSIOL A, V164, P805, DOI 10.1007/BF00616752; STROGAIZ SH, 1994, NONLINEAR DYNAMICS C; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; TOMINAGA K, 1994, NEUROSCI LETT, V166, P81, DOI 10.1016/0304-3940(94)90845-1; VANDENPOL AN, 1986, NEUROSCIENCE, V17, P643, DOI 10.1016/0306-4522(86)90037-0; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Wagner S, 1997, NATURE, V387, P598, DOI 10.1038/42468; Welsh DK, 1996, BRAIN RES, V706, P30, DOI 10.1016/0006-8993(95)01172-2; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; WELSH DK, 1995, THESIS HARVARD U CAM; WINTREE AT, 1967, J THEOR BIOL, V16, P15; Worden, 1974, NEUROSCIENCES 3RD ST, P437	32	385	390	0	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					855	860		10.1016/S0092-8674(00)80473-0	http://dx.doi.org/10.1016/S0092-8674(00)80473-0			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413994	hybrid			2022-12-24	WOS:A1997YL43900016
J	Siegel, D; Lopez, J				Siegel, D; Lopez, J			Trends in antihypertensive drug use in the United States - Do the JNC V recommendations affect prescribing?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; HYPERTENSION; THERAPY; TRIALS; MEN	Context.-The choice of pharmacological treatment for the approximately 50 million people in the United States with hypertension has important therapeutic and financial implications. Objectives.-To describe national antihypertensive medication prescribing patterns for 1992 and 1995; to explore the influence of the Fifth Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC V), published in 1993, which recommended diuretics and beta-blockers as first-line antihypertensive therapy unless contraindicated; and to estimate the impact of these prescribing patterns on the cost of antihypertensive treatment. Design.-All prescriptions for drugs approved for the treatment of hypertension dispensed by 35 000 retail pharmacies were tabulated for 1992 and 1995 (62% of all US retail pharmacies were surveyed). Main Outcome Measures.-Number of prescriptions for each dosage form of medication and national cost estimates based on wholesale costs of medications dispensed. Results.-In 1992, of the 10 most frequently prescribed antihypertensive drugs, 3 were calcium antagonists, 3 were angiotensin-converting enzyme (ACE) inhibitors, 3 were beta-blockers, and 1 was the combination of triamterene and hydrochlorothiazide. In 1995, 4 were calcium antagonists, 3 were ACE inhibitors, 1 was a beta-blocker, 1 was the combination of triamterene and hydrochlorothiazide, and 1 an alpha-blocker, In 1992, calcium antagonists accounted for 33% of antihypertensive prescriptions compared with 38% in 1995, ACE inhibitor use went from 25% to 33%, beta-blocker use from 18% to 11%, and diuretic use from 16% to 8%, The estimated wholesale costs for calcium antagonists in 1995 dollars increased from $2.67 billion in 1992 to $2.86 billion in 1995; ACE inhibitor costs increased from $1.37 billion to $1.67 billion; costs for diuretics declined from $353 million to $168 million; and costs for beta-blockers declined from $763 million to $433 million. Conclusions.-From 1992 to 1995 use of calcium antagonists and ACE inhibitors for treatment of hypertension increased and diuretics and beta-blockers declined, suggesting that the recommendations from JNC V had little effect on prescribing patterns, The cost implications of these practice patterns are enormous.	DEPT VET AFFAIRS, NO CALIF HLTH CARE SYST, SERV PHARM, MARTINEZ, CA 94553 USA; UNIV CALIF DAVIS, DEPT MED, DAVIS, CA USA	University of California System; University of California Davis	Siegel, D (corresponding author), DEPT VET AFFAIRS, NO CALIF HLTH CARE SYST, MED SERV 111, 150 MUIR RD, MARTINEZ, CA 94553 USA.							[Anonymous], 1988, ARCH INTERN MED, V148, P1023; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; COLLINS JG, 1993, VITAL HLTH STAT 10, V182, P1; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Conti C R, 1996, Am J Cardiol, V78, P13, DOI 10.1016/S0002-9149(96)00733-3; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; Kaplan NM, 1996, JAMA-J AM MED ASSOC, V275, P1577, DOI 10.1001/jama.275.20.1577; Lenfant C, 1996, JAMA-J AM MED ASSOC, V275, P1604, DOI 10.1001/jama.275.20.1604; MANOLIO TA, 1995, ARCH INTERN MED, V155, P829, DOI 10.1001/archinte.155.8.829; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; PSATY BM, 1995, JAMA-J AM MED ASSOC, V273, P1436, DOI 10.1001/jama.273.18.1436; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; RAMSPACHER S, 1996, HOSP HARM, V31, P624; Schmieder RE, 1996, JAMA-J AM MED ASSOC, V275, P1507, DOI 10.1001/jama.275.19.1507; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V267, P1083, DOI 10.1001/jama.267.8.1083; SIMONSEN LLP, 1993, PHARM TIMES, V59, P29; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; Soumerai SB, 1988, AUST J HOSP PHARM S, V18, P9; *US DHHS, 1994, HEART FAIL MAN PAT L; WEBER MA, 1993, ARCH INTERN MED, V153, P149, DOI 10.1001/archinte.153.2.149; WILKES MS, 1992, ANN INTERN MED, V116, P912, DOI 10.7326/0003-4819-116-11-912; 1996, PHARM TIMES, V62, P27; 1995, 1995 DRUG TOPICS RED; 1993, AM DRUG, V207, P49; 1996, AM DRUG, V212, P18	28	165	169	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1745	1748		10.1001/jama.278.21.1745	http://dx.doi.org/10.1001/jama.278.21.1745			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388150				2022-12-24	WOS:A1997YH98700028
J	Kondo, M; Weissman, IL; Akashi, K				Kondo, M; Weissman, IL; Akashi, K			Identification of clonogenic common lymphoid progenitors in mouse bone marrow	CELL			English	Article							HEMATOPOIETIC STEM-CELLS; RECEPTOR-GAMMA-CHAIN; B-CELL; C-KIT; INTERLEUKIN-7 RECEPTOR; T-CELLS; TRANSCRIPTIONAL CONTROL; MURINE INTERLEUKIN-7; DENDRITIC CELLS; PRECURSOR CELLS	The existence of a common lymphoid progenitor that can only give rise to T cells, B cells, and natural killer (NK) cells remains controversial and constitutes an important gap in the hematopoietic lineage maps. Here, we report that the Lin(-)IL-7R(+)Thy-1(-)Sca-1(lo)c-Kit(lo) population from adult mouse bone marrow possessed a rapid lymphoid-restricted (T, B, and NK) reconstitution capacity in vivo but completely lacked myeloid differentiation potential either in vivo or in vitro. A single Lin(-)IL-7R(+)Thy-1(-)Sca-1(lo)c-Kit(lo) cell could generate at least both T and B cells. These data provide direct evidence for the existence of common lymphoid progenitors in sites of early hematopoiesis.	STANFORD UNIV,SCH MED,DEPT PATHOL,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University					NCI NIH HHS [CA42551] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042551] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 1996, IMMUNITY, V5, P147, DOI 10.1016/S1074-7613(00)80491-4; AKASHI K, 1991, J CELL PHYSIOL, V148, P446, DOI 10.1002/jcp.1041480317; AKASHI K, 1993, LEUKEMIA RES, V17, P549, DOI 10.1016/0145-2126(93)90083-W; Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; ANTICA M, 1994, BLOOD, V84, P111; ANTIN JH, 1992, BLOOD, V80, P2964; ARDAVIN C, 1993, NATURE, V362, P761, DOI 10.1038/362761a0; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Carlyle JR, 1997, J EXP MED, V186, P173, DOI 10.1084/jem.186.2.173; Clevers HC, 1996, IMMUNOL TODAY, V17, P336, DOI 10.1016/0167-5699(96)10019-0; COLLINS LS, 1987, J IMMUNOL, V138, P1082; Corcoran AE, 1996, EMBO J, V15, P1924, DOI 10.1002/j.1460-2075.1996.tb00543.x; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; FISCHER A, 1992, Immunodeficiency Reviews, V3, P83; GALY A, 1995, IMMUNITY, V3, P459, DOI 10.1016/1074-7613(95)90175-2; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GODFREY DI, 1992, J IMMUNOL, V149, P2281; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARRISON DE, 1992, P NATL ACAD SCI USA, V89, P10134, DOI 10.1073/pnas.89.21.10134; HIRAYAMA F, 1995, BLOOD, V86, P4527, DOI 10.1182/blood.V86.12.4527.bloodjournal86124527; HIRAYAMA F, 1992, P NATL ACAD SCI USA, V89, P5907, DOI 10.1073/pnas.89.13.5907; IKUTA K, 1991, INT J CELL CLONING, V9, P451; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; Kawamoto H, 1997, INT IMMUNOL, V9, P1011, DOI 10.1093/intimm/9.7.1011; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; Kondo M, 1997, IMMUNITY, V7, P155, DOI 10.1016/S1074-7613(00)80518-X; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; LI CL, 1992, J EXP MED, V175, P1443, DOI 10.1084/jem.175.6.1443; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; Markert M L, 1994, Immunodeficiency, V5, P141; MATSUZAKI Y, 1993, J EXP MED, V178, P1283, DOI 10.1084/jem.178.4.1283; McKinstry WJ, 1997, BLOOD, V89, P65, DOI 10.1182/blood.V89.1.65.65_65_71; Mebius RE, 1997, IMMUNITY, V7, P493, DOI 10.1016/S1074-7613(00)80371-4; MIRRO J, 1986, BLOOD, V67, P689; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; MULDER AH, 1987, EXP HEMATOL, V15, P99; MULLERSIEBURG CE, 1986, CELL, V44, P653, DOI 10.1016/0092-8674(86)90274-6; NAKAHATA T, 1982, J CELL PHYSIOL, V113, P455, DOI 10.1002/jcp.1041130314; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; OKADA S, 1991, BLOOD, V78, P1706; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; SMITH LG, 1991, P NATL ACAD SCI USA, V88, P2728; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPANGRUDE GJ, 1990, J IMMUNOL, V145, P3661; SUDA J, 1984, BLOOD, V64, P393; SUDA T, 1989, BLOOD, V74, P1936; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; THOMAS ED, 1991, BLOOD CELLS, V17, P259; UCHIDA N, 1992, J EXP MED, V175, P175, DOI 10.1084/jem.175.1.175; VISSER JWM, 1990, EXP HEMATOL, V18, P248; vonFreedenJeffry U, 1997, IMMUNITY, V7, P147, DOI 10.1016/S1074-7613(00)80517-8; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WEISSMAN IL, 1994, IMMUNITY, V1, P529, DOI 10.1016/1074-7613(94)90042-6; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0	70	1582	1618	3	56	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					661	672		10.1016/S0092-8674(00)80453-5	http://dx.doi.org/10.1016/S0092-8674(00)80453-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393859	Bronze			2022-12-24	WOS:A1997YH96000013
J	Linderoth, NA; Simon, MN; Russel, M				Linderoth, NA; Simon, MN; Russel, M			The filamentous phage pIV multimer visualized by scanning transmission electron microscopy	SCIENCE			English	Article							GRAM-NEGATIVE BACTERIA; OUTER-MEMBRANE PROTEIN; SECRETION; EXPORT; CHANNELS; PATHWAY; PORINS; FORMS	A family of homomultimeric outer-membrane proteins termed secretins mediates the secretion of large macromolecules such as enzymes and filamentous bacteriophages across bacterial outer membranes to the extracellular milieu. The secretin encoded by done filamentous phage fl was purified. Mass determination of individual molecules by scanning transmission electron microscopy revealed two forms, a unit multimer composed of about 14 subunits and a multimer dimer. The secretin is roughly cylindrical and has an internal diameter of about 80 angstroms, which is large enough to accommodate filamentous phage (diameter of 65 angstroms).	ROCKEFELLER UNIV,NEW YORK,NY 10021; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	Rockefeller University; United States Department of Energy (DOE); Brookhaven National Laboratory					PHS HHS [P41-4401777] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Chen LY, 1996, J BIOL CHEM, V271, P2703, DOI 10.1074/jbc.271.5.2703; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Daefler S, 1997, J MOL BIOL, V266, P978, DOI 10.1006/jmbi.1996.0866; Drake SL, 1995, MOL MICROBIOL, V18, P975, DOI 10.1111/j.1365-2958.1995.18050975.x; ENDEMANN H, 1995, J MOL BIOL, V250, P496, DOI 10.1006/jmbi.1995.0393; GENIN S, 1994, MOL GEN GENET, V243, P112, DOI 10.1007/BF00283883; Hardie KR, 1996, EMBO J, V15, P978, DOI 10.1002/j.1460-2075.1996.tb00434.x; HOBBS M, 1993, MOL MICROBIOL, V10, P233, DOI 10.1111/j.1365-2958.1993.tb01949.x; KAZMIERCZAK BI, 1994, J MOL BIOL, V238, P187, DOI 10.1006/jmbi.1994.1280; LAVER WG, 1969, VIROLOGY, V38, P105, DOI 10.1016/0042-6822(69)90132-9; Lee CA, 1997, TRENDS MICROBIOL, V5, P148, DOI 10.1016/S0966-842X(97)01029-9; Lindeberg M, 1996, MOL MICROBIOL, V20, P175, DOI 10.1111/j.1365-2958.1996.tb02499.x; LINDEROTH N, UNPUB; Linderoth NA, 1996, J BACTERIOL, V178, P1962, DOI 10.1128/jb.178.7.1962-1970.1996; LIU J, 1993, P NATL ACAD SCI USA, V90, P10653, DOI 10.1073/pnas.90.22.10653; Model P., 1988, BACTERIOPHAGES, P375; NEWHALL WJ, 1980, INFECT IMMUN, V27, P475, DOI 10.1128/IAI.27.2.475-482.1980; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RUSSEL M, 1991, MOL MICROBIOL, V5, P1607, DOI 10.1111/j.1365-2958.1991.tb01907.x; RUSSEL M, 1995, TRENDS MICROBIOL, V3, P223, DOI 10.1016/S0966-842X(00)88929-5; RUSSEL M, 1994, SCIENCE, V265, P612, DOI 10.1126/science.8036510; Russel M, 1997, GENE, V192, P23, DOI 10.1016/S0378-1119(96)00801-3; SALMOND GPC, 1993, TRENDS BIOCHEM SCI, V18, P7, DOI 10.1016/0968-0004(93)90080-7; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Shevchik VE, 1997, EMBO J, V16, P3007, DOI 10.1093/emboj/16.11.3007; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910; Wall J., 1979, INTRO ANAL ELECTRON, P333; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WALL JS, 1985, P 43 ANN M EL MICR S, P716	30	123	124	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1635	1638		10.1126/science.278.5343.1635	http://dx.doi.org/10.1126/science.278.5343.1635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374466				2022-12-24	WOS:A1997YJ87400045
J	Slusarski, DC; Corces, VG; Moon, RT				Slusarski, DC; Corces, VG; Moon, RT			Interaction of Wnt and a frizzled homologue triggers G-protein-linked phosphatidylinositol signalling	NATURE			English	Article							SIGNALING PATHWAY; RECEPTOR; PHOSPHOLIPASE-A2	In Drosophila, members of the frizzled family of tissue-polarity genes encode proteins that are likely to function as cell-surface receptors of the type known as Wnt receptors, and to initiate signal transduction across the cell membrane(1,2), although how they do this is unclear. We show here that the rat protein Frizzled-2 causes an increase in the release of intracellular calcium which is enhanced by Xwnt-5a, a member of the Wnt family. This release of intracellular calcium is suppressed by an inhibitor of the enzyme inositol monophosphatase and hence of the phosphatidylinositol signalling pathway; this suppression can be rescued by injection of the compound myo-inositol, which overcomes the decrease in this intermediate caused by the inhibitor. Agents that inhibit specific G-protein subunits, pertussis toxin, GDP-beta-S and alpha-transducin also inhibit the calcium release triggered by Xwnt-5a and rat Frizzled-2. Our results indicate that some Wnt proteins work through specific Frizzled homologues to stimulate the phosphatidylinositol signalling pathway via heterotrimeric G-protein subunits.	UNIV WASHINGTON, SCH MED, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT PHARMACOL, SEATTLE, WA 98195 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Johns Hopkins University			Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408; Corces, Victor/0000-0001-5140-4337; Slusarski, Diane/0000-0003-3793-8636				ATACK JR, 1993, J NEUROCHEM, V60, P652, DOI 10.1111/j.1471-4159.1993.tb03197.x; Ault KT, 1996, DEVELOPMENT, V122, P2033; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; LEREA CL, 1989, NEURON, V3, P367, DOI 10.1016/0896-6273(89)90261-4; REINHARD E, 1995, DEV BIOL, V170, P50, DOI 10.1006/dbio.1995.1194; SILK ST, 1989, J BIOL CHEM, V264, P21466; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Wang YS, 1996, J BIOL CHEM, V271, P4468; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1	17	526	537	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 27	1997	390	6658					410	413		10.1038/37138	http://dx.doi.org/10.1038/37138			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389482				2022-12-24	WOS:A1997YH54900066
J	Kaletta, T; Schnabel, H; Schnabel, R				Kaletta, T; Schnabel, H; Schnabel, R			Binary specification of the embryonic lineage in Caenorhabditis elegans	NATURE			English	Article							C-ELEGANS; CELLULAR INTERACTIONS; POLARITY; PROTEIN; PATTERN; LOCUS; GLP-1; AXES	In Caenorhabditis elegans, the early embryo contains five somatic founder cells (known as AB, MS, E, C and D) which give rise to very different lineages, Two simply produce twenty intestinal (E) or muscle (D) cells each, whereas the remainder produce a total of 518 cells which collectively contribute in a complex pattern to a variety of tissues(1). A central problem in embryonic development is to understand how the developmental potential of blastomeres is restricted to permit the terminal expression of such complex differentiation patterns, Here we identify a gene, lit-1, that appears to play a central role in controlling the asymmetry of cell division during embryogenesis in C. elegans. Mutants in lit-1 suggest that its product controls up to six consecutive binary snitches which cause one of the two equivalent cells produced at each cleavage to assume a posterior fate. Most blastomere identities in C, elegans may therefore stem from a process of stepwise binary diversification.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society			Kaletta, Titus/F-5361-2012					Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; GOLDSTEIN B, 1995, J CELL BIOL, V129, P1071, DOI 10.1083/jcb.129.4.1071; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; Hodgkin J, 1997, GENETICS, V146, P149; Hunter CP, 1996, CELL, V87, P217, DOI 10.1016/S0092-8674(00)81340-9; HUTTER H, 1995, DEVELOPMENT, V121, P1559; HUTTER H, 1994, DEVELOPMENT, V120, P2051; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Lin HF, 1997, TRENDS GENET, V13, P33, DOI 10.1016/S0168-9525(96)10050-0; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; RIDDLE DL, 1997, MONOGRAPH COLD SPRIN, V33; RiveraPomar R, 1996, TRENDS GENET, V12, P478, DOI 10.1016/0168-9525(96)10044-5; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; Schnabel R, 1997, DEV BIOL, V184, P234, DOI 10.1006/dbio.1997.8509; SCHNABEL R, 1990, DEVELOPMENT, V108, P107; Schnabel R, 1996, BIOESSAYS, V18, P591, DOI 10.1002/bies.950180711; STJOHNSTON D, 1992, CELL, V68, P201; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; Wood WB, 1988, NEMATODE CAENORHABDI	24	134	139	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					294	298		10.1038/36869	http://dx.doi.org/10.1038/36869			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384382				2022-12-24	WOS:A1997YG66700065
J	Bouma, MJ; Kovats, RS; Goubet, SA; Cox, JSH; Haines, A				Bouma, MJ; Kovats, RS; Goubet, SA; Cox, JSH; Haines, A			Global assessment of El Nino's disaster burden	LANCET			English	Article							SOUTHERN-OSCILLATION; MALARIA; EVENTS; ENSO	Background Natural disasters have profound effects on health and require medical intervention as part of relief operations. The world's populations are becoming increasingly Vulnerable to extreme weather events, which are responsible for most natural disasters. The El Nino Southern Oscillation (ENSO) is the most prominent global climate system associated with year-to-year weather variability and extreme events. We have estimated the burden on human health of natural disasters associated with ENSO. Methods We used time-series regression analysis of the relation between El Nino years and the annual rates of persons affected by natural disasters per 1000 population during 1964-93, globally and also by region and disaster type. Correlations between sea-surface temperature (SST) anomalies (index of ENSO) and the rates of persons affected by natural disasters per 1000 population were determined globally, by region and by disaster type. Findings The rate of persons affected by natural disasters worldwide is strongly associated with ENSO; rates are greater during the first El Nino year (p=0.05) and the following year (p=0.01) than in the pre-Nino year. The correlation between rates of persons affected by natural disasters and SST anomalies in the Eastern Pacific (a key ENSO indicator) is highest in the last quarter of the previous year (r=0.53, p<0.01). These associations are strongest in South Asia, the region where more than 50% of all disaster Victims live. Worldwide, rates of persons affected by drought/famine (half of all disaster victims) and by Volcanic eruptions show significant associations with the ENSO cycle, being highest in the post-Nino year and El Nino year, respectively, and being significantly associated with SST anomalies. Interpretation The strong relation between ENSO and populations affected by natural disasters can be described as a ''natural disaster cycle''. Determining the phase in this cycle, using SST from the Eastern Equatorial Pacific, could benefit disaster preparedness on a global scale, for South Asia in particular, and for all populations affected by drought/famine and volcanic disasters.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT INFECT & TROP DIS, LONDON WC1E 7HT, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 7HT, ENGLAND; ROYAL FREE HOSP, SCH MED, JOINT DEPT PRIMARY CARE & POPULAT SCI, LONDON, ENGLAND; UCL, SCH MED, JOINT DEPT PRIMARY CARE & POPULAT SCI, LONDON W1N 8AA, ENGLAND	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; UCL Medical School				Kovats, Sari/0000-0002-4823-8099; Haines, Andy/0000-0002-8053-4605				[Anonymous], 1997, PUBLIC HLTH CONSEQUE; Bouma MJ, 1996, TROP MED INT HEALTH, V1, P86, DOI 10.1046/j.1365-3156.1996.d01-7.x; BOUMA MJ, 1994, LANCET, V343, P1440, DOI 10.1016/S0140-6736(94)92569-0; BUCHANONSMITH M, 1996, FAMINE EARLY WARNING; CANE MA, 1994, NATURE, V370, P204, DOI 10.1038/370204a0; CHATFIELD C, 1992, ANAL TIME SERIES INT, P136; CHEN D, 1995, SCIENCE, V269, P1699, DOI 10.1126/science.269.5231.1699; DILLEY M, 1995, DISASTERS, V19, P181, DOI 10.1111/j.1467-7717.1995.tb00338.x; Glantz M. H., 1994, P WORKSH ENSO FEWS B; GLANTZ MH, 1982, OCEANUS, V27, P14; *INT FED RED CROSS, 1996, WORLD DIS REP 1996; International Decade for Natural Disaster Reduction, 1994, YOK STRAT PLAN ACT S; McCarthy M, 1997, LANCET, V350, P344; MICMICHAEL AJ, 1996, CLIMATE CHANGE HUMAN; NICHOLLS N, 1988, J CLIMATOL, V8, P91, DOI 10.1002/joc.3370080109; PARKER DE, 1994, J GEOPHYS RES, V99, P373; Quinn W. H., 1987, J GEOPHYS RES, V92, P449; ROPELEWSKI CF, 1987, MON WEATHER REV, V115, P1606, DOI 10.1175/1520-0493(1987)115<1606:GARSPP>2.0.CO;2; SAPIR DG, 1992, DISASTERS, V16, P74, DOI 10.1111/j.1467-7717.1992.tb00378.x; SPENNEMANN DHR, 1995, DISASTERS, V19, P194, DOI 10.1111/j.1467-7717.1995.tb00339.x; *UN, 1995, DEM YB 1993; *WORLD MET ORG, 1998, 819 WMO; WU GX, 1992, MON WEATHER REV, V120, P958, DOI 10.1175/1520-0493(1992)120<0958:AGSOTR>2.0.CO;2	23	61	64	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1435	1438		10.1016/S0140-6736(97)04509-1	http://dx.doi.org/10.1016/S0140-6736(97)04509-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371167				2022-12-24	WOS:A1997YF95300010
J	Moritz, S; Bates, T; Henderson, SM; Humphreys, S; Michell, MJ				Moritz, S; Bates, T; Henderson, SM; Humphreys, S; Michell, MJ			Variation in management of small invasive breast cancers detected on screening in the former South East Thames region: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CLINICAL-TRIAL; SURVIVAL; RADIOTHERAPY; IRRADIATION; LUMPECTOMY; SURGERY; WOMEN	Objective: To examine the variation in surgical and adjuvant treatment of breast cancer of known histology and detected on screening in a large cohort of patients treated by the surgeons of a health region, Design: Part prospective, part retrospective observational study; using the databases of a region's breast screening programme and of the cancer registry. Setting: The former South East Thames redon. Subjects: 600 women aged 49-79 who presented during 1991-2 with invasive breast cancer up to 20 mm in diameter that had been detected on screening. These patients were treated by 35 surgeons. Main outcome measures: Mastectomy rate by surgeon and the use of adjuvant treatment (radiotherapy, tamoxifen, and chemotherapy) were compared with risk factors, tumour grade, resection margins, and axillary node status. Results: The mastectomy rate varied between nil and 80%, although the numbers at these extremes were small (0/13 v 8/10). Surgeons operating on more than 20 such cases had a lower mastectomy rate (15%) than surgeons treating fewer cases (23%), but this difference was confounded by variation in casemix. There were also wide variations in mastectomy rates and in axillary sampling rates that were independent of casemix or caseload. There was broad agreement on the use of adjuvant tamoxifen (94%), but few patients received chemotherapy (2.5%). 78 patients (19%) did not receive radiotherapy, including 51 out of 317 patients with unfavourable tumours, and 26 patients did not receive tamoxifen. Whether the patient received adjuvant treatment was more dependent on referral by the surgeon than the risk factors for local recurrence and was independent of caseload. Conclusion: Mastectomy rates for similar rumours vary widely by surgeon independently of casemix or caseload, but surgeons with a higher caseload tend to have a lower mastectomy rate. Omission of postoperative radiotherapy or tamoxifen after conservative treatment is not related to risk factors for local recurrence or caseload, Confidential feedback of treatment profiles to individual surgeons has been used, but when benefit has been established treatment should be guided by evidence based protocol.	WILLIAM HARVEY HOSP, ASHFORD TN24 OLZ, KENT, ENGLAND; UNIV LONDON KINGS COLL HOSP, S THAMES E BREAST SCREENING QUAL ASSURANCE REFERE, LONDON SE5 9RS, ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London			Bates, Tom/AAB-1893-2021	Bates, Tom/0000-0001-5554-1945				ABE O, 1992, LANCET, V339, P71; ABE O, 1995, NEW ENGL J MED, V333, P1444; [Anonymous], 1992, Lancet, V339, P1; ANSELL D, 1993, CANCER, V72, P2974, DOI 10.1002/1097-0142(19931115)72:10<2974::AID-CNCR2820721019>3.0.CO;2-M; Ayanian JZ, 1996, BREAST CANCER RES TR, V40, P65, DOI 10.1007/BF01806003; BAAK JPA, 1992, HUM PATHOL, V23, P989, DOI 10.1016/0046-8177(92)90259-6; BASNETT I, 1992, EUR J CANCER, V28A, P1945, DOI 10.1016/0959-8049(92)90233-R; Baum M, 1996, BRIT MED J, V312, P1155; BELL J, 1994, BRIT MED J, V308, P1508, DOI 10.1136/bmj.308.6942.1508a; Berrino F, 1995, IARC SCI PUBLICATION, V132; BLAMEY RW, 1994, BRIT MED J, V309, P1076, DOI 10.1136/bmj.309.6961.1076; *BRIT ASS SURG ONC, 1992, BASO 2 TRIAL PROT RA; CAMPBELL I, 1993, ANN ROY COLL SURG, V75, P13; CHOUILLET AM, 1994, BRIT MED J, V308, P168, DOI 10.1136/bmj.308.6922.168; CLARK RM, 1992, JNCI-J NATL CANCER I, V84, P683, DOI 10.1093/jnci/84.9.683; *DEP HLTH, 1995, POP HLTH OUTC IND 19; *DEP HLTH, 1994, POL FRAM WORK COMM C; Dixon JM, 1996, BRIT J SURG, V83, P997, DOI 10.1002/bjs.1800830737; DIXON JM, 1995, BRIT MED J, V311, P1515, DOI 10.1136/bmj.311.7019.1515; FENTIMAN IS, 1991, LANCET, V337, P221, DOI 10.1016/0140-6736(91)92172-X; FISHER B, 1995, NEW ENGL J MED, V333, P1456, DOI 10.1056/NEJM199511303332203; GELBER RD, 1994, J NATL CANCER I, V86, P652, DOI 10.1093/jnci/86.9.652; Gillis CR, 1996, BRIT MED J, V312, P145, DOI 10.1136/bmj.312.7024.145; Harries SA, 1997, BREAST, V6, P21, DOI 10.1016/S0960-9776(97)90538-5; ISCOE NA, 1994, CAN MED ASSOC J, V150, P345; LILJEGREN G, 1994, JNCI-J NATL CANCER I, V86, P717, DOI 10.1093/jnci/86.9.717; MCCARTHY M, 1991, EUR J CANCER, V27, P579, DOI 10.1016/0277-5379(91)90222-Y; MORRIS J, 1992, BRIT J SURG, V79, P1312, DOI 10.1002/bjs.1800791223; Moss S M, 1994, J Med Screen, V1, P193; *NAT COORD GROUP S, 1996, NHS BSP PUBL, V20; NATTINGER AB, 1992, NEW ENGL J MED, V326, P1102, DOI 10.1056/NEJM199204233261702; Richards MA, 1996, BRIT J CANCER, V73, P751, DOI 10.1038/bjc.1996.131; SACKS NPM, 1992, BREAST, V1, P41; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; Schnitt SJ, 1996, CANCER, V77, P1094, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1094::AID-CNCR14>3.3.CO;2-J; VANDONGEN JA, 1992, EUR J CANCER, V28A, P801, DOI 10.1016/0959-8049(92)90118-L; VERONESI U, 1990, EUR J CANCER, V26, P668, DOI 10.1016/0277-5379(90)90113-8; YARNOLD JR, 1994, BRIT MED J, V308, P714, DOI 10.1136/bmj.308.6930.714a	38	24	24	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 15	1997	315	7118					1266	1272		10.1136/bmj.315.7118.1266	http://dx.doi.org/10.1136/bmj.315.7118.1266			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390053	Green Published			2022-12-24	WOS:A1997YG64500019
J	Furukawa, T; Morrow, EM; Cepko, CL				Furukawa, T; Morrow, EM; Cepko, CL			Crx, a novel otx-like homeobox gene, shows photoreceptor-specific expression and regulates photoreceptor differentiation	CELL			English	Article							RAT OPSIN GENE; TISSUE-SPECIFIC EXPRESSION; TRANSCRIPTION FACTOR GENE; NUCLEAR-PROTEIN BINDING; CIS-ACTING ELEMENT; MOLECULAR-GENETICS; NERVOUS-SYSTEM; CELL-DEVELOPMENT; UPSTREAM REGION; RHODOPSIN GENE	We have isolated a novel otx-like homeobox gene, Crx, from the mouse retina. Crx expression is restricted to developing and mature photoreceptor cells. CRX bound and transactivated the sequence TAATCC/A, which is found upstream of several photoreceptor-specific genes, including the opsin genes from many species. Overexpression of Crx using a retroviral vector increased the frequency of clones containing exclusively rod photoreceptors and reduced the frequency of clones containing amacrine interneurons and Muller glial cells. In addition, presumptive photoreceptor cells expressing a dominant-negative form of CRX failed to form proper photoreceptor outer segments and terminals. Crx is a novel photoreceptor-specific transcription factor and plays a crucial role in the differentiation of photoreceptor cells.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute			Morrow, Eric/J-2767-2013	Morrow, Eric/0000-0003-3430-3520	NEI NIH HHS [R01 EY0 8064] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008064] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AHMAD I, 1990, BIOCHEM BIOPH RES CO, V173, P463, DOI 10.1016/S0006-291X(05)81081-2; Ahmad I, 1995, DEV BRAIN RES, V90, P184, DOI 10.1016/0165-3806(96)83500-0; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BALLYCUIF L, 1995, MECH DEVELOP, V49, P49, DOI 10.1016/0925-4773(94)00301-3; BLITZ IL, 1995, DEVELOPMENT, V121, P993; BOBOLA N, 1995, J BIOL CHEM, V270, P1289, DOI 10.1074/jbc.270.3.1289; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; CEPKO CL, 1997, CURRENT PROTOCOLS MO; Chen SM, 1996, J BIOL CHEM, V271, P28549, DOI 10.1074/jbc.271.45.28549; CHIU MI, 1994, J NEUROSCI, V14, P3426; Chou WH, 1996, NEURON, V17, P1101, DOI 10.1016/S0896-6273(00)80243-3; Conlon FL, 1996, DEVELOPMENT, V122, P2427; Dowling J. E., 1987, RETINA APPROACHABLE; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; FIELDSBERRY SC, 1992, P NATL ACAD SCI USA, V89, P693, DOI 10.1073/pnas.89.2.693; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Furukawa T, 1997, P NATL ACAD SCI USA, V94, P3088, DOI 10.1073/pnas.94.7.3088; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HICKS D, 1987, J HISTOCHEM CYTOCHEM, V35, P1317, DOI 10.1177/35.11.3655327; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; JIN YS, 1994, NATURE, V372, P780, DOI 10.1038/372780a0; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; LAVAIL MM, 1987, INVEST OPHTH VIS SCI, V28, P1043; LI YB, 1994, MECH DEVELOP, V48, P229, DOI 10.1016/0925-4773(94)90062-0; LIOU GI, 1991, BIOCHEM BIOPH RES CO, V181, P159, DOI 10.1016/S0006-291X(05)81395-6; LIOU GI, 1994, DEV BIOL, V161, P345, DOI 10.1006/dbio.1994.1036; Liu Q, 1996, ONCOGENE, V12, P207; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; MORI H, 1994, MOL BRAIN RES, V27, P221, DOI 10.1016/0169-328X(94)90004-3; NATHANS J, 1989, SCIENCE, V245, P831, DOI 10.1126/science.2788922; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NI M, 1992, CURR EYE RES, V11, P219, DOI 10.3109/02713689209001773; NIR I, 1984, J CELL BIOL, V98, P1788, DOI 10.1083/jcb.98.5.1788; PANNESE M, 1995, DEVELOPMENT, V121, P707; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Saha MS, 1992, CURR OPIN GENET DEV, V2, P582, DOI 10.1016/S0959-437X(05)80176-5; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; STEPANIK PL, 1993, EXP EYE RES, V57, P189, DOI 10.1006/exer.1993.1114; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; TAKAO M, 1988, VISION RES, V28, P471, DOI 10.1016/0042-6989(88)90169-1; TREISMAN J, 1989, CELL, V59, P553; TUMER DL, 1987, NATURE, V328, P131; Vandendries ER, 1996, DEV BIOL, V173, P243, DOI 10.1006/dbio.1996.0020; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; YANG XJ, 1993, J NEUROSCI, V13, P3006; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307; YU X, 1994, J MOL NEUROSCI, V5, P259, DOI 10.1007/BF02736726; YU X, 1993, BIOCHEM BIOPH RES CO, V191, P76, DOI 10.1006/bbrc.1993.1186; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	60	693	710	5	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					531	541		10.1016/S0092-8674(00)80439-0	http://dx.doi.org/10.1016/S0092-8674(00)80439-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390562	Bronze			2022-12-24	WOS:A1997YG49200014
J	Ivics, Z; Hackett, PB; Plasterk, RH; Izsvak, Z				Ivics, Z; Hackett, PB; Plasterk, RH; Izsvak, Z			Molecular reconstruction of Sleeping beauty, a Tc1-like transposon from fish, and its transposition in human cells	CELL			English	Article							P-ELEMENT; CAENORHABDITIS-ELEGANS; GENE-TRANSFER; MUTAGENESIS; DROSOPHILA; ZEBRAFISH; SUPERFAMILY; SEQUENCES; GENOME; TC3	Members of the Tc1/mariner superfamily of transposons isolated from fish appear to be transpositionally inactive due to the accumulation of mutations. Molecular phylogenetic data were used to construct a synthetic transposon, Sleeping Beauty, which could be identical or equivalent to an ancient element that dispersed in fish genomes in part by horizontal transmission between species. A consensus sequence of a transposase gene of the salmonid subfamily of elements was engineered by eliminating the inactivating mutations. Sleeping Beauty transposase binds to the inverted repeats of salmonid transposons in a substrate-specific manner, and it mediates precise cut-and-paste transposition in fish as well as in mouse and human cells. Sleeping Beauty is an active DNA-transposon system from vertebrates for genetic transformation and insertional mutagenesis.	UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108; UNIV MINNESOTA,INST HUMAN GENET,ST PAUL,MN 55108; NETHERLANDS CANC INST,DIV MOL BIOL,NL-1066 CX AMSTERDAM,NETHERLANDS; HUNGARIAN ACAD SCI,BIOL RES CTR,INST BIOCHEM,H-6701 SZEGED,HUNGARY	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Netherlands Cancer Institute; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center			Wilson, Matthew H/K-3193-2013		NCRR NIH HHS [R01-RR06625] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006625] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADEY NB, 1994, P NATL ACAD SCI USA, V91, P1569, DOI 10.1073/pnas.91.4.1569; Beall EL, 1997, GENE DEV, V11, P2137, DOI 10.1101/gad.11.16.2137; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; COLLOMS SD, 1994, NUCLEIC ACIDS RES, V22, P5548, DOI 10.1093/nar/22.25.5548; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; DEVON RS, 1995, NUCLEIC ACIDS RES, V23, P1644, DOI 10.1093/nar/23.9.1644; DOAK TG, 1994, P NATL ACAD SCI USA, V91, P942, DOI 10.1073/pnas.91.3.942; Gibbs P. D. L., 1994, Molecular Marine Biology and Biotechnology, V3, P317; GIERL A, 1988, EMBO J, V7, P4045, DOI 10.1002/j.1460-2075.1988.tb03298.x; Gonzales AE, 1996, VET MICROBIOL, V48, P283, DOI 10.1016/0378-1135(95)00143-3; GOODIER JL, 1994, J MOL BIOL, V241, P26, DOI 10.1006/jmbi.1994.1470; Gueiros FJ, 1997, SCIENCE, V276, P1716, DOI 10.1126/science.276.5319.1716; HANDLER AM, 1993, ARCH INSECT BIOCHEM, V22, P373, DOI 10.1002/arch.940220306; Hartl DL, 1997, TRENDS GENET, V13, P197, DOI 10.1016/S0168-9525(97)01087-1; Ivics Z, 1996, P NATL ACAD SCI USA, V93, P5008, DOI 10.1073/pnas.93.10.5008; IZSVAK Z, 1995, MOL GEN GENET, V247, P312, DOI 10.1007/BF00293199; IZSVAK Z, 1997, IN PRESS J BIOCH CEL; JERMANN TM, 1995, NATURE, V374, P57, DOI 10.1038/374057a0; Kidwell MG, 1992, CURR OPIN GENET DEV, V2, P868, DOI 10.1016/S0959-437X(05)80109-1; Koga A, 1996, NATURE, V383, P30, DOI 10.1038/383030a0; Lam WL, 1996, J MOL BIOL, V257, P359, DOI 10.1006/jmbi.1996.0168; Lam WL, 1996, P NATL ACAD SCI USA, V93, P10870, DOI 10.1073/pnas.93.20.10870; Lampe DJ, 1996, EMBO J, V15, P5470, DOI 10.1002/j.1460-2075.1996.tb00930.x; Lee MD, 1996, VET MICROBIOL, V50, P143, DOI 10.1016/0378-1135(96)00007-7; Lohe AR, 1997, P NATL ACAD SCI USA, V94, P1293, DOI 10.1073/pnas.94.4.1293; LOHE AR, 1995, MOL BIOL EVOL, V12, P62, DOI 10.1093/oxfordjournals.molbev.a040191; LOUKERIS TG, 1995, SCIENCE, V270, P2002, DOI 10.1126/science.270.5244.2002; MICHAEL SF, 1994, BIOTECHNIQUES, V16, P410; OOSUMI T, 1995, NATURE, V378, P873; OSBORNE BI, 1995, CURR OPIN CELL BIOL, V7, P406, DOI 10.1016/0955-0674(95)80097-2; PLASTERK RH, 1995, METHOD CELL BIOL, P59; Plasterk RHA, 1996, CURR TOP MICROBIOL, V204, P125; RADICE AD, 1994, MOL GEN GENET, V244, P606, DOI 10.1007/BF00282750; RIO DC, 1988, J MOL BIOL, V200, P411, DOI 10.1016/0022-2836(88)90250-1; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Smit AFA, 1996, P NATL ACAD SCI USA, V93, P1443, DOI 10.1073/pnas.93.4.1443; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; VANLUENEN HGAM, 1994, CELL, V79, P293, DOI 10.1016/0092-8674(94)90198-8; Vos JC, 1996, GENE DEV, V10, P755, DOI 10.1101/gad.10.6.755; VOS JC, 1994, EMBO J, V13, P6125, DOI 10.1002/j.1460-2075.1994.tb06959.x; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	41	1011	1129	4	87	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					501	510		10.1016/S0092-8674(00)80436-5	http://dx.doi.org/10.1016/S0092-8674(00)80436-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390559	Bronze			2022-12-24	WOS:A1997YG49200011
J	Hu, YM; Wang, YQ; Luo, ZX; Li, CK				Hu, YM; Wang, YQ; Luo, ZX; Li, CK			A new symmetrodont mammal from China and its implications for mammalian evolution	NATURE			English	Article							FUNCTIONAL-ANATOMY; SHOULDER GIRDLE; EAR	A new symmetrodont mammal has been discovered in the Mesozoic era (Late Jurassic or Early Cretaceous period) of Liaoning Province, China, Archaic therian mammals, including symmetrodonts, are extinct relatives of the living marsupial and placental therians. However, these archaic therians have been mostly documented by fragmentary fossils. This new fossil taxon, represented by a nearly complete postcranial skeleton and a partial skull with dentition, is the best-preserved symmetrodont mammal yet discovered. It provides a new insight into the relationships of the major lineages of mammals and the evolution of the mammalian skeleton. Our analysis suggests that this new taxon represents a part of the early therian radiation before the divergence of living marsupials and placentals; that therians and multituberculates are more closely related to each other than either group is to other mammalian lineages; that archaic therians lacked the more parasagittal posture of the forelimb of most living therian mammals; and that archaic therians, such as symmetrodonts, retained the primitive feature of a finger-like promontorium (possibly with a straight cochlea) of the non-therian mammals. The fully coiled cochlea evolved later in more derived therian mammals, and is therefore convergent to the partially coiled cochlea of monotremes.	CARNEGIE MUSEUM NAT HIST, SECT VERTEBRATE PALEONTOL, PITTSBURGH, PA 15213 USA; CHINESE ACAD SCI, INST VERTEBRATE PALEONTOL & PALEOANTHROPOL, BEIJING 100044, PEOPLES R CHINA	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS			Luo, Zhe-XI/AAU-2263-2021					Cassiliano M.L., 1979, P150; Chen P., 1980, B NANJING I GEOL PAL, V1, P22; CHEN PJ, 1994, CRETACEOUS RES, V15, P245, DOI 10.1006/cres.1994.1015; Cifelli R.L., 1990, Journal of Vertebrate Paleontology, V10, P332; Clemens W. A., 1963, Palaeontology, V6, P373; Crompton A., 1971, EARLY MAMMALS, P65; Crompton A.W., 1979, P59; CROMPTON AW, 1993, MAMMAL PHYLOGENY, P30; FOX RC, 1985, J PALEONTOL, V59, P21; Gambaryan PP, 1997, ACTA PALAEONTOL POL, V42, P13; GRAYBEAL A, 1989, ZOOL J LINN SOC-LOND, V96, P107, DOI 10.1111/j.1096-3642.1989.tb01823.x; HOPSON JA, 1994, MAJOR FEATURES VERTE, P190; Hou LH, 1996, SCIENCE, V274, P1164, DOI 10.1126/science.274.5290.1164; HOU LH, 1995, NATURE, V377, P616, DOI 10.1038/377616a0; JENKINS FA, 1973, AM J ANAT, V137, P281, DOI 10.1002/aja.1001370304; JENKINS FA, 1976, PHILOS T ROY SOC B, V273, P387, DOI 10.1098/rstb.1976.0022; JENKINS FA, 1974, J MORPHOL, V144, P71, DOI 10.1002/jmor.1051440105; JENKINS FA, 1979, J ZOOL, V188, P379; JENKINS FA, 1988, J VERTEBR PALEONTOL, V6, P1; Ji Q., 1996, CHINESE GEOL, V233, P30; Ji Q., 1997, CHINESE GEOL, V238, P38; Jin F, 1996, VERTEBRATA PALASIATI, V34, P102; KEMP TS, 1983, ZOOL J LINN SOC-LOND, V77, P353, DOI 10.1111/j.1096-3642.1983.tb00859.x; KERMACK KA, 1981, ZOOL J LINN SOC-LOND, V71, P1, DOI 10.1111/j.1096-3642.1981.tb01127.x; Kielan-Jaworowska Zofia, 1994, Fossils and Strata, V36, P1; KIELANJAWOROWSKA Z, 1987, NATURE, V326, P871, DOI 10.1038/326871a0; KIELANJAWOROWSKA Z, 1986, PHILOS T R SOC B, V313, P525, DOI 10.1098/rstb.1986.0055; KLIMA M, 1987, ADV ANAT EMBRYOL CEL, V109, P1; Klima M., 1973, Advances Anat Embryol Cell Biol, V47, P1; KRAUSE D W, 1983, Bulletin of the Museum of Comparative Zoology, V150, P199; Krebs B., 1991, Berliner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V133, P1; Lillegraven J.A., 1991, Contributions to Geology University of Wyoming, V28, P39; Luo Z., 1991, Journal of Vertebrate Paleontology, V11, P220; LUO ZX, 1994, J VERTEBR PALEONTOL, V14, P341, DOI 10.1080/02724634.1994.10011564; LUO ZX, 1995, J VERTEBR PALEONTOL, V15, P113, DOI 10.1080/02724634.1995.10011211; Marshall Larry G., 1995, Memoires du Museum National d'Histoire Naturelle, V165, P21; MENG J, 1995, NATURE, V377, P141, DOI 10.1038/377141a0; MENG J, 1995, J VERTEBR PALEONTOL, V15, P122, DOI 10.1080/02724634.1995.10011212; Rougier G.W., 1992, Journal of Vertebrate Paleontology, V12, P188; Rougier G.W., 1993, THESIS U NACL BUENOS; Rougier Guillermo W., 1996, American Museum Novitates, V3183, P1; Rowe T., 1988, Journal of Vertebrate Paleontology, V8, P241; SERENO PC, 1995, NATURE, V377, P144, DOI 10.1038/377144a0; SMIPSON GG, 1928, CATALOGUE MESOZOIC M; SMITH PE, 1995, CAN J EARTH SCI, V32, P1426, DOI 10.1139/e95-115; Wang Yuanqing, 1995, P221; Wible J.R., 1991, Journal of Vertebrate Paleontology, V11, P1; WIBLE JR, 1993, MAMMAL PHYLOGENY, V1, P45; Zeller U., 1989, ABHANDLUNGEN SENCKEN, V545, P1; [No title captured]	50	180	212	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					137	142		10.1038/36505	http://dx.doi.org/10.1038/36505			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367151				2022-12-24	WOS:A1997YF49400043
J	Smith, GD; Hart, C; Ferrell, C; Upton, M; Hole, D; Hawthorne, V; Watt, G				Smith, GD; Hart, C; Ferrell, C; Upton, M; Hole, D; Hawthorne, V; Watt, G			Birth weight of offspring and mortality in the Renfrew and Paisley study: prospective observational study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; BODY-FAT DISTRIBUTION; RISK-FACTORS; URBAN SCOTLAND; HIP RATIO; WOMEN; MEN; DETERMINANTS	Objective: To investigate the association between birth weight of offspring and mortality among fathers and mothers in the west of Scotland. Design: Prospective observational study. Participants: 794 married couples in Renfrew district of the west of Scotland. Main outcome measures: Mortality from all causes and from cardiovascular disease over 15 year follow up. Results: Women who had heavier babies were taller, had higher body mass index and better lung function, and were less likely to be smokers than mothers of lighter babies. Fathers of heavier babies were taller and less likely to be smokers than fathers of lighter babies. Mortality was inversely related to offspring's birth weight for both mothers (relative rate for a 1 kg lower birth weight 1.82 (95% confidence interval 1.23 to 2.70)) and fathers (relative rate 1.35 (1.03 to 1.79)). For mortality from cardiovascular disease, inverse associations were seen for mothers (2.00 (1.18 to 3.33)) and fathers (1.52 (1.03 to 2.17)). Adjustment for blood pressure, plasma cholesterol, body mass index, height, social class, area based deprivation category, smoking, lung function, angina, bronchitis, and electrocardiographic evidence of ischaemia had little effect on these risk estimates, although levels of statistical significance were reduced. Conclusions: Birth weight of offspring was related inversely to mortality, from all causes and cardiovascular disease, in this cohort. The strength of this association was greater than would have been expected by the degree of concordance of birth weights across generations, but an extensive range of potential confounding factors could not account for the association. Mortality is therefore influenced by a factor related to birth weight that is transmissible across generations.	UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW G12 8RZ,LANARK,SCOTLAND; UNIV GLASGOW,WOODSIDE HLTH CTR,DEPT GEN PRACTICE,GLASGOW G20 7LR,LANARK,SCOTLAND; RUCHILL HOSP,W SCOTLAND CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,LANARK,SCOTLAND; UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48109	University of Glasgow; University of Glasgow; University of Glasgow; University of Michigan System; University of Michigan	Smith, GD (corresponding author), UNIV BRISTOL,DEPT SOCIAL MED,CANYNGE HALL,BRISTOL BS8 2PR,AVON,ENGLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Upton, Mark/0000-0003-0839-1141				Alberman E, 1992, Paediatr Perinat Epidemiol, V6, P134, DOI 10.1111/j.1365-3016.1992.tb00755.x; BARKER DJP, 1995, NUTR CHILD HLTH; Brown JE, 1996, EPIDEMIOLOGY, V7, P62, DOI 10.1097/00001648-199601000-00011; EMANUEL I, 1993, ISSUES REV TERATOL, V6, P47; Emery E M, 1993, Am J Health Promot, V7, P342; Frankel S, 1996, PUBLIC HEALTH, V110, P139, DOI 10.1016/S0033-3506(96)80066-7; *GEN REG OFF, 1966, GEN REG OFF CLASS OC; Godfrey KM, 1997, BRIT J OBSTET GYNAEC, V104, P663, DOI 10.1111/j.1471-0528.1997.tb11975.x; HART N, 1993, POPULATION STUDIES, V47, P24; HAWTHORNE VM, 1995, SCOT MED J, V40, P102, DOI 10.1177/003693309504000402; *IND SCI COMM SMOK, 1988, 4 REP IND SCI COMM S; KLEBANOFF MA, 1989, PEDIATRICS, V84, P343; KOUPILOVA I, IN PRESS J EPIDEMIOL; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; LANGHOFFROOS J, 1987, CLIN GENET, V32, P240; LARSSON B, 1992, AM J EPIDEMIOL, V135, P266, DOI 10.1093/oxfordjournals.aje.a116280; Little R E, 1987, Paediatr Perinat Epidemiol, V1, P19, DOI 10.1111/j.1365-3016.1987.tb00084.x; MAGNUS P, 1984, CLIN GENET, V26, P397; OUNSTED M, 1986, ANN HUM BIOL, V13, P143, DOI 10.1080/03014468600008281; Pembrey M., 1996, Acta Geneticae Medicae et Gemellologiae, V45, P111; PETERS TJ, 1983, BRIT J OBSTET GYNAEC, V90, P1040, DOI 10.1111/j.1471-0528.1983.tb06442.x; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; POWER C, 1994, BRIT MED J, V308, P1270, DOI 10.1136/bmj.308.6939.1270; RICHEDWARDS J, 1995, AM J EPIDEMIOL, V141, pS78; SANDERSON M, 1995, PAEDIATR PERINAT EP, V9, P391, DOI 10.1111/j.1365-3016.1995.tb00162.x; *SAS I, 1991, SAS LANG PROC US 2 V; SCHMIDT MI, 1992, DIABETES CARE, V15, P912, DOI 10.2337/diacare.15.7.912; SELLERS TA, 1992, NEW ENGL J MED, V326, P1323, DOI 10.1056/NEJM199205143262004; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SUTTON GC, 1980, ANN HUM BIOL, V7, P449, DOI 10.1080/03014468000004561; Wang XB, 1995, NEW ENGL J MED, V333, P1744, DOI 10.1056/NEJM199512283332606; WATT GCM, 1995, SCOT MED J, V40, P108, DOI 10.1177/003693309504000403; WILD RA, 1990, FERTIL STERIL, V54, P255; World Health Organization, 1977, INT CLASS DIS	34	106	106	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1189	1193		10.1136/bmj.315.7117.1189	http://dx.doi.org/10.1136/bmj.315.7117.1189			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393220	Green Published			2022-12-24	WOS:A1997YF25200017
J	Trapp, BD; Peterson, J; Ransohoff, RM; Rudick, R; Mork, S; Bo, L				Trapp, BD; Peterson, J; Ransohoff, RM; Rudick, R; Mork, S; Bo, L			Axonal transection in the lesions of multiple sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; AMYLOID PRECURSOR PROTEIN; MONOCLONAL-ANTIBODIES DISTINGUISH; MYELIN-ASSOCIATED GLYCOPROTEIN; DISEASE PROGRESSION; N-ACETYLASPARTATE; NERVOUS-SYSTEM; CALIBER; BRAIN; NEUROFILAMENTS	Background Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system and is the most common cause of neurologic disability in young adults. Despite antiinflammatory or immunosuppressive therapy, most patients have progressive neurologic deterioration that may reflect axonal loss. We conducted pathological studies of brain tissues to define the changes in axons in patients with multiple sclerosis. Methods Brain tissue was obtained at autopsy from 11 patients with multiple sclerosis and 4 subjects without brain disease. Fourteen active multiple-sclerosis lesions, 33 chronic active lesions, and samples of normal-appearing white matter were examined for demyelination, inflammation, and axonal pathologic changes by immunohistochemistry and confocal microscopy. Axonal transection, identified by the presence of terminal axonal ovoids, was detected in all 47 lesions and quantified in 18 lesions. Results Transected axons were a consistent feature of the lesions of multiple sclerosis, and their frequency was related to the degree of inflammation within the lesion. The number of transected axons per cubic millimeter of tissue averaged 11,236 in active lesions, 3138 at the hypocellular edges of chronic active lesions, 875 in the hypocellular centers of chronic active lesions, and less than 1 in normal-appearing white matter from the control brains. Conclusions Transected axons are common in the; lesions of multiple sclerosis, and axonal transection may be the pathologic correlate of the irreversible neurologic impairment in this disease. (C) 1998, Massachusetts Medical Society.	Cleveland Clin Fdn, Dept Neurosci, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Mellen Ctr Multiple Sclerosis Res, Cleveland, OH 44195 USA; Haukeland Hosp, Dept Pathol, N-5021 Bergen, Norway	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Bergen; Haukeland University Hospital	Trapp, BD (corresponding author), Cleveland Clin Fdn, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Mörk, Sverre Jarl/AAW-1330-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035058] Funding Source: NIH RePORTER; NINDS NIH HHS [R01NS35058] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARBUTHNOTT ER, 1980, J PHYSIOL-LONDON, V308, P125, DOI 10.1113/jphysiol.1980.sp013465; ARNOLD DL, 1994, ANN NEUROL, V36, P76, DOI 10.1002/ana.410360115; Bo L, 1996, J NEUROPATH EXP NEUR, V55, P1060, DOI 10.1097/00005072-199655100-00006; BO L, 1994, J NEUROIMMUNOL, V51, P135, DOI 10.1016/0165-5728(94)90075-2; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; BORNSTEI.MB, 1965, SCIENCE, V148, P1242, DOI 10.1126/science.148.3674.1242; CHARCOT M, 1868, GAZ HOSP, P557; CHARCOT M, 1868, GAZ HOSP, P141; COCHRAN E, 1991, AM J PATHOL, V139, P485; Davie CA, 1995, BRAIN, V118, P1583, DOI 10.1093/brain/118.6.1583; DAVIE CA, 1994, BRAIN, V117, P49, DOI 10.1093/brain/117.1.49; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; DeStefano N, 1995, ANN NEUROL, V38, P901, DOI 10.1002/ana.410380610; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; DUQUETTE P, 1995, NEUROLOGY, V45, P1277; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; FRUTTIGER M, 1995, EUR J NEUROSCI, V7, P511, DOI 10.1111/j.1460-9568.1995.tb00347.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; Hohlfeld R, 1997, BRAIN, V120, P865, DOI 10.1093/brain/120.5.865; Hsieh S-T, 1993, BRAIN PATHOL, V3, P307; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; Jm C., 1868, GAZ HOPITAUX, P554; LEE VMY, 1986, J NEUROSCI, V6, P850; LEE VMY, 1987, J NEUROSCI, V7, P3474; Losseff NA, 1996, BRAIN, V119, P701, DOI 10.1093/brain/119.3.701; Losseff NA, 1996, BRAIN, V119, P2009, DOI 10.1093/brain/119.6.2009; Matthews PM, 1996, BRAIN, V119, P715, DOI 10.1093/brain/119.3.715; MCDONALD WI, 1994, J NEUROPATH EXP NEUR, V53, P338, DOI 10.1097/00005072-199407000-00003; MCFARLAND HF, 1992, ANN NEUROL, V32, P758, DOI 10.1002/ana.410320609; MEHTA V, 1995, MOL BRAIN RES, V31, P151, DOI 10.1016/0169-328X(95)00044-S; MILLIGAN NM, 1987, J NEUROL NEUROSUR PS, V50, P511, DOI 10.1136/jnnp.50.5.511; NAKAGAWA T, 1995, J CELL BIOL, V129, P411, DOI 10.1083/jcb.129.2.411; Narayanan S, 1997, ANN NEUROL, V41, P385, DOI 10.1002/ana.410410314; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; PRINEAS JW, 1981, ANN NEUROL, V10, P149, DOI 10.1002/ana.410100205; PRINEAS JW, 1984, ANN NY ACAD SCI, V436, P11, DOI 10.1111/j.1749-6632.1984.tb14773.x; PRINEAS JW, 1985, HDB CLIN NEUROLOGY, V47, P213; RAINE CS, 1989, LAB INVEST, V60, P714; RUDICK RA, 1996, ANN NEUROL, V40, P516; Sanchez I, 1996, J NEUROSCI, V16, P5095; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; TRAPP BD, 1989, J CELL BIOL, V109, P2417, DOI 10.1083/jcb.109.5.2417; Trapp BD, 1997, J CELL BIOL, V137, P459, DOI 10.1083/jcb.137.2.459; Weinshenker BG, 1996, NEUROL CLIN, V14, P291, DOI 10.1016/S0733-8619(05)70257-7; WEINSHENKER BG, 1989, BRAIN, V112, P133, DOI 10.1093/brain/112.1.133; WINDEBANK AJ, 1985, J NEUROSCI, V5, P1563	54	3171	3248	3	161	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	1998	338	5					278	285		10.1056/NEJM199801293380502	http://dx.doi.org/10.1056/NEJM199801293380502			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT963	9445407				2022-12-24	WOS:000071665200002
J	Biervert, C; Schroeder, BC; Kubisch, C; Berkovic, SF; Propping, P; Jentsch, TJ; Steinlein, OK				Biervert, C; Schroeder, BC; Kubisch, C; Berkovic, SF; Propping, P; Jentsch, TJ; Steinlein, OK			A potassium channel mutation in neonatal human epilepsy	SCIENCE			English	Article							CONVULSIONS; GENE; CHROMOSOME-20; K(V)LQT1; PROTEINS; MYOKYMIA; SUBUNIT; CLONING; ATAXIA; FORM	Benign familial neonatal convulsions (BFNC) is an autosomal dominant epilepsy of infancy, with loci mapped to human chromosomes 20q13.3 and 8q24. By positional cloning, a potassium channel gene (KCNQ2) located on 20q13.3 was isolated and found to be expressed in brain. Expression of KCNQ2 in frog (Xenopus laevis) oocytes led to potassium-selective currents that activated slowly with depolarization. In a large pedigree with BFNC, a five-base pair insertion would delete more than 300 amino acids from the KCNQ2 carboxyl terminus. Expression of the mutant channel did not yield measurable currents. Thus, impairment of potassium-dependent repolarization is likely to cause this age-specific epileptic syndrome.	Univ Hamburg, Zentrum Mol Neurobiol, Hamburg, Germany; Univ Bonn, Inst Human Genet, D-5300 Bonn, Germany; Univ Melbourne, Dept Med Neurol, Melbourne, Vic, Australia	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Bonn; University of Melbourne	Jentsch, TJ (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol, Hamburg, Germany.	Jentsch@plexus.uke.uni-hamburg.de; steinlein@snphysio2.wilhelm.uni-bonn.de	jiang, yu/HGU-0029-2022; Kubisch, Christian/F-1893-2011	Kubisch, Christian/0000-0003-4220-0978; Berkovic, Samuel/0000-0003-4580-841X; Jentsch, Thomas/0000-0002-3509-2553				Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BERKOVIC SF, 1994, ARCH NEUROL-CHICAGO, V51, P1125, DOI 10.1001/archneur.1994.00540230063014; Berkovic SF, 1997, BRAIN DEV-JPN, V19, P13, DOI 10.1016/S0387-7604(96)00060-5; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; BRUNT ERP, 1990, BRAIN, V113, P1361, DOI 10.1093/brain/113.5.1361; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; Lee MP, 1997, NAT GENET, V15, P181, DOI 10.1038/ng0297-181; LEPPERT M, 1989, NATURE, V337, P647, DOI 10.1038/337647a0; LEWIS TB, 1993, AM J HUM GENET, V53, P670; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Ptacek LJ, 1997, NEUROMUSCULAR DISORD, V7, P250, DOI 10.1016/S0960-8966(97)00046-1; RONEN GM, 1993, NEUROLOGY, V43, P1355, DOI 10.1212/WNL.43.7.1355; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SCHROEDER BC, UNPUB; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; STEINLEIN O, 1994, GENOMICS, V22, P493, DOI 10.1006/geno.1994.1420; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; Steinlein OK, 1997, HUM MOL GENET, V6, P943, DOI 10.1093/hmg/6.6.943; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Wollnik B, 1997, HUM MOL GENET, V6, P1943, DOI 10.1093/hmg/6.11.1943; Yokoyama M, 1996, DNA Res, V3, P311, DOI 10.1093/dnares/3.5.311	27	859	910	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	1998	279	5349					403	406		10.1126/science.279.5349.403	http://dx.doi.org/10.1126/science.279.5349.403			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430594				2022-12-24	WOS:000071570800052
J	Zhang, HM; Forde, BG				Zhang, HM; Forde, BG			An Arabidopsis MADS box gene that controls nutrient-induced changes in root architecture	SCIENCE			English	Article							NITRATE; PLANTS; GROWTH; PRODUCTIVITY; EXPRESSION; RESPONSES; THALIANA; ROLES	The development of plant root systems is sensitive to the availability and distribution of nutrients within the soil. For example, lateral roots proliferate preferentially within nitrate (NO3-)-rich soil patches. A NO3--inducible Arabidopsis gene (ANR1), was identified that encodes a member of the MADS box family of transcription factors. Transgenic plants in which ANR1 was repressed had an altered sensitivity to NO3- and no longer responded to NO3--rich zones by lateral root proliferation, indicating that ANR1 is a key determinant of developmental plasticity in Arabidopsis roots.	IACR Rothamsted, Dept Biochem & Physiol, Harpenden AL5 2JQ, Herts, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Forde, BG (corresponding author), IACR Rothamsted, Dept Biochem & Physiol, Harpenden AL5 2JQ, Herts, England.		Forde, Brian G/C-6554-2009	Forde, Brian G/0000-0001-7973-7280				AGREN GI, 1987, PLANT CELL ENVIRON, V10, P579, DOI 10.1111/j.1365-3040.1987.tb01838.x; CRAWFORD NM, 1995, PLANT CELL, V7, P859, DOI 10.1105/tpc.7.7.859; DREW MC, 1973, J EXP BOT, V24, P1189, DOI 10.1093/jxb/24.6.1189; FITTER AH, 1991, NEW PHYTOL, V118, P383, DOI 10.1111/j.1469-8137.1991.tb00019.x; GAMBORG OL, 1968, EXP CELL RES, V50, P151, DOI 10.1016/0014-4827(68)90403-5; GRANATO TC, 1989, J EXP BOT, V40, P263, DOI 10.1093/jxb/40.2.263; GUERINEAU F, 1992, PLANT MOL BIOL, V18, P815, DOI 10.1007/BF00020027; HACKETT C, 1972, AUST J BIOL SCI, V25, P1169, DOI 10.1071/BI9721169; HUTCHINGS MJ, 1994, ADV ECOL RES, V25, P159, DOI 10.1016/S0065-2504(08)60215-9; JORGENSEN R, 1990, TRENDS BIOTECHNOL, V8, P340, DOI 10.1016/0167-7799(90)90220-R; LYNCH J, 1995, PLANT PHYSIOL, V109, P7, DOI 10.1104/pp.109.1.7; REDINBAUGH MG, 1991, PHYSIOL PLANTARUM, V82, P640, DOI 10.1111/j.1399-3054.1991.tb02958.x; ROBINSON D, 1994, NEW PHYTOL, V127, P635, DOI 10.1111/j.1469-8137.1994.tb02969.x; ROUNSLEY SD, 1995, PLANT CELL, V7, P1259, DOI 10.1105/tpc.7.8.1259; SATTELMACHER B, 1988, PLANT ROOTS THEIR EN, P149; Scheible WR, 1997, PLANT J, V11, P671, DOI 10.1046/j.1365-313X.1997.11040671.x; SCHIEFELBEIN JW, 1991, PLANT CELL, V3, P1147, DOI 10.1105/tpc.3.11.1147; Theissen G, 1996, J MOL EVOL, V43, P484, DOI 10.1007/PL00006110; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TREWAVAS AJ, 1983, INTERACTIONS NITROGE, P97; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WEIGEL DA, 1995, REV GENET, V29, P19; WIERSUM L. K., 1958, ACTA BOT NEERLANDICA, V7, P174; WILKINSON JQ, 1993, MOL GEN GENET, V239, P289, DOI 10.1007/BF00281630; Zachgo S, 1997, PLANT J, V11, P1043, DOI 10.1046/j.1365-313X.1997.11051043.x; ZHANG H, UNPUB	26	893	1017	13	210	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					407	409		10.1126/science.279.5349.407	http://dx.doi.org/10.1126/science.279.5349.407			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430595				2022-12-24	WOS:000071570800053
J	Kuehn, MJ; Herrmann, JM; Schekman, R				Kuehn, MJ; Herrmann, JM; Schekman, R			COPII-cargo interactions direct protein sorting into ER-derived transport vesicles	NATURE			English	Article							AMINO-ACID PERMEASES; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; COATED VESICLES; YEAST; COMPONENT; COMPLEX; TRANSLOCATION; COATOMER; FAMILY	Vesicles coated with coat protein complex II (COPII) selectively transport molecules (cargo) and vesicle fusion proteins from the endoplasmic reticulum (ER) to the Golgi complex(1-3). We have investigated the role of coat proteins in cargo selection and recruitment. We isolated integral membrane and soluble cargo proteins destined for transport from the ER in complexes formed in the presence of Sar1 and Sec23/24, a subset of the COPII components, and GTP or GMP-PNP. Vesicle fusion proteins of the vSNARE family and Emp24, a member of a putative cargo carrier family(4), were also found in COPII complexes. The inclusion of amino-acid permease molecules into the complex depended on the presence of Shr3, a protein required for the permease to leave the ER3,5. Resident ER proteins Sec61, BiP (Kar2) and Shr3 were not included in the complexes, indicating that the COPII components bound specifically to vesicle cargo. COPII-cargo complexes and putative cargo adaptor-cargo complexes were also isolated from COPII vesicles. Our results indicate that cargo packaging signals and soluble cargo adaptors are recognized by a recruitment complex comprising Sar1-GTP and Sec23/24.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Schekman, R (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Barker Hall, Berkeley, CA 94720 USA.		Kuehn, Meta/AAL-2950-2021	Kuehn, Meta/0000-0003-0519-3019				BARLOWE C, 1993, J BIOL CHEM, V268, P873; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; Kuehn MJ, 1996, J CELL BIOL, V135, P585, DOI 10.1083/jcb.135.3.585; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SIKORSKI RS, 1989, GENETICS, V122, P19; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; Yeung T, 1995, J BIOL CHEM, V270, P30567, DOI 10.1074/jbc.270.51.30567; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	19	319	326	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 8	1998	391	6663					187	190		10.1038/34438	http://dx.doi.org/10.1038/34438			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428766				2022-12-24	WOS:000071380900054
J	Picciotto, MR; Zoli, M; Rimondini, R; Lena, C; Marubio, LM; Pich, EM; Fuxe, K; Changeux, JP				Picciotto, MR; Zoli, M; Rimondini, R; Lena, C; Marubio, LM; Pich, EM; Fuxe, K; Changeux, JP			Acetylcholine receptors containing the beta 2 subunit are involved in the reinforcing properties of nicotine	NATURE			English	Article							VENTRAL TEGMENTAL AREA; H-3 DOPAMINE RELEASE; NUCLEUS-ACCUMBENS; AUTORADIOGRAPHIC ANALYSIS; RAT-BRAIN; INVITRO; MODULATION; PITUITARY; STRIATUM; SYSTEM	Release of the neurotransmitter dopamine in the mesolimbic system of the brain mediates the reinforcing properties of several drugs of abuse, including nicotine(1). Here we investigate the contribution of the high-affinity neuronal nicotinic acetylcholine receptor(2) to the effects of nicotine on the mesolimbic dopamine system in mice lacking the beta 2 subunit of this receptor(3). We found that nicotine stimulates dopamine release in the ventral striatum of wild-type mice but not in the ventral striatum of beta 2-mutant mice. Using patch-clamp recording, we show that mesencephalic dopaminergic neurons from mice without the beta 2 subunit no longer respond to nicotine, and that self-administration of nicotine is attenuated in these mutant mice. Our results strongly support the idea that the beta 2-containing neuronal nicotinic acetycholine receptor is involv ed in mediating the reinforcing properties of nicotine.	Inst Pasteur, CNRS, UA D128, F-75724 Paris, France; Karolinska Inst, Dept Histol, S-10401 Stockholm, Sweden; Glaxo Wellcome Res & Dev Ltd, Geneva Biomed Res Inst, CH-1228 Geneva, Switzerland	Centre National de la Recherche Scientifique (CNRS); Karolinska Institutet; GlaxoSmithKline	Changeux, JP (corresponding author), Inst Pasteur, CNRS, UA D128, 28 Rue Dr Roux, F-75724 Paris, France.		Zoli, Michele/C-8899-2016; Rimondini, Roberto/B-2500-2010; Léna, Clément/P-6929-2019; Picciotto, Marina R./F-8747-2012; Léna, Clément/ABE-4862-2021; , clement/ADN-8076-2022	Zoli, Michele/0000-0002-8034-2849; Rimondini, Roberto/0000-0003-4099-513X; Léna, Clément/0000-0002-1431-7717; Picciotto, Marina R./0000-0002-4404-1280; Léna, Clément/0000-0002-1431-7717; Fuxe, Kjell/0000-0001-8491-4288				Blaha CD, 1996, J NEUROSCI, V16, P714; CALABRESI P, 1989, BRIT J PHARMACOL, V98, P135, DOI 10.1111/j.1476-5381.1989.tb16873.x; CLARKE PBS, 1988, J PHARMACOL EXP THER, V246, P701; CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; DAWSON TM, 1986, J NEUROSCI, V6, P2352; GRACE AA, 1989, J NEUROSCI, V9, P3463; GRADY S, 1992, J NEUROCHEM, V59, P848, DOI 10.1111/j.1471-4159.1992.tb08322.x; GRAHAME NJ, 1995, PHARMACOL BIOCHEM BE, V51, P827, DOI 10.1016/0091-3057(95)00047-Z; HENNINGFIELD JE, 1983, PHARMACOL BIOCHEM BE, V19, P887, DOI 10.1016/0091-3057(83)90099-0; IZENWASSER S, 1991, J NEUROCHEM, V56, P603, DOI 10.1111/j.1471-4159.1991.tb08192.x; KAUFMAN MJ, 1991, SYNAPSE, V9, P177, DOI 10.1002/syn.890090304; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LeNovere N, 1996, EUR J NEUROSCI, V8, P2428; LUETJE CW, 1991, J NEUROSCI, V11, P837; MANSOUR A, 1990, J NEUROSCI, V10, P2587; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MEMO M, 1986, J NEUROCHEM, V47, P1689, DOI 10.1111/j.1471-4159.1986.tb13075.x; NISELL M, 1994, SYNAPSE, V16, P36, DOI 10.1002/syn.890160105; PICCIOTTO MR, 1995, NATURE, V374, P65, DOI 10.1038/374065a0; Pich EM, 1997, SCIENCE, V275, P83; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; REAVILL C, 1990, NEUROPHARMACOLOGY, V29, P619, DOI 10.1016/0028-3908(90)90022-J; RHEINLAND JE, 1986, LIFE SCI, V39, P2185; RIMONDINI R, 1994, NEUROSCI LETT, V177, P53, DOI 10.1016/0304-3940(94)90043-4; RISINGER FO, 1995, PHARMACOL BIOCHEM BE, V51, P457, DOI 10.1016/0091-3057(95)00007-J; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; STOLERMAN IP, 1995, MED RES REV, V15, P47, DOI 10.1002/med.2610150105; TESSARI M, 1995, PSYCHOPHARMACOLOGY, V121, P282, DOI 10.1007/BF02245640	29	1030	1052	3	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	1998	391	6663					173	177		10.1038/34413	http://dx.doi.org/10.1038/34413			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428762				2022-12-24	WOS:000071380900050
J	Quillent, C; Oberlin, E; Braun, J; Rousset, D; Gonzalez-Canali, G; Metais, P; Montagnier, L; Virelizier, JL; Arenzana-Seisdedos, F; Beretta, A				Quillent, C; Oberlin, E; Braun, J; Rousset, D; Gonzalez-Canali, G; Metais, P; Montagnier, L; Virelizier, JL; Arenzana-Seisdedos, F; Beretta, A			HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene	LANCET			English	Article							CHEMOKINE RECEPTOR GENE; HIV-1 INFECTION; INDIVIDUALS; PROGRESSION; MIP-1-ALPHA; RESISTANCE; MIP-1-BETA; COFACTOR; CLONING; ALLELE	Background Despite multiple exposures to HIV-1, some individuals remain uninfected, and their peripheral-blood mononuclear cells (PBMC) are resistant to in-vitro infection by primary HIV-1 isolates. Such resistance has been associated with a homozygous 32-base-pair deletion (Delta 32) in the C-C chemokine receptor gene CCR5. We examined other mutations of the CCR5 gene that could be associated with resistance to HIV-1 infection. Methods We assessed the susceptibility of PBMC to in-vitro infection by HIV-1 isolates that use the CCR5 as the major coreceptor for Viral entry in 18 men who had frequent unprotected sexual intercourse with a seropositive partner. We also did genotypic analysis of CCR5 alleles. One of the 18 exposed bur uninfected men (who we refer to as ExU2) showed total resistance to in-vitro infection by CCR5-dependent viruses, and was found to carry a CCR5 Delta 32 allele and a single point mutation (T-->A) at position 303 on the other allele, To find out whether the CCR5 mutation was restricted to ExU2's family or existed in the general population, we did genetic analyses of the CCR5 genotype in ExU2's father and sister and also in 209 healthy blood donors who were not exposed to HIV-1. Findings The m303 mutation found in ExU2 introduced a premature stop codon and prevented the expression of a functional coreceptor. The family studies revealed that the m303 mutant allele was inherited as a single mendelian trait. Genotype analysis showed that three of the 209 healthy blood donors were heterozygous for the mutant allele. Interpretation We characterise a new CCR5 gene mutation, present in the general population, that prevents expression of functional coreceptors from the abnormal allele and confers resistance to HIV-1 infection when associated to the Delta 32 CCR5 mutant gene.	Hop St Joseph, Ctr Integre Rech Bioclin SIDA, F-75014 Paris, France; Inst Pasteur, Unite Immunol Virale, Paris, France; Inst Pasteur, Unite Oncol Virale, F-75724 Paris, France	Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Beretta, A (corresponding author), Hop St Joseph, Ctr Integre Rech Bioclin SIDA, F-75014 Paris, France.		Oberlin, Estelle/M-4915-2018; Arenzana-Seisdedos, Fernando/E-5835-2016; Rousset, Dominique/A-4209-2009; Rousset, Dominique/S-5400-2019	Oberlin, Estelle/0000-0002-8200-9548; Rousset, Dominique/0000-0002-1473-3147				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DORANZ BJ, 1996, CELL, V85, P1159; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Theodorou I, 1997, LANCET, V349, P1219; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	25	218	226	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					14	18		10.1016/S0140-6736(97)09185-X	http://dx.doi.org/10.1016/S0140-6736(97)09185-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433423				2022-12-24	WOS:000071253100010
J	Koehler, JE; Sanchez, MA; Garrido, CS; Whitfeld, MJ; Chen, FM; Berger, TG; Rodriguez-Barradas, MC; LeBoit, PE; Tappero, JW				Koehler, JE; Sanchez, MA; Garrido, CS; Whitfeld, MJ; Chen, FM; Berger, TG; Rodriguez-Barradas, MC; LeBoit, PE; Tappero, JW			Molecular epidemiology of Bartonella infections in patients with bacillary angiomatosis-peliosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Joint Session on Emerging Pathogens, Infectious-Diseases-Society-of-America National Meeting / 36th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 15-20, 1996	NEW ORLEANS, LOUISIANA	Infectious Dis Soc Amer			CAT-SCRATCH DISEASE; HUMAN-IMMUNODEFICIENCY-VIRUS; HENSELAE SP-NOV; ROCHALIMAEA-HENSELAE; EPITHELIOID ANGIOMATOSIS; IDENTIFICATION; BACTEREMIA; FEVER; SEPTICEMIA; QUINTANA	Background Bacillary angiomatosis and bacillary peliosis are vascular proliferative manifestations of infection with species of the genus bartonella that occur predominantly in patients infected with the human immunodeficiency virus, Two species, Bartonella henselae and B. quintana, have been associated with bacillary angiomatosis, but culture and speciation are difficult, and there has been little systematic evaluation ol the species-specific disease characteristics. We studied 49 patients seen over eight years who were infected with bartonella species identified by molecular techniques and who had clinical lesions consistent with bacillary angiomatosis-peliosis. Methods In this case-control study, a standardized questionnaire about exposures was administered to patients with bacillary angiomatosis-peliosis and to 96 marched controls. The infecting bartonella species were determined by molecular techniques. Results Of the 49 patients with bacillary angiomatosis-peliosis, 26 (53 percent) were infected with B. henselae and 23 (47 percent) with B. quintana. Subcutaneous and lytic bone lesions were strongly associated with B. quintana, whereas peliosis hepatis was associated exclusively with B. henselae, Patients with B, henselae infection were identified throughout the study period and were epidemiologically linked to cat and flea exposure (P less than or equal to 0.004), whereas those with B, quintana were clustered and were characterized by low income (P=0.003), homelessness (P=0.004), and exposure to lice (P=0.03), Prior treatment with macrolide antibiotics appeared to be protective against infection with either species. Conclusions B. henselae and B, quintana, the organisms that cause bacillary angiomatosis-peliosis, are associated with different epidemiologic risk factors and with predilections for involvement of different organs. (C) 1997, Massachusetts Medical Society.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif Berkeley, Sch Publ Hlth, Program Epidemiol, Berkeley, CA 94720 USA; Vet Affairs Med Ctr, Med Serv, Infect Dis Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; Centers for Disease Control & Prevention - USA	Koehler, JE (corresponding author), Univ Calif San Francisco, Dept Med, Box 0654,521 Parnassus Ave,Rm C-443, San Francisco, CA 94143 USA.			Whitfeld, Margot/0000-0003-4509-4461	FOGARTY INTERNATIONAL CENTER [D43TW000003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036075] Funding Source: NIH RePORTER; FIC NIH HHS [D43-TW00003] Funding Source: Medline; NIAID NIH HHS [R29 AI36075] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAL KA, 1994, NEW ENGL J MED, V330, P1509, DOI 10.1056/NEJM199405263302108; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BAKER JA, 1946, J EXP MED, V84, P37, DOI 10.1084/jem.84.1.37; BIRTLES RJ, 1995, INT J SYST BACTERIOL, V45, P1, DOI 10.1099/00207713-45-1-1; CARITHERS HA, 1985, AM J DIS CHILD, V139, P1124, DOI 10.1001/archpedi.1985.02140130062031; Chomel BB, 1996, J CLIN MICROBIOL, V34, P1952, DOI 10.1128/JCM.34.8.1952-1956.1996; COCKERELL CJ, 1987, LANCET, V2, P654; Dean A. G., 1990, EPI INFO VERSION 5 W; DOLAN MJ, 1993, ANN INTERN MED, V118, P331, DOI 10.7326/0003-4819-118-5-199303010-00002; KOEHLER JE, 1994, JAMA-J AM MED ASSOC, V271, P531, DOI 10.1001/jama.271.7.531; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; Lawson PA, 1996, MED MICROBIOL LETT, V5, P64; LEBOIT PE, 1989, AM J SURG PATHOL, V13, P909, DOI 10.1097/00000478-198911000-00001; Margileth A M, 1993, Adv Pediatr Infect Dis, V8, P1; MARULLO S, 1992, J INFECT DIS, V166, P1462, DOI 10.1093/infdis/166.6.1462-a; MAURIN M, 1995, ANTIMICROB AGENTS CH, V39, P2387, DOI 10.1128/AAC.39.11.2387; MohleBoetani JC, 1996, CLIN INFECT DIS, V22, P794, DOI 10.1093/clinids/22.5.794; MYERS WF, 1984, ANTIMICROB AGENTS CH, V25, P690, DOI 10.1128/AAC.25.6.690; PERKOCHA LA, 1990, NEW ENGL J MED, V323, P1581, DOI 10.1056/NEJM199012063232302; REED JA, 1992, AM J SURG PATHOL, V16, P650, DOI 10.1097/00000478-199207000-00003; REGNERY RL, 1992, LANCET, V339, P1443, DOI 10.1016/0140-6736(92)92032-B; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; RODRIGUEZBARRADAS MC, 1995, J CLIN MICROBIOL, V33, P1089, DOI 10.1128/JCM.33.5.1089-1093.1995; SLATER LN, 1990, NEW ENGL J MED, V323, P1587, DOI 10.1056/NEJM199012063232303; SPACH DH, 1995, NEW ENGL J MED, V332, P424, DOI 10.1056/NEJM199502163320703; STOLER MH, 1983, AM J CLIN PATHOL, V80, P714, DOI 10.1093/ajcp/80.5.714; STRONG RP, 1918, TRENCH FEVER REPORT; TAPPERO JW, 1993, ANN INTERN MED, V118, P363, DOI 10.7326/0003-4819-118-5-199303010-00007; TAPPERO JW, 1993, JAMA-J AM MED ASSOC, V269, P770, DOI 10.1001/jama.269.6.770; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992; Whitfeld MJ, 1997, CLIN INFECT DIS, V24, P562, DOI 10.1093/clind/24.4.562; ZANGWILL KM, 1993, NEW ENGL J MED, V329, P8, DOI 10.1056/NEJM199307013290102	33	210	214	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 25	1997	337	26					1876	1883		10.1056/NEJM199712253372603	http://dx.doi.org/10.1056/NEJM199712253372603			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN051	9407154				2022-12-24	WOS:000071128200003
J	Tesmer, JJG; Sunahara, RK; Gilman, AG; Sprang, SR				Tesmer, JJG; Sunahara, RK; Gilman, AG; Sprang, SR			Crystal structure of the catalytic domains of adenylyl cyclase in a complex with G(s alpha).GTP gamma S	SCIENCE			English	Article							GUANYLATE-CYCLASE; GS-ALPHA; STEREOCHEMICAL COURSE; MOLECULAR-CLONING; ESCHERICHIA-COLI; GTP HYDROLYSIS; G-PROTEIN; MECHANISM; EXPRESSION; DIVERSITY	The crystal structure of a soluble, catalytically active form of adenylyl cyclase in a complex with its stimulatory heterotrimeric G protein alpha subunit (G(S alpha)) and forskolin was determined to a resolution of 2.3 angstroms. When P-site inhibitors were soaked into native crystals of the complex, the active site of adenylyl cyclase was located and structural elements important for substrate recognition and catalysis were identified. On the basis of these and other structures, a molecular mechanism is proposed for the activation of adenylyl cyclase by G(S alpha).	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Sunahara, Roger/AAJ-8667-2020	Tesmer, John/0000-0003-1125-3727	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038828, R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38828, DK46371] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AN SZ, 1997, J BIOL CHEM, V272, P18849; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Chen YB, 1997, P NATL ACAD SCI USA, V94, P2711, DOI 10.1073/pnas.94.6.2711; CHINKERS M, 1991, ANN REV BIOCH, V60, P563; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; ECKSTEIN F, 1981, J BIOL CHEM, V256, P9118; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GERLT JA, 1980, J BIOL CHEM, V255, P331; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; Grishina G, 1997, J BIOL CHEM, V272, P20619, DOI 10.1074/jbc.272.33.20619; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; ITOH H, 1991, J BIOL CHEM, V266, P16226; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOCH KW, 1990, J BIOL CHEM, V265, P9659; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAKANE M, 1990, J BIOL CHEM, V265, P16841; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PERONA JJ, 1993, BIOCHEMISTRY-US, V32, P8758, DOI 10.1021/bi00085a006; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SENTER PD, 1983, J BIOL CHEM, V258, P6741; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SRTYMIUK PJ, 1997, NATURE, V388, P33; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Xia ZG, 1997, CURR OPIN NEUROBIOL, V7, P391, DOI 10.1016/S0959-4388(97)80068-2; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Zhang GY, 1997, PROTEIN SCI, V6, P903; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	52	635	649	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1907	1916		10.1126/science.278.5345.1907	http://dx.doi.org/10.1126/science.278.5345.1907			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9417641				2022-12-24	WOS:A1997YL00200024
J	Wagner, JA; Varga, K; Ellis, EF; Rzigalinski, BA; Martin, BR; Kunos, G				Wagner, JA; Varga, K; Ellis, EF; Rzigalinski, BA; Martin, BR; Kunos, G			Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock	NATURE			English	Article							NITRIC-OXIDE; HYPOTENSIVE ACTION; BRAIN CONSTITUENT; ANANDAMIDE; ANTAGONIST; CELLS	Anandamide, an endogenous cannabinoid ligand(1), binds to CB1 cannabinoid receptors(2) in the brain and mimics the neurobehavioural actions of marijuana(3,4). Cannabinoids and anandamide also elicit hypotension mediated by peripheral CB1 receptors(5-8). Here we report that a selective CB1 receptor antagonist, SR141716A(9), elicits an increase in blood pressure in rats subjected to haemorrhagic shock, whereas similar treatment of normotensive rats or intracerebroventricular administration of the antagonist during shock do not affect blood pressure. Blood from haemorrhaged rats causes hypotension in normal rats, which can be prevented by SR141716A but not by inhibition of nitric oxide synthase in the recipient. Macrophages and platelets from haemorrhaged rats elicit CB1 receptor-mediated hypotension in normotensive recipients, and incorporate arachidonic acid or ethanolamine into a product that co-elutes with anandamide on reverse-phase high-performance liquid chromatography. Also, macrophages from control rats stimulated with ionomycin or bacterial phospholipase D produce anandamide, as identified by gas chromatography and mass spectrometry. These findings indicate that activation of peripheral CB1 cannabinoid receptors contributes to haemorrhagic hypotension, and anandamide produced by macrophages may be a mediator of this effect.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298	Virginia Commonwealth University								Aiura K, 1997, J INFECT DIS, V175, P123, DOI 10.1093/infdis/175.1.123; AMRUTHESH SC, 1992, J NEUROCHEM, V58, P503, DOI 10.1111/j.1471-4159.1992.tb09749.x; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; COLLINS JA, 1969, ARCH SURG-CHICAGO, V99, P484; CORTAS NK, 1990, CLIN CHEM, V36, P1440; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; diMarzo V, 1996, BIOCHEM J, V316, P977, DOI 10.1042/bj3160977; Ellis EF, 1995, AM J PHYSIOL-HEART C, V269, pH1859, DOI 10.1152/ajpheart.1995.269.6.H1859; FELDER CC, 1992, MOL PHARMACOL, V42, P838; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; GEBREMEDHIN G, 1996, FASEB J, V10, pA302; HOLADAY JW, 1983, ANNU REV PHARMACOL, V23, P541, DOI 10.1146/annurev.pa.23.040183.002545; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Lake KD, 1997, HYPERTENSION, V29, P1204, DOI 10.1161/01.HYP.29.5.1204; Lake KD, 1997, J PHARMACOL EXP THER, V281, P1030; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; NAZIRI W, 1995, J SURG RES, V59, P146, DOI 10.1006/jsre.1995.1146; Peitzman AB, 1995, CURR PROB SURG, V32, P927; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; VARGA K, 1995, EUR J PHARMACOL, V278, P279, DOI 10.1016/0014-2999(95)00181-J; Varga K, 1996, HYPERTENSION, V28, P682, DOI 10.1161/01.HYP.28.4.682	25	244	248	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					518	521		10.1038/37371	http://dx.doi.org/10.1038/37371			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394002				2022-12-24	WOS:A1997YJ86500054
J	Ermler, U; Grabarse, W; Shima, S; Goubeaud, M; Thauer, RK				Ermler, U; Grabarse, W; Shima, S; Goubeaud, M; Thauer, RK			Crystal structure of methyl coenzyme M reductase: The key enzyme of biological methane formation	SCIENCE			English	Article							METHYLCOENZYME-M METHYLREDUCTASE; F430 PENTAMETHYL ESTER; METHANOBACTERIUM-THERMOAUTOTROPHICUM; METHANOGENIC BACTERIA; COMPONENT-C; INVITRO METHANOGENESIS; STRAIN MARBURG; SYSTEM; NICKEL; SPECTROSCOPY	Methyl-coenzyme M reductase (MCR), the enzyme responsible for the microbial formation of methane, is a 300-kilodalton protein organized as a hexamer in an alpha(2) beta(2) gamma(2) arrangement. The crystal structure of the enzyme from Methanobacterium thermoautotrophicum, determined at 1.45 angstrom resolution for the inactive enzyme state MCRox1-silent, reveals that two molecules of the nickel porphinoid coenzyme F-430 are embedded between the subunits alpha,alpha',beta, and gamma and alpha',alpha,beta', and gamma', forming two identical active sites. Each site is accessible for the substrate methyl-coenzyme M through a narrow channel locked after binding of the second substrate coenzyme B. Together with a second structurally characterized enzyme state (MCRsilent) containing the heterodisulfide of coenzymes M and B, a reaction mechanism is proposed that uses a radical intermediate and a nickel organic compound.	UNIV MARBURG, MIKROBIOL LAB, D-35043 MARBURG, GERMANY; MAX PLANCK INST TERR MIKROBIOL, D-35043 MARBURG, GERMANY	Philipps University Marburg; Max Planck Society	Ermler, U (corresponding author), MAX PLANCK INST BIOPHYS, HEINRICH HOFFMAN STR 7, D-60528 FRANKFURT, GERMANY.							AHN YH, 1991, J AM CHEM SOC, V113, P4700, DOI 10.1021/ja00012a059; ALBRACHT SPJ, 1988, BIOCHIM BIOPHYS ACTA, V955, P86, DOI 10.1016/0167-4838(88)90182-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERKESSEL A, 1991, BIOORG CHEM, V19, P101, DOI 10.1016/0045-2068(91)90047-S; BOKRANZ M, 1988, J BACTERIOL, V170, P568, DOI 10.1128/jb.170.2.568-577.1988; BONACKER LG, 1993, EUR J BIOCHEM, V217, P587, DOI 10.1111/j.1432-1033.1993.tb18281.x; BRNGER AT, 1992, XPLOR MANUAL VERSION; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COWTAN KD, 1994, PROTEIN CRYSTALLOGR, V31, P83; ELLEFSON WL, 1981, J BIOL CHEM, V256, P4259; ELLERMANN J, 1988, EUR J BIOCHEM, V172, P669, DOI 10.1111/j.1432-1033.1988.tb13941.x; Ermler U, 1997, STRUCTURE, V5, P635, DOI 10.1016/S0969-2126(97)00219-0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FARBER G, 1991, HELV CHIM ACTA, V74, P697, DOI 10.1002/hlca.19910740404; Goubeaud M, 1997, EUR J BIOCHEM, V243, P110, DOI 10.1111/j.1432-1033.1997.00110.x; HARTZELL PL, 1986, P NATL ACAD SCI USA, V83, P6726, DOI 10.1073/pnas.83.18.6726; HARTZELL PL, 1987, J BIOL CHEM, V262, P5581; HOGAN KB, 1991, NATURE, V354, P181, DOI 10.1038/354181a0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; JAUN B, 1990, HELV CHIM ACTA, V73, P2209, DOI 10.1002/hlca.19900730818; JAUN B, 1993, MET IONS BIOL SYST, V29, P287; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1992, PROTEIN CRYSTALLOGR, V26, P83; LIN SK, 1992, HELV CHIM ACTA, V75, P1478, DOI 10.1002/hlca.19920750504; LIN SK, 1991, HELV CHIM ACTA, V74, P1725, DOI 10.1002/hlca.19910740814; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; NOLL KM, 1986, BIOCHEM BIOPH RES CO, V139, P889, DOI 10.1016/S0006-291X(86)80261-3; Nolling J, 1996, INT J SYST BACTERIOL, V46, P1170, DOI 10.1099/00207713-46-4-1170; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PFALTZ A, 1982, HELV CHIM ACTA, V65, P828, DOI 10.1002/hlca.19820650320; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; ROSPERT S, 1991, FEBS LETT, V291, P371, DOI 10.1016/0014-5793(91)81323-Z; ROUVIERE PE, 1989, J BACTERIOL, V171, P4556, DOI 10.1128/jb.171.9.4556-4562.1989; SCOTT RA, 1986, FRONTIERS BIOINORGAN, P20; Sheldon Garrett Ward, 1991, P CCP4 STUD WEEK, P3; Shima S, 1997, J BIOCHEM, V121, P829, DOI 10.1093/oxfordjournals.jbchem.a021660; Thauer R, 1997, ANTON LEEUW INT J G, V71, P21, DOI 10.1023/A:1000149705588; WOLFE RS, 1991, ANNU REV MICROBIOL, V45, P1, DOI 10.1146/annurev.mi.45.100191.000245	46	418	445	3	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	1997	278	5342					1457	1462		10.1126/science.278.5342.1457	http://dx.doi.org/10.1126/science.278.5342.1457			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367957				2022-12-24	WOS:A1997YG85800043
J	Mannesse, CK; Derkx, FHM; deRidder, MAJ; MainintVeld, AJ; vanderCammen, TJM				Mannesse, CK; Derkx, FHM; deRidder, MAJ; MainintVeld, AJ; vanderCammen, TJM			Adverse drug reactions in elderly patients as contributing factor for hospital admission: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							OPERATIONAL ASSESSMENT; ALGORITHM		ERASMUS UNIV ROTTERDAM,INST EPIDEMIOL & BIOSTAT,ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	Mannesse, CK (corresponding author), UNIV HOSP ROTTERDAM DIJKZIGT,DEPT INTERNAL MED 1,DIV GERIATR MED,ROOM D442,DR MOLEWATERPLEIN 40,NL-3015 GD ROTTERDAM,NETHERLANDS.							*BRIT MED ASS ROYA, 1994, BRIT NAT FORM; Egberts TCG, 1996, BRIT MED J, V313, P530; HUTCHINSON TA, 1979, JAMA-J AM MED ASSOC, V242, P633, DOI 10.1001/jama.242.7.633; KRAMER MS, 1979, JAMA-J AM MED ASSOC, V242, P623, DOI 10.1001/jama.242.7.623; VANKRAAIJ DJW, 1994, NETH J MED, V44, P166	5	67	70	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1057	1058		10.1136/bmj.315.7115.1057	http://dx.doi.org/10.1136/bmj.315.7115.1057			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366733	Green Published			2022-12-24	WOS:A1997YD44500023
J	Rowe, T; Dascher, C; Bannykh, S; Plutner, H; Balch, WE				Rowe, T; Dascher, C; Bannykh, S; Plutner, H; Balch, WE			Role of vesicle-associated syntaxin 5 in the assembly of pre-Golgi intermediates	SCIENCE			English	Article							STOMATITIS-VIRUS GLYCOPROTEIN; ENDOPLASMIC-RETICULUM; PROTEIN-TRANSPORT; CELL-SURFACE; ALPHA-SNAP; FUSION; DOCKING; COPII; ACTIVATION; EXOCYTOSIS	Syntaxins are thought to function during vesicular transport as receptors on the target membrane and to contribute to the specificity of membrane docking and fusion by interacting with vesicle-associated receptors. Here, syntaxin 5 (Syn5) was shown to be an integral component of endoplasmic reticulum-derived transport vesicles. This pool, but not the target, Golgi-associated Syn5 pool, was essential for the assembly of vesicular-tubular pre-Golgi intermediates and the delivery of cargo to the Golgi. The requirement for vesicle-associated Syn5 in transport suggests a reevaluation of the basis for operation of the early secretory pathway.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Balch, WE (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	webalch@scripps.edu			NCI NIH HHS [CA58689] Funding Source: Medline; NIGMS NIH HHS [GM 42336] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; Dascher C, 1996, J BIOL CHEM, V271, P15866, DOI 10.1074/jbc.271.27.15866; DASCHER C, 1994, J BIOL CHEM, V269, P29363; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; Fleischer S, 1974, Methods Enzymol, V31, P6; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hui N, 1997, MOL BIOL CELL, V8, P1777, DOI 10.1091/mbc.8.9.1777; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; ROWE T, UNPUB; Sacher M, 1997, J BIOL CHEM, V272, P17134, DOI 10.1074/jbc.272.27.17134; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1991, J CELL SCI, V100, P415; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Steel GJ, 1996, EMBO J, V15, P745, DOI 10.1002/j.1460-2075.1996.tb00410.x; TANG BL, 1995, EUR J CELL BIOL, V68, P397; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	42	98	98	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	1998	279	5351					696	700		10.1126/science.279.5351.696	http://dx.doi.org/10.1126/science.279.5351.696			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445473				2022-12-24	WOS:000071731500034
J	Wang, YD; DuBois, JL; Hedman, B; Hodgson, KO; Stack, TDP				Wang, YD; DuBois, JL; Hedman, B; Hodgson, KO; Stack, TDP			Catalytic galactose oxidase models: Biomimetic Cu(II)-phenoxyl-radical reactivity	SCIENCE			English	Article							CRYSTAL-STRUCTURE; ACTIVE-SITE; COPPER; COMPLEXES; OXIDATION; ALCOHOLS; SYSTEM	Biomimetic functional models of the mononuclear copper enzyme galactose oxidase are presented that catalytically oxidize benzylic and allylic alcohols to aldehydes with O-2 under mild conditions, The mechanistic fidelity between the models and the natural system is pronounced. Modest structural mimicry proves sufficient to transfer an unusual ligand-based radical mechanism, previously unprecedented outside the protein matrix, to a simple chemical system.	Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Stanford University	Hedman, B (corresponding author), Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA.			Wang, Yadong/0000-0003-2067-382X	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050730, R01GM050730] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-01209] Funding Source: Medline; NIGMS NIH HHS [GM50730] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLPAS GJ, 1991, INORG CHEM, V30, P920, DOI 10.1021/ic00005a010; COOKSON PG, 1975, J ORGANOMET CHEM, V99, pC31, DOI 10.1016/S0022-328X(00)88466-1; DuBois JL, 1997, J AM CHEM SOC, V119, P8578, DOI 10.1021/ja9717673; FILIPPONI A, 1991, SOLID STATE COMMUN, V78, P265, DOI 10.1016/0038-1098(91)90194-Z; Groves John T., 1995, P3; GROVES JT, 1988, STUD ORG CHEM AMSTER, V33, P541; Halfen JA, 1997, J AM CHEM SOC, V119, P8217, DOI 10.1021/ja9700663; Hamilton G., 1973, OXIDASES RELATED RED, V1, P103; HAMILTON GA, 1978, J AM CHEM SOC, V100, P1899, DOI 10.1021/ja00474a042; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; KARLIN KD, 1994, J AM CHEM SOC, V116, P1324, DOI 10.1021/ja00083a018; KAU LS, 1987, J AM CHEM SOC, V109, P6433, DOI 10.1021/ja00255a032; KITAJIMA N, 1986, J CHEM SOC CHEM COMM, P1504, DOI 10.1039/c39860001504; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; KNOWLES PF, 1995, INORG CHEM, V34, P3895, DOI 10.1021/ic00119a010; KOCH WO, 1996, ANGEW CHEM INT EDIT, V34, P2671; LEE SC, 1993, INORG CHEM, V32, P4745, DOI 10.1021/ic00074a016; MARADUFU A, 1971, CAN J CHEMISTRY, V49, P3429, DOI 10.1139/v71-575; Marko IE, 1996, SCIENCE, V274, P2044, DOI 10.1126/science.274.5295.2044; MCMILLEN DF, 1982, ANNU REV PHYS CHEM, V33, P493, DOI 10.1146/annurev.pc.33.100182.002425; REGLIER M, 1990, J CHEM SOC CHEM COMM, P1752, DOI 10.1039/c39900001752; Sokolowski A, 1997, J AM CHEM SOC, V119, P8889, DOI 10.1021/ja970417d; SOKOLOWSKI A, 1996, J CHEM SOC CHEM COMM, P1671; SOLOMON EI, 1984, COMMENTS INORG CHEM, V0003, P00227; Wachter RM, 1996, J AM CHEM SOC, V118, P2782, DOI 10.1021/ja9519896; Wang YD, 1996, J AM CHEM SOC, V118, P13097, DOI 10.1021/ja9621354; WESTRE TE, 1995, J AM CHEM SOC, V117, P1566, DOI 10.1021/ja00110a012; WHITTAKER MM, 1993, BIOPHYS J, V64, P762, DOI 10.1016/S0006-3495(93)81437-1; WHITTAKER MM, 1989, J BIOL CHEM, V264, P7104; WOLFE WC, 1962, ANAL CHEM, V34, P1328, DOI 10.1021/ac60190a040; Zondervan C, 1997, CHEM COMMUN, P419, DOI 10.1039/a607779j	32	419	421	2	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					537	540		10.1126/science.279.5350.537	http://dx.doi.org/10.1126/science.279.5350.537			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438841				2022-12-24	WOS:000071616000038
J	O'Leary, TJ; Tellado, M; Buckner, SB; Ali, IS; Stevens, A; Ollayos, CW				O'Leary, TJ; Tellado, M; Buckner, SB; Ali, IS; Stevens, A; Ollayos, CW			PAPNET-assisted rescreening of cervical smears - Cost and accuracy compared with a 100% manual rescreening strategy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY ASSURANCE; NEGATIVE SMEARS; TESTING SYSTEM; BENEFITS; INCREASE; EFFICACY; CYTOLOGY	Context.-The Food and Drug Administration has recently approved several devices that use computerized image analysis to rescreen Papanicolaou (Pap) smears that have already been examined by cytotechnologists. Physicians and laboratories must decide whether the utility of these devices justifies the cost. Objective.-To determine the effectiveness and cost of PAPNET-assisted rescreening in identifying cervical abnormalities not identified by manual rescreening. Design.-PAPNET-assisted rescreening of 5478 Pap smears obtained in 1994 and 1995 previously identified as "within normal limits" or "benign changes" on both initial and random screening. Patients.-Female service members and dependents aged 12 to 88 years. Setting.-Air Force clinics in the United States and Japan. Intervention.-Rescreening of Pap smears by PAPNET, followed by reevaluation of abnormal smears by the consensus panel, consisting of 3 cytotechnologists and 3 pathologists. Main Outcome Measures.-Proportion of Pap smears initially screened as normal identified as abnormal by both PAPNET and consensus panel; costs of rescreening. Results.-PAPNET screening identified 1614 (29%) slides requiring additional microscopic review, On further review, 448 (8% of total) had possibly abnormal cells, Ultimately, 11 of these cases were reviewed by the consensus panel for potentially atypical cells, Of these 11 cases, 5 were reclassified as atypical squamous cells of undetermined significance (ASCUS) and 1 as atypical glandular cells of undetermined significance (AGUS). No additional squamous intraepithelial neoplasia (SIL) was identified in these smears; the patient with a diagnosis of AGUS on rescreening was diagnosed as having a low-grade SIL (LSIL) on follow-up, Costs were $5825 to $33 781 for each additional ASCUS or AGUS diagnosis, A cost of $17 475 to $101 343 is expected for each case of LSIL identified by PAPNET-assisted rescreening and not by traditional manual rescreening. Conclusions.-PAPNET-assisted rescreening identified a few more cases of ASCUS than did manual rescreening, but at a relatively high cost, The costs of rescreening should be carefully compared with the expected efficacy in reducing cervical cancer mortality.	Armed Forces Inst Pathol, Dept Cellular Pathol, Washington, DC 20306 USA	United States Department of Defense	O'Leary, TJ (corresponding author), Armed Forces Inst Pathol, Dept Cellular Pathol, 14th St & Alaska Ave NW, Washington, DC 20306 USA.	tjo@afip.mil	Oleary, Timothy/AAE-5219-2021; Oleary, Timothy/AAF-2829-2021	O'LEARY, TIMOTHY/0000-0002-2435-9136				ASHFAQ R, 1995, DIAGN CYTOPATHOL, V13, P31, DOI 10.1002/dc.2840130108; BOON ME, 1993, DIAGN CYTOPATHOL, V9, P411, DOI 10.1002/dc.2840090408; BOON ME, 1994, MODERN PATHOL, V7, P957; Boon ME, 1996, ACTA CYTOL, V40, P1109; CRANE M, 1996, MED ECON, P177; HENDEE WR, 1989, JAMA-J AM MED ASSOC, V262, P1672; HUSAIN OAN, 1994, ANAL CELL PATHOL, V6, P157; Hutchinson ML, 1996, ACTA CYTOL, V40, P4; KAMINSKY FC, 1995, ACTA CYTOL, V39, P232; Kok MR, 1996, CANCER, V78, P112, DOI 10.1002/(SICI)1097-0142(19960701)78:1<112::AID-CNCR16>3.0.CO;2-2; KOSS LG, 1994, AM J CLIN PATHOL, V101, P220, DOI 10.1093/ajcp/101.2.220; Mango LJ, 1996, ACTA CYTOL, V40, P138; NEUHAUSER D, 1975, NEW ENGL J MED, V293, P226, DOI 10.1056/NEJM197507312930504; OUWERKERKNOORDAM E, 1994, CYTOPATHOLOGY, V5, P211, DOI 10.1111/j.1365-2303.1994.tb00422.x; Patten SF, 1996, ACTA CYTOL, V40, P45; Rosenthal DL, 1996, ACTA CYTOL, V40, P120; Ryan MR, 1996, AM J CLIN PATHOL, V105, P711; SCHWARZ PJ, 1981, PUBLIC HEALTH REP, V96, P547; SHERMAN ME, 1994, MODERN PATHOL, V7, P578; SLAGEL DD, 1995, DIAGN CYTOPATHOL, V13, P26, DOI 10.1002/dc.2840130107; Vooijs GP, 1996, ACTA CYTOL, V40, P14; Vuong P. N., 1995, Archives d'Anatomie et de Cytologie Pathologiques, V43, P147; Waugh N, 1996, CYTOPATHOLOGY, V7, P249, DOI 10.1046/j.1365-2303.1996.40182401.x; Wied GL, 1996, ACTA CYTOL, V40, P1; Wilbur DC, 1996, ACTA CYTOL, V40, P127	25	60	61	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					235	237		10.1001/jama.279.3.235	http://dx.doi.org/10.1001/jama.279.3.235			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR124	9438746	Bronze			2022-12-24	WOS:000071460700036
J	Ahsan, H; Neugut, AI				Ahsan, H; Neugut, AI			Radiation therapy for breast cancer and increased risk for esophageal carcinoma	ANNALS OF INTERNAL MEDICINE			English	Article							LUNG-CANCER; TUMORS; CHEMOTHERAPY	Background: Several case reports have suggested an association between radiation therapy for breast cancer and the subsequent occurrence of esophageal carcinomas. Objective: To examine the association between radiation therapy for breast cancer and subsequent esophageal squamous-cell carcinomas and adenocarcinomas. Design: Population-based retrospective cohort study. Setting: Population-based U.S. cancer registries. Patients: 220 806 women in whom breast cancer was diagnosed between 1 January 1973 and 31 December 1993; 1 216 853 person-years of follow-up. Measurements: Age- and period-adjusted standardized incidence ratio as a measure of relative risk for the second primary cancer. Results: In women who had received radiation therapy for breast cancer, the relative risk for esophageal squamous-cell carcinoma increased to 5.42 (95% CI, 2.33 to 10.68) and the relative risk for esophageal adenocarcinoma increased to 4.22 (CI, 0.47 to 15.25) 10 or more years after radiation therapy. No increased risk was seen for either type of carcinoma among patients with breast cancer who did not receive radiation therapy. Conclusion: The risk for esophageal carcinoma is increased in women who receive radiation therapy for breast cancer.	Columbia Univ, Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, Div Oncol, New York, NY 10032 USA	Columbia University; Columbia University	Ahsan, H (corresponding author), Columbia Univ, Sch Publ Hlth, Div Epidemiol, 600 W 168th St, New York, NY 10032 USA.							Ahsan H, 1997, CANCER EPIDEM BIOMAR, V6, P779; AHSAN H, 1995, J CLIN ONCOL, V13, P2931, DOI 10.1200/JCO.1995.13.12.2931; BRESLOW NE, 1987, IARC SCI PUBL, V82, P65; Cartei G, 1996, EUR J CANCER PREV, V5, P400; DAVIS FG, 1989, CANCER RES, V49, P6130; DOLL R, 1981, BRIT J RADIOL, V54, P179, DOI 10.1259/0007-1285-54-639-179; Fekete F, 1994, Dysphagia, V9, P289; GATES O, 1968, AM J PATHOL, V53, P667; GOFFMAN TE, 1983, CANCER, V52, P1808, DOI 10.1002/1097-0142(19831115)52:10<1808::AID-CNCR2820521008>3.0.CO;2-W; Greenberg PAC, 1996, J CLIN ONCOL, V14, P2197, DOI 10.1200/JCO.1996.14.8.2197; HARRIS JR, 1988, INT J RADIAT ONCOL, V15, P497, DOI 10.1016/S0360-3016(98)90034-7; INSKIP PD, 1994, J NATL CANCER I, V86, P983, DOI 10.1093/jnci/86.13.983; Kelsey JL., 1996, METHODS OBSERVATIONA; *NAT AC SCI, 1980, BIOL EFF ION RAD EFF, P431; NEUGUT AI, 1993, CANCER, V71, P3054, DOI 10.1002/1097-0142(19930515)71:10<3054::AID-CNCR2820711027>3.0.CO;2-N; Neugut AI, 1997, CANCER, V79, P1600, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1600::AID-CNCR24>3.0.CO;2-0; OCONNELL EW, 1984, GASTROINTEST RADIOL, V9, P287, DOI 10.1007/BF01887853; SHERRILL DJ, 1984, CANCER, V54, P726, DOI 10.1002/1097-0142(1984)54:4<726::AID-CNCR2820540422>3.0.CO;2-X; SHIMIZU T, 1990, JPN J SURG, V20, P97, DOI 10.1007/BF02470720; *SURV EP END RES S, 1996, PROGR PUBL US DAT 19; THOMPSON DE, 1994, RADIAT RES, V137, pS17, DOI 10.2307/3578892; VANAGUNAS A, 1990, AM J GASTROENTEROL, V85, P808; WANG JX, 1990, INT J CANCER, V45, P889, DOI 10.1002/ijc.2910450519	23	74	74	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1998	128	2					114	117		10.7326/0003-4819-128-2-199801150-00007	http://dx.doi.org/10.7326/0003-4819-128-2-199801150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR200	9441571				2022-12-24	WOS:000071470800006
J	Gill, TM; Robison, JT; Tinetti, ME				Gill, TM; Robison, JT; Tinetti, ME			Difficulty and dependence: Two components of the disability continuum among community-living older persons	ANNALS OF INTERNAL MEDICINE			English	Article						activities of daily living; aged; disabled persons; independent living; geriatric assessment	PHYSICAL-DISABILITY; FUNCTIONAL STATUS; ADULTS; PREDICTORS; ELDERS; HEALTH; POPULATIONS; IMPAIRMENT; DESIGN; FALLS	Background: Although most epidemiologic studies have defined disability in basic activities of daily living (BADLs) as dependence, some investigators have argued that BADL disability should be defined as degree of difficulty. Objective: To determine whether the responses to questions about difficulty and dependence provide complementary information that together can depict the continuum of disability more fully than the response to either question alone. Setting: General community. Participants: 1065 persons 72 years of age and older. Measurements: On the basis of self-reported information collected at baseline, participants were categorized into three BADL groups: independent without difficulty, independent with difficulty, and dependent. Additional baseline information was collected on several measures of higher-level function and physical performance. Follow-up information was collected on regular home care visits and BADL function at 1 and 3 years and on hospitalizations, admissions to skilled-nursing facilities, and deaths over a 4-year period. Results: In a cross-sectional analysis, the proportion of participants with poor higher-level function and physical performance increased substantially across the three BADL groups. In a longitudinal analysis, the rates of hospitalization and regular home care visits for the independent without difficulty group, the independent with difficulty group, and the dependent group were 46%, 57%, and 72% (P < 0.001) and 17%, 30%, and 49% (P < 0.001), respectively; survival curves for admission to a skilled-nursing facility and death differed significantly for each pair-wise comparison. Among persons who were BADL independent, those with difficulty were significantly more likely to develop BADL dependence over a 3-year period than those without difficulty (31% compared with 18%; P < 0.001). Conclusions: In the assessment of BADL function in older persons, questions about difficulty and dependence provide complementary information that together can depict the continuum of disability more fully than either question alone.	Yale Univ, Sch Med, Genet Program, New Haven, CT 06504 USA	Yale University	Gill, TM (corresponding author), Yale Univ, Sch Med, Genet Program, Room 17B-TMP,POB 208025, New Haven, CT 06504 USA.		Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368	NATIONAL INSTITUTE ON AGING [R01AG007449, T32AG000153, P60AG010469] Funding Source: NIH RePORTER; NIA NIH HHS [5T32-AG00153, P60 AG-10469, R01 AG-07449] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENVENUTI F, 1995, J AM GERIATR SOC, V43, P479, DOI 10.1111/j.1532-5415.1995.tb06092.x; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; Crawford SL, 1997, J AM GERIATR SOC, V45, P338, DOI 10.1111/j.1532-5415.1997.tb00950.x; DIPIETRO L, 1993, MED SCI SPORT EXER, V25, P628; ETTINGER WH, 1994, J AM GERIATR SOC, V42, P1035, DOI 10.1111/j.1532-5415.1994.tb06206.x; FERRUCCI L, 1991, J GERONTOL, V46, pM52, DOI 10.1093/geronj/46.2.M52; Ferrucci L, 1996, J CLIN EPIDEMIOL, V49, P1089, DOI 10.1016/0895-4356(96)00231-4; FILLENBAUM GG, 1981, J GERONTOL, V36, P428, DOI 10.1093/geronj/36.4.428; Fried LP, 1996, J GERONTOL A-BIOL, V51, pM206, DOI 10.1093/gerona/51A.5.M206; FRIED LP, 1994, J CLIN EPIDEMIOL, V47, P747, DOI 10.1016/0895-4356(94)90172-4; GILL TM, 1995, J GERONTOL A-BIOL, V50, pM235, DOI 10.1093/gerona/50A.5.M235; GILL TM, 1995, J AM GERIATR SOC, V43, P603, DOI 10.1111/j.1532-5415.1995.tb07192.x; Gill TM, 1996, J GERONTOL A-BIOL, V51, pM283, DOI 10.1093/gerona/51A.6.M283; Gill TM, 1997, J GEN INTERN MED, V12, P757, DOI 10.1046/j.1525-1497.1997.07161.x; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; HARRIS T, 1989, AM J PUBLIC HEALTH, V79, P698, DOI 10.2105/AJPH.79.6.698; JETTE AM, 1994, SOC SCI MED, V38, P937, DOI 10.1016/0277-9536(94)90426-X; JETTE AM, 1985, J CHRON DIS, V38, P59, DOI 10.1016/0021-9681(85)90008-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; KEIL JE, 1989, J CLIN EPIDEMIOL, V42, P521, DOI 10.1016/0895-4356(89)90148-0; Kempen GIJM, 1996, SOC SCI MED, V43, P1601, DOI 10.1016/S0277-9536(96)00057-3; KEMPEN GIJM, 1990, GERONTOLOGIST, V30, P497, DOI 10.1093/geront/30.4.497; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PINSKY JL, 1987, J CHRON DIS, V40, pS159, DOI 10.1016/S0021-9681(87)80045-0; REUBEN DB, 1995, J AM GERIATR SOC, V43, P936, DOI 10.1111/j.1532-5415.1995.tb05540.x; ROOS NP, 1991, AM J PUBLIC HEALTH, V81, P63, DOI 10.2105/AJPH.81.1.63; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806; TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140; VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1; WIENER JM, 1990, J GERONTOL, V45, pS229, DOI 10.1093/geronj/45.6.S229	35	184	184	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1998	128	2					96	+		10.7326/0003-4819-128-2-199801150-00004	http://dx.doi.org/10.7326/0003-4819-128-2-199801150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YR200	9441588				2022-12-24	WOS:000071470800003
J	Fraser, CM; Casjens, S; Huang, WM; Sutton, GG; Clayton, R; Lathigra, R; White, O; Ketchum, KA; Dodson, R; Hickey, EK; Gwinn, M; Dougherty, B; Tomb, JF; Fleischmann, RD; Richardson, D; Peterson, J; Kerlavage, AR; Quackenbush, J; Salzberg, S; Hanson, M; vanVugt, R; Palmer, N; Adams, MD; Gocayne, J; Weidman, J; Utterback, T; Watthey, L; McDonald, L; Artiach, P; Bowman, C; Garland, S; Fujii, C; Cotton, MD; Horst, K; Roberts, K; Hatch, B; Smith, HO; Venter, JC				Fraser, CM; Casjens, S; Huang, WM; Sutton, GG; Clayton, R; Lathigra, R; White, O; Ketchum, KA; Dodson, R; Hickey, EK; Gwinn, M; Dougherty, B; Tomb, JF; Fleischmann, RD; Richardson, D; Peterson, J; Kerlavage, AR; Quackenbush, J; Salzberg, S; Hanson, M; vanVugt, R; Palmer, N; Adams, MD; Gocayne, J; Weidman, J; Utterback, T; Watthey, L; McDonald, L; Artiach, P; Bowman, C; Garland, S; Fujii, C; Cotton, MD; Horst, K; Roberts, K; Hatch, B; Smith, HO; Venter, JC			Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi	NATURE			English	Article							RIBOSOMAL-RNA GENES; LINEAR CHROMOSOME; CIRCULAR-PLASMID; ESCHERICHIA-COLI; AGENT; REPLICATION; ORGANIZATION; INFECTIVITY; ORIGIN; DNA	The genome of the bacterium Borrelia burgdorferi B31, the aetiologic agent of Lyme disease, contains a linear chromosome of 910,725 base pairs and at least 17 linear and circular plasmids with a combined size of more than 533,000 base pairs. The chromosome contains 853 genes encoding a basic set of proteins for DNA replication, transcription, translation, solute transport and energy metabolism, but, like Mycoplasma genitalium, it contains no genes for cellular biosynthetic reactions. Because B. burgdorferi and M. genitalium are distantly related eubacteria, we suggest that their limited metabolic capacities reflect convergent evolution by gene loss from more metabolically competent progenitors. Of 430 genes on 11 plasmids, most have no known biological function; 39% of plasmid genes are paralogues that form 47 gene families. The biological significance of the multiple plasmid-encoded genes is not clear, although they may be involved in antigenic variation or immune evasion.	UNIV UTAH,DEPT ONCOL SCI,DIV MOL BIOL & GENET,SALT LAKE CITY,UT 84132; MEDIMMUNE INC,GAITHERSBURG,MD 20878	Utah System of Higher Education; University of Utah; AstraZeneca; Medimmune	Fraser, CM (corresponding author), INST GENOM RES,9712 MED CTR DR,ROCKVILLE,MD 20850, USA.		Salzberg, Steven L/F-6162-2011; Salzberg, Steven/Q-6514-2019	Salzberg, Steven L/0000-0002-8859-7432; Salzberg, Steven/0000-0002-8859-7432; Fraser, Claire/0000-0003-1462-2428; Quackenbush, John/0000-0002-2702-5879; Kerlavage, Anthony/0000-0002-3954-9653				BARBOUR AG, 1986, MICROBIOL REV, V50, P381, DOI 10.1128/MMBR.50.4.381-400.1986; BARBOUR AG, 1988, J CLIN MICROBIOL, V26, P475, DOI 10.1128/JCM.26.3.475-478.1988; BARBOUR AG, 1987, SCIENCE, V237, P409, DOI 10.1126/science.3603026; BARBOUR AG, 1983, CURR MICROBIOL, V8, P123, DOI 10.1007/BF01566969; BARBOUR AG, 1996, J BACTERIOL, V178, P6625; BARIL C, 1989, RES MICROBIOL, V140, P507, DOI 10.1016/0923-2508(89)90083-1; BRANDT ME, 1990, INFECT IMMUN, V58, P983, DOI 10.1128/IAI.58.4.983-991.1990; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; Casjens S, 1997, MOL MICROBIOL, V26, P581, DOI 10.1046/j.1365-2958.1997.6051963.x; CASJENS S, 1993, MOL MICROBIOL, V8, P967, DOI 10.1111/j.1365-2958.1993.tb01641.x; CASJENS S, 1995, J BACTERIOL, V177, P2769, DOI 10.1128/jb.177.10.2769-2780.1995; Casjens S, 1997, J BACTERIOL, V179, P217, DOI 10.1128/jb.179.1.217-227.1997; CASJENS S, IN PRESS BACTERIAL G; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CUMOW AW, 1997, P NATL ACAD SCI USA, V94, P11819; DAVIDSON BE, 1992, J BACTERIOL, V174, P3766, DOI 10.1128/JB.174.11.3766-3774.1992; DUNN JJ, 1994, J BACTERIOL, V176, P2706, DOI 10.1128/JB.176.9.2706-2717.1994; FERDOWS MS, 1989, P NATL ACAD SCI USA, V86, P5969, DOI 10.1073/pnas.86.15.5969; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; GAZUMYAN A, 1994, GENE, V146, P57, DOI 10.1016/0378-1119(94)90833-8; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HINNEBUSCH J, 1990, MOL MICROBIOL, V4, P811, DOI 10.1111/j.1365-2958.1990.tb00651.x; HINNEBUSCH J, 1992, J BACTERIOL, V174, P5251, DOI 10.1128/JB.174.16.5251-5257.1992; IBBA M, IN PRESS P NATL ACAD; JOHNSON RC, 1984, INT J SYST BACTERIOL, V34, P496, DOI 10.1099/00207713-34-4-496; KITTEN T, 1990, P NATL ACAD SCI USA, V87, P6077, DOI 10.1073/pnas.87.16.6077; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; NORRIS SJ, 1995, INFECT IMMUN, V63, P2206, DOI 10.1128/IAI.63.6.2206-2212.1995; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; OJAIMI C, 1994, MICROBIOL-SGM, V140, P2931, DOI 10.1099/13500872-140-11-2931; OLD IG, 1992, FEMS MICROBIOL LETT, V99, P245, DOI 10.1111/j.1574-6968.1992.tb05575.x; Reizer J, 1996, Microb Comp Genomics, V1, P151; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; SADZIENE A, 1992, J EXP MED, V176, P799, DOI 10.1084/jem.176.3.799; SALZBERG S, IN PRESS NUCL ACIDS; SCHWAN TG, 1988, INFECT IMMUN, V56, P1831, DOI 10.1128/IAI.56.8.1831-1836.1988; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TRAKTMAN P, 1996, DNA REPLICATION EUKA, P775; Xu YN, 1996, INFECT IMMUN, V64, P3870, DOI 10.1128/IAI.64.9.3870-3876.1996; Zhang JR, 1997, CELL, V89, P275, DOI 10.1016/S0092-8674(00)80206-8; Zuckert WR, 1996, J BACTERIOL, V178, P2287	49	1645	2156	3	111	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					580	586		10.1038/37551	http://dx.doi.org/10.1038/37551			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403685				2022-12-24	WOS:A1997YK85300040
J	Nightingale, SL				Nightingale, SL			Interim recommendations issued for patients exposed to fenfluramine and dexfenfluramine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1728	1728						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388135				2022-12-24	WOS:A1997YH98700007
J	Kamijo, T; Zindy, F; Roussel, MF; Quelle, DE; Downing, JR; Ashmun, RA; Grosveld, G; Sherr, CJ				Kamijo, T; Zindy, F; Roussel, MF; Quelle, DE; Downing, JR; Ashmun, RA; Grosveld, G; Sherr, CJ			Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19(ARF)	CELL			English	Article							AUSTRALIAN MELANOMA KINDREDS; CELL-CYCLE INHIBITION; FAMILIAL MELANOMA; HUMAN CANCERS; SPONTANEOUS IMMORTALIZATION; RETINOBLASTOMA-PROTEIN; P16(INK4) EXPRESSION; EMBRYO FIBROBLASTS; P53-DEFICIENT MICE; CDK INHIBITORS	The INK4a tumor suppressor locus encodes p16(INK4a), an inhibitor of cyclin D-dependent kinases, and p19(ARF), an alternative reading frame protein that also blocks cell proliferation. Surprisingly, mice lacking p19(ARF) but expressing functional p16(INK4a) develop tumors early in life. Their embryo fibroblasts (MEFs) do not senesce and are transformed by oncogenic Ha-ras alone. Conversion of ARF(+/+) or ARF(+/-) MEF strains to continuously proliferating cell lines involves loss of either p19(ARF) or p53. p53-mediated checkpoint control is unperturbed in ARF-null fibroblast strains, whereas p53-negative cell lines are resistant to p19(ARF)-induced growth arrest. Therefore, INK4a encodes growth inhibitory proteins that act upstream of the retinoblastoma protein and p53. Mutations and deletions targeting this locus in cancer cells are unlikely to be functionally equivalent.	ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT PATHOL & LAB MED, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT EXPT ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital			Roussel, Martine F/F-1469-2016; Sherr, Charles J/N-8074-2018; Downing, James R./N-8102-2018	Roussel, Martine F/0000-0002-1740-8139; Sherr, Charles J/0000-0002-5516-6206; Quelle, Dawn/0000-0001-8776-0122	NCI NIH HHS [CA71907, CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA071907, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DURO D, 1995, ONCOGENE, V11, P21; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; FUKUSAWA K, 1996, SCIENCE, V271, P1744; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hara E, 1996, MOL CELL BIOL, V16, P859; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HARVEY M, 1993, ONCOGENE, V8, P2457; Herzog CR, 1996, ONCOGENE, V13, P1885; HIRAMA T, 1995, BLOOD, V86, P841; Holland EA, 1995, ONCOGENE, V11, P2289; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kubo Y, 1997, BIOCHEM BIOPH RES CO, V232, P38, DOI 10.1006/bbrc.1997.6217; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NAITO M, 1989, CARCINOGENESIS, V3, P187; Noble JR, 1996, ONCOGENE, V13, P1259; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Parry D, 1996, MOL CELL BIOL, V16, P3844; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; QUELLE DE, 1997, P NATL ACAD SCI USA, V94, P3436; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REINERS JJ, 1984, CARCINOGENESIS, V5, P301, DOI 10.1093/carcin/5.3.301; REYMOND A, 1995, ONCOGENE, V11, P1173; Reznikoff CA, 1996, CANCER RES, V56, P2886; RITTLING SR, 1992, ONCOGENE, V7, P935; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P6200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STONE S, 1995, CANCER RES, V55, P2988; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; Tanaka H, 1997, INT J CANCER, V70, P437, DOI 10.1002/(SICI)1097-0215(19970207)70:4<437::AID-IJC11>3.3.CO;2-I; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VANDEURSEN J, 1995, P NATL ACAD SCI USA, V92, P7376, DOI 10.1073/pnas.92.16.7376; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WICK ST, 1995, ONCOGENE, V11, P2013; YANG R, 1995, CANCER RES, V55, P2503; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	65	1329	1377	0	25	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 28	1997	91	5					649	659		10.1016/S0092-8674(00)80452-3	http://dx.doi.org/10.1016/S0092-8674(00)80452-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393858	Bronze			2022-12-24	WOS:A1997YH96000012
J	Kumar, A; Commane, M; Flickinger, TW; Horvath, CM; Stark, GR				Kumar, A; Commane, M; Flickinger, TW; Horvath, CM; Stark, GR			Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; TARGETED DISRUPTION; INTERFERON-ALPHA; ACTIVATION; TRANSCRIPTION; INHIBITION; PATHWAY; GAMMA; GENE; PROTEINS	Signal transducers and activators of transcription (STATs) enhance transcription of specific genes in response to cytokines and growth factors. STAT1 is also required for efficient constitutive expression of the caspases Ice, Cpp32, and Ich-l in human fibroblasts. As a consequence, STAT1-null cells are resistant to apoptosis by tumor necrosis factor alpha (TNF-alpha). Reintroduction of STAT1 alpha restored both TNF-alpha-induced apoptosis and the expression of Ice, Cpp32, and Ich-1. Variant STAT1 proteins carrying point mutations that inactivate domains required for STAT dimer formation nevertheless restored protease expression and sensitivity to apoptosis, indicating that the functions of STAT1 required for these activities are different from those that mediate induced gene expression.	CLEVELAND CLIN FDN,LERNER RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195; ROCKEFELLER UNIV,MOL CELL BIOL LAB,NEW YORK,NY 10021	Cleveland Clinic Foundation; Rockefeller University				Horvath, Curt/0000-0003-2449-225X	NCI NIH HHS [P01 CA62220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHATTERJEEKISHO.M, UNPUB; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FRAER A, 1996, CELL, V85, P781; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; HOVANESIAN AG, 1993, SEMIN VIROL, V4, P23; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LEUNG SY, UNPUB; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RUBEN BY, 1988, CANCER RES, V48, P6006; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Wilson Z. E., UNPUB	27	430	438	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1630	1632		10.1126/science.278.5343.1630	http://dx.doi.org/10.1126/science.278.5343.1630			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374464				2022-12-24	WOS:A1997YJ87400043
J	Sijbesma, RP; Beijer, FH; Brunsveld, L; Folmer, BJB; Hirschberg, JHKK; Lange, RFM; Lowe, JKL; Meijer, EW				Sijbesma, RP; Beijer, FH; Brunsveld, L; Folmer, BJB; Hirschberg, JHKK; Lange, RFM; Lowe, JKL; Meijer, EW			Reversible polymers formed from self-complementary monomers using quadruple hydrogen bonding	SCIENCE			English	Article							ASSOCIATION CHAIN POLYMERS; COPOLYMERS	Units of 2-ureido-4-pyrimidone that dimerize strongly in a self-complementary array of four cooperative hydrogen bonds were used as the associating end group in reversible self-assembling polymer systems. The unidirectional design of the binding sites prevents uncontrolled multidirectional association or gelation. Linear polymers and reversible networks were formed from monomers with two and three binding sites, respectively. The thermal and environmental control over lifetime and bond strength makes many properties, such as viscosity, chain length, and composition, tunable in a way not accessible to traditional polymers. Hence, polymer networks with thermodynamically controlled architectures can be formed, for use in, for example, coatings and hot melts, where a reversible, strongly temperature-dependent rheology is highly advantageous.	EINDHOVEN UNIV TECHNOL,ORGAN CHEM LAB,NL-5600 MB EINDHOVEN,NETHERLANDS; DSM RES BV,NL-6160 MD GELEEN,NETHERLANDS	Eindhoven University of Technology; DSM NV			Sijbesma, Rintje Pieter P/D-3551-2012; Lewis, Christopher L/I-8254-2015; Meijer, E.W./K-7632-2013	Sijbesma, Rintje Pieter P/0000-0002-8975-636X; Meijer, E.W./0000-0003-4126-7492; Brunsveld, Luc/0000-0001-5675-511X				Aggeli A, 1997, NATURE, V386, P259, DOI 10.1038/386259a0; ALEXANDER C, 1994, MACROMOL SYMP, V77, P283, DOI 10.1002/masy.19940770130; BEIJER FH, UNPUB; BLADON P, 1993, MACROMOLECULES, V26, P6604, DOI 10.1021/ma00076a045; CATES ME, 1987, MACROMOLECULES, V20, P2289, DOI 10.1021/ma00175a038; DUCHARME Y, 1988, J ORG CHEM, V53, P5787, DOI 10.1021/jo00259a037; EISENBACH CD, 1995, MACROMOL CHEM PHYSIC, V196, P1077, DOI 10.1002/macp.1995.021960410; Flory P. J, 1953, PRINCIPLES POLYM CHE; Fouquey C., 1990, ADV MATER, V2, P254; HILGER C, 1992, MACROMOLECULES, V25, P2498, DOI 10.1021/ma00035a031; KOTERA M, 1994, J CHEM SOC CHEM COMM, P197, DOI 10.1039/c39940000197; LEE CM, 1994, POLYMER, V35, P4550, DOI 10.1016/0032-3861(94)90801-X; LEHN JM, 1993, MAKROMOL CHEM-M SYMP, V69, P1, DOI 10.1002/masy.19930690103; LILLYA CP, 1992, MACROMOLECULES, V25, P2076, DOI 10.1021/ma00034a003; MOLLER M, 1987, ACS S SER, V350, pCH7; MURRAY TJ, 1992, J AM CHEM SOC, V114, P4010, DOI 10.1021/ja00036a079; STPOURCAIN CB, 1995, MACROMOLECULES, V28, P4116, DOI 10.1021/ma00116a010	17	1851	1923	31	835	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1601	1604		10.1126/science.278.5343.1601	http://dx.doi.org/10.1126/science.278.5343.1601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374454				2022-12-24	WOS:A1997YJ87400033
J	Higgins, RM; West, N; Edmunds, ME; Dukes, DC; Kashi, H; Jurewicz, A; Lam, FT				Higgins, RM; West, N; Edmunds, ME; Dukes, DC; Kashi, H; Jurewicz, A; Lam, FT			Effect of a strict HLA matching policy on distribution of cadaveric kidney transplants to Indo-Asian and white European recipients: regional study	BRITISH MEDICAL JOURNAL			English	Article									WALSGRAVE GEN HOSP,TRANSPLANT UNIT,COVENTRY CV2 2DX,W MIDLANDS,ENGLAND		Higgins, RM (corresponding author), WALSGRAVE GEN HOSP,DIALYSIS UNIT,COVENTRY CV2 2DX,W MIDLANDS,ENGLAND.							GASTON RS, 1993, JAMA-J AM MED ASSOC, V270, P1352, DOI 10.1001/jama.270.11.1352; HIGGINS RM, 1995, Q J MED, V89, P522; TAKIFF H, 1988, TRANSPLANTATION, V45, P410, DOI 10.1097/00007890-198802000-00033	3	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 22	1997	315	7119					1354	1355		10.1136/bmj.315.7119.1354	http://dx.doi.org/10.1136/bmj.315.7119.1354			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402778	Green Published			2022-12-24	WOS:A1997YJ21800025
J	Rosen, ED; Chan, JCY; Idusogie, E; Clotman, F; Vlasuk, G; Luther, T; Jalbert, LR; Albrecht, S; Zhong, L; Lissens, A; Schoonjans, L; Moons, L; Collen, D; Castellino, FJ; Carmeliet, P				Rosen, ED; Chan, JCY; Idusogie, E; Clotman, F; Vlasuk, G; Luther, T; Jalbert, LR; Albrecht, S; Zhong, L; Lissens, A; Schoonjans, L; Moons, L; Collen, D; Castellino, FJ; Carmeliet, P			Mice lacking factor VII develop normally but suffer fatal perinatal bleeding	NATURE			English	Article							VISCERAL YOLK-SAC; TISSUE FACTOR; BLOOD-COAGULATION; EXPRESSION; INITIATOR; DEFICIENT; BIOLOGY; PROTEIN; EMBRYOS; CELLS	Blood coagulation in vivo is initiated by factor VII (FVII) binding to its cellular receptor tissue factor (TF)(1-4). FVII is the only known ligand for TF, so it was expected that FVII-deficient embryos would have a similar phenotype to TF-deficient embryos, which have defective vitello-embryonic circulation and die around 9.5 days of gestation(5-8), Surprisingly, we find that FVII-deficient (FVII-/-) embryos developed normally, FVII-/- mice succumbed perinatally because of fatal haemorrhaging from normal blood vessels. At embryonic day 9.5, maternal-fetal transfer of FVII was undetectable and survival of embryos did not depend on TF-FVII-initiated fibrin formation. Thus, the TF-/- embryonic lethal and the FVII-/- survival-phenotypes suggest a role for TF during embryogenesis beyond fibrin formation.	FLANDERS INTERUNIV, INST BIOTECHNOL, CTR TRANSGENE TECHNOL & GENE THERAPY, B-3000 LOUVAIN, BELGIUM; UNIV NOTRE DAME, CTR TRANSGENE RES, NOTRE DAME, IN 46556 USA; UNIV NOTRE DAME, DEPT CHEM & BIOCHEM, NOTRE DAME, IN 46556 USA; UNIV LOUVAIN, LAB DEV GENET, B-1348 LOUVAIN, BELGIUM; CORVAS INT INC, SAN DIEGO, CA 92121 USA; TECH UNIV DRESDEN, INST PATHOL, D-01307 DRESDEN, GERMANY	University of Notre Dame; University of Notre Dame; Technische Universitat Dresden			Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821; Moons, Lieve (Godelieve)/0000-0003-0186-1411				Albrecht S, 1996, THROMB HAEMOSTASIS, V75, P772; Auerbach R, 1996, STEM CELLS, V14, P269, DOI 10.1002/stem.140269; BEEBY TL, 1993, THROMB HAEMOSTASIS, V70, P465; BOURGET P, 1995, CLIN PHARMACOKINET, V28, P161, DOI 10.2165/00003088-199528020-00006; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P6258, DOI 10.1073/pnas.93.13.6258; Camerer E, 1996, THROMB RES, V81, P1, DOI 10.1016/0049-3848(95)00209-X; Carmeliet P, 1997, AM J PATHOL, V150, P761; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; FREEMAN SJ, 1981, J EMBRYOL EXP MORPH, V66, P223; FREEMAN SJ, 1983, J EMBRYOL EXP MORPH, V73, P307; Idusogie E, 1996, THROMB HAEMOSTASIS, V75, P481; ISHII S, 1995, ARZNEIMITTEL-FORSCH, V45-1, P644; KUMADA T, 1988, BLOOD, V71, P728; LANDOR M, 1995, ANN ALLERG ASTHMA IM, V74, P279; Luther T, 1996, AM J PATHOL, V149, P101; MORRISSEY JH, 1993, BLOOD, V81, P734; NEMERSON Y, 1995, THROMB HAEMOSTASIS, V74, P180; PETERSEN LC, 1995, THROMB RES, V79, P1, DOI 10.1016/0049-3848(95)00069-4; Sato Y, 1996, THROMB HAEMOSTASIS, V75, P389; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Stanssens P, 1996, P NATL ACAD SCI USA, V93, P2149, DOI 10.1073/pnas.93.5.2149; Toomey JR, 1997, P NATL ACAD SCI USA, V94, P6922, DOI 10.1073/pnas.94.13.6922; Toomey JR, 1996, BLOOD, V88, P1583; VANMAELEFABRY G, 1995, TOXICOL IN VITRO, V9, P671, DOI 10.1016/0887-2333(95)00064-F	29	181	185	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					290	294		10.1038/36862	http://dx.doi.org/10.1038/36862			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384381				2022-12-24	WOS:A1997YG66700064
J	Edelmann, W; Yang, K; Umar, A; Heyer, J; Lau, K; Fan, KH; Liedtke, W; Cohen, PE; Kane, MF; Lipford, JR; Yu, NJ; Crouse, GF; Pollard, JW; Kunkel, T; Lipkin, M; Kolodner, R; Kucherlapati, R				Edelmann, W; Yang, K; Umar, A; Heyer, J; Lau, K; Fan, KH; Liedtke, W; Cohen, PE; Kane, MF; Lipford, JR; Yu, NJ; Crouse, GF; Pollard, JW; Kunkel, T; Lipkin, M; Kolodner, R; Kucherlapati, R			Mutation in the mismatch repair gene Msh6 causes cancer susceptibility	CELL			English	Article							NONPOLYPOSIS COLON-CANCER; COLORECTAL TUMORIGENESIS; HETERODUPLEX REPAIR; TUMOR-CELLS; DNA; MICE; HETERODIMER; HOMOLOG; MOUSE; DEFICIENCY	Mice carrying a null mutation in the mismatch repair gene Msh6 were generated by gene targeting. Cells that were homozygous for the mutation did not produce any detectable MSH6 protein, and extracts prepared from these cells were defective for repair of single nucleotide mismatches. Repair of 1, 2, and 4 nucleotide insertion/deletion mismatches was unaffected. Mice that were homozygous for the mutation had a reduced life span. The mice developed a spectrum of tumors, the most predominant of which were gastrointestinal tumors and B-as well as T-cell lymphomas. The tumors did not show any microsatellite instability. We conclude that MSH6 mutations, like those in some other members bf the family of mismatch repair genes, lead to cancer susceptibility, and germline mutations in this gene may be associated with a cancer predisposition syndrome that does not show microsatellite instability.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL GENET,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV & MOL BIOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,STRANG CANC RES LAB,BRONX,NY 10461; NIEHS,NIH,RES TRIANGLE PK,NC 27709; DANA FARBER CANC INST,BOSTON,MA 02115; LUDWIG INST CANC RES,LA JOLLA,CA 92093; EMORY UNIV,ATLANTA,GA 30322	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Harvard University; Dana-Farber Cancer Institute; Ludwig Institute for Cancer Research; Emory University	Edelmann, W (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		Kucherlapati, Raju/ABC-8807-2021; Liedtke, Wolfgang B/G-4633-2011; Liedtke, Wolfgang/GNH-1878-2022		NCI NIH HHS [CA 67944, CA 54050, CA 44704] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA044704, R01CA067944, R01CA054050] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BOYER JC, 1995, CANCER RES, V55, P6062; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Corradi A, 1996, GENOMICS, V36, P288, DOI 10.1006/geno.1996.0464; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; KOLODNER RD, 1995, CANCER RES, V55, P242; Kolodner Richard D., 1994, Current Opinion in Biotechnology, V5, P585, DOI 10.1016/0958-1669(94)90079-5; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Malkhosyan S, 1996, MUTAT RES-DNAGING G, V316, P249, DOI 10.1016/S0921-8734(96)90007-7; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PETTOMAKI P, 1997, IN PRESS GASTROENTER; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; Reitmair AH, 1996, CANCER RES, V56, P3842; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; SIROTKIN AM, 1995, P NATL ACAD SCI USA, V92, P6434, DOI 10.1073/pnas.92.14.6434; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; THOMAS DC, 1995, METHODS COMPANION ME, P187; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637	51	303	312	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					467	477		10.1016/S0092-8674(00)80433-X	http://dx.doi.org/10.1016/S0092-8674(00)80433-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390556	Bronze			2022-12-24	WOS:A1997YG49200008
J	Kenny, B; DeVinney, R; Stein, M; Reinscheid, DJ; Frey, EA; Finlay, BB				Kenny, B; DeVinney, R; Stein, M; Reinscheid, DJ; Frey, EA; Finlay, BB			Enteropathogenic E-coli (EPEC) transfers its receptor for intimate adherence into mammalian cells	CELL			English	Article							ESCHERICHIA-COLI; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; EFFACING LESIONS; GENETIC-LOCUS; PROTEIN; ACTIN; PHOSPHORYLATION; EXPRESSION; SECRETION	Enteropathogenic E. coli (EPEC) belongs to a group of bacterial pathogens that induce epithelial cell actin rearrangements resulting in pedestal formation beneath adherent bacteria. This requires the secretion of specific virulence proteins needed for signal transduction and intimate adherence. EPEC interaction induces tyrosine phosphorylation of a protein in the host membrane, Hp90, which is the receptor for the EPEC outer membrane protein, intimin. Hp90-intimin interaction is essential for intimate attachment and pedestal formation. Here, we demonstrate that Hp90 is actually a bacterial protein (Tir). Thus, this bacterial pathogen inserts its own receptor into mammalian cell surfaces, to which it then adheres to trigger additional host signaling events and actin nucleation. It is also tyrosine-phosphorylated upon transfer into the host cell.	UNIV BRITISH COLUMBIA, DEPT BIOCHEM & MOL BIOL, DEPT MICROBIOL & IMMUNOL, BIOTECHNOL LAB, VANCOUVER, BC V6T 1Z3, CANADA	University of British Columbia				, Brendan/0000-0001-7455-360X				BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; DONNENBERG MS, 1993, J CLIN INVEST, V92, P1412, DOI 10.1172/JCI116717; DONNENBERG MS, 1992, INFECT IMMUN, V60, P3953, DOI 10.1128/IAI.60.10.3953-3961.1992; DONNENBERG MS, 1990, FEMS MICROBIOL LETT, V69, P83, DOI 10.1016/0378-1097(90)90417-O; Donnenberg MS, 1997, TRENDS MICROBIOL, V5, P109, DOI 10.1016/S0966-842X(97)01000-7; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P441; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; FINLAY BB, 1992, INFECT IMMUN, V60, P2541, DOI 10.1128/IAI.60.6.2541-2543.1992; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; FOUBISTER V, 1994, J EXP MED, V179, P993, DOI 10.1084/jem.179.3.993; FOUBISTER V, 1994, INFECT IMMUN, V62, P3038, DOI 10.1128/IAI.62.7.3038-3040.1994; Frankel G, 1996, J BIOL CHEM, V271, P20359, DOI 10.1074/jbc.271.34.20359; FRANKEL G, 1994, INFECT IMMUN, V62, P1835, DOI 10.1128/IAI.62.5.1835-1842.1994; GOMEZDUARTE OG, 1995, INFECT IMMUN, V63, P1767; ISMAILI A, 1995, INFECT IMMUN, V63, P3316, DOI 10.1128/IAI.63.9.3316-3326.1995; JARVIS KG, 1995, P NATL ACAD SCI USA, V92, P7996, DOI 10.1073/pnas.92.17.7996; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; Kenny B, 1997, INFECT IMMUN, V65, P2528, DOI 10.1128/IAI.65.7.2528-2536.1997; KENNY B, 1995, P NATL ACAD SCI USA, V92, P7991, DOI 10.1073/pnas.92.17.7991; Kenny B, 1997, INFECT IMMUN, V65, P2606, DOI 10.1128/IAI.65.7.2606-2612.1997; Kenny B, 1996, MOL MICROBIOL, V20, P313, DOI 10.1111/j.1365-2958.1996.tb02619.x; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; MANJARREZHERNANDEZ HA, 1992, LANCET, V339, P521, DOI 10.1016/0140-6736(92)90340-9; McDaniel TK, 1997, MOL MICROBIOL, V23, P399, DOI 10.1046/j.1365-2958.1997.2311591.x; MCDANIEL TK, 1995, P NATL ACAD SCI USA, V92, P1664, DOI 10.1073/pnas.92.5.1664; Mecsas J, 1996, EMERG INFECT DIS, V2, P271, DOI 10.3201/eid0204.960403; Rosenshine I, 1996, INFECT IMMUN, V64, P966, DOI 10.1128/IAI.64.3.966-973.1996; ROSENSHINE I, 1992, EMBO J, V11, P3551, DOI 10.1002/j.1460-2075.1992.tb05438.x; Rosenshine I, 1996, EMBO J, V15, P2613, DOI 10.1002/j.1460-2075.1996.tb00621.x; Stein M, 1996, J BACTERIOL, V178, P6546, DOI 10.1128/jb.178.22.6546-6554.1996; Stone KD, 1996, MOL MICROBIOL, V20, P325, DOI 10.1111/j.1365-2958.1996.tb02620.x	31	958	988	0	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 14	1997	91	4					511	520		10.1016/S0092-8674(00)80437-7	http://dx.doi.org/10.1016/S0092-8674(00)80437-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390560	Bronze			2022-12-24	WOS:A1997YG49200012
J	Cleeland, CS; Gonin, R; Baez, L; Loehrer, P; Pandya, KJ				Cleeland, CS; Gonin, R; Baez, L; Loehrer, P; Pandya, KJ			Pain and treatment of pain in minority patients with cancer - The Eastern Cooperative Oncology Group minority outpatient pain study	ANNALS OF INTERNAL MEDICINE			English	Article							MANAGEMENT; SEVERITY	Background: Clinics that primarily see members of ethnic minority groups have been found to provide inadequate treatment of cancer-related pain. The extent of undertreatment of pain in these patients and the factors that contribute to undertreatment are not known. Objectives: To evaluate the severity of cancer-related pain and the adequacy of prescribed analgesics in minority outpatients with cancer. Design: Prospective clinical study. Setting: Eastern Cooperative Oncology Group. Patients: 281 minority outpatients with recurrent or metastatic cancer. Measurements: Patients and physicians independently rated severity of pain, pain-related functional impairment, and pain relief obtained by taking analgesic drugs. Analgesic adequacy was determined on the basis of accepted guidelines. Results: 77% of patients reported disease-related pain or took analgesics; 41% of patients reporting pain had severe pain. Sixty-five percent of minority patients did not receive guideline-recommended analgesic prescriptions compared with 50% of nonminority patients (P < 0.001). Hispanic patients in particular reported less pain relief and had less adequate analgesia. Conclusions: The awareness that minority patients do not receive adequate pain control and that better assessment of pain is needed may improve control of cancer-related pain in this patient population.	WESTAT CORP, ROCKVILLE, MD 20850 USA; SAN JUAN COMMUNITY CLIN ONCOL PROGRAM, SAN JUAN, PR 00936 USA; INDIANA UNIV, MED CTR, DEPT MED, DIV HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA; ST MARYS HOSP, DEPT MED, HEMATOL ONCOL UNIT, ROCHESTER, NY 14611 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, HOUSTON, TX 77030 USA	Westat; Indiana University System; Indiana University-Purdue University Indianapolis; University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA 21076, CA 23318, CA 49883] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA049883, U10CA023318, U10CA021076] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], [No title captured]; [Anonymous], 1991, EFFECT CANC QUALITY; ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; CLEELAND C, 1991, CANCER, V67, P823, DOI 10.1002/1097-0142(19910201)67:3+<823::AID-CNCR2820671412>3.0.CO;2-S; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Cleeland CS, 1996, PAIN, V67, P267, DOI 10.1016/0304-3959(96)03131-4; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; FORD ES, 1995, HEALTH SERV RES, V30, P237; MCDONALD DD, 1994, RES NURS HEALTH, V17, P45, DOI 10.1002/nur.4770170107; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; Raczynski James M., 1993, Ethnicity and Disease, V3, P290; SATARIANO ER, 1992, AM J PUBLIC HEALTH, V82, P195, DOI 10.2105/AJPH.82.2.195; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; TODD KH, 1994, JAMA-J AM MED ASSOC, V271, P925, DOI 10.1001/jama.271.12.925; *US DEP HHS PHS, 1994, AHCPR PUBL; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; WARD SE, 1993, PAIN, V52, P319, DOI 10.1016/0304-3959(93)90165-L	17	380	385	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					813	816		10.7326/0003-4819-127-9-199711010-00006	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YD898	9382402				2022-12-24	WOS:A1997YD89800005
J	Carithers, RL				Carithers, RL			Effect of interferon on hepatitis B	LANCET			English	Editorial Material							ETIOLOGY; VIRUS		Univ Washington, Med Ctr, Dept Med, Seattle, WA 98105 USA	University of Washington; University of Washington Seattle	Carithers, RL (corresponding author), Univ Washington, Med Ctr, Dept Med, Seattle, WA 98105 USA.							BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; Evans AA, 1997, J INFECT DIS, V176, P845, DOI 10.1086/516538; Lau DTY, 1997, GASTROENTEROLOGY, V113, P1660, DOI 10.1053/gast.1997.v113.pm9352870; Lau G. K. K., 1997, Hepatology, V26, p259A; LOK ASF, 1990, J HEPATOL, V10, P29, DOI 10.1016/0168-8278(90)90069-4; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011	7	6	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					157	157						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449867				2022-12-24	WOS:000071616300006
J	Koehler, CM; Jarosch, E; Tokatlidis, K; Schmid, K; Schweyen, RJ; Schatz, G				Koehler, CM; Jarosch, E; Tokatlidis, K; Schmid, K; Schweyen, RJ; Schatz, G			Import of mitochondrial carriers mediated by essential proteins of the intermembrane space	SCIENCE			English	Article							ADP-ATP CARRIER; SACCHAROMYCES-CEREVISIAE; YEAST MITOCHONDRIA; INNER MEMBRANE; TRANSLOCATION; MUTAGENESIS; CONTAINS; STEPS	In order to reach the inner membrane of the mitochondrion, multispanning carrier proteins must cross the aqueous intermembrane space. Two essential proteins of that space, Tim10p and Tim12p, were shown to mediate import of multispanning carriers into the inner membrane. Both proteins formed a complex with the inner membrane protein Tim22p. Tim10p readily dissociated from the complex and was required to transport carrier precursors across the outer membrane; Tim12p was firmly bound to Tim22p and mediated the insertion of carriers into the inner membrane. Neither protein was required for protein import into the other mitochondrial compartments. Both proteins may function as intermembrane space chaperones for the highly insoluble carrier proteins.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; Univ Vienna, Inst Mikrobiol & Genet, A-1030 Vienna, Austria	University of Basel; University of Vienna	Schatz, G (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.			Tokatlidis, Kostas/0000-0001-6295-8183; Jarosch, Ernst/0000-0002-5897-3492				ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; [Anonymous], 1991, Methods Enzymol, V194, P1; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; DIETMEIER K, 1993, J BIOL CHEM, V268, P25958; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GEITZ RD, 1991, YEAST, V7, P253; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; Jarosch E, 1996, J BIOL CHEM, V271, P17219, DOI 10.1074/jbc.271.29.17219; Jarosch E, 1997, MOL GEN GENET, V255, P157, DOI 10.1007/s004380050484; KOEHLER CM, UNPUB; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Palmieri L, 1996, FEBS LETT, V399, P299, DOI 10.1016/S0014-5793(96)01350-6; PFANNER N, 1987, J BIOL CHEM, V262, P14851; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; ROSPERT S, 1994, J BIOL CHEM, V269, P17279; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; SMAGULA C, 1988, J BIOL CHEM, V263, P6783; SMAGULA CS, 1988, J CELL BIOCHEM, V36, P323, DOI 10.1002/jcb.240360402; STAPLES RR, 1993, GENETICS, V135, P981; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; WALDHERR M, 1993, CURR GENET, V24, P301, DOI 10.1007/BF00336780	32	258	261	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					369	373		10.1126/science.279.5349.369	http://dx.doi.org/10.1126/science.279.5349.369			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430585				2022-12-24	WOS:000071570800043
J	[Anonymous]				[Anonymous]			Needle exchange programmes in the USA: time to act now	LANCET			English	Editorial Material																			0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 10	1998	351	9096					75	75						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439484				2022-12-24	WOS:000071591900001
J	Bloom, BR				Bloom, BR			The highest attainable standard: Ethical issues in AIDS vaccines	SCIENCE			English	Article							CONTROLLED TRIAL; PERTUSSIS		Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA	Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine	Bloom, BR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA.	bloom@aecom.yu.edu						Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; *CIOMS WHO, 1982, INT ETH GUID BIOM RE; CJ Murray, 1996, GLOBAL BURDEN DIS CO, VI; Council of Europe, 1997, CONV PROT HUM RIGHTS; deWachter MAM, 1997, HASTINGS CENT REP, V27, P13, DOI 10.2307/3528021; Dommel FW, 1997, KENNEDY INST ETHIC J, V7, P259, DOI 10.1353/ken.1997.0023; Gazzard BG, 1997, LANCET, V349, P1086, DOI 10.1016/S0140-6736(96)12073-0; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; MELLORS JW, 1997, ANN INTERN MED, V126, P12946; *NAT COMM PROT HUM, 1988, BELM REP ETH PRINC G; RIIS P, COMMUNICATION; *UNAIDS, 1997, P M HELD 23 24 SEPT; *US PHS, 1990, CONS INT COLL HUM IM; VanHeyningen WE, 1983, CHOLERA AM SCI EXPER; Varmus H, 1997, NEW ENGL J MED, V337, P1003, DOI 10.1056/NEJM199710023371411; World Bank, 1993, WORLD DEV REP 1993 I; World Medical Association, 1964, DECL HELS	20	55	56	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					186	188		10.1126/science.279.5348.186	http://dx.doi.org/10.1126/science.279.5348.186			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9446225				2022-12-24	WOS:000071408100027
J	Phelan, P; Stebbings, LA; Baines, RA; Bacon, JP; Davies, JA; Ford, C				Phelan, P; Stebbings, LA; Baines, RA; Bacon, JP; Davies, JA; Ford, C			Drosophila Shaking-B protein forms gap junctions in paired Xenopus oocytes	NATURE			English	Article							GIANT FIBER SYSTEM; SYNAPTIC CONNECTIVITY; MOLECULAR-BASIS; NERVOUS-SYSTEM; VOLTAGE; EXPRESSION; MELANOGASTER; CONNEXINS; MUTATIONS; LOCUS	In most multicellular organisms direct cell-cell communication is mediated by the intercellular channels of gap junctions. These channels allow the exchange of ions and molecules that are believed to be essential for cell signalling during development and in some differentiated tissues, Proteins called connexins, which are products of a multigene family, are the structural components of vertebrate gap junctions(1,2). Surprisingly, molecular homologues of the connexins have not been described in any invertebrate. A separate gene family, which includes the Drosophila genes shaking-B and l(1)ogre, and the Caenorhabditis elegans genes unc-7 and eat-5, encodes transmembrane proteins with a predicted structure similar to that of the connexins(3-9). shaking-B and eat-5 are required for the formation of functional gap junctions(8,10). To test directly whether Shaking-B is a channel protein, we expressed it in paired Xenopus oocytes. Here we show that Shaking-B localizes to the membrane, and that its presence induces the formation of functional intercellular channels. To our knowledge, this is the first structural component of an invertebrate gap junction to be characterized.	Univ Sussex, Sch Biol Sci, Sussex Ctr Neurosci, Brighton BN1 9QG, E Sussex, England; Univ Sussex, Sch Biol Sci, Dept Genet & Dev, Brighton BN1 9QG, E Sussex, England	University of Sussex; University of Sussex	Phelan, P (corresponding author), Univ Sussex, Sch Biol Sci, Sussex Ctr Neurosci, Brighton BN1 9QG, E Sussex, England.	bafb5@central.sussex.ac.uk		Phelan, Pauline/0000-0002-9348-837X; Baines, Richard/0000-0001-8571-4376				BARNES TM, 1994, TRENDS GENET, V10, P303, DOI 10.1016/0168-9525(94)90023-X; BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; BRUZZONE R, 1995, FEBS LETT, V358, P301, DOI 10.1016/0014-5793(94)01457-C; BRUZZONE R, 1994, J CELL SCI, V107, P955; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; CHEVALIER S, 1995, J CELL SCI, V108, P1831; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; CROMPTON D, 1995, DEV BIOL, V170, P142, DOI 10.1006/dbio.1995.1203; EBIHARA L, 1989, SCIENCE, V243, P1194, DOI 10.1126/science.2466337; GHO M, 1994, J PHYSIOL-LONDON, V481, P371, DOI 10.1113/jphysiol.1994.sp020446; HANSEN P, 1981, STAIN TECHNOL, V56, P287; HENNEMANN H, 1992, J BIOL CHEM, V267, P17225; HOMYK T, 1980, MOL GEN GENET, V177, P553; KRISHNAN SN, 1993, CELL, V73, P967, DOI 10.1016/0092-8674(93)90274-T; KRISHNAN SN, 1995, P NATL ACAD SCI USA, V92, P2021, DOI 10.1073/pnas.92.6.2021; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Phelan P, 1996, J NEUROSCI, V16, P1101; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; Starich TA, 1996, J CELL BIOL, V134, P537, DOI 10.1083/jcb.134.2.537; STARICH TA, 1993, GENETICS, V133, P527; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; THOMAS JB, 1984, J NEUROSCI, V4, P530; VERSELIS VK, 1991, BIOPHYS J, V59, P114, DOI 10.1016/S0006-3495(91)82204-4; WATANABE T, 1990, GENETICS, V126, P1033; WILDERS R, 1992, BIOPHYS J, V63, P942, DOI 10.1016/S0006-3495(92)81664-8; Willecke K, 1996, J BIOENERG BIOMEMBR, V28, P319, DOI 10.1007/BF02110108	26	132	139	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	1998	391	6663					181	184		10.1038/34426	http://dx.doi.org/10.1038/34426			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428764				2022-12-24	WOS:000071380900052
J	Annegers, JF; Hauser, WA; Coan, SP; Rocca, WA				Annegers, JF; Hauser, WA; Coan, SP; Rocca, WA			A population-based study of seizures after traumatic brain injuries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPILEPSY	Background The risk of seizures is increased after traumatic brain injury, but the extent and duration of the increase in risk are unknown. The purpose of this study was to identify the characteristics of brain injuries that are associated with the development of seizures. Methods We identified 4541 children and adults with traumatic brain injury (characterized by loss of consciousness, post-traumatic amnesia, or skull fracture) in Olmsted County, Minnesota, during the period from 1935 through 1984. Injuries were classified as mild (loss of consciousness or amnesia lasting less than 30 minutes), moderate (loss of consciousness for 30 minutes to 24 hours or a skull fracture), or severe (loss of consciousness or amnesia for more than 24 hours, subdural hematoma, or brain contusion). We compared the incidence of new unprovoked seizures in this cohort with population rates, using standardized incidence ratios and Cox proportional-hazards analysis. Results The overall standardized incidence ratio was 3.1 (95 percent confidence interval, 2.5 to 3.8). The standardized incidence ratio was 1.5 (95 percent confidence interval, 1.0 to 2.2) after mild injuries but with no increase over the expected number after five years, 2.9 (95 percent confidence interval, 1.9 to 4.1) after moderate injuries, and 17.0 (95 percent confidence interval, 12.3 to 23.6) after severe injuries, In the multivariate analysis, significant risk factors for later seizures were brain contusion with subdural hematoma, skull fracture, loss of consciousness or amnesia for more than one day, and an age of 65 years or older. Conclusions The increased risk of seizures after traumatic brain injury varies greatly according to the severity of the injury and the time since the injury. (C) 1998, Massachusetts Medical Society.	Univ Texas, Sch Publ Hlth, Houston, TX 77225 USA; Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY USA; Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55905 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Columbia University; Mayo Clinic	Annegers, JF (corresponding author), Univ Texas, Sch Publ Hlth, POB 20186, Houston, TX 77225 USA.		Rocca, Walter/Z-5335-2019; Hauser, W Allen/AAB-5277-2020; Ritter, Stefanie L/D-9312-2012		NIAMS NIH HHS [AR30582] Funding Source: Medline; NINDS NIH HHS [NS16308] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS016308] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANNEGERS JF, 1988, NEUROLOGY, V38, P1407, DOI 10.1212/WNL.38.9.1407; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1976, EPILEPSIA, V17, P1, DOI 10.1111/j.1528-1157.1976.tb03375.x; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Jennett B., 1975, EPILEPSY NONMISSILE, V2nd; KLEINBAUM DG, 1986, EPIDEMIOLOGIC RES PR, P103; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; PENFIELD W, 1945, RES PUBL ASSOC RES N, V24, P620; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; *STATACORP, 1997, STATA REF MAN REL 5, V1; WALKER AE, 1989, SURG NEUROL, V32, P235, DOI 10.1016/0090-3019(89)90185-7; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006	12	642	668	0	33	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 1	1998	338	1					20	24		10.1056/NEJM199801013380104	http://dx.doi.org/10.1056/NEJM199801013380104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN801	9414327				2022-12-24	WOS:000071209200004
J	Savchenko, A; Barnes, S; Kramer, RH				Savchenko, A; Barnes, S; Kramer, RH			Cyclic-nucleotide-gated channels mediate synaptic feedback by nitric oxide	NATURE			English	Article							EXCITATORY AMINO-ACIDS; CONE PHOTORECEPTORS; HIPPOCAMPAL-NEURONS; GUANYLYL CYCLASE; HORIZONTAL CELLS; TURTLE RETINA; RELEASE; CALCIUM; GMP; TRANSMISSION	Cyclic-nucleotide-gated (CNG) channels in outer segments of vertebrate photoreceptors generate electrical signals in response to changes in cyclic GMP concentration during phototransduction(1). CNG channels also allow the influx of Ca2+, which is essential for photoreceptor adaptation(2). In cone photoreceptors, cGMP triggers an increase in membrane capacitance indicative of exocytosis, suggesting that CNG channels are also involved in synaptic function(3), Here we examine whether CNG channels reside in cone terminals and whether they regulate neurotransmitter release, specifically in response to nitric oxide (NO), a retrograde transmitter that increases cGMP synthesis and potentiates synaptic transmission in the brain(4-6). Using intact retina, we show that endogenous NO modulates synapses between cones and horizontal cells. In experiments on isolated cones, we show directly that CNG channels occur in dusters and are indirectly activated by S-nitrosocysteine (SNC), an NO donor. Furthermore, both SNC and pCPT-cGMP, a membrane-permeant analogue of cGMP, trigger the release of transmitter from the cone terminals, The NO-induced transmitter release is suppressed by guanylate cyclase inhibitors and prevented by direct activation of CNG channels, indicating that their activation is required for NO to elicit release. These results expand our view of CNG channel function to include the regulation of synaptic transmission and mediation of the presynaptic effects of NO.	UNIV MIAMI,SCH MED,DEPT MOL & CELLULAR PHARMACOL,MIAMI,FL 33101; UNIV CALGARY,NEUROSCI RES GRP,CALGARY,AB T2N 4N1,CANADA	University of Miami; University of Calgary					NEI NIH HHS [P30 EY003176] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY003176] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARANCIO O, 1995, NATURE, V376, P74, DOI 10.1038/376074a0; BARNES S, 1992, J NEUROPHYSIOL, V68, P745, DOI 10.1152/jn.1992.68.3.745; BARNES S, 1989, J GEN PHYSIOL, V94, P719, DOI 10.1085/jgp.94.4.719; BAYLOR DA, 1971, J PHYSIOL-LONDON, V214, P265, DOI 10.1113/jphysiol.1971.sp009432; Bradley J, 1997, J NEUROSCI, V17, P1993; Broillet MC, 1996, NEURON, V16, P377, DOI 10.1016/S0896-6273(00)80055-0; COPENHAGEN DR, 1989, NATURE, V341, P536, DOI 10.1038/341536a0; DIXON DB, 1997, IN PRESS J NEUROSCI; Finn JT, 1996, ANNU REV PHYSIOL, V58, P395, DOI 10.1146/annurev.ph.58.030196.002143; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; HORN R, 1991, BIOPHYS J, V60, P433, DOI 10.1016/S0006-3495(91)82069-0; Kingston PA, 1996, P NATL ACAD SCI USA, V93, P10440, DOI 10.1073/pnas.93.19.10440; KOCH KW, 1994, EMBO J, V13, P3312, DOI 10.1002/j.1460-2075.1994.tb06633.x; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; KURENNY DR, 1995, NEURON, V13, P315; LIEPE BA, 1994, J NEUROSCI, V14, P7641; MARICQ AV, 1988, NEURON, V1, P503, DOI 10.1016/0896-6273(88)90181-X; MEFFERT MK, 1994, NEURON, V12, P1235, DOI 10.1016/0896-6273(94)90440-5; MULSCH A, 1988, J PHARMACOL EXP THER, V247, P282; NORMANN RA, 1979, J PHYSIOL-LONDON, V286, P509, DOI 10.1113/jphysiol.1979.sp012634; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PICCOLINO M, 1981, J NEUROPHYSIOL, V45, P363, DOI 10.1152/jn.1981.45.3.363; RIEKE F, 1994, NEURON, V13, P863, DOI 10.1016/0896-6273(94)90252-6; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; TACHIBANA M, 1991, J NEUROSCI, V11, P2199; WATANABE SI, 1988, J NEUROSCI, V8, P2334; Wilkinson MF, 1996, J GEN PHYSIOL, V107, P621, DOI 10.1085/jgp.107.5.621; WU SM, 1994, ANNU REV PHYSIOL, V56, P141; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; ZIMMERMAN AL, 1985, P NATL ACAD SCI USA, V82, P8813, DOI 10.1073/pnas.82.24.8813	31	153	160	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 25	1997	390	6661					694	698		10.1038/37803	http://dx.doi.org/10.1038/37803			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM508	9414163	Green Accepted			2022-12-24	WOS:A1997YM50800034
J	Egeland, GM; Middaugh, JP				Egeland, GM; Middaugh, JP			Balancing fish consumption benefits with mercury exposure	SCIENCE			English	Editorial Material							FETAL METHYLMERCURY; DIET				Egeland, GM (corresponding author), ALASKA DEPT HLTH & SOCIAL SERV,DIV PUBL HLTH,EPIDEMIOL SECT,ANCHORAGE,AK 99524, USA.							Anderson Paul D., 1995, P104; BAKIR F, 1973, SCIENCE, V181, P230, DOI 10.1126/science.181.4096.230; BANG HO, 1971, LANCET, V1, P1143, DOI 10.1016/S0140-6736(71)91658-8; Bauernfeind J., 1980, Vitamin E, P99; CRUMP K, 1995, RISK ANAL, V15, P523, DOI 10.1111/j.1539-6924.1995.tb00345.x; DAHL R, 1996, NEUROTOXICOL TERATOL, V18, P1; Daviglus ML, 1997, NEW ENGL J MED, V336, P1046, DOI 10.1056/NEJM199704103361502; *EPA, 1996, EPA452R96001F; GRANDJEAN P, 1995, NEUROTOXICOLOGY, V16, P27; GRANDJEAN P, 1994, CLIN CHEM, V40, P1395; GRANDJEAN P, 1992, ARCH ENVIRON HEALTH, V47, P185, DOI 10.1080/00039896.1992.9938348; GRANDJEAN P, 1997, NEUROTOXICOL TERATOL, V20, P1; Hansen J.C., 1989, Meddelelser om Gronland Man & Society, V12, P161; HOLMAN RT, 1991, P NATL ACAD SCI USA, V88, P4835, DOI 10.1073/pnas.88.11.4835; IPCS, 1990, ENV HLTH CRIT 101 ME; Kinsella JE., 1987, SEAFOODS FISH OILS H; Marsh DO, 1995, NEUROTOXICOLOGY, V16, P717; MARSH DO, 1987, ARCH NEUROL-CHICAGO, V44, P1017, DOI 10.1001/archneur.1987.00520220023010; Myers GJ, 1995, NEUROTOXICOLOGY, V16, P629; *NIH, 1995, EFF FISH OILS POL OM; Shkilnyk A., 1985, POISON STRONGER THAN; SIU KWM, 1989, OCCURRENCE DISTRIBUT, P263; SKERFVING SB, 1976, B WORLD HEALTH ORGAN, V54, P101; TOLLEFSON L, 1986, ENVIRON HEALTH PERSP, V68, P203, DOI 10.2307/3430265; UAUYDAGACH R, 1995, CLIN PERINATOL, V22, P157; USHER PJ, 1995, COMMUNICATING CONTAM; WHEATLEY B, 1994, ARCT MED RES S2, V53, P386	27	117	124	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1904	1905		10.1126/science.278.5345.1904	http://dx.doi.org/10.1126/science.278.5345.1904			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9417640				2022-12-24	WOS:A1997YL00200023
J	Studitsky, VM; Kassavetis, GA; Geiduschek, EP; Felsenfeld, G				Studitsky, VM; Kassavetis, GA; Geiduschek, EP; Felsenfeld, G			Mechanism of transcription through the nucleosome by eukaryotic RNA polymerase	SCIENCE			English	Article							CHAIN ELONGATION; INITIATION; TEMPLATES; DNA; CHROMATIN; COMPLEXES; INVITRO	Nucleosomes, the nucleohistone subunits of chromatin, are present on transcribed eukaryotic genes but do not prevent transcription. It is shown here that the large yeast RNA polymerase III transcribes through a single nucleosome. This takes place through a direct internal nucleosome transfer in which histones never leave the DNA template, During this process, the polymerase pauses with a pronounced periodicity of 10 to 11 base pairs, which is consistent with restricted rotation in the DNA loop formed during transfer. Transcription through nucleosomes by the eukaryotic enzyme and by much smaller prokaryotic RNA polymerases thus shares many features, reflecting an important property of nucleosomes.	NIDDKD,MOL BIOL LAB,NIH,BETHESDA,MD 20892; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California San Diego; University of California System; University of California San Diego			Studitsky, Vasily/A-9382-2014					BARDELEBEN C, 1994, J MOL BIOL, V235, P1193, DOI 10.1006/jmbi.1994.1073; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; CLARK DJ, 1995, NUCLEOSOME, P207; DUBANDGOULET I, 1992, J MOL BIOL, V224, P981, DOI 10.1016/0022-2836(92)90464-U; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; LUSE D, 1995, CHROMATIN STRUCTURE, P104; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; NDLER E, 1997, CELL, V89, P33; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; TENHEGGELERBORDIER B, 1995, EMBO J, V14, P2561, DOI 10.1002/j.1460-2075.1995.tb07254.x; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T	25	161	162	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1960	1963		10.1126/science.278.5345.1960	http://dx.doi.org/10.1126/science.278.5345.1960			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395401				2022-12-24	WOS:A1997YL00200039
J	Lee, DH; Severin, K; Yokobayashi, Y; Ghadiri, MR				Lee, DH; Severin, K; Yokobayashi, Y; Ghadiri, MR			Emergence of symbiosis in peptide self-replication through a hypercyclic network	NATURE			English	Article							COILED-COILS; ORGANIZATION; PRINCIPLE; EVOLUTION; SYSTEM; RNA	Symbiosis is an association between different organisms that leads to a reciprocal enhancement of their ability to survive, Similar mutually beneficial relationships can operate at the molecular level in the form of a hypercycle, a collective of two or more self-replicating species interlinked through a cyclic catalytic network(1-5). The superposition of cross-catalysis onto autocatalytic replication integrates the members of the hypercycle into a single system that reproduces through a second-order (or higher) form of nonlinear autocatalysis. The hypercycle population as a whole is therefore able to compete more efficiently for existing resources than any one member on its own. In addition, the effects of beneficial mutations of any one member are spread over the entire population, The formation of hypercycles has been suggested as an important step in the transition from inanimate to living chemistry(6), and a large number of hypercycles are expected to be embedded within the complex networks of living systems(7). But only one naturally occurring hypercycle has been well documented(8), while two autocatalytic chemical systems may contain vestiges of hypercyclic organization(9,10). Here we report a chemical system that constitutes a dear example of a minimal hypercyclic network, in which two otherwise competitive self-replicating peptides symbiotically catalyse each others' production.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute			Yokobayashi, Yohei/B-5898-2009	Yokobayashi, Yohei/0000-0002-2417-1934; Severin, Kay/0000-0003-2224-7234				ACHILLES T, 1993, ANGEW CHEM INT EDIT, V32, P1198, DOI 10.1002/anie.199311981; EIGEN M, 1978, NATURWISSENSCHAFTEN, V65, P341, DOI 10.1007/BF00439699; EIGEN M, 1991, BIOCHEMISTRY-US, V30, P11005, DOI 10.1021/bi00110a001; EIGEN M, 1977, NATURWISSENSCHAFTEN, V64, P541, DOI 10.1007/BF00450633; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; EIGEN M, 1978, NATURWISSENSCHAFTEN, V65, P7, DOI 10.1007/BF00420631; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HONG JI, 1992, SCIENCE, V255, P848, DOI 10.1126/science.255.5046.848; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; Kauffman S. A., 1993, ORIGINS ORDER; KUPPERS BO, 1990, ORIGIN BIOL INFORMAT; Lee DH, 1996, NATURE, V382, P525, DOI 10.1038/382525a0; LEE DH, IN PRESS CURR OPIN C; MULLERHEROLD U, 1983, J THEOR BIOL, V102, P569, DOI 10.1016/0022-5193(83)90391-0; RICARD J, 1986, EUR J BIOCHEM, V155, P183, DOI 10.1111/j.1432-1033.1986.tb09475.x; Severin K, 1997, NATURE, V389, P706, DOI 10.1038/39556; Severin K, 1997, CHEM-EUR J, V3, P1017, DOI 10.1002/chem.19970030706; SEVERIN K, IN PRESS ANGEW CHEM; von Kiedrowski G., 1993, BIOORG CHEM FRONT, V3, P113	20	194	200	2	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					591	594		10.1038/37569	http://dx.doi.org/10.1038/37569			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403686				2022-12-24	WOS:A1997YK85300043
J	Basso, O; Olsen, J; Johansen, AMT; Christensen, K				Basso, O; Olsen, J; Johansen, AMT; Christensen, K			Change in social status and risk of low birth weight in Denmark: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							FOR-GESTATIONAL-AGE; HEALTH; SMOKING	Objective: To estimate the risk of having a low birth-weight infant associated with changes in social, environmental, and genetic factors. Design: Population based, historical cohort study using the Danish medical birth registry and Statistic Denmark's fertility database. Subjects: All women who had a low birthweight infant (<2500 g) (index birth) and a subsequent liveborn infant (outcome birth) in Denmark between 1980 and 1992 (exposed cohort, n = 11 069) and a random sample of the population who gave birth to an infant weighing greater than or equal to 2500 g and to a subsequent liveborn infant (unexposed cohort, n = 10 211), Main outcome measures: Risk of having a low birthweight infant in the outcome birth as a function of changes in male partner, area of residence, type of job, and social status between the two births. Results: Women in the exposed cohort showed a high risk (18.5%) of having a subsequent low birthweight infant while women in the unexposed cohort had a risk of 2.8%. After adjustment for initial social status, a decline in social statics increased the absolute risk of having a low birthweight infant by about 5% in both cohorts, though this was significant only in the unexposed cohort, Change of male partner did not modify the risk of low birth weight in either cohort. Conclusion: Having had a low birthweight infant and a decline in social status are strong risk factors for having a low birthweight infant subsequently.	DANISH NATL BOARD HLTH,COPENHAGEN,DENMARK; ODENSE UNIV,CTR HLTH & SOCIAL POLICY,DK-5230 ODENSE M,DENMARK	University of Southern Denmark	Basso, O (corresponding author), AARHUS UNIV,DANISH EPIDEMIOL SCI CTR,DEPT EPIDEMIOL & SOCIAL MED,GULDBERGSGADE 10,DK-8000 AARHUS C,DENMARK.		Basso, Olga/E-5384-2010; Christensen, Kaare/C-2360-2009	Basso, Olga/0000-0001-9298-4921; Christensen, Kaare/0000-0002-5429-5292				BAKKETEIG LS, 1979, AM J OBSTET GYNECOL, V135, P1086, DOI 10.1016/0002-9378(79)90742-7; BAKKETEIG LS, 1986, EARLY HUM DEV, V14, P187, DOI 10.1016/0378-3782(86)90180-5; Bartley M, 1996, BRIT MED J, V313, P445; *DANM STAT, 1996, FERT DAT; *DANM STAT, 1986, DANM STAT ERHV 1 APR; KLINE J, 1989, CONCEPTION BIRTH EPI, P231; KNUDSEN LB, 1993, VITALSTATISTIK, V1, P33; LAHELMA E, 1989, UNEMPLOYMENT POVERTY, P135; LIE RT, 1994, NEW ENGL J MED, V331, P1, DOI 10.1056/NEJM199407073310101; MacGillivray I, 1988, TWINNING TWINS; MORRISON J, 1991, AUST NZ J OBSTET GYN, V31, P114, DOI 10.1111/j.1479-828X.1991.tb01795.x; MORTON NE, 1955, ANN HUM GENET, V20, P125; MUTALE T, 1991, BRIT J OBSTET GYNAEC, V98, P166, DOI 10.1111/j.1471-0528.1991.tb13363.x; Nordentoft M, 1996, AM J PUBLIC HEALTH, V86, P347, DOI 10.2105/AJPH.86.3.347; NORDSTROM ML, 1996, SCAND J SOC MED, V1, P55; OLSEN J, 1993, SCAND J SOC MED, V21, P90, DOI 10.1177/140349489302100206; Olsen J, 1997, EPIDEMIOLOGY, V8, P6, DOI 10.1097/00001648-199701000-00001; Power C, 1996, BRIT MED J, V313, P449; RAINE T, 1994, OBSTET GYNECOL, V84, P485; Read A W, 1993, Paediatr Perinat Epidemiol, V7, P177, DOI 10.1111/j.1365-3016.1993.tb00392.x; Read A W, 1991, Paediatr Perinat Epidemiol, V5, P138, DOI 10.1111/j.1365-3016.1991.tb00695.x; RUSH D, 1983, J EPIDEMIOL COMMUN H, V37, P249, DOI 10.1136/jech.37.4.249; *SUNDH, 1995, MED FODS 1993, P2; VLIETINCK R, 1989, BEHAV GENET, V19, P151, DOI 10.1007/BF01065890; Wang XB, 1995, NEW ENGL J MED, V333, P1744, DOI 10.1056/NEJM199512283332606; WILCOX MA, 1995, ACTA OBSTET GYN SCAN, V74, P15, DOI 10.3109/00016349509009936	26	29	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1498	1502		10.1136/bmj.315.7121.1498	http://dx.doi.org/10.1136/bmj.315.7121.1498			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YK986	9420490	Green Published			2022-12-24	WOS:A1997YK98600019
J	Erkinjuntti, T; Ostbye, T; Steenhuis, R; Hachinski, V				Erkinjuntti, T; Ostbye, T; Steenhuis, R; Hachinski, V			The effect of different diagnostic criteria on the prevalence of dementia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DSM-III-R; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; APOLIPOPROTEIN-E; NINDS-AIREN; ICD-10; POPULATION; HEALTH; DISORDERS; ATROPHY	Background There are several widely used sets of criteria for the diagnosis of dementia, but little is known about their degree of agreement and their effects on estimates of the prevalence of dementia. Methods We examined 1879 men and women 65 years of age or older who were enrolled in the Canadian Study of Health and Aging and calculated the proportion given a diagnosis of dementia according to six commonly used classification systems: the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM), third edition (DSM-III), the third edition, revised, of the DSM (DSM-III-R), the fourth edition of the DSM (DSM-IV), the World Health Organization's International Classification of Diseases (ICD), 9th revision (ICD-9) and 10th revision (ICD-10), and the Cambridge Examination for Mental Disorders of the Elderly (CAMDEX). The degree of concordance among classification schemes and the importance of various factors in determining diagnostic agreement or disagreement were examined. Results The proportion of subjects with dementia varied from 3.1 percent when we used the criteria of the ICD-10 to 29.1 percent when the DSM-III criteria were used. The six classification systems identified different groups of subjects as having dementia; only 20 subjects were given a diagnosis of dementia according to all six systems. The classifications based on the various systems differed little according to the patients' age, sex, educational level, or status with respect to institutionalization. The factors that most often caused disagreement in diagnosis between DSM-III and ICD-10 were long-term memory, executive function, social activities, and duration of symptoms. Conclusions The commonly used criteria for diagnosis can differ by a factor of 10 in the number of subjects classified as having dementia. Such disagreement has serious implications for research and treatment, as well as for the right of many older persons to drive, make a will, and handle financial affairs. (C) 1997, Massachusetts Medical Society.	UNIV WESTERN ONTARIO,DEPT EPIDEMIOL & BIOSTAT,LONDON,ON N6A 5C1,CANADA; UNIV HELSINKI,DEPT NEUROL,MEMORY RES UNIT,HELSINKI,FINLAND; UNIV WESTERN ONTARIO,DEPT CLIN NEUROL SCI,LONDON,ON N6A 5C1,CANADA; LONDON HLTH SCI CTR,PSYCHOL SERV,LONDON,ENGLAND	Western University (University of Western Ontario); University of Helsinki; Western University (University of Western Ontario)								American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3; American Psychological Association, 1994, DIAGN STAT MAN MENT, V4th; BRONISCH T, 1994, PSYCHOPATHOLOGY, V27, P312, DOI 10.1159/000284889; Cummings JL, 1992, DEMENTIA CLIN APPROA; ERKINJUNTTI T, 1993, ARCH NEUROL-CHICAGO, V50, P305, DOI 10.1001/archneur.1993.00540030069017; ERKINJUNTTI T, 1993, CEREBROVASC DIS, V3, P3, DOI 10.1159/000108661; FICHTER MM, 1995, BRIT J PSYCHIAT, V166, P621, DOI 10.1192/bjp.166.5.621; Fox NC, 1996, LANCET, V348, P94, DOI 10.1016/S0140-6736(96)05228-2; FRATIGLIONI L, 1991, NEUROLOGY, V41, P1886, DOI 10.1212/WNL.41.12.1886; HACHINSKI V, 1992, LANCET, V340, P645; HENDERSON AS, 1994, PSYCHOL MED, V24, P473, DOI 10.1017/S0033291700027446; HILLER W, 1994, PSYCHOPATHOLOGY, V27, P19, DOI 10.1159/000284844; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; OSTBYE T, 1994, CAN MED ASSOC J, V151, P1457; OSTBYE T, 1995, CAN MED ASSOC J, V152, P158; Pohjasvaara T, 1997, STROKE, V28, P785, DOI 10.1161/01.STR.28.4.785; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; SCHUCKIT MA, 1994, ADDICTION, V89, P1629, DOI 10.1111/j.1360-0443.1994.tb03764.x; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; Soininen HS, 1996, TRENDS NEUROSCI, V19, P224, DOI 10.1016/0166-2236(96)10027-8; STEENHUIS RE, 1995, J CLIN EXP NEUROPSYC, V17, P773, DOI 10.1080/01688639508405166; TATEMICHI T K, 1992, Neurology, V42, P413; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TOMASSON K, 1993, ACTA PSYCHIAT SCAND, V88, P311, DOI 10.1111/j.1600-0447.1993.tb03465.x; TUOKKO H, 1995, J CLIN EXP NEUROPSYC, V17, P352, DOI 10.1080/01688639508405129; Wetterling T, 1996, STROKE, V27, P30, DOI 10.1161/01.STR.27.1.30; *WHO, 1992, INT CLASS DIS, P311; World Health Organization, 1977, INT CLASS DIS; 1994, CAN MED ASSOC J, V150, P899	33	338	346	3	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 4	1997	337	23					1667	1674		10.1056/NEJM199712043372306	http://dx.doi.org/10.1056/NEJM199712043372306			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YJ871	9385127				2022-12-24	WOS:A1997YJ87100006
J	OhkiHamazaki, H; Watase, K; Yamamoto, K; Ogura, H; Yamano, M; Yamada, K; Maeno, H; Imaki, J; Kikuyama, S; Wada, E; Wada, K				OhkiHamazaki, H; Watase, K; Yamamoto, K; Ogura, H; Yamano, M; Yamada, K; Maeno, H; Imaki, J; Kikuyama, S; Wada, E; Wada, K			Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity	NATURE			English	Article							LUNG-CARCINOMA CELLS; LEPTIN LEVELS; MOLECULAR-CLONING; PEPTIDE RECEPTOR; PLASMA	Mammalian bombesin-like peptides are widely distributed in the central nervous system as well as in the gastrointestinal tract, where they modulate smooth-muscle contraction, exocrine and endocrine processes, metabolism and behaviour(1). They bind to G-protein-coupled receptors on the cell surface to elicit their effects, Bombesin-like peptide receptors cloned so far include, gastrin-releasing peptide receptor (GRP-R)(2,3), neuromedin B receptor (NMB-R)(4,5), and bombesin receptor subtype-3 (BRS-3)(6,7). However, despite the molecular characterization of BRS-3, determination of its function has been difficult as a result of its low affinity for bombesin and its lack of an identified natural ligand, We have generated BRS-3-deficient mice in an attempt to determine the in vivo function of the receptor, Mice lacking functional BRS-3 developed a mild obesity, associated with hypertension and impairment of glucose metabolism, They also exhibited reduced metabolic rate, increased feeding efficiency and subsequent hyperphagia, Our data suggest that BRS-3 is required for the regulation of endocrine processes and metabolism responsible for energy balance and adiposity, BRS-3-deficient mice provide a useful new model for the investigation of human obesity and associated diseases.	TOKYO INST PSYCHIAT,DEPT NEUROCHEM,SETAGAYA KU,TOKYO 156,JAPAN; WASEDA UNIV,SCH EDUC,DEPT BIOL,SHINJUKU KU,TOKYO 16950,JAPAN; EISAI & CO LTD,TSUKUBA RES LABS,TSUKUBA,IBARAKI 30026,JAPAN; OSAKA PREFECTURAL COLL HLTH SCI,HABIKINO,OSAKA 583,JAPAN; NIPPON MED COLL,DEPT ANAT,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Institute of Psychiatry; Waseda University; Eisai Co Ltd; Nippon Medical School	OhkiHamazaki, H (corresponding author), NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DEPT DEGENERAT NEUROL DIS,KODAIRA,TOKYO 187,JAPAN.		Ohki-Hamazaki, Hiroko/R-5489-2019	Ohki-Hamazaki, Hiroko/0000-0003-4658-5385; Yamamoto, Kazutoshi/0000-0002-7935-7015				BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; BOUILLAUD F, 1986, J BIOL CHEM, V261, P1487; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; FATHI Z, 1993, J BIOL CHEM, V268, P5979; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; GORBULEV V, 1992, EUR J BIOCHEM, V208, P405, DOI 10.1111/j.1432-1033.1992.tb17201.x; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; LEBACQVERHEYDEN AM, 1990, HDB EXPT PHARM, V95, P71; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OhkiHamazaki H, 1997, BRAIN RES, V762, P165, DOI 10.1016/S0006-8993(97)00380-6; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4; Wu JM, 1996, MOL PHARMACOL, V50, P1355; YAMAMOTO K, 1982, ENDOCRINOL JAPON, V29, P159; YANOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435	19	239	250	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					165	169		10.1038/36568	http://dx.doi.org/10.1038/36568			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367152				2022-12-24	WOS:A1997YF49400052
J	delPeso, L; GonzalezGarcia, M; Page, C; Herrera, R; Nunez, G				delPeso, L; GonzalezGarcia, M; Page, C; Herrera, R; Nunez, G			Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt	SCIENCE			English	Article							CELL-DEATH; ONCOGENE; APOPTOSIS; SURVIVAL; BCL-2	BAD is a distant member of the Bcl-2 family that promotes cell death. Phosphorylation of BAD prevents this. BAD phosphorylation induced by interleukin-3 (IL-3) was inhibited by specific inhibitors of phosphoinositide 3-kinase (PI 3-kinase), Akt, a survival-promoting serine-threonine protein kinase, was activated by IL-3 in a PI 3-kinase-dependent manner. Active, but not inactive, forms of AM were found to phosphorylate BAD in vivo and in vitro at the same residues that are phosphorylated in response to IL-3, Thus, the proapoptotic function of BAD is regulated by the PI 3-kinase-Akt pathway.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR COMPREHENS CANC,ANN ARBOR,MI 48109; WARNER LAMBERT PARKE DAVIS,PHARMACEUT RES DIV,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Pfizer			del Peso, Luis/K-9391-2014; Nuñez, Gabriel/A-7160-2014	del Peso, Luis/0000-0003-4014-5688; 	NCI NIH HHS [CA-64556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DELPESO L, UNPUB; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRANKE TF, 1997, CELL, V88, P355; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	24	1034	1066	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					687	689						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381178				2022-12-24	WOS:A1997YC32300054
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Worlds collide	SCIENCE			English	Editorial Material																		Feng MZ, 1997, NAT BIOTECHNOL, V15, P866, DOI 10.1038/nbt0997-866	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					501	501						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9381146				2022-12-24	WOS:A1997YB35500055
J	Ravelli, ACJ; van der Meulen, JHP; Michels, RPJ; Osmond, C; Barker, DJP; Hales, CN; Bleker, OP				Ravelli, ACJ; van der Meulen, JHP; Michels, RPJ; Osmond, C; Barker, DJP; Hales, CN; Bleker, OP			Glucose tolerance in adults after prenatal exposure to famine	LANCET			English	Article							LOW-PROTEIN-DIET; DEPENDENT DIABETES-MELLITUS; CARDIOVASCULAR RISK-FACTORS; CORONARY HEART-DISEASE; FETAL GROWTH; BIRTH-WEIGHT; THRIFTY PHENOTYPE; INFANT GROWTH; YOUNG MEN; INSULIN	Background Reduced growth in utero is associated with type 2 (non-insulin-dependent) diabetes and impaired glucose tolerance in adult life. There is no direct evidence in human beings that maternal nutrition during gestation affects insulin-glucose metabolism. We investigated glucose tolerance in people born around the time of famine in the Netherlands during 1944-45. Methods We included 702 people born between Nov 1, 1943, and Feb 28, 1947, in Amsterdam, for whom we had detailed prenatal and birth records. We compared glucose and insulin responses to a standard oral glucose load in participants exposed to famine at any stage during gestation (exposed participants) with those who were born in the year before or conceived in the year after the famine (non-ex posed participants). Findings Glucose concentrations were increased 2 h after a standard glucose load among exposed participants (p=0.006), and were highest in men and women exposed during mid and late gestation. Mean 2 h glucose concentration among non-exposed participants was 5.8 mmol/L; concentrations were 0.5 mmol/L (95% Cl 0.1-0.9) higher among participants exposed during late gestation, 0.4 mmol/L (0-0.8) higher among those exposed during mid gestation, and 0.1 mmol/L (-0.4 to 0.6) among those exposed during early gestation. Participants born as thin babies to mothers with low bodyweights had the highest concentrations and concentrations were especially high among people exposed to famine who became obese as adults, Prenatal exposure to famine was related to increased fasting proinsulin (p=0.05) and 2 h insulin concentrations (p=0.04), which suggests an association with insulin resistance. Interpretation Prenatal exposure to famine, especially during late gestation, is linked to decreased glucose tolerance in adults. Poor nutrition in utero may lead to permanent changes in insulin-glucose metabolism, even if the effect on fetal growth is small. This effect of famine on glucose tolerance is especially important in people who become obese.	Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1100 DE Amsterdam Zuidoost, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1100 DE Amsterdam Zuidoost, Netherlands; Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton, Hants, England; Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QQ, England; Univ Amsterdam, Acad Med Ctr, Dept Obstet & Gynaecol, NL-1100 DE Amsterdam Zuidoost, Netherlands	University of Amsterdam; University of Amsterdam; University of Southampton; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Amsterdam	van der Meulen, JHP (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, POB 22700, NL-1100 DE Amsterdam Zuidoost, Netherlands.		Ravelli, Anita CJ/ABR-1494-2022	Osmond, Clive/0000-0002-9054-4655; van der Meulen, Jan/0000-0002-9451-2335; Ravelli, Anita CJ/0000-0002-3447-8286				Bakker B., 1997, SOCIALE WETENSCHAPPE, V40, P1; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; Burger G., 1948, MALNUTRITION STARVAT; COOK JTE, 1993, BRIT MED J, V306, P302, DOI 10.1136/bmj.306.6873.302; Curhan GC, 1996, CIRCULATION, V94, P3246, DOI 10.1161/01.CIR.94.12.3246; DAHRI S, 1991, DIABETES, V40, P115, DOI 10.2337/diab.40.2.S115; FALL CHD, 1995, BRIT MED J, V310, P428, DOI 10.1136/bmj.310.6977.428; Forrester TE, 1996, BRIT MED J, V312, P156; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HALES CN, 1994, DIABETOLOGIA, V37, pS162, DOI 10.1007/BF00400840; HARDING JE, 1995, REPROD FERT DEVELOP, V7, P539, DOI 10.1071/RD9950539; Hofman PL, 1997, J CLIN ENDOCR METAB, V82, P402, DOI 10.1210/jc.82.2.402; Holemans K, 1996, J SOC GYNECOL INVEST, V3, P71, DOI 10.1016/1071-5576(95)00046-1; IglesiasBarreira V, 1996, ENDOCRINOLOGY, V137, P3797, DOI 10.1210/en.137.9.3797; Kramer MS, 1996, LANCET, V348, P1254, DOI 10.1016/S0140-6736(05)65750-9; Law CM, 1996, DIABETIC MED, V13, pS49; LAW CM, 1995, DIABETIC MED, V12, P24, DOI 10.1111/j.1464-5491.1995.tb02057.x; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; LUMEY LH, 1995, EUR J OBSTET GYN R B, V61, P23, DOI 10.1016/0028-2243(95)02149-M; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROBINSON S, 1992, DIABETOLOGIA, V35, P444, DOI 10.1007/BF02342441; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; Stein Z., 1975, FAMINE HUM DEV DUTCH; SWENNE I, 1987, DIABETES, V36, P454, DOI 10.2337/diabetes.36.4.454; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157; Wareham N J, 1995, Diabet Med, V12, P931; Whincup PH, 1997, DIABETOLOGIA, V40, P319, DOI 10.1007/s001250050681; YAJNIK CS, 1995, DIABETIC MED, V12, P330, DOI 10.1111/j.1464-5491.1995.tb00487.x	34	1095	1121	0	82	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					173	177		10.1016/S0140-6736(97)07244-9	http://dx.doi.org/10.1016/S0140-6736(97)07244-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449872				2022-12-24	WOS:000071616300011
J	Kiefer, JR; Mao, C; Braman, JC; Beese, LS				Kiefer, JR; Mao, C; Braman, JC; Beese, LS			Visualizing DNA replication in a catalytically active Bacillus DNA polymerase crystal	NATURE			English	Article							ESCHERICHIA-COLI; KLENOW FRAGMENT; KINETIC MECHANISM; NUCLEIC-ACIDS; FIDELITY; BINDING	DNA polymerases copy DNA templates with remarkably high fidelity, checking for correct base-pair formation both at nucleotide insertion and at subsequent DNA extension steps(1-3). Despite extensive biochemical, genetic and structural studies(2,4), the mechanism by which nucleotides are correctly incorporated is not known, Here we present high-resolution crystal structures of a thermostable bacterial (Bacillus stearothermophiIus) DNA polymerase large fragment(5) with DNA primer templates bound productively at the polymerase active site. The active site retains catalytic activity, allowing direct observation of the products of several rounds of nucleotide incorporation, The polymerase also retains its ability to discriminate between correct and incorrectly paired nucleotides in the crystal, Comparison of the structures of successively translocated complexes allows the structural features for the sequence-independent molecular recognition of correctly formed base pairs to be deduced unambiguously. These include extensive interactions with the first four to five base pairs in the minor groove, location of the terminal base pair in a pocket of excellent steric complementarity favouring correct base-pair formation, and a conformational switch from B-form to underwound A-form DNA at the polymerase active site.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Stratagene, La Jolla, CA 92017 USA	Duke University	Beese, LS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.		beese, lorena/G-4993-2010	Kiefer, James/0000-0001-6317-0902				Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; *COLL COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P607; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DICKERSON DE, 1997, OXFORD HDB NUCL ACID; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joyce CM, 1997, P NATL ACAD SCI USA, V94, P1619, DOI 10.1073/pnas.94.5.1619; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kiefer JR, 1997, STRUCTURE, V5, P95, DOI 10.1016/S0969-2126(97)00169-X; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARKINSON G, 1996, ACTA CRYSTALLOGR D, V52, P557; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; Saenger W., 1984, PRINCIPLES NUCL ACID; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; STEITZ TA, 1987, COLD SPRING HARB SYM, V52, P465, DOI 10.1101/SQB.1987.052.01.053; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	30	482	494	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					304	307		10.1038/34693	http://dx.doi.org/10.1038/34693			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440698				2022-12-24	WOS:000071484400057
J	Brown, DR; Qin, KF; Herms, JW; Madlung, A; Manson, J; Strome, R; Fraser, PE; Kruck, T; vonBohlen, A; SchulzSchaeffer, W; Giese, A; Westaway, D; Kretzschmar, H				Brown, DR; Qin, KF; Herms, JW; Madlung, A; Manson, J; Strome, R; Fraser, PE; Kruck, T; vonBohlen, A; SchulzSchaeffer, W; Giese, A; Westaway, D; Kretzschmar, H			The cellular prion protein binds copper in vivo	NATURE			English	Article							SERUM-ALBUMIN; HIGH-AFFINITY; COMPLEX; REGION; SITE; PRP	The normal cellular form of prion protein (PrPC) is a precursor to the pathogenic protease-resistant forms (PrPSc) believed to cause scrapie, bovine spongiform encephalopathy (BSE) and Creutzfeldt-Jakob disease(1). Its amino terminus contains the octapeptide PHGGGWGQ, which is repeated four times and is among the best-preserved regions of mammalian PrPC. Here we show that the amino-terminal domain of PrPC exhibits five to six sites that bind copper (Cu(II)) presented as a glycine chelate. At neutral pH, binding occurs with positive cooperativity, with binding affinity compatible with estimates for extracellular, labile copper. Two lines of independently derived PrPC gene-ablated (Prnp(0/0)) mice exhibit severe reductions in the copper content of membrane-enriched brain extracts and similar reductions in synaptosomal and endosome-enriched subcellular fractions. Prnp(0/0) mice also have altered cellular phenotypes, including a reduction in the activity of copper/zinc superoxide dismutase and altered electrophysiological responses in the presence of excess copper. These findings indicate that PrPC can exist in a Cu-metalloprotein form in vivo.	UNIV GOTTINGEN,DEPT NEUROPATHOL,D-37075 GOTTINGEN,GERMANY; UNIV TORONTO,CTR RES NEURODEGENERAT DIS,TORONTO,ON M5S 3H2,CANADA; UNIV TORONTO,DEPT LAB MED & PATHOBIOL,TORONTO,ON M5S 3H2,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5S 3H2,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO,ON M5S 3H2,CANADA; NEUROPATHOGENESIS UNIT,EDINBURGH EA 3TF,MIDLOTHIAN,SCOTLAND; INST SPEKTROCHEM & ANGEW SPEKTROSKOPIE,D-44013 DORTMUND,GERMANY	University of Gottingen; University of Toronto; University of Toronto; University of Toronto; University of Toronto			Brown, David/A-4083-2008; Herms, Jochen/D-3518-2011; von Bohlen, Alex/C-2450-2008; Giese, Armin/F-3271-2010	von Bohlen, Alex/0000-0002-1572-6176; Giese, Armin/0000-0002-8238-4102				Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; CURZON G, 1960, BIOCHEM J, V74, P279, DOI 10.1042/bj0740279; GIROUX E, 1981, J INORG BIOCHEM, V14, P359, DOI 10.1016/S0162-0134(00)80292-5; GOLDFARB LG, 1991, P NATL ACAD SCI USA, V88, P10926, DOI 10.1073/pnas.88.23.10926; HARTTER DE, 1988, J BIOL CHEM, V263, P799; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; KLOCKENKAMPER R, 1992, ANAL CHEM, V64, pA1115, DOI 10.1021/ac00047a001; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LAU SJ, 1971, J BIOL CHEM, V246, P5938; Linder M, 1991, BIOCH COPPER; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; Martell A. E., 1974, CRITICAL STABILITY C; MASUOKA J, 1993, J BIOL CHEM, V268, P21533; Miura T, 1996, FEBS LETT, V396, P248, DOI 10.1016/0014-5793(96)01104-0; NAGY A, 1984, J NEUROCHEM, V43, P1114, DOI 10.1111/j.1471-4159.1984.tb12851.x; NARAHASHI T, 1994, CELL MOL NEUROBIOL, V14, P599, DOI 10.1007/BF02088671; NEUMANN PZ, 1967, J CLIN INVEST, V46, P646, DOI 10.1172/JCI105566; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; SARKAR B, 1968, CAN J BIOCHEM CELL B, V46, P601, DOI 10.1139/o68-092; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SOLDATI T, 1995, METHOD ENZYMOL, V257, P253; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4	27	1107	1137	4	129	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 25	1997	390	6661					684	687		10.1038/37783	http://dx.doi.org/10.1038/37783			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM508	9414160				2022-12-24	WOS:A1997YM50800031
J	McCune, JM				McCune, JM			Animal models of HIV-1 disease	SCIENCE			English	Article							SCID-HU MOUSE; IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN HEMATOLYMPHOID DIFFERENTIATION; TRANSGENIC MODELS; IN-VIVO; REPLICATION; CELLS		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DIV AIDS,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	McCune, JM (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,GLADSTONE INST VIROL & IMMUNOL,POB 419100,SAN FRANCISCO,CA 94110, USA.							AKKINA RK, 1994, BLOOD, V84, P1393; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; Bonyhadi ML, 1997, J VIROL, V71, P4707, DOI 10.1128/JVI.71.6.4707-4716.1997; JAMIESON BD, 1994, J VIROL, V68, P3478, DOI 10.1128/JVI.68.6.3478-3485.1994; Kitchen SG, 1997, J VIROL, V71, P6928, DOI 10.1128/JVI.71.9.6928-6934.1997; Klotman PE, 1996, CURR TOP MICROBIOL, V206, P197; Levy JA, 1996, J MED PRIMATOL, V25, P163, DOI 10.1111/j.1600-0684.1996.tb00013.x; LEWIS AD, 1995, TRENDS BIOTECHNOL, V13, P142, DOI 10.1016/S0167-7799(00)88925-8; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MCCUNE JM, 1992, BONE MARROW TRANSPL, V9, P74; MCCUNE JM, 1990, SEMIN VIROL, V1, P229; MOCARSKI ES, 1993, P NATL ACAD SCI USA, V90, P104, DOI 10.1073/pnas.90.1.104; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; Rabin L, 1996, ANTIMICROB AGENTS CH, V40, P755, DOI 10.1128/AAC.40.3.755; RONCAROLO M, 1995, HUMAN HEMATOPOIESIS; SU L, 1995, IMMUNITY, V2, P25, DOI 10.1016/1074-7613(95)90076-4; Su LS, 1997, VIROLOGY, V227, P45, DOI 10.1006/viro.1996.8338; TARYLEHMANN M, 1994, J EXP MED, V180, P1817, DOI 10.1084/jem.180.5.1817; Toggas SM, 1996, CURR TOP MICROBIOL, V206, P223	19	35	39	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2141	2142		10.1126/science.278.5346.2141	http://dx.doi.org/10.1126/science.278.5346.2141			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9432722				2022-12-24	WOS:A1997YM23500058
J	Rieder, R; Economou, T; Wanke, H; Turkevich, A; Crisp, J; Bruckner, J; Dreibus, G; McSween, HY				Rieder, R; Economou, T; Wanke, H; Turkevich, A; Crisp, J; Bruckner, J; Dreibus, G; McSween, HY			The chemical composition of Martian soil and rocks returned by the mobile alpha proton x-ray spectrometer: Preliminary results from the x-ray mode	SCIENCE			English	Article								The alpha proton x-ray spectrometer (APXS) on board the rover of the Mars Pathfinder mission measured the chemical composition of six soils and five rocks at the Ares Vallis landing site, The soil analyses show similarity to those determined by the Viking missions. The analyzed rocks were partially covered by dust but otherwise compositionally similar to each other. They are unexpectedly high in silica and potassium, but low in magnesium compared to martian soils and martian meteorites, The analyzed rocks are similar in composition to terrestrial andesites and close to the mean composition of Earth's crust. Addition of a mafic component and reaction products of volcanic gases to the local rock material is necessary to explain the soil composition.	MAX PLANCK INST CHEM,D-55020 MAINZ,GERMANY; UNIV CHICAGO,ENRICO FERMI INST,CHICAGO,IL 60637; CALTECH,JET PROP LAB,PASADENA,CA 91109; UNIV TENNESSEE,DEPT GEOL SCI,KNOXVILLE,TN 37996	Max Planck Society; University of Chicago; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Tennessee System; University of Tennessee Knoxville			Crisp, Joy/H-8287-2016	Crisp, Joy/0000-0002-3202-4416				BAIRD AK, 1976, SCIENCE, V194, P1288, DOI 10.1126/science.194.4271.1288; BANIN A., 2000, MARS, P594; CLARK BC, 1993, GEOCHIM COSMOCHIM AC, V57, P4575, DOI 10.1016/0016-7037(93)90183-W; CLARK BC, 1979, GEOPHYS RES LETT, V6, P811, DOI 10.1029/GL006i010p00811; CLARK BC, 1982, J GEOPHYS RES, V87, P59, DOI 10.1029/JB087iB12p10059; ECONOMOU TE, 1976, NUCL INSTRUM METHODS, V134, P391, DOI 10.1016/0029-554X(76)90298-6; ECONOMOU TE, 1970, J GEOPHYS RES, V75, P6514, DOI 10.1029/JB075i032p06514; Eugster O, 1997, GEOCHIM COSMOCHIM AC, V61, P2749, DOI 10.1016/S0016-7037(97)00115-4; Golombek MP, 1997, J GEOPHYS RES-PLANET, V102, P3967, DOI 10.1029/96JE03318; LEBAS MJ, 1986, J PETROL, V27, P745, DOI 10.1093/petrology/27.3.745; Longhi J., 1992, MARS, V1, P184, DOI [10.2307/j.ctt207g59v.10, DOI 10.2307/J.CTT207G59V.10]; MCSWEEN HY, 1985, REV GEOPHYS, V23, P391, DOI 10.1029/RG023i004p00391; Rieder R, 1997, J GEOPHYS RES-PLANET, V102, P4027, DOI 10.1029/96JE03918; WANKE H, 1988, PHILOS T R SOC A, V325, P545, DOI 10.1098/rsta.1988.0067	14	370	377	1	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1771	1774		10.1126/science.278.5344.1771	http://dx.doi.org/10.1126/science.278.5344.1771			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388173				2022-12-24	WOS:A1997YJ90100039
J	Zhang, BL; Gallegos, M; Puoti, A; Durkin, E; Fields, S; Kimble, J; Wickens, MP				Zhang, BL; Gallegos, M; Puoti, A; Durkin, E; Fields, S; Kimble, J; Wickens, MP			A conserved RNA-binding protein that regulates sexual fates in the C-elegans hermaphrodite germ line	NATURE			English	Article							3' UNTRANSLATED REGION; CAENORHABDITIS-ELEGANS; MESSENGER-RNA; TRANSLATIONAL REGULATION; DROSOPHILA EMBRYO; SPLICING FACTORS; GENE; NANOS; PATTERN; PUMILIO	The nematode Caenorhabditis elegans has two sexes, males and hermaphrodites. Hermaphrodites initially produce sperm but switch to producing oocytes. This switch appears to be controlled by the 3' untranslated region of fem-3 messenger RNA. We have now identified a binding factor (FBF) which is a cytoplasmic protein that binds specifically to the regulatory region of fem-3 3'UTR and mediates the sperm/oocyte switch. The RNA-binding domain of FBF consists of a stretch of eight tandem repeats and two short flanking regions. This structural element is conserved in several proteins Including Drosophila Pumilio, a regulatory protein that controls pattern formation in the fly by binding to a 3'UTR. We propose that FBF and Pumilio are members of a widespread family of sequence-specific RNA-binding proteins.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT GENET,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT MED,SEATTLE,WA 98195; UNIV WISCONSIN,HOWARD HUGHES MED INST,DEPT MED GENET,MADISON,WI 53706; UNIV WISCONSIN,LAB CELL & MOL BIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Puoti, Alessandro/E-5700-2012; Puoti, Alessandro/ABE-9963-2021	Puoti, Alessandro/0000-0002-1396-7662				AHRINGER J, 1992, EMBO J, V11, P2303, DOI 10.1002/j.1460-2075.1992.tb05289.x; AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; AHRINGER J, 1991, THESIS U WISCONSIN M; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312; BARTON MK, 1987, GENETICS, V115, P107; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; COGLIEVINA M, 1995, YEAST, V11, P767, DOI 10.1002/yea.320110808; CRITTENDEN SL, 1994, DEVELOPMENT, V120, P2901; Curtis D, 1997, EMBO J, V16, P834, DOI 10.1093/emboj/16.4.834; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; FITCH DHA, 1997, C ELEGANS, V2, P815; FU XD, 1995, RNA, V1, P663; GEBAUER R, 1997, BIOESSAYS, V19, P23; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; GRAHAM PL, 1993, DEV GENET, V14, P471, DOI 10.1002/dvg.1020140608; GRAHAM PL, 1993, GENETICS, V133, P919; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HODGKIN J, 1980, GENETICS, V96, P649; HODGKIN J, 1986, GENETICS, V114, P15; Hodgkin J, 1997, C ELEGANS, P881; LEHMANN R, 1991, DEVELOPMENT, V112, P679; Macdonald PM, 1996, CURR OPIN GENET DEV, V6, P403, DOI 10.1016/S0959-437X(96)80060-8; MACDONALD PM, 1992, DEVELOPMENT, V114, P221; MEYER BJ, 1997, C ELEGANS, V2, P209; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; SCHEDL T, 1989, GENETICS, V123, P755; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; SHEDL T, 1988, GENETICS, V119, P43; SINGER RH, 1993, CURR BIOL, V3, P719, DOI 10.1016/0960-9822(93)90079-4; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WARD S, 1986, J CELL BIOL, V102, P1778, DOI 10.1083/jcb.102.5.1778; Waterston Robert H., 1997, Cold Spring Harbor Monograph Series, V33, P23; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WHARTON RP, 1992, SEMINARS DEV BIOL, V3, P391; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Wickens M., 1996, TRANSLATIONAL CONTRO, P411; ZAMORE P, IN PRESS RNA; [No title captured]	46	416	431	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					477	484		10.1038/37297	http://dx.doi.org/10.1038/37297			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9393998				2022-12-24	WOS:A1997YJ86500041
J	Giannou, C				Giannou, C			Antipersonnel landmines: facts, fictions, and priorities	BRITISH MEDICAL JOURNAL			English	Article							LAND MINES; MOZAMBIQUE; INJURIES				Giannou, C (corresponding author), RED CROSS,INT COMM,DIV HLTH OPERAT,CAMPAIGN BAN ANTIPERSONNEL MINES,CH-1202 GENEVA,SWITZERLAND.							ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; ASCHERIO A, 1995, LANCET, V346, P721, DOI 10.1016/S0140-6736(95)91501-X; COUPLAND R, 1997, ASSISTANCE VICTIMS A; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; *INT COMM RED CROS, 1996, ANT LANDM FRIEND FOE; *INT COMM RED CROS, 1995, WORLDW EP LANDM INJ; Jeffrey SJ, 1996, J ACCID EMERG MED, V13, P343; KAKAR F, 1996, PREHOSPITAL DISASTER, V11, P13; STOVER E, 1994, JAMA-J AM MED ASSOC, V272, P1245	9	18	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1453	1454		10.1136/bmj.315.7120.1453	http://dx.doi.org/10.1136/bmj.315.7120.1453			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418100	Green Published			2022-12-24	WOS:A1997YJ67200036
J	Meddings, DR				Meddings, DR			Weapons injuries during and after periods of conflict: retrospective analysis	BRITISH MEDICAL JOURNAL			English	Article								Objective: To assess the relative frequency of weapon injuries during conflict and after periods of conflict in the absence of disarmament. Design: Retrospective analysis of a database of war wounds. Setting: Region with a protracted conflict between rival combatant groups and a subsequent transition to the uncontested military authority of a single power. Subjects: 2332 people who received weapons injuries during the conflict or post-conflict periods and were admitted to hospital within 24 hours of injury. Main outcome measures: Percentage change in mean monthly admission rate by weapon type between conflict and post-conflict periods; annual incidence of injury by weapon type during conflict and post-conflict periods; percentage change in annual incidence by weapon type between conflict and post-conflict periods. Results: Mean monthly admission rates for-injuries from fragmentation munitions decreased by 8% between conflict and post-conflict periods and by 23% for injuries from mines and 32% for gunshot injuries. The decline in admissions for all injuries was 23%. After adjustment for population growth over the study period, declines in annual incidence were 22% for fragmentation munitions injuries, 34% for mine injuries, and 40% for gunshot injuries. The decline in incidence for all injuries was 33%. In-hospital mortality from weapons related injuries increased from 2.5% to 6.1% (P < 0.001) between conflict and post-conflict periods. Conclusions: In this setting, continued availability of weapons is associated with increased mortality and a level of injuries from weapons that is only somewhat reduced from that observed during a period of conflict.			Meddings, DR (corresponding author), INT COMM RED CROSS,19 AVE PAIX,CH-1202 GENEVA,SWITZERLAND.							COUPLAND RM, 1996, MED GLOBAL SURVIVAL, V3, pA1; COUPLAND RM, 1994, RECENT ADV SURG, P121; COX D, 1996, MANAGING ARMS PEACE, P83; EISEMAN B, 1979, J TRAUMA, V19, P848, DOI 10.1097/00005373-197911000-00011; GAMBA V, 1997, SOC SIEGE CRIME VIOL, P1; GAMBA V, 1996, MANAGING ARMS PEACE, pR13; Klare M. T., 1995, LETHAL COMMERCE GLOB; Smith C., 1995, LETHAL COMMERCE GLOB, P61; Williams P., 1997, SOC SIEGE CRIME VIOL; Zawels Estanislao A, 1996, MANAGING ARMS PEACE	10	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1417	1420		10.1136/bmj.315.7120.1417	http://dx.doi.org/10.1136/bmj.315.7120.1417			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418089	Green Published			2022-12-24	WOS:A1997YJ67200025
J	Husman, AMD; Koot, M; Cornelissen, M; Keet, IPM; Brouwer, M; Broersen, SM; Bakker, M; Roos, MTL; Prins, M; deWolf, F; Coutinho, RA; Miedema, F; Goudsmit, J; Schuitemaker, H				Husman, AMD; Koot, M; Cornelissen, M; Keet, IPM; Brouwer, M; Broersen, SM; Bakker, M; Roos, MTL; Prins, M; deWolf, F; Coutinho, RA; Miedema, F; Goudsmit, J; Schuitemaker, H			Association between CCR5 genotype and the clinical course of HIV-1 infection	ANNALS OF INTERNAL MEDICINE			English	Article						human immunodeficiency virus infections; CCR5 genotype; biological markers; viral load; CD4 lymphocyte count	HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE; TYPE-1 INFECTION; HOMOSEXUAL-MEN; BIOLOGICAL PHENOTYPE; PROGRESSION; AIDS; INDIVIDUALS; RECEPTOR; PATHOGENESIS	Background: Heterozygosity for a 32-nucleotide deletion in the C-C chemokine receptor 5 gene (CCR5 Delta 32) is associated with delayed disease progression in persons infected with HIV-1. Objective: To compare the predictive value of CCR5 genotype with that of established markers in the clinical course of HIV-1 infection. Design: Retrospective longitudinal study and nested case-control study. The latter included only long-term survivors, who were individually matched with progressors. Setting: Amsterdam, the Netherlands. Participants: 364 homosexual men with HIV-1 infection. Measurements: Polymerase chain reaction was used for CCR5 genotyping. Univariate and multivariate Cox proportional hazard analyses were done for disease progression with CCR5 genotype, CD4(+) T-lymphocyte counts, T-lymphocyte function, HIV-1 biological phenotype (syncytium-inducing or non-syncytium-inducing HIV-1), and viral RNA load in serum as covariates. Results: In the case-control study, 48% of long-term survivors were heterozygous for CCR5 Delta 32 compared with 9% of progressors (odds ratio, 6.9 [95% CI, 1.9 to 24.8]). in the total study sample, CCR5 Delta 32 heterozygotes had significantly delayed disease progression (P < 0.001; relative hazard, 0.4 [CI, 0.3 to 0.6]), a 1.5-fold slower decrease in CD4(+) T-lymphocyte count (P = 0.01), and a 2.6-fold lower viral RNA load (P = 0.01) at approximately 2.3 years after seroconversion compared with CCR5 wild-type homozygotes. At the end of the study, both groups showed the same prevalence of syncytium-inducing HIV-1, but CCR5 Delta 32 heterozygotes had a delayed conversion rate. The protective effect of CCR5 Delta 32 heterozygosity was stronger in the presence of only non-syncytium-inducing HIV-1. The CCR5 genotype predicted disease progression independent of viral RNA load, CD4(+) T-lymphocyte counts, T-lymphocyte function, and HIV-1 biological phenotype. Conclusions: The addition of CCR5 genotype to currently available laboratory markers may allow better estimation of the clinical course of HIV-1 infection.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CENT LAB, DEPT CLIN VIROIMMUNOL, NL-1066 CX AMSTERDAM, NETHERLANDS; DEPT CLIN VIROIMMUNOL, LAB EXPT & CLIN IMMUNOL, NL-1066 CX AMSTERDAM, NETHERLANDS									Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BLOEMENA E, 1989, J IMMUNOL METHODS, V122, P161, DOI 10.1016/0022-1759(89)90260-3; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DEGRUTTOLA V, 1994, BIOMETRICS, V50, P1003, DOI 10.2307/2533439; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DEWOLF F, 1988, J INFECT DIS, V158, P615, DOI 10.1093/infdis/158.3.615; DEWOLF F, IN PRESS AIDS; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EugenOlsen J, 1997, AIDS, V11, P305, DOI 10.1097/00002030-199703110-00007; Faucett CL, 1996, STAT MED, V15, P1663, DOI 10.1002/(SICI)1097-0258(19960815)15:15<1663::AID-SIM294>3.0.CO;2-1; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; Fouchier RAM, 1995, AIDS RES HUM RETROV, V11, P1473, DOI 10.1089/aid.1995.11.1473; GROENINK M, 1993, SCIENCE, V260, P1513, DOI 10.1126/science.8502996; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; KLEIN MR, 1994, J INFECT DIS, V169, P1244, DOI 10.1093/infdis/169.6.1244; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; Koot M, 1996, J INFECT DIS, V173, P349, DOI 10.1093/infdis/173.2.349; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; PHILLIPS AN, 1992, AIDS, V6, P1391, DOI 10.1097/00002030-199211000-00025; ROOS MTL, 1995, J INFECT DIS, V171, P531, DOI 10.1093/infdis/171.3.531; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; VANGEMEN B, 1994, J VIROL METHODS, V49, P157, DOI 10.1016/0166-0934(94)90040-X; VANGRIENSVEN GJP, 1989, BMJ-BRIT MED J, V298, P218, DOI 10.1136/bmj.298.6668.218; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665; 1987, MMWR-MORBID MORTAL W, V36, P15	41	228	231	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					882	+		10.7326/0003-4819-127-10-199711150-00004	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382366				2022-12-24	WOS:A1997YF54500004
J	Jones, CM; OBrien, K; Blinkhorn, AS; Rood, JP				Jones, CM; OBrien, K; Blinkhorn, AS; Rood, JP			Dentists' agreement on treatment of asymptomatic impacted third molar teeth: interview study	BRITISH MEDICAL JOURNAL			English	Article							3RD MOLARS; REMOVAL		UNIV MANCHESTER,DEPT DENT MED & SURG,MANCHESTER M15 6FH,LANCS,ENGLAND	University of Manchester				O'Brien, Kevin/0000-0001-5747-247X				[Anonymous], 1980, J Oral Surg, V38, P235; ISMAIL SM, 1989, BRIT MED J, V298, P707, DOI 10.1136/bmj.298.6675.707; LOPES V, 1995, BRIT J ORAL MAX SURG, V33, P33, DOI 10.1016/0266-4356(95)90083-7; MERCIER P, 1992, INT J ORAL MAX SURG, V21, P17, DOI 10.1016/S0901-5027(05)80447-3; SHEPHERD JP, 1994, BRIT MED J, V309, P620, DOI 10.1136/bmj.309.6955.620	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1204	1204		10.1136/bmj.315.7117.1204	http://dx.doi.org/10.1136/bmj.315.7117.1204			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393225	Green Published			2022-12-24	WOS:A1997YF25200022
J	Vijan, S; Hofer, TP; Hayward, RA				Vijan, S; Hofer, TP; Hayward, RA			Estimated benefits of glycemic control in microvascular complications in type 2 diabetes	ANNALS OF INTERNAL MEDICINE			English	Article						diabetes mellitus, non-insulin-dependent; blood glucose; diabetic angiopathies; kidney failure, chronic; diabetic retinopathy	INTENSIVE INSULIN THERAPY; METABOLIC CONTROL; VASCULAR-DISEASE; RISK-FACTORS; GLYCOSYLATED HEMOGLOBIN; CLINICAL PROTEINURIA; GLYCATED HEMOGLOBIN; PLASMA-GLUCOSE; RENAL-FAILURE; LONDON COHORT	Background: The benefits of intensive glycemic control in patients with type 2 diabetes are not well quantified. It is therefore not clear which patients will benefit most from aggressive glycemic control. Objective: To evaluate the efficacy of glycemic control in type 2 diabetes. Design: Markov decision model. Patients: Diabetic patients at a health maintenance organization. Main Outcome Measures: Risks for developing blindness and end-stage renal disease; number of patients and patient-years needed to treat to prevent complications. Results: For a patient in whom diabetes developed before 50 years of age, reducing hemoglobin A(1c) levels from 9% to 7% results in an estimated 2.3-percentage point decrease (from 2.6% to 0.3%) in lifetime risk for blindness due to retinopathy. The same change in a patient with diabetes onset at 65 years of age would be expected to decrease the risk for blindness by 0.5 percentage points (from 0.5% to < 0.1%). However, the Markov model predicts substantially greater benefit when moving from poor to moderate glycemic control than when moving from moderate to almost-normal glycemic control. Targeting less than 20% of the patients at one health maintenance organization for intensified therapy may prevent more than 80% of the preventable patient-time spent blind. The risks for end-stage renal disease and the risk reduction provided by improved glycemic control are lower than those for blindness. Conclusions: This probability model, based on extrapolation from the experience with type 1 diabetes, suggests that patients with early onset of type 2 diabetes will accrue substantial benefit from almost-normal glycemic control. In patients with later onset, moderate glycemic control prevents most end-stage complications caused by microvascular disease. These results have important implications for informing patients and allocating health care resources.	VET AFFAIRS CTR PRACTICE MANAGEMENT & OUTCOMES RE, ANN ARBOR, MI USA; UNIV MICHIGAN, SCH MED, ANN ARBOR, MI USA	University of Michigan System; University of Michigan			Hofer, Timothy Philip/AAC-9238-2022	Hofer, Timothy/0000-0003-0434-8787	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006665] Funding Source: NIH RePORTER; AHRQ HHS [HSO 6665-01] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABRAIRA C, 1995, DIABETES CARE, V18, P1113, DOI 10.2337/diacare.18.8.1113; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; [Anonymous], 1995, Diabetes, V44, P1249; [Anonymous], 1995, DIABETES, V44, P968; [Anonymous], 1994, DIABETES CARE, V17, P616; [Anonymous], 1991, Ophthalmology, V98, P786; AVORN J, 1984, NEW ENGL J MED, V310, P1294, DOI 10.1056/NEJM198405173102005; BABA T, 1992, DIABETES RES CLIN PR, V16, P157, DOI 10.1016/0168-8227(92)90088-9; Clark CM, 1996, ANN INTERN MED, V124, P184, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00022; CLOSE CF, 1995, BMJ-BRIT MED J, V311, P973; Colwell JA, 1996, ANN INTERN MED, V124, P178, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00020; Colwell JA, 1996, DIABETES CARE, V19, P896, DOI 10.2337/diacare.19.8.896; COOPER ME, 1988, DIABETIC MED, V5, P361, DOI 10.1111/j.1464-5491.1988.tb01006.x; DECKERT T, 1991, DIABETIC MED, V8, P533; DWYER MS, 1985, DIABETES CARE, V8, P316, DOI 10.2337/diacare.8.4.316; ENGERMAN R, 1977, DIABETES, V26, P760, DOI 10.2337/diabetes.26.8.760; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; GALL MA, 1993, DIABETOLOGIA, V36, P1071, DOI 10.1007/BF02374501; Harris MI, 1996, ANN INTERN MED, V124, P117, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00007; HAYWARD RA, 1997, IN PRESS JAMA; Henry RR, 1996, ANN INTERN MED, V124, P175, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00019; HUMPHREY LL, 1989, ANN INTERN MED, V111, P788, DOI 10.7326/0003-4819-111-10-788; Jarrett R J, 1984, Diabet Med, V1, P17; JOHN L, 1994, DIABETES CARE, V17, P888, DOI 10.2337/diacare.17.8.888; Klein R, 1996, ANN INTERN MED, V124, P90, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00003; KLEIN R, 1988, JAMA-J AM MED ASSOC, V260, P2864, DOI 10.1001/jama.260.19.2864; KLEIN R, 1993, DIABETES CARE, V16, P1325, DOI 10.2337/diacare.16.10.1325; KLEIN R, 1985, DIABETES AM, P1; KROLEWSKI AS, 1977, DIABETOLOGIA, V13, P345, DOI 10.1007/BF01223277; KROLEWSKI AS, 1995, NEW ENGL J MED, V332, P1251, DOI 10.1056/NEJM199505113321902; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; LIU QZ, 1993, DIABETOLOGIA, V36, P428, DOI 10.1007/BF00402279; MATLOCK MB, 1988, DIABETLOGIA, V31, P82; MCCANCE DR, 1994, BRIT MED J, V308, P1323, DOI 10.1136/bmj.308.6940.1323; Medhi J, 1994, STOCHASTIC PROCESSES; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; MORISAKI N, 1994, J AM GERIATR SOC, V42, P142, DOI 10.1111/j.1532-5415.1994.tb04941.x; MORRISH NJ, 1990, DIABETOLOGIA, V33, P542, DOI 10.1007/BF00404142; MORRISH NJ, 1990, DIABETOLOGIA, V33, P538, DOI 10.1007/BF00404141; MOSS SE, 1988, OPHTHALMOLOGY, V95, P1340; MOSS SE, 1994, OPHTHALMOLOGY, V101, P1061; MOSS SE, 1992, ARCH INTERN MED, V152, P610, DOI 10.1001/archinte.152.3.610; MOSS SE, 1994, ARCH INTERN MED, V154, P2473; MUGGEO M, 1995, DIABETOLOGIA, V38, P318, DOI 10.1007/s001250050288; *NAT CTR HLTH STAT, 1995, VIT STAT US B, V2; Nathan DM, 1996, ANN INTERN MED, V124, P86, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00002; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; PANZRAM G, 1981, DIABETOLOGIA, V20, P587; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; Peters B.G., 1994, J EUROPEAN PUBLIC PO, V1, P9, DOI [10.1080/13501769408406945, DOI 10.1080/13501769408406945]; PIART J, 1978, DIABETES CARE, V1, P252; PIART J, 1978, DIABETES CARE, V1, P168; POWRIE JK, 1994, BRIT MED J, V309, P1608, DOI 10.1136/bmj.309.6969.1608; RUDBERG S, 1993, DIABETOLOGIA, V36, P1309, DOI 10.1007/BF00400811; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHENFIELD GM, 1979, DIABETES METAB, V5, P149; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; STEPHENSON JM, 1995, DIABETIC MED, V12, P149, DOI 10.1111/j.1464-5491.1995.tb00446.x; TEUSCHER A, 1994, LANCET, V343, P1097, DOI 10.1016/S0140-6736(94)90206-2; TURNER RC, 1991, DIABETOLOGIA, V34, P877; UUSITUPA MIJ, 1993, DIABETOLOGIA, V36, P1175, DOI 10.1007/BF00401063; VANDERZWAAG R, 1983, DIABETES CARE, V6, P341, DOI 10.2337/diacare.6.4.341; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; VIBERTI GC, 1983, BRIT MED J, V286, P598, DOI 10.1136/bmj.286.6365.598; WELBORN TA, 1984, DIABETOLOGIA, V27, P568, DOI 10.1007/BF00276969; WEST KM, 1983, DIABETES CARE, V6, P361, DOI 10.2337/diacare.6.4.361; YIP J, 1993, BRIT MED J, V306, P1235; 1989, MMWR-MORBID MORTAL W, V38, P546	69	166	167	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					788	+		10.7326/0003-4819-127-9-199711010-00003	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD898	9382399				2022-12-24	WOS:A1997YD89800002
J	De Guzman, RN; Wu, ZR; Stalling, CC; Pappalardo, L; Borer, PN; Summers, MF				De Guzman, RN; Wu, ZR; Stalling, CC; Pappalardo, L; Borer, PN; Summers, MF			Structure of the HIV-1 nucleocapsid protein bound to the SL3 Psi-RNA recognition element	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRIPLE-RESONANCE NMR; ACID-BINDING-PROTEINS; MURINE LEUKEMIA-VIRUS; SIDE-CHAIN RESONANCES; GAG GENE-PRODUCTS; CYS-HIS BOX; PACKAGING SIGNAL; ZINC FINGERS; POSTTRANSLATIONAL MODIFICATIONS	The three-dimensional structure of the human immunodeficiency virus-type 1 (HIV-1) nucleocapsid protein (NC) bound to the SL3 stem-loop recognition element of the genomic Psi RNA packaging signal has been determined by heteronuclear magnetic resonance spectroscopy. Tight binding (dissociation constant, similar to 100 nM) is mediated by specific interactions between the amino-and carboxyl-terminal CCHC-type zinc knuckles of the NC protein and the G(7) and G(9) nucleotide bases, respectively, of the G(6)-G(7)-A(8)-G(9) RNA tetraloop. A(8) packs against the amino-terminal knuckle and forms a hydrogen bond with conserved Arg(32), and residues Lys(3) to Arg(10) of NC form a 3(10) helix that binds to the major groove of the RNA stem and also packs against the amino-terminal zinc knuckle. The structure provides insights into the mechanism of viral genome recognition, explains extensive amino acid conservation within NC, and serves as a basis for the development of inhibitors designed to interfere with genome encapsidation.	Syracuse Univ, Dept Chem, Syracuse, NY 13244 USA; Univ Maryland Baltimore Cty, Howard Hughes Med Inst, Baltimore, MD 21250 USA; Univ Maryland Baltimore Cty, Dept Chem & Biochem, Baltimore, MD 21250 USA	Syracuse University; Howard Hughes Medical Institute; University System of Maryland; University of Maryland Baltimore County; University System of Maryland; University of Maryland Baltimore County	Summers, MF (corresponding author), Syracuse Univ, Dept Chem, Syracuse, NY 13244 USA.		Pappalardo, Lucia/ABA-9311-2020	Pappalardo, Lucia/0000-0002-4491-2082; Pinnix, Chelsea/0000-0003-3982-3664; Borer, Philip N/0000-0003-1633-5393	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042561, R01GM032691, R29GM042561] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42561, GM32691] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; Allain FHT, 1996, NATURE, V380, P646, DOI 10.1038/380646a0; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Batey RT, 1995, METHOD ENZYMOL, V261, P300; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERKOWITZ RD, 1995, J VIROL, V69, P6445, DOI 10.1128/JVI.69.10.6445-6456.1995; CLAVEL F, 1990, J VIROL, V64, P5230, DOI 10.1128/JVI.64.10.5230-5234.1990; CLEVER J, 1995, J VIROL, V69, P2101, DOI 10.1128/JVI.69.4.2101-2109.1995; Clever JL, 1997, J VIROL, V71, P3407, DOI 10.1128/JVI.71.5.3407-3414.1997; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DICKSON C, 1984, RNA TUMOR VIRUSES, V1, P513; DUPRAZ P, 1990, J VIROL, V64, P4978, DOI 10.1128/JVI.64.10.4978-4987.1990; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; Foster MP, 1997, NAT STRUCT BIOL, V4, P605, DOI 10.1038/nsb0897-605; GORELICK RJ, 1993, J VIROL, V67, P4027, DOI 10.1128/JVI.67.7.4027-4036.1993; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; GORELICK RJ, 1990, J VIROL, V64, P3207, DOI 10.1128/JVI.64.7.3207-3211.1990; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HARRISON GP, 1992, J VIROL, V66, P4144, DOI 10.1128/JVI.66.7.4144-4153.1992; HAYASHI T, 1993, FEBS LETT, V327, P213, DOI 10.1016/0014-5793(93)80172-Q; HAYASHI T, 1992, VIROLOGY, V188, P590, DOI 10.1016/0042-6822(92)90513-O; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; IKURA M, 1991, Journal of Biomolecular NMR, V1, P299, DOI 10.1007/BF01875522; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JENTOFT JE, 1988, P NATL ACAD SCI USA, V85, P7094, DOI 10.1073/pnas.85.19.7094; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE W, 1994, FEBS LETT, V350, P87, DOI 10.1016/0014-5793(94)00740-3; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; LUBAN J, 1994, J VIROL, V68, P3784, DOI 10.1128/JVI.68.6.3784-3793.1994; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; McBride MS, 1996, J VIROL, V70, P2963, DOI 10.1128/JVI.70.5.2963-2973.1996; McDonnell NB, 1997, J MED CHEM, V40, P1969, DOI 10.1021/jm970147+; MERIC C, 1989, J VIROL, V63, P1558; MERIC C, 1988, J VIROL, V62, P3328; MERVIS RJ, 1988, J VIROL, V62, P3993, DOI 10.1128/JVI.62.11.3993-4002.1988; MEYERS G, 1995, HUMAN RETROVIRUSES A; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; MUHANDIRAM DR, 1993, J BIOMOL NMR, V3, P463; Nicholls A., GRASP GRAPHICAL REPR; OTTMANN M, 1995, J VIROL, V69, P1778, DOI 10.1128/JVI.69.3.1778-1784.1995; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PAPPALARDO L, UNPUB; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POZNANSKY M, 1991, J VIROL, V65, P532, DOI 10.1128/JVI.65.1.532-536.1991; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; Ramos A, 1997, CURR OPIN STRUC BIOL, V7, P317, DOI 10.1016/S0959-440X(97)80046-2; RICE WG, 1993, P NATL ACAD SCI USA, V90, P9721, DOI 10.1073/pnas.90.20.9721; RICE WG, 1995, SCIENCE, V270, P1194, DOI 10.1126/science.270.5239.1194; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; Rice WG, 1997, NAT MED, V3, P341, DOI 10.1038/nm0397-341; Rice WG, 1996, REV MED VIROL, V6, P187, DOI 10.1002/(SICI)1099-1654(199612)6:4&lt;187::AID-RMV176&gt;3.0.CO;2-F; SAKAGUCHI K, 1993, P NATL ACAD SCI USA, V90, P5219, DOI 10.1073/pnas.90.11.5219; Schmitz U, 1996, RNA, V2, P1213; SOUTH TL, 1993, PROTEIN SCI, V2, P3; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; Vandevelde M, 1996, AIDS RES HUM RETROV, V12, P567, DOI 10.1089/aid.1996.12.567; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; Wuthrich K., 1986, NMR PROTEINS NUCL AC; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291; WYATT JR, 1991, BIOTECHNIQUES, V11, P764; Ye XM, 1995, CHEM BIOL, V2, P827, DOI 10.1016/1074-5521(95)90089-6; Ye XM, 1996, NAT STRUCT BIOL, V3, P1026, DOI 10.1038/nsb1296-1026; YOU JC, 1993, J BIOL CHEM, V268, P16519; YU XL, 1995, CHEM RES TOXICOL, V8, P586, DOI 10.1021/tx00046a013; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	89	589	600	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	1998	279	5349					384	388		10.1126/science.279.5349.384	http://dx.doi.org/10.1126/science.279.5349.384			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430589				2022-12-24	WOS:000071570800047
J	Brenner, H; Rothenbacher, D; Bode, G; Adler, G				Brenner, H; Rothenbacher, D; Bode, G; Adler, G			Relation of smoking and alcohol and coffee consumption to active Helicobacter pylori infection: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							CAMPYLOBACTER-PYLORI; LIVING-CONDITIONS; POPULATION; CHILDHOOD; GASTRITIS; SECRETION; ETHANOL; LIFE; RISK; AGE	Objective: To assess the relation of smoking and alcohol and coffee consumption to active Helicobacter pylori infection. Design: Cross sectional study of patients attending a general practitioner Active H pylori infection was measured by the C-13-urea breath test and detailed quantitative information on smoking and on alcohol and coffee consumption was obtained by a standardised self administered questionnaire. Setting: One general practice in Germany. Subjects: 447 patients aged 15-79 who had not had peptic ulcer disease or treatment for H pylori infection. Main outcome measures: Prevalence of H pylori infection according to smoking and alcohol and coffee consumption. Results: Overall prevalence of infection was 21% (94/447). There was no significant relation between smoking and active H pylori infection. Alcohol consumption showed a negative dose-response relation and coffee consumption a positive dose-response relation with active infection. After adjustment for potential confounders, the odds ratios for patients who drank less than or equal to 75 g and >75 g of ethanol a week compared with non-drinkers were 0.90 (95% confidence interval 0.55 to 1.59) and 0.33 (0.16 to 0.68), respectively (P value for trend 0.005, assuming that 1 litre of beer and 0.5 l of nine contain on average 50 g of ethanol in south Germany). Adjusted odds ratios for patients who drank <3 cups and greater than or equal to 3 cups of coffee per day compared with those who did not drink coffee were 1.49 (0.71 to 3.12) and 2.49 (1.23 to 5.03), respectively (P value for trend 0.007). Conclusion: These results suggest a protective effect of alcohol consumption against active infection with H pyolri and an opposite effect of coffee consumption.	UNIV ULM,DEPT INTERNAL MED 1,D-89069 ULM,GERMANY	Ulm University	Brenner, H (corresponding author), UNIV ULM,DEPT EPIDEMIOL,D-89069 ULM,GERMANY.		Brenner, Hermann/B-4627-2017; Brenner, Hermann/ABE-6383-2020	Brenner, Hermann/0000-0002-6129-1572; Brenner, Hermann/0000-0002-6129-1572; Rothenbacher, Dietrich/0000-0002-3563-2791				[Anonymous], 1993, Gut, V34, P1672; BATESON MC, 1993, POSTGRAD MED J, V69, P41, DOI 10.1136/pgmj.69.807.41; BRENNER H, 1994, EPIDEMIOLOGY, V5, P510; CHODOS JE, 1988, AM J GASTROENTEROL, V83, P1226; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; ENDOH K, 1994, GASTROENTEROLOGY, V107, P864, DOI 10.1016/0016-5085(94)90138-4; FONTHAM ETH, 1995, AM J GASTROENTEROL, V90, P1094; GASBARRINI G, 1995, GUT, V36, P838, DOI 10.1136/gut.36.6.838; GILBOA S, 1995, INT J EPIDEMIOL, V24, P232, DOI 10.1093/ije/24.1.232; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; HOOKNIKANNE J, 1991, DIGESTION, V50, P92, DOI 10.1159/000200745; JIAN R, 1986, DIGEST DIS SCI, V31, P604, DOI 10.1007/BF01318691; MAXTON DG, 1990, POSTGRAD MED J, V66, P717, DOI 10.1136/pgmj.66.779.717; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MEYER B, 1991, GUT, V32, P347, DOI 10.1136/gut.32.4.347; *NIH CONS DEV PAN, 1994, JAMA-J AM MED ASSOC, V272, P65; PARSONNET J, 1992, GASTROENTEROLOGY, V102, P41, DOI 10.1016/0016-5085(92)91782-Y; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086; PAUNIO M, 1994, EUR J EPIDEMIOL, V10, P205, DOI 10.1007/BF01730371; ROBERT A, 1983, AM J PHYSIOL, V245, pG113, DOI 10.1152/ajpgi.1983.245.1.G113; ROKKAS T, 1987, AM J GASTROENTEROL, V82, P1149; *SAS I, 1990, SAS LANG REF; SINGER MV, 1987, GASTROENTEROLOGY, V93, P1247, DOI 10.1016/0016-5085(87)90252-6; WEBB PM, 1994, BRIT MED J, V308, P750, DOI 10.1136/bmj.308.6931.750; Weisse ME, 1995, BRIT MED J, V311, P1657, DOI 10.1136/bmj.311.7021.1657	25	118	121	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1489	1492		10.1136/bmj.315.7121.1489	http://dx.doi.org/10.1136/bmj.315.7121.1489			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9420488	Green Published			2022-12-24	WOS:A1997YK98600016
J	Monaghan, AP; Bock, D; Gass, P; Schwager, A; Wolfer, DP; Lipp, HP; Schutz, G				Monaghan, AP; Bock, D; Gass, P; Schwager, A; Wolfer, DP; Lipp, HP; Schutz, G			Defective limbic system in mice lacking the tailless gene	NATURE			English	Article							RECEPTOR SUPERFAMILY; DROSOPHILA; MOUSE; HIPPOCAMPUS; RAT	The gene tailless is a member of the superfamily of genes that encode transcription factors of the ligand-activated nuclear receptor type, and is expressed in the invertebrate and vertebrate brain(1-4). In mice, its transcripts are restricted to the periventricular zone of the forebrain(4), the site of origin of neurons and glia. Here we use homologous recombination to generate mice that lack a functional tailless protein. Homozygous mutant mice are viable at birth, indicating that tailless is not required for prenatal survival; however, adult mutant mice show a reduction in the size of rhinencephalic and limbic structures, including the olfactory, infrarhinal and entorhinal cortex, amygdala and dentate gyrus. Both male and female mice are more aggressive than usual and females lack normal maternal instincts. These animals therefore enable a molecular approach to be taken towards understanding the genetic architecture and morphogenesis of the forebrain.	GERMAN CANC RES CTR,DIV MOL BIOL CELL 1,D-69120 HEIDELBERG,GERMANY; UNIV ZURICH IRCHEL,INST ANAT,CH-8057 ZURICH,SWITZERLAND	Helmholtz Association; German Cancer Research Center (DKFZ); University of Zurich			Wolfer, David P/B-3293-2016	Wolfer, David P/0000-0002-5957-1401				ALBERT DJ, 1984, NEUROSCI BIOBEHAV R, V8, P5, DOI 10.1016/0149-7634(84)90017-4; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; EDWARDS DA, 1993, PHYSIOL BEHAV, V53, P611, DOI 10.1016/0031-9384(93)90162-9; GASS P, 1992, NEUROSCIENCE, V48, P315, DOI 10.1016/0306-4522(92)90493-L; GILAD GM, 1979, BRAIN RES, V160, P17, DOI 10.1016/0006-8993(79)90597-3; GOODLETT CR, 1982, PHYSIOL BEHAV, V28, P1077, DOI 10.1016/0031-9384(82)90178-0; Gray JA, 1982, NEUROPSYCHOLOGY ANXI, DOI 10.1002/9780470720394.ch2; KAESTNER KH, 1994, GENE, V148, P67, DOI 10.1016/0378-1119(94)90234-8; KAESTNER KH, 1994, GENOMICS, V20, P377, DOI 10.1006/geno.1994.1191; Kandel E., 1995, APPLETON LANGE NORWA, V6, P425; Keefe J. O., 1978, HIPPOCAMPUS COGNITIV; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MONAGHAN AP, 1995, DEVELOPMENT, V121, P839; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; REZNIKOV KY, 1991, ADV ANAT EMBRYOL CEL, V122, P1; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; YU RT, 1994, NATURE, V370, P375, DOI 10.1038/370375a0	20	150	158	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					515	517		10.1038/37364	http://dx.doi.org/10.1038/37364			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394001				2022-12-24	WOS:A1997YJ86500053
J	Ransohoff, DF; Harris, RP				Ransohoff, DF; Harris, RP			Lessons from the mammography screening controversy: Can we improve the debate?	ANNALS OF INTERNAL MEDICINE			English	Article							BREAST-CANCER; DECISION; RISK	The debate about breast cancer screening for women in their 40s has become so contentious that effective communication and rational discussion on this topic have been compromised. This contentiousness might be defused by understanding the reasons for it. The debate is less about facts than it is about perceptions and values. There is disagreement about how to fairly describe facts about risk and how to avoid misperceptions that may distort assessment of risk. Other sources of disagreement concern the potential harms of screening, the relative roles of physicians and patients in decision making, and how to factor cost into screening decisions. The entire decision-making process has also been highly charged by single-issue advocacy groups and a kind of gender rivalry. Several approaches might help defuse the debate and improve discussion. First, those on both sides of the debate might agree on several things: 1) that the evidence from clinical trials is widely agreed-upon and thus that a main task now is to factor in the values of individual women who are making decisions; 2) that the values of women may differ substantially and that those differences should be respected; 3) that both individuals and the public should be fully and fairly informed about the pros and cons of screening; and 4) that cost-effectiveness should at least be considered during the decision-making process. Lessons from this debate may apply to other medical problems that have small degrees of risk and whose management is strongly debated.			Ransohoff, DF (corresponding author), UNIV N CAROLINA, SCH MED, CB 7105, CHAPEL HILL, NC 27599 USA.							*ACS, 1997, WORKSH GUID BREAST C; BARRY MJ, 1995, MED CARE, V33, P771, DOI 10.1097/00005650-199508000-00003; BERNSTEIN PL, 1997, GODS REMARKABLE STOD; BLACK WC, 1995, J NATL CANCER I, V87, P720, DOI 10.1093/jnci/87.10.720; BRODY J, 1997, NY TIMES        1007, pB9; BRODY J, 1997, NY TIMES        1007, pB14; Coley CM, 1997, ANN INTERN MED, V126, P468, DOI 10.7326/0003-4819-126-6-199703150-00010; Degner LF, 1997, JAMA-J AM MED ASSOC, V277, P1485, DOI 10.1001/jama.277.18.1485; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2493, DOI 10.1001/jama.263.18.2493; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P441, DOI 10.1001/jama.263.3.441; Elmore J. G., 1997, JGIM, V12, P107; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; ERNSTER VL, 1997, NIH CONS DEV C BREAS; Fisher R., 1991, GETTING YES NEGOTIAT; Flood AB, 1996, J GEN INTERN MED, V11, P342, DOI 10.1007/BF02600045; Gordis L, 1997, J NATL CANCER I, V89, P1015, DOI 10.1093/jnci/89.14.1015; HARRIS R, 1995, ANN INTERN MED, V122, P539, DOI 10.7326/0003-4819-122-7-199504010-00011; Harris R., 1996, JGIM, V11, P124; JAROFF L, 1996, TIME            0401, P58; Kasper J F, 1992, QRB Qual Rev Bull, V18, P183; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; MILLER BA, 1993, NIH PUB; Morgan M. W., 1997, JGIM, V12, P62; *NAT CANC I, 1997, NAT CANC ADV BOARD I; REDELMEIER DA, 1993, JAMA-J AM MED ASSOC, V270, P72, DOI 10.1001/jama.270.1.72; REDELMEIER DA, 1995, JAMA-J AM MED ASSOC, V273, P302, DOI 10.1001/jama.273.4.302; Roter DL, 1997, JAMA-J AM MED ASSOC, V277, P350, DOI 10.1001/jama.277.4.350; SHAPIRO S, 1971, J AMER MED ASSOC, V215, P1777; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; Thune I, 1997, NEW ENGL J MED, V336, P1269, DOI 10.1056/NEJM199705013361801; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; WAGNER JL, 1995, BPH146 OFF TECHN ASS; Willan AR, 1997, CONTROL CLIN TRIALS, V18, P121, DOI 10.1016/S0197-2456(96)00092-X; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; Woolf SH, 1997, BRIT MED J, V314, P989, DOI 10.1136/bmj.314.7086.989; WOOLF SH, 1997, WASHINGTON POST 0504, pC5; WOOLF SH, 1997, WASHINGTON POST 0504, pC1; 1997, NY TIMES        0320, P10	41	51	51	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					1029	1034		10.7326/0003-4819-127-11-199712010-00016	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00016			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412285				2022-12-24	WOS:A1997YJ08000011
J	Rowe, PM				Rowe, PM			Signalling an end to transplant rejection?	LANCET			English	News Item																			0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1526	1526		10.1016/S0140-6736(05)63956-6	http://dx.doi.org/10.1016/S0140-6736(05)63956-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9417481				2022-12-24	WOS:A1997YH11500028
J	vandenBerg, C; Willemsen, V; Hendriks, G; Weisbeek, P; Scheres, B				vandenBerg, C; Willemsen, V; Hendriks, G; Weisbeek, P; Scheres, B			Short-range control of cell differentiation in the Arabidopsis root meristem	NATURE			English	Article							SHOOT; REGULATOR; CLAVATA1; GENES; FATE	Meristems are distinctive regions of plants that have capacity for continuous growth. Their developmental activity generates the majority of plant organs(1). It is currently unknown how cell division and cell differentiation are orchestrated in meristems, although genetic studies have demonstrated the relevance of a proper balance between the two processes(2-6), Root meristems contain a distinct central region of mitotically inactive cells, the quiescent centre(7), the function of which has remained elusive until now. Here we present laser ablation and genetic data that show that in Arabidopsis thalinna the quiescent centre inhibits differentiation of surrounding cells. Differentiation regulation occurs within the range of a single cell, in a manner strikingly similar to examples in animal development, such as during delamination of Drosophila neuroblasts(8). Our data indicate that pattern formation in the root meristem is controlled by a balance between short-range signals inhibiting differentiation and signals that reinforce cell fate decisions(9).	UNIV UTRECHT,DEPT MOL CELL BIOL,NL-3584 CH UTRECHT,NETHERLANDS	Utrecht University			Hendriks, Giel/A-9731-2010	Scheres, Ben/0000-0001-5400-9578				BARLOW P, 1974, NEW PHYTOL, V73, P937, DOI 10.1111/j.1469-8137.1974.tb01323.x; CHENG JC, 1995, PLANT PHYSIOL, V107, P365, DOI 10.1104/pp.107.2.365; CLARK SE, 1993, DEVELOPMENT, V119, P397; Clark SE, 1996, DEVELOPMENT, V122, P1567; CLARK SE, 1995, DEVELOPMENT, V121, P2057; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; CLOWES F. A. L., 1956, NEW PHYTOL, V55, P29, DOI 10.1111/j.1469-8137.1956.tb05264.x; Endrizzi K, 1996, PLANT J, V10, P967, DOI 10.1046/j.1365-313X.1996.10060967.x; FELDMAN LJ, 1975, CAN J BOT, V53, P2796, DOI 10.1139/b75-307; HEJNOWICZ Z, 1991, PLANTA, V184, P1, DOI 10.1007/BF00208228; JACKSON D, 1994, DEVELOPMENT, V120, P405; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; Meyerowitz EM, 1997, CELL, V88, P299, DOI 10.1016/S0092-8674(00)81868-1; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; Scheres B, 1996, PLANT SOIL, V187, P97, DOI 10.1007/BF00011661; SCHERES B, 1994, DEVELOPMENT, V120, P2475; SINHA NR, 1993, GENE DEV, V7, P787, DOI 10.1101/gad.7.5.787; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0	18	498	516	5	81	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					287	289		10.1038/36856	http://dx.doi.org/10.1038/36856			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384380	Green Submitted			2022-12-24	WOS:A1997YG66700063
J	Wald, NJ; Law, MR; Morris, JK; Bagnall, AM				Wald, NJ; Law, MR; Morris, JK; Bagnall, AM			Helicobacter pylori infection and mortality from ischaemic heart disease: negative result from a large, prospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK-FACTORS; MYOCARDIAL-INFARCTION; SEROPOSITIVITY; ASSOCIATION; CANCER	Objective-To determine whether there is an independent association between Hel Design-Prospective study with measurement of IgG antibody titres specific to H pylori on stored serum samples from 648 men who died from ischaemic heart disease and 1296 age matched controls who did not (nested case-control design). Subjects-21 520 professional men aged 35-64 who attended the British United Provident Association (BUPA) medical centre in London between 1975 and 1982 for routine medical examination. Main outcome measure-Death from ischaemic heart disease. Results-The odds of death from ischaemic heart disease in men with H pylori infection relative to that in men without infection was 1.06 (95% confidence interval 0.86 to 1.31), In a separate group of 206 people attending the centre, plasma fibrinogen was virtually the same in those who were positive for H pylori (2.62 g/l) and those who were negative (2.64 g/l). Conclusions-A study that by its size and design minimised both random error and socioeconomic bias found no relation between H pylori infection and ischaemic heart disease. The validity of the study was shown by its confirmation of the recognised association between H pylori infection and stomach cancer (odds ratio 4.0 (1.9 to 8.2); P < 0.001). Eradication of H pylori infection may greatly reduce the incidence of stomach cancer, one of the most common causes of death from cancer worldwide, but it cannot be expected to have any effect in preventing ischaemic heart disease.	ROYAL LONDON SCH MED & DENT, LONDON EC1M 6BQ, ENGLAND	University of London; Queen Mary University London	Wald, NJ (corresponding author), ST BARTHOLOMEWS, BUPA EPIDEMIOL RES GRP, DEPT ENVIRONM & PREVENT MED, WOLFSON INST PREVENT MED, LONDON, ENGLAND.		Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021; Morris, Joan/AAT-9211-2020	Morris, Joan/0000-0002-7164-612X				Aceti A, 1996, BRIT MED J, V313, P428; AROMAA A, 1996, GUT S2, V3, pA91; Balaban DH, 1996, GASTROENTEROLOGY, V110, pA55; Caselli M., 1996, Gut, V39, pA91; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; Gerning N. Ossei, 1996, Gut, V39, pA91; Lip GYH, 1996, BRIT MED J, V312, P250; MALNICK SDH, 1996, GUT, V39, pA63; MARTINDEARGILA C, 1995, LANCET, V346, P310, DOI 10.1016/S0140-6736(95)92195-8; MCDONAGH TA, 1996, GUT               S1, V38, pA1; MENDALL MA, 1994, BRIT HEART J, V71, P437; MORGANDO A, 1995, LANCET, V345, P1380; MURRAY LJ, 1995, BRIT HEART J, V74, P497; Niemela S, 1996, HEART, V75, P573, DOI 10.1136/hrt.75.6.573; Parente F, 1997, BRIT MED J, V314, P1318, DOI 10.1136/bmj.314.7090.1318; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; Ponzetto A, 1996, BRIT MED J, V312, P251; Rathbone B, 1996, HEART, V76, P308, DOI 10.1136/hrt.76.4.308; Strandberg T. E., 1996, Gut, V39, pA92; Strandberg TE, 1997, BRIT MED J, V314, P1317, DOI 10.1136/bmj.314.7090.1317; Vakil N., 1996, Gut, V39, pA91; WALD N, 1980, LANCET, V2, P813; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1; WEBB PM, 1994, BRIT MED J, V308, P750, DOI 10.1136/bmj.308.6931.750; Whincup PH, 1996, HEART, V75, P568, DOI 10.1136/hrt.75.6.568	27	127	134	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 8	1997	315	7117					1199	1201		10.1136/bmj.315.7117.1199	http://dx.doi.org/10.1136/bmj.315.7117.1199			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393222	Green Published			2022-12-24	WOS:A1997YF25200019
J	Davis, KD; Kiss, ZHT; Luo, L; Tasker, RR; Lozano, AM; Dostrovsky, JO				Davis, KD; Kiss, ZHT; Luo, L; Tasker, RR; Lozano, AM; Dostrovsky, JO			Phantom sensations generated by thalamic microstimulation	NATURE			English	Article							ADULT HUMAN BRAIN; CORTICAL REORGANIZATION; SOMATOSENSORY CORTEX; NERVOUS-SYSTEM; MONKEYS; DEAFFERENTATION; AMPUTATION; PLASTICITY; DIGIT; PAIN	Many amputees have a sense of their missing 'phantom' limb(1-3) Amputation can alter the representation of the body's surface in the cerebral cortex(4-14) and thalamus(15,16), but it is unclear how these changes relate to such phantom sensations, One possibility is that, in amputees who experience phantom sensations, the region of the thalamus that originally represented the missing limb remains functional and can give rise to phantom sensations even when some thalamic 'limb' neurons begin to respond to stimulation of other body regions, Here we use microelectrode recording and microstimulation during functional stereotactic mapping of the ventrocaudal thalamus in amputees to determine both the responses of the neurons to stimulation of the skin and the perceptual effects of electrical activation of these neurons. Thalamic mapping revealed an unusually large thalamic stump representation, consistent with the findings from animal experiments. We also found that thalamic stimulation in amputees with a phantom limb could evoke phantom sensations, including pain, even in regions containing neurons responsive to tactile stimulation of the stump, These findings support the hypothesis that the thalamic representation of the amputated limb remains functional. in amputees with phantoms.	Univ Toronto, Dept Surg, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Playfair Neurosci Unit, Toronto, ON M5T 2S8, Canada	University of Toronto; University of Toronto; University of Toronto	Davis, KD (corresponding author), Univ Toronto, Dept Surg, Toronto, ON M5T 2S8, Canada.		Lozano, Andres M/A-5058-2012; Kiss, Zelma/D-2342-2016	Lozano, Andres M./0000-0001-8257-3694; Kiss, Zelma/0000-0002-8656-2690				AGLIOTI S, 1994, NEUROREPORT, V5, P473, DOI 10.1097/00001756-199401120-00026; CALFORD MB, 1991, SOMATOSENS MOT RES, V8, P249, DOI 10.3109/08990229109144748; CARLEN PL, 1978, NEUROLOGY, V28, P211, DOI 10.1212/WNL.28.3.211; Clarke S, 1996, NEUROREPORT, V7, P2853, DOI 10.1097/00001756-199611250-00009; Davis KD, 1996, J NEUROPHYSIOL, V75, P1026, DOI 10.1152/jn.1996.75.3.1026; Doetsch GS, 1997, SOMATOSENS MOT RES, V14, P6, DOI 10.1080/08990229771178; ELBERT T, 1994, NEUROREPORT, V5, P2593, DOI 10.1097/00001756-199412000-00047; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; Florence SL, 1995, J NEUROSCI, V15, P8083; HALLIGAN PW, 1993, NEUROREPORT, V4, P233, DOI 10.1097/00001756-199303000-00001; Kew JJM, 1997, J NEUROPHYSIOL, V77, P2753, DOI 10.1152/jn.1997.77.5.2753; KISS ZHT, 1994, STEREOT FUNCT NEUROS, V62, P153, DOI 10.1159/000098612; Knecht S, 1995, NEUROSCI LETT, V201, P262, DOI 10.1016/0304-3940(95)12186-2; LENZ FA, 1988, J NEUROSURG, V68, P630, DOI 10.3171/jns.1988.68.4.0630; LENZ FA, 1988, J NEUROPHYSIOL, V59, P299, DOI 10.1152/jn.1988.59.2.299; LENZ FA, 1994, J NEUROPHYSIOL, V72, P1570, DOI 10.1152/jn.1994.72.4.1570; MELZACK R, 1990, TRENDS NEUROSCI, V13, P88, DOI 10.1016/0166-2236(90)90179-E; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RAMACHANDRAN VS, 1993, P NATL ACAD SCI USA, V90, P10413, DOI 10.1073/pnas.90.22.10413; Rasmusson D, 1996, J COMP NEUROL, V364, P92; RASMUSSON DD, 1982, J COMP NEUROL, V205, P313, DOI 10.1002/cne.902050402; SHERMAN RA, 1984, PAIN, V18, P83, DOI 10.1016/0304-3959(84)90128-3; TASKER RR, 1995, NEUROSURG CLIN N AM, V6, P73; Tsoukatos J., 1996, Society for Neuroscience Abstracts, V22, P98; WALL JT, 1992, J NEUROSCI, V12, P3445; WALL PD, 1971, NATURE, V232, P542, DOI 10.1038/232542a0; YANG TT, 1994, NEUROREPORT, V5, P701, DOI 10.1097/00001756-199402000-00010	29	168	173	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					385	387		10.1038/34905	http://dx.doi.org/10.1038/34905			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450753				2022-12-24	WOS:000071604200053
J	Pappalardo, RT; Head, JW; Greeley, R; Sullivan, RJ; Pilcher, C; Schubert, G; Moore, WB; Carr, MH; Moore, JM; Belton, MJS; Goldsby, DL				Pappalardo, RT; Head, JW; Greeley, R; Sullivan, RJ; Pilcher, C; Schubert, G; Moore, WB; Carr, MH; Moore, JM; Belton, MJS; Goldsby, DL			Geological evidence for solid-state convection in Europa's ice shell	NATURE			English	Article							SATELLITES; WATER	The ice-rich surface of the jovian satellite Europa is sparsely cratered, suggesting that this moon might be geologically active today(1). Moreover, models of the satellite's interior indicate that tidal interactions with Jupiter might produce enough heat to maintain a subsurface liquid water layer(2-5). But the mechanisms of interior heat loss and resurfacing are currently unclear, as is the question of whether Europa has (or had at one time) a liquid water ocean(6,7). Here we report on the morphology and geological interpretation of distinct surface features-pits, domes and spots-discovered in high-resolution images of Europa obtained by the Galileo spacecraft. The features are interpreted as the surface manifestation of diapirs, relatively warm localized ice masses that have risen buoyantly through the subsurface. We find that the formation of the features can be explained by thermally induced solid-state convection within an ice shell, possibly overlying a liquid water layer. Our results are consistent with the possibility that Europa has a liquid water ocean beneath a surface layer of ice, but further tests and observations are needed to demonstrate this conclusively.	Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; NASA Headquarters, Washington, DC 20546 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; US Geol Survey, Menlo Park, CA 94025 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Natl Opt Astron Observ, Tucson, AZ 85726 USA	Brown University; Arizona State University; Arizona State University-Tempe; National Aeronautics & Space Administration (NASA); University of California System; University of California Los Angeles; United States Department of the Interior; United States Geological Survey; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; National Optical Astronomy Observatory	Pappalardo, RT (corresponding author), Brown Univ, Dept Geol Sci, Providence, RI 02912 USA.		Pappalardo, Robert/AAP-8953-2021	Pappalardo, Robert/0000-0003-2571-4627; Goldsby, David/0000-0002-9004-0086				Anderson JD, 1997, SCIENCE, V276, P1236, DOI 10.1126/science.276.5316.1236; CARR MH, 1995, J GEOPHYS RES-PLANET, V100, P18935, DOI 10.1029/95JE00971; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CASSEN PM, 1982, SATELLITES JUPITER, P93; DURHAM WB, 1992, J GEOPHYS RES-PLANET, V97, P20883, DOI 10.1029/92JE02326; GEISSLER P, 1997, P WORKSH REM SENS PL; Geissler PE, 1998, NATURE, V391, P368, DOI 10.1038/34869; Goldsby DL, 1997, SCRIPTA MATER, V37, P1399, DOI 10.1016/S1359-6462(97)00246-7; GOLDSBY DL, 1997, LUNAR PLANET SCI, V28, P429; GREELEY R, 1997, LUN PLAN SCI C ABSTR, V28, P455; GREENBERG R, 1997, LUN PLAN SCI C ABSTR, V28, P457; HOBBS PV, 1974, ICE PHYSICS; Jenyon M.K., 1986, SALT TECTONICS; KARGEL JS, 1991, ICARUS, V94, P368, DOI 10.1016/0019-1035(91)90235-L; Lucchitta B.K., 1982, SATELLITES JUPITER, P521; MCKINNON WB, 1997, B AM ASTRON SOC, V29, P984; MUELLER S, 1988, ICARUS, V76, P437, DOI 10.1016/0019-1035(88)90014-0; OBRIEN GD, 1968, AAPG BULL, V8, P1; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; OJAKANGAS GW, 1989, ICARUS, V81, P242, DOI 10.1016/0019-1035(89)90053-5; PAPPALARDO R, 1996, EOS, V78, pS203; REYNOLDS RT, 1979, GEOPHYS RES LETT, V6, P121, DOI 10.1029/GL006i002p00121; ROSS MN, 1987, NATURE, V325, P133, DOI 10.1038/325133a0; SCHENK P, 1993, GEOLOGY, V21, P299, DOI 10.1130/0091-7613(1993)021<0299:DOTARO>2.3.CO;2; Schubert G., 1986, SATELLITES, P224; Squyres S. W., 1986, SATELLITES, P293; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; STENGEL KC, 1982, J FLUID MECH, V120, P411, DOI 10.1017/S0022112082002821; WILLIAMS KK, 1997, EOS, V78, pF415	29	258	260	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					365	368		10.1038/34862	http://dx.doi.org/10.1038/34862			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450750				2022-12-24	WOS:000071604200046
J	Goldfeld, AE; Delgado, JC; Thim, S; Bozon, MV; Uglialoro, AM; Turbay, D; Cohen, C; Yunis, EJ				Goldfeld, AE; Delgado, JC; Thim, S; Bozon, MV; Uglialoro, AM; Turbay, D; Cohen, C; Yunis, EJ			Association of an HLA-DQ allele with clinical tuberculosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NECROSIS-FACTOR-ALPHA; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; DNA; AMPLIFICATION; POLYMORPHISM; INFECTION; RELEVANCE; HLA-DR1; VIRUS	Context.-Although tuberculosis (TB) is the leading worldwide cause of death due to an infectious disease, the extent to which progressive clinical disease is associated with genetic host factors remains undefined. Objective.-To determine the distribution of HLA antigens and the frequency of 2 alleles of the tumor necrosis factor alpha (TNF-alpha) gene in unrelated individuals with clinical TB (cases) compared with individuals with no history of clinical TB (controls) in a population with a high prevalence of TB exposure. Design.-A 2-stage, case-control molecular typing study conducted in 1995-1996. Setting.-Three district hospitals in Svay Rieng Province in rural Cambodia. Patients.-A total of 78 patients with clinical TB and 49 controls were included in the first stage and 48 patients with TB and 39 controls from the same area and socioeconomic status were included in the second stage. Main Outcome Measures.-Presence of HLA class I and class II alleles determined by sequence-specific oligonucleotide probe hybridization and presence of 2 TNF-alpha alleles determined by restriction fragment length polymorphism analysis. Results.-In the first stage, 7 DQB1*0503 alleles were detected among 156 alleles derived from patients with TB, whereas no DQB1*0503 alleles were found among the 98 alleles derived from controls (P=.04), There was no detectable difference in the distribution of the 2 TNF-alpha alleles in patients with TB compared with controls, In the second stage, we tested for the presence of a single variable, the DQB1*0503 allele, and found 9 DQB1*0503 alleles among 96 alleles derived from patients with TB and no DQB1*0503 alleles among 78 alleles in controls (P=.005), Conclusions.-The HLA-DQB1*0503 allele is significantly associated with susceptibility to TB in Cambodian patients and, to our knowledge, is the first identified gene associated with development of clinical TB.	Dana Farber Canc Inst, Div Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Immunogenet, Boston, MA 02115 USA; Dana Farber Canc Inst, Blood Bank, Boston, MA 02115 USA; Phnom Penh, Cambodian Hlth Comm, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Goldfeld, AE (corresponding author), Dana Farber Canc Inst, Div Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	anne_goldfeld@macmailgw.dfci.harvard.edu	Goldfeld, Anne/AAF-1818-2019		NHLBI NIH HHS [HL29583] Funding Source: Medline; NIMH NIH HHS [MH 40279] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH040279, P30MH040279] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BLOOM BR, 1994, TUBERCULOSIS PATHOGE; BODMER JG, 1995, TISSUE ANTIGENS, V46, P1; BOTHAMLEY GH, 1989, J INFECT DIS, V159, P549, DOI 10.1093/infdis/159.3.549; Bozon MV, 1996, TISSUE ANTIGENS, V47, P512, DOI 10.1111/j.1399-0039.1996.tb02593.x; BRAHMAJOTHI V, 1991, TUBERCLE, V72, P123, DOI 10.1016/0041-3879(91)90039-U; Brinkman BMN, 1996, J INFLAMM, V46, P32; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CEREB N, 1995, TISSUE ANTIGENS, V45, P1, DOI 10.1111/j.1399-0039.1995.tb02408.x; COHN DL, 1993, AIDS, V7, pS195, DOI 10.1097/00002030-199301001-00025; dCruzGrote D, 1996, LANCET, V348, P1071, DOI 10.1016/S0140-6736(95)11031-3; Farmer P, 1991, Semin Respir Infect, V6, P254; FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2; GOLDFEL AE, 1994, COMMUNICATION   0210; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; KHOMENKO AG, 1990, TUBERCLE, V71, P187, DOI 10.1016/0041-3879(90)90074-I; Kimura A., 1991, HLA 1991 P 11 INT HI, VVolume 1, P397; MILES SH, 1984, AM REV RESPIR DIS, V130, P827; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; OPELZ G, 1991, LANCET, V338, P461, DOI 10.1016/0140-6736(91)90540-6; PORTER JDH, 1994, ANNU REV PUBL HEALTH, V15, P303; Rajalingam R, 1996, J INFECT DIS, V173, P669, DOI 10.1093/infdis/173.3.669; RITH DN, 1996, P C ANT ACT CAMB PHN; Rom WN, 1996, TUBERCULOSIS, Vxxv; ROOK GAW, 1990, PATHOL BIOL, V38, P276; SALAZAR M, 1992, TISSUE ANTIGENS, V40, P116, DOI 10.1111/j.1399-0039.1992.tb02102.x; SKAMENE E, 1994, IMMUNOBIOLOGY, V191, P451, DOI 10.1016/S0171-2985(11)80451-1; STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; *UN CHILDR FUND, 1990, CAMB SIT WOM CHILDR; *WHO, 1994, WHO REP TB EP; WILSON AG, 1993, J EXP MED, V177, P557, DOI 10.1084/jem.177.2.557; YUNIS JJ, 1993, TISSUE ANTIGENS, V41, P37, DOI 10.1111/j.1399-0039.1993.tb01975.x; YUNIS JJ, 1992, TISSUE ANTIGENS, V40, P41, DOI 10.1111/j.1399-0039.1992.tb01956.x	36	180	186	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					226	228		10.1001/jama.279.3.226	http://dx.doi.org/10.1001/jama.279.3.226			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR124	9438744				2022-12-24	WOS:000071460700034
J	Howard, G; Wagenknecht, LE; Burke, GL; Diez-Roux, A; Evans, GW; McGovern, P; Nieto, J; Tell, GS				Howard, G; Wagenknecht, LE; Burke, GL; Diez-Roux, A; Evans, GW; McGovern, P; Nieto, J; Tell, GS			Cigarette smoking and progression of atherosclerosis - The atherosclerosis risk in communities (ARIC) study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTIMA-MEDIA THICKNESS; POPULATION-BASED ULTRASONOGRAPHY; CORONARY HEART-DISEASE; CAROTID ATHEROSCLEROSIS; PASSIVE SMOKING; WALL THICKNESS; CARDIOVASCULAR HEALTH; ARTERY; DETERMINANTS; MORTALITY	Context.-Cigarette smoking is a powerful risk factor for incident heart disease and stroke, but the relationship of active and passive smoking with the progression of atherosclerosis has not been described. Objective.-To examine the impact of active smoking and exposure to environmental tobacco smoke (ETS) on the progression of atherosclerosis. Design.-A longitudinal assessment of the relationship between smoking exposure evaluated at the initial visit and the 3-year change in atherosclerosis. Setting.-A population-based cohort of middle-aged adults from 4 communities in the United States. Participants.-A total of 10914 participants from the Atherosclerosis Risk in Communities (ARIC) study enrolled between 1987 and 1989. Main Outcome Measure.-Change in atherosclerosis from baseline to the 5-year follow-up as indexed by intimal-medial thickness of the carotid artery assessed by ultrasound and adjusted for demographic characteristics, cardiovascular risk factors, and lifestyle variables. Results.-Exposure to cigarette smoke was associated with progression of atherosclerosis. Relative to never smokers and after adjustment for demographic characteristics, cardiovascular risk factors, and lifestyle variables, current cigarette smoking was associated with a 50% increase in the progression of atherosclerosis (mean progression rate over 3 years, 43.0 mu m for current and 28.7 mu m for never smokers, regardless of ETS exposure), and past smoking was associated with a 25% increase (mean progression rate over 3 years, 35.8 mu m for past smokers and 28.7 mu m for never smokers). Relative to those not exposed to ETS, exposure to ETS was associated with a 20% increase (35.2 mu m for those exposed to ETS vs 29.3 mu m for those not exposed). The impact of smoking on atherosclerosis progression was greater for subjects with diabetes and hypertension. Although more pack-years of exposure was independently associated with faster progression (P<.001), after controlling for the number of pack-years, the progression rates of current and past smokers did not differ (P=.11). Conclusions.-Both active smoking and ETS exposure are associated with the progression of an index of atherosclerosis. Smoking is of particular concern for patients with diabetes and hypertension. The fact that pack-years of smoking but not current vs past smoking was associated with progression of atherosclerosis suggests that some adverse effects of smoking may be cumulative and irreversible.	Wake Forest Univ, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA; Univ Minnesota, Dept Epidemiol, Minneapolis, MN USA; Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Bergen, Norway	Wake Forest University; Johns Hopkins University; University of Minnesota System; University of Minnesota Twin Cities; University of Bergen	Howard, G (corresponding author), Wake Forest Univ, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA.		Tell, Grethe/G-5639-2015	Tell, Grethe/0000-0003-1386-1638; Howard, George/0000-0002-3068-5720	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055015, N01HC055016, N01HC055018] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-55018, N01-HC-55016, N01-HC-55015] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1991, J Neuroimaging, V1, P68; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; BELCARO G, 1995, VASA-J VASCULAR DIS, V24, P227; BOTS ML, 1993, ARTERIOSCLER THROMB, V13, P64, DOI 10.1161/01.ATV.13.1.64; BYINGTON RP, 1994, CIRCULATION, V90, P1; Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302; CROUSE JR, 1992, CONTROL CLIN TRIALS, V13, P495, DOI 10.1016/0197-2456(92)90206-F; DECKERT T, 1989, DIABETOLOGIA, V32, P219, DOI 10.1007/BF00285287; DELCKER A, 1995, STROKE, V26, P2016, DOI 10.1161/01.STR.26.11.2016; DIEZROUX AV, 1995, PREV MED, V24, P48, DOI 10.1006/pmed.1995.1007; EVANS GW, 1996, CIRCULATION, V93, P624; FORD ES, 1991, AM J EPIDEMIOL, V133, P1220, DOI 10.1093/oxfordjournals.aje.a115834; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GAY EC, 1992, DIABETES CARE, V15, P947, DOI 10.2337/diacare.15.8.947; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; HOWARD G, 1994, ARCH INTERN MED, V154, P1277; KEYS A, 1957, LANCET, V2, P959; MACK WJ, 1993, STROKE, V24, P1779, DOI 10.1161/01.STR.24.12.1779; MARGITIC SE, 1992, CONTROL CLIN TRIALS, V13, P293; OLEARY DH, 1991, STROKE, V22, P1155, DOI 10.1161/01.STR.22.9.1155; RICHEDWARDS JW, 1995, NEW ENGL J MED, V332, P1758, DOI 10.1056/NEJM199506293322607; RILEY WA, 1991, J NEUROIMAGING, V1, P168; SALONEN R, 1990, ATHEROSCLEROSIS, V81, P33, DOI 10.1016/0021-9150(90)90056-O; SALONEN R, 1991, J INTERN MED, V229, P225, DOI 10.1111/j.1365-2796.1991.tb00336.x; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STEENLAND K, 1992, JAMA-J AM MED ASSOC, V38, P113; SUAREZ L, 1984, AM J EPIDEMIOL, V120, P670, DOI 10.1093/oxfordjournals.aje.a113933; TELL GS, 1989, JAMA-J AM MED ASSOC, V261, P1178; TELL GS, 1994, CIRCULATION, V90, P2905, DOI 10.1161/01.CIR.90.6.2905; *US OFF SMOK HLTH, 1989, HLTH CONS SMOK CARD, P179; WAGENKNECHT LE, 1992, AM J PUBLIC HEALTH, V82, P33, DOI 10.2105/AJPH.82.1.33; WELLS AJ, 1994, J AM COLL CARDIOL, V24, P546, DOI 10.1016/0735-1097(94)90315-8; WILLARD JC, 1995, VITAL HTLH STAT, V263, P1; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; 1995, CONSUMER REPORTS, V20, P27	35	504	545	2	31	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	1998	279	2					119	124		10.1001/jama.279.2.119	http://dx.doi.org/10.1001/jama.279.2.119			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ015	9440661	Bronze			2022-12-24	WOS:000071338900028
J	Zhao, HQ; Ivic, L; Otaki, JM; Hashimoto, M; Mikoshiba, K; Firestein, S				Zhao, HQ; Ivic, L; Otaki, JM; Hashimoto, M; Mikoshiba, K; Firestein, S			Functional expression of a mammalian odorant receptor	SCIENCE			English	Article							MEDIATED GENE-TRANSFER; RECOMBINANT ADENOVIRUS; OLFACTORY EPITHELIUM; CYSTIC-FIBROSIS; CELLS; NEURONS; MOUSE; RECOGNITION; FAMILY; VECTOR	Candidate mammalian odorant receptors were first cloned some 6 years ago. The physiological function of these receptors in initiating transduction in olfactory receptor neurons remains to be established. Here, a recombinant adenovirus was used to drive expression of a particular receptor gene in an increased number of sensory neurons in the rat olfactory epithelium. Electrophysiological recording showed that increased expression of a single gene led to greater sensitivity to a small subset of odorants.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Yale Univ, Interdept Neurosci Program, New Haven, CT 06510 USA; RIKEN, Tsukuba Life Sci Ctr, Mol Neurobiol Lab, Tsukuba, Ibaraki 305, Japan	Columbia University; Yale University; RIKEN	Firestein, S (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.		Hashimoto, Mitsuhiro/G-1981-2010; Oka, Yoshitaka/C-9670-2010; Mikoshiba, Katsuhiko/N-7943-2015	Hashimoto, Mitsuhiro/0000-0002-8751-4068; Oka, Yoshitaka/0000-0002-3482-3051; 				BECKER TC, 1994, PROTEIN EXPRESSION A, P162; Breer Heinz, 1994, Seminars in Cell Biology, V5, P25, DOI 10.1006/scel.1994.1004; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Hashimoto M, 1996, HUM GENE THER, V7, P149, DOI 10.1089/hum.1996.7.2-149; Holtmaat AJGD, 1996, MOL BRAIN RES, V41, P148, DOI 10.1016/0169-328X(96)00085-X; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; LANCET D, 1993, CURR BIOL, V3, P668, DOI 10.1016/0960-9822(93)90064-U; LESALLE GL, 1993, SCIENCE, V259, P988; LOWE G, 1993, NATURE, V366, P283, DOI 10.1038/366283a0; MACKAYSIM A, 1994, J NEUROPHYSIOL, V71, pC15; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MORI K, 1995, PROG NEUROBIOL, V45, P585, DOI 10.1016/0301-0082(94)00058-P; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; OTTOSON D, 1956, ACTA PHYSIOL SC S122, V35, P1; Ottoson D, 1971, HDB SENSORY PHYSIO 1, V4, P95; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; RESTREPO D, 1995, EXPT CELL BIOL TASTE, P387; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SATO T, 1994, J NEUROPHYSIOL, V72, P2980, DOI 10.1152/jn.1994.72.6.2980; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; SHENK T, 1996, FIELDS VIROLOGY, V2, P2111; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; SHIRLEY SG, 1987, BIOCHEM J, V245, P185, DOI 10.1042/bj2450185; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; WELERDIECK C, 1997, CHEM SENSES, V22, P467; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K; Zhang Y, 1997, P NATL ACAD SCI USA, V94, P12162, DOI 10.1073/pnas.94.22.12162; Zhao HQ, 1996, J NEUROBIOL, V30, P521, DOI 10.1002/(SICI)1097-4695(199608)30:4<521::AID-NEU7>3.0.CO;2-5	36	488	502	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					237	242		10.1126/science.279.5348.237	http://dx.doi.org/10.1126/science.279.5348.237			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422698				2022-12-24	WOS:000071408100045
J	Chesebro, B				Chesebro, B			Prion diseases - BSE and prions: Uncertainties about the agent	SCIENCE			English	Article							CREUTZFELDT-JAKOB-DISEASE; TRANSGENIC MICE; NEURODEGENERATION; PROTEIN		NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Chesebro, B (corresponding author), NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, Hamilton, MT 59840 USA.							Aguzzi A, 1997, NATURE, V389, P795, DOI 10.1038/39758; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BRUCE ME, 1997, COMMUNICATION; Chesebro B, 1997, NAT MED, V3, P491, DOI 10.1038/nm0597-491; Cousens SN, 1997, BRIT MED J, V315, P389, DOI 10.1136/bmj.315.7105.389; CUGHEY B, 1997, TRENDS CELL BIOL, V7, P56; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; Tateishi J, 1996, NEUROLOGY, V46, P532, DOI 10.1212/WNL.46.2.532; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	14	145	149	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					42	43		10.1126/science.279.5347.42	http://dx.doi.org/10.1126/science.279.5347.42			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9441410				2022-12-24	WOS:000071323900032
J	Schwartz, LB				Schwartz, LB			Understanding human parturition	LANCET			English	Editorial Material							PROGESTERONE RECEPTORS; LABOR; ESTRADIOL; PREGNANCY; TERM		NYU, Med Ctr, Dept Obstet & Gynaecol, New York, NY 10016 USA	New York University	Schwartz, LB (corresponding author), NYU, Med Ctr, Dept Obstet & Gynaecol, New York, NY 10016 USA.							AMBRUS G, 1994, ENDOCRINOLOGY, V135, P2772, DOI 10.1210/en.135.6.2772; BECK P, 1978, OBSTET GYNECOL, V51, P686; CHWALISZ K, 1994, HUM REPROD, V9, P131, DOI 10.1093/humrep/9.suppl_1.131; Faber BM, 1996, OBSTET GYNECOL, V88, P174, DOI 10.1016/0029-7844(96)00136-6; FLINT APF, 1975, BIOCHEM SOC T, V3, P1189, DOI 10.1042/bst0031189; GIANNOPOULOS G, 1979, J CLIN ENDOCR METAB, V49, P100, DOI 10.1210/jcem-49-1-100; HOW H, 1995, OBSTET GYNECOL, V86, P936, DOI 10.1016/0029-7844(95)00306-C; JOHNSTON TA, 1993, BRIT J OBSTET GYNAEC, V100, P483, DOI 10.1111/j.1471-0528.1993.tb15277.x; Karalis K, 1996, NAT MED, V2, P556, DOI 10.1038/nm0596-556; KHANDAWOOD FS, 1984, AM J OBSTET GYNECOL, V150, P510; PADAYACHI T, 1990, J STEROID BIOCHEM, V37, P509, DOI 10.1016/0960-0760(90)90394-Z; PERROTAPPLANAT M, 1994, J CLIN ENDOCR METAB, V78, P216, DOI 10.1210/jc.78.1.216; Rezapour M, 1997, OBSTET GYNECOL, V89, P918, DOI 10.1016/S0029-7844(97)00116-6; Rezapour M, 1996, STEROIDS, V61, P338, DOI 10.1016/0039-128X(96)00035-9; WILSON L, 1996, REPROD ENDOCRINOLOGY, P452	15	14	15	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1792	1793		10.1016/S0140-6736(05)63632-X	http://dx.doi.org/10.1016/S0140-6736(05)63632-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428247	hybrid			2022-12-24	WOS:000071102500004
J	Huala, E; Oeller, PW; Liscum, E; Han, IS; Larsen, E; Briggs, WR				Huala, E; Oeller, PW; Liscum, E; Han, IS; Larsen, E; Briggs, WR			Arabidopsis NPH1: A protein kinase with a putative redox-sensing domain	SCIENCE			English	Article							LIGHT-INDUCED PHOSPHORYLATION; AZOTOBACTER-VINELANDII NIFL; NUCLEOTIDE-SEQUENCE; POTASSIUM CHANNEL; SIGNAL-TRANSDUCTION; MEMBRANE-PROTEIN; GENE-EXPRESSION; HIGHER-PLANTS; THALIANA; DROSOPHILA	The NPH1 (nonphototropic hypocotyl 1) gene encodes an essential component acting very early in the signal-transduction chain for phototropism. Arabidopsis NPH? contains a serine-threonine kinase domain and LOV1 and LOV2 repeats that share similarity (36 to 56 percent) with Halobacterium salinarium Bat, Azotobacter vinelandii NIFL, Neurospora crassa White Collar-1, Escherichia call Aer, and the fag family of potassium-channel proteins from Drosophila and mammals. Sequence similarity with a known (NIFL) and a suspected (Aer) flavoprotein suggests that NPH1 LOV1 and LOV2 may be flavin-binding domains that regulate kinase activity in response to blue light-induced redox changes.	CARNEGIE INST WASHINGTON, DEPT PLANT BIOL, STANFORD, CA 94305 USA	Carnegie Institution for Science			Huala, Eva L/B-1377-2009	Huala, Eva/0000-0003-4631-7241; Liscum, Emmanuel/0000-0002-8672-9315				AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; ALLMEIER H, 1992, GENE, V111, P11, DOI 10.1016/0378-1119(92)90597-I; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel F, 1989, MOL REPROD DEV, V1, P146; Ballario P, 1996, EMBO J, V15, P1650, DOI 10.1002/j.1460-2075.1996.tb00510.x; BAUR B, 1994, PLANT PHYSIOL, V106, P1225, DOI 10.1104/pp.106.3.1225; Bibikov SI, 1997, J BACTERIOL, V179, P4075, DOI 10.1128/jb.179.12.4075-4079.1997; BLANCO G, 1993, MOL MICROBIOL, V9, P869, DOI 10.1111/j.1365-2958.1993.tb01745.x; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DRUMMOND MH, 1987, MOL MICROBIOL, V1, P37, DOI 10.1111/j.1365-2958.1987.tb00524.x; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; GROPP F, 1994, P NATL ACAD SCI USA, V91, P5475, DOI 10.1073/pnas.91.12.5475; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hill S, 1996, P NATL ACAD SCI USA, V93, P2143, DOI 10.1073/pnas.93.5.2143; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; KHURANA J P, 1989, Planta (Heidelberg), V178, P400, DOI 10.1007/BF00391868; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LEONG D, 1988, J BACTERIOL, V170, P4903, DOI 10.1128/jb.170.10.4903-4909.1988; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; Lin C., 1996, PLANT PHYSIOL, V110, P1047; LIN X, 1991, P NATL ACAD SCI USA, V88, P6951, DOI 10.1073/pnas.88.16.6951; LISCUM E, 1995, PLANT CELL, V7, P473, DOI 10.1105/tpc.7.4.473; LISCUM E, ANAL BIOTECHNOLOGY G; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; NARBERHAUS F, 1995, J BACTERIOL, V177, P5078, DOI 10.1128/jb.177.17.5078-5087.1995; PALMER JM, 1993, PLANT PHYSIOL, V102, P1211, DOI 10.1104/pp.102.4.1211; RAINA R, 1993, MOL GEN GENET, V237, P400, DOI 10.1007/BF00279444; Rebbapragada A, 1997, P NATL ACAD SCI USA, V94, P10541, DOI 10.1073/pnas.94.20.10541; REYMOND P, 1992, PLANT PHYSIOL, V100, P655, DOI 10.1104/pp.100.2.655; REYMOND P, 1992, P NATL ACAD SCI USA, V89, P4718, DOI 10.1073/pnas.89.10.4718; SHORT TW, 1994, PLANT PHYSIOL, V104, P1317, DOI 10.1104/pp.104.4.1317; SHORT TW, 1994, ANNU REV PLANT PHYS, V45, P143, DOI 10.1146/annurev.pp.45.060194.001043; Siddavattam D, 1995, MOL GEN GENET, V249, P629, DOI 10.1007/BF00418032; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; TYTGAT J, 1993, J BIOL CHEM, V268, P23777; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; WADA M, COMMUNICATION; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; ZABEAU M, 1993, Patent No. 4026297; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	45	585	622	0	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 19	1997	278	5346					2120	2123		10.1126/science.278.5346.2120	http://dx.doi.org/10.1126/science.278.5346.2120			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405347				2022-12-24	WOS:A1997YM23500052
J	McKernan, MG; ShinnickGallagher, P				McKernan, MG; ShinnickGallagher, P			Fear conditioning induces a lasting potentiation of synaptic currents in vitro	NATURE			English	Article							PAIRED-PULSE FACILITATION; LONG-TERM POTENTIATION; MEDIAL GENICULATE-BODY; LATERAL NUCLEUS; RAT HIPPOCAMPUS; NMDA RECEPTORS; PATCH-CLAMP; CA1 REGION; AMYGDALA; TRANSMISSION	The amygdala plays a critical role in the mediation of emotional responses, particularly fear, in both humans and animals(1-4). Fear conditioning, a conditioned learning paradigm, has served as a model for emotional learning in animals, and the neuroanatomical circuitry underlying the auditory fear-conditioning paradigm is well characterized(5). Synaptic transmission in the medial geniculate nucleus (MGN) to lateral nucleus of the amygdala (LA) pathway, a key segment of the auditory fear conditioning circuit, is mediated largely through N-methyl-D-aspartate (NMDA) and non-NMDA (such as alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)) glutamate receptors(6); the potential for neural plasticity in this pathway is suggested by its capacity to support long-term potentiation (LTP)(7,8). Here we report a long-lasting increase in the synaptic efficacy of the MGN-LA pathway attributable to fear-conditioning itself, rather than an electrically induced model of learning. Fear-conditioned animals show a presynaptic facilitation of AMPA-receptor-mediated transmission, directly measured in vitro with whole-cell recordings in lateral amygdala neurons. These findings represent one of the first in vitro measures of synaptic plasticity resulting from emotional learning by whole animals.	UNIV TEXAS,MED BRANCH,DEPT PHARMACOL & TOXICOL,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston								ALDOLPHS R, 1994, NATURE, V372, P669; ANDREASEN M, 1994, J NEUROPHYSIOL, V72, P326, DOI 10.1152/jn.1994.72.1.326; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; CASSELLA JV, 1986, PHYSIOL BEHAV, V36, P377, DOI 10.1016/0031-9384(86)90032-6; CLARK KA, 1994, EXP BRAIN RES, V101, P272, DOI 10.1007/BF00228747; CLUGNET MC, 1990, J NEUROSCI, V10, P2818; CREAGER R, 1980, J PHYSIOL-LONDON, V299, P409, DOI 10.1113/jphysiol.1980.sp013133; DAVIS M, 1994, TRENDS NEUROSCI, V17, P208, DOI 10.1016/0166-2236(94)90106-6; DAVIS M, 1993, BEHAV BRAIN RES, V58, P175, DOI 10.1016/0166-4328(93)90102-V; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KIM M, 1993, BEHAV NEURAL BIOL, V59, P5, DOI 10.1016/0163-1047(93)91075-X; KUHNT U, 1994, NEUROSCIENCE, V62, P391, DOI 10.1016/0306-4522(94)90374-3; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; LEDOUX JE, 1985, J COMP NEUROL, V242, P182, DOI 10.1002/cne.902420204; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; LI XF, 1995, EXP BRAIN RES, V105, P87; LIN JW, 1988, J NEUROSCI, V8, P1313; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; Maren S, 1996, MOL NEUROBIOL, V13, P1, DOI 10.1007/BF02740749; McKernan M. G., 1996, Society for Neuroscience Abstracts, V22, P1536; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; MULLER D, 1990, SYNAPSE, V5, P94, DOI 10.1002/syn.890050203; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; Neugebauer V, 1997, J NEUROSCI, V17, P983; PARSONS CG, 1994, NEUROPHARMACOLOGY, V33, P589, DOI 10.1016/0028-3908(94)90163-5; ROGAN MT, 1995, NEURON, V15, P127, DOI 10.1016/0896-6273(95)90070-5; Scott SK, 1997, NATURE, V385, P254, DOI 10.1038/385254a0; SHULZ P, 1994, J NEUROSCI, V14, P5325	29	611	620	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					607	611		10.1038/37605	http://dx.doi.org/10.1038/37605			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403689				2022-12-24	WOS:A1997YK85300049
J	Uozumi, N; Kume, K; Nagase, T; Nakatani, N; Ishii, S; Tashiro, F; Komagata, Y; Maki, K; Ikuta, K; Ouchi, Y; Miyazaki, J; Shimizu, T				Uozumi, N; Kume, K; Nagase, T; Nakatani, N; Ishii, S; Tashiro, F; Komagata, Y; Maki, K; Ikuta, K; Ouchi, Y; Miyazaki, J; Shimizu, T			Role of cytosolic phospholipase A(2) in allergic response and parturition	NATURE			English	Article							PLATELET-ACTIVATING-FACTOR; ARACHIDONIC-ACID; MAST-CELLS; GENE DISRUPTION; DEFICIENT MICE; RECEPTOR; MOUSE; PHOSPHORYLATION; TRANSLOCATION; KINASE	Phospholipase A(2) (PLA(2)) comprises a superfamily of enzymes that hydrolyse the ester bond of phospholipids at the sn-2 position(1-3). Among the members of this superfamily, cytosolic PLA(2) has attracted attention because it preferentially hydrolyses arachidonoyl phospholipids and is activated by submicromolar concentrations of Ca2+ ions and by phosphorylation by mitogen-activated protein kinases (MAP kinases)(4-8). Here we investigate the function of cytosolic PLA(2) in vivo by using homologous recombination to generate mice deficient in this enzyme. These mice showed a marked decrease in their production of eicosanoids and platelet-activating factor in peritoneal macrophages. Their ovalbumin-induced anaphylactic responses were significantly reduced, as was their bronchial reactivity to methacholine. Female mutant mice failed to deliver offspring, but these could be rescued by administration of a progesterone-receptor antagonist to the mother at term. Considered together with previous findings(9-15), our results indicate that cytosolic PLA(2) plays a non-redundant role in allergic responses and reproductive physiology.	UNIV TOKYO,FAC MED,DEPT BIOCHEM & MOL BIOL,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT GERIATR,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DIS RELATED GENE REGULAT RES SANDOZ,BUNKYO KU,TOKYO 113,JAPAN; TOHOKU UNIV,INST DEV AGING & CANC,AOBA KU,SENDAI,MIYAGI 98077,JAPAN	University of Tokyo; University of Tokyo; University of Tokyo; Tohoku University			Miyazaki, Jun-ichi/N-1976-2015; Uozumi, Nobuyuki/AAG-3252-2019	Miyazaki, Jun-ichi/0000-0003-2475-589X; Ikuta, Koichi/0000-0003-1319-1021; Kume, Kazuhiko/0000-0003-4232-1657				AOKI Y, 1995, J IMMUNOL METHODS, V186, P225, DOI 10.1016/0022-1759(95)00147-3; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CURRIE S, 1994, BIOCHEM J, V304, P923, DOI 10.1042/bj3040923; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dudley DJ, 1996, BIOL REPROD, V55, P992, DOI 10.1095/biolreprod55.5.992; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GOLDBERG VJ, 1975, PHYSIOL REV, V55, P325, DOI 10.1152/physrev.1975.55.3.325; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; Irvin CG, 1997, AM J PHYSIOL-LUNG C, V272, pL1053, DOI 10.1152/ajplung.1997.272.6.L1053; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Nagase T, 1996, AM J RESP CRIT CARE, V154, P504, DOI 10.1164/ajrccm.154.2.8756829; NAKATANI Y, 1994, J IMMUNOL, V153, P796; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; ONEILL C, 1989, LANCET, V2, P769; Prescott SM, 1997, J BIOL CHEM, V272, P15043, DOI 10.1074/jbc.272.24.15043; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHARP JD, 1994, J BIOL CHEM, V269, P23250; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X	30	582	602	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					618	622		10.1038/37622	http://dx.doi.org/10.1038/37622			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403692				2022-12-24	WOS:A1997YK85300052
J	OBrien, E				OBrien, E			Walk in peace: banish landmines from our globe	BRITISH MEDICAL JOURNAL			English	Article											OBrien, E (corresponding author), ROYAL COLL SURGEONS IRELAND,SCH MED,ST STEPHENS GREEN,DUBLIN 2,IRELAND.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1456	1458		10.1136/bmj.315.7120.1456	http://dx.doi.org/10.1136/bmj.315.7120.1456			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418101	Green Published			2022-12-24	WOS:A1997YJ67200038
J	Correll, CC; Freeborn, B; Moore, PB; Steitz, TA				Correll, CC; Freeborn, B; Moore, PB; Steitz, TA			Metals, motifs, and recognition in the crystal structure of a 5S rRNA domain	CELL			English	Article							5-S RIBOSOMAL-RNA; ESCHERICHIA-COLI; BINDING-SITES; MAJOR GROOVE; HAMMERHEAD RIBOZYME; ALPHA-SARCIN; PROTEINS; LOOP; CONFORMATION; COMPLEX	Two new RNA structures portray how non-Watson-Crick base pairs and metal ions can produce a unique RNA shape suitable for recognition by proteins. The crystal structures of a 62 nt domain of E. coli 5S ribosomal RNA and a duplex dodecamer encompassing an internal loop E have been determined at 3.0 and 1.5 Angstrom, respectively. This loop E region is distorted by three ''cross-strand purine stacks'' and three novel, water-mediated noncanonical base pairs and stabilized by a four metal ion zipper. These features give its minor groove a unique hydrogen-bonding surface and make the adjacent major groove wide enough to permit recognition by the ribosomal protein L25, which is expected to bind to this surface.	YALE UNIV, DEPT MOL BIOPHYS & BIOCHEM, NEW HAVEN, CT 06520 USA; YALE UNIV, DEPT CHEM, NEW HAVEN, CT 06520 USA; HOWARD HUGHES MED INST, NEW HAVEN, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute			Steitz, Thomas A./C-6559-2009		NIGMS NIH HHS [GM-54216, GM-22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMEGUID SS, 1983, J MOL BIOL, V171, P207, DOI 10.1016/S0022-2836(83)80353-2; Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; Biswas R, 1997, J MOL BIOL, V267, P1149, DOI 10.1006/jmbi.1997.0936; BRUNEL C, 1991, J MOL BIOL, V221, P293; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cate JH, 1996, STRUCTURE, V4, P1221, DOI 10.1016/S0969-2126(96)00129-3; Cate JH, 1997, NAT STRUCT BIOL, V4, P553, DOI 10.1038/nsb0797-553; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; Correll CC, 1997, J BIOMOL STRUCT DYN, V15, P165, DOI 10.1080/07391102.1997.10508183; Dallas A, 1995, BIOCHEM CELL BIOL, V73, P887, DOI 10.1139/o95-096; DOUTHWAITE S, 1982, BIOCHEMISTRY-US, V21, P2313, DOI 10.1021/bi00539a007; DOUTHWAITE S, 1979, NUCLEIC ACIDS RES, V6, P2453, DOI 10.1093/nar/6.7.2453; GAUTHERET D, 1995, RNA, V1, P807; Gluck A, 1996, J MOL BIOL, V256, P838, DOI 10.1006/jmbi.1996.0130; HARTMANN RK, 1988, NUCLEIC ACIDS RES, V16, P3511, DOI 10.1093/nar/16.8.3511; HUBER PW, 1984, P NATL ACAD SCI-BIOL, V81, P322, DOI 10.1073/pnas.81.2.322; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM JL, 1992, THESIS YALE U NEW HA; LEONTIS NB, 1984, NUCLEIC ACIDS RES, V12, P2193, DOI 10.1093/nar/12.4.2193; LEONTIS NB, 1986, BIOCHEMISTRY-US, V25, P7386, DOI 10.1021/bi00371a021; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOORE PB, 1996, RIBOSOMAL RNA STRUCT, P199; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan  T., 1993, RNA WORLD, P271; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; RABINOVICH D, 1988, J MOL BIOL, V200, P151, DOI 10.1016/0022-2836(88)90340-3; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P120; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SHEN Z, 1994, J MOL BIOL, V241, P415, DOI 10.1006/jmbi.1994.1517; SZEWCZAK AA, 1995, J MOL BIOL, V247, P81, DOI 10.1006/jmbi.1994.0124; TOUKIFIMPA R, 1989, BIOCHEMISTRY-US, V28, P5840, DOI 10.1021/bi00440a021; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013; WU M, 1995, BIOCHEMISTRY-US, V34, P3204, DOI 10.1021/bi00010a009	43	357	359	2	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 28	1997	91	5					705	712		10.1016/S0092-8674(00)80457-2	http://dx.doi.org/10.1016/S0092-8674(00)80457-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393863	Bronze			2022-12-24	WOS:A1997YH96000017
J	Kawano, T; Cui, JQ; Koezuka, Y; Toura, I; Kaneko, Y; Motoki, K; Ueno, H; Nakagawa, R; Sato, H; Kondo, E; Koseki, H; Taniguchi, M				Kawano, T; Cui, JQ; Koezuka, Y; Toura, I; Kaneko, Y; Motoki, K; Ueno, H; Nakagawa, R; Sato, H; Kondo, E; Koseki, H; Taniguchi, M			CD1d-restricted and TCR-mediated activation of V(alpha)14 NKT cells by glycosylceramides	SCIENCE			English	Article							RECEPTOR-ALPHA-CHAIN; T-CELLS; ANTITUMOR ACTIVITIES; POSITIVE SELECTION; BONE-MARROW; EXPRESSION; THYMOCYTES; ANTIGEN; GALACTOSYLCERAMIDES; MOLECULES	Natural killer T (NKT) lymphocytes express an invariant T cell antigen receptor (TCR) encoded by the V(alpha)14 and J(alpha)281 gene segments. A glycosylceramide-containing alpha-anomeric sugar with a longer fatty acyl chain (C-26) and sphingosine base (C-18) was identified as a ligand for this TCR. Glycosylceramide-mediated proliferative responses of V(alpha)14 NKT cells were abrogated by treatment with chloroquine-concanamycin A or by monoclonal antibodies against CD1dN(beta)8, CD40/CD40L, or B7/CTLA-4/CD28, but not by interference with the function of a transporter-associated protein. Thus, this lymphocyte shares distinct recognition systems with either T or NK cells.	CHIBA UNIV,SCH MED,DIV MOL IMMUNOL,CTR BIOMED SCI,CHUO KU,CHIBA 260,JAPAN; PHARMACEUT RES LAB,KIRIN BREWERY,TAKASAKI,GUMMA 37012,JAPAN; JAPAN SCI & TECHNOL CORP,CORE RES EVOL SCI & TECHNOL PROJECT,TOKYO,JAPAN	Chiba University; Kirin Brewery Company Limited; Japan Science & Technology Agency (JST)			Koseki, Haruhiko/I-3825-2014; Taniguchi, Masaru/N-7932-2015	Koseki, Haruhiko/0000-0001-8424-5854; Taniguchi, Masaru/0000-0001-7821-7179				ADACHI Y, 1995, P NATL ACAD SCI USA, V92, P1200, DOI 10.1073/pnas.92.4.1200; ALI S, 1993, BIOCHEMISTRY-US, V32, P11696, DOI 10.1021/bi00094a028; BALLAS ZK, 1990, J IMMUNOL, V145, P1039; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BENDELAC A, 1995, J EXP MED, V182, P2091, DOI 10.1084/jem.182.6.2091; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BREIMER ME, 1975, J LIPID RES, V16, P189; BRUTKIEWICZ RR, 1995, J EXP MED, V182, P1913, DOI 10.1084/jem.182.6.1913; BUDD RC, 1987, J EXP MED, V166, P577, DOI 10.1084/jem.166.2.577; Chen YH, 1997, IMMUNITY, V6, P459, DOI 10.1016/S1074-7613(00)80289-7; CORVER J, 1995, J VIROL, V69, P3220, DOI 10.1128/JVI.69.5.3220-3223.1995; COSTANTINO V, 1995, LIEBIGS ANN, P1471; CROSSMAN MW, 1984, BIOCHIM BIOPHYS ACTA, V795, P411, DOI 10.1016/0005-2760(84)90092-4; CROWLEY M, 1989, CELL IMMUNOL, V118, P108, DOI 10.1016/0008-8749(89)90361-4; CUI J, 1997, SCIENCE, V278, P263; DAHIYA R, 1986, LIPIDS, V21, P107, DOI 10.1007/BF02534429; FOWLKES BJ, 1987, NATURE, V329, P251, DOI 10.1038/329251a0; IMAI K, 1986, P NATL ACAD SCI USA, V83, P8708, DOI 10.1073/pnas.83.22.8708; JENSEN PE, 1988, J IMMUNOL, V141, P2545; KARLSSON KA, 1973, BIOCHIM BIOPHYS ACTA, V316, P317, DOI 10.1016/0005-2760(73)90072-6; KAWAHARA K, 1994, BIOSCI BIOTECH BIOCH, V58, P600, DOI 10.1271/bbb.58.600; KAWASAKI S, 1994, J BACTERIOL, V176, P284, DOI 10.1128/JB.176.2.284-290.1994; Kobayashi E, 1995, ONCOL RES, V7, P529; Koseki H, 1989, Int Immunol, V1, P557, DOI 10.1093/intimm/1.6.557; LAINE RA, 1987, METHOD ENZYMOL, V138, P186; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; LAVIE Y, 1994, BBA-MOL CELL RES, V1220, P323, DOI 10.1016/0167-4889(94)90156-2; LEVITSKY HI, 1991, J IMMUNOL, V146, P1113; MAKINO Y, 1995, INT IMMUNOL, V7, P1157, DOI 10.1093/intimm/7.7.1157; Makino Y, 1996, P NATL ACAD SCI USA, V93, P6516, DOI 10.1073/pnas.93.13.6516; MASUDA K, 1997, J IMMUNOL, V158, P276; Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3; Mieza MA, 1996, J IMMUNOL, V156, P4035; MORETTA L, 1994, ADV IMMUNOL, V55, P341; MORITA M, 1995, J MED CHEM, V38, P2176, DOI 10.1021/jm00012a018; MOTOKI K, 1995, BIOL PHARM BULL, V18, P1487; NATORI T, 1993, TETRAHEDRON LETT, V34, P5591, DOI 10.1016/S0040-4039(00)73889-5; NISHIMURA K, 1985, J BIOCHEM-TOKYO, V98, P1247, DOI 10.1093/oxfordjournals.jbchem.a135391; NISHIMURA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P269; OKABE K, 1968, BIOCHEM BIOPH RES CO, V31, P137, DOI 10.1016/0006-291X(68)90043-0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; Prigozy TI, 1997, IMMUNITY, V6, P187, DOI 10.1016/S1074-7613(00)80425-2; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Sugita M, 1996, SCIENCE, V273, P349, DOI 10.1126/science.273.5273.349; SVENNERHOLM L, 1972, BIOCHIM BIOPHYS ACTA, V280, P626, DOI 10.1016/0005-2760(72)90142-7; SYKES M, 1990, J IMMUNOL, V145, P3209; Taniguchi M, 1996, P NATL ACAD SCI USA, V93, P11025, DOI 10.1073/pnas.93.20.11025; WATANABE K, 1976, J BIOL CHEM, V251, P2385; WIBO M, 1974, J CELL BIOL, V63, P430, DOI 10.1083/jcb.63.2.430; WOO JT, 1992, EUR J BIOCHEM, V207, P383, DOI 10.1111/j.1432-1033.1992.tb17061.x; YOKOYAMA WM, 1995, P NATL ACAD SCI USA, V92, P3081, DOI 10.1073/pnas.92.8.3081; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	53	2051	2158	1	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1626	1629		10.1126/science.278.5343.1626	http://dx.doi.org/10.1126/science.278.5343.1626			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374463				2022-12-24	WOS:A1997YJ87400042
J	Li, P; Nijhawan, D; Budihardjo, I; Srinivasula, SM; Ahmad, M; Alnemri, ES; Wang, XD				Li, P; Nijhawan, D; Budihardjo, I; Srinivasula, SM; Ahmad, M; Alnemri, ES; Wang, XD			Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade	CELL			English	Article							PROGRAMMED CELL-DEATH; CAENORHABDITIS-ELEGANS; CYSTEINE PROTEASE; INTERLEUKIN-1-BETA-CONVERTING ENZYME; ICE/CED-3 PROTEASE; BCL-2 PROTEIN; LAMIN-A; GENE; ENCODES; HOMOLOG	We report here the purification of the third protein factor, Apaf-3, that participates in caspase-3 activation in vitro. Apaf-3 was identified as a member of the caspase family, caspase-9. Caspase-9 and Apaf-1 bind to each other via their respective NH2-terminal CED-3 homologous domains in the presence of cytochrome c and dATP, an event that leads to caspase-9 activation. Activated caspase-9 in turn cleaves and activates caspase-3. Depletion of caspase-9 from S-100 extracts diminished caspase-3 activation. Mutation of the active site of caspase-9 attenuated the activation of caspase-3 and cellular apoptotic response in vivo, indicating that caspase-9 is the most upstream member of the apoptotic protease cascade that is triggered by cytochrome c and dATP.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; THOMAS JEFFERSON UNIV,CTR APOPTOSIS RES,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Jefferson University; Jefferson University			Alnemri, Emad S/B-4526-2010	Wang, Xiaodong/0000-0001-9885-356X	NIA NIH HHS [AG13487] Funding Source: Medline; NIGMS NIH HHS [GM08014, GMRO1-55942] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; An B, 1996, FEBS LETT, V399, P158, DOI 10.1016/S0014-5793(96)01311-7; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CACIOLAROSEN L, 1996, J EXP MED, V183, P1957; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; DEJONG D, 1994, CANCER RES, V54, P256; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Eguchi Y, 1997, CANCER RES, V57, P1835; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICHOLSON WD, 1997, TRENDS BIOCHEM SCI, V257, P299; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SKOOG L, 1974, J BIOL CHEM, V249, P6434; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; SRINIVASULA SM, 1996, P NATL ACAD SCI USA, V93, P14488; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Ubeda M, 1997, J BIOL CHEM, V272, P19562, DOI 10.1074/jbc.272.31.19562; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	62	6041	6272	16	419	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					479	489		10.1016/S0092-8674(00)80434-1	http://dx.doi.org/10.1016/S0092-8674(00)80434-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390557	Bronze			2022-12-24	WOS:A1997YG49200009
J	Harvey, I; Frankel, S; Marks, R; Shalom, D; Morgan, M				Harvey, I; Frankel, S; Marks, R; Shalom, D; Morgan, M			Foot morbidity and exposure to chiropody: population based study	BRITISH MEDICAL JOURNAL			English	Article									UNIV WALES COLL CARDIFF,COLL MED,DEPT DERMATOL,CARDIFF CF4 4XN,S GLAM,WALES; TEMPLE PEACE & HLTH,CTR APPL PUBL HLTH,CARDIFF CF1 3NW,S GLAM,WALES	Cardiff University	Harvey, I (corresponding author), DEPT SOCIAL MED,CANYNGE HALL,BRISTOL BS8 2PR,AVON,ENGLAND.		Morgan, Maria/D-3379-2009	Morgan, Maria/0000-0002-5182-7222				BENNETT N, 1996, RESULTS 1994 GEN HOU; BRYAN S, 1991, HEALTH POLICY, V18, P169, DOI 10.1016/0168-8510(91)90098-I; CARTWRIGHT A, 1986, MORE TROUBLE FEET; *CHIR TASK FORC, 1994, FEET 1; Harvey I, 1996, BRIT J CANCER, V74, P1302, DOI 10.1038/bjc.1996.534	5	29	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1054	1055		10.1136/bmj.315.7115.1054	http://dx.doi.org/10.1136/bmj.315.7115.1054			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366731	Green Published			2022-12-24	WOS:A1997YD44500020
J	Greene, EA; Pietrokovski, S; Henikoff, S; Bork, P; Attwood, TK; Hood, L; Bairoch, A				Greene, EA; Pietrokovski, S; Henikoff, S; Bork, P; Attwood, TK; Hood, L; Bairoch, A			Building gene families	SCIENCE			English	Article									EUROPEAN MOL BIOL LAB, HEIDELBERG, GERMANY; MAX DELBRUCK CTR MOL MED, BERLIN, GERMANY; UCL, LONDON WC1E 6BT, ENGLAND; UNIV WASHINGTON, SEATTLE, WA 98195 USA; UNIV GENEVA, CH-1211 GENEVA 4, SWITZERLAND	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of London; University College London; University of Washington; University of Washington Seattle; University of Geneva	Greene, EA (corresponding author), FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Bairoch, Amos/X-7411-2019; Bork, Peer/F-1813-2013	Bairoch, Amos/0000-0003-2826-6444; Bork, Peer/0000-0002-2627-833X; Henikoff, Steven/0000-0002-7621-8685; Pietrokovski, Shmuel/0000-0001-8573-5863					0	1	1	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					615	626						12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381172				2022-12-24	WOS:A1997YC32300040
J	Kelner, KL				Kelner, KL			The importance of telomerase	SCIENCE			English	Editorial Material																		Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822	5	3	3	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					600	600		10.1126/science.278.5338.600	http://dx.doi.org/10.1126/science.278.5338.600			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381167				2022-12-24	WOS:A1997YC32300035
J	Kawai, A; Woodruff, J; Healey, JH; Brennan, MF; Antonescu, CR; Ladanyi, M				Kawai, A; Woodruff, J; Healey, JH; Brennan, MF; Antonescu, CR; Ladanyi, M			SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KRUPPEL-ASSOCIATED BOX; TRANSLOCATION BREAKPOINTS; X-CHROMOSOME; CLASSIFICATION; IDENTIFICATION; DIAGNOSIS; SYT-SSX2; PROTEINS; FEATURES; SURVIVAL	Background Synovial sarcomas account for up to 10 percent of soft-tissue sarcomas and include two major histologic subtypes, biphasic and monophasic, defined respectively by the presence and absence of glandular epithelial differentiation in a background of spindle tumor cells, A characteristic SYT-SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11) is detectable in almost all synovial sarcomas, The translocation fuses the SYT gene from chromosome 18 to either of two highly homologous genes at Xp11, SSX1 or SSX2. SYT-SSX1 and SYT-SSX2 are thought to function as aberrant transcriptional regulators. We attempted to determine the influence of the two alternative forms of the SYT-SSX fusion gene on tumor morphology and clinical outcome in patients with this sarcoma. Methods We analyzed SYT-SSX fusion transcripts in 45 synovial sarcomas (33 monophasic and 12 biphasic) by the reverse-transcriptase polymerase chain reaction and compared the results with relevant clinical and pathological data. Results The SYT-SSX1 and SYT-SSX2 fusion transcripts were detected in 29 (64 percent) and 16 (36 percent) of the tumors, respectively. There was a significant relation (P=0.003) between histologic subtype (monophasic vs. biphasic) and SSX1 or SSX2 involvement in the fusion transcript: all 12 biphasic synovial sarcomas had an SYT-SSX1 fusion transcript, and all 16 tumors that were positive for SYT-SSX2 were monophasic. Kaplan-Meier analysis of 39 patients with localized tumors showed that the 15 patients with SYT-SSX2 had significantly better metastasis-free survival than the 24 patients with SYT-SSX1 (P=0.03 by multivariate analysis; relative risk, 3.0). There were no significant correlations between the type of SYT-SSX transcript and age, sex, tumor location and size, whether there were metastases at diagnosis, or whether patients underwent chemotherapy. Histologic subtype alone was not prognostically important. Conclusions The type of SYT-SSX fusion transcript correlates with both the histologic subtype and the clinical behavior of synovial sarcoma. SYT-SSX fusion transcripts are a defining diagnostic marker of synovial sarcomas and may also yield important independent prognostic information. (C) 1998, Massachusetts Medical Society.	Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Ladanyi, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.		Ladanyi, Marc/AAG-8585-2019	Healey, John/0000-0002-0802-1186				ARGANI P, IN PRESS MOD PATHOL; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; BRODSKY JT, 1992, CANCER-AM CANCER SOC, V70, P484, DOI 10.1002/1097-0142(19920715)70:2<484::AID-CNCR2820700217>3.0.CO;2-7; CAGLE LA, 1987, CANCER, V59, P1810, DOI 10.1002/1097-0142(19870515)59:10<1810::AID-CNCR2820591021>3.0.CO;2-R; Chand A, 1995, GENOMICS, V30, P545, DOI 10.1006/geno.1995.1275; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Connelly EF, 1996, SEMIN ONCOL, V23, P16; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; DEALAVA E, IN PRESS J CLIN ONCO; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; deLeeuw B, 1996, CYTOGENET CELL GENET, V73, P179, DOI 10.1159/000134334; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P757; FLIGMAN I, 1995, AM J PATHOL, V147, P1592; JANZ M, 1995, J PATHOL, V175, P391, DOI 10.1002/path.1711750405; KAMPE CE, 1993, CANCER-AM CANCER SOC, V72, P2161, DOI 10.1002/1097-0142(19931001)72:7<2161::AID-CNCR2820720716>3.0.CO;2-2; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kelly KM, 1997, J CLIN ONCOL, V15, P1831, DOI 10.1200/JCO.1997.15.5.1831; KRALL RA, 1981, AM J SURG PATHOL, V5, P137, DOI 10.1097/00000478-198103000-00005; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; LIMON J, 1991, GENE CHROMOSOME CANC, V3, P338, DOI 10.1002/gcc.2870030504; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; ODA Y, 1993, AM J SURG PATHOL, V17, P35, DOI 10.1097/00000478-199301000-00004; PAPPO AS, 1994, J CLIN ONCOL, V12, P2360, DOI 10.1200/JCO.1994.12.11.2360; Pisters PWT, 1996, J CLIN ONCOL, V14, P1679, DOI 10.1200/JCO.1996.14.5.1679; RENWICK PJ, 1995, CYTOGENET CELL GENET, V70, P58, DOI 10.1159/000133992; ROOSER B, 1989, CANCER, V63, P2182, DOI 10.1002/1097-0142(19890601)63:11<2182::AID-CNCR2820631120>3.0.CO;2-Y; ROSEN G, 1994, CANCER, V73, P2506, DOI 10.1002/1097-0142(19940515)73:10<2506::AID-CNCR2820731009>3.0.CO;2-S; Shipley J, 1996, AM J PATHOL, V148, P559; SHIPLEY JM, 1994, ONCOGENE, V9, P1447; Singer S, 1996, J CLIN ONCOL, V14, P1201, DOI 10.1200/JCO.1996.14.4.1201; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; SREEKANTAIAH C, 1994, AM J PATHOL, V144, P1121; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245	35	473	500	1	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 15	1998	338	3					153	160		10.1056/NEJM199801153380303	http://dx.doi.org/10.1056/NEJM199801153380303			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ414	9428816				2022-12-24	WOS:000071384500003
J	Vlahov, D; Graham, N; Hoover, D; Flynn, C; Bartlett, JG; Margolick, JB; Lyles, CM; Nelson, KE; Smith, D; Holmberg, S; Farzadegan, H				Vlahov, D; Graham, N; Hoover, D; Flynn, C; Bartlett, JG; Margolick, JB; Lyles, CM; Nelson, KE; Smith, D; Holmberg, S; Farzadegan, H			Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users - Plasma viral load and CD4(+) cell count	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; PNEUMOCYSTIS-CARINII; PERIPHERAL-BLOOD; CUBIC MILLIMETER; RNA; QUANTITATION; PROGRESSION; ZIDOVUDINE; THERAPY; COHORT	Context.-Plasma human immunodeficiency virus type 1 (HIV-1) viral load and CD4(+) cell count are used to predict prognosis of persons infected with HIV. However, whether combining these markers improves prognostic accuracy and whether they predict prognosis for injection drug users (IDUs) and nonwhite persons infected with HIV has not been extensively investigated. Objective.-To evaluate plasma viral load and CD4(+) cell count as prognostic indicators for the acquired immunodeficiency syndrome (AIDS) and infectious disease deaths. Design.-Cohort study initiated in 1988 and 1989 with follow-up for up to 7.9 years. Participants.-Injection drug users infected with HIV recruited from the community in Baltimore, Md. Main Outcome Measures.-Plasma HIV-1 RNA and CD4(+) cell count measured at baseline compared with time to first clinical AIDS diagnosis and death due to an infectious disease. Results.-Of 522 subjects, 96% were African American, 80% were male, 96% injected drugs within the past 6 months, and the median age was 33 years. A total of 146 cases of AIDS and 119 infectious disease deaths were seen during a median follow-up period of 6.4 years. Time-fixed baseline levels of viral load and CD4(+) cell count were independent predictors of progression to AIDS and infectious disease deaths, but in proportional hazards models, viral load had better predictive value than CD4(+) cell count. Kaplan-Meier analysis of time to AIDS and to infectious disease deaths by Viral load (<500, 500-9999, 10 000-29 999, greater than or equal to 30 000 copies/mL) at 3 levels of CD4(+) cell count (<0.20, 0.20-0.49, and greater than or equal to 0.50X10(9)/L [<200, 200-499, and greater than or equal to 500/uL]) was reduced to a 5-stage classification scheme using a backward stepwise regression procedure. The 5-year cumulative probabilities for AIDS and infectious disease deaths ranged from 0% and 0%, respectively, for group I (viral load, <500 copies/mL; CD4(+) cell count, 0.50X10(9)/L) to 81.2% and 76.1% respectively, for group V (viral load, greater than or equal to 10000 copies/mL; CD4(+) cell count, 0.20X10(9)/L). Conclusions.-In this study, plasma HIV-1 viral load independently and in combination with CD4(+) cell count measurements provided powerful prognostic information for progression to AIDS and death caused by infectious disease in a population of predominantly African American IDUs. Combining categories of both markers provided a simple method for prognostically staging HIV disease.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Ctr Dis Control & Prevent, Div HIV AIDS, Atlanta, GA USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Centers for Disease Control & Prevention - USA	Vlahov, D (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Room E-6008,615 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004334, R37DA004334] Funding Source: NIH RePORTER; NIDA NIH HHS [DA04334] Funding Source: Medline; PHS HHS [U54/CCU306802] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CAIAFFA WT, 1994, AM J RESP CRIT CARE, V150, P1493, DOI 10.1164/ajrccm.150.6.7952605; *CDC, 1992, MMWR-MORBID MORTAL W, V41, pRR17; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; CHAISSON RE, 1991, AIDS, V5, P177, DOI 10.1097/00002030-199102000-00007; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; Cox D. R., 1984, ANAL SURVIVAL DATA; ESCAICH S, 1992, AIDS RES HUM RETROV, V8, P1833, DOI 10.1089/aid.1992.8.1833; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FARZADEGAN H, 1996, 11 INT C AIDS JUL 7; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; HARRISON K, 1995, J ACQ IMMUN DEF SYND, V10, P386; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; HOLODNIY M, 1995, J CLIN MICROBIOL, V33, P1562, DOI 10.1128/JCM.33.6.1562-1566.1995; HOLODNIY M, 1993, J ACQ IMMUN DEF SYND, V6, P366; HOOVER DR, 1995, DRUGS, V49, P20, DOI 10.2165/00003495-199549010-00003; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Manoff SB, 1996, EPIDEMIOLOGY, V7, P566, DOI 10.1097/00001648-199611000-00001; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; MUNOZ A, 1992, J ACQ IMMUN DEF SYND, V5, P694; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; SOLOMON L, 1995, J DRUG ISSUES, V25, P225, DOI 10.1177/002204269502500115; VLAHOV D, 1991, J DRUG ISSUES, V21, P767; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YERLY S, 1992, J INFECT DIS, V166, P269, DOI 10.1093/infdis/166.2.269	30	167	175	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					35	40		10.1001/jama.279.1.35	http://dx.doi.org/10.1001/jama.279.1.35			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424041				2022-12-24	WOS:000071295100032
J	Chen, ZL; Strickland, S				Chen, ZL; Strickland, S			Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin	CELL			English	Article							ADULT-RAT BRAIN; EXTRACELLULAR-MATRIX; NERVOUS-SYSTEM; GRANULE NEURONS; KAINIC ACID; ACTIVATOR; GENE; EXPRESSION; SURVIVAL; SEIZURE	Excess excitatory amino acids can provoke neuronal death in the hippocampus, and the extracellular proteases tissue plasminogen activator (tPA) and plasmin (ogen) have been implicated in this death. To investigate substrates for plasmin that might influence neuronal degeneration, extracellular matrix (ECM) protein expression was examined. Laminin is expressed in the hippocampus and disappears after excitotoxin injection. Laminin disappearance precedes neuronal death, is spatially coincident with regions that exhibit neuronal loss, and is blocked by either tPA-deficiency or infusion of a plasmin inhibitor, both of which also block neuronal degeneration. Preventing neuron-laminin interaction by infusion of anti-laminin antibodies into tPA-deficient mice restores excitotoxic sensitivity to their hippocampal neurons. These results indicate that disruption of neuron-ECM interaction via tPA/plasmin catalyzed degradation of laminin sensitizes hippocampal neurons to cell death.	SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Genet Program, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Strickland, S (corresponding author), SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA.			Strickland, Sidney/0000-0002-3072-9244	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035704] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-35704] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; ANDERSSON PB, 1991, NEUROSCIENCE, V42, P201, DOI 10.1016/0306-4522(91)90159-L; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARROLL PM, 1994, DEVELOPMENT, V120, P3173; CHEN ZL, 1995, J NEUROSCI, V15, P5088; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; COYLE JT, 1978, J COMP NEUROL, V180, P301, DOI 10.1002/cne.901800208; Einheber S, 1996, J COMP NEUROL, V370, P105; EMSBERGER U, 1989, DEV BIOL, V135, P250; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gualandris A, 1996, J NEUROSCI, V16, P2220; HAGG T, 1989, NEURON, V3, P721, DOI 10.1016/0896-6273(89)90241-9; JUCKER M, 1992, BRAIN RES, V586, P166, DOI 10.1016/0006-8993(92)91390-Z; KALCHEIM C, 1987, EMBO J, V6, P2871, DOI 10.1002/j.1460-2075.1987.tb02589.x; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; LIESI P, 1989, EXP NEUROL, V105, P86, DOI 10.1016/0014-4886(89)90175-1; Liesi P, 1996, J CELL BIOL, V134, P477, DOI 10.1083/jcb.134.2.477; LIOTTA LA, 1981, CANCER RES, V41, P4629; LuckenbillEdds L, 1997, BRAIN RES REV, V23, P1, DOI 10.1016/S0165-0173(96)00013-6; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MURTOMAKI S, 1992, J NEUROSCI RES, V32, P261, DOI 10.1002/jnr.490320216; MURTOMAKI S, 1995, DEV BIOL, V168, P635, DOI 10.1006/dbio.1995.1108; Niquet J, 1996, DEV BRAIN RES, V95, P227, DOI 10.1016/S0165-3806(96)00089-2; Parmer RJ, 1997, J BIOL CHEM, V272, P1976, DOI 10.1074/jbc.272.3.1976; PAULSSON M, 1988, EUR J BIOCHEM, V177, P477, DOI 10.1111/j.1432-1033.1988.tb14397.x; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; ROGERS SL, 1986, DEV BIOL, V113, P429, DOI 10.1016/0012-1606(86)90177-6; SALONEN EM, 1984, FEBS LETT, V172, P29, DOI 10.1016/0014-5793(84)80866-2; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; Strickland S, 1996, COLD SPRING HARB SYM, V61, P739; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Tsirka SE, 1997, J NEUROSCI, V17, P543; Tsirka SE, 1997, P NATL ACAD SCI USA, V94, P9779, DOI 10.1073/pnas.94.18.9779; VENSTROM KA, 1993, FASEB J, V7, P996, DOI 10.1096/fasebj.7.11.8370483; YAMAMOTO T, 1988, J NEUROL SCI, V84, P1, DOI 10.1016/0022-510X(88)90169-4	46	527	544	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					917	925		10.1016/S0092-8674(00)80483-3	http://dx.doi.org/10.1016/S0092-8674(00)80483-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428515	Bronze			2022-12-24	WOS:000071281400009
J	Letrilliart, L; Desenclos, JC; Flahault, A				Letrilliart, L; Desenclos, JC; Flahault, A			Risk factors for winter outbreak of acute diarrhoea in France: case-control study	BRITISH MEDICAL JOURNAL			English	Article							ANTIBIOTIC-ASSOCIATED DIARRHEA; GASTROENTERITIS	Objectives: To assess the potential role of consumption of shellfish (particularly raw oysters) and tap water in the winter epidemic of acute diarrhoea in France. Design: Population based, case-control study during the 1995-6 winter epidemic of acute diarrhoea in France. Setting: A national network comprising 1% of general practitioners in France. Subjects: 568 pairs of cases and controls consulting in general practice and interviewed by 209 doctors from 26 December 1995 to 31 January 1996. Cases and controls were matched for age, doctor, and time of consultation. Main outcome measures: Adjusted relative risk of diarrhoea estimated from conditional logistic regression. Results: The risk of acute diarrhoea was not increased in people who had recently eaten raw oysters (odds ratio 1.1; 95% confidence interval 0.9% to 1.4%) or other shellfish such as clams, cockles, and mussels, or in those people who usually consumed tap rather than bottled water (0.8; 0.6% to 1.1%). The risk was, however, increased in people who had had recent contact with a person with diarrhoea, either within the household (adjusted odds ratio 5.0) or in the workplace (3.1), and in people who lived with a child less than or equal to 2 years of age (1.6). Recent treatment with either oral penicillin or cephalosporin was also independently associated with acute diarrhoea in winter. Conclusions: The winter epidemic of acute diarrhoea in France is probably not caused by consumption of either shellfish or tap water. A viral aetiology, however, is suggested by the speed with which the acute diarrhoea is transmitted.	Inst Fed St Antoine Rech Sante, INSERM, U444, Paris, France; Reseau Natl Sante Publ, St Maurice, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Letrilliart, L (corresponding author), Inst Fed St Antoine Rech Sante, INSERM, U444, Paris, France.							BARTLETT JG, 1992, CLIN INFECT DIS, V15, P573, DOI 10.1093/clind/15.4.573; Carrat F, 1996, BEH, P143; DAURAT G, 1994, B EPIDEMIOL HEBD, V37, P170; DUFOUR A, 1995, OPINIONS FRANCAIS EN; FLAHAULT A, 1995, LANCET, V346, P162, DOI 10.1016/S0140-6736(95)91214-2; Fourquet F, 1997, LANCET, V349, P794; GARTHRIGHT WE, 1988, PUBLIC HEALTH REP, V103, P107; GEORGE WL, 1984, REV INFECT DIS, V6, pS208; Glass RI, 1996, J INFECT DIS, V174, pS5, DOI 10.1093/infdis/174.Supplement_1.S5; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; LAURSEN E, 1994, J EPIDEMIOL COMMUN H, V48, P453, DOI 10.1136/jech.48.5.453; LeBaron C W, 1990, MMWR Recomm Rep, V39, P1; *MET FRANC, 1996, B CLIM ANN 1995; MORSE DL, 1986, NEW ENGL J MED, V314, P678, DOI 10.1056/NEJM198603133141103; Ryan MJ, 1996, J INFECT DIS, V174, pS12, DOI 10.1093/infdis/174.Supplement_1.S12; SURAWICZ CM, 1989, GASTROENTEROLOGY, V96, P981, DOI 10.1016/0016-5085(89)91613-2; THOMPSON SC, 1994, J PAEDIATR CHILD H, V30, P210, DOI 10.1111/j.1440-1754.1994.tb00621.x; WATSON AJM, 1992, BRIT MED J, V304, P1302, DOI 10.1136/bmj.304.6837.1302; World Health Organisation, 1993, MAN PREV DIARRH PRAC	19	24	24	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1645	1649		10.1136/bmj.315.7123.1645a	http://dx.doi.org/10.1136/bmj.315.7123.1645a			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448526	Green Published			2022-12-24	WOS:000071149400009
J	Gangakhedkar, RR; Bentley, ME; Divekar, AD; Gadkari, D; Mehendale, SM; Shepherd, ME; Bollinger, RC; Quinn, TC				Gangakhedkar, RR; Bentley, ME; Divekar, AD; Gadkari, D; Mehendale, SM; Shepherd, ME; Bollinger, RC; Quinn, TC			Spread of HIV infection in married monogamous women in India	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEXUALLY-TRANSMITTED DISEASES; IMMUNODEFICIENCY-VIRUS TYPE-1; EPIDEMIC; CLINICS	Context.-A high prevalence of human immunodeficiency virus (HIV) infection in female sex workers (FSWs) and men who attend sexually transmitted disease (STD) clinics poses al risk for spread of infection to other populations. Objective.-To examine spread of HIV to a low-risk population by comparing prevalence of, and risk factors for, HIV and STDs in FSWs and non-FSWs. Methods.-Women attending STD clinics in Pune, India, were assessed for STDs and HIV from May 13, 1993, to July 11, 1996. Demographic and behavioral information was collected, and clinical and laboratory assessment was performed. Main Outcome Measure.-Prevalence and risk determinants of HIV infection. Results.-Of 916 women enrolled, 525 were FSWs and 391 were non-FSWs. Prevalence of HIV in FSWs and non-FSWs was 49.9% and 13.6%, respectively (P<.001). In multivariate analysis, inconsistent condom use and genital ulcer disease or genital warts were associated with prevalent HIV in FSWs. History of sexual contact with a partner with an STD was associated with HIV in non-FSWs. Conclusions.-Infection with HIV is increasing in non-FSWs, previously thought to be at low risk in India. Since history of sexual contact with their only sex partner was the only risk factor significantly associated with HIV infection, it is likely that these women are being infected by their spouses. This underscores the need for strengthening partner-notification strategies and counseling facilities in India.	JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,BALTIMORE,MD 21205; NATL AIDS RES INST,PUNE,MAHARASHTRA,INDIA; NIAID,BETHESDA,MD 20892; NIH,BETHESDA,MD 20892	Johns Hopkins University; Indian Council of Medical Research (ICMR); ICMR - National AIDS Research Institute (NARI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA			Quinn, Thomas/A-2494-2010	Bollinger, Robert/0000-0002-6798-6834	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033879] Funding Source: NIH RePORTER; FIC NIH HHS [D43-TW0000] Funding Source: Medline; NCRR NIH HHS [RR-00722] Funding Source: Medline; NIAID NIH HHS [AI-33879] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOLLINGER RC, 1995, MEDICINE, V74, P97, DOI 10.1097/00005792-199503000-00005; GUPTA GR, 1996, WOMENS EXPERIENCE; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; Lalvani A, 1996, LANCET, V347, P1349, DOI 10.1016/S0140-6736(96)91007-7; MANE P, 1992, AIDS PREVENTION; MEHENDALE SM, 1995, J INFECT DIS, V172, P1486, DOI 10.1093/infdis/172.6.1486; Mehendale SM, 1996, INDIAN J MED RES, V104, P327; NAG M, 1996, SEXUAL BEHAV AIDS IN, P26; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; RAMASUBBAN R, 1994, WOMEN HLTH DEV INDIA, P212; RODRIGUES JJ, 1995, BRIT MED J, V311, P283, DOI 10.1136/bmj.311.7000.283; STONE AB, 1994, AIDS S1, V8, pS285; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001	15	210	212	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2090	2092		10.1001/jama.278.23.2090	http://dx.doi.org/10.1001/jama.278.23.2090			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403424				2022-12-24	WOS:A1997YK98700039
J	Von Korff, M; Gruman, J; Schaefer, J; Curry, SJ; Wagner, EH				Von Korff, M; Gruman, J; Schaefer, J; Curry, SJ; Wagner, EH			Collaborative management of chronic illness	ANNALS OF INTERNAL MEDICINE			English	Article							BEHAVIORAL MEDICINE INTERVENTIONS; ACUTE MYOCARDIAL-INFARCTION; ARTHRITIS SELF-MANAGEMENT; CONGESTIVE-HEART-FAILURE; QUALITY-OF-LIFE; PATIENT EDUCATION; PSYCHOSOCIAL INTERVENTIONS; DIABETES-MELLITUS; CONTROLLED TRIAL; CANCER-PATIENTS	In chronic illness, day-to-day care responsibilities fall most heavily on patients and their families. Effective collaborative relationships with health care providers can help patients and families better handle self-care tasks. Collaborative management is care that strengthens and supports self-care in chronic illness while assuring that effective medical, preventive, and health maintenance interventions take place. In this paper, the following essential elements of collaborative management developed in light of behavioral principles and empirical evidence about effective care in chronic illness are discussed: 1) collaborative definition of problems, in which patient-defined problems are identified along with medical problems diagnosed by physicians; 2) targeting, goal setting, and planning, in which patients and providers focus on a specific problem, set realistic objectives, and develop an action plan for attaining those objectives in the context of patient preferences and readiness; 3) creation of a continuum of selfmanagement training and support services, in which patients have access to services that teach skills needed to carry out medical regimens, guide health behavior changes, and provide emotional support; and 4) active and sustained follow-up, in which patients are contacted at specified intervals to monitor health status, identify potential complications, and check and reinforce progress in implementing the care plan. These elements make up a common core of services for chronic illness care that need not be reinvented for each disease.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Ctr Advancement Hlth, Washington, DC 20009 USA	Group Health Cooperative	Von Korff, M (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.		Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213; VonKorff, Michael/0000-0001-5386-8477				ALARANTA H, 1994, SPINE, V19, P1339, DOI 10.1097/00007632-199406000-00007; ANDERSEN BL, 1992, J CONSULT CLIN PSYCH, V60, P552, DOI 10.1037/0022-006X.60.4.552; BAILEY WC, 1990, ARCH INTERN MED, V150, P1664, DOI 10.1001/archinte.150.8.1664; BAUM D, 1986, J ASTHMA, V23, P49, DOI 10.3109/02770908609077475; BERESFORD SAA, 1992, AM J PUBLIC HEALTH, V82, P79, DOI 10.2105/AJPH.82.1.79; BOLTON MB, 1991, J GEN INTERN MED, V6, P401, DOI 10.1007/BF02598160; BROWN SA, 1992, RES NURS HEALTH, V15, P409, DOI 10.1002/nur.4770150603; Burg MM., 1994, ANN BEHAV MED, V16, P109, DOI 10.1093/abm/16.2.109; CLARK NM, 1992, GERONTOLOGIST, V32, P438, DOI 10.1093/geront/32.4.438; CLARK NM, 1992, HEALTH EDUC QUART, V19, P341, DOI 10.1177/109019819201900306; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; CLARK NM, 1994, J ASTHMA, V31, P427, DOI 10.3109/02770909409089484; CLARK NM, 1989, CHEST, V95, P1110, DOI 10.1378/chest.95.5.1110; Clark NM., 1991, SAGE J, V3, P3, DOI DOI 10.1177/089826439100300101; CURRY SJ, 1993, J CONSULT CLIN PSYCH, V61, P790, DOI 10.1037/0022-006X.61.5.790; CURRY SJ, 1994, ANNU REV PUBL HEALTH, V15, P345; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; FAWZY FI, 1995, ARCH GEN PSYCHIAT, V52, P100; FAWZY FI, 1990, ARCH GEN PSYCHIAT, V47, P720; FIATARONE MA, 1993, J AM GERIATR SOC, V41, P333, DOI 10.1111/j.1532-5415.1993.tb06714.x; Frasure-Smith N, 1995, J Cardiopulm Rehabil, V15, P103; GILOTH BE, 1990, PATIENT EDUC COUNS, V15, P29, DOI 10.1016/0738-3991(90)90005-6; GLASGOW RE, 1992, DIABETES CARE, V15, P1423, DOI 10.2337/diacare.15.10.1423; GLASGOW RE, 1989, HEALTH PSYCHOL, V8, P285, DOI 10.1037/0278-6133.8.3.285; GLASGOW RE, 1992, PATIENT EDUC COUNS, V19, P61, DOI 10.1016/0738-3991(92)90102-O; GLASGOW RE, 1995, DIABETES CARE, V18, P117, DOI 10.2337/diacare.18.1.117; Glasgow RE, 1996, DIABETES CARE, V19, P835, DOI 10.2337/diacare.19.8.835; GLYNN TJ, 1990, HEALTH EDUC QUART, V17, P329, DOI 10.1177/109019819001700308; GOODALL TA, 1991, HEALTH PSYCHOL, V10, P1, DOI 10.1037/0278-6133.10.1.1; GREENE B, 1994, J CONSULT CLIN PSYCH, V62, P576, DOI 10.1037/0022-006X.62.3.576; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; GRUESSER M, 1993, DIABETES CARE, V16, P1268, DOI 10.2337/diacare.16.9.1268; GUSTAFSON DH, 1994, J AM MED INFORM ASSN, P604; Haynes R. B., 1979, COMPLIANCE HLTH CARE; HELLER RF, 1993, AM J CARDIOL, V72, P759, DOI 10.1016/0002-9149(93)91058-P; HELLMAN CJC, 1990, BEHAV MED, V16, P165, DOI 10.1080/08964289.1990.9934605; HILTON S, 1986, LANCET, V1, P26; HIRANO PC, 1994, PATIENT EDUC COUNS, V24, P9, DOI 10.1016/0738-3991(94)90024-8; Hoffman C, 1996, JAMA-J AM MED ASSOC, V276, P1473, DOI 10.1001/jama.276.18.1473; Holman H, 1988, Trans Assoc Am Physicians, V101, P173; IGNACIOGARCIA JM, 1995, AM J RESP CRIT CARE, V151, P353, DOI 10.1164/ajrccm.151.2.7842191; INUI TS, 1985, MED CARE, V23, P521, DOI 10.1097/00005650-198505000-00013; JAMES LD, 1993, BEHAV THER, V24, P305, DOI 10.1016/S0005-7894(05)80271-0; JENKINS CD, 1995, BEHAV MED, V21, P53, DOI 10.1080/08964289.1995.9933742; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; KELLY JA, 1993, AM J PSYCHIAT, V150, P1679; KIRKMAN MS, 1994, DIABETES CARE, V17, P840, DOI 10.2337/diacare.17.8.840; KOSTIS JB, 1994, CHEST, V106, P996, DOI 10.1378/chest.106.4.996; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; LEWIN B, 1992, LANCET, V339, P1036, DOI 10.1016/0140-6736(92)90547-G; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; LORIG K, 1993, HEALTH EDUC QUART, V20, P17, DOI 10.1177/109019819302000104; LORIG K, 1984, GERONTOLOGIST, V24, P455; Lorig K, 1993, GENERATIONS, V3, P11; Lorig K., 1994, LIVING HLTH LIFE CHR; MALONE JM, 1989, AM J SURG, V158, P520, DOI 10.1016/0002-9610(89)90183-9; MAZZE RS, 1994, DIABETES CARE, V17, P5; MAZZE RS, 1994, DIABETES CARE, V17, P56; MAZZUCA SA, 1982, J CHRON DIS, V35, P521, DOI 10.1016/0021-9681(82)90071-6; MEYER TJ, 1995, HEALTH PSYCHOL, V14, P101, DOI 10.1037/0278-6133.14.2.101; MONTGOMERY EB, 1994, AM J MED, V97, P429, DOI 10.1016/0002-9343(94)90322-0; OSMAN LM, 1994, BRIT MED J, V308, P568, DOI 10.1136/bmj.308.6928.568; Patterson J.M., 1994, ANN BEHAV MED, V16, P131, DOI [DOI 10.1093/ABM/16.2.131, 10.1093/abm/16.2.131]; Payne T H, 1995, HMO Pract, V9, P101; PAYNE TJ, 1994, J PSYCHOSOM RES, V38, P409, DOI 10.1016/0022-3999(94)90102-3; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037//0022-006X.51.3.390; RENE J, 1992, ARTHRITIS RHEUM, V35, P511, DOI 10.1002/art.1780350504; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; ROBINSON TN, 1989, COMPUT METH PROG BIO, V30, P137, DOI 10.1016/0169-2607(89)90065-5; Ruggiero L., 1993, DIABETES SPECTRUM, V6, P22; RUTTAN VW, 1988, GENERATION DIFFUSION, P69; SCHAFER LC, 1986, DIABETES CARE, V9, P179, DOI 10.2337/diacare.9.2.179; Sikkema KJ, 1996, ANN BEHAV MED, V18, P40, DOI 10.1007/BF02903938; SOBEL DS, 1995, PSYCHOSOM MED, V57, P234, DOI 10.1097/00006842-199505000-00005; SPIEGEL D, 1989, LANCET, V2, P888; STEWART AL, 1994, J CLIN EPIDEMIOL, V47, P719, DOI 10.1016/0895-4356(94)90169-4; STUCK AE, 1995, NEW ENGL J MED, V333, P1184, DOI 10.1056/NEJM199511023331805; TOBIN D, 1986, HDB CLIN INTERVENTIO; Turner JA, 1996, SPINE, V21, P2851, DOI 10.1097/00007632-199612150-00010; *U CAL, 1996, CHRON CAR AM 21 CENT; VANELDERENVANKEMENADE T, 1994, BRIT J CLIN PSYCHOL, V33, P367, DOI 10.1111/j.2044-8260.1994.tb01133.x; VINICOR F, 1987, J CHRON DIS, V40, P345, DOI 10.1016/0021-9681(87)90050-6; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; WEINBERER M, 1995, J GEN INTERN MED, V10, P59, DOI 10.1007/BF02600227	85	837	844	2	81	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1097	1102		10.7326/0003-4819-127-12-199712150-00008	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YL262	9412313				2022-12-24	WOS:000070936600007
J	Kume, S; Muto, A; Inoue, T; Suga, K; Okano, H; Mikoshiba, K				Kume, S; Muto, A; Inoue, T; Suga, K; Okano, H; Mikoshiba, K			Role of inositol 1,4,5-trisphosphate receptor in ventral signaling in Xenopus embryos	SCIENCE			English	Article							ERYTHROID-DIFFERENTIATION FACTOR; BONE MORPHOGENETIC PROTEIN-4; EARLY AMPHIBIAN EMBRYOS; MESODERM INDUCTION; NEURAL INDUCTION; HOMEOBOX GENE; SPEMANN ORGANIZER; LAEVIS EMBRYOS; EARLY RESPONSE; LITHIUM	The inositol 1,4,5-trisphosphate (IP3) receptor is a calcium ion channel involved in the release of free Ca2+ from intracellular stores. For analysis of the role of IP3-induced Ca2+ release (IICR) on patterning of the embryonic body, monoclonal antibodies that inhibit IICR were produced. Injection of these blocking antibodies into the ventral part of early Xenopus embryos induced modest dorsal differentiation. A close correlation between IICR blocking potencies and ectopic dorsal axis induction frequency suggests that an active IP3-Ca2+ signal may participate in the modulation of ventral differentiation.	UNIV TOKYO,INST MED SCI,DEPT MOL NEUROBIOL,MINATO KU,TOKYO 108,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT NEUROANAT,SUITA,OSAKA 565,JAPAN; CORE RES EVOLUT SCI & TECHNOL,JST,SUITA,OSAKA 565,JAPAN; RIKEN,BRAIN SCI INST,WAKO,SAITAMA 35101,JAPAN	University of Tokyo; Osaka University; Japan Science & Technology Agency (JST); RIKEN	Kume, S (corresponding author), ERATO,JST,MIKOSHIBA CALCIOSIGNAL NET PROJECT,MEGURO KU,2-9-3 SHIMO MEGURO,TOKYO 153,JAPAN.		Kume, Shoen/M-4356-2016; Okano, Hideyuki/I-7584-2019; Mikoshiba, Katsuhiko/N-7943-2015; Inoue, Takafumi/AAM-9533-2020	Kume, Shoen/0000-0002-4292-205X; Inoue, Takafumi/0000-0002-2728-0060				ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; ATACK JR, 1993, J NEUROCHEM, V60, P652, DOI 10.1111/j.1471-4159.1993.tb03197.x; Ault KT, 1996, DEVELOPMENT, V122, P2033; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BUSA WB, 1989, DEV BIOL, V132, P315, DOI 10.1016/0012-1606(89)90228-5; CHEN YP, 1994, DEV BIOL, V161, P70, DOI 10.1006/dbio.1994.1008; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COOKE J, 1988, DEVELOPMENT, V102, P85; DALE L, 1992, DEVELOPMENT, V115, P573; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FUKUDA K, 1987, NATURE, V327, P623, DOI 10.1038/327623a0; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KUEM S, 1997, MECH DEVELOP, V66, P157; Kume S, 1997, DEV BIOL, V182, P228, DOI 10.1006/dbio.1996.8479; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; KUME S, UNPUB; LETTICE LA, 1993, DEVELOPMENT, V117, P263; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; Muto A, 1996, J CELL BIOL, V135, P181, DOI 10.1083/jcb.135.1.181; NIEUWKOOP PD, 1967, NORMAL DEV TABLE XEN; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; SMITH JC, 1983, J EMBRYOL EXP MORPH, V78, P299; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; STACHEL SE, 1993, DEVELOPMENT, V117, P1261; STUTZ F, 1986, J MOL BIOL, V187, P349, DOI 10.1016/0022-2836(86)90438-9; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355	44	98	99	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1940	1943		10.1126/science.278.5345.1940	http://dx.doi.org/10.1126/science.278.5345.1940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395395				2022-12-24	WOS:A1997YL00200033
J	Whitfield, CR; Raafat, A; Urbaniak, SJ				Whitfield, CR; Raafat, A; Urbaniak, SJ			Underreporting of mortality from RhD haemolytic disease in Scotland and its implications: retrospective review	BRITISH MEDICAL JOURNAL			English	Article							PROPHYLAXIS		UNIV ABERDEEN,REG TRANSFUS CTR,DEPT MED & THERAPEUT,ACAD TRANSFUS MED UNIT,ABERDEEN AB9 2ZW,SCOTLAND	University of Aberdeen	Whitfield, CR (corresponding author), UNIV GLASGOW,QUEEN MOTHERS MATERN HOSP,DEPT OBSTET & GYNAECOL,GLASGOW G3 8SH,LANARK,SCOTLAND.							Bowman J M, 1988, Transfus Med Rev, V2, P129, DOI 10.1016/S0887-7963(88)70039-5; CLARKE C, 1994, J ROY COLL PHYS LOND, V28, P310; MURPHY KW, 1994, CONT REV OBSTETRICS, V6, P61; THORNTON JG, 1989, BMJ-BRIT MED J, V298, P1671, DOI 10.1136/bmj.298.6689.1671; Vick S, 1996, HEALTH ECON, V5, P319, DOI 10.1002/(SICI)1099-1050(199607)5:4<319::AID-HEC211>3.0.CO;2-6	5	21	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1504	1505		10.1136/bmj.315.7121.1504	http://dx.doi.org/10.1136/bmj.315.7121.1504			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9420492	Green Published			2022-12-24	WOS:A1997YK98600021
J	Martin, KA; Wyatt, R; Farzan, M; Choe, H; Marcon, L; Desjardins, E; Robinson, J; Sodroski, J; Gerard, C; Gerard, NP				Martin, KA; Wyatt, R; Farzan, M; Choe, H; Marcon, L; Desjardins, E; Robinson, J; Sodroski, J; Gerard, C; Gerard, NP			CD4-independent binding of SIV gp120 to rhesus CCR5	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN; OLIGOMERIC STRUCTURE; HTLV-III; AIDS PATIENTS; T-CELLS; RECEPTOR; HIV-1; CD4; IDENTIFICATION	CCR5 and CD4 are coreceptors for immunodeficiency virus entry into target cells, The gp120 envelope glycoprotein from human immunodeficiency virus strain HIV-1(YU2) bound human CCR5 (CCR5(hu)) or rhesus macaque CCR5 (CCR5(rh)) only in the presence of CD4. The gp120 from simian immunodeficiency virus strain SIVmac239 bound CCR5(rh) without CD4, but CCR5(hu) remained CD4-dependent. The CD4-independent binding of SIVmac239 gp120 depended on a single amino acid, Asp(13), in the CCR5(rh) amino-terminus. Thus, CCR5-binding moieties on the immunodeficiency virus envelope glycoprotein can be generated by interaction with CD4 or by direct interaction with the CCR5 amino-terminus. These results may have implications for the evolution of receptor use among lentiviruses as well as utility in the development of effective intervention.	DANA FARBER CANC INST,DIV HUMAN RETROVIROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHILDRENS HOSP,PERLMUTTER LAB,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; UNIV PADUA,SCH MED,INST MICROBIOL,I-35121 PADUA,ITALY; HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; TULANE UNIV,MED CTR,DEPT PEDIAT,NEW ORLEANS,LA 70112; BETH ISRAEL DEACONESS HOSP,DEPT MED,CHILDRENS HOSP,PERLMUTTER LAB,BOSTON,MA 02115; BETH ISRAEL DEACONESS HOSP,DEPT PEDIAT,CHILDRENS HOSP,PERLMUTTER LAB,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; University of Padua; Harvard University; Harvard T.H. Chan School of Public Health; Tulane University; Harvard University; Beth Israel Deaconess Medical Center; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Boston Children's Hospital				Martin, Kathleen/0000-0002-1748-0034; Farzan, Michael/0000-0002-2990-5319	NHLBI NIH HHS [HL51366, HL36162] Funding Source: Medline; NIAID NIH HHS [AI41581] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051366, R37HL036162, R01HL036162] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; ENDRESMJ, 1996, CELL, V87, P745; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; FARZAN M, IN PRESS J VIROL; GERARD NP, UNPUB; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; KANG CY, 1993, J IMMUNOL, V151, P449; KENT KA, 1995, J MED PRIMATOL, V24, P145, DOI 10.1111/j.1600-0684.1995.tb00160.x; Kent KA, 1993, P 8 C CENT GARD I PA, P167; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Marcon L, 1997, J VIROL, V71, P2522, DOI 10.1128/JVI.71.3.2522-2527.1997; MARTIN KH, UNPUB; PINTER A, 1989, J VIROL, V63, P2674, DOI 10.1128/JVI.63.6.2674-2679.1989; RHODES AD, 1994, J GEN VIROL, V75, P207, DOI 10.1099/0022-1317-75-1-207; ROBEY WG, 1985, SCIENCE, V228, P593, DOI 10.1126/science.2984774; Robinson J, UNPUB; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; SCHAWALLER M, 1989, VIROLOGY, V172, P367, DOI 10.1016/0042-6822(89)90142-6; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Willett BJ, 1997, NATURE, V385, P587, DOI 10.1038/385587a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WYATT RE, UNPUB	35	106	107	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1470	1473		10.1126/science.278.5342.1470	http://dx.doi.org/10.1126/science.278.5342.1470			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367961				2022-12-24	WOS:A1997YG85800047
J	Brambilla, R; Gnesutta, N; Minichiello, L; White, G; Roylance, AJ; Herron, CE; Ramsey, M; Wolfer, DP; Cestari, V; RossiArnaud, C; Grant, SGN; Chapman, PF; Lipp, HP; Sturani, E; Klein, R				Brambilla, R; Gnesutta, N; Minichiello, L; White, G; Roylance, AJ; Herron, CE; Ramsey, M; Wolfer, DP; Cestari, V; RossiArnaud, C; Grant, SGN; Chapman, PF; Lipp, HP; Sturani, E; Klein, R			A role for the Ras signalling pathway in synaptic transmission and long-term memory	NATURE			English	Article							MUSCARINIC RECEPTORS; EXCHANGE FACTOR; PROTEIN; POTENTIATION; ACTIVATION; AMYGDALA; MICE; IDENTIFICATION; PLASTICITY; INDUCTION	Members of the Ras subfamily of small guanine-nucleotide-binding proteins are essential for controlling normal and malignant cell proliferation as well as cell differentiation(1). The neuronal-specific guanine-nucleotide-exchange factor, Ras-GRF/CDC25Mm (refs 2-4), induces Ras signalling in response to Ca2+ influx(5) and activation of G-protein-coupled receptors in vitro(6), suggesting that it plays a role in neurotransmission and plasticity in vivo(7). Here we report that mice lacking Ras-GRF are impaired in the process of memory consolidation, as revealed by emotional conditioning tasks that require the function of the amygdala; learning and short-term memory are intact. Electrophysiological measurements in the basolateral amygdala reveal that long-term plasticity is abnormal in mutant mice. In contrast, Ras-GRF mutants do not reveal major deficits in spatial learning tasks such as the Morris water maze, a test that requires hippocampal function. Consistent with apparently normal hippocampal functions, Ras-GRF mutants show normal NMDA (N-methyl-D-aspartate) receptor-dependent long-term potentiation in this structure. These results implicate Ras-GRF signalling via the Ras/MAP kinase pathway in synaptic events leading to formation of long-term memories.	EUROPEAN MOL BIOL LAB,D-69117 HEIDELBERG,GERMANY; UNIV MILAN,DIPARTIMENTO FISIOL & BIOCHIM GEN,I-20133 MILAN,ITALY; UNIV WALES COLL CARDIFF,SCH MOL & MED BIOSCI,PHYSIOL UNIT,CARDIFF CF1 3US,S GLAM,WALES; UNIV EDINBURGH,CTR GENOME RES,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,CTR NEUROSCI,EDINBURGH EH8 9LE,MIDLOTHIAN,SCOTLAND; UNIV ZURICH,INST ANAT,CH-8057 ZURICH,SWITZERLAND; CNR,IST PSICOBIOL & PSICOFARMACOL,I-00198 ROME,ITALY; UNIV ROMA LA SAPIENZA,DIPARTIMENTO PSICOL,I-00185 ROME,ITALY	European Molecular Biology Laboratory (EMBL); University of Milan; Cardiff University; University of Edinburgh; University of Edinburgh; University of Zurich; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome			Brambilla, Riccardo/A-6082-2010; Klein, Ruediger/C-6147-2008; ROSSI-ARNAUD, Clelia/J-7870-2019; Minichiello, Liliana/AAA-7190-2022; Wolfer, David P/B-3293-2016; Gnesutta, Nerina/I-5432-2015	Klein, Ruediger/0000-0002-3109-0163; ROSSI-ARNAUD, Clelia/0000-0001-5006-6583; Wolfer, David P/0000-0002-5957-1401; Gnesutta, Nerina/0000-0002-2465-8881; Grant, Seth/0000-0001-8732-8735; Cestari, Vincenzo/0000-0002-9623-157X; Brambilla, Riccardo/0000-0003-3569-5706	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAHILL L, 1990, BEHAV NEUROSCI, V104, P532, DOI 10.1037/0735-7044.104.4.532; CELIO MR, 1990, NEUROSCIENCE, V35, P375, DOI 10.1016/0306-4522(90)90091-H; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHAPMAN PF, 1992, SYNAPSE, V11, P310, DOI 10.1002/syn.890110406; CHAPMAN PF, 1990, SYNAPSE, V6, P271, DOI 10.1002/syn.890060306; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Maren S, 1996, NEURON, V16, P237, DOI 10.1016/S0896-6273(00)80041-0; Marshall C., 1995, GUIDEBOOK SMALL GTPA, P65; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; Martinez JL, 1996, ANNU REV PSYCHOL, V47, P173, DOI 10.1146/annurev.psych.47.1.173; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MAYFORD M, 1995, CURR OPIN NEUROBIOL, V5, P141, DOI 10.1016/0959-4388(95)80019-0; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MULLER U, 1994, CELL, V79, P755, DOI 10.1016/0092-8674(94)90066-3; OLTON DS, 1978, BRAIN RES, V139, P215; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Plass C, 1996, NAT GENET, V14, P106, DOI 10.1038/ng0996-106; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; SCHUTZ RA, 1979, PHYSIOL BEHAV, V23, P97, DOI 10.1016/0031-9384(79)90128-8; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; WATANABE Y, 1995, NEUROSCI RES, V21, P317, DOI 10.1016/0168-0102(94)00867-F; ZIPPEL R, 1997, MOL BRAIN RES, V48, P140; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	30	389	399	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					281	286		10.1038/36849	http://dx.doi.org/10.1038/36849			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384379				2022-12-24	WOS:A1997YG66700062
J	Hu, FB; Stampfer, MJ; Manson, JE; Rimm, E; Colditz, GA; Rosner, BA; Hennekens, CH; Willett, WC				Hu, FB; Stampfer, MJ; Manson, JE; Rimm, E; Colditz, GA; Rosner, BA; Hennekens, CH; Willett, WC			Dietary fat intake and the risk of coronary heart disease in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADIPOSE-TISSUE; FOLLOW-UP; PLASMA-LIPOPROTEINS; SERUM-CHOLESTEROL; ACID COMPOSITION; UNITED-STATES; MORTALITY; LIPIDS; DEATH; MEN	Background The relation between dietary intake of specific types of fat, particularly trans unsaturated fat, and the risk of coronary disease remains unclear. We therefore studied this relation in women enrolled in the Nurses' Health Study. Methods We prospectively studied 80,082 women who were 34 to 59 years of age and had no known coronary disease, stroke, cancer, hypercholesterolemia, or diabetes in 1980. Information on diet was obtained at base line and updated during follow-up by means of validated questionnaires. During 14 years of follow-up, we documented 939 cases of nonfatal myocardial infarction or death from coronary heart disease. Multivariate analyses included age, smoking status, total energy intake, dietary cholesterol intake, percentages of energy obtained from protein and specific types of fat, and other risk factors. Results Each increase of 5 percent of energy intake from saturated fat, as compared with equivalent energy intake from carbohydrates, was associated with a 17 percent increase in the risk of coronary disease (relative risk, 1.17; 95 percent confidence interval, 0.97 to 1.41; P=0.10). As compared with equivalent energy from carbohydrates, the relative risk for a 2 percent increment in energy intake from trans unsaturated fat was 1.93 (95 percent confidence interval, 1.43 to 2.61; P<0.001); that for a 5 percent increment in energy from monounsaturated fat was 0.81 (95 percent confidence interval, 0.65 to 1.00; P=0.05); and that for a 5 percent increment in energy from polyunsaturated fat was 0.62 (95 percent confidence interval, 0.46 to 0.85; P=0.003). Total fat intake was not significantly related to the risk of coronary disease (for a 5 percent increase in energy from fat, the relative risk was 1.02; 95 percent confidence interval, 0.97 to 1.07; P=0.55). We estimated that the replacement of 5 percent of energy from saturated fat with energy from unsaturated fats would reduce risk by 42 percent (95 percent confidence interval, 23 to 56; P<0.001) and that the replacement of 2 percent of energy from trans fat with energy from unhydrogenated, unsaturated fats would re; duce risk by 53 percent (95 percent confidence interval, 34 to 67; P<0.001). Conclusions Our findings suggest that replacing saturated and trans unsaturated fats with unhydrogenated monounsaturated and polyunsaturated fats is more effective in preventing coronary heart disease in women than reducing overall fat intake. (C) 1997, Massachusetts Medical Society.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, CHANNING LAB, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Hu, FB (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009; Robles-Sardin, Alma E/M-7714-2015; Cole, Tim J/B-7883-2008; Hu, Frank/C-1919-2013	Colditz, Graham/0000-0002-7307-0291; Robles-Sardin, Alma E/0000-0003-2044-7793; Cole, Tim J/0000-0001-5711-8200; 	NCI NIH HHS [CA40356] Funding Source: Medline; NHLBI NIH HHS [HL24074, HL34594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARO A, 1995, LANCET, V345, P273, DOI 10.1016/S0140-6736(95)90273-2; Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; *DEP AGR, 1992, AGR HDB SERIES; ENIG MG, 1983, J AM OIL CHEM SOC, V60, P1788, DOI 10.1007/BF02680357; Esrey KL, 1996, J CLIN EPIDEMIOL, V49, P211, DOI 10.1016/0895-4356(95)00066-6; FEHILY AM, 1993, BRIT J NUTR, V69, P303, DOI 10.1079/BJN19930035; GARG A, 1992, DIABETES CARE, V15, P1572, DOI 10.2337/diacare.15.11.1572; GOLDBOURT U, 1993, CARDIOLOGY, V82, P100, DOI 10.1159/000175862; GORDON T, 1981, CIRCULATION, V63, P500, DOI 10.1161/01.CIR.63.3.500; GRUNDY S M, 1982, Circulation, V65, p839A; GRUNDY SM, 1988, ARTERIOSCLEROSIS, V8, P95, DOI 10.1161/01.ATV.8.1.95; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; Katan MB, 1997, NEW ENGL J MED, V337, P563; KATAN MB, 1995, ANNU REV NUTR, V15, P473, DOI 10.1146/annurev.nutr.15.1.473; KEYS A, 1966, AM J CLIN NUTR, V19, P175; KINSELLA JE, 1981, AM J CLIN NUTR, V34, P2307, DOI 10.1093/ajcn/34.10.2307; Krauss RM, 1996, CIRCULATION, V94, P1795, DOI 10.1161/01.CIR.94.7.1795; KROMHOUT D, 1984, AM J EPIDEMIOL, V119, P733, DOI 10.1093/oxfordjournals.aje.a113794; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; LONDON SJ, 1991, AM J CLIN NUTR, V54, P340, DOI 10.1093/ajcn/54.2.340; MCGEE DL, 1984, AM J EPIDEMIOL, V119, P667, DOI 10.1093/oxfordjournals.aje.a113788; MCKEIGUE P, 1995, LANCET, V345, P269, DOI 10.1016/S0140-6736(95)90269-4; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; MORRIS JN, 1977, BMJ-BRIT MED J, V2, P1307, DOI 10.1136/bmj.2.6098.1307; Norris J, 1997, AM J PUBLIC HEALTH, V87, P740, DOI 10.2105/AJPH.87.5.740; PARTHASARATHY S, 1990, P NATL ACAD SCI USA, V87, P3894, DOI 10.1073/pnas.87.10.3894; Pietinen P, 1997, AM J EPIDEMIOL, V145, P876, DOI 10.1093/oxfordjournals.aje.a009047; POSNER BM, 1991, ARCH INTERN MED, V151, P1181, DOI 10.1001/archinte.151.6.1181; ROBERTS TL, 1995, LANCET, V345, P278, DOI 10.1016/S0140-6736(95)90274-0; Rose G, 1982, CARDIOVASCULAR SURVE; Sacks F, 1994, J Cardiovasc Risk, V1, P3, DOI 10.1097/00043798-199406000-00002; SHEKELLE RB, 1982, AM J EPIDEMIOL, V115, P506, DOI 10.1093/oxfordjournals.aje.a113332; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; SLOVER HT, 1985, J AM OIL CHEM SOC, V62, P775, DOI 10.1007/BF03028753; STAMLER J, 1988, ARCH PATHOL LAB MED, V112, P1032; TRICHOPOULOS D, 1995, LANCET, V345, P1108; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; WILLETT WC, 1994, AM J PUBLIC HEALTH, V84, P722, DOI 10.2105/AJPH.84.5.722	40	1167	1231	2	126	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 20	1997	337	21					1491	1499		10.1056/NEJM199711203372102	http://dx.doi.org/10.1056/NEJM199711203372102			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG249	9366580				2022-12-24	WOS:A1997YG24900002
J	Prodeus, AP; Zhou, XN; Maurer, M; Galli, SJ; Carroll, MC				Prodeus, AP; Zhou, XN; Maurer, M; Galli, SJ; Carroll, MC			Impaired mast cell-dependent natural immunity in complement C3-deficient mice	NATURE			English	Article							NECROSIS-FACTOR-ALPHA; ARTHUS REACTION; TNF-ALPHA; INFECTION; RELEASE; MOUSE; C5A; HISTAMINE; RECEPTOR	The complement system is widely regarded as essential for normal inflammation, not least because of its ability to activate mast cells(1-5). However, recent studies have called into question the importance of complement in several examples of mast cell-dependent inflammatory responses(6-9). To investigate the role of complement in mast cell-dependent natural immunity, we examined the responses of complement-deficient mice(10,11) to caecal ligation and puncture(12), model of acute septic peritonitis(12,13) that is dependent on mast cells and tumour necrosis factor-alpha (TNF-alpha). We found that C4- or C3-deficient mice(10,11) '' were much more sensitive to caecal ligation and puncture than wild-type (WT) controls (100% versus 20% in 24-h mortality, respectively). C3-deficient mice also exhibited reductions in peritoneal mast cell degranulation, production of TNF-alpha, neutrophil infiltration and clearance of bacteria. Treating the C3-deficient mice with purified C3 protein enhanced activation of peritoneal mast cells, TNF-alpha production, neutrophil recruitment, opsonophagocytosis of bacteria and resistance to caecal ligation and puncture, confirming that the defects were complement-dependent. These results provide formal evidence that complement activation is essential for the full expression of innate immunity in this mast cell-dependent model of bacterial infection.	BETH ISRAEL DEACONESS MED CTR,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center	Prodeus, AP (corresponding author), HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115, USA.		Maurer, Marcus/ABG-2174-2020	Maurer, Marcus/0000-0002-4121-481X				Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; BRILES DE, 1981, J EXP MED, V153, P694, DOI 10.1084/jem.153.3.694; DASILVA WD, 1967, J EXP MED, V125, P921, DOI 10.1084/jem.125.5.921; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Epstein J, 1996, CURR OPIN IMMUNOL, V8, P29, DOI 10.1016/S0952-7915(96)80101-4; Fischer MB, 1996, J IMMUNOL, V157, P549; Fischer MB, 1997, J IMMUNOL, V159, P976; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.immunol.12.1.775; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; Hopken UE, 1996, NATURE, V383, P86, DOI 10.1038/383086a0; JOHNSON AR, 1975, IMMUNOLOGY, V28, P1067; LEALBERUMEN I, 1994, J IMMUNOL, V152, P5468; LEPOW IH, 1970, AM J PATHOL, V61, P13; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; NILSSON UR, 1967, J EXP MED, V125, P1, DOI 10.1084/jem.125.1.1; RAMOS BF, 1994, J IMMUNOL, V152, P1380; REID KBM, 1981, ANNU REV BIOCHEM, V50, P433, DOI 10.1146/annurev.bi.50.070181.002245; Reid RR, 1997, J IMMUNOL, V159, P970; Sylvestre D, 1996, J EXP MED, V184, P2385, DOI 10.1084/jem.184.6.2385; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VRANIAN G, 1981, J IMMUNOL, V126, P2302; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2; ZHANG Y, 1991, J CLIN INVEST, V88, P841, DOI 10.1172/JCI115385	30	224	228	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					172	175		10.1038/36586	http://dx.doi.org/10.1038/36586			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367154				2022-12-24	WOS:A1997YF49400054
J	Ryan, CM; Schoenfeld, DA; Thorpe, WP; Sheridan, RL; Cassem, EH; Tompkins, RG				Ryan, CM; Schoenfeld, DA; Thorpe, WP; Sheridan, RL; Cassem, EH; Tompkins, RG			Objective estimates of the probability of death from burn injuries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROMPT ESCHAR EXCISION; INHALATION INJURY; MORTALITY	Background Over the past 20 years, there has been remarkable improvement in the chances of survival of patients treated in burn centers. A simple, accurate system for objectively estimating the probability of death would be useful in counseling patients and making medical decisions. Methods We conducted a retrospective review of all 1665 patients with acute burn injuries admitted from 1990 to 1994 to Massachusetts General Hospital and the Shriners Burns Institute in Boston. Using logistic-regression analysis, we developed probability estimates for the prediction of mortality based on a minimal set of well-defined variables. The resulting mortality formula was used to determine whether changes in mortality have occurred since 1984, and it was tested prospectively on all 530 patients with acute burn injuries admitted in 1995 or 1996. Results Of the 1665 patients (mean [+/-SD] age, 21+/-20 years; mean burn size, 14+/-20 percent of body-surface area), 1598 (96 percent) lived to discharge. The mean length of stay was 21+/-29 days. Three risk factors for death were identified: age greater than 60 years, more than 40 percent of body-surface area burned, and inhalation injury. The mortality formula we developed predicts 0.3 percent, 3 percent, 33 percent, or approximately 90 percent mortality, depending on whether zero, one, two, or three risk factors are present. The results of the prospective test of the formula were similar. A large increase in the proportion of patients who chose not to be resuscitated complicated comparisons of mortality over time. Conclusions The probability of death after burns is low and can be predicted soon after injury on the basis of simple, objective clinical criteria. (C) 1998, Massachusetts Medical Society.	Massachusetts Gen Hosp, Shriners Burns Inst, Boston, MA 02114 USA; Massachusetts Gen Hosp, Sumner Redstone Burn Ctr, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA; Massachusetts Gen Hosp, Surg Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Psychiat Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Tompkins, RG (corresponding author), Massachusetts Gen Hosp, Trauma Serv, Bigelow 1302, Boston, MA 02114 USA.			Ryan, Colleen/0000-0002-6455-936X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM021700, T32GM007035] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM P50-21700, GM T32-07035] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURKE JF, 1974, J TRAUMA, V14, P389, DOI 10.1097/00005373-197405000-00005; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; MANKTELOW A, 1989, J TRAUMA, V29, P203, DOI 10.1097/00005373-198902000-00009; Monafo WW, 1996, NEW ENGL J MED, V335, P1581, DOI 10.1056/NEJM199611213352108; PECK M D, 1991, Journal of Burn Care and Rehabilitation, V12, P282, DOI 10.1097/00004630-199105000-00017; PRUITT BA, 1964, ANN SURG, V159, P396; RYAN CM, 1995, ANN SURG, V222, P163, DOI 10.1097/00000658-199508000-00008; Ryan CM, 1997, J AM GERIATR SOC, V45, P1283, DOI 10.1111/j.1532-5415.1997.tb03792.x; Saffle Jeffrey R., 1995, Journal of Burn Care and Rehabilitation, V16, P219, DOI 10.1097/00004630-199505000-00002; SCHOENFELD DA, 1982, STATISTICS MED RES, P432; SHERIDAN RL, 1997, SURG SCI PRINCIPLES, P422; SHIRANI KZ, 1987, ANN SURG, V205, P82, DOI 10.1097/00000658-198701000-00015; TOMPKINS RG, 1988, ANN SURG, V208, P577, DOI 10.1097/00000658-198811000-00006; TOMPKINS RG, 1986, ANN SURG, V204, P272, DOI 10.1097/00000658-198609000-00006; TREDGET EE, 1990, ANN SURG, V212, P720, DOI 10.1097/00000658-199012000-00011; ZAWACKI BE, 1979, ANN SURG, V189, P1, DOI 10.1097/00000658-197901000-00001	16	488	510	2	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	1998	338	6					362	366		10.1056/NEJM199802053380604	http://dx.doi.org/10.1056/NEJM199802053380604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV426	9449729				2022-12-24	WOS:000071822200004
J	Strickler, HD; Rosenberg, PS; Devesa, SS; Hertel, J; Fraumeni, JF; Goedert, JJ				Strickler, HD; Rosenberg, PS; Devesa, SS; Hertel, J; Fraumeni, JF; Goedert, JJ			Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN BRAIN-TUMORS; CHOROID-PLEXUS; DNA-SEQUENCES; SV40	Context.-Poliovirus vaccine contaminated with live simian virus 40 (SV40), a polyomavirus that is tumorigenic in rodents, was used extensively in the United States between 1955 and 1963, Simian virus 40 DNA has recently been detected in several rare human tumors, including ependymomas, osteosarcomas. mesotheliomas. Objective.-To determine the risk of ependymoma, osteosarcoma, and mesothelioma among Americans who as children received SV40-contaminated poliovirus vaccine. Design.-Retrospective cohort study using data from the Surveillance, Epidemiology, and End Results program (1973-1993) and the Connecticut Tumor Registry (1950-1969), as well as national mortality statistics (1947-1973). Setting.-United States. Participants.-Birth cohorts that were likely to have received SV40-contaminated poliovirus vaccine as infants, born 1956 through 1962 (60 811 730 person-years of observation); as children, born 1947 through 1952 (46 430 953 person-years); or that were unexposed, born 1964 through 1969 (44 959 979 peron-years). Main Outcome Measures.-Relative risk (RR) of each cancer among exposed compared with unexposed birth cohorts. Results.-Age-specific cancer rates were generally low and were not significantly elevated in birth cohorts exposed to SV40-contaminated vaccine, Specifically, compared with the unexposed, the relative risk of ependymoma was not increased in the cohorts exposed as infants (RR, 1.06; 95% confidence interval [CI], 0.69-1.63), or as children (RR, 0.98; 95% CI, 0.57-1.69) nor did the exposed have an increased risk of all brain cancers. Osteosarcoma incidence also showed no relation to exposure as infants (RR, 0.87; 95% CI, 0.71-1.06) or children (RR, 0.85; 95% CI, 0.59-1.22). Last, mesotheliomas were not significantly associated with exposure, although the cohorts studied have not. yet reached the age at which these tumors tend to occur. Conclusions.-After more than 30 years of follow-up, exposure to SV40-contaminated poliovirus vaccine was not associated with significantly increased rates of ependymomas and other brain cancers, osteosarcomas, or mesotheliomas in the United States.	NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Rockville, MD 20852 USA; Informat Management Syst, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Strickler, HD (corresponding author), NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, 6130 Execut Blvd,EPN Room 434, Rockville, MD 20852 USA.			Rosenberg, Philip/0000-0001-6349-9126				BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1996, ONCOGENE, V13, P527; DIAMANDO.GT, 1973, JNCI-J NATL CANCER I, V50, P1347, DOI 10.1093/jnci/50.5.1347; DORFMAN HD, 1995, CANCER, V75, P203, DOI 10.1002/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V; EDDY BE, 1961, P SOC EXP BIOL MED, V107, P191; EDDY BE, 1962, FED PROC, V21, P930; Farwell J R, 1979, Trans Am Neurol Assoc, V104, P261; FRAUMENI JF, 1963, JAMA-J AM MED ASSOC, V185, P713, DOI 10.1001/jama.1963.03060090045016; GEISSLER E, 1990, PROG MED VIROL, V37, P211; HAENSZEL W, 1962, JNCI-J NATL CANCER I, V28, P947; HEINONEN OP, 1973, INT J EPIDEMIOL, V2, P229, DOI 10.1093/ije/2.3.229; INNIS MD, 1968, NATURE, V219, P972, DOI 10.1038/219972a0; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; Martini F, 1996, CANCER RES, V56, P4820; MORTIMER EA, 1981, NEW ENGL J MED, V305, P1517, DOI 10.1056/NEJM198112173052507; POLEDNAK AP, 1995, CANCER, V75, P330, DOI 10.1002/1097-0142(19950101)75:1+<330::AID-CNCR2820751315>3.0.CO;2-5; SALONEN T, 1976, ANN CLIN RES, V8, P27; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; STEWART AM, 1965, LANCET, V2, P789; ZIPPIN C, 1995, CANCER, V76, P2343, DOI 10.1002/1097-0142(19951201)76:11<2343::AID-CNCR2820761124>3.0.CO;2-#	21	130	133	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	1998	279	4					292	295		10.1001/jama.279.4.292	http://dx.doi.org/10.1001/jama.279.4.292			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT472	9450713	Bronze			2022-12-24	WOS:000071607000036
J	Hemesath, TJ; Price, ER; Takemoto, C; Badalian, T; Fisher, DE				Hemesath, TJ; Price, ER; Takemoto, C; Badalian, T; Fisher, DE			MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes	NATURE			English	Article							RECEPTOR TYROSINE KINASE; CULTURED MAST-CELLS; GENE-EXPRESSION; MI/MI GENOTYPE; MELANOMA-CELLS; IN-VIVO; MOUSE; ACTIVATION; MUTATIONS; PROTEIN	Germline mutations at loci encoding the transcription factor Microphthalmia (Mi), the cytokine receptor c-Kit, or its ligand Steel factor (Sl) result in strikingly similar defects in mast cell and melanocyte development(1-3). Here we describe a biochemical link between Kit signalling and the activity of Mi. Stimulation of melanoma cells with Sl results in activation of MAP kinase, which in turn phosphorylates Mi at a consensus target serine. This phosphorylation upregulates Mi transactivation of the tyrosinase pigmentation gene promoter. In addition to modulating pigment production, such signalling may regulate the expression of genes essential for melanocyte survival and development. The pathway represents a new application of the general MAP kinase machinery in transducing a signal between a tissue-specific receptor at the cell surface and a tissue-specific transcription factor in the nucleus.	Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Fisher, DE (corresponding author), Childrens Hosp, Div Pediat Hematol Oncol, 44 Binney St, Boston, MA 02115 USA.	david_fisher@dfci.harvard.edu	Takemoto, Clifford M/Y-7558-2018					Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; EBI Y, 1992, BLOOD, V80, P1454; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; ISOZAKI K, 1994, AM J PATHOL, V145, P827; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; OKUDA K, 1992, BLOOD, V79, P2880; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; TACHIBANA M, 1994, HUM MOL GENET, V3, P553, DOI 10.1093/hmg/3.4.553; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tsujimura T, 1996, BLOOD, V88, P1225, DOI 10.1182/blood.V88.4.1225.bloodjournal8841225; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058	27	529	547	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	1998	391	6664					298	301		10.1038/34681	http://dx.doi.org/10.1038/34681			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440696				2022-12-24	WOS:000071484400055
J	Hakim, AA; Petrovitch, H; Burchfiel, CM; Ross, GW; Rodriguez, BL; White, LR; Yano, K; Curb, JD; Abbott, RD				Hakim, AA; Petrovitch, H; Burchfiel, CM; Ross, GW; Rodriguez, BL; White, LR; Yano, K; Curb, JD; Abbott, RD			Effects of walking on mortality among nonsmoking retired men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; MIDDLE-AGED MEN; PHYSICAL-ACTIVITY; JAPANESE MEN; PROGRAM; RISK; DIETARY; STROKE; HAWAII; WEIGHT	Background The potential benefit of low-intensity activity in terms of longevity among older men has not been clearly documented. We examined the association between walking and mortality in a cohort of retired men who were nonsmokers and physically capable of participating in low-intensity activities on a daily basis. Methods We studied 707 nonsmoking retired men, 61 to 81 years of age, who were enrolled in the Honolulu Heart Program. The distance walked (miles per day) was recorded at a base-line examination, which took place between 1980 and 1982. Data on overall mortality (from any cause) were collected over a 12-year period of follow-up. Results During the follow-up period, there were 208 deaths. After adjustment for age, the mortality rate among the men who walked less than 1 mile (1.6 km) per day was nearly twice that among those who walked more than 2 miles (3.2 km) per day (40.5 percent vs. 23.8 percent, P=0.001). The cumulative incidence of death after 12 years for the most active walkers was reached in less than 7 years among the men who were least active. The distance walked remained inversely related to mortality after adjustment for overall measures of activity and other risk factors (P = 0.01). Conclusions Our findings in older physically capable men indicate that regular walking is associated with a lower overall mortality rate, Encouraging elderly people to walk may benefit their health. (C) 1998, Massachusetts Medical Society.	Univ Virginia, Sch Med, Div Biostat, Charlottesville, VA 22908 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; Univ Hawaii, John A Burns Sch Med, Dept Med, Honolulu, HI 96822 USA; Kuakini Med Ctr, Honolulu Heart Program, Honolulu, HI 96817 USA; NHLBI, Honolulu Epidemiol Res Sect, Epidemiol & Biometry Program, Honolulu, HI USA; Dept Vet Affairs, Honolulu, HI USA; NIA, Honolulu, HI USA	University of Virginia; University of Minnesota System; University of Minnesota Twin Cities; University of Hawaii System; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Abbott, RD (corresponding author), Univ Virginia, Sch Med, Div Biostat, Box 600, Charlottesville, VA 22908 USA.				DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC005102] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011091] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR/AI 11091] Funding Source: Medline; NHLBI NIH HHS [N01-HC-05102] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT RD, 1994, AM J EPIDEMIOL, V139, P881, DOI 10.1093/oxfordjournals.aje.a117094; CASTELLI WP, 1977, J CHRON DIS, V30, P147, DOI 10.1016/0021-9681(77)90082-0; COX DR, 1972, J R STAT SOC B, V34, P187; DONAHUE RP, 1988, AM J PUBLIC HEALTH, V78, P683, DOI 10.2105/AJPH.78.6.683; GARCIAPALMIERI MR, 1982, AM J CARDIOL, V50, P749, DOI 10.1016/0002-9149(82)91229-2; GARRISON RJ, 1983, JAMA-J AM MED ASSOC, V249, P2199, DOI 10.1001/jama.249.16.2199; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; Heilbrun L K, 1985, Hawaii Med J, V44, P294; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P818; LANE PW, 1982, BIOMETRICS, V38, P613, DOI 10.2307/2530043; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; LINDSTED KD, 1991, J CLIN EPIDEMIOL, V44, P355, DOI 10.1016/0895-4356(91)90074-J; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; SHERMAN SE, 1994, AM HEART J, V128, P965, DOI 10.1016/0002-8703(94)90596-7; SIMONSICK EM, 1993, AM J PUBLIC HEALTH, V83, P1443, DOI 10.2105/AJPH.83.10.1443; YANO K, 1984, AM J EPIDEMIOL, V119, P653, DOI 10.1093/oxfordjournals.aje.a113787; YANO K, 1986, ARTERIOSCLEROSIS, V6, P422, DOI 10.1161/01.ATV.6.4.422	21	381	387	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 8	1998	338	2					94	99		10.1056/NEJM199801083380204	http://dx.doi.org/10.1056/NEJM199801083380204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YQ039	9420340				2022-12-24	WOS:000071341300004
J	Albert, CM; Hennekens, CH; O'Donnell, CJ; Ajani, UA; Carey, VJ; Willett, WC; Ruskin, JN; Manson, JE				Albert, CM; Hennekens, CH; O'Donnell, CJ; Ajani, UA; Carey, VJ; Willett, WC; Ruskin, JN; Manson, JE			Fish consumption and risk of sudden cardiac death	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; FOOD FREQUENCY QUESTIONNAIRE; POLYUNSATURATED FATTY-ACIDS; VENTRICULAR-FIBRILLATION; MYOCARDIAL-INFARCTION; MORTALITY; OMEGA-3-FATTY-ACIDS; REPRODUCIBILITY; POPULATION; PHYSICIANS	Context.-Dietary fish intake has been associated with a reduced risk of fatal cardiac end points, but not with nonfatal end points. Dietary fish intake may have a selective benefit on fatal arrhythmias and therefore sudden cardiac death. Objective.-To investigate prospectively the association between fish consumption and the risk of sudden cardiac death. Design.-Prospective cohort study. Setting.-The US Physicians' Health Study. Patients.-A total of 20 551 US male physicians 40 to 84 years of age and free of myocardial infarction, cerebrovascular disease, and cancer at baseline who completed an abbreviated, semiquantitative food frequency questionnaire on fish consumption and were then followed up to 11 years. Main Outcome Measure.-Incidence of sudden cardiac death (death within 1 hour of symptom onset) as ascertained by hospital records and reports of next of kin. Results.-There were 133 sudden deaths over the course of the study. After controlling for age, randomized aspirin and beta carotene assignment, and coronary risk factors, dietary fish intake was associated with a reduced risk of sudden death, with an apparent threshold effect at a consumption level of 1 fish meal per week (P for trend=.03). For men who consumed fish at least once per week, the multivariate relative risk of sudden death was 0.48 (95% confidence interval, 0.24-0.96; P=.04) compared with men who consumed fish less than monthly. Estimated dietary n-3 fatty acid intake from seafood also was associated with a reduced risk of sudden death but without a significant trend across increasing categories of intake. Neither dietary fish consumption nor n-3 fatty acid intake was associated with a reduced risk of total myocardial infarction, nonsudden cardiac death, or total cardiovascular mortality. However, fish consumption was associated with a significantly reduced risk of total mortality. Conclusion.-These prospective data suggest that consumption of fish at least once per week may reduce the risk of sudden cardiac death in men.	Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02215 USA; Massachusetts Gen Hosp, Dept Med, Cardiac Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; NHLBI, Framingham Heart Study, Framingham, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Albert, CM (corresponding author), Brigham & Womens Hosp, Dept Med, Div Prevent Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.			Albert, Christine/0000-0002-2081-1121	NCI NIH HHS [CA-34944, CA-40360] Funding Source: Medline; NHLBI NIH HHS [HL-26490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM HEART ASS, 1995, HEART STROK FACTS S; [Anonymous], 1988, NEW ENGL J MED, V318, P262; ASCHERIO A, 1995, NEW ENGL J MED, V332, P977, DOI 10.1056/NEJM199504133321501; BILLMAN GE, 1994, P NATL ACAD SCI USA, V91, P4427, DOI 10.1073/pnas.91.10.4427; Broughton KS, 1997, AM J CLIN NUTR, V65, P1011, DOI 10.1093/ajcn/65.4.1011; BURR ML, 1989, LANCET, V2, P757; Christensen JH, 1997, AM J CARDIOL, V79, P1670, DOI 10.1016/S0002-9149(97)00220-8; COX DR, 1972, J R STAT SOC B, V34, P187; CURB JD, 1985, NEW ENGL J MED, V313, P821; Daviglus ML, 1997, NEW ENGL J MED, V336, P1046, DOI 10.1056/NEJM199704103361502; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; DOBSON AJ, 1983, AM J EPIDEMIOL, V117, P397, DOI 10.1093/oxfordjournals.aje.a113558; DOLECEK TA, 1992, P SOC EXP BIOL MED, V200, P177, DOI 10.3181/00379727-200-43413; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; GOLDSTEIN S, 1984, J AM COLL CARDIOL, V3, P1111, DOI 10.1016/S0735-1097(84)80167-9; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; GUALLAR E, 1995, J AM COLL CARDIOL, V25, P387, DOI 10.1016/0735-1097(94)00370-6; Hartikainen JEK, 1996, J AM COLL CARDIOL, V28, P296, DOI 10.1016/0735-1097(96)00169-6; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HEPBURN FN, 1986, J AM DIET ASSOC, V86, P788; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; HUNTER DJ, 1992, AM J EPIDEMIOL, V135, P418, DOI 10.1093/oxfordjournals.aje.a116302; Kang JX, 1996, CIRCULATION, V94, P1774, DOI 10.1161/01.CIR.94.7.1774; KANNEL WB, 1987, AM HEART J, V113, P799, DOI 10.1016/0002-8703(87)90722-8; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; KROMHOUT D, 1995, INT J EPIDEMIOL, V24, P340, DOI 10.1093/ije/24.2.340; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; KULLER L, 1967, MEDICINE, V46, P341, DOI 10.1097/00005792-196707000-00003; MCLENNAN PL, 1992, AM HEART J, V123, P1555, DOI 10.1016/0002-8703(92)90809-A; MISHINA T, 1985, PROSTATE, V6, P423, DOI 10.1002/pros.2990060411; MORRIS MC, 1995, AM J EPIDEMIOL, V142, P166, DOI 10.1093/oxfordjournals.aje.a117615; NORELL SE, 1986, BRIT MED J, V293, P426, DOI 10.1136/bmj.293.6544.426; SHEKELLE RB, 1985, NEW ENGL J MED, V313, P820; SIMOPOULOS AP, 1991, AM J CLIN NUTR, V54, P438, DOI 10.1093/ajcn/54.3.438; SISCOVICK DS, 1995, JAMA-J AM MED ASSOC, V274, P1363, DOI 10.1001/jama.274.17.1363; *USDA, 1963, AGR HDB SER, V8; VALENZUELA TD, 1992, JAMA-J AM MED ASSOC, V267, P272, DOI 10.1001/jama.267.2.272; VOLLSET SE, 1985, NEW ENGL J MED, V313, P820; *WHO, 1971, ISCH HEART DIS REG R; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	41	695	718	0	40	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					23	28		10.1001/jama.279.1.23	http://dx.doi.org/10.1001/jama.279.1.23			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424039				2022-12-24	WOS:000071295100030
J	Hawton, K				Hawton, K			Integration of treatments for male erectile dysfunction	LANCET			English	Editorial Material							THERAPY		Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England	University of Oxford	Hawton, K (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.							ALTHOF SE, 1989, J SEX MARITAL THER, V15, P121; BANCROFT J, 1989, HUMAN SEXUALITY ITS; Boolell M, 1996, BRIT J UROL, V78, P257, DOI 10.1046/j.1464-410X.1996.10220.x; HAWTON K, 1995, BRIT J PSYCHIAT, V167, P307, DOI 10.1192/bjp.167.3.307; Jeremy JY, 1997, BRIT J UROL, V79, P958, DOI 10.1046/j.1464-410X.1997.00206.x; PADMANATHAN H, 1997, NEW ENGL J MED, V336, P309; SPECKENS AEM, 1995, ARCH SEX BEHAV, V24, P157, DOI 10.1007/BF01541579; Stravynski A, 1997, BRIT J PSYCHIAT, V170, P338, DOI 10.1192/bjp.170.4.338	8	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					7	8		10.1016/S0140-6736(05)78097-1	http://dx.doi.org/10.1016/S0140-6736(05)78097-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433420				2022-12-24	WOS:000071253100006
J	Shaw, LM; Rabinovitz, I; Wang, HHF; Toker, A; Mercurio, AM				Shaw, LM; Rabinovitz, I; Wang, HHF; Toker, A; Mercurio, AM			Activation of phosphoinositide 3-OH kinase by the alpha 6 beta 4 integrin promotes carcinoma invasion	CELL			English	Article							PROTEIN-KINASE; ACTIN POLYMERIZATION; CELL-ADHESION; E-CADHERIN; S6 KINASE; RAC; EXPRESSION; CDC42; HEMIDESMOSOMES; RHO	We demonstrate that the alpha 6 beta 4 integrin promotes carcinoma invasion through a preferential and localized targeting of phosphoinositide-3 OH kinase (PI3K) activity. Stable expression of alpha 6 beta 4 increased carcinoma invasion in a PI3K-dependent manner, and transient expression of a constitutively active PI3K increased invasion in the absence of alpha 6 beta 4. Ligation of alpha 6 beta 4 stimulated significantly more PI3K activity than ligation of beta 1 integrins, establishing specificity among integrins for PI3K activation. alpha 6 beta 4-regutated PI3K activity was required for the formation of lamellae, dynamic sites of motility, in carcinoma cells. The small G protein Rac is required downstream of PI3K for invasion. These studies define a mechanism by which the alpha 6 beta 4 integrin promotes carcinoma invasion and invoke a novel function for PI3K signaling.	Beth Israel Deaconess Med Ctr, Dept Med, GI Div, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Boston Biomed Res Inst, Boston, MA 02114 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Boston Biomedical Research Institute	Shaw, LM (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, GI Div, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [P01CA044704] Funding Source: NIH RePORTER; NCI NIH HHS [CA44704] Funding Source: Medline; PHS HHS [A139264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBINI A, 1987, CANCER RES, V47, P3239; BIRCHMEIER W, 1995, CIBA F SYMP, V189, P124; Borradori L, 1996, CURR OPIN CELL BIOL, V8, P647, DOI 10.1016/S0955-0674(96)80106-2; CANTLEY LC, 1994, J CELL SCI S, V18, P121; CAO C, 1996, CANCER RES, V56, P4811; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FALCIONI R, 1986, CANCER RES, V46, P5772; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Green KJ, 1996, FASEB J, V10, P871, DOI 10.1096/fasebj.10.8.8666164; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Harden N, 1996, MOL CELL BIOL, V16, P1896; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; HEMLER ME, 1989, J BIOL CHEM, V264, P6529; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KENNEL SJ, 1989, J BIOL CHEM, V264, P15515; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; LOTZ MM, 1990, CELL REGUL, V1, P249, DOI 10.1091/mbc.1.3.249; Lu PJ, 1996, BIOCHEMISTRY-US, V35, P14027, DOI 10.1021/bi961878z; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P4385, DOI 10.1002/j.1460-2075.1995.tb00113.x; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; RABINOVITZ I, 1997, IN PRESS J CELL BIOL; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Serini G, 1996, J NATL CANCER I, V88, P442, DOI 10.1093/jnci/88.7.442; Shaw LM, 1996, CANCER RES, V56, P959; Sheetz Michael P., 1994, Seminars in Cell Biology, V5, P149, DOI 10.1006/scel.1994.1019; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tani T, 1996, AM J PATHOL, V149, P781; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; VANWAES C, 1991, CANCER RES, V51, P2395; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324	62	531	542	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					949	960		10.1016/S0092-8674(00)80486-9	http://dx.doi.org/10.1016/S0092-8674(00)80486-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428518	Bronze			2022-12-24	WOS:000071281400012
J	Wu, Y; Kuzma, J; Marechal, E; Graeff, R; Lee, HC; Foster, R; Chua, NH				Wu, Y; Kuzma, J; Marechal, E; Graeff, R; Lee, HC; Foster, R; Chua, NH			Abscisic acid signaling through cyclic ADP-Ribose in plants	SCIENCE			English	Article							SEA-URCHIN EGGS; ARABIDOPSIS-THALIANA; CA2+ RELEASE; INOSITOL TRISPHOSPHATE; TRANSDUCTION PATHWAYS; PROTEIN PHOSPHATASE; TRANSGENIC PLANTS; CYTOSOLIC CA-2+; GUARD-CELLS; EXPRESSION	Abscisic acid (ABA) is the primary hormone that mediates plant responses to stresses such as cold, drought, and salinity. Single-cell microinjection experiments in tomato were used to identify possible intermediates involved in ABA signal transduction. Cyclic ADP-ribose (cADPR) was identified as a signaling molecule in the ABA response and Mras shown to exert its effects by way of calcium. Bioassay experiment is showed that the amounts of cADPR in Arabidopsis thaliana plants increased in response to ABA treatment and before ASA-induced gene expression.	ROCKEFELLER UNIV, PLANT MOL BIOL LAB, NEW YORK, NY 10021 USA; UNIV MINNESOTA, DEPT PHYSIOL, MINNEAPOLIS, MN 55455 USA	Rockefeller University; University of Minnesota System; University of Minnesota Twin Cities			Lee, Hon Cheung/C-4329-2009; Graeff, Richard Milton/B-3425-2011	Kuzma, Jennifer/0000-0003-4456-9613	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17484] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; [Anonymous], UNPUB; Barnes SA, 1996, PLANT CELL, V8, P601, DOI 10.1105/tpc.8.4.601; BENFEY PN, 1989, EMBO J, V8, P2195, DOI 10.1002/j.1460-2075.1989.tb08342.x; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOWLER C, 1994, GENE DEV, V8, P2188, DOI 10.1101/gad.8.18.2188; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BOWLER C, 1994, CELL, V79, P743; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; CHANDLER PM, 1994, ANNU REV PLANT PHYS, V45, P113, DOI 10.1146/annurev.pp.45.060194.000553; CHANG YC, 1991, PLANT PHYSIOL, V97, P1260, DOI 10.1104/pp.97.3.1260; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; deBruxelles GL, 1996, PLANT PHYSIOL, V111, P381, DOI 10.1104/pp.111.2.381; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GIRAUDAT J, 1994, PLANT MOL BIOL, V26, P1557, DOI 10.1007/BF00016490; Hey SJ, 1997, PLANTA, V202, P85, DOI 10.1007/s004250050106; HIRAYAMA T, 1995, P NATL ACAD SCI USA, V92, P3903, DOI 10.1073/pnas.92.9.3903; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; JEFFERSON RA, 1987, EMBO J, V6, P3901; KEARNS EV, 1993, PLANT PHYSIOL, V102, P711, DOI 10.1104/pp.102.3.711; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; Knetsch MLW, 1996, PLANT CELL, V8, P1061, DOI 10.1105/tpc.8.6.1061; Kuo AL, 1996, PLANT CELL, V8, P259, DOI 10.1105/tpc.8.2.259; KURKELA S, 1992, PLANT MOL BIOL, V19, P689, DOI 10.1007/BF00026794; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; Lee HC, 1996, BIOL SIGNAL, V5, P101; LEE HC, 1991, J BIOL CHEM, V266, P2276; LEE HC, 1995, RYANODINE RECEPTORS, P31; Lee YS, 1996, PLANT PHYSIOL, V110, P987, DOI 10.1104/pp.110.3.987; Leung J, 1997, PLANT CELL, V9, P759, DOI 10.1105/tpc.9.5.759; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; Masuda W, 1997, FEBS LETT, V405, P104, DOI 10.1016/S0014-5793(97)00168-3; MCAINSH MR, 1990, NATURE, V343, P186, DOI 10.1038/343186a0; Merlot S, 1997, PLANT PHYSIOL, V114, P751, DOI 10.1104/pp.114.3.751; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; Muir SR, 1996, FEBS LETT, V395, P39, DOI 10.1016/0014-5793(96)01000-9; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; NEUHAUS G, 1994, CELL, V79, P743; PARCY F, 1994, PLANT CELL, V6, P1567, DOI 10.1105/tpc.6.11.1567; Pei ZM, 1997, PLANT CELL, V9, P409, DOI 10.1105/tpc.9.3.409; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; SCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9535, DOI 10.1073/pnas.92.21.9535; SCHROEDER JI, 1990, P NATL ACAD SCI USA, V87, P9305, DOI 10.1073/pnas.87.23.9305; Sheen J, 1996, SCIENCE, V274, P1900, DOI 10.1126/science.274.5294.1900; Terry MJ, 1996, J BIOL CHEM, V271, P21681, DOI 10.1074/jbc.271.35.21681; THOMASHOW MF, 1994, ARABIDOPSIS, P807, DOI DOI 10.1101/0.807-834; VASIL V, 1995, PLANT CELL, V7, P1511, DOI 10.1105/tpc.7.9.1511; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; Wu Y, 1996, PLANT J, V10, P1149, DOI 10.1046/j.1365-313X.1996.10061149.x; YAMAGUCHISHINOZAKI K, 1993, MOL GEN GENET, V236, P331, DOI 10.1007/BF00277130	56	307	345	2	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2126	2130		10.1126/science.278.5346.2126	http://dx.doi.org/10.1126/science.278.5346.2126			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405349				2022-12-24	WOS:A1997YM23500054
J	Century, KS; Shapiro, AD; Repetti, PP; Dahlbeck, D; Holub, E; Staskawicz, BJ				Century, KS; Shapiro, AD; Repetti, PP; Dahlbeck, D; Holub, E; Staskawicz, BJ			NDR1, a pathogen-induced component required for Arabidopsis disease resistance	SCIENCE			English	Article							LEUCINE-RICH REPEAT; ARTIFICIAL CHROMOSOME LIBRARY; PERONOSPORA-PARASITICA; YAC LIBRARY; THALIANA; GENE; IDENTIFICATION; TOMATO; LOCUS; CONSTRUCTION	Plant disease resistance (R) genes confer an ability to resist infection by pathogens expressing specific corresponding avirulence genes. In Arabidopsis thaliana, resistance to both bacterial and fungal pathogens, mediated by several R gene products, requires the NDR1 gene. Positional cloning was used to isolate NDR1, which encodes a 660-base pair open reading frame. The predicted 219-amino acid sequence suggests that NDR1 may be associated with a membrane. NDR1 expression is induced in response to pathogen challenge and may function to integrate various pathogen recognition signals.	UNIV CALIF BERKELEY, DEPT PLANT & MICROBIAL BIOL, BERKELEY, CA 94720 USA; HORT RES INT, DEPT PLANT PATHOL & WEED SCI, WELLESBOURNE CV35 9EF, WARWICK, ENGLAND	University of California System; University of California Berkeley; University of Warwick								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; CENTURY KS, 1995, P NATL ACAD SCI USA, V92, P6597, DOI 10.1073/pnas.92.14.6597; CREUSOT F, 1995, PLANT J, V8, P763, DOI 10.1046/j.1365-313X.1995.08050763.x; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; Freialdenhoven A, 1996, PLANT CELL, V8, P5, DOI 10.1105/tpc.8.1.5; Gopalan S, 1996, PLANT J, V10, P591, DOI 10.1046/j.1365-313X.1996.10040591.x; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; HAMMONDKOSACK KE, 1994, PLANT CELL, V6, P361, DOI 10.2307/3869756; HOLUB EB, 1994, MOL PLANT MICROBE IN, V7, P223, DOI 10.1094/MPMI-7-0223; JORGENSEN RA, 1987, PLANT MOL BIOL, V8, P3, DOI 10.1007/BF00016429; KARRER EE, IN PRESS PLANT MOL B; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KUNKEL BN, 1993, PLANT CELL, V5, P865, DOI 10.1105/tpc.5.8.865; Parker JE, 1996, PLANT CELL, V8, P2033, DOI 10.1105/tpc.8.11.2033; PONGOR S, 1994, NUCLEIC ACIDS RES, V22, P3610; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; SCHMIDT R, 1992, AUST J PLANT PHYSIOL, V19, P341, DOI 10.1071/PP9920341; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WHALEN MC, 1988, P NATL ACAD SCI USA, V85, P6743, DOI 10.1073/pnas.85.18.6743; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49	29	282	308	3	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 12	1997	278	5345					1963	1965		10.1126/science.278.5345.1963	http://dx.doi.org/10.1126/science.278.5345.1963			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395402				2022-12-24	WOS:A1997YL00200040
J	Chen, WB; Kelly, MA; OpitzAraya, X; Thomas, RE; Low, MJ; Cone, RD				Chen, WB; Kelly, MA; OpitzAraya, X; Thomas, RE; Low, MJ; Cone, RD			Exocrine gland dysfunction in MC5-R-deficient mice: Evidence for coordinated regulation of exocrine gland function by melanocortin peptides	CELL			English	Article							MELANOCYTE-STIMULATING HORMONE; RAT LACRIMAL GLAND; MOLECULAR-CLONING; HARDERIAN-GLAND; ALPHA-MSH; MALE-MOUSE; RECEPTOR; EXPRESSION; SECRETION; SYSTEM	The effects of pituitary-derived melanocortin peptides are primarily attributed to ACTH-mediated adrenocortical glucocorticoid production. Identification of a widely distributed receptor for ACTH/MSH peptides, the melanocortin-5 receptor (MC5-R), suggested non-steroidally mediated systemic effects of these peptides. Targeted disruption of the MC5-R produced mice with a severe defect in water repulsion and thermoregulation due to decreased production of sebaceous lipids. High levels of MC5-R was found in multiple exocrine tissues, including Harderian, preputial, lacrimal, and sebaceous glands, and was also shown to be required for production and stress-regulated synthesis of porphyrins by the Harderian gland and ACTH/MSH-regulated protein secretion by the lacrimal gland. These data show a requirement for the MC5-R in multiple exocrine glands for the production of numerous products, indicative of a coordinated system for regulation of exocrine gland function by melanocortin peptides.	OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA	Oregon Health & Science University			Chen, Wenbiao/ABG-1276-2020	Chen, Wenbiao/0000-0002-0750-8275; Low, Malcolm/0000-0002-9900-3708; Kelly, Michele/0000-0003-1799-055X	NIAMS NIH HHS [AR42415] Funding Source: Medline; NICHD NIH HHS [HD30236] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD030236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042415] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABEL EL, 1994, HORM BEHAV, V28, P139, DOI 10.1006/hbeh.1994.1011; ABEL EL, 1992, PSYCHONEUROENDOCRINO, V17, P255, DOI 10.1016/0306-4530(92)90065-F; BARRETT P, 1994, J MOL ENDOCRINOL, V12, P203, DOI 10.1677/jme.0.0120203; BIJLSMA WA, 1983, EUR J PHARMACOL, V92, P231, DOI 10.1016/0014-2999(83)90291-1; BOTELHO SY, 1973, AM J PHYSIOL, V224, P1119, DOI 10.1152/ajplegacy.1973.224.5.1119; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONSON FH, 1971, J REPROD FERTIL, V25, P279; BUCKLEY DI, 1981, P NATL ACAD SCI-BIOL, V78, P7431, DOI 10.1073/pnas.78.12.7431; CARR WJ, 1970, J COMP PHYSIOL PSYCH, V71, P223, DOI 10.1037/h0029164; CATANIA A, 1993, ENDOCR REV, V14, P564, DOI 10.1210/er.14.5.564; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; CHHAJLANI V, 1993, BIOCHEM BIOPH RES CO, V195, P866, DOI 10.1006/bbrc.1993.2125; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; COSSU G, 1989, DEV BIOL, V131, P331, DOI 10.1016/S0012-1606(89)80006-5; DARTT DA, 1994, ADV EXP MED BIOL, V350, P1; EBLING FJ, 1969, J ENDOCRINOL, V45, P257, DOI 10.1677/joe.0.0450257; EBLING FJ, 1974, J INVEST DERMATOL, V62, P161, DOI 10.1111/1523-1747.ep12676781; EBLING FJ, 1975, J ENDOCRINOL, V66, P407, DOI 10.1677/joe.0.0660407; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; FENG JD, 1987, BRAIN RES BULL, V18, P473, DOI 10.1016/0361-9230(87)90111-0; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1994, BIOCHEM BIOPH RES CO, V200, P1214, DOI 10.1006/bbrc.1994.1580; GANTZ I, 1993, J BIOL CHEM, V268, P8246; GOOLAMALI SK, 1974, J INVEST DERMATOL, V63, P253, DOI 10.1111/1523-1747.ep12680076; GRIFFON N, 1994, BIOCHEM BIOPH RES CO, V200, P1007, DOI 10.1006/bbrc.1994.1550; GRUBER KA, 1989, AM J PHYSIOL, V257, pR681, DOI 10.1152/ajpregu.1989.257.4.R681; HARLOW HJ, 1984, PHYSIOL ZOOL, V57, P349, DOI 10.1086/physzool.57.3.30163724; Huang QH, 1997, J NEUROSCI, V17, P3343; JAHN R, 1982, EUR J BIOCHEM, V126, P623, DOI 10.1111/j.1432-1033.1982.tb06826.x; LABBE O, 1994, BIOCHEMISTRY-US, V33, P4543, DOI 10.1021/bi00181a015; LEEMAN SE, 1967, ENDOCRINOLOGY, V81, P803, DOI 10.1210/endo-81-4-803; LEIBA H, 1990, EUR J PHARMACOL, V181, P71, DOI 10.1016/0014-2999(90)90246-3; Li SJ, 1996, J NEUROSCI, V16, P5182; MACALUSO A, 1994, J NEUROSCI, V14, P2377; MARGOLIS FL, 1971, ARCH BIOCHEM BIOPHYS, V145, P373, DOI 10.1016/0003-9861(71)90050-6; Mogil Jefrey S., 1996, Physiology and Behavior, V59, P123, DOI 10.1016/0031-9384(95)02073-X; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; NOWELL NW, 1980, PHYSIOL BEHAV, V24, P5, DOI 10.1016/0031-9384(80)90006-2; ORSULAK PJ, 1972, BIOL REPROD, V6, P219, DOI 10.1093/biolreprod/6.2.219; PAWELEK JM, 1976, J INVEST DERMATOL, V66, P201, DOI 10.1111/1523-1747.ep12482134; PAYNE AP, 1994, J ANAT, V185, P1; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SCHAUER E, 1994, J CLIN INVEST, V93, P2258, DOI 10.1172/JCI117224; SIEGRIST W, 1989, CANCER RES, V49, P6352; SMOCK T, 1981, BRAIN RES, V212, P202, DOI 10.1016/0006-8993(81)90052-4; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Spike R.C., 1992, HARDERIAN GLANDS POR, P165; STEWART ME, 1991, ADV LIPID RES, V24, P263; Strand F L, 1993, Rev Neurosci, V4, P321; TATRO JB, 1987, ENDOCRINOLOGY, V121, P1900, DOI 10.1210/endo-121-5-1900; TATRO JB, 1990, BRAIN RES, V536, P124, DOI 10.1016/0006-8993(90)90016-5; THIESSEN DD, 1980, PHYSIOL BEHAV, V24, P417, DOI 10.1016/0031-9384(80)90229-2; THODY AJ, 1983, PHYSIOL BEHAV, V31, P67, DOI 10.1016/0031-9384(83)90097-5; THODY AJ, 1973, NATURE, V245, P207, DOI 10.1038/245207a0; THODY AJ, 1976, J ENDOCRINOL, V71, P279, DOI 10.1677/joe.0.0710279; VALENTA JG, 1968, SCIENCE, V161, P599, DOI 10.1126/science.161.3841.599; WATSON SJ, 1979, EUR J PHARMACOL, V58, P101, DOI 10.1016/0014-2999(79)90351-0; WETTERBERG L, 1970, SCIENCE, V168, P996, DOI 10.1126/science.168.3934.996; YU JH, 1983, P SOC EXP BIOL MED, V173, P467	61	397	426	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 12	1997	91	6					789	798		10.1016/S0092-8674(00)80467-5	http://dx.doi.org/10.1016/S0092-8674(00)80467-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413988	Bronze			2022-12-24	WOS:A1997YL43900010
J	Knowlton, JR; Johnston, SC; Whitby, FG; Realini, C; Zhang, ZG; Rechsteiner, M; Hill, CP				Knowlton, JR; Johnston, SC; Whitby, FG; Realini, C; Zhang, ZG; Rechsteiner, M; Hill, CP			Structure of the proteasome activator REG alpha (PA28 alpha)	NATURE			English	Article							PROTEIN-DEGRADATION; 20S PROTEASOME; MULTICATALYTIC PROTEASE; 20-S PROTEASOME; REGULATOR PA28; PURIFICATION	The specificity of the 20S proteasome, which degrades many intracellular proteins, is regulated by protein complexes that bind to one or both ends of the cylindrical proteasome structure(1-5). One of these regulatory complexes, the 11S regulator (known as REG or PA28), stimulates proteasome peptidase activity(6,7) and enhances the production of antigenic peptides for presentation by class I molecules of the major histocompatibility complex (MHC)(8,9). The three REG subunits that have been identified REG alpha, REG beta and REG gamma (also known as the Ki antigen).	UNIV UTAH, DEPT BIOCHEM, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah								AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; Ahn K, 1996, J BIOL CHEM, V271, P18237, DOI 10.1074/jbc.271.30.18237; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1996, XPLOR VERSION 3 843; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hoffman L, 1996, CURR TOP CELL REGUL, V34, P1, DOI 10.1016/S0070-2137(96)80001-X; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; Johnston SC, 1997, PROTEIN SCI, V6, P2469; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1993, J BIOL CHEM, V268, P22514; MA CP, 1992, J BIOL CHEM, V267, P10515; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; Realini C, 1997, J BIOL CHEM, V272, P25483, DOI 10.1074/jbc.272.41.25483; REALINI C, 1994, J BIOL CHEM, V269, P20727; Song XL, 1996, J BIOL CHEM, V271, P26410, DOI 10.1074/jbc.271.42.26410; USTRELL V, 1995, FEBS LETT, V376, P155, DOI 10.1016/0014-5793(95)01257-9; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199	30	147	150	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 11	1997	390	6660					639	643		10.1038/37670	http://dx.doi.org/10.1038/37670			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403698				2022-12-24	WOS:A1997YK85300058
J	Wiesmann, C; Fuh, G; Christinger, HW; Eigenbrot, C; Wells, JA; deVos, AM				Wiesmann, C; Fuh, G; Christinger, HW; Eigenbrot, C; Wells, JA; deVos, AM			Crystal structure at 1.7 angstrom resolution of VEGF in complex with domain 2 of the Flt-1 receptor	CELL			English	Article							ENDOTHELIAL GROWTH-FACTOR; IMMUNOGLOBULIN SUPERFAMILY; SIGNAL-TRANSDUCTION; TYROSINE KINASE; LIGAND-BINDING; ANGIOGENESIS; IDENTIFICATION; VASCULOGENESIS; EXPRESSION; LETHALITY	Vascular endothelial growth factor (VEGF) is a homodimeric hormone that induces proliferation of endothelial cells through binding to the kinase domain receptor and the Fms-like tyrosine kinase receptor (Flt-1), the extracellular portions of which consist of seven immunoglobulin domains. We show that the second and third domains of Flt-1 are necessary and sufficient for binding VEGF with near-native affinity, and that domain 2 alone binds only 60-fold less tightly than wild-type. The crystal structure of the complex between VEGF and the second domain of Flt-1 shows domain 2 in a predominantly hydrophobic interaction with the ''poles'' of the VEGF dimer. Based on this structure and on mutational data, we present a model of VEGF bound to the first four domains of Flt-1.	GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech			Wells, Jim A/O-9854-2016	Wiesmann, Christian/0000-0002-4092-9880				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Barleon B, 1997, J BIOL CHEM, V272, P10382; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Christinger HW, 1996, PROTEINS, V26, P353, DOI 10.1002/(SICI)1097-0134(199611)26:3<353::AID-PROT9>3.0.CO;2-E; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V231, P596, DOI 10.1006/bbrc.1997.6156; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; FINNERTY H, 1993, ONCOGENE, V8, P2293; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HEMMINGSEN JM, 1994, PROTEIN SCI, V3, P1927, DOI 10.1002/pro.5560031104; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemmon MA, 1997, J BIOL CHEM, V272, P6311, DOI 10.1074/jbc.272.10.6311; MAHADEVAN D, 1995, J BIOL CHEM, V270, P27595, DOI 10.1074/jbc.270.46.27595; MERRIT EA, 1994, ACTA CRYSTALLOGR D, V53, P240; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; [No title captured]	41	410	474	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					695	704		10.1016/S0092-8674(00)80456-0	http://dx.doi.org/10.1016/S0092-8674(00)80456-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393862	Bronze			2022-12-24	WOS:A1997YH96000016
J	Fichera, ME; Roos, DS				Fichera, ME; Roos, DS			A plastid organelle as a drug target in apicomplexan parasites	NATURE			English	Article							TOXOPLASMA-GONDII; MACROLIDE ANTIBIOTICS; CLINDAMYCIN; ENCEPHALITIS; AZITHROMYCIN; INHIBITION; QUINOLONES; SPIRAMYCIN; RESISTANT; MUTANTS	Parasites of the phylum Apicomplexa include many important human and veterinary pathogens such as Plasmodium (malaria), Toxoplasma (a leading opportunistic infection associated with AIDS and congenital neurological birth defects), and Eimeria (an economically significant disease of poultry and cattle)(1-4). Recent studies have identified an unusual organelle in these parasites(5-7): a plastid that appears to have been acquired by secondary endosymbiosis of a green alga(7). Here ive show that replication of the apicomplexan plastid (apicoplast) genome in Toxoplasma gondii tachyzoites can be specifically inhibited using ciprofloxacin, and that this inhibition blocks parasite replication. Moreover, parasite death occurs with peculiar kinetics that are identical to those observed after exposure to clindamycin and macrolide antibiotics(8,9), which have been proposed to target protein synthesis in the apicoplast(9,10). Conversely, clindamycin (and functionally related compounds) immediately inhibits plastid replication upon drug application-the earliest effect so far described for these antibiotics. Our results directly link apicoplast function with parasite survival, validating this intriguing organelle as an effective target for parasiticidal drug design.	UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania				Roos, David Siker/0000-0001-6725-4089				ARAUJO FG, 1991, EUR J CLIN MICROBIOL, V10, P519, DOI 10.1007/BF01963942; BECKERS CJM, 1995, J CLIN INVEST, V95, P367, DOI 10.1172/JCI117665; *CDC, HLTH INF; CUNDLIFFE E, 1990, RIBOSOME, P479; DANNEMANN B, 1992, ANN INTERN MED, V116, P33, DOI 10.7326/0003-4819-116-1-33; FICHERA ME, 1995, ANTIMICROB AGENTS CH, V39, P1530, DOI 10.1128/AAC.39.7.1530; FURET YX, 1991, EUR J CLIN MICROBIOL, V10, P249, DOI 10.1007/BF01966997; Haberkorn A, 1996, PARASITOL RES, V82, P193, DOI 10.1007/s004360050094; Khan AA, 1996, ANTIMICROB AGENTS CH, V40, P1855, DOI 10.1128/AAC.40.8.1855; KIM K, 1993, SCIENCE, V262, P911, DOI 10.1126/science.8235614; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; KRAJCOVIC J, 1989, ANTIMICROB AGENTS CH, V33, P1883, DOI 10.1128/AAC.33.11.1883; LANE HC, 1994, ANN INTERN MED, V120, P945, DOI 10.7326/0003-4819-120-11-199406010-00007; Le Bras Jacques, 1996, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V190, P471; LEVINE ND, 1988, J PROTOZOOL, V35, P518, DOI 10.1111/j.1550-7408.1988.tb04141.x; Lewis RJ, 1996, BIOESSAYS, V18, P661, DOI 10.1002/bies.950180810; LUFT BJ, 1993, NEW ENGL J MED, V329, P995, DOI 10.1056/NEJM199309303291403; MCCABE RE, 1989, DRUGS, V38, P973, DOI 10.2165/00003495-198938060-00008; McConkey GA, 1997, J BIOL CHEM, V272, P2046, DOI 10.1074/jbc.272.4.2046; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; PFEFFERKORN ER, 1992, ANTIMICROB AGENTS CH, V36, P1091, DOI 10.1128/AAC.36.5.1091; PFEFFERKORN ER, 1994, ANTIMICROB AGENTS CH, V38, P31, DOI 10.1128/AAC.38.1.31; PFEFFERKORN ER, 1993, J PARASITOL, V79, P559, DOI 10.2307/3283383; ROGERS MJ, 1997, RNA, V3, P1; ROIZEN N, 1995, PEDIATRICS, V95, P11; ROOS DS, 1994, METHOD CELL BIOL, V45, P28; Srivastava IK, 1997, J BIOL CHEM, V272, P3961, DOI 10.1074/jbc.272.7.3961; Vogel G, 1997, SCIENCE, V275, P1422, DOI 10.1126/science.275.5305.1422; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; YOON CK, 1997, NY TIMES        0311, pC3	30	454	472	1	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					407	409		10.1038/37132	http://dx.doi.org/10.1038/37132			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389481				2022-12-24	WOS:A1997YH54900065
J	Bennett, P; Edwards, D				Bennett, P; Edwards, D			Use of magnesium sulphate in obstetrics	LANCET			English	Editorial Material							CEREBRAL-PALSY; PRETERM LABOR; SULFATE; RISK				Bennett, P (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED, DIV PAEDIAT OBSTET & GYNAECOL, LONDON W12 0HS, ENGLAND.			Bennett, Phillip/0000-0002-6253-4919				ATKINSON MW, 1995, AM J OBSTET GYNECOL, V173, P1219, DOI 10.1016/0002-9378(95)91357-2; COTTON DB, 1984, J REPROD MED, V29, P92; deHaan HH, 1997, AM J OBSTET GYNECOL, V176, P18, DOI 10.1016/S0002-9378(97)80005-1; DULEY L, 1995, LANCET, V345, P1455; HIGBY K, 1993, AM J OBSTET GYNECOL, V168, P1247, DOI 10.1016/0002-9378(93)90376-T; LUCAS MJ, 1995, NEW ENGL J MED, V333, P201, DOI 10.1056/NEJM199507273330401; NELSON KB, 1995, PEDIATRICS, V95, P263; PANETH N, 1997, PEDIATRICS, V99, pE11; PENRICE J, 1997, PEDIATR RES, V41, P1; Schendel DE, 1996, JAMA-J AM MED ASSOC, V276, P1805, DOI 10.1001/jama.276.22.1805; Witlin AG, 1997, AM J OBSTET GYNECOL, V176, P623, DOI 10.1016/S0002-9378(97)70558-1	11	29	29	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1491	1491		10.1016/S0140-6736(05)63935-9	http://dx.doi.org/10.1016/S0140-6736(05)63935-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388392				2022-12-24	WOS:A1997YH11500003
J	Babior, BM; Matzner, Y				Babior, BM; Matzner, Y			The familial Mediterranean fever gene - Cloned at last	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FLUIDS		HADASSAH UNIV HOSP, IL-91240 JERUSALEM, ISRAEL	Hebrew University of Jerusalem	Babior, BM (corresponding author), SCRIPPS RES INST, LA JOLLA, CA 92037 USA.				NIAID NIH HHS [AI-24227] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024227, R01AI024227] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aksentijevich I, 1997, CELL, V90, P797; Bernot A, 1997, NAT GENET, V17, P25; GOLDFINGER SE, 1972, NEW ENGL J MED, V287, P1302; MATZNER Y, 1984, NEW ENGL J MED, V311, P287, DOI 10.1056/NEJM198408023110503; MATZNER Y, 1984, BLOOD, V63, P629; MATZNER Y, 1995, CRIT REV ONCOL HEMAT, V18, P197, DOI 10.1016/1040-8428(94)00130-L	6	53	54	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 20	1997	337	21					1548	1549		10.1056/NEJM199711203372112	http://dx.doi.org/10.1056/NEJM199711203372112			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG249	9366590				2022-12-24	WOS:A1997YG24900012
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			BLAST off!	SCIENCE			English	Editorial Material																		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999	2	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					501	502						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9381147				2022-12-24	WOS:A1997YB35500056
J	Doublie, S; Tabor, S; Long, AM; Richardson, CC; Ellenberger, T				Doublie, S; Tabor, S; Long, AM; Richardson, CC; Ellenberger, T			Crystal structure of a bacteriophage T7 DNA replication complex at 2.2 angstrom resolution	NATURE			English	Article							ESCHERICHIA-COLI THIOREDOXIN; I KLENOW FRAGMENT; POLYMERASE-I; DEOXYNUCLEOSIDE TRIPHOSPHATE; DEOXYRIBONUCLEIC-ACID; EXONUCLEASE ACTIVITY; PROTEIN; MECHANISM; RESIDUES; MUTANT	DNA polymerases change their specificity for nucleotide substrates with each catalytic cycle, while achieving error frequencies in the range of 10(-5) to 10(-6). Here we present a 2.2 Angstrom crystal structure of the replicative DNA polymerase from bacteriophage T7 complexed with a primer-template and a nucleoside triphosphate in the polymerase active site. The structure illustrates how nucleotides are selected in a template-directed manner, and provides a structural basis for a metal-assisted mechanism of phosphoryl transfer by a large group of related polymerases.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ellenberger, T (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	stabor@heckle.med.harvard.edu; tome@jeckle.med.harvard.edu		Doublie, Sylvie/0000-0002-6294-5304				ADLER S, 1983, J BIOL CHEM, V258, P6956; ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bedford E, 1997, P NATL ACAD SCI USA, V94, P479, DOI 10.1073/pnas.94.2.479; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BRUNGER AT, 1992, XPLOR VERSOIN 3 1 SY; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; BURGERS PMJ, 1979, J BIOL CHEM, V254, P6889; CARTER CW, 1992, CRYSTALLIZATION NUCL, P47; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Himawan JS, 1996, J BIOL CHEM, V271, P19999, DOI 10.1074/jbc.271.33.19999; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joyce CM, 1997, P NATL ACAD SCI USA, V94, P1619, DOI 10.1073/pnas.94.5.1619; Kaushik N, 1996, BIOCHEMISTRY-US, V35, P7256, DOI 10.1021/bi960537i; Kiefer JR, 1997, STRUCTURE, V5, P95, DOI 10.1016/S0969-2126(97)00169-X; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; MODRICH P, 1975, J BIOL CHEM, V250, P5508; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Rould MA, 1997, METHOD ENZYMOL, V276, P461, DOI 10.1016/S0076-6879(97)76072-5; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; TABOR S, 1989, J BIOL CHEM, V264, P6447; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Yang XM, 1997, J BIOL CHEM, V272, P6599, DOI 10.1074/jbc.272.10.6599	50	1075	1105	1	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	1998	391	6664					251	258		10.1038/34593	http://dx.doi.org/10.1038/34593			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440688				2022-12-24	WOS:000071484400040
J	Reed, BA; Habicht, JP				Reed, BA; Habicht, JP			Sales of food aid as sign of distress, not excess	LANCET			English	Article								In 1996 the sale and export of food aid from refugee camps near Uvira, Zaire, prompted a reduction in donated rations. However, research has revealed that the sales did not reflect an excess of food in the camps. They were provoked by the absence of important components of the food basket, by cultural aversion to the staple (maize) and oil provided, by difficulties in food preparation, and by the refugees' limited ability to diversify their diet and cover pressing non-food needs. Food sales improved the micronutrient content of diets but at the expense of energy lost from an already energy-deficient diet. At most 23% of the refugee households were eating sufficient and adequate diets; the poorest one-fifth of households were twice as likely to sell or exchange food as were other households and their diets were the worst. These findings demonstrate the perils of the gap between policy and practice in food aid distribution.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	Cornell University	Habicht, JP (corresponding author), Cornell Univ, Div Nutr Sci, Savage Hall, Ithaca, NY 14853 USA.							CHRISTENSEN H, 1982, 823 UN RES I SOC DEV, P1; Hansch S., 1992, Journal of Refugee Studies, V5, P300, DOI 10.1093/jrs/5.3-4.300; Harrell-Bond B., 1992, Journal of Refugee Studies, V5, P205, DOI 10.1093/jrs/5.3-4.205; Shoham J, 1996, DISASTERS, V20, P338, DOI 10.1111/j.1467-7717.1996.tb01048.x; Wilson K. B., 1992, Journal of Refugee Studies, V5, P226, DOI 10.1093/jrs/5.3-4.226; *WORLD FOOD PROGR, 1994, MEM UND JOINT WORK A	6	16	16	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					128	130		10.1016/S0140-6736(97)06329-0	http://dx.doi.org/10.1016/S0140-6736(97)06329-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439508	hybrid			2022-12-24	WOS:000071591900044
J	Nightingale, SL				Nightingale, SL			List of disqualified investigators available an Internet	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					9	9		10.1001/jama.279.1.9	http://dx.doi.org/10.1001/jama.279.1.9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424027				2022-12-24	WOS:000071295100004
J	Schnieke, AE; Kind, AJ; Ritchie, WA; Mycock, K; Scott, AR; Ritchie, M; Wilmut, I; Colman, A; Campbell, KHS				Schnieke, AE; Kind, AJ; Ritchie, WA; Mycock, K; Scott, AR; Ritchie, M; Wilmut, I; Colman, A; Campbell, KHS			Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts	SCIENCE			English	Article							EMBRYONIC-CELL-LINES; MOUSE GENOME; COMPENDIUM; KNOCKOUTS; CHALLENGES; EXPRESSION; CATTLE; GENE; MICE	Ovine primary fetal fibroblasts were cotransfected with a neomycin resistance marker gene (neo) and a human coagulation factor IX genomic construct designed for expression of the encoded protein in sheep milk. Two cloned transfectants and a population ol neomycin (G418)-resistant cells were used as donors for nuclear transfer to enucleated oocytes. Six transgenic lambs were liveborn: Three produced from cloned cells contained factor IX and neo transgenes, whereas three produced from the uncloned population contained the marker gene only. Somatic cells can therefore be subjected to genetic manipulation in vitro and produce viable animals by nuclear transfer. Production of transgenic sheep by nuclear transfer requires fewer than half the animals needed for pronuclear microinjection.	ROSLIN INST, ROSLIN EH25 9PS, MIDLOTHIAN, SCOTLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Schnieke, AE (corresponding author), PPL THERAPEUT, ROSLIN EH25 9PP, MIDLOTHIAN, SCOTLAND.			Schnieke, Angelika/0000-0002-5761-9635				BOWEN RA, 1994, BIOL REPROD, V50, P664, DOI 10.1095/biolreprod50.3.664; BRANDON EP, 1995, CURR BIOL, V5, P873, DOI 10.1016/S0960-9822(95)00177-1; BRANDON EP, 1995, CURR BIOL, V5, P625, DOI 10.1016/S0960-9822(95)00127-8; BRANDON EP, 1995, CURR BIOL, V5, P758, DOI 10.1016/S0960-9822(95)00152-7; BROWNLEE GG, 1987, BIOCHEM SOC T, V15, P1; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; CARVER AS, 1993, BIO-TECHNOL, V11, P1263; Cibelli J. B., 1997, Theriogenology, V47, P241, DOI 10.1016/S0093-691X(97)82368-0; Damak S, 1996, BIO-TECHNOL, V14, P185, DOI 10.1038/nbt0296-185; EYESTONE WH, 1994, REPROD FERT DEVELOP, V6, P647, DOI 10.1071/RD9940647; Gerfen RW, 1995, ANIM BIOTECHNOL, V6, P1, DOI 10.1080/10495399509525828; GRIFFITHS R, 1993, MOL ECOL, V2, P405, DOI 10.1111/j.1365-294X.1993.tb00034.x; HAMMER RE, 1985, NATURE, V315, P680, DOI 10.1038/315680a0; JALLAT S, 1990, EMBO J, V9, P3295, DOI 10.1002/j.1460-2075.1990.tb07529.x; KILL IR, 1991, J CELL SCI, V100, P869; KIRKPATRICK BW, 1993, J REPROD FERTIL, V98, P335, DOI 10.1530/jrf.0.0980335; Kruip TAM, 1997, THERIOGENOLOGY, V47, P43, DOI 10.1016/S0093-691X(96)00338-X; NOTARIANNI E, 1991, J REPROD FERTIL, P255; Ramirez-Solis Ramiro, 1994, Current Opinion in Biotechnology, V5, P528, DOI 10.1016/0958-1669(94)90069-8; SHIM H, 1997, THERIOGENOLOGY, V47, P425; Stice SL, 1996, BIOL REPROD, V54, P100, DOI 10.1095/biolreprod54.1.100; Takada T, 1997, NAT BIOTECHNOL, V15, P458, DOI 10.1038/nbt0597-458; THOMPSON EM, 1995, P NATL ACAD SCI USA, V92, P1317, DOI 10.1073/pnas.92.5.1317; Walker SK, 1996, THERIOGENOLOGY, V45, P111, DOI 10.1016/0093-691X(95)00360-K; WALL RJ, 1992, THERIOGENOLOGY, V38, P337, DOI 10.1016/0093-691X(92)90239-N; Wells DN, 1997, BIOL REPROD, V57, P385, DOI 10.1095/biolreprod57.2.385; WHEELER MB, 1994, REPROD FERT DEVELOP, V6, P563, DOI 10.1071/RD9940563; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; YULL F, 1995, P NATL ACAD SCI USA, V92, P10899, DOI 10.1073/pnas.92.24.10899	30	650	849	2	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 19	1997	278	5346					2130	2133		10.1126/science.278.5346.2130	http://dx.doi.org/10.1126/science.278.5346.2130			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405350				2022-12-24	WOS:A1997YM23500055
J	Woolf, SH; Lawrence, RS				Woolf, SH; Lawrence, RS			Preserving scientific debate and patient choice - Lessons from the consensus panel on mammography screening	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BREAST-CANCER; DECISION-MAKING; PARTICIPATE; PHYSICIANS		JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BALTIMORE, MD USA	Johns Hopkins University	Woolf, SH (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT FAMILY PRACTICE, 3712 CHARLES STEWART DR, FAIRFAX, VA 22033 USA.							BEGLEY S, 1997, NEWSWEEK        0224, P55; Berwick DM, 1996, JAMA-J AM MED ASSOC, V275, P877, DOI 10.1001/jama.275.11.877; BJURSTAM N, 1997, MONOGR NATL CANC I, V22, P53; Budetti PP, 1997, JAMA-J AM MED ASSOC, V277, P193; Coley CM, 1997, ANN INTERN MED, V126, P480; DEBER RB, 1994, CAN MED ASSOC J, V151, P423; Ernster VL, 1997, AM J PUBLIC HEALTH, V87, P1103, DOI 10.2105/AJPH.87.7.1103; Fletcher SW, 1997, NEW ENGL J MED, V336, P1180, DOI 10.1056/NEJM199704173361612; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; Gordis L, 1997, J NATL CANCER I, V89, P1015, DOI 10.1093/jnci/89.14.1015; GRADY D, 1992, ANN INTERN MED, V117, P1038; GRIFFITH RS, 1992, PRIMARY CARE, V19, P535; HARRIS R, 1995, ANN INTERN MED, V122, P539, DOI 10.7326/0003-4819-122-7-199504010-00011; Hendrick R E, 1997, J Natl Cancer Inst Monogr, P87; HOROWITZ M, 1985, JAMA-J AM MED ASSOC, V253, P1929, DOI 10.1001/jama.253.13.1929; Kassirer JP, 1997, NEW ENGL J MED, V336, P1747, DOI 10.1056/NEJM199706123362409; KASSIRER JP, 1983, NEW ENGL J MED, V308, P898, DOI 10.1056/NEJM198304143081511; KASSIRER JP, 1981, NEW ENGL J MED, V305, P1465, DOI 10.1056/NEJM198112103052409; Kerlikowske K, 1997, J Natl Cancer Inst Monogr, P79; KOLATA G, 1997, NY TIMES        0224, pA1; Kolata G., 1997, NY TIMES        0128, pC1; KOLATA G, 1997, NY TIMES        0124, pA12; Marwick C, 1997, JAMA-J AM MED ASSOC, V277, P519, DOI 10.1001/jama.277.7.519; MCCONNELL JD, 1994, AHCPR PUBL; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; *NCAB, 1997, JNCI-J NATL CANCER I, V89, P417; Pauker SG, 1997, NEW ENGL J MED, V336, P1243, DOI 10.1056/NEJM199704243361708; SHAPIRO J, 1979, NEW ENGL J MED, V301, P211, DOI 10.1056/NEJM197907263010410; SLACK WV, 1977, LANCET, V2, P240; SNOWE OJ, 1997, WASHINGTON POST 0211, pA21; STRULL WM, 1984, JAMA-J AM MED ASSOC, V252, P2990, DOI 10.1001/jama.252.21.2990; Tabar L, 1996, INT J CANCER, V68, P693; Taubes G, 1997, SCIENCE, V276, P27, DOI 10.1126/science.276.5309.27; Taubes G, 1997, SCIENCE, V275, P1056, DOI 10.1126/science.275.5303.1056; Woolf SH, 1997, J FAM PRACTICE, V45, P205; WOOLF SH, 1993, ARCH INTERN MED, V153, P2646, DOI 10.1001/archinte.153.23.2646	36	29	29	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2105	2108		10.1001/jama.278.23.2105	http://dx.doi.org/10.1001/jama.278.23.2105			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403427				2022-12-24	WOS:A1997YK98700042
J	Saitoh, O; Kubo, Y; Miyatani, Y; Asano, T; Nakata, H				Saitoh, O; Kubo, Y; Miyatani, Y; Asano, T; Nakata, H			RGS8 accelerates G-protein-mediated modulation of K+ currents	NATURE			English	Article							MUSCARINIC POTASSIUM CHANNEL; GTPASE-ACTIVATING PROTEINS; BETA-GAMMA-SUBUNITS; INWARD RECTIFIER; XENOPUS OOCYTES; ALPHA-SUBUNITS; FAMILY; CELLS; DESENSITIZATION; INHIBITION	Transmembrane signal transduction via heterotrimeric G proteins is reported to be inhibited by RGS (regulators of G-protein signalling) proteins(1-4). These RGS proteins work by increasing the GTPase activity of G protein alpha-subunits (G alpha), thereby driving G proteins into their inactive GDP-bound form(5-7). However, it is not known how RGS proteins regulate the kinetics of physiological responses that depend on G proteins. Here we report the isolation of a full-length complementary DNA encoding a neural-tissue-specific RGS protein, RGS8, and the determination of its function. We show that RGS8 binds preferentially to the alpha-subunits G alpha o and G alpha i3 and that it functions as a GTPase-activating protein (GAP). When co-expressed in Xenopus oocytes with a G-protein-coupled receptor and a G-protein-coupled inwardly rectifying K+ channel (GIRK1/2), RGS8 accelerated not only the turning off but also the turning on of the GIRK1/2 current upon receptor stimulation, without affecting the dose-response relationship. We conclude that RGS8 accelerates the modulation of G-protein-coupled channels and is not just a simple negative regulator. This property of RGS8 may be crucial for the rapid regulation of neuronal excitability upon stimulation of G-protein-coupled receptors.	TOKYO METROPOLITAN INST NEUROSCI,DEPT NEUROPHYSIOL,FUCHU,TOKYO 183,JAPAN; INST DEV RES,AICHI HUMAN SERV CTR,DEPT BIOCHEM,KASUGAI,AICHI 48003,JAPAN	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Saitoh, O (corresponding author), TOKYO METROPOLITAN INST NEUROSCI,DEPT MOL & CELLULAR NEUROBIOL,2-6 MUSASHIDAI,FUCHU,TOKYO 183,JAPAN.			Kubo, Yoshihiro/0000-0001-6707-0837				Abe M, 1996, EXP CELL RES, V229, P48, DOI 10.1006/excr.1996.0342; ASANO T, 1988, J BIOCHEM-TOKYO, V103, P950, DOI 10.1093/oxfordjournals.jbchem.a122392; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Saugstad JA, 1996, J NEUROSCI, V16, P5979; SHUI Z, 1995, J PHYSIOL-LONDON, V487, P359, DOI 10.1113/jphysiol.1995.sp020885; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; Sodickson DL, 1996, J NEUROSCI, V16, P6374; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Werner P, 1996, MOL PHARMACOL, V49, P656; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865	24	183	189	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					525	529		10.1038/37385	http://dx.doi.org/10.1038/37385			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394004				2022-12-24	WOS:A1997YJ86500056
J	Sellers, TA; Mink, PJ; Cerhan, JR; Zheng, W; Anderson, KE; Kushi, LH; Folsom, AR				Sellers, TA; Mink, PJ; Cerhan, JR; Zheng, W; Anderson, KE; Kushi, LH; Folsom, AR			The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer	ANNALS OF INTERNAL MEDICINE			English	Article							POSTMENOPAUSAL WOMEN; MENOPAUSAL ESTROGEN; OLDER WOMEN; FOLLOW-UP; METAANALYSIS; DISEASE	Background: The risks and benefits of hormone replacement therapy (HRT) are of considerable interest and importance, especially in terms of whether they differ among subsets of women. Objective: To determine whether HRT is associated with increased risks for breast cancer and total mortality in women with a family history of breast cancer. Design: Prospective cohort study. Setting: Population-based sample of midwestern post-menopausal women enrolled in an observational study of risk factors for cancer. Participants: Random sample of 41 837 female Iowa residents 55 to 69 years of age. Measurements: Incidence rates of and relative risks for breast cancer (n = 1085) and total mortality (n = 2035) th rough 8 years of follow-up were calculated by using data from the State Health Registry of Iowa and the National Death Index. Results: A family history of breast cancer was reported by 12.2% of the cohort at risk. Among women with a family history of breast cancer, those who currently used HRT and had done so for at least 5 years developed breast cancer at an age-adjusted annual rate of 61 cases per 10 000 person-years (95% CI, 28 to 94 cases); this rate was not statistically significantly higher than the rate in women who had never used HRT (46 cases per 10 000 person-years ICI, 36 to 55 cases]). Among women with a family history, those who used HRT had a significantly lower risk for total mortality than did women who had never used HRT (relative risk, 0.67 [CI, 0.51 to 0.89]), including total cancer-related mortality (relative risk, 0.75 [CI, 0.50 to 1.12]). The age-adjusted annual mortality rate for women using HRT for at least 5 years was 46 deaths per 10 000 person-years (CI, 19 to 74 deaths); this is roughly half the rate seen in women who had never used HRT (80 deaths per In 000 person-years [CI, 69 to 92 deaths]). Conclusions: These data suggest that HRT use in women with a family history of breast cancer is not associated with a significantly increased incidence of breast cancer but is associated with a significantly reduced total mortality rate.	UNIV IOWA, IOWA CITY, IA 52242 USA	University of Iowa	Sellers, TA (corresponding author), UNIV MINNESOTA, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.		Zheng, Wei/O-3351-2013; zhang, weihua/GXV-1334-2022	Zheng, Wei/0000-0003-1226-070X; Kushi, Lawrence/0000-0001-9136-1175; Cerhan, James/0000-0002-7482-178X	NCI NIH HHS [R01 CA39742, T32CA09607] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039742, T32CA009607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1994, NIH PUBLICATION, V94-1447; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; BISGARD KM, 1994, AM J EPIDEMIOL, V139, P990, DOI 10.1093/oxfordjournals.aje.a116948; BLACKMAN JA, 1995, NEW ENGL J MED, V333, P1355; Breslow N., 1987, STATISTICAL METHODS; BRINTON LA, 1993, EPIDEMIOL REV, V15, P66, DOI 10.1093/oxfordjournals.epirev.a036117; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; BRINTON LA, 1981, CANCER-AM CANCER SOC, V47, P2517, DOI 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO;2-L; CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5; Colditz GA, 1996, J NATL CANCER I, V88, P365, DOI 10.1093/jnci/88.6.365; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; FOLSOM AR, 1990, AM J EPIDEMIOL, V131, P794, DOI 10.1093/oxfordjournals.aje.a115570; FOLSOM AR, 1995, AM J PUBLIC HEALTH, V85, P1128, DOI 10.2105/AJPH.85.8_Pt_1.1128; FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P483, DOI 10.1001/jama.269.4.483; GO RCP, 1983, J NATL CANCER I, V71, P455; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HEMMINKI E, 1988, AM J PUBLIC HEALTH, V78, P1478, DOI 10.2105/AJPH.78.11.1479; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HENDERSON BE, 1996, CANC EPIDEMIOLOGY PR, P1022; HOOVER R, 1981, J NATL CANCER I, V67, P815; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KUSHI LH, 1988, AM J EPIDEMIOL, V128, P740, DOI 10.1093/oxfordjournals.aje.a115027; MILLS PK, 1989, CANCER, V64, P591, DOI 10.1002/1097-0142(19890801)64:3<591::AID-CNCR2820640305>3.0.CO;2-U; NEWCOMB PA, 1995, AM J EPIDEMIOL, V142, P788, DOI 10.1093/oxfordjournals.aje.a117717; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; *SAS I, 1985, SAS US GUID; SCHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491, DOI 10.1007/BF01831376; SILLEROARENAS M, 1992, OBSTET GYNECOL, V79, P286; STANFORD JL, 1995, JAMA-J AM MED ASSOC, V274, P137, DOI 10.1001/jama.274.2.137; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STURGEON SR, 1995, EPIDEMIOLOGY, V6, P227, DOI 10.1097/00001648-199505000-00006; WHO (World Health Organization), 1977, MAN INT STAT CLASS D; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; YANG CP, 1992, CANCER CAUSE CONTROL, V3, P475, DOI 10.1007/BF00051360	40	146	150	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					973	980		10.7326/0003-4819-127-11-199712010-00004	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412302				2022-12-24	WOS:A1997YJ08000003
J	Collins, FS; Guyer, MS; Chakravarti, A				Collins, FS; Guyer, MS; Chakravarti, A			Variations on a theme: Cataloging human DNA sequence variation	SCIENCE			English	Editorial Material							DEPENDENT DIABETES-MELLITUS; POSITIONAL CLONING; HUMAN GENOME; GENE; MUTATION; CANCER; BREAST		CASE WESTERN RESERVE UNIV,CTR HUMAN GENET,DEPT GENET,CLEVELAND,OH 44106	Case Western Reserve University	Collins, FS (corresponding author), NATL HUMAN GENOME RES INST,NIH,BETHESDA,MD 20892, USA.							BALLABIO A, 1993, NAT GENET, V3, P277, DOI 10.1038/ng0493-277; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; COLLINS FS, 1991, NAT GENET, V1, P3; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Gerhold D, 1996, BIOESSAYS, V18, P973, DOI 10.1002/bies.950181207; GRANT SFA, 1996, NAT GENET, V14, P205; KAISER J, 1996, SCIENCE, V271, P749; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; LIVAK KJ, 1995, PCR METH APPL, V4, P357; Marshall E, 1997, SCIENCE, V277, P1752, DOI 10.1126/science.277.5333.1752; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; PAPADOPOULOS N, 1994, SCIENCE, V263; Pastinen T, 1997, GENOME RES, V7, P606, DOI 10.1101/gr.7.6.606; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Shuber AP, 1997, HUM MOL GENET, V6, P337, DOI 10.1093/hmg/6.3.337; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	29	783	834	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1580	1581		10.1126/science.278.5343.1580	http://dx.doi.org/10.1126/science.278.5343.1580			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9411782				2022-12-24	WOS:A1997YJ87400028
J	Alexander, FE				Alexander, FE			Blood transfusion and risk of non-Hodgkin lymphoma	LANCET			English	Editorial Material							TIME TRENDS				Alexander, FE (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PUBL HLTH SCI,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							Adami J, 1997, ANN INTERN MED, V127, P365, DOI 10.7326/0003-4819-127-5-199709010-00004; BLOMBERG J, 1993, EUR J CANCER, V29A, P2101, DOI 10.1016/0959-8049(93)90042-E; Brandt L, 1996, BRIT J CANCER, V73, P1148, DOI 10.1038/bjc.1996.220; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; CARTWRIGHT RA, 1992, CANCER RES, V52, pS5441; Cerhan JR, 1997, J NATL CANCER I, V89, P314, DOI 10.1093/jnci/89.4.314; CERHAN JR, 1993, ANN INTERN MED, V119, P8, DOI 10.7326/0003-4819-119-1-199307010-00002; DEVESA SS, 1992, CANCER RES, V52, pS5432; GELB AB, 1994, HUM PATHOL, V25, P953, DOI 10.1016/0046-8177(94)90018-3; HARTGE P, 1992, CANCER RES, V52, pS5566; MANN R, 1994, J TRAUMA, V37, P220, DOI 10.1097/00005373-199408000-00012; Mckinney P A, 1990, Leuk Lymphoma, V2, P67, DOI 10.3109/10428199009042516; MEMON A, 1994, INT J CANCER, V58, P366, DOI 10.1002/ijc.2910580310; RollandPortal I, 1997, INT J EPIDEMIOL, V26, P945, DOI 10.1093/ije/26.5.945; Schreiber GB, 1997, J ACQ IMMUN DEF SYND, V14, P263, DOI 10.1097/00042560-199703010-00011	15	8	8	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1414	1415		10.1016/S0140-6736(05)64203-1	http://dx.doi.org/10.1016/S0140-6736(05)64203-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371161				2022-12-24	WOS:A1997YF95300004
J	Fix, AD; Strickland, GT; Grant, J				Fix, AD; Strickland, GT; Grant, J			Tick bites and Lyme disease in an endemic setting - Problematic use of serologic testing and prophylactic antibiotic therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BORRELIA-BURGDORFERI; ERYTHEMA MIGRANS; PREVENTION; AREA; MANIFESTATIONS; SERODIAGNOSIS; DIAGNOSIS; MARYLAND; CHILDREN	Context.-The use of serologic testing to diagnose Lyme disease (LD) is a source of controversy. Expert recommendations also discourage the routine use of antibiotic therapy for prophylaxis of LD following tick bites, but the extent to which physicians in endemic areas have adopted these recommendations is not known. Objective.-To assess the pattern of use of serologic testing and antibiotic therapy for tick bites and LD and associated charges for management in an endemic area. Design.-Active surveillance of patient-physician encounters for tick bites and LD. Setting.-Primary care practices on the Eastern Shore of Maryland. Patients.-Consecutive sample of 232 patients with tick bites, LD (defined by physician diagnosis in medical record), and suspected LD (physician notation of possible, but not definite LD) seen in 1995. Main Outcome Measures.-Serologic testing for LD, test results, antibiotic therapy, and direct costs of management. Results.-Surveillance identified 142 patients (61.2%) with diagnoses of tick bites, 40 patients (17.2%) with LD, and 50 patients (21.6%) with suspected LD. Of the 142 patients seen for tick bites, 95 (67%) underwent serologic testing for LD. Of these, 93 patients had initial negative or equivocal results; 24 (26%) of the 93 had convalescent testing, with 1 seroconversion. Seventy-eight patients (55%) with a diagnosis of tick bite received antibiotic therapy. No patients with tick bite developed clinical LD. Serologic testing for LD was performed for 36 patients (90%) with a diagnosis of LD and 46 patients (92%) with suspected LD. In most cases, antibiotics were prescribed before serologic test results became available. Convalescent testing was not performed for 37 (86%) of the 43 patients with suspected LD who had initial negative or equivocal results. Of these 37 patients, 25 (68%) did not receive antibiotic therapy. Direct charges for treatment of these 232 patients totaled $47 595, one third of which was attributable to serologic testing. A total of 32% of direct charges were for patients with tick bites, 48% were for patients with LD, and 20% were for patients with suspected LD. Conclusions.-In this setting, most patients consulting physicians for tick bites received prophylactic antibiotic therapy of unproven efficacy and underwent unnecessary, costly serologic testing. Despite almost universal use in this study, serologic testing for LD did not appear to influence treatment of patients diagnosed as having LD.	Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Kent Cty Hlth Dept, Chestertown, MD USA	University System of Maryland; University of Maryland Baltimore	Fix, AD (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, 660 Redwood St, Baltimore, MD 21201 USA.				PHS HHS [R01MS07813-04] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGRE F, 1993, AM J DIS CHILD, V147, P945, DOI 10.1001/archpedi.1993.02160330035013; AgueroRosenfeld ME, 1996, J CLIN MICROBIOL, V34, P1; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P590; BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BINGHAM PM, 1995, PEDIATRICS, V96, P1053; *CDC, 1991, CONN MED, V55, P691; COSTELLO CM, 1989, J INFECT DIS, V159, P136, DOI 10.1093/infdis/159.1.136; Coyle BS, 1996, J INFECT DIS, V173, P1260, DOI 10.1093/infdis/173.5.1260; Craven RB, 1996, EMERG INFECT DIS, V2, P136, DOI 10.3201/eid0202.960211; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; Dean A.G., 1994, EPI INFO VERSION 6 W; DRESSLER F, 1991, ANN INTERN MED, V115, P533, DOI 10.7326/0003-4819-115-7-533; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; EPPES SC, 1994, CLIN PEDIATR, V33, P130, DOI 10.1177/000992289403300301; ETTESTAD PJ, 1995, J INFECT DIS, V171, P356, DOI 10.1093/infdis/171.2.356; FALCO RC, 1988, AM J EPIDEMIOL, V128, P1146; FEDER HM, 1992, CLIN INFECT DIS, V15, P788, DOI 10.1093/clind/15.5.788; Gerber M A, 1995, Conn Med, V59, P195; Gerber MA, 1996, NEW ENGL J MED, V335, P1270, DOI 10.1056/NEJM199610243351703; Johnson BJB, 1996, J INFECT DIS, V174, P346, DOI 10.1093/infdis/174.2.346; LEY C, 1994, JAMA-J AM MED ASSOC, V271, P460, DOI 10.1001/jama.271.6.460; MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; *MAR DEP HLTH MENT, 1996, MED MED J, V45, P715; Nachamkin I, 1996, CLIN DIAGN LAB IMMUN, V3, P287, DOI 10.1128/CDLI.3.3.287-289.1996; NADELMAN RD, 1993, LANCET, V342, P1052, DOI 10.1016/0140-6736(93)92907-B; Nocton J J, 1995, Adv Intern Med, V40, P69; SHAPIRO ED, 1992, NEW ENGL J MED, V327, P1769, DOI 10.1056/NEJM199212173272501; Sood SK, 1997, J INFECT DIS, V175, P996, DOI 10.1086/514009; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; Steinberg SH, 1996, ANN EPIDEMIOL, V6, P24, DOI 10.1016/1047-2797(95)00096-8; Warshafsky S, 1996, J GEN INTERN MED, V11, P329, DOI 10.1007/BF02600042; WORMSER GP, 1995, MT SINAI J MED, V62, P188; Ziska MH, 1996, INFECTION, V24, P182, DOI 10.1007/BF01713336; 1993, MMWR MORB MORTAL WKL, V42, P345	36	48	52	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					206	210		10.1001/jama.279.3.206	http://dx.doi.org/10.1001/jama.279.3.206			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR124	9438740	Bronze			2022-12-24	WOS:000071460700030
J	Wu, GY; Cline, HT				Wu, GY; Cline, HT			Stabilization of dendritic arbor structure in vivo by CaMKII	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; POSTSYNAPTIC DENSITY PROTEIN; GROWTH CONE MOTILITY; NEURITE OUTGROWTH; SYNAPTIC TRANSMISSION; FUNCTIONAL COMPONENTS; ELECTRICAL-ACTIVITY; GENETIC DISSECTION; EXPRESSION	Calcium-calmodulin-dependent protein kinase II (CaMKII) promotes the maturation of retinotectal glutamatergic synapses in Xenopus. Whether CaMKII activity also controls morphological maturation of optic tectal neurons was tested using in vivo time-lapse imaging of single neurons over periods of up to 5 days. Dendritic arbor elaboration slows with maturation, in correlation with the onset of CaMKII expression. Elevating CaMKII activity in young neurons by viral expression of constitutively active CaMKII slowed dendritic growth to a rate comparable to that of mature neurons. CaMKII overexpression stabilized dendritic structure in more mature neurons, whereas CaMKII inhibition increased their dendritic growth. Thus, endogenous CaMKII activity limits dendritic growth and stabilizes dendrites, and it may act as an activity-dependent mediator of neuronal maturation.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Cline, HT (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	cline@cshl.org						ALFORD S, 1993, J PHYSIOL-LONDON, V469, P693, DOI 10.1113/jphysiol.1993.sp019838; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; COHAN CS, 1986, SCIENCE, V232, P1638, DOI 10.1126/science.3715470; Colman H, 1997, SCIENCE, V275, P356, DOI 10.1126/science.275.5298.356; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; Davis GW, 1996, NEURON, V17, P669, DOI 10.1016/S0896-6273(00)80199-3; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; FIELDS RD, 1990, J NEUROSCI, V10, P2950; GOSHIMA Y, 1993, J NEUROSCI, V13, P559; HAYDON PG, 1994, J NEUROBIOL, V25, P694, DOI 10.1002/neu.480250609; ISAAC JTR, 1997, NEURON, V18, P1; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KELLY PT, 1985, DEV BRAIN RES, V18, P211, DOI 10.1016/0165-3806(85)90265-2; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; LANKFORD KL, 1989, J CELL BIOL, V109, P1229, DOI 10.1083/jcb.109.3.1229; LAZAR G, 1973, J ANAT, V116, P347; Liao DZ, 1996, LEARN MEMORY, V3, P138, DOI 10.1101/lm.3.2-3.138; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1994, P NATL ACAD SCI USA, V91, P8170, DOI 10.1073/pnas.91.17.8170; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Masse T, 1997, J NEUROSCI, V17, P924; MATTSON MP, 1988, J NEUROSCI, V8, P2087; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; MURRAY KD, 1994, NEUROSCIENCE, V60, P37, DOI 10.1016/0306-4522(94)90202-X; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; Otmakhov N, 1997, J NEUROSCI, V17, P5357; PERKEL DJ, 1993, J PHYSIOL-LONDON, V471, P481, DOI 10.1113/jphysiol.1993.sp019911; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; REGEHR WG, 1992, J NEUROSCI, V12, P4202; Scheetz AJ, 1996, EUR J NEUROSCI, V8, P1322, DOI 10.1111/j.1460-9568.1996.tb01594.x; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; Stewart BA, 1996, J NEUROSCI, V16, P3877; Tashima K, 1996, J NEUROCHEM, V66, P57; TSUJIMOTO T, 1990, J NEUROSCI, V10, P2059; WANG J, 1994, NEURON, V13, P1373, DOI 10.1016/0896-6273(94)90422-7; WANG JH, 1995, NEURON, V15, P443, DOI 10.1016/0896-6273(95)90048-9; Witte S, 1996, J NEUROBIOL, V31, P219, DOI 10.1002/(SICI)1097-4695(199610)31:2<219::AID-NEU7>3.0.CO;2-E; Wu G., UNPUB; Wu GY, 1996, SCIENCE, V274, P972, DOI 10.1126/science.274.5289.972; WU GY, 1995, NEURON, V14, P681, DOI 10.1016/0896-6273(95)90211-2; ZHONG Y, 1995, J NEUROSCI, V15, P6679; Zou DJ, 1996, NEURON, V16, P529, DOI 10.1016/S0896-6273(00)80072-0	50	306	314	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					222	226		10.1126/science.279.5348.222	http://dx.doi.org/10.1126/science.279.5348.222			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422694				2022-12-24	WOS:000071408100041
J	Nern, A; Arkowitz, RA				Nern, A; Arkowitz, RA			A GTP-exchange factor required for cell orientation	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; MATING FACTOR; GENE-PRODUCT; YEAST-CELLS; POLARIZATION; PROTEIN; CDC42; CDC24; GRADIENTS; PATHWAY	The Rho-family of GTPases and their regulators are essential for cytoskeletal reorganization and transcriptional activation in response to extracellular signals(1,2). Little is known about what Links these molecules to membrane receptors. In the budding yeast Saccharomyces cerevisiae, haploid cells respond to mating pheromone through a G-protein-coupled receptor and the beta gamma subunit of the G protein(3), resulting in arrest of the cell cycle, transcriptional activation, and polarized growth towards a mating partner(4,5). The Rho-family GTPase Cdc42 and its exchange factor Cdc24 have been implicated in the mating process(6,7), but their specific role is unknown. Here we report the identification of cdc24 alleles that do not affect vegetative growth but drastically reduce the ability of yeast cells to mate, When exposed to mating pheromone, these mutants arrest growth, activate transcription, and undergo characteristic morphological and actin-cytoskeleton polarization, However, the mutants are unable to orient towards a pheromone gradient, and instead position their mating projection adjacent to their previous bud site. The mutants are specifically defective in the binding of Cdc24 to the G-protein beta gamma subunit, Our results demonstrate that the association of an exchange factor and the beta gamma subunit of a hetero-trimeric G protein links receptor-mediated activation to oriented cell growth.	MRC, Mol Biol Lab, Div Cell Biol, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Arkowitz, RA (corresponding author), MRC, Mol Biol Lab, Div Cell Biol, Hills Rd, Cambridge CB2 2QH, England.	ra2@mrc-lmb.cam.ac.uk	arkowitz, robert/ABC-1860-2021	arkowitz, robert/0000-0002-5216-5013				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMS AEM, 1991, METHOD ENZYMOL, V194, P729; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CHENEVERT J, 1994, GENETICS, V136, P1287; DORER R, 1995, J CELL BIOL, V131, P845, DOI 10.1083/jcb.131.4.845; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; Hirschman JE, 1997, J BIOL CHEM, V272, P240; James P, 1996, GENETICS, V144, P1425; LANGLEROUAULT F, 1995, NUCLEIC ACIDS RES, V23, P3079, DOI 10.1093/nar/23.15.3079; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; MIYAMOTO S, 1991, BIOCHEM BIOPH RES CO, V181, P604, DOI 10.1016/0006-291X(91)91233-3; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; Rose M. D., 1991, METHODS YEAST GENETI; SEGALL JE, 1993, P NATL ACAD SCI USA, V90, P8332, DOI 10.1073/pnas.90.18.8332; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; VALTZ N, 1995, J CELL BIOL, V131, P863, DOI 10.1083/jcb.131.4.863; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	30	116	118	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	1998	391	6663					195	198		10.1038/34458	http://dx.doi.org/10.1038/34458			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428768				2022-12-24	WOS:000071380900056
J	Nightingale, SL				Nightingale, SL			Rezulin labeling updated to recommend more frequent patient monitoring	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.							1997, JAMA, V278, P1728	1	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					9	9		10.1001/jama.279.1.9	http://dx.doi.org/10.1001/jama.279.1.9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424027				2022-12-24	WOS:000071295100003
J	Lewis, JE; Kristan, WB				Lewis, JE; Kristan, WB			A neuronal network for computing population vectors in the leech	NATURE			English	Article							LOCAL BENDING REFLEX; SENSORY INFORMATION; NEURAL NETWORKS; INTERNEURONS	The correlation of neuronal activity with sensory input and behavioural output has revealed that information is often encoded in the activity of many neurons across a population, that is, a neural population code is used(1,2). The possible algorithms that downstream networks use to read out this population code have been studied by manipulating the activity of a few neurons in a population(3,4). We have used this approach to study population coding in a small network underlying the leech local bend, a body bend directed away from a touch stimulus(5), Because of the small size of this network we are able to monitor and manipulate the complete set of sensory inputs to the network. We show here that the population vector(6) formed by the spike counts of the active mechanosensory neurons is well correlated with bend direction, A model based on the known connectivity of the identified neurons in the local bend network can account for our experimental results, and is suitable for reading out the neural population vector, Thus, for the first time to our knowledge, it is possible to link a proposed algorithm for neural population coding with synaptic and network mechanisms in an experimental system.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Kristan, WB (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.							ABBOTT LF, 1994, Q REV BIOPHYS, V27, P291, DOI 10.1017/S0033583500003024; Batschelet E, 1981, CIRCULAR STAT BIOL; CARLTON T, 1995, J COMP PHYSIOL A, V177, P781, DOI 10.1007/BF00187637; GEOGOPOULOS A, 1994, NEURON, V13, P257; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Groh JM, 1997, J NEUROSCI, V17, P4312; Gur M, 1997, J NEUROSCI, V17, P2914; KRISTAN WB, 1982, J EXP BIOL, V96, P143; KRISTAN WB, 1982, J EXP BIOL, V96, P161; LEE CK, 1988, NATURE, V332, P357, DOI 10.1038/332357a0; LEWIS JE, 1997, THESIS U CALIFORNIA; LOCKERY SR, 1990, J NEUROSCI, V10, P1816; LOCKERY SR, 1990, J NEUROSCI, V10, P1811; LOCKERY SR, 1989, NATURE, V340, P468, DOI 10.1038/340468a0; LOCKERY SR, 1992, J NEUROSCI, V12, P3877; MILLER JP, 1991, J NEUROPHYSIOL, V66, P1680, DOI 10.1152/jn.1991.66.5.1680; MULLER KJ, 1981, NEUROBIOLOGY LEECH; Salinas E, 1994, J Comput Neurosci, V1, P89, DOI 10.1007/BF00962720; SALINAS E, 1995, J NEUROSCI, V15, P6461; SALZMAN CD, 1994, SCIENCE, V264, P231, DOI 10.1126/science.8146653; Shaw BK, 1997, J NEUROSCI, V17, P786; SPARKS DL, 1997, NEURONS NETWORKS MOT, P21	22	95	95	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					76	79		10.1038/34172	http://dx.doi.org/10.1038/34172			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422507				2022-12-24	WOS:000071326100051
J	Nichol, G; Dennis, DT; Steere, AC; Lightfoot, R; Wells, G; Shea, B; Tugwell, P				Nichol, G; Dennis, DT; Steere, AC; Lightfoot, R; Wells, G; Shea, B; Tugwell, P			Test-treatment strategies for patients suspected of having Lyme disease: A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article							BORRELIA-BURGDORFERI; DECISION-MAKING; HEART-BLOCK; MYOSITIS; DERMATOMYOSITIS; MANIFESTATIONS; FIBROMYALGIA; POPULATION; ARTHRITIS; DIAGNOSIS	Purpose: To examine the cost-effectiveness of test-treatment strategies for patients suspected of having Lyme disease. Data Sources: The medical literature was searched for information on outcomes and costs. Expert opinion was sought for information on utilities. Study Selection: Articles that described patient population, diagnostic criteria, dose and duration of therapy, and criteria for assessment of outcomes. Data Extraction: The decision analysis evaluated the following strategies: 1) no testing-no treatment; 2) testing with enzyme-linked immunosorbent assay (ELISA) followed by antibiotic treatment of patients with positive results; 3) two-step testing with ELISA followed by Western blot and antibiotic treatment for patients with positive results on either test; and 4) empirical antibiotic therapy. Three patient scenarios were considered: myalgic symptoms, rash resembling erythema migrans, and recurrent oligoarticular inflammatory arthritis. Results were calculated as costs per quality-adjusted life-year and were subjected to sensitivity analysis. Adjustment was made for the diagnostic value of common clinical features of Lyme disease. Data Synthesis: For myalgic symptoms without other features suggestive of Lyme disease, the no testing-no treatment strategy was most economically attractive (that is, had the most favorable cost-effectiveness ratio). For rash, empirical antibiotic therapy was less costly and more effective than other strategies. For oligoarticular arthritis with a history of rash and tick bite, two-step testing was associated with the lowest cost-effectiveness ratio. Testing with ELISA and empirical antibiotic therapy cost an additional $880 000 and $34 000 per quality-adjusted life-year, respectively. For oligoarticular arthritis with one or no other features suggestive of Lyme disease, two-step testing was most economically attractive. Conclusions: Neither testing nor antibiotic treatment is cost-effective if the pretest probability of Lyme disease is low. Empirical antibiotic therapy is recommended if the pretest probability is high, and two-step testing is recommended if the pretest probability is intermediate.	Ottawa Gen Hosp, Dept Med, Ottawa, ON K1H 8L6, Canada; Ottawa Civic Hosp, Clin Epidemiol Unit, Ottawa, ON K1Y 4E9, Canada; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Ft Collins, CO 80521 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Univ Kentucky, Kentucky Clin J511, Div Rheumatol, Lexington, KY 40536 USA; Tufts Univ, Med Ctr, Boston, MA 02111 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Centers for Disease Control & Prevention - USA; Tufts Medical Center; University of Kentucky; Tufts University	Tugwell, P (corresponding author), Ottawa Gen Hosp, Dept Med, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.		Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556; Steere, Allen/0000-0002-5268-9853				*AM MED ASS CTR HL, 1993, PHYS MARK STAT PROF; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P590; ATLAS E, 1988, ANN INTERN MED, V109, P245, DOI 10.7326/0003-4819-109-3-245; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; BERGER BW, 1989, REV INFECT DIS, V11, pS1475; BLAAUW I, 1992, J CLIN EPIDEMIOL, V45, P1229, DOI 10.1016/0895-4356(92)90163-H; BURDGE DR, 1993, CLIN INFECT DIS, V16, P558, DOI 10.1093/clind/16.4.558; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; COCKBURN J, 1987, BRIT MED J, V295, P814, DOI 10.1136/bmj.295.6602.814; DATTWYLER RJ, 1988, LANCET, V1, P1191; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; EPPES SC, 1994, CLIN PEDIATR, V33, P130, DOI 10.1177/000992289403300301; ETTESTAD PJ, 1995, J INFECT DIS, V171, P356, DOI 10.1093/infdis/171.2.356; FRASER DD, 1992, CLIN EXP RHEUMATOL, V10, P387; GEISLER WO, 1977, PARAPLEGIA, V14, P262, DOI 10.1038/sc.1976.44; Gold MR, 1996, COST EFFECTIVENESS H; GUSTAFSON R, 1992, EUR J CLIN MICROBIOL, V11, P894, DOI 10.1007/BF01962369; HOFFMANN JC, 1995, ARTHRITIS RHEUM-US, V38, P1157, DOI 10.1002/art.1780380820; HOROWITZ HW, 1994, CLIN INFECT DIS, V18, P166, DOI 10.1093/clinids/18.2.166; HSU VM, 1993, ARTHRITIS RHEUM, V36, P1493, DOI 10.1002/art.1780361103; JACOBS P, 1995, PHARMACOECONOMICS, V8, P182, DOI 10.2165/00019053-199508030-00002; Jung P I, 1994, Md Med J, V43, P447; KARLSSON M, 1994, NEUROLOGY, V44, P1203, DOI 10.1212/WNL.44.7.1203; KARMA A, 1995, AM J OPHTHALMOL, V119, P127, DOI 10.1016/S0002-9394(14)73864-4; KENGEN RAM, 1989, CLIN NUCL MED, V14, P728, DOI 10.1097/00003072-198910000-00002; Lew EA, 1990, MED RISKS TRENDS MOR; LEY C, 1994, JAMA-J AM MED ASSOC, V271, P460, DOI 10.1001/jama.271.6.460; LIGHTFOOT RW, 1993, ANN INTERN MED, V119, P503, DOI 10.7326/0003-4819-119-6-199309150-00010; LOGIGIAN EL, 1992, NEUROLOGY, V42, P303, DOI 10.1212/WNL.42.2.303; LUI NY, 1989, ARTHRITIS RHEUM, V32, pS46; MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; MALANE MS, 1991, ANN INTERN MED, V114, P490, DOI 10.7326/0003-4819-114-6-490; MCALISTER HF, 1989, ANN INTERN MED, V110, P339, DOI 10.7326/0003-4819-110-5-339; *MED EC, 1993, DRUG TOP RED BOOK; MELSKI JW, 1993, ARCH DERMATOL, V129, P709, DOI 10.1001/archderm.129.6.709; *NAT CTR HLTH STAT, 1994, ANN SUMM BIRTHS MARR; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; REIK L, 1979, MEDICINE, V58, P281, DOI 10.1097/00005792-197907000-00001; REIMERS CD, 1993, J NEUROL, V240, P278, DOI 10.1007/BF00838161; RUBIN DA, 1992, PACE, V15, P252, DOI 10.1111/j.1540-8159.1992.tb06492.x; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SCHMUTZHARD E, 1986, KLIN WOCHENSCHR, V64, P1204, DOI 10.1007/BF01728463; SCHOEN RT, 1991, ARTHRITIS RHEUM, V34, P1056, DOI 10.1002/art.1780340817; SCHOENEN J, 1989, J NEUROL NEUROSUR PS, V52, P1002, DOI 10.1136/jnnp.52.8.1002; SEIDENBERG KB, 1990, AM J OPHTHALMOL, V109, P13, DOI 10.1016/S0002-9394(14)75571-0; SHADICK NA, 1994, ANN INTERN MED, V121, P560, DOI 10.7326/0003-4819-121-8-199410150-00002; SMITH JL, 1991, J CLIN NEURO-OPHTHAL, V11, P7; Sox HC, 1988, MED DECISION MAKING; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1980, ANN INTERN MED, V93, P1, DOI 10.7326/0003-4819-93-1-1; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1994, ARTHRITIS RHEUM-US, V37, P878, DOI 10.1002/art.1780370616; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1; Tugwell P, 1997, ANN INTERN MED, V127, P1109, DOI 10.7326/0003-4819-127-12-199712150-00011; Wharton M, 1990, MMWR Recomm Rep, V39, P1; 1993, MMWR MORB MORTAL WKL, V42, P39; 1995, MMWR MORB MORTAL WKL, V44, P459; 1996, MMWR MORB MORTAL WKL, V45, P481; 1994, MMWR MORB MORTAL WKL, V43, P564	66	45	46	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					37	48		10.7326/0003-4819-128-1-199801010-00007	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00007			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424980				2022-12-24	WOS:000071158000007
J	Klein, MA; Frigg, R; Flechsig, E; Raeber, AJ; Kalinke, U; Bluethmann, H; Bootz, F; Suter, M; Zinkernagel, RM; Aguzzi, A				Klein, MA; Frigg, R; Flechsig, E; Raeber, AJ; Kalinke, U; Bluethmann, H; Bootz, F; Suter, M; Zinkernagel, RM; Aguzzi, A			A crucial role for B cells in neuroinvasive scrapie	NATURE			English	Article							FOLLICULAR DENDRITIC CELLS; NECROSIS-FACTOR RECEPTOR-1; MICE LACKING; DEFICIENT MICE; T-CELLS; PROTEIN; MOUSE; PRP; REPLICATION; RESISTANT	Although prion proteins are most efficiently propagated through intracerebral inoculation, peripheral administration has caused the diseases kuru, iatrogenic Creutzfeldt-Jakob disease (CJD), bovine spongiform encephalopathy (BSE) and new-variant CJD(1,2). The development of neurological disease after peripheral inoculation depends on prion expansion within cells of the lymphoreticular system(3,4). Here we investigate the identity of these cells by using a panel of immune-deficient mice inoculated with prions intraperitoneally: we found that defects affecting only T lymphocytes had no apparent effect, but that all mutations that disrupted the differentiation and response of B lymphocytes prevented the development of clinical scrapie. As an absence of B cells and of antibodies correlates with severe defects in follicular dendritic cells, a lack of any of these three components may prevent the development of clinical scrapie. However, we found that scrapie developed after peripheral inoculation in mice expressing immunoglobulins that were exclusively of the M subclass and without detectable specificity for the normal form of the prion PrPc, and in mice which had differentiated B cells but no functional follicular dendritic cells. We conclude that differentiated B cells are crucial for neuroinvasion by scrapie, regardless of the specificity of their receptors.	UNIV ZURICH,INST NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH,INST MOL BIOL,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH,INST EXPT IMMUNOL,CH-8091 ZURICH,SWITZERLAND; HOFFMANN LA ROCHE AG,CH-4070 BASEL,SWITZERLAND; UNIV ZURICH,INST LAB ANIM SCI,CH-8057 ZURICH,SWITZERLAND	University of Zurich; University of Zurich; University of Zurich; Roche Holding; University of Zurich				Aguzzi, Adriano/0000-0002-0344-6708; Kalinke, Ulrich/0000-0003-0503-9564				Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; Brandner S, 1996, P NATL ACAD SCI USA, V93, P13148, DOI 10.1073/pnas.93.23.13148; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Eigen M, 1996, BIOPHYS CHEM, V63, pA1, DOI 10.1016/S0301-4622(96)02250-8; FARQUHAR CF, 1989, J VIROL METHODS, V24, P215, DOI 10.1016/0166-0934(89)90023-2; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Fraser H, 1996, J GEN VIROL, V77, P1935, DOI 10.1099/0022-1317-77-8-1935; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; HUMPHREY JH, 1984, EUR J IMMUNOL, V14, P859, DOI 10.1002/eji.1830140916; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Kalinke U, 1996, IMMUNITY, V5, P639, DOI 10.1016/S1074-7613(00)80277-0; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Lasmezas CI, 1996, J VIROL, V70, P1292; LeHir M, 1996, J EXP MED, V183, P2367, DOI 10.1084/jem.183.5.2367; LEUNG WPF, 1991, CELL, V65, P443; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; NONOYAMA S, 1993, J IMMUNOL, V150, P3817; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	29	417	425	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 25	1997	390	6661					687	690		10.1038/37789	http://dx.doi.org/10.1038/37789			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM508	9414161				2022-12-24	WOS:A1997YM50800032
J	Gillman, MW; Cupples, LA; Millen, BE; Ellison, RC; Wolf, PA				Gillman, MW; Cupples, LA; Millen, BE; Ellison, RC; Wolf, PA			Inverse association of dietary fat with development of ischemic stroke in men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; SPONTANEOUSLY HYPERTENSIVE RATS; JAPANESE MEN; BLOOD-PRESSURE; FOLLOW-UP; MORTALITY; RISK; POPULATIONS; CALIFORNIA; PROGRAM	Context.-A few ecological and cohort studies in Asian populations suggest an inverse association of the intake of both fat and saturated fat with risk of stroke. However, data among western populations are scant. Objective.-To examine the association of stroke incidence with intake of fat and type of fat among middle-aged US men during 20 years of follow-up. Design and Setting.-The Framingham Heart Study, a population-based cohort study. Participants.-A total of 832 men, aged 45 through 65 years, who were free of cardiovascular disease at baseline (1966-1969). Measurements and Data Analysis.-The diet of each subject was assessed at baseline by a single 24-hour dietary recall, from which intakes of energy and macronutrients were estimated. In Kaplan-Meier analyses, we calculated age-adjusted cumulative incidence rates of stroke. Using Cox regression, we estimated stroke incidence relative risks during 20 years of follow-up. Main Outcome Measure.-Incidence of ischemic stroke, which occurred in 61 subjects during the follow-up period. Results.-Mean intakes were 10 975 kJ for energy; 114g (39% of energy) for total fat; 44g (15%) for saturated fat; 46 g (16%) for monounsaturated fat; and 16 g (5%) for polyunsaturated fat. Risk of ischemic stroke declined across the increasing quintile of total fat (log-rank trend P=.008), saturated fat (P=.002), and monounsaturated fat (P=.008) but not polyunsaturated fat (P=.33). The age-and energy-adjusted relative risk for each increment of 3% of energy from total fat was 0.85 (95% confidence interval [CI], 0.78-0.94); for an increment of 1% from saturated fat, 0.91 (95% CI, 0.85-0.98); and for 1% from monounsaturated fat, 0.89 (95% CI, 0.83-0.96). Adjustment for cigarette smoking, glucose intolerance, body mass index, blood pressure, blood cholesterol level, physical activity, and intake of vegetables and fruits and alcohol did not materially change the results. Too few cases of hemorrhagic stroke (n=14) occurred to draw inferences. Conclusion.-Intakes of fat, saturated fat, and monounsaturated fat were associated with reduced risk of ischemic stroke in men.	Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA USA; Boston Univ, Sch Publ Hlth, Boston, MA USA; Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Boston University; Boston University; Boston University	Gillman, MW (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, 126 Brookline Ave,Suite 200, Boston, MA 02215 USA.			Ellison, Robert Curtis/0000-0002-0582-7467; Wolf, Philip/0000-0002-3628-301X	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01HC 38038] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELL LL, 1952, J BIOL CHEM, V195, P357; BENFANTE R, 1994, STROKE, V25, P814, DOI 10.1161/01.STR.25.4.814; BRONNER LL, 1995, NEW ENGL J MED, V333, P1392, DOI 10.1056/NEJM199511233332106; CUPPLES LA, 1995, STAT MED, V14, P1731, DOI 10.1002/sim.4780141603; CUPPLES LA, 1987, NIH PUBLICATION; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; GARCIAPALMIERI MR, 1980, AM J CLIN NUTR, V33, P1818, DOI 10.1093/ajcn/33.8.1818; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; Gillman MW, 1997, EPIDEMIOLOGY, V8, P144, DOI 10.1097/00001648-199703000-00004; GORDON T, 1981, CIRCULATION, V63, P500, DOI 10.1161/01.CIR.63.3.500; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; IKEDA K, 1987, J NUTR SCI VITAMINOL, V33, P31, DOI 10.3177/jnsv.33.31; KANNEL WB, 1987, AM HEART J, V113, P1489, DOI 10.1016/0002-8703(87)90666-1; Katan MB, 1997, NEW ENGL J MED, V337, P563; Key TJA, 1996, BMJ-BRIT MED J, V313, P775, DOI 10.1136/bmj.313.7060.775; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; KIMURA N, 1983, PREV MED, V12, P222, DOI 10.1016/0091-7435(83)90198-6; KLATSKY AL, 1987, J AM COLL CARDIOL, V9, pA78; KULLER L, 1971, AM J EPIDEMIOL, V93, P1; LAPIDUS L, 1986, AM J CLIN NUTR, V44, P444, DOI 10.1093/ajcn/44.4.444; MANN GV, 1962, AM J CLIN NUTR, V11, P200, DOI 10.1093/ajcn/11.3.200; MANSON JE, 1994, CIRCULATION, V89, P932; MCGEE D, 1985, INT J EPIDEMIOL, V14, P97, DOI 10.1093/ije/14.1.97; OMURA T, 1987, SOC SCI MED, V24, P401, DOI 10.1016/0277-9536(87)90212-7; POSNER BM, 1991, ARCH INTERN MED, V151, P1181, DOI 10.1001/archinte.151.6.1181; Qizilbash N, 1995, LANCET, V346, P1647; REED D, 1985, HYPERTENSION, V7, P405, DOI 10.1161/01.HYP.7.3_Pt_1.405; REED DM, 1990, AM J EPIDEMIOL, V131, P579, DOI 10.1093/oxfordjournals.aje.a115542; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SHIMOKAWA T, 1988, LIFE SCI, V43, P2067, DOI 10.1016/0024-3205(88)90356-6; SIMON JA, 1995, STROKE, V26, P778, DOI 10.1161/01.STR.26.5.778; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; SYME SL, 1975, AM J EPIDEMIOL, V102, P477, DOI 10.1093/oxfordjournals.aje.a112185; TAKEYA Y, 1984, STROKE, V15, P15, DOI 10.1161/01.STR.15.1.15; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; TILLOTSON JL, 1973, AM J CLIN NUTR, V26, P177, DOI 10.1093/ajcn/26.2.177; Willett W., 1990, NUTR EPIDEMIOLOGY; YAMORI Y, 1977, JPN HEART J, V18, P551; YAMORI Y, 1987, PREVENTION CARDIOVAS, P163	41	149	152	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	1997	278	24					2145	2150		10.1001/jama.278.24.2145	http://dx.doi.org/10.1001/jama.278.24.2145			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM043	9417007				2022-12-24	WOS:000071022200029
J	Barbas, CF; Heine, A; Zhong, GF; Hoffmann, T; Gramatikova, S; Bjornestedt, R; List, B; Anderson, J; Stura, EA; Wilson, IA; Lerner, RA				Barbas, CF; Heine, A; Zhong, GF; Hoffmann, T; Gramatikova, S; Bjornestedt, R; List, B; Anderson, J; Stura, EA; Wilson, IA; Lerner, RA			Immune versus natural selection: Antibody aldolases with enzymic rates but broader scope	SCIENCE			English	Article							RABBIT MUSCLE ALDOLASE; AMINO-ACID SEQUENCE; ACTIVE-SITE; ACETOACETATE DECARBOXYLASE; CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGES; REACTIVE IMMUNIZATION; CATALYTIC ANTIBODIES; IONIZATION CONSTANT; REPORTER GROUP	Structural and mechanistic studies show that when the selection criteria of the immune system are changed, catalytic antibodies that have the efficiency of natural enzymes evolve, but the catalytic antibodies are much more accepting of a wide range of substrates. The catalytic antibodies were prepared by reactive immunization, a process whereby the selection criteria of the immune system are changed from simple binding to chemical reactivity. This process yielded aldolase catalytic antibodies that approximated the rate acceleration of the natural enzyme used in glycolysis. Unlike the natural enzyme, however, the antibody aldolases catalyzed a variety of aldol reactions and decarboxylations. The crystal structure of one of these antibodies identified the reactive lysine residue that was selected in the immunization process. This lysine is deeply buried in a hydrophobic pocket at the base of the binding site, thereby accounting for its perturbed pK(a).			Barbas, CF (corresponding author), Scripps Res Inst, SKAGGS INST CHEM BIOL, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Stura, Enrico A./A-2793-2010; List, Benjamin/A-2121-2014	Stura, Enrico A./0000-0001-6718-2118; 	NATIONAL CANCER INSTITUTE [P01CA027489] Funding Source: NIH RePORTER; NCI NIH HHS [CA27489] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERY WJ, 1977, ANGEW CHEM INT EDIT, V16, P285, DOI 10.1002/anie.197702851; AREVALO JH, 1993, J MOL BIOL, V231, P103, DOI 10.1006/jmbi.1993.1260; BALDWIN JE, 1982, TETRAHEDRON, V38, P2939, DOI 10.1016/0040-4020(82)85023-0; BALDWIN JE, UNPUB; Bjornestedt R, 1996, J AM CHEM SOC, V118, P11720, DOI 10.1021/ja9620797; BRADY RL, 1992, J MOL BIOL, V227, P253, DOI 10.1016/0022-2836(92)90695-G; BRUICE PY, 1990, J AM CHEM SOC, V112, P7361, DOI 10.1021/ja00176a041; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Castellano J.A., 1992, HDB DISPLAY TECHNOLO; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; FASTREZ J, 1973, BIOCHEMISTRY-US, V12, P1067, DOI 10.1021/bi00730a008; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FREY PA, 1971, J AM CHEM SOC, V93, P7266, DOI 10.1021/ja00755a024; GUDDAT LW, 1994, J MOL BIOL, V236, P247, DOI 10.1006/jmbi.1994.1133; HANSCH C, 1970, J PHARM SCI, V59, P731, DOI 10.1002/jps.2600590602; HESTER G, 1991, FEBS LETT, V292, P237, DOI 10.1016/0014-5793(91)80875-4; Highbarger LA, 1996, BIOCHEMISTRY-US, V35, P41, DOI 10.1021/bi9518306; HINE J, 1972, J AM CHEM SOC, V94, P190, DOI 10.1021/ja00756a033; HsiehWilson LC, 1996, P NATL ACAD SCI USA, V93, P5363, DOI 10.1073/pnas.93.11.5363; Jencks W. P., 1975, CATALYSIS CHEM ENZYM; JOHN RA, 1995, BBA-PROTEIN STRUCT M, V1248, P81, DOI 10.1016/0167-4838(95)00025-P; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabat EA, 1991, SEQUENCES PROTEINS I; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; KOKESH FC, 1971, J AM CHEM SOC, V93, P7270, DOI 10.1021/ja00755a025; LAI CY, 1974, SCIENCE, V183, P1204, DOI 10.1126/science.183.4130.1204; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JK, 1997, SCIENCE, V276, P942, DOI 10.1126/science.276.5314.942; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; MARSH JJ, 1992, TRENDS BIOCHEM SCI, V17, P110, DOI 10.1016/0968-0004(92)90247-7; MORRIS AJ, 1994, BIOCHEMISTRY-US, V33, P12291, DOI 10.1021/bi00206a036; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REYMOND JL, 1995, J ORG CHEM, V60, P6970, DOI 10.1021/jo00126a057; Richardson J.S., 1990, PREDICTION PROTEIN S, P1; RUTTER WJ, 1964, FED PROC, V23, P1248; SCHMIDT DE, 1971, BIOCHEMISTRY-US, V10, P1249; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SHELDRICK GM, 1996, SHELXL 96 PROGRAM CR; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; VLAHOS CJ, 1986, J BIOL CHEM, V261, P1049; WADA H, 1962, J BIOL CHEM, V237, P133; WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WIRSCHING P, 1995, SCIENCE, V270, P1775, DOI 10.1126/science.270.5243.1775; WONG CH, 1995, ANGEW CHEM INT EDIT, V34, P412, DOI 10.1002/anie.199504121; Zhong GF, 1997, J AM CHEM SOC, V119, P8131, DOI 10.1021/ja970944x; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	51	340	355	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2085	2092		10.1126/science.278.5346.2085	http://dx.doi.org/10.1126/science.278.5346.2085			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405338				2022-12-24	WOS:A1997YM23500043
J	Lee, SJ; Kuntz, KM; Horowitz, MM; McGlave, PB; Goldman, JM; Sobocinski, KA; Hegland, J; Kollman, C; Parsons, SK; Weinstein, MC; Weeks, JC; Antin, JH				Lee, SJ; Kuntz, KM; Horowitz, MM; McGlave, PB; Goldman, JM; Sobocinski, KA; Hegland, J; Kollman, C; Parsons, SK; Weinstein, MC; Weeks, JC; Antin, JH			Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: A decision analysis	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC MYELOID-LEUKEMIA; CHRONIC GRANULOCYTIC-LEUKEMIA; GRAFT-VERSUS-LEUKEMIA; INTERFERON-ALPHA THERAPY; CHRONIC-PHASE; MULTIVARIATE-ANALYSIS; HOST DISEASE; PROGNOSTIC DISCRIMINATION; PATIENT CHARACTERISTICS; CYTOGENETIC RESPONSE	Background: Chronic myelogenous leukemia (CML) is an indolent but ultimately fatal disease. Because the natural history of CML varies and quality of life with CML may be excellent until shortly before death, deciding whether and when to pursue unrelated donor bone marrow transplantation is often difficult. Objective: To compare early transplantation, delayed transplantation, and no transplantation ?or patients with chronic-phase CML on the basis of discounted, quality-adjusted life expectancy. Design: A Markov model comparing different strategies was constructed. This model considers patient age, quality of life, risk aversion, and the competing risks for CML progression and transplant toxicity. Setting: Therapeutic decision at the time of diagnosis of CML. Patients: The base case is a 35-year-old patient with intermediate-prognosis CML. Younger and older patients with better and worse prognoses are also evaluated. Intervention: Early transplantation, delayed transplantation, and no transplantation. Measurements: Quality-adjusted, discounted life expectancy. Results: For patients with newly diagnosed CML, transplantation within the first year provides the greatest quality-adjusted expected survival, although this benefit decreases with increasing patient age. For a 35-year-old patient with intermediate-prognosis CML, transplantation within the first year results in 5.3 more discounted, quality-adjusted years of life expectancy than does no transplantation. This finding is robust even with varying baseline assumptions. Conclusions: These results support the use of early unrelated donor bone marrow transplantation for most patients with CML.	Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Natl Marrow Donor Program, Minneapolis, MN 55413 USA; Royal Postgrad Med Sch, Dept Haematol, London W12 0NN, England; Med Coll Wisconsin, Int Bone Marrow Transplant Registry, Ctr Stat, Milwaukee, WI 53226 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; University of Minnesota System; University of Minnesota Twin Cities; National Marrow Donor Program; Imperial College London; Medical College of Wisconsin	Lee, SJ (corresponding author), Dana Farber Canc Inst, Ctr Outcomes & Policy Res, 454 Brookline Ave,Suite 23, Boston, MA 02115 USA.		horowitz, Mary/ABH-2173-2021		NCI NIH HHS [P01-CA-40053, CP-21161] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040053] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAN NC, 1995, LANCET, V345, P1392, DOI 10.1016/S0140-6736(95)92596-1; ANTIN JH, 1993, BLOOD, V82, P2273; BACIGALUPO A, 1993, BONE MARROW TRANSPL, V12, P443; BEATTY PG, 1988, TRANSPLANTATION, V45, P714, DOI 10.1097/00007890-198804000-00010; Bhatia R, 1997, BLOOD, V89, P2623, DOI 10.1182/blood.V89.8.2623; BIGGS JC, 1992, BLOOD, V80, P1352; BORTIN MM, 1993, BONE MARROW TRANSPL, V12, P97; CERVANTES F, 1982, BLOOD, V60, P1298; CHAMPLIN RE, 1988, SEMIN HEMATOL, V25, P74; CHAPMAN GB, 1995, MED DECIS MAKING, V15, P373, DOI 10.1177/0272989X9501500408; DEVERGIE A, 1990, BONE MARROW TRANSPL, V5, P379; DROBYSKI WR, 1993, BLOOD, V82, P2310; Duell T, 1997, ANN INTERN MED, V126, P184, DOI 10.7326/0003-4819-126-3-199702010-00002; Enright H, 1996, BLOOD, V88, P714, DOI 10.1182/blood.V88.2.714.bloodjournal882714; Enright H, 1996, BONE MARROW TRANSPL, V17, P537; GALIMBERTI M, 1994, BONE MARROW TRANSPL, V13, P197; GIRALT S, 1995, BLOOD, V86, P4337, DOI 10.1182/blood.V86.11.4337.bloodjournal86114337; Gluckman E, 1996, BLOOD, V88, P2436; GOLDMAN JM, 1993, BLOOD, V82, P2235; GRATWOHL A, 1993, BONE MARROW TRANSPL, V12, P509; Gratwohl A, 1996, BRIT J HAEMATOL, V92, P35, DOI 10.1046/j.1365-2141.1996.00292.x; Guilhot F, 1997, NEW ENGL J MED, V337, P223, DOI 10.1056/NEJM199707243370402; Hasford J, 1996, BLOOD, V87, P5384, DOI 10.1182/blood.V87.12.5384.bloodjournal87125384; HEHLMANN R, 1993, BLOOD, V82, P398, DOI 10.1182/blood.V82.2.398.bloodjournal822398; HEHLMANN R, 1994, BLOOD, V84, P4064, DOI 10.1182/blood.V84.12.4064.bloodjournal84124064; KANTARJIAN HM, 1995, ANN INTERN MED, V122, P254, DOI 10.7326/0003-4819-122-4-199502150-00003; Kantarjian HM, 1996, BLOOD, V87, P3069, DOI 10.1182/blood.V87.8.3069.bloodjournal8783069; KANTARJIAN HM, 1990, AM J MED, V88, P1, DOI 10.1016/0002-9343(90)90119-X; KANTARJIAN HM, 1985, BLOOD, V66, P1326; KARANAS A, 1968, BLOOD, V32, P445, DOI 10.1182/blood.V32.3.445.445; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; MACKINNON S, 1995, BLOOD, V86, P1261, DOI 10.1182/blood.V86.4.1261.bloodjournal8641261; MARKS DI, 1993, ANN INTERN MED, V119, P207, DOI 10.7326/0003-4819-119-3-199308010-00005; MARTIN PJ, 1988, BLOOD, V72, P1978; MCGLAVE P, 1993, BLOOD, V81, P543; MCGLAVE PB, 1994, LANCET, V343, P1486, DOI 10.1016/S0140-6736(94)92589-5; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; OHNISHI K, 1995, BLOOD, V86, P906; OZER H, 1993, BLOOD, V82, P2975; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PORTER DL, 1994, NEW ENGL J MED, V330, P100, DOI 10.1056/NEJM199401133300204; REDELMEIER DA, 1993, MED DECIS MAKING, V13, P212, DOI 10.1177/0272989X9301300306; SACCHI S, 1995, J CLIN ONCOL, V13, P2401, DOI 10.1200/JCO.1995.13.9.2401; SEGEL GB, 1986, BLOOD, V68, P1055; SIMON W, 1988, BRIT J HAEMATOL, V70, P31, DOI 10.1111/j.1365-2141.1988.tb02430.x; SOKAL JE, 1984, BLOOD, V63, P789, DOI 10.1182/blood.V63.4.789.789; SOKAL JE, 1985, BLOOD, V66, P1352; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; SPIERS ASD, 1979, BRIT J HAEMATOL, V41, P1, DOI 10.1111/j.1365-2141.1979.tb03675.x; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; TURA S, 1994, NEW ENGL J MED, V330, P820; TURA S, 1981, BRIT J HAEMATOL, V47, P105, DOI 10.1111/j.1365-2141.1981.tb02765.x; TURA S, 1992, HAEMATOLOGICA, V77, P204; von Neumann J., 1953, THEORY GAMES EC BEHA; WAGNER JE, 1992, J CLIN ONCOL, V10, P779, DOI 10.1200/JCO.1992.10.5.779; WETZLER M, 1995, AM J MED, V99, P402, DOI 10.1016/S0002-9343(99)80189-2	56	60	60	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1080	1088		10.7326/0003-4819-127-12-199712150-00005	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412310				2022-12-24	WOS:000070936600004
J	Powell, RJ; Holbrook, MR; Stevens, A				Powell, RJ; Holbrook, MR; Stevens, A			Pyoderma gangrenosum and its treatment	LANCET			English	Editorial Material									QUEENS MED CTR,DEPT HISTOPATHOL,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham	Powell, RJ (corresponding author), QUEENS MED CTR,DEPT CLIN IMMUNOL,NOTTINGHAM NG7 2UH,ENGLAND.							ABUELMAGD K, 1991, TRANSPLANT P, V23, P3328; BECHSTEIN WO, 1993, TRANSPLANT P, V25, P702; Bulvik S, 1997, BRIT J DERMATOL, V136, P637, DOI 10.1111/j.1365-2133.1997.tb02169.x; CHAMPION RH, 1992, TXB DERMATOLOGY, P1922; Chow RKP, 1996, J AM ACAD DERMATOL, V34, P1047, DOI 10.1016/S0190-9622(96)90285-6; Enk AH, 1997, LANCET, V350, P494, DOI 10.1016/S0140-6736(05)63084-X; MARTIS WL, 1992, ARCH DERMATOL, V128, P1060; NORWACK R, 1997, LANCET, V349, P774; Ostraat O, 1995, TRANSPLANT P, V27, P3540; Tamir A, 1996, DERMATOLOGY, V192, P252, DOI 10.1159/000246377	10	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 13	1997	350	9093					1720	1721		10.1016/S0140-6736(05)63568-4	http://dx.doi.org/10.1016/S0140-6736(05)63568-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL554	9413459				2022-12-24	WOS:A1997YL55400004
J	Fahlke, C; Yu, HT; Beck, CL; Rhodes, TH; George, AL				Fahlke, C; Yu, HT; Beck, CL; Rhodes, TH; George, AL			Pore-forming segments in voltage-gated chloride channels	NATURE			English	Article							MOLECULAR-BASIS; DOMINANT; MYOTONIA; CELLS	The ability to differentiate between ions is a property of ion channels that is crucial for their biological functions', However, the fundamental structural features that define anion selectivity and distinguish anion-permeable from cation-permeable channels are poorly understood, Voltage-gated chloride (Cl-) channels belonging to the ClC family are ubiquitous and have been predicted to play important roles in many diverse physiological(2) and pathophysiological(3-5) processes. We have identified regions of a human skeletal muscle ClC isoform that contribute to formation of its anion-selective conduction pathway. A core structural element (pi region) of the CIC channel pore spans an accessibility barrier between the internal and external milieu, and contains an evolutionarily conserved sequence motif: GKxGPxxH. Neighbouring sequences in the third and fifth transmembrane segments also contribute to isoform-specific differences in anion selectivity, The conserved motif in the Cl- channel Pl region may constitute a 'signature' sequence for an anion-selective ion pore by analogy with the homologous GYG sequence that is essential for selectivity in voltage-gated potassium ion (K+) channel pores(6-8).	VANDERBILT UNIV,SCH MED,DEPT MED NEPHROL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,CTR MOL NEUROSCI,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University			Fahlke, Christoph/G-3635-2013	Fahlke, Christoph/0000-0001-8602-9952				AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; DANI JA, 1983, J GEN PHYSIOL, V81, P255, DOI 10.1085/jgp.81.2.255; Fahlke C, 1997, P NATL ACAD SCI USA, V94, P2729, DOI 10.1073/pnas.94.6.2729; Fahlke C, 1996, BIOPHYS J, V71, P695, DOI 10.1016/S0006-3495(96)79269-X; FAHLKE C, 1995, NEURON, V15, P463, DOI 10.1016/0896-6273(95)90050-0; FAHLKE C, J GEN PHYSIOL, V110, P551; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hille B., 1992, IONIC CHANNELS EXCIT; JENTSCH TJ, 1994, CURR TOP MEMBR, V42, P35, DOI 10.1016/S0070-2161(08)60817-5; KAWASAKI M, 1994, NEURON, V12, P597, DOI 10.1016/0896-6273(94)90215-1; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; SchmidtRose T, 1997, P NATL ACAD SCI USA, V94, P7633, DOI 10.1073/pnas.94.14.7633; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0	21	159	161	2	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					529	532		10.1038/37391	http://dx.doi.org/10.1038/37391			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394005				2022-12-24	WOS:A1997YJ86500057
J	Pidoplichko, VI; DeBiasi, M; Williams, JT; Dani, JA				Pidoplichko, VI; DeBiasi, M; Williams, JT; Dani, JA			Nicotine activates and desensitizes midbrain dopamine neurons	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR; SYNAPTIC TRANSMISSION; RAT; ADDICTION; SYSTEM	Tobacco use in developed countries is estimated to be the single largest cause of premature death(1), Nicotine is the primary component of tobacco that drives use, and like other addictive drugs, nicotine reinforces self-administration and place preference in animal studies(2-5). Midbrain dopamine neurons normally help to shape behaviour by reinforcing biologically rewarding events, but addictive drugs such as cocaine can inappropriately exert a reinforcing influence by acting upon the mesolimbic dopamine system(3-6). Here we show that the same concentration of nicotine achieved by smokers activates and desensitizes multiple nicotinic receptors thereby regulating the activity of mesolimbic dopamine neurons, Initial application of nicotine can increase the activity of the dopamine neurons, which could mediate the rewarding aspects of tobacco use, Prolonged exposure to even these low concentrations of nicotine, however, can cause desensitization of the nicotinic receptors, which helps to explain acute tolerance to nicotine's effects, The effects suggest a cellular basis for reports that the first cigarette of the day is the most pleasurable, whereas the effect of subsequent cigarettes may depend on the interplay between activation and desensitization of multiple nicotinic receptors(5).	BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOL PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA; OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA	Baylor College of Medicine; Baylor College of Medicine; Oregon Health & Science University			De Biasi, Mariella/M-7646-2017	De Biasi, Mariella/0000-0002-0687-8872				ALKONDON M, 1993, J PHARMACOL EXP THER, V265, P1455; BENOWITZ NL, 1989, PROG BRAIN RES, V79, P279; Bonci A, 1996, NEURON, V16, P631, DOI 10.1016/S0896-6273(00)80082-3; Briggs CA, 1996, NEUROPHARMACOLOGY, V35, P407, DOI 10.1016/0028-3908(96)00006-8; CALABRESI P, 1989, BRIT J PHARMACOL, V98, P135, DOI 10.1111/j.1476-5381.1989.tb16873.x; CHANGEUX JP, 1984, SCIENCE, V225, P1335, DOI 10.1126/science.6382611; CLARKE PBS, 1993, PROG BRAIN RES, V98, P77; CLARKE PBS, 1991, ADV PHAR SC, P285; CORRIGALL WA, 1994, BRAIN RES, V653, P278, DOI 10.1016/0006-8993(94)90401-4; CORRIGALL WA, 1991, PSYCHOPHARMACOLOGY, V104, P171, DOI 10.1007/BF02244174; CORRIGALL WA, 1989, PSYCHOPHARMACOLOGY, V99, P473, DOI 10.1007/BF00589894; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; Gray R, 1996, NATURE, V383, P713, DOI 10.1038/383713a0; HENNINGFIELD JE, 1993, DRUG ALCOHOL DEPEN, V33, P23, DOI 10.1016/0376-8716(93)90030-T; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; KANG Y, 1993, NEUROSCI RES, V18, P209, DOI 10.1016/0168-0102(93)90056-V; LESTER RAJ, 1994, NEUROPHARMACOLOGY, V33, P27, DOI 10.1016/0028-3908(94)90093-0; MARKS MJ, 1992, J NEUROSCI, V12, P2765; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MERCURI NB, 1995, EUR J NEUROSCI, V7, P462, DOI 10.1111/j.1460-9568.1995.tb00342.x; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; Pich EM, 1997, SCIENCE, V275, P83; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SEGUELA P, 1993, J NEUROSCI, V13, P596; STOLERMAN IP, 1991, TRENDS PHARMACOL SCI, V12, P467, DOI 10.1016/0165-6147(91)90638-9; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; WONNACOTT S, 1990, TRENDS PHARMACOL SCI, V11, P216, DOI 10.1016/0165-6147(90)90242-Z	30	565	572	0	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 27	1997	390	6658					401	404		10.1038/37120	http://dx.doi.org/10.1038/37120			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389479				2022-12-24	WOS:A1997YH54900063
J	Culpepper, L; Froom, J				Culpepper, L; Froom, J			Routine antimicrobial treatment of acute otitis media - Is it necessary?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT STREPTOCOCCUS-PNEUMONIAE; PLACEBO-CONTROLLED TRIAL; ANTIBIOTIC-TREATMENT; BACTERIAL-MENINGITIS; DRUG-RESISTANCE; DAY-CARE; CHILDREN; PENICILLIN; DIAGNOSIS; THERAPY		SUNY STONY BROOK, SCH MED, DEPT FAMILY MED, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Culpepper, L (corresponding author), BOSTON UNIV, SCH MED, DEPT FAMILY MED, 1 BOSTON MED CTR PL, BOSTON, MA 02118 USA.			Culpepper, Larry/0000-0002-7655-0477	AHRQ HHS [R01 HS0703503] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		APPELBAUM PC, 1987, EUR J CLIN MICROBIOL, V6, P367, DOI 10.1007/BF02013089; APPELMAN CLM, 1991, BMJ-BRIT MED J, V303, P1450, DOI 10.1136/bmj.303.6815.1450; BAIN J, 1985, BRIT MED J, V291, P1243, DOI 10.1136/bmj.291.6504.1243; BARNETT ED, 1995, PEDIATR CLIN N AM, V42, P509; BLUESTONE CD, 1988, OTITIS MEDIA INFANTS, P45; BURKE P, 1991, BRIT MED J, V303, P558, DOI 10.1136/bmj.303.6802.558; Centers for Disease Control, 1994, MORBIDITY MORTALITY, V43, P1; CLAESSEN JQPJ, 1992, CLIN OTOLARYNGOL, V17, P251, DOI 10.1111/j.1365-2273.1992.tb01838.x; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; DENEELING AJ, 1993, RESISTENTIE TEGEN AN; DESAINTONGE DMC, 1982, BRIT MED J, V284, P1078; EAVEY RD, 1985, J PEDIATR-US, V106, P402, DOI 10.1016/S0022-3476(85)80664-8; FADEN H, 1992, ANN OTO RHINOL LARYN, V101, P87, DOI 10.1177/000348949210100119; FADEN H, 1994, PEDIATR INFECT DIS J, V13, P609, DOI 10.1097/00006454-199407000-00005; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; Froom J, 1993, Arch Fam Med, V2, P841, DOI 10.1001/archfami.2.8.841; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; HALSTED C, 1968, AM J DIS CHILD, V115, P542, DOI 10.1001/archpedi.1968.02100010544003; HARRISON CJ, 1985, PEDIATR INFECT DIS J, V4, P641, DOI 10.1097/00006454-198511000-00009; HENDERSON FW, 1988, J INFECT DIS, V157, P256, DOI 10.1093/infdis/157.2.256; HENDRICKSE WA, 1988, PEDIATR INFECT DIS J, V7, P14, DOI 10.1097/00006454-198801000-00005; HOWIE VM, 1972, CLIN PEDIATR, V11, P205, DOI 10.1177/000992287201100407; KALEIDA PH, 1991, PEDIATRICS, V87, P466; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; KLEIN JO, 1994, CLIN INFECT DIS, V19, P823, DOI 10.1093/clinids/19.5.823; KOSHLAND DE, 1992, SCIENCE, V257, P1021, DOI 10.1126/science.257.5073.1021; LAXDAL OE, 1970, CAN MED ASSOC J, V102, P263; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MEISTRUPLARSEN KI, 1983, ACTA OTO-LARYNGOL, V96, P99, DOI 10.3109/00016488309132879; MYGIND N, 1981, CLIN OTOLARYNGOL, V6, P5, DOI 10.1111/j.1365-2273.1981.tb01781.x; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; ROSENFELD RM, 1994, J PEDIATR-US, V124, P355, DOI 10.1016/S0022-3476(94)70356-6; SLOAS MM, 1992, PEDIATR INFECT DIS J, V11, P662; Stephenson J, 1996, JAMA-J AM MED ASSOC, V275, P175, DOI 10.1001/jama.275.3.175; SUGITA R, 1983, INT J PEDIATR OTORHI, V6, P135; TOUWOTTEN FWMM, 1992, FAM PRACT, V9, P255, DOI 10.1093/fampra/9.3.255; TRUJILLO H, 1989, PEDIATR INFECT DIS J, V8, P361, DOI 10.1097/00006454-198906000-00007; VAN DISHOECK H A, 1959, Acta Otolaryngol, V50, P250; van Klingeren B, 1992, Ned Tijdschr Geneeskd, V136, P860; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; VANBUCHEM FL, 1981, LANCET, V2, P883	42	47	47	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	1997	278	20					1643	1645		10.1001/jama.278.20.1643	http://dx.doi.org/10.1001/jama.278.20.1643			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG859	9388073				2022-12-24	WOS:A1997YG85900002
J	Xue, D; Horvitz, HR				Xue, D; Horvitz, HR			Caenorhabditis elegans CED-9 protein is a bifunctional cell-death inhibitor	NATURE			English	Article							C-ELEGANS; CYSTEINE PROTEASE; BCL-2; GENE; P35; APOPTOSIS; SURVIVAL; ENCODES; EXPRESSION; PREVENTION	The Caenorhabditis elegans gene ced-9 prevents cells from undergoing programmed cell death and encodes a protein similar to the mammalian cell-death inhibitor Bcl-2 (refs 1-7). We show here that the CED-9 protein is a substrate for the C. elegans cell-death protease CED-3 (refs 8, 9), which is a member of a family of cysteine proteases first defined by CED-3 and human interleukin-1 beta converting enzyme (ICE)(10-12). CED-9 can be cleaved by CED-3 at two sites near its amino terminus, and the presence of at least one of these sites is important for complete protection by CED-9 against cell death. Cleavage of CED-9 by CED-3 generates a carboxy-terminal product that resembles Bcl-2 in sequence and in function. Bcl-2 and the baculovirus protein p35, which inhibits cell death in different species through a mechanism that depends on the presence of its cleavage site for the CED-3/ICE family of proteases(9,13-17), inhibit cell death additively in C. elegans, Our results indicate that CED-9 prevents programmed cell death in C. elegans through two distinct mechanisms: first, CED-9 may, by analogy with p35 (refs 9, 17), directly inhibit the CED-3 protease by an interaction involving the CED-3 cleavage sites in CED-9; second, CED-9 may directly or indirectly inhibit CED-3 by means of a protective mechanism similar to that used by mammalian Bcl-2.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)				XUE, DING/0000-0002-8429-8136				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; HAY BA, 1994, DEVELOPMENT, V120, P2121; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; NUNEZ G, 1990, J IMMUNOL, V144, P3602; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	30	98	111	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					305	308		10.1038/36889	http://dx.doi.org/10.1038/36889			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384385				2022-12-24	WOS:A1997YG66700068
J	Schriger, DL; Baraff, LJ; Rogers, WH; Cretin, S				Schriger, DL; Baraff, LJ; Rogers, WH; Cretin, S			Implementation of clinical guidelines using a computer charting system - Effect on the initial care of health care workers exposed to body fluids	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY; PERFORMANCE; EMERGENCY; POLICIES; DELIVERY; AUDIT	Context.-While clinical guidelines are considered an important mechanism to improve the quality of medical care, problems with implementation may limit their effectiveness, Few empirical data exist about the effect of computer-based systems for application of clinical guidelines on quality of care. Objective.-To determine whether real-time presentation of clinical guidelines using an electronic medical record can increase compliance with guidelines. Design.-Prospective off-on-off, interrupted time series with intent-to-treat analysis. Setting.-University hospital emergency department. Subjects.-Patients were 280 health care workers (50 in the baseline control phase, 156 in the intervention phase, and 74 in the postintervention control phase) who presented for initial treatment of occupational body fluid exposures, including 89% (248/280) who sustained punctures and 81% (208/257) who were exposed to blood. Physicians included resident physicians and attending physicians working in the emergency department during the study. Interventions.-Implementation of a computer charting system that provides real-time information regarding history and recommendations for laboratory testing, treatment, and disposition based on rules derived from clinical guidelines. Main Outcome Measures.-Quality of care as determined by essential items documented in the medical record and in aftercare instructions, compliance with testing and treatment guidelines, and total charges and percentage of charges attributable to guideline-endorsed activities. Results.-Mean percent documentation of 7 essential items regarding patient history in the medical record increased from 57% during the baseline period to 98% in the intervention phase (42% increase; 95% confidence interval [CI], 34%-49%) and 11 items in aftercare instruction increased from 31% at baseline to 93% during the intervention phase (62% increase; 95% CI, 51%-74%), but both decreased to baseline when the computer system was removed. Percent compliance with 4 laboratory testing guidelines increased from 63% at baseline to 83% during the intervention phase (20% increase; 95% CI, 9%-31%) but decreased to 52% when the computer system was removed, Compliance with 5 treatment guidelines increased from 83% at baseline to 96% during the intervention phase (13% increase; 95% CI, 9%-17%) and decreased to 84% following the intervention. Percentage of charges incurred for indicated laboratory tests and treatment increased from 44% at baseline to 81% during the intervention phase (37% increase; 95% CI, 22%-52%) and decreased to 36% following the intervention. Average total per-patient charges were $460, $384, and $373 in each phase, respectively. Conclusions.-Use of a computer-based system for clinical guidelines for management of patients with occupational exposure to body fluids improved documentation, compliance with guidelines, and percentage of charges spent on indicated activities, while decreasing overall charges. The parameters returned to baseline when the computer system was removed.	TUFTS UNIV NEW ENGLAND MED CTR, HLTH INST, BOSTON, MA 02111 USA; SHAN CRETIN & ASSOCIATES, SANTA MONICA, CA USA	Tufts Medical Center	Schriger, DL (corresponding author), UNIV CALIF LOS ANGELES, MED CTR, CTR EMERGENCY MED, 924 WESTWOOD BLVD, SUITE 300, LOS ANGELES, CA 90024 USA.			Schriger, David/0000-0003-0242-1127	AHRQ HHS [R18HS06284] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AG HLTH CAR POL R, 1997, GUID MED OUTC; Balas EA, 1996, J AM MED INFORM ASSN, V3, P56, DOI 10.1136/jamia.1996.96342649; BARAFF LJ, 1990, ANN EMERG MED, V19, P45; EDDY DM, 1982, NEW ENGL J MED, V307, P343, DOI 10.1056/NEJM198208053070604; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P877; EDDY DM, 1994, METHODOLOGY PERSPECT, P5; EISENBERG JM, 1981, JAMA-J AM MED ASSOC, V246, P2195, DOI 10.1001/jama.246.19.2195; GLASZIOU PP, 1994, MED DECIS MAKING, V14, P207; GO GW, 1991, ANN EMERG MED, V20, P1341, DOI 10.1016/S0196-0644(05)81078-9; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HOLBROOK J, 1990, ANN EMERG MED, V19, P139, DOI 10.1016/S0196-0644(05)81798-6; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LOMAS J, 1993, ANN NY ACAD SCI, V703, P226, DOI 10.1111/j.1749-6632.1993.tb26351.x; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; RICEJ A, 1995, MATH STAT DATA ANAL, P153; Schriger D. L., 1989, Proceedings: The Thirteenth Annual Symposium on Computer Applications in Medical Care (Cat. No.89TH0286-5), P611; Schriger DL, 1996, ANN EMERG MED, V27, P655; SHIFFMAN RN, 1994, MED DECIS MAKING, V14, P245, DOI 10.1177/0272989X9401400306; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; *STAT, 1997, STAT REF MAN REL 5, pU235; TIERNEY WM, 1987, ANN INTERN MED, V107, P569, DOI 10.7326/0003-4819-107-4-569; TIERNEY WM, 1988, JAMA-J AM MED ASSOC, V259, P1194, DOI 10.1001/jama.259.8.1194; TOEPP MC, 1996, DIRECTORY PRACTICE P; *US C, 1994, H608 OTA US C, V198; *US C, 1994, OTAH608 US C, P177; WEARS RL, 1994, ACAD EMERG MED, V1, pA35; Woolf SH, 1994, METHODOLOGY PERSPECT, P105; 1996, MMWR-MORBID MORTAL W, V45, P468	31	106	105	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	1997	278	19					1585	1590		10.1001/jama.278.19.1585	http://dx.doi.org/10.1001/jama.278.19.1585			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF407	9370504				2022-12-24	WOS:A1997YF40700039
J	Imai, T; Hieshima, K; Haskell, C; Baba, M; Nagira, M; Nishimura, M; Kakizaki, M; Takagi, S; Nomiyama, H; Schall, TJ; Yoshie, O				Imai, T; Hieshima, K; Haskell, C; Baba, M; Nagira, M; Nishimura, M; Kakizaki, M; Takagi, S; Nomiyama, H; Schall, TJ; Yoshie, O			Identification and molecular characterization of fractalkine receptor CX(3)CR1, which mediates both leukocyte migration and adhesion	CELL			English	Article							PROTEIN-COUPLED RECEPTOR; CHEMOATTRACTANT RECEPTORS; CHEMOKINE RECEPTORS; EXPRESSION; INFLAMMATION; BIOLOGY; GENE	Leukocyte trafficking at the endothelium requires both cellular adhesion molecules and chemotactic factors. Fractalkine, a novel transmembrane molecule with a CX3C-motif chemokine domain atop a mucin stalk, induces both adhesion and migration of leukocytes. Here we identify a seven-transmembrane high-affinity receptor for fractalkine and show that it mediates both the adhesive and migratory functions of fractalkine. The receptor, now termed CX(3)CR1, requires pertussis toxin-sensitive G protein signaling to induce migration but not to support adhesion, which also occurs without other adhesion molecules but requires the architecture of a chemokine domain atop the mucin stalk. Natural killer cells predominantly express CX(3)CR1 and respond to fractalkine in both migration and adhesion. Thus, fractalkine and CX(3)CR1 represent new types of leukocyte trafficking regulators, performing both adhesive and chemotactic functions.	KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,KUMAMOTO 860,JAPAN; DNAX RES INST MOL & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304	Kumamoto University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Imai, T (corresponding author), SHIONOGI INST MED SCI,SETTSU 566,JAPAN.		Hieshima, Kunio/AAF-7040-2019; Nomiyama, Hisayuki/F-2840-2013	Hieshima, Kunio/0000-0002-7786-4646; Nomiyama, Hisayuki/0000-0002-2716-4043; Yoshie, Osamu/0000-0003-4353-5809				Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; COMBADIERE C, 1995, DNA CELL BIOL, V14, P673, DOI 10.1089/dna.1995.14.673; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; OIN S, 1996, EUR J IMMUNOL, V26, P640; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; RAPORT CJ, 1995, GENE, V163, P295, DOI 10.1016/0378-1119(95)00336-5; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803	21	1096	1162	1	63	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					521	530		10.1016/S0092-8674(00)80438-9	http://dx.doi.org/10.1016/S0092-8674(00)80438-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390561	Bronze			2022-12-24	WOS:A1997YG49200013
J	Rameh, LE; Tolias, KF; Duckworth, BC; Cantley, LC				Rameh, LE; Tolias, KF; Duckworth, BC; Cantley, LC			A new pathway for synthesis of phosphatidylinositol-4,5-bisphosphate	NATURE			English	Article							PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE; POLYPHOSPHOINOSITIDES; 3,4-BISPHOSPHATE; PHOSPHORYLATION; 3-MONOPHOSPHATE; PURIFICATION; SEQUENCE; 4-KINASE; KINASES; CLONING	Phosphatidylinositol-4,5-bisphosphate (PtdIns-4,5-P-2), a key molecule in the phosphoinositide signalling-pathway, was thought to be synthesized exclusively by phosphorylation of PtdIns-4-P at the D-5 position of the inositol ring. The enzymes that produce PtdIns-4,5-P-2 in vitro fall into two related subfamilies (type I and type II PtdInsP-5-OH kinases, or PIP(5)Ks) based on their enzymatic properties and sequence similarities(1). Here we have reinvestigated the substrate specificities of these enzymes. As expected, the type I enzyme phosphorylates PtdIns-4-P at the D- 5 position of the inositol ring. Surprisingly, the type II enzyme, which is abundant in some tissues, phosphorylates PtdIns-5-P at the D-4 position, and thus should be considered as a 4-OH kinase, or PIP(4)K. The earlier error in characterizing the activity of the type II enzyme is due to the presence of contaminating PtdIns-5-P in commercial preparations of PtdIns-4-P. Although PtdIns-5-P was previously thought not to exist in vivo, we find evidence for the presence of this lipid in mammalian fibroblasts, establishing a new pathway for PtdIns-4,5-P-2 synthesis.	BETH ISRAEL DEACONESS MED CTR, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center	Rameh, LE (corresponding author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Tolias, Kimberley/0000-0002-2092-920X				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; GRAZIANI A, 1992, BIOCHEM J, V284, P39, DOI 10.1042/bj2840039; Hinchliffe KA, 1996, EMBO J, V15, P6516, DOI 10.1002/j.1460-2075.1996.tb01042.x; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; LING LE, 1989, J BIOL CHEM, V264, P5080; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; MEYERS R, 1997, J BIOL CHEM, V272, P4385; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; YAMAMOTO K, 1990, BIOCHEM BIOPH RES CO, V168, P466, DOI 10.1016/0006-291X(90)92344-Y; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	18	342	356	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 13	1997	390	6656					192	196		10.1038/36621	http://dx.doi.org/10.1038/36621			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367159				2022-12-24	WOS:A1997YF49400059
J	Miyakawa, T; Yagi, T; Kitazawa, H; Yasuda, M; Kawai, N; Tsuboi, K; Niki, H				Miyakawa, T; Yagi, T; Kitazawa, H; Yasuda, M; Kawai, N; Tsuboi, K; Niki, H			Fyn-kinase as a determinant of ethanol sensitivity: Relation to NMDA-receptor function	SCIENCE			English	Article							D-ASPARTATE RECEPTOR; POSTSYNAPTIC DENSITY FRACTION; LONG-TERM POTENTIATION; MUTANT MICE LACKING; TYROSINE PHOSPHORYLATION; GABA(A) RECEPTORS; A RECEPTORS; SUBUNIT 2B; RAT; ALCOHOL	Animals vary in their sensitivity to ethanol, a trait at least partly determined by genetic factors. In order to identify possible responsible genes, mice lacking Fyn, a non-receptor type tyrosine kinase, were investigated. These mice were hypersensitive to the hypnotic effect of ethanol. The administration of ethanol enhanced tyrosine phosphorylation of the N-methyl-D-aspartate receptor (NMDAR) in the hippocampus of control mice but not in Fyn-deficient mice. An acute tolerance to ethanol inhibition of NMDAR-mediated excitatory postsynaptic potentials in hippocampal slices developed in control mice but not in Fyn-deficient mice. These results indicate that Fyn affects behavioral, biochemical, and physiological responses to ethanol.	RIKEN,BRAIN SCI INST,NEUROBIOL EMOT LAB,WAKO,SAITAMA 35101,JAPAN; NATL INST PHYSIOL SCI,LAB NEUROBIOL & BEHAV GENET,OKAZAKI,AICHI 444,JAPAN; JICHI MED SCH,DEPT PHYSIOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; UNIV TOKYO,FAC LETTERS,DEPT PSYCHOL,BUNKYO KU,TOKYO 113,JAPAN	RIKEN; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Jichi Medical University; University of Tokyo			Miyakawa, Tsuyoshi/A-7741-2008	Miyakawa, Tsuyoshi/0000-0003-0137-8200				Crabbe JC, 1996, NAT GENET, V14, P98, DOI 10.1038/ng0996-98; CRABBE JC, 1994, SCIENCE, V264, P1715, DOI 10.1126/science.8209252; GROVER CA, 1994, BRAIN RES, V642, P70, DOI 10.1016/0006-8993(94)90906-7; HARRIS RA, 1995, P NATL ACAD SCI USA, V92, P3658, DOI 10.1073/pnas.92.9.3658; HARRIS RA, 1991, ANN NY ACAD SCI, V625, P508, DOI 10.1111/j.1749-6632.1991.tb33881.x; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; LOVINGER DM, 1990, J NEUROSCI, V10, P1372; Menegoz M, 1995, NEUROREPORT, V7, P125, DOI 10.1097/00001756-199512290-00030; MIYAKAWA T, 1994, MOL BRAIN RES, V27, P179, DOI 10.1016/0169-328X(94)90201-1; Miyakawa T, 1996, NEUROREPORT, V7, P2723, DOI 10.1097/00001756-199611040-00063; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; ROIVAINEN R, 1995, P NATL ACAD SCI USA, V92, P1891, DOI 10.1073/pnas.92.6.1891; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; Rosenblum K, 1997, J NEUROSCI, V17, P5129; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; SUZUKI T, 1995, BIOCHEM BIOPH RES CO, V216, P582, DOI 10.1006/bbrc.1995.2662; Tabakoff B, 1996, NEURON, V16, P909, DOI 10.1016/S0896-6273(00)80113-0; THURSTON AW, 1992, BIOCHEM BIOPH RES CO, V185, P1062, DOI 10.1016/0006-291X(92)91734-8; TSUBOKAWA H, 1994, NEUROSCIENCE, V59, P291, DOI 10.1016/0306-4522(94)90597-5; VALENZUELA CF, 1995, MOL BRAIN RES, V31, P165, DOI 10.1016/0169-328X(95)00048-W; WAFFORD KA, 1990, SCIENCE, V249, P291, DOI 10.1126/science.1695761; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	27	252	252	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					698	701		10.1126/science.278.5338.698	http://dx.doi.org/10.1126/science.278.5338.698			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381182				2022-12-24	WOS:A1997YC32300058
J	Pal, R; GarzinoDemo, A; Markham, PD; Burns, J; Brown, M; Gallo, RC; DeVico, AL				Pal, R; GarzinoDemo, A; Markham, PD; Burns, J; Brown, M; Gallo, RC; DeVico, AL			Inhibition of HIV-1 infection by the beta-chemokine MDC	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TERMINAL SEQUENCE; DENDRITIC CELLS; CLINICAL STATE; FLOW-CYTOMETRY; T-CELLS; REPLICATION; INDIVIDUALS; INTERLEUKIN-8; RECEPTOR	CD8(+) T lymphocytes from individuals infected with human immunodeficiency virus-type 1 (HIV-1) secrete a soluble activity that suppresses infection by HIV-1. A protein associated with this activity was purified from the culture supernatant of an immortalized CD8(+) T cell clone and identified as the beta-chemokine macrophage-derived chemokine (MDC). MDC suppressed infection of CD8(+) cell-depleted peripheral blood mononuclear cells by primary non-syncytium-inducing and syncytium-inducing isolates of HIV-1 and the T cell line-adapted isolate HIV-1(IIIB). MDC was expressed in activated, but not resting, peripheral blood mononuclear cells and binds a receptor on activated primary T cells. These observations indicate that beta-chemokines are responsible for a major proportion of HIV-1-specific suppressor activity produced by primary T cells.	UNIV MARYLAND, INST HUMAN VIROL, BALTIMORE, MD 21201 USA; ADV BIOSCI LABS, KENSINGTON, NSW 20895, AUSTRALIA; UNIV MARYLAND, SCH MED, INST HUMAN DEV, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT IMMUNOL & MICROBIOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore				Garzino-Demo, Alfredo/0000-0002-4095-6950	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI055279] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-55279] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BADOLATO R, 1995, J IMMUNOL, V155, P4004; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Barker TD, 1996, J IMMUNOL, V156, P4476; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; Blackbourn DJ, 1996, P NATL ACAD SCI USA, V93, P13125, DOI 10.1073/pnas.93.23.13125; BLUEL CC, 1996, NATURE, V382, P829; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; BURNS J, IN PRESS BIOTECHNIQU; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DEVICO AL, UNPUB; Dittmar MT, 1997, NATURE, V385, P495, DOI 10.1038/385495a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GARZINODEMO A, 1995, HUM GENE THER, V6, P177, DOI 10.1089/hum.1995.6.2-177; GARZINODEMO A, UNPUB; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; Greimers R, 1996, CYTOMETRY, V23, P205, DOI 10.1002/(SICI)1097-0320(19960301)23:3<205::AID-CYTO4>3.0.CO;2-H; HE J, 1997, NATURE, V385, P6445; HEBERT CA, 1990, J IMMUNOL, V145, P3033; Jansson M, 1996, P NATL ACAD SCI USA, V93, P15382, DOI 10.1073/pnas.93.26.15382; Kinter AL, 1996, P NATL ACAD SCI USA, V93, P14076, DOI 10.1073/pnas.93.24.14076; LINDLEY I, 1988, P NATL ACAD SCI USA, V85, P9199, DOI 10.1073/pnas.85.23.9199; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; MARKHAM PD, 1983, INT J CANCER, V31, P413, DOI 10.1002/ijc.2910310404; MARKHAM PD, 1984, INT J CANCER, V33, P13, DOI 10.1002/ijc.2910330104; Moriuchi H, 1996, P NATL ACAD SCI USA, V93, P15341, DOI 10.1073/pnas.93.26.15341; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Paliard X, 1996, AIDS, V10, P1317, DOI 10.1097/00002030-199610000-00002; PATTERSON S, 1987, J GEN VIROL, V68, P1177, DOI 10.1099/0022-1317-68-4-1177; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; Proost Paul, 1996, Methods (Orlando), V10, P82, DOI 10.1006/meth.1996.0082; Rubbert A, 1997, AIDS RES HUM RETROV, V13, P63, DOI 10.1089/aid.1997.13.63; SCHMID I, 1992, CYTOMETRY, V13, P204, DOI 10.1002/cyto.990130216; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; VANDAMME J, 1990, EUR J IMMUNOL, V20, P2113, DOI 10.1002/eji.1830200933; VANDAMME J, 1989, EUR J BIOCHEM, V181, P337; WALKER CM, 1989, CELL IMMUNOL, V119, P470, DOI 10.1016/0008-8749(89)90259-1; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; YOSHIMURA T, 1989, MOL IMMUNOL, V26, P87; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0	53	183	194	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					695	698		10.1126/science.278.5338.695	http://dx.doi.org/10.1126/science.278.5338.695			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381181				2022-12-24	WOS:A1997YC32300057
J	Echard, A; Jollivet, F; Martinez, O; Lacapere, JJ; Rousselet, A; Janoueix-Lerosey, I; Goud, B				Echard, A; Jollivet, F; Martinez, O; Lacapere, JJ; Rousselet, A; Janoueix-Lerosey, I; Goud, B			Interaction of a Golgi-associated kinesin-like protein with Rab6	SCIENCE			English	Article							HEAVY-CHAIN; BINDING; TRANSPORT; MOTOR; MICROTUBULES; EFFECTOR; DOMAINS; BRAIN; NCD	Rab guanosine triphosphatases regulate vesicular transport and membrane traffic within eukaryotic cells. Here, a kinesin-like protein that interacts with guanosine triphosphate (GTP)-bound forms of Rab6 was identified. This protein, termed Rabkinesin-6, was localized to the Golgi apparatus and shown to play a role in the dynamics of this organelle. The carboxyl-terminal domain of Rabkinesin-6, which contains the Rab6-interacting domain, inhibited the effects of Rab6-GTP on intracellular transport, Thus, a molecular motor is a potential effector of a Rab protein, and coordinated action between members of these two families of proteins could control membrane dynamics and directional vesicular traffic.	Inst Curie, CNRS, Unite Mixte Rech 144 & 168, F-75248 Paris 05, France; Inst Curie, INSERM, U248, F-75248 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Goud, B (corresponding author), Inst Curie, CNRS, Unite Mixte Rech 144 & 168, 26 Rue Ulm, F-75248 Paris 05, France.	bgoud@curie.fr	Janoueix-Lerosey, Isabelle/G-1758-2018; Goud, Bruno/GWC-4807-2022	Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; Echard, Arnaud/0000-0001-7402-1398				ANDREWS SB, 1993, P NATL ACAD SCI USA, V90, P6503, DOI 10.1073/pnas.90.14.6503; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; BRONDYK WH, 1995, MOL CELL BIOL, V15, P1137; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; DERETIC D, 1995, J CELL SCI, V108, P215; Diaz E, 1997, J CELL BIOL, V138, P283, DOI 10.1083/jcb.138.2.283; ECHARD A, UNPUB; FEIGUIN F, 1994, J CELL BIOL, V127, P1021, DOI 10.1083/jcb.127.4.1021; Goodson HV, 1997, CURR OPIN CELL BIOL, V9, P18, DOI 10.1016/S0955-0674(97)80147-0; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; JASMIN BJ, 1989, P NATL ACAD SCI USA, V86, P7218, DOI 10.1073/pnas.86.18.7218; Johannes L, 1996, J CELL SCI, V109, P2875; JOHANNES L, UNPUB; KURIYAMA R, 1994, J CELL SCI, V107, P3485; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MARTINEZ O, 1997, THESIS U PARIS; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; ROA M, 1993, J CELL SCI, V106, P789; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	37	406	418	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	1998	279	5350					580	585		10.1126/science.279.5350.580	http://dx.doi.org/10.1126/science.279.5350.580			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438855				2022-12-24	WOS:000071616000052
J	Weiskopf, RB; Viele, MK; Feiner, J; Kelley, S; Lieberman, J; Noorani, M; Leung, JM; Fisher, DM; Murray, WR; Toy, P; Moore, MA				Weiskopf, RB; Viele, MK; Feiner, J; Kelley, S; Lieberman, J; Noorani, M; Leung, JM; Fisher, DM; Murray, WR; Toy, P; Moore, MA			Human cardiovascular and metabolic response to acute, severe isovolemic anemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 17-25, 1996	NEW ORLEANS, LA	Amer Soc Anesthesiologists			OXYGEN DELIVERY; HEMODYNAMICS; HEMODILUTION; TRANSFUSION	Context.-Although concern over the risks of red blood cell transfusion has resulted in several practice guidelines for transfusion, lack of data regarding the physiological effects of anemia in humans has caused uncertainty regarding the blood hemoglobin (Hb) concentration requiring treatment. Objective.-To test the hypothesis that acute isovolemic reduction of blood Hb concentration to 50 g/L in healthy resting humans would produce inadequate cardiovascular compensation and result in tissue hypoxia secondary to inadequate oxygen transport. Design.-Before and after interventional study. Setting.-Academic tertiary care medical center. Participants.-Conscious healthy patients (n=11) prior to anesthesia and surgery and volunteers not undergoing surgery (n=21). Interventions.-Aliquots of blood (450-900 mL) were removed to reduce blood Hb concentration from 131 (2) g/L to 50 (1) g/L [mean (SE)]. Isovolemia was maintained with 5% human albumin and/or autologous plasma. Cardiovascular parameters, arterial and mixed venous oxygen content, oxyhemoglobin saturation, and arterial blood lactate were measured before and after removal of each aliquot of blood, Electrocardiogram and, in a subset, Holter monitor were monitored continuously. Main Outcome Measures.-"Critical" oxygen delivery (TO2) as assessed by oxygen consumption ((V)over dot O-2), plasma lactate concentration, and ST changes on electrocardiogram. Results.-Acute, isovolemic reduction of Hb concentration decreased systemic vascular resistance and TO2 and increased heart rate, stroke volume, and cardiac index (each P<.001). We did not find evidence of inadequate oxygenation: (V)over dot O-2 increased slightly from a mean (SD) of 3.07 (0.44) mL of oxygen per kilogram per minute (mL O-2.kg(-1).min(-1)) to 3.42 (0.54) mL O-2.kg(-1).min(-1) (P<.001) and plasma lactate concentration did not change (0.81 [0.11] mmol/L to 0.62 [0.19] mmol/L; P=.09). Two subjects developed significant ST changes on Holter monitor: one apparently related to body position or activity, the other to an increase in heart rate (at an Hb concentration of 46-53 g/L); both occurred in young women and resolved without sequelae. Conclusions.-Acute isovolemic reduction of blood Hb concentration to 50 g/L in conscious healthy resting humans does not produce evidence of inadequate systemic TO2, as assessed by lack of change of (V)over dot O-2 and plasma lactate concentration. Analysis of Hotter readings suggests that at this Hb concentration in this resting healthy population, myocardial ischemia would occur infrequently.	Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weiskopf, RB (corresponding author), Univ Calif San Francisco, Dept Anesthesia, 521 Parnassus Ave,C450, San Francisco, CA 94143 USA.	weiskopf@jemo.ucsf.edu			NHLBI NIH HHS [1 P50HL54476] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054476] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS RP, 1982, J APPL PHYSIOL, V53, P660, DOI 10.1152/jappl.1982.53.3.660; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Beal B., 1992, NONMEM USERS GUIDE; BEAL SL, 1985, DRUG FATE METABOLISM; BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700; CAIN SM, 1977, J APPL PHYSIOL, V42, P228, DOI 10.1152/jappl.1977.42.2.228; CAIN SM, 1965, AM J PHYSIOL, V209, P604, DOI 10.1152/ajplegacy.1965.209.3.604; CHAITMAN BR, 1981, AM J CARDIOL, V47, P1335, DOI 10.1016/0002-9149(81)90267-8; CHAMORRO G, 1973, CIRC RES, V33, P530; COHN PF, 1985, AM J MED, V79, P2, DOI 10.1016/0002-9343(85)90486-3; FAITHFULL NS, 1992, ADV EXP MED BIOL, V317, P55; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; JAN KM, 1977, AM J PHYSIOL, V233, pH106, DOI 10.1152/ajpheart.1977.233.1.H106; LEVINE E, 1990, TRANSFUSION, V30, P11, DOI 10.1046/j.1537-2995.1990.30190117621.x; LOWENSTEIN E, 1987, CARDIAC ANESTHESIA; MICHENFELDERJD, 1988, ANESTHESIA BRAIN; MURRAY JF, 1969, AM J PHYSIOL, V216, P638, DOI 10.1152/ajplegacy.1969.216.3.638; NOLDGE GFE, 1992, ANESTH ANALG, V75, P660; RESTORFF WV, 1975, PFLUG ARCH EUR J PHY, V357, P25, DOI 10.1007/BF00584542; RESTORFF WV, 1975, PFLUG ARCH EUR J PHY, V357, P15, DOI 10.1007/BF00584541; Royal College of Physicians of Edinburgh, 1994, TRANSFUSION MED, V4, P177; VANWOERKENS ECSM, 1992, ANESTH ANALG, V75, P818; VIELE MK, 1994, TRANSFUSION, V34, P396, DOI 10.1046/j.1537-2995.1994.34594249050.x; WOHLGELERNTER D, 1986, J AM COLL CARDIOL, V7, P1245, DOI 10.1016/S0735-1097(86)80143-7	24	429	450	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					217	221		10.1001/jama.279.3.217	http://dx.doi.org/10.1001/jama.279.3.217			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YR124	9438742	Bronze			2022-12-24	WOS:000071460700032
J	Gray, RH; Wawer, MJ; Serwadda, D; Sewankambo, N; Li, CJ; Wabwire-Mangen, F; Paxton, L; Kiwanuka, N; Kigozi, G; Konde-Lule, J; Quinn, TC; Gaydos, CA; McNairn, D				Gray, RH; Wawer, MJ; Serwadda, D; Sewankambo, N; Li, CJ; Wabwire-Mangen, F; Paxton, L; Kiwanuka, N; Kigozi, G; Konde-Lule, J; Quinn, TC; Gaydos, CA; McNairn, D			Population-based study of fertility in women with HIV-1 infection in Uganda	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LIGASE CHAIN-REACTION; PREGNANCY; MORTALITY; DISTRICT; DISEASE; COHORT; IMPACT; RATES; URINE	Background To assess the effects of HIV-1 and other sexually transmitted infections on pregnancy, we undertook cross-sectional and prospective-studies of a rural population in Rakai district, Uganda. Methods 4813 sexually active women aged 15-49 years were surveyed to find out the prevalence of pregnancy by interview and selective urinary human chorionic gonadotropin tests. The incidence of recognised conception and frequency of pregnancy loss were assessed by follow-up. Samples were taken to test for HIV-1 infection, syphilis, and other sexually transmitted diseases. Findings At time of survey, 757 (21.4%) of 3544 women without HIV-1 infection or syphilis were pregnant, compared with 46 (14.6%) of 316 HIV-1-negative women with active syphilis, 117 (14.2%) of 823 HIV-1-positive women with no concurrent syphilis, and 11 (8.5%) of 130 women with both syphilis and HIV-1 infection. The multivariate adjusted odds ratio of pregnancy in HIV-1-infected women was 0.45 (95% CI 0.35-0.57); the odds of pregnancy were low both in HIV-1-infected women without symptoms (0.49 [0.39-0.62]) and in women with symptoms of HIV-1-associated disease (0.23 [0.11-0.48]). In women with concurrent HIV-1 infection and syphilis the odds ratio was 0.28 (0.14-0.55). The incidence rate of recognised pregnancy during the prospective followup study was lower in HIV-1-positive than in HIV-1-negative women (23.5 vs 30.1 per 100 woman-years; adjusted risk ratio 0.73 [0.57-0.93]). Rates of pregnancy loss were higher among HIV-1-infected than uninfected women (18.5 vs 12.2%; odds ratio 1.50 [1.01-2.27]). The prevalence of HIV-1 infection was significantly lower in pregnant than in non-pregnant women (13.9 vs 21.3%). Interpretation Pregnancy prevalence is greatly reduced in HIV-1-infected women, owing to lower rates of conception and increased rates of pregnancy loss. HIV-1 surveillance confined to pregnant women underestimates the magnitude of the HIV-1 epidemic in the general population.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Populat Dynam, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Med, Baltimore, MD 21205 USA; Columbia Univ, Sch Publ Hlth, Ctr Populat & Family Hlth, New York, NY USA; Makerere Univ, Inst Publ Hlth, Kampala, Uganda; Makerere Univ, Dept Med, Kampala, Uganda; Rakai Project, Entebbe, Uganda; NIAID, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; Columbia University; Makerere University; Makerere University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Gray, RH (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Populat Dynam, Room 4030,615 N Wolfe St, Baltimore, MD 21205 USA.		Quinn, Thomas/A-2494-2010; Gaydos, Charlotte A./E-9937-2010	Sewankambo, Nelson/0000-0001-9362-053X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD006268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034826] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI34826-03] Funding Source: Medline; NICHD NIH HHS [5P30HD06268] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN S, 1993, AM J PUBLIC HEALTH, V83, P705, DOI 10.2105/AJPH.83.5.705; ASSIMWEOKIROR G, 1995, 9 INT C AIDS STDS AF, P14; BACKE E, 1993, AIDS, V7, P896, DOI 10.1097/00002030-199306000-00025; Bongaarts J, 1996, POPUL DEV REV, V22, P21, DOI 10.2307/2137685; BRETTLE RP, 1995, AIDS, V9, P1177, DOI 10.1097/00002030-199510000-00010; Carpenter LM, 1997, HLTH TRANSITION R S2, V7, P113; CHENG CY, 1997, J INFECT DIS, V174, P1390; Chu SY, 1996, OBSTET GYNECOL, V87, P195, DOI 10.1016/0029-7844(95)00399-1; DAVIS SF, 1995, JAMA-J AM MED ASSOC, V274, P952, DOI 10.1001/jama.274.12.952; HILLIER SL, 1993, AM J OBSTET GYNECOL, V169, P455, DOI 10.1016/0002-9378(93)90340-O; HOCKE C, 1995, OBSTET GYNECOL, V86, P886, DOI 10.1016/0029-7844(95)00257-R; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; KAMENGA MC, 1995, AM J OBSTET GYNECOL, V172, P919, DOI 10.1016/0002-9378(95)90022-5; KIGADYE RM, 1993, AIDS, V7, P849, DOI 10.1097/00002030-199306000-00014; KORN A, 1994, J ACQ IMMUN DEF SYND, V9, P361; KRIEGER JN, 1991, J INFECT DIS, V164, P464, DOI 10.1093/infdis/164.3.464; LANGSTON C, 1995, J INFECT DIS, V172, P1451, DOI 10.1093/infdis/172.6.1451; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; PAPE JW, 1989, PAHO B, V23, P50; PECKHAM C, 1995, NEW ENGL J MED, V333, P298, DOI 10.1056/NEJM199508033330507; RYDER RW, 1991, AIDS, V5, P1521, DOI 10.1097/00002030-199112000-00016; Schulz K, 1990, HOMES SEXUALLY TRANS, P821; SEWANKAMBO NK, 1994, AIDS, V8, P1707, DOI 10.1097/00002030-199412000-00011; SMITH KR, 1995, J CLIN MICROBIOL, V33, P455, DOI 10.1128/JCM.33.2.455-457.1995; Steinberg Shari, 1995, pS16; TAHA TE, 1995, INT J EPIDEMIOL, V24, P1022, DOI 10.1093/ije/24.5.1022; TEMMERMAN M, 1994, INT J GYNECOL OBSTET, V44, P107, DOI 10.1016/0020-7292(94)90062-0; TEMMERMAN M, 1995, AIDS, V9, P1057, DOI 10.1097/00002030-199509000-00011; TEMMERMAN M, 1994, OBSTET GYNECOL, V83, P495, DOI 10.1097/00006250-199404000-00002; *US BUR CENS, 1995, 9 INT C AIDS STDS AF, P1; WASSERHEIT JN, 1992, REPROD BIOL, P7; WAWER MJ, 1991, BRIT MED J, V303, P1303, DOI 10.1136/bmj.303.6813.1303; WOODS JW, 1994, BIOL BIOMETRY DEMOGR, P305	33	223	225	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					98	103		10.1016/S0140-6736(97)09381-1	http://dx.doi.org/10.1016/S0140-6736(97)09381-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439494	hybrid			2022-12-24	WOS:000071591900011
J	Friend, SH; Oliff, A				Friend, SH; Oliff, A			Emerging uses for genomic information in drug discovery	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUMAN HOMOLOG; GENE		Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Merck Res Labs, W Point, PA 19486 USA	Fred Hutchinson Cancer Center; Merck & Company	Friend, SH (corresponding author), Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.							DOYE V, 1995, TRENDS GENET, V11, P235, DOI 10.1016/S0168-9525(00)89057-5; DOYE V, 1995, TRENDS GENET, V11, P293; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SEKELSKY JJ, 1995, GENETICS, V139, P1347	9	24	24	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	1998	338	2					125	126		10.1056/NEJM199801083380211	http://dx.doi.org/10.1056/NEJM199801083380211			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ039	9420347				2022-12-24	WOS:000071341300011
J	Lowe, J; Amos, LA				Lowe, J; Amos, LA			Crystal structure of the bacterial cell-division protein FtsZ	NATURE			English	Article							NUCLEOTIDE-BINDING-PROTEIN; ESCHERICHIA-COLI; SECONDARY STRUCTURE; TUBULIN; MECHANISM; GTPASE	Bacterial cell division ends with septation, the constriction of the cell wall and cell membranes that leads to the formation of two daughter cells(1,2). During septation, FtsZ, a protein of relative molecular mass 40,000 which is ubiquitous in eubacteria and is also found in archaea and chloroplasts(3), localizes early at the division site to form a ring-shaped septum. This septum is required for the mechanochemical process of membrane constriction(4). FtsZ is a GTPase(5,6) with weak sequence homology to tubulins(7). The nature of FtsZ polymers in vivo is unknown, but FtsZ can form tubules, sheets and minirings in vitro(8,9). Here we report the crystal structure at 2.8 Angstrom resolution of recombinant FtsZ from the hyperthermophilic methanogen Methanococcus jannaschii. FtsZ has two domains, one of which is a GTPase domain with a fold related to one found in the proteins p21(ras) and elongation factor EF-Tu. The carboxy-terminal domain, whose function is unknown, is a four-stranded beta-sheet tilted by 90 degrees against the beta-sheet of the GTPase domain. The two domains are arranged around a central helix GDP binding is different from that typically found in GTPases and involves four phosphate-binding loops and a sugar-binding loop in the first domain, with guanine being recognized by residues in the central connecting helix The three-dimensional structure of FtsZ is similar to the structure of alpha- and beta-tubulin(10).	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Lowe, J (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Löwe, Jan/B-3882-2011; Löwe, Jan/X-6998-2019	Lowe, Jan/0000-0002-5218-6615; Amos, Linda/0000-0001-8305-5346				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRAMHILL D, 1994, P NATL ACAD SCI USA, V91, P5813, DOI 10.1073/pnas.91.13.5813; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BULT CJ, 1996, NATURE, V269, P496; CHOOK YM, 1994, J MOL BIOL, V240, P476, DOI 10.1006/jmbi.1994.1462; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; dePereda JM, 1996, BIOCHEMISTRY-US, V35, P14203, DOI 10.1021/bi961357b; DONACHIE WD, 1993, ANNU REV MICROBIOL, V47, P199, DOI 10.1146/annurev.mi.47.100193.001215; ERICKSON HP, 1995, CELL, V80, P367, DOI 10.1016/0092-8674(95)90486-7; Erickson HP, 1997, TRENDS CELL BIOL, V7, P362, DOI 10.1016/S0962-8924(97)01108-2; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1991, RECENT CHANGES MOSFL; LINSE K, 1988, J BIOL CHEM, V263, P15205; LUTKENHAUS J, 1993, MOL MICROBIOL, V9, P403, DOI 10.1111/j.1365-2958.1993.tb01701.x; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Park J. T., 1992, NATURE, V359, P251; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Rothfield LI, 1997, CELL, V88, P581, DOI 10.1016/S0092-8674(00)81899-1; Sackett D L, 1995, Subcell Biochem, V24, P255; Sage CR, 1995, BIOCHEMISTRY-US, V34, P16870; SHELDRICK GM, 1991, ISOMORPHOUS REPLACEM, P23; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S	30	699	731	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	1998	391	6663					203	206		10.1038/34472	http://dx.doi.org/10.1038/34472			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428770				2022-12-24	WOS:000071380900058
J	Feig, AL; Scott, WG; Uhlenbeck, OC				Feig, AL; Scott, WG; Uhlenbeck, OC			Inhibition of the hammerhead ribozyme cleavage reaction by site-specific binding of Tb(III)	SCIENCE			English	Article							SELF-CLEAVAGE; TRANSFER-RNA; CRYSTAL-STRUCTURE; METAL-BINDING; OLIGORIBONUCLEOTIDES; MECHANISM; PHOSPHOROTHIOATE; REQUIREMENTS; EUROPIUM; DOMAIN	Terbium(III) [Tb(III)] was shown to inhibit the hammerhead ribozyme by competing with a single magnesium(II) ion, X-ray crystallography revealed that the Tb(III) ion binds to a site adjacent to an essential guanosine in the catalytic core of the ribozyme, approximately 10 angstroms from the cleavage site. Synthetic modifications near this binding site yielded an RNA substrate that was resistant to Tb(III) binding and capable of being cleaved, even in the presence of up to 20 micromolar Tb(III). it is suggested that the magnesium(II) ion thought to bind at this site may act as a switch, affecting the conformational changes required to achieve the transition state.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	University of Colorado System; University of Colorado Boulder; Indiana University System; Indiana University Bloomington	Uhlenbeck, OC (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.		Feig, Andrew/B-7414-2011	Feig, Andrew/0000-0002-5783-1097; Scott, William/0000-0002-9273-3564	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036944, R01GM036944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-36944, R01 GM087721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Bassi GS, 1996, RNA, V2, P756; BASSI GS, 1995, NAT STRUCT BIOL, V2, P45, DOI 10.1038/nsb0195-45; BRUNGER AT, 1987, XPLOR VERSION 3 1; Cate JH, 1996, STRUCTURE, V4, P1221, DOI 10.1016/S0969-2126(96)00129-3; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; ClouetDOrval B, 1996, RNA, V2, P483; DRAPER DE, 1985, BIOPHYS CHEM, V21, P91, DOI 10.1016/0301-4622(85)85011-0; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; FEIG AL, UNPUB; FORSTER AC, 1987, COLD SPRING HARB SYM, V52, P249, DOI 10.1101/SQB.1987.052.01.030; HENDRIX C, 1995, BIOCHEM BIOPH RES CO, V210, P67, DOI 10.1006/bbrc.1995.1628; HENDRIX C, 1995, NUCLEIC ACIDS RES, V23, P51, DOI 10.1093/nar/23.1.51; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; Holbrook SR, 1997, BIOPOLYMERS, V44, P3; HORROCKS WDW, 1993, METHOD ENZYMOL, V226, P495, DOI 10.1016/0076-6879(93)26023-3; JACK A, 1977, J MOL BIOL, V111, P315, DOI 10.1016/S0022-2836(77)80054-5; JONES TA, 1992, O MANUAL MANUAL O VE; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; KUIMELIS RG, 1995, J AM CHEM SOC, V117, P11019, DOI 10.1021/ja00149a030; Maniatis T., 1982, MOL CLONING LAB MANU; McKay DB, 1996, RNA, V2, P395; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MORET E, 1991, J LESS-COMMON MET, V171, P273, DOI 10.1016/0022-5088(91)90151-S; Peracchi A, 1996, P NATL ACAD SCI USA, V93, P11522, DOI 10.1073/pnas.93.21.11522; Peracchi A, 1997, J BIOL CHEM, V272, P26822, DOI 10.1074/jbc.272.43.26822; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; RINGER DP, 1980, ANAL BIOCHEM, V103, P337, DOI 10.1016/0003-2697(80)90620-X; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; Scott WG, 1996, SCIENCE, V274, P2065, DOI 10.1126/science.274.5295.2065; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; Segel I.H, 1993, ENZYME KINETICS; SHELDON CC, 1990, NUCLEIC ACIDS MOL BI, V4, P227; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; SYMONS RH, 1989, TRENDS BIOCHEM SCI, V14, P445, DOI 10.1016/0968-0004(89)90103-5; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; Weinstein LB, 1997, NATURE, V388, P805, DOI 10.1038/42076; WOLFSON JM, 1975, BIOCHEMISTRY-US, V14, P1436, DOI 10.1021/bi00678a014	41	115	116	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					81	84		10.1126/science.279.5347.81	http://dx.doi.org/10.1126/science.279.5347.81			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417029				2022-12-24	WOS:000071323900044
J	Jaworek, T; Neher, D; Wegner, G; Wieringa, RH; Schouten, AJ				Jaworek, T; Neher, D; Wegner, G; Wieringa, RH; Schouten, AJ			Electromechanical properties of an ultrathin layer of directionally aligned helical polypeptides	SCIENCE			English	Article							BENZYL-L-GLUTAMATE; SILICON CRYSTAL-SURFACE; LANGMUIR-BLODGETT-FILM; CHEMICAL-REACTION; 2ND-HARMONIC GENERATION; THIN-FILMS; CRA FILM; POLYMERS; PIEZOELECTRICITY; MONOLAYERS	The electromechanical properties of a monomolecular film of poly-gamma-benzyl-L-glutamate (PBLG) 15 nanometers thick grafted at the carboxyl-terminal end to a flat aluminum surface were measured. The field-induced change in film thickness, dominated by a large inverse-piezoelectric effect, demonstrates that the "grafting-from" technique forces the chains into a parallel arrangement. The mechanical plate modulus of the film as determined by electrostriction agrees with the theoretical prediction for a single PBLG molecule along the chain axis. The experiments show that ultrathin polypeptide layers with large persistent polarization can be fabricated by the grafting approach.	Max Planck Inst Polymerforsch, D-55128 Mainz, Germany; Univ Groningen, Dept Polymer Chem, NL-9747 AG Groningen, Netherlands	Max Planck Society; University of Groningen	Wegner, G (corresponding author), Max Planck Inst Polymerforsch, Ackermannweg 10, D-55128 Mainz, Germany.		Neher, Dieter/A-9334-2015; Colella, Stefano/A-7040-2008	Colella, Stefano/0000-0003-3139-6055				Advincula R, 1996, POLYM ADVAN TECHNOL, V7, P571; Beyer D, 1995, THIN SOLID FILMS, V271, P73, DOI 10.1016/0040-6090(96)80085-X; Block H., 1983, POLY GAMMA BENZYL L; BLOCK H, 1992, POLYMER, V33, P2489; Blum G, 1995, ADV MATER, V7, P1017, DOI 10.1002/adma.19950071210; BURLAND DM, 1994, CHEM REV, V94, P31, DOI 10.1021/cr00025a002; CRESSWELL JP, 1992, THIN SOLID FILMS, V210, P216, DOI 10.1016/0040-6090(92)90215-W; DUDA G, 1988, THIN SOLID FILMS, V159, P221, DOI 10.1016/0040-6090(88)90633-5; Eckert T, 1996, MACROMOL RAPID COMM, V17, P767, DOI 10.1002/marc.1996.030171103; FUKADA E, 1968, ULTRASONICS      OCT, P229; FURUKAWA T, 1984, JPN J APPL PHYS 2, V23, pL677, DOI 10.1143/JJAP.23.L677; HALLER I, 1978, J AM CHEM SOC, V100, P8050, DOI 10.1021/ja00494a003; Heise A, 1997, LANGMUIR, V13, P723, DOI 10.1021/la960467g; HELFRICH J, 1994, MACROMOLECULES, V27, P472, DOI 10.1021/ma00080a022; JACKSON CL, 1991, POLYMER, V32, P221, DOI 10.1016/0032-3861(91)90005-4; KURTH DG, 1995, LANGMUIR, V11, P3061, DOI 10.1021/la00008a035; LEVINE BF, 1976, J CHEM PHYS, V65, P1989, DOI 10.1063/1.433297; Lin WB, 1996, J AM CHEM SOC, V118, P8034, DOI 10.1021/ja960395f; Luo Y, 1997, CHEM PHYS LETT, V275, P145, DOI 10.1016/S0009-2614(97)00731-8; LUPO D, 1988, J OPT SOC AM B, V5, P300, DOI 10.1364/JOSAB.5.000300; MACHIDA S, 1992, J CHEM SOC CHEM COMM, P1628, DOI 10.1039/c39920001628; MACHIDA S, 1992, J CHEM SOC CHEM COMM, P1626, DOI 10.1039/c39920001626; Machida S, 1995, LANGMUIR, V11, P4838, DOI 10.1021/la00012a041; MARTIN PG, 1987, POLYMER, V28, P897, DOI 10.1016/0032-3861(87)90160-1; MCGRUM NG, 1967, ANELASTIC DIELECTRIC; MOPSIK FI, 1975, J APPL PHYS, V46, P4204, DOI 10.1063/1.321433; NACIRI J, 1995, MACROMOLECULES, V28, P5274, DOI 10.1021/ma00119a016; NIZZOLI F, 1989, PHYS REV B, V40, P3323, DOI 10.1103/PhysRevB.40.3323; OOSTERLING MLCM, 1995, POLYMER, V36, P4463, DOI 10.1016/0032-3861(95)96854-2; PALACIOS P, 1991, ANGEW MAKROMOL CHEM, V193, P77, DOI 10.1002/apmc.1991.051930108; SANO K, 1992, CHEM LETT, P1477, DOI 10.1246/cl.1992.1477; SESSLER GM, 1987, TOP APPL PHYS, P7; SINGER KD, 1987, J OPT SOC AM B, V4, P968, DOI 10.1364/JOSAB.4.000968; Stupp SI, 1997, SCIENCE, V276, P384, DOI 10.1126/science.276.5311.384; TOKARSKI Z, 1994, CHEM MATER, V6, P2063, DOI 10.1021/cm00047a028; URANO TI, 1994, J CHEM SOC CHEM COMM, P231, DOI 10.1039/c39940000231; WADA A, 1962, POLYAMINO ACIDS POLY, P131; WHITESELL JK, 1994, MOL CRYST LIQ CRYS A, V240, P251, DOI 10.1080/10587259408029736; WHITESELL JK, 1993, SCIENCE, V261, P73, DOI 10.1126/science.261.5117.73; WHITESELL JK, 1994, ANGEW CHEM, V106, P921; WIENNGA RH, UNPUB; Wieringa RH, 1996, MACROMOLECULES, V29, P3032, DOI 10.1021/ma9508358; Winkelhahn HJ, 1996, MACROMOLECULES, V29, P6865, DOI 10.1021/ma960080k; WINKELHAHN HJ, 1994, APPL PHYS LETT, V64, P1347, DOI 10.1063/1.111930	44	127	128	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					57	60		10.1126/science.279.5347.57	http://dx.doi.org/10.1126/science.279.5347.57			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417021	Green Submitted			2022-12-24	WOS:000071323900036
J	Sakahira, H; Enari, M; Nagata, S				Sakahira, H; Enari, M; Nagata, S			Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis	NATURE			English	Article							CELL-DEATH; PROTEASES; FAS; EXPRESSION; SURVIVAL; GENOME; BCL-2	Various molecules such as cytokines and anticancer drugs, as well as factor deprivation, rapidly induce apoptosis (programmed cell death)(1,2), which is morphologically characterized by cell shrinkage and the blebbing of plasma membranes and by nuclear condensation(3,4). Caspases, particularly caspase 3, are proteases that are activated during apoptosis and which cleave substrates such as poly(ADP-ribose) polymerase, actin, fodrin, and lamin(5,6). Apoptosis is also accompanied by the internucleosomal degradation of chromosomal DNA(7-9). In the accompanying Article(10), we have identified and molecularly cloned a caspase-activated deoxyribonuclease (CAD) and its inhibitor (ICAD). Here we show that caspase 3 cleaves ICAD and inactivates its CAD-inhibitory effect, We identified two caspase-3 cleavage sites in ICAD by site-directed mutagenesis. When human Jurkat cells were transformed with ICAD-expressing plasmid, occupation of the receptor Fas, which normally triggers apoptosis, did not result in DNA degradation, The ICAD transformants were also resistant to staurosporine-induced DNA degradation, although staurosporine still killed the cells by activating caspase. Our results indicate that activation of CAD downstream of the caspase cascade is responsible for internucleosomal DNA degradation during apoptosis, and that ICAD works as an inhibitor of this process.	Osaka Univ, Sch Med, Dept Genet, Osaka 565, Japan; Osaka Biosci Inst, Osaka 565, Japan	Osaka University	Nagata, S (corresponding author), Osaka Univ, Sch Med, Dept Genet, 2-2 Yamada Oka, Osaka 565, Japan.		Enari, Masato/E-5507-2014; Nagata, Shigekazu/AAG-3203-2019	Enari, Masato/0000-0003-4293-3848; Nagata, Shigekazu/0000-0001-9758-8426; Duriez, Patrick/0000-0003-1814-2552				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Peitsch Manuel C., 1994, Trends in Cell Biology, V4, P37, DOI 10.1016/0962-8924(94)90002-7; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; WYLLIE AH, 1984, J PATHOL, V142, P66	28	1360	1403	0	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					96	99		10.1038/34214	http://dx.doi.org/10.1038/34214			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422513				2022-12-24	WOS:000071326100057
J	Kramer, A; Keitel, T; Winkler, K; Stocklein, W; Hohne, W; SchneiderMergener, J				Kramer, A; Keitel, T; Winkler, K; Stocklein, W; Hohne, W; SchneiderMergener, J			Molecular basis for the binding promiscuity of an anti-p24 (HIV-1) monoclonal antibody	CELL			English	Article							PEPTIDE COMBINATORIAL LIBRARIES; ANTIGEN INTERACTIONS; CROSS-REACTIVITY; ESCHERICHIA-COLI; HIGH-AFFINITY; B-CELLS; PROTEIN; GENERATION; EXPRESSION; SURFACE	Multiple binding capabilities utilized by specific protein-to-protein interactions in molecular recognition events are being documented increasingly but remain poorly understood at the molecular level. We identified five unrelated peptides that compete with each other for binding to the paratope region of the monoclonal anti-p24 (HIV-1) antibody CB4-1 by using a synthetic positional scanning combinatorial library XXXX[B-1,B-2,B-3,X-1,X-2,X-3]XXXX (14 mers; 68,590 peptide mixtures in total) prepared by spot synthesis. Complete sets of substitution analogs of the five peptides revealed key interacting residues, information that led to the construction of binding supertopes derived from each peptide. These supertope sequences were identified in hundreds of heterologous proteins, and those proteins that could be obtained were shown to bind CB4-1. Implications of these findings for immune escape mechanisms and autoimmunity are discussed.	HUMBOLDT UNIV BERLIN,KLINIKUM CHARITE,INST MED IMMUNOL,D-10098 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,KLINIKUM CHARITE,INST BIOCHEM,D-10098 BERLIN,GERMANY; MAX DELBRUCK CENTRUM,UNIV POTSDAM,INST BIOCHEM & MOL PHYSIOL,D-13122 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Potsdam				Kramer, Achim/0000-0001-9671-6078				Appel JR, 1996, MOL DIVERS, V2, P29, DOI 10.1007/BF01718697; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; BACCALA R, 1989, P NATL ACAD SCI USA, V86, P4624, DOI 10.1073/pnas.86.12.4624; BEREK C, 1988, IMMUNOL REV, V105, P5, DOI 10.1111/j.1600-065X.1988.tb00763.x; BURASTERO SE, 1988, J EXP MED, V168, P1979, DOI 10.1084/jem.168.6.1979; CARDOZO T, 1995, PROTEINS, V23, P403, DOI 10.1002/prot.340230314; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; CHRISTIAN RB, 1992, J MOL BIOL, V227, P711, DOI 10.1016/0022-2836(92)90219-A; Cornall RJ, 1995, CURR OPIN IMMUNOL, V7, P804, DOI 10.1016/0952-7915(95)80052-2; CUMANO A, 1986, EMBO J, V5, P2459, DOI 10.1002/j.1460-2075.1986.tb04522.x; DECIECHI PA, 1995, MOL DIV, V1, P79; Demangel C, 1996, MOL IMMUNOL, V33, P909, DOI 10.1016/S0161-5890(96)00058-2; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Ehrhard B, 1996, BIOCHEMISTRY-US, V35, P9097, DOI 10.1021/bi9603534; Forster T. H., 1946, NATURWISSENSCHAFTEN, V6, P166; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; Geysen H M, 1988, J Mol Recognit, V1, P32, DOI 10.1002/jmr.300010107; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GUILBERT B, 1982, J IMMUNOL, V128, P2779; HAUSDORF G, 1994, J VIROL METHODS, V50, P1, DOI 10.1016/0166-0934(94)90158-9; Hohne W E, 1993, Mol Immunol, V30, P1213, DOI 10.1016/0161-5890(93)90140-7; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JAHN S, 1995, IMMUNOBIOLOGY, V193, P400, DOI 10.1016/S0171-2985(11)80427-4; KAPLAN MH, 1962, LANCET, V1, P706; KARLSSON R, 1995, ANAL BIOCHEM, V228, P274, DOI 10.1006/abio.1995.1350; Keitel T, 1997, CELL, V91, P811, DOI 10.1016/S0092-8674(00)80469-9; KRAMER A, 1995, MOL IMMUNOL, V32, P459, DOI 10.1016/0161-5890(95)00006-Z; KRAMER A, 1997, IN PRESS METH MOL BI, V87; Kramer Achim, 1994, Methods (Orlando), V6, P388, DOI 10.1006/meth.1994.1039; MALIN R, 1995, J AM CHEM SOC, V117, P11821, DOI 10.1021/ja00152a031; MARIUZZA RA, 1993, CURR OPIN IMMUNOL, V5, P50, DOI 10.1016/0952-7915(93)90080-C; NEEDELS MC, 1993, P NATL ACAD SCI USA, V90, P10700, DOI 10.1073/pnas.90.22.10700; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; OSHANNESSY DJ, 1990, ANAL BIOCHEM, V191, P1, DOI 10.1016/0003-2697(90)90377-L; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; PINILLA C, 1995, PEPTIDE RES, V8, P250; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; PINILLA C, 1993, MOL IMMUNOL, V30, P577, DOI 10.1016/0161-5890(93)90032-7; ROGGENBUCK D, 1994, SCAND J IMMUNOL, V40, P64, DOI 10.1111/j.1365-3083.1994.tb03434.x; ROSSLER D, 1995, MED MICROBIOL IMMUN, V184, P23, DOI 10.1007/BF00216786; SCHNEIDERMERGEN.J, 1996, COMBINATORIAL LIB, P53; SHARON J, 1990, P NATL ACAD SCI USA, V87, P4814, DOI 10.1073/pnas.87.12.4814; STIGLER RD, 1995, PROTEIN ENG, V8, P471, DOI 10.1093/protein/8.5.471; Valadon P, 1996, J MOL BIOL, V261, P11, DOI 10.1006/jmbi.1996.0438; VANREGENMORTEL MHV, 1994, IMMUNOCHEMISTRY, P277; VOLKMERENGERT R, 1994, LETT PEPT SCI, V1, P243; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WING MG, 1995, CLIN EXP IMMUNOL, V99, P313, DOI 10.1111/j.1365-2249.1995.tb05551.x; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; ZHANG ZX, 1994, CLIN EXP IMMUNOL, V96, P403	55	159	172	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					799	809		10.1016/S0092-8674(00)80468-7	http://dx.doi.org/10.1016/S0092-8674(00)80468-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413989	Bronze			2022-12-24	WOS:A1997YL43900011
J	Hershey, GKK; Friedrich, MF; Esswein, LA; Thomas, ML; Chatila, TA				Hershey, GKK; Friedrich, MF; Esswein, LA; Thomas, ML; Chatila, TA			The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEMATOPOIETIC-CELL PHOSPHATASE; HYPER-IGE SYNDROME; TYROSINE PHOSPHORYLATION; GAMMA-CHAIN; SH2 DOMAIN; IL-4; ERYTHROPOIETIN; ALLERGENS; EXPOSURE; ASTHMA	Background Atopic diseases are very common, and atopy has a strong genetic predisposition. Methods Using single-strand conformation polymorphism analysis and DNA sequencing, we searched for mutations in the alpha subunit of the interleukin-4 receptor that would predispose persons to atopy. We examined the prevalence of the alleles among patients with allergic inflammatory disorders and among 50 prospectively recruited adults. Subjects with atopy were identified on the basis of an elevated serum IgE level (greater than or equal to 95 IU per milliliter) or a positive radioimmunosorbent test in response to standard inhalant allergens. The signaling function of mutant interleukin-4 receptor alpha was examined by flow cytometry, binding assays, and immunoblotting. Results A novel interleukin-4 receptor alpha allele was identified in which guanine was substituted for adenine at nucleotide 1902, causing a change from glutamine to arginine at position 576 (R576) in the cytoplasmic domain of the interleukin-4 receptor alpha protein. The R576 allele was common among patients with allergic inflammatory disorders (found in 3 of 3 patients with the hyper-IgE syndrome and 4 of 7 patients with severe atopic dermatitis) and among the 50 prospectively recruited adults (found in 13 of 20 subjects with atopy and 5 of 30 without atopy; P=0.001; relative risk of atopy among those with a mutant allele, 9.3). The R576 allele was associated with higher levels of expression of CD23 by interleukin-4 than the wild-type allele. This enhanced signaling was associated with a change in the binding specificity of the adjacent tyrosine residue at position 575 to signal-transducing molecules. Conclusions The R576 allele of interleukin-4 receptor alpha is strongly associated with atopy. This mutation may predispose persons to allergic diseases by altering the signaling function of the receptor. (C) 1997, Massachusetts Medical Society.	WASHINGTON UNIV, SCH MED, DEPT PEDIAT, DIV IMMUNOL RHEUMATOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, CTR IMMUNOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)				Chatila, Talal/0000-0001-7439-2762; Khurana Hershey, Gurjit/0000-0001-6663-977X				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Bonnefoy JY, 1996, ANN NY ACAD SCI, V796, P59, DOI 10.1111/j.1749-6632.1996.tb32567.x; BUCKLEY RH, 1996, IMMUNOLOGIC DISORDER, P409; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COOKSON WOCM, 1988, LANCET, V1, P86; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; GALIZZI JP, 1990, INT IMMUNOL, V2, P669, DOI 10.1093/intimm/2.7.669; Geha R S, 1989, Immunodefic Rev, V1, P155; Gelderloos JA, 1996, ONCOGENE, V13, P2367; Glantz SA., 1997, PRIMER BIOSTATISTICS; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUANG SK, 1993, ANN ALLERGY, V70, P347; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Imani F, 1997, J BIOL CHEM, V272, P7927, DOI 10.1074/jbc.272.12.7927; ISHIZAKA A, 1990, IMMUNOLOGY, V70, P414; KIRCHNER SG, 1985, RADIOLOGY, V156, P362, DOI 10.1148/radiology.156.2.4011897; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEWIS DB, 1993, P NATL ACAD SCI USA, V90, P11618, DOI 10.1073/pnas.90.24.11618; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Oakes SA, 1996, IMMUNITY, V5, P605, DOI 10.1016/S1074-7613(00)80274-5; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; SOKOL L, 1995, BLOOD, V86, P15, DOI 10.1182/blood.V86.1.15.bloodjournal86115; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stavnezer J, 1996, ADV IMMUNOL, V61, P79, DOI 10.1016/S0065-2776(08)60866-4; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; VERCELLI D, 1990, J CLIN INVEST, V85, P1666, DOI 10.1172/JCI114618; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YOUNG RP, 1994, CLIN EXP ALLERGY, V24, P431, DOI 10.1111/j.1365-2222.1994.tb00931.x; YOUNG RP, 1992, CLIN EXP ALLERGY, V22, P205, DOI 10.1111/j.1365-2222.1992.tb03074.x; ZEIGER RS, 1993, ALLERGY PRINCIPLES P, V2, P1137	48	587	631	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 11	1997	337	24					1720	1725		10.1056/NEJM199712113372403	http://dx.doi.org/10.1056/NEJM199712113372403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK653	9392697				2022-12-24	WOS:A1997YK65300003
J	Cardo, DM; Culver, DH; Ciesielski, CA; Srivastava, PU; Marcus, R; Abiteboul, D; Heptonstall, J; Ippolito, G; Lot, F; McKibben, P; Bell, DM				Cardo, DM; Culver, DH; Ciesielski, CA; Srivastava, PU; Marcus, R; Abiteboul, D; Heptonstall, J; Ippolito, G; Lot, F; McKibben, P; Bell, DM			A case-control study of HIV seroconversion in health care workers after percutaneous exposure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ZIDOVUDINE TREATMENT; HEPATITIS-B; RISK; TRANSMISSION; INFECTION; TYPE-1; BLOOD; INFANT	Background The average risk of human immunodeficiency virus (HIV) infection after percutaneous exposure to HIV-infected blood is 0.3 percent, but the factors that influence this risk are not well understood. Methods We conducted a case-control study Of health care workers with occupational, percutaneous exposure to HIV-infected blood. The case patients were those who became seropositive after exposure to HIV, as reported by national surveillance systems in France, Italy, the United Kingdom, and the United States. The controls were health care workers in a prospective surveillance project who were exposed to HIV but did not seroconvert. Results Logistic-regression analysis based on 33 case patients and 665 controls showed that significant risk factors for seroconversion were deep injury (odds ratio=15; 95 percent confidence interval, 6.0 to 41), injury with a device that was visibly contaminated with the source patient's blood (odds ratio=6.2; 95 percent confidence interval, 2.2 to 21), a procedure involving a needle placed in the source patient's artery or vein (odds ratio=4.3; 95 percent confidence interval, 1.7 to 12), and exposure to a source patient who died of the acquired immunodeficiency syndrome within two months afterward (odds ratio=5.6; 95 percent confidence interval, 2.0 to 16). The case patients were significantly less likely than the controls to have taken zidovudine after the exposure (odds ratio=0.19; 95 percent confidence interval, 0.06 to 0.52). Conclusions The risk of HIV infection after percutaneous exposure increases with a larger volume of blood and, probably, a higher titer of HIV in the source patient's blood. Postexposure prophylaxis with zidovudine appears to be protective. (C) 1997, Massachusetts Medical Society.	CTR DIS CONTROL,NATL CTR HIV STD & TB PREVENT,DIV HIV AIDS,ATLANTA,GA 30333; INST NATL RECH & SECUR,PARIS,FRANCE; GRP ETUD RISQUE EXPOSIT SANG,PARIS,FRANCE; PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND; CTR RIFERIMENTO AIDS COORDINAMENTO STUDIO ITALIAN,ROME,ITALY; RESEAU NATL SANTE PUBL,ST MAURICE,FRANCE	Centers for Disease Control & Prevention - USA; Public Health England	Cardo, DM (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,1600 CLIFTON RD,MAIL STOP E-68,ATLANTA,GA 30333, USA.		Ippolito, Giuseppe/J-7207-2017	Marcus, Ruthanne/0000-0002-9094-0674; Ippolito, Giuseppe/0000-0002-1076-2979				BELL DM, 1992, INFECT AGENT DIS, V1, P263; BELL DM, 1997, AM J MED 5B, V102; BLACK R, 1997, AM J MED, V102; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; CHAMBERLAND ME, IN PRESS HOSP INFECT; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; GERBERDING JL, 1994, J INFECT DIS, V170, P1410, DOI 10.1093/infdis/170.6.1410; GERBERDING JL, 1997, AM J MED 5B, V102; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; IPPOLITO G, 1993, ARCH INTERN MED, V153, P1451, DOI 10.1001/archinte.153.12.1451; JOCHIMSEN EM, 1997, AM J MED 5B, V102; Katz MH, 1997, NEW ENGL J MED, V336, P1097, DOI 10.1056/NEJM199704103361512; LAFON SW, 1993, 30 INT C ANT AG CHEM; LOES SK, 1995, NEW ENGL J MED, V333, P1367; LOES SK, 1995, NEW ENGL J MED, V333, P408; LOT F, 1995, B EPIDEMIOL HEBD, V44, P193; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; *PHS, 1990, MMWR-MORBID MORTAL W, V39, P1; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; Weisburd Guillermo, 1996, P460; 1995, MMWR-MORBID MORTAL W, V44, P929; 1996, MMWR-MORBID MORTAL W, V45, P468; 1991, MMWR-MORBID MORTAL W, V40, P1	27	781	818	0	31	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 20	1997	337	21					1485	1490		10.1056/NEJM199711203372101	http://dx.doi.org/10.1056/NEJM199711203372101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG249	9366579				2022-12-24	WOS:A1997YG24900001
J	Meystre, CJN; Burley, NMJ; Ahmedzai, S				Meystre, CJN; Burley, NMJ; Ahmedzai, S			What investigations and procedures do patients in hospices want? Interview based survey of patients and their nurses	BRITISH MEDICAL JOURNAL			English	Article							CARDIOPULMONARY-RESUSCITATION; CANCER; VIEWS		UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,SECT PALLIAT MED,DEPT SURG & ANAESTHET SCI,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield	Meystre, CJN (corresponding author), LEICESTERSHIRE HOSPICE,LEICESTER LE3 9QE,LEICS,ENGLAND.			Ahmedzai, Sam/0000-0002-2028-8510				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; HILL ME, 1994, BRIT MED J, V308, P1677, DOI 10.1136/bmj.308.6945.1677; MORGAN R, 1994, BRIT MED J, V308, P1677, DOI 10.1136/bmj.308.6945.1677a; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; WHO, 1979, WHO HDB REP RES CANC	5	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1202	1203		10.1136/bmj.315.7117.1202	http://dx.doi.org/10.1136/bmj.315.7117.1202			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393223	Green Published			2022-12-24	WOS:A1997YF25200020
J	Campbell, AJ; Robertson, MC; Gardner, MM; Norton, RN; Tilyard, MW; Buchner, DM				Campbell, AJ; Robertson, MC; Gardner, MM; Norton, RN; Tilyard, MW; Buchner, DM			Randomised controlled trial of a general practice programme of home based exercise to prevent falls in elderly women	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FICSIT TRIALS; OLDER ADULTS; RISK-FACTORS; TAI-CHI; COMMUNITY; BALANCE; INTERVENTION; STRENGTH	Objective: To assess the effectiveness of a home exercise programme of strength and balance retraining exercises in reducing falls and injuries in elderly women. Design: Randomised controlled trial of an individually tailored programme of physical therapy in the home (exercise group, n=116) compared with the usual care and an equal number of social visits (control group, n=117). Setting 17 general practices in Dunedin, New Zealand. Subjects: Women aged 80 years and older living in the community and registered with a general practice in Dunedin. Main outcome measures: Number of falls and injuries related to falls and time between falls during one year of follow up; changes in muscle strength and balance measures after six months. Results: After one year there were 152 falls in the control group and 88 falls in the exercise group. The mean (SD) rate of falls was lower in the exercise than the control group (0.87 (1.29) v 1.34 (1.93) falls per year respectively; difference 0.47; 95% confidence interval 0.04 to 0.90). The relative hazard for the first four falls in the exercise group compared with the control group was 0.68 (0.52 to 0.90). The relative hazard for a first fall with injury in the exercise group compared with the control group was 0.61 (0.39 to 0.97). After six months, balance had improved in the exercise group (difference between groups in change in balance score 0.43 (0.21 to 0.65). Conclusions: An individual programme of strength and balance retraining exercises improved physical function and was effective in reducing falls and injuries in women 80 years and older.	UNIV AUCKLAND, SCH MED, INJURY PREVENT RES CTR, AUCKLAND, NEW ZEALAND; UNIV OTAGO SCH MED, DUNEDIN SCH MED, DEPT GEN PRACTICE, DUNEDIN, NEW ZEALAND; VA PUGET SOUND HLTH CARE SYST, SEATTLE, WA 98108 USA	University of Auckland; University of Otago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Campbell, AJ (corresponding author), UNIV OTAGO SCH MED, DUNEDIN SCH MED, DEPT MED, POB 913, DUNEDIN, NEW ZEALAND.		Robertson, Mary Clare/A-3964-2009					BUCHNER DM, 1993, J AM GERIATR SOC, V41, P297, DOI 10.1111/j.1532-5415.1993.tb06708.x; CAMPBELL AJ, 1989, J GERONTOL, V44, pM112, DOI 10.1093/geronj/44.4.m112; DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; Glynn RJ, 1996, BMJ-BRIT MED J, V312, P364; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; HU MH, 1994, J GERONTOL, V49, pM52, DOI 10.1093/geronj/49.2.M52; King AC, 1997, JAMA-J AM MED ASSOC, V277, P32, DOI 10.1001/jama.277.1.32; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LORD SR, 1995, J AM GERIATR SOC, V43, P1198, DOI 10.1111/j.1532-5415.1995.tb07394.x; Myers AH, 1996, BONE, V18, pS87, DOI 10.1016/8756-3282(95)00384-3; OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.1995.03520410035023; SPEECHLEY M, 1991, J AM GERIATR SOC, V39, P46, DOI 10.1111/j.1532-5415.1991.tb05905.x; Tinetti ME, 1996, AM J EPIDEMIOL, V144, P389; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4; WILSON L A, 1973, Age and Ageing, V2, P92, DOI 10.1093/ageing/2.2.92; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x; Wolfson L, 1996, J AM GERIATR SOC, V44, P498, DOI 10.1111/j.1532-5415.1996.tb01433.x	24	729	754	1	98	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 25	1997	315	7115					1065	1069		10.1136/bmj.315.7115.1065	http://dx.doi.org/10.1136/bmj.315.7115.1065			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YD445	9366737	Green Published			2022-12-24	WOS:A1997YD44500027
J	DeGrendele, HC; Estess, P; Siegelman, MH				DeGrendele, HC; Estess, P; Siegelman, MH			Requirement for CD44 in activated T cell extravasation into an inflammatory site	SCIENCE			English	Article							ADHESION MOLECULE; ENDOTHELIAL-CELLS; HYALURONATE; LYMPHOCYTES; RECOGNITION; MIGRATION; ARTHRITIS; ANTIGEN; INVIVO; SUPERANTIGENS	Leukocytes extravasate from the blood into inflammatory sites through complementary ligand interactions between leukocytes and endothelial cells, Activation of T cells increases their binding to hyaluronate (HA) and enables CD44-mediated primary adhesion (rolling). This rolling could be induced in vivo in murine V(beta)8(+) T cells in response to specific superantigen stimulation; it was initially found in lymph nodes, then in peripheral blood, and finally within the peritoneum, the original inflamed site. The migration of V(beta)8(+) cells into the peritoneal cavity was dependent on CD44 and HA, as shown by inhibition studies. Thus, CD44-HA interactions can target lymphocytes to specific extralymphoid effector sites.	UNIV TEXAS, SW MED CTR, DEPT PATHOL, MOL PATHOL LAB, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NCI NIH HHS [R01 CA57471] Funding Source: Medline; NHLBI NIH HHS [HL56746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057471] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CAHILL RNP, 1976, J EXP MED, V143, P870, DOI 10.1084/jem.143.4.870; CAMP RL, 1993, J EXP MED, V178, P497, DOI 10.1084/jem.178.2.497; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; DeGrendele HC, 1997, J IMMUNOL, V159, P2549; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; DEGRENDELE HC, UNPUB; GUY GD, 1978, J EXP MED, V148, P1661; HAYNES BF, 1991, ARTHRITIS RHEUM, V34, P1434; HERRMANN T, 1992, EUR J IMMUNOL, V22, P1935, DOI 10.1002/eji.1830220739; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; JONES DA, 1993, BIOPHYS J, V65, P1560, DOI 10.1016/S0006-3495(93)81195-0; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KENNETT RH, 1980, MONOCLONAL ANTIBODIE; KOSTER FT, 1971, J EXP MED, V133, P864, DOI 10.1084/jem.133.4.864; LESLEY J, 1994, J EXP MED, V180, P383, DOI 10.1084/jem.180.1.383; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MACKAY CR, 1991, IMMUNOL TODAY, V12, P189, DOI 10.1016/0167-5699(91)90051-T; MAROKO PR, 1977, NEW ENGL J MED, V296, P898, DOI 10.1056/NEJM197704212961603; MCCORMACK JE, 1993, J IMMUNOL, V150, P3785; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; MOHAMADZADEH M, UNPUB; SCHERER MT, 1993, ANNU REV CELL BIOL, V9, P101, DOI 10.1146/annurev.cb.09.110193.000533; SPRENT J, 1971, CELL IMMUNOL, V2, P171, DOI 10.1016/0008-8749(71)90036-0; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SZLAVY L, 1985, ANGIOLOGY, V36, P452, DOI 10.1177/000331978503600707; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Zeidler A, 1995, AUTOIMMUNITY, V21, P245, DOI 10.3109/08916939509001943	32	460	482	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	1997	278	5338					672	675		10.1126/science.278.5338.672	http://dx.doi.org/10.1126/science.278.5338.672			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381175				2022-12-24	WOS:A1997YC32300051
J	Mukhopadhyay, CK; Attieh, ZK; Fox, PL				Mukhopadhyay, CK; Attieh, ZK; Fox, PL			Role of ceruloplasmin in cellular iron uptake	SCIENCE			English	Article							K562 CELLS; SERUM IRON; FET3 GENE; TRANSFERRIN; METABOLISM; YEAST; HEMOCHROMATOSIS; FERROXIDASE; DEFICIENCY; TRANSPORT	Individuals with hereditary ceruloplasmin (Cp) deficiency have profound iron accumulation in most tissues, which suggests that Cp is important for normal release of cellular iron. Here, in contrast to expectations, Cp was shown to increase iron uptake by HepG2 cells, increasing the apparent affinity for the substrate by three times. Consistent with its role in iron uptake, Cp synthesis was regulated by iron supply and was increased four- to fivefold after iron depletion. Unlike other iron controllers that are posttranscriptionally regulated, Cp synthesis was transcriptionally regulated. Thus, iron-deficient cells could increase Cp synthesis to maintain intracellular iron homeostasis, so that defects would lead to global accumulation of iron in tissues.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Fox, PL (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	foxp@cesmtp.ccf.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052692, P01HL029582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29582, HL52692] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BACON BR, 1988, ANN NY ACAD SCI, V526, P155, DOI 10.1111/j.1749-6632.1988.tb55502.x; BATEY RG, 1980, DIGEST DIS SCI, V25, P340, DOI 10.1007/BF01308057; BOUMA ME, 1989, IN VITRO CELL DEV B, V25, P267; BREUER W, 1995, J BIOL CHEM, V270, P24209, DOI 10.1074/jbc.270.41.24209; BRITTON RS, 1994, IRON METABOLISM HLTH, P311; BROCK JH, 1994, IRON METABOLISM HLTH, P353; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Hart EB, 1928, J BIOL CHEM, V77, P796; HERSHKO C, 1978, BRIT J HAEMATOL, V40, P255, DOI 10.1111/j.1365-2141.1978.tb03662.x; Kaplan J, 1996, J CLIN INVEST, V98, P3, DOI 10.1172/JCI118772; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LOGAN JI, 1994, Q J MED, V87, P663; MORITA H, 1995, ANN NEUROL, V37, P646, DOI 10.1002/ana.410370515; MUKHOPADHYAY C, UNPUB; OSAKI S, 1969, J BIOL CHEM, V244, P5757; OSAKI S, 1971, J BIOL CHEM, V246, P3018; OSAKI S, 1966, J BIOL CHEM, V241, P2746; PARKES JG, 1995, BBA-GEN SUBJECTS, V1243, P373, DOI 10.1016/0304-4165(94)00162-Q; RAGAN HA, 1969, AM J PHYSIOL, V217, P1320, DOI 10.1152/ajplegacy.1969.217.5.1320; ROESER HP, 1970, J CLIN INVEST, V49, P2408, DOI 10.1172/JCI106460; Ryden L., 1984, COPP PROTEINS COPP E, V3, P37; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; STEIN BS, 1986, J BIOL CHEM, V261, P319; WHITE S, 1992, BIOCHIM BIOPHYS ACTA, V1136, P28, DOI 10.1016/0167-4889(92)90081-L; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	30	170	176	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	1998	279	5351					714	717		10.1126/science.279.5351.714	http://dx.doi.org/10.1126/science.279.5351.714			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445478				2022-12-24	WOS:000071731500039
J	Hirota, S; Isozaki, K; Moriyama, Y; Hashimoto, K; Nishida, T; Ishiguro, S; Kawano, K; Hanada, M; Kurata, A; Takeda, M; Tunio, GM; Matsuzawa, Y; Kanakura, Y; Shinomura, Y; Kitamura, Y				Hirota, S; Isozaki, K; Moriyama, Y; Hashimoto, K; Nishida, T; Ishiguro, S; Kawano, K; Hanada, M; Kurata, A; Takeda, M; Tunio, GM; Matsuzawa, Y; Kanakura, Y; Shinomura, Y; Kitamura, Y			Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors	SCIENCE			English	Article							RECEPTOR TYROSINE KINASE; LIGAND-INDEPENDENT ACTIVATION; HUMAN SMALL-INTESTINE; INTERSTITIAL-CELLS; BONE-MARROW; MAST-CELLS; W-LOCUS; CONSTITUTIVE ACTIVATION; POSSIBLE INVOLVEMENT; SUBMUCOSAL BORDER	Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the human digestive tract, but their molecular etiology and cellular origin are unknown. Sequencing of c-kit complementary DNA, which encodes a proto-oncogenic receptor tyrosine kinase (KIT), from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains. All of the corresponding mutant KIT proteins were constitutively activated without the KIT ligand, stem cell factor (SCF). Stable transfection of the mutant c-kit complementary DNAs induced malignant transformation of Ba/F3 murine lymphoid cells, suggesting that the mutations contribute to tumor development. GISTs may originate from the interstitial cells of Cajal (ICCs) because the development of ICCs is dependent on the SCF-KIT interaction and because, like GISTs, these cells express both KIT and CD34.	Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Dept Internal Med 2, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Dept Surg 1, Suita, Osaka 565, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Div Pathol, Osaka, Japan; Osaka Rosai Hosp, Div Pathol, Sakai, Osaka, Japan; Toyonaka Municipal Hosp, Div Pathol, Toyonaka, Osaka, Japan; Osaka Natl Hosp, Div Pathol, Osaka, Japan; Osaka Univ, Sch Med, Dept Hematol Oncol, Suita, Osaka 565, Japan	Osaka University; Osaka University; Osaka University; Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka Rosai Hospital; Osaka National Hospital; Osaka University	Kitamura, Y (corresponding author), Osaka Univ, Sch Med, Dept Pathol, Yamada Oka 2-2, Suita, Osaka 565, Japan.	kitamura@patho.med.osaka-u.ac.jp						ASHMAN LK, 1991, BLOOD, V78, P30; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; CATLETT JP, 1991, BLOOD, V78, P3186; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; FAUSSONEPELLEGRINI MS, 1990, CAN J PHYSIOL PHARM, V68, P1437, DOI 10.1139/y90-218; FAUSSONEPELLEGRINI MS, 1989, J SUBMICR CYTOL PATH, V21, P439; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HIROTA S, 1995, LAB INVEST, V72, P64; HIROTA S, 1993, ARCH PATHOL LAB MED, V117, P996; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; ISOZAKI K, 1995, GASTROENTEROLOGY, V109, P456, DOI 10.1016/0016-5085(95)90333-X; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, BLOOD, V53, P492; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; MAEDA H, 1992, DEVELOPMENT, V116, P369; MATSUDA R, 1993, AM J PATHOL, V142, P339; MIETTINEN M, 1995, AM J SURG PATHOL, V19, P207, DOI 10.1097/00000478-199502000-00009; MONIHAN JM, 1994, HISTOPATHOLOGY, V25, P469, DOI 10.1111/j.1365-2559.1994.tb00009.x; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; RUMESSEN JJ, 1993, GASTROENTEROLOGY, V104, P343, DOI 10.1016/0016-5085(93)90400-7; RUMESSEN JJ, 1993, LAB INVEST, V68, P481; RUMESSEN JJ, 1992, GASTROENTEROLOGY, V102, P56, DOI 10.1016/0016-5085(92)91784-2; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; TSUJIMURA T, 1994, BLOOD, V83, P2619; Tsujimura T, 1996, BLOOD, V87, P273; VANDERIJN M, 1994, HUM PATHOL, V25, P776; Vanderwinden JM, 1996, GASTROENTEROLOGY, V111, P901, DOI 10.1016/S0016-5085(96)70057-4; Vanderwinden JM, 1996, GASTROENTEROLOGY, V111, P279, DOI 10.1053/gast.1996.v111.pm8690192; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	35	3246	3546	3	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					577	580		10.1126/science.279.5350.577	http://dx.doi.org/10.1126/science.279.5350.577			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438854				2022-12-24	WOS:000071616000051
J	Geissler, PE; Greenberg, R; Hoppa, G; Helfenstein, P; McEwen, A; Pappalardo, R; Tufts, R; Ockert-Bell, M; Sullivan, R; Greeley, R; Belton, MJS; Denk, T; Clark, B; Burns, J; Veverka, J				Geissler, PE; Greenberg, R; Hoppa, G; Helfenstein, P; McEwen, A; Pappalardo, R; Tufts, R; Ockert-Bell, M; Sullivan, R; Greeley, R; Belton, MJS; Denk, T; Clark, B; Burns, J; Veverka, J		Galileo Imaging Team	Evidence for non-synchronous rotation of Europa	NATURE			English	Article							ICE SHELL; GALILEAN SATELLITES; POLAR WANDER	Non-synchronous rotation of Europa was predicted on theoretical grounds(1), by considering the orbitally averaged torque exerted by Jupiter on the satellite's tidal bulges, If Europa's orbit were circular, or the satellite were comprised of a frictionless fluid without tidal dissipation, this torque would average to zero. However, Europa has a small forced eccentricity e approximate to 0.01 (ref. 2), generated by its dynamical interaction with Io and Ganymede, which should cause the equilibrium spin rate of the satellite to be slightly faster than synchronous, Recent gravity data(3) suggest that there may be a permanent asymmetry in Europa's interior mass distribution which is large enough to offset the tidal torque; hence, if non-synchronous rotation is observed, the surface is probably decoupled from the interior by a subsurface layer of liquid(4) or ductile ice(1), Non-synchronous rotation was invoked to explain Europa's global system of lineaments and an equatorial region of rifting seen in Voyager images(5,6). Here we report an analysis of the orientation and distribution of these surface features, based on initial observations made by the Galileo spacecraft. We find evidence that Europa spins faster than the synchronous rate (or did so in the past), consistent with the possibility of a global subsurface ocean.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85712 USA; Cornell Univ, Lab Planetary Sci, Ithaca, NY 14853 USA; Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; Natl Opt Astron Observ, Tucson, AZ 85726 USA; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; DLR, Inst Planetary Explorat, D-12489 Berlin, Germany	University of Arizona; Cornell University; Brown University; National Optical Astronomy Observatory; Arizona State University; Arizona State University-Tempe; Helmholtz Association; German Aerospace Centre (DLR)	Geissler, PE (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85712 USA.	geissler@pirl.lpl.arizona.edu	Sullivan, Robert/AAR-8193-2020; Pappalardo, Robert/AAP-8953-2021	Pappalardo, Robert/0000-0003-2571-4627				Anderson JD, 1997, SCIENCE, V276, P1236, DOI 10.1126/science.276.5316.1236; Belton MJS, 1996, SCIENCE, V274, P377, DOI 10.1126/science.274.5286.377; BURNS JA, 1986, SATELLITES, pCH1; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; GREENBERG R, 1984, ICARUS, V58, P186, DOI 10.1016/0019-1035(84)90038-1; GREENBERG R, 1997, LUN PLAN SCI C ABSTR, V28, P457; HELFENSTEIN P, 1985, ICARUS, V61, P175, DOI 10.1016/0019-1035(85)90099-5; HOPPA GV, 1997, LUNAR PLANET SCI, V28, P597; Leith AC, 1996, ICARUS, V120, P387, DOI 10.1006/icar.1996.0058; LUCCHITTA BK, 1982, SATELLITES JUPITER, pCH14; MCEWEN AS, 1986, NATURE, V321, P49, DOI 10.1038/321049a0; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; OJAKANGAS GW, 1989, ICARUS, V81, P242, DOI 10.1016/0019-1035(89)90053-5; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; PIERI DC, 1981, NATURE, V289, P17, DOI 10.1038/289017a0; SCHENK PM, 1989, ICARUS, V79, P75, DOI 10.1016/0019-1035(89)90109-7; SULLIVAN R, 1997, LUNAR PLANET SCI, V28, P1395	17	89	93	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					368	370		10.1038/34869	http://dx.doi.org/10.1038/34869			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450751				2022-12-24	WOS:000071604200047
J	Jull, AJT; Courtney, C; Jeffrey, DA; Beck, JW				Jull, AJT; Courtney, C; Jeffrey, DA; Beck, JW			Isotopic evidence for a terrestrial source of organic compounds found in martian meteorites Allan Hills 84001 and Elephant Moraine 79001	SCIENCE			English	Article							ACCELERATOR MASS-SPECTROMETRY; SNC METEORITES; WEATHERING PRODUCTS; ALH 84001; CARBON; EETA-79001; MARS; ALH84001; NITROGEN; OXYGEN	Stepped-heating experiments on martian meteorites Allan Hills 84001 (ALH84001) and Elephant Moraine 79001 (EETA79001) revealed low-temperature (200 to 430 degrees Celsius) fractions with a carbon isotopic composition delta(13)C between -22 and -33 per mil and a carbon-14 content that is 40 to 60 percent of that of modern terrestrial carbon, consistent with a terrestrial origin for most of the organic material. Intermediate-temperature (400 to 600 degrees Celsius) carbonate-rich fractions of ALH84001 have delta(13)C of +32 to 140 per mil with a low carbon-14 content, consistent with an extraterrestrial origin, whereas some of the carbonate fraction of EETA79001 is terrestrial, In addition, ALH84001 contains a small preterrestrial carbon component of unknown origin that combusts at intermediate temperatures. This component is likely a residual acid-insoluble carbonate or a more refractory organic phase.	Univ Arizona, Natl Sci Fdn, Arizona Accelerator Mass Spect Facil, Tucson, AZ 85721 USA	National Science Foundation (NSF); University of Arizona	Jull, AJT (corresponding author), Univ Arizona, Natl Sci Fdn, Arizona Accelerator Mass Spect Facil, Tucson, AZ 85721 USA.							Ash RD, 1996, NATURE, V380, P57, DOI 10.1038/380057a0; Bada JL, 1998, SCIENCE, V279, P362, DOI 10.1126/science.279.5349.362; Becker L, 1997, GEOCHIM COSMOCHIM AC, V61, P475, DOI 10.1016/S0016-7037(96)00400-0; CARR RH, 1985, NATURE, V314, P248, DOI 10.1038/314248a0; CLAYTON RN, 1988, GEOCHIM COSMOCHIM AC, V52, P925, DOI 10.1016/0016-7037(88)90363-8; DONAHUE DJ, 1990, RADIOCARBON, V32, P135, DOI 10.1017/S0033822200040121; DONAHUE DJ, 1995, INT J MASS SPECTROM, V143, P235, DOI 10.1016/0168-1176(94)04132-Q; Friedman I., 1977, DATA GEOCHEMISTRY; Garrison DH, 1997, METEORIT PLANET SCI, V32, pA45; GOODING JL, 1988, GEOCHIM COSMOCHIM AC, V52, P909, DOI 10.1016/0016-7037(88)90361-4; GRADY MM, 1994, METEORITICS, V29, P469; GRADY MM, 1988, GEOCHIM COSMOCHIM AC, V52, P2855, DOI 10.1016/0016-7037(88)90152-4; Harvey RP, 1996, NATURE, V382, P49, DOI 10.1038/382049a0; HUTCHINS KS, 1997, THESIS U COLORADO; JAGOUTZ E, 1994, METEORITICS, V29, P478; JULL AJT, 1989, GEOCHIM COSMOCHIM AC, V53, P2095, DOI 10.1016/0016-7037(89)90327-X; JULL AJT, 1995, METEORITICS, V30, P311, DOI 10.1111/j.1945-5100.1995.tb01129.x; Jull AJT, 1997, J GEOPHYS RES-PLANET, V102, P1663, DOI 10.1029/96JE03111; JULL AJT, 1988, GEOCHIM COSMOCHIM AC, V52, P1309, DOI 10.1016/0016-7037(88)90285-2; LEVIN I, 1985, RADIOCARBON, V27, P1, DOI 10.1017/S0033822200006895; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; Neupert U, 1997, METEORIT PLANET SCI, V32, pA98; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; SLOTA PJ, 1987, RADIOCARBON, V29, P303; SPERGEL MS, 1986, J GEOPHYS RES-SOLID, V91, pD483, DOI 10.1029/JB091iB04p0D483; Taylor RE, 1987, RADIOCARBON DATING A; Turner G, 1997, GEOCHIM COSMOCHIM AC, V61, P3835, DOI 10.1016/S0016-7037(97)00285-8; Valley JW, 1997, SCIENCE, V275, P1633, DOI 10.1126/science.275.5306.1633; WRIGHT IP, 1989, NATURE, V340, P220, DOI 10.1038/340220a0; WRIGHT IP, 1988, GEOCHIM COSMOCHIM AC, V52, P917, DOI 10.1016/0016-7037(88)90362-6; WRIGHT IP, 1992, GEOCHIM COSMOCHIM AC, V56, P817, DOI 10.1016/0016-7037(92)90100-W; WRIGHT IP, 1997, LUNAR PLANET SCI, V28, P1591; [No title captured]	35	119	125	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	1998	279	5349					366	369		10.1126/science.279.5349.366	http://dx.doi.org/10.1126/science.279.5349.366			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430584				2022-12-24	WOS:000071570800042
J	Cnattingius, S; Bergstrom, R; Lipworth, L; Kramer, MS				Cnattingius, S; Bergstrom, R; Lipworth, L; Kramer, MS			Prepregnancy weight and the risk of adverse pregnancy outcomes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BODY-MASS INDEX; PRETERM BIRTH; WOMEN; PREECLAMPSIA; GAIN; STILLBIRTH; PREVALENCE; NUTRITION; INFANTS	Background Obesity before pregnancy is associated with an increased risk of several adverse outcomes of pregnancy. The risk profiles among lean, normal, or mildly overweight women are not, however, well established. Methods We studied the associations between prepregnancy body-mass index (defined as the weight in kilograms divided by the square of the height in meters) and the frequency of late fetal death, early neonatal death, preterm delivery, and delivery of a small-for-gestational-age infant in a population-based cohort of 167,750 women in Sweden in 1992 and 1993. The women were categorized as follows, according to body-mass index: lean, less than 20.0; normal, 20.0 through 24.9; overweight, 25.0 through 29.9; and obese, 30.0 or more. The estimates were adjusted for maternal age, parity, smoking, educa tion, whether the mother was living with the father, and maternal height. Results Among nulliparous women, the odds ratios for late fetal death were increased among women with higher body-mass indexes as compared with lean women, as follows: normal women, 2.2 (95 percent confidence interval, 1.2 to 4.1); overweight women, 3.2 (95 percent confidence interval, 1.6 to 6.2); and obese women, 4.3 (95 percent confidence interval, 2.0 to 9.3). Among parous women, only obese women had a significant increase in the risk of late fetal death (odds ratio, 2.0; 95 percent confidence interval, 1.2 to 3.3). Among nulliparous women, the risk of very preterm delivery (at less than or equal to 32 weeks' gestation) was significantly increased among obese as compared with lean women (odds ratio, 1.6; 95 percent confidence interval, 1.1 to 2.3), whereas among parous women, the risk was highest among those who were lean. The risk of delivering a small-for-gestational-age infant decreased more with increasing body-mass index among parous than among nulliparous women. Conclusions Higher maternal weight before pregnancy increases the risk of late fetal death, although it protects against the delivery of a small-for-gestational-age infant. (C) 1998, Massachusetts Medical Society.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Uppsala Univ, Dept Stat, S-75105 Uppsala, Sweden; Mt Sinai Sch Med, Dept Community Med, New York, NY USA; McGill Univ, Fac Med, Dept Pediat, Montreal, PQ, Canada; McGill Univ, Fac Med, Dept Biostat & Epidemiol, Montreal, PQ, Canada	Karolinska Institutet; Uppsala University; Icahn School of Medicine at Mount Sinai; McGill University; McGill University	Cnattingius, S (corresponding author), Karolinska Inst, Dept Med Epidemiol, POB 281, S-17177 Stockholm, Sweden.							[Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; BERKOWITZ GS, 1993, EPIDEMIOL REV, V15, P414, DOI 10.1093/oxfordjournals.epirev.a036128; ESKENAZI, 1995, AM J OBSTET GYNECOL, V173, P950; ESKENAZI B, 1993, AM J OBSTET GYNECOL, V169, P1112, DOI 10.1016/0002-9378(93)90265-K; ESKENAZI B, 1991, JAMA-J AM MED ASSOC, V266, P237; Galuska DA, 1996, AM J PUBLIC HEALTH, V86, P1729, DOI 10.2105/AJPH.86.12.1729; GLEICHER N, 1986, AM J OBSTET GYNECOL, V154, P1044, DOI 10.1016/0002-9378(86)90747-7; *I MED, 1992, NUTR PREGN LACT IMPL; Institute of Medicine (Subcommittees on Nutritional Status and Weight Gain During Pregnancy and Dietary Intake and Nutrient Supplements During Pregnancy Committee on Nutritional Status During Pregnancy and Lactation Food and Nutrition Board), 1990, NUTR PREGN 1; KAMINSKI M, 1973, INT J EPIDEMIOL, V2, P195, DOI 10.1093/ije/2.2.195; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; KRAMER MS, 1992, AM J EPIDEMIOL, V136, P574, DOI 10.1093/oxfordjournals.aje.a116535; KRASOVEC K, 1991, B WORLD HEALTH ORGAN, V69, P523; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUSKOWSKAWOLK A, 1993, J EPIDEMIOL COMMUN H, V47, P195, DOI 10.1136/jech.47.3.195; *LIB ALLM FORL, 1986, SWED VERS INT CLASS; LITTLE RE, 1993, AM J EPIDEMIOL, V137, P1177, DOI 10.1093/oxfordjournals.aje.a116620; LUCAS A, 1988, BRIT MED J, V296, P1495, DOI 10.1136/bmj.296.6635.1495; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Marsal K, 1996, ACTA PAEDIATR, V85, P843, DOI 10.1111/j.1651-2227.1996.tb14164.x; MEYER MB, 1976, AM J EPIDEMIOL, V103, P464, DOI 10.1093/oxfordjournals.aje.a112248; MITCHELL MC, 1989, J AM DIET ASSOC, V89, P634; NAEYE RL, 1990, AM J CLIN NUTR, V52, P273, DOI 10.1093/ajcn/52.2.273; NAEYE RL, 1979, AM J OBSTET GYNECOL, V135, P3; RANTAKALLIO P, 1995, J CLIN EPIDEMIOL, V48, P199, DOI 10.1016/0895-4356(94)00130-I; RYDHSTROM H, 1994, ACTA OBSTET GYN SCAN, V73, P779, DOI 10.3109/00016349409072504; SKODOVA Z, 1991, Cor et Vasa, V33, P114; STEIN ZA, 1984, SEMIN PERINATOL, V8, P5; STONE JL, 1994, OBSTET GYNECOL, V83, P357; WOLFE HM, 1991, AM J OBSTET GYNECOL, V164, P1306, DOI 10.1016/0002-9378(91)90705-V; WYNN A H A, 1991, Nutrition and Health (Bicester), V7, P69	31	748	767	0	59	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 15	1998	338	3					147	152		10.1056/NEJM199801153380302	http://dx.doi.org/10.1056/NEJM199801153380302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ414	9428815	Bronze			2022-12-24	WOS:000071384500002
J	Goldin-Meadow, S; Mylander, C				Goldin-Meadow, S; Mylander, C			Spontaneous sign systems created by deaf children in two cultures	NATURE			English	Article							GESTURAL COMMUNICATION; LANGUAGE-DEVELOPMENT; PARENTAL INPUT	Deaf children whose access to usable conventional linguistic input, signed or spoken, is severely limited nevertheless use gesture to communicate(1-3). These gestures resemble natural language in that they are structured at the level both of sentence(4) and of word(5). Although the inclination Ito use gesture maybe traceable to the fact that the deaf children's]tearing parents, like all speakers, gesture as they talk(6), the children themselves are responsible for introducing language-like structure into their gestures(7). We have explored the robustness of this phenomenon by observing deaf children of hearing parents in two cultures, an American and a Chinese culture, that differ in their child-rearing practices(8-12) and in the way gesture is used in relation to speech(13). The spontaneous sign systems developed in these cultures shared a number of structural similarities: patterned production and deletion of semantic elements ii the surface structure of a sentence; patterned ordering of those elements within the sentence; and concatenation of propositions within a sentence. These striking similarities offer critical empirical input towards resolving the ongoing debate about the 'innateness' of language in human infants(14-16).	Univ Chicago, Dept Psychol, Chicago, IL 60637 USA	University of Chicago	Goldin-Meadow, S (corresponding author), Univ Chicago, Dept Psychol, 5730 S Woodlawn Ave, Chicago, IL 60637 USA.		Galantucci, Bruno/E-5770-2010					CHEN CS, 1988, HUM DEV, V31, P351, DOI 10.1159/000276334; Chomsky Noam., 1965, ASPECTS THEORY SYNTA; Dixon R. M. W., 1994, ERGATIVITY; Dixon R. M. W., 1976, GRAMMATICAL CATEGORI, P112; Fant L. J., 1972, AMESLAN; FEYEREISEN P, 1991, GESTURE SPEECH; GLEITMAN L, 1995, LANGUAGE INVITATION, V1, P1; Goldin-Meadow S., 1996, INT J PRIMATOL, V17, P145; GOLDINMEADOW S, 1994, COGNITIVE PSYCHOL, V27, P259, DOI 10.1006/cogp.1994.1018; GOLDINMEADOW S, 1995, COGNITION, V56, P195, DOI 10.1016/0010-0277(95)00662-I; GOLDINMEADOW S, 1983, SCIENCE, V221, P372, DOI 10.1126/science.6867713; GOLDINMEADOW S, 1984, MONOGR SOC RES CHILD, V49, P1, DOI 10.2307/1165838; GOLDINMEADOW S, 1977, SCIENCE, V197, P401, DOI 10.1126/science.877567; McNeill D., 1992, HAND MIND WHAT HANDS; MCNEILL D, UNPUB LANGUAGE GESTU; Miller PJ, 1997, CHILD DEV, V68, P557, DOI 10.2307/1131678; MOORES DF, 1974, LANGUAGE PERSPECTIVE, P377; PETITTO LA, 1988, DEV LANGUAGE LANGUAG, P187; Pinker S, 1995, LANGUAGE INSTINCT; SIEGEL S., 1956, NONPARAMETRIC STAT B; Stevenson H W, 1990, Monogr Soc Res Child Dev, V55, P1; TERVOORT BT, 1961, AM ANN DEAF, V106, P436; Wang X.-L., 1996, RES FAMILY RESOURCES, P363; Wimsatt W.C., 1986, INTEGRATING SCI DISC, P185, DOI 10.1007/978-94-010-9435-1_11; YOUNG NF, 1972, AMERASIA J, V1, P31; Zar JH., 1999, BIOSTAT ANAL	26	175	176	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					279	281		10.1038/34646	http://dx.doi.org/10.1038/34646			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YR328	9440690				2022-12-24	WOS:000071484400049
J	Grady, TA; Chiu, AC; Snader, CE; Marwick, TH; Thomas, JD; Pashkow, FJ; Lauer, MS				Grady, TA; Chiu, AC; Snader, CE; Marwick, TH; Thomas, JD; Pashkow, FJ; Lauer, MS			Prognostic significance of exercise-induced left bundle-branch block	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; CLINICAL-SIGNIFICANCE; HEART-DISEASE	Context.-Approximately 0.5% of all patients who undergo exercise testing develop a transient left bundle-branch block (LBBB) during exercise, but its prognostic significance is unclear. Objective.-To determine whether exercise-induced LBBB is an independent predictor of mortality and cardiac morbidity. Design.-Matched control cohort study. Between September 1990 and February 10, 1994, 17 277 exercise stress tests were performed on patients. Setting.-Tertiary care, academic medical center. Patients.-From the cohort, 70 cases of exercise-induced LBBB were identified. The controls comprised 70 individuals without LBBB at rest or during exercise that matched the 70 cases based on age, test date, sex, prior history of coronary artery disease, hypertension, diabetes, smoking, and beta-blocker use. Main Outcome Measures.-All-cause mortality, percutaneous coronary intervention, open heart surgery, nonfatal myocardial infarction, documented symptomatic or sustained ventricular tachydysrhythmia, or implantation of a permanent pacemaker or an implantable cardiac defibrillator. Results.-A total of 37 events (28 events from the exercise-induced LBBB cases and 9 from the control cohort) occurred in 25 patients (17 exercise-induced LBBB patients and 8 control patients) during a mean follow-up period of 3.7 (0.9 years) (median, 3.8 years [range, 0.9-5.2 years]). There were 7 deaths, of which 5 occurred among patients with exercise-induced LBBB. Four-year Kaplan-Meier event rates were 19% among exercise-induced LBBB patients and 10% among controls (log-rank chi(2), 5.2; P=.02). After further adjusting for small differences in age, exercise-induced LBBB remained associated with a higher risk of primary events (adjusted relative risk, 2.78; 95% confidence interval, 1.16-6.65; P=.02). Conclusion.-Exercise-induced LBBB independently predicts a higher risk of death and major cardiac events.	Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplant Med, George M & Linda H Kaufman Ctr Heart Failure, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Lauer, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplant Med, George M & Linda H Kaufman Ctr Heart Failure, Desk F-25, Cleveland, OH 44195 USA.		Lauer, Michael S/L-9656-2013; Marwick, Thomas H/C-7261-2013	Lauer, Michael S/0000-0002-9217-8177; Marwick, Thomas H/0000-0001-9065-0899				[Anonymous], STRESS TESTING PRINC; BOUNHOURE J, 1991, ARCH MAL COEUR VAISS, V842, P167; BRUCE RA, 1980, AM J CARDIOL, V46, P371, DOI 10.1016/0002-9149(80)90003-X; CHAPMAN JH, 1977, CHEST, V71, P776, DOI 10.1378/chest.71.6.776; CHOU T, 1995, ELECTROCARDIOGRAPHY, P939; COX DR, 1972, J R STAT SOC B, V34, P187; *CRIT COMM NEW YOR, 1994, NOM CRIT DIAGN DIS H, P210; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; GIBBONS R, 1997, AM J CARDIOL, V30, P260; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HAND M, 1988, AM HEART J, V118, P23; HEINSIMER JA, 1987, AM J CARDIOL, V60, P1065, DOI 10.1016/0002-9149(87)90353-5; HERTZEANU H, 1992, EUR HEART J, V13, P1447, DOI 10.1093/oxfordjournals.eurheartj.a060084; HINDMAN MC, 1978, CIRCULATION, V58, P679, DOI 10.1161/01.CIR.58.4.679; KAFKA H, 1984, AM J CARDIOL, V54, P676, DOI 10.1016/0002-9149(84)90276-5; MCNEER JF, 1978, CIRCULATION, V57, P64, DOI 10.1161/01.CIR.57.1.64; MORAN JF, 1992, J ELECTROCARDIOL, V3, P229; *SAS INC, 1996, SAS STAT SOFTW CHANG, P835; SCHNEIDER JF, 1979, ANN INTERN MED, V90, P303, DOI 10.7326/0003-4819-90-3-303; VASEY C, 1985, AM J CARDIOL, V56, P892, DOI 10.1016/0002-9149(85)90777-5; VIEWEG WVR, 1976, CHEST, V69, P123, DOI 10.1378/chest.69.1.123; VIRTANEN KS, 1982, CHEST, V81, P326, DOI 10.1378/chest.81.3.326; WAYNE V, 1993, AM J CARDIOLF, V52, P283; WILLIAMS MA, 1988, AM J CARDIOL, V61, P346, DOI 10.1016/0002-9149(88)90942-3	24	58	72	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	1998	279	2					153	156		10.1001/jama.279.2.153	http://dx.doi.org/10.1001/jama.279.2.153			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ015	9440667	Bronze			2022-12-24	WOS:000071338900034
J	Shisler, JL; Senkevich, TG; Berry, MJ; Moss, B				Shisler, JL; Senkevich, TG; Berry, MJ; Moss, B			Ultraviolet-induced cell death blocked by a selenoprotein from a human dermatotropic poxvirus	SCIENCE			English	Article							MOLLUSCUM CONTAGIOSUM VIRUS; VACCINIA VIRUS; SELENOCYSTEINE INCORPORATION; GENE-EXPRESSION; MAMMALIAN-CELLS; SEQUENCE; EUKARYOTES; APOPTOSIS; BIOLOGY; ELEMENT	Selenium, an essential trace element, is a component of prokaryotic and eukaryotic antioxidant proteins, A candidate selenoprotein homologous to glutathione peroxidase was deduced from the sequence of molluscum contagiosum, a poxvirus that causes persistent skin neoplasms in children and acquired immunodeficiency syndrome (AIDS) patients. Selenium was incorporated into this protein during biosynthesis, and a characteristic stem-loop structure near the end of the messenger RNA was required for alternative selenocysteine decoding of a potential UGA stop codon within the open reading frame. The selenoprotein protected human keratinocytes against cytotoxic effects of ultraviolet irradiation and hydrogen peroxide, providing a mechanism for a virus to defend itself against environmental stress.	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Inst Med, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University	Moss, B (corresponding author), NIAID, Viral Dis Lab, NIH, 4 Ctr Dr,MSC 0445, Bethesda, MD 20892 USA.			Moss, Bernard/0000-0002-2154-8564; Shisler, Joanna/0000-0003-4833-1557	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047320] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47320] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BSL MR, 1997, P NATL ACAD SCI USA, V94, P5531; BULLER RML, 1995, VIROLOGY, V213, P655, DOI 10.1006/viro.1995.0037; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Fife KH, 1996, VIROLOGY, V226, P95, DOI 10.1006/viro.1996.0631; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOTTLIEB SL, 1994, INT J DERMATOL, V33, P453, DOI 10.1111/j.1365-4362.1994.tb02853.x; HAAKE AR, 1993, J INVEST DERMATOL, V101, P107, DOI 10.1111/1523-1747.ep12363594; Henseleit U, 1996, ARCH DERMATOL RES, V288, P676, DOI 10.1007/s004030050123; Hu SM, 1997, J BIOL CHEM, V272, P9621; Lee BJ, 1996, MOL CELLS, V6, P509; LOW CC, 1996, TRENDS BIOCHEM SCI, V21, P203; Manji GA, 1997, J VIROL, V71, P4509, DOI 10.1128/JVI.71.6.4509-4516.1997; Martin GW, 1996, RNA, V2, P171; MASSUNG RF, 1994, VIROLOGY, V201, P215, DOI 10.1006/viro.1994.1288; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; Porter C D, 1992, Mol Cell Biol Hum Dis Ser, V1, P233; Senkevich TG, 1997, VIROLOGY, V233, P19, DOI 10.1006/viro.1997.8607; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Walczak R, 1996, RNA, V2, P367; WARD GA, 1995, P NATL ACAD SCI USA, V92, P6773, DOI 10.1073/pnas.92.15.6773; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	30	127	134	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					102	105		10.1126/science.279.5347.102	http://dx.doi.org/10.1126/science.279.5347.102			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417017				2022-12-24	WOS:000071323900050
J	Middeldorp, S; Henkens, CMA; Koopman, MMW; van Pampus, ECM; Hamulyak, K; van der Meer, J; Prins, MH; Buller, HR				Middeldorp, S; Henkens, CMA; Koopman, MMW; van Pampus, ECM; Hamulyak, K; van der Meer, J; Prins, MH; Buller, HR			The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article						thrombophlebitis; thromboembolism; heterozygote; mutation; factor	ACTIVATED PROTEIN-C; DEEP-VEIN THROMBOSIS; COAGULATION-FACTOR-V; RESISTANCE; OUTPATIENTS; POPULATION; DEFICIENCY; PREGNANCY; THERAPY; WOMEN	Background: The factor V Leiden mutation is a genetic defect associated with an increased incidence of Venous thromboembolism. When the incidence of venous thromboembolism in relatives of patients known to have the mutation outweighs the disadvantages of prophylactic strategies, family screening may be necessary. Objective: To determine the incidence of venous thromboembolism in first-degree relatives of symptomatic carriers of the factor V Leiden mutation. Design: Retrospective blinded study. Setting: University hospitals. Participants: 437 first-degree relatives of 112 heterozygous propositi and 30 relatives of 6 homozygous propositi. Measurements: Before DNA testing, information on previous venous thromboembolism and concomitant risk factors was obtained. Relatives with and without the FV: Q(506) mutation were compared. Results: The annual incidence of thromboembolism in relatives of heterozygous propositi was 0.45% (95% CI, 0.28% to 0.61%) in those with the mutation and 0.10% (CI, 0.02% to 0.19%) in those without the mutation (relative risk, 4.2 [CI, 1.8 to 9.9]). Among carriers, the incidence increased from 0.25% (CI, 0.12% to 0.49%) in the 15- to 30-year-old age group to 1.1% (CI, 0.24% to 3.33%) in persons older than 60 years of age. Half of the episodes of Venous thromboembolism occurred spontaneously, 20% were related to surgery, and 30% were associated with pregnancy or use of oral contraceptives. Conclusions: The observed low annual risk for venous thromboembolism in persons carrying the factor V Leiden mutation does not seem to outweigh the risks for bleeding associated with coumarin prophylaxis or justify discouragement of the use of oral contraceptives. A general policy of screening the families of all patients with the factor V Leiden mutation does not seem to be indicated. The observations in this moderate-size, retrospective study need to be confirmed by prospective follow-up studies.	Univ Amsterdam, Acad Med Ctr, Ctr Haemostas Thrombos Atheroscl & Inflamm Res, NL-1105 AZ Amsterdam, Netherlands; Ziekenhuis Rivienland, Dept Intern Med, NL-4002 WP Tiel, Netherlands; Univ Hosp Maastricht, Dept Haematol, NL-6229 HX Maastricht, Netherlands; Univ Groningen Hosp, Dept Haematol, Div Haematostasis Thrombosis & Rheol, NL-9713 EZ Groningen, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Maastricht University; Maastricht University Medical Centre (MUMC); University of Groningen; University of Amsterdam; Academic Medical Center Amsterdam	Middeldorp, S (corresponding author), Univ Amsterdam, Acad Med Ctr, Ctr Haemostas Thrombos Atheroscl & Inflamm Res, F-4,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Middeldorp, Saskia/ABI-8197-2020	Middeldorp, Saskia/0000-0002-1006-6420				ALLAART CF, 1995, BRIT MED J, V311, P910; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BRIDEY F, 1995, THROMB HAEMOSTASIS, V74, P1382; Dahlback B, 1996, LANCET, V347, P1346, DOI 10.1016/S0140-6736(96)91004-1; Desmarais S, 1996, LANCET, V347, P1374, DOI 10.1016/S0140-6736(96)91013-2; Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257; Friederich PW, 1996, ANN INTERN MED, V125, P955, DOI 10.7326/0003-4819-125-12-199612150-00003; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; KIERKEGAARD A, 1983, ACTA OBSTET GYN SCAN, V62, P239, DOI 10.3109/00016348309155799; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LANDEFELD CS, 1989, AM J MED, V87, P144; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; ROSENDAAL FR, 1991, LANCET, V337, P260, DOI 10.1016/0140-6736(91)90867-O; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; Vandenbroucke JP, 1996, BRIT MED J, V313, P1127, DOI 10.1136/bmj.313.7065.1127; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4	21	183	185	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					15	+		10.7326/0003-4819-128-1-199801010-00003	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424976	Green Submitted			2022-12-24	WOS:000071158000003
J	Smith, GD; Frankel, S; Yarnell, J				Smith, GD; Frankel, S; Yarnell, J			Sex and death: are they related? Findings from the Caerphilly cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; MYOCARDIAL-INFARCTION; LAY EPIDEMIOLOGY; HEALTH-EDUCATION; MORTALITY; PREVENTION; WOMEN; RISK; MEN	Objective: To examine the relation between frequency of orgasm and mortality, Study design: Cohort study with a 10 year follow up. Setting: The town of Caerphilly, South Wales, and five adjacent villages. Subjects: 918 men aged 45-59 at time of recruitment between 1979 and 1983. Main outcome measures: All deaths and deaths from coronary heart disease. Result: Mortality risk was 50% lower in the group with high orgasmic frequency than in the group with low orgasmic frequency, with evidence of a dose-response relation across the groups. Age adjusted odds ratio for all cause mortality was 2.0 for the group with low frequency of orgasm (95% confidence interval 1.1 to 3.5, test for trend P = 0.02). With adjustment for risk factors this became 1.9 (1.0 to 3.4, test for trend P = 0.04). Death from coronary heart disease and from other causes showed similar associations with frequency of orgasm, although the gradient was most marked for deaths from coronary heart disease. Analysed in terms of actual frequency of orgasm, the odds ratio for total mortality associated with an increase in 100 orgasms per year was 0.64 (0.44 to 0.95). Conclusion: Sexual activity seems to have a protective effect on men's health.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT12 6BJ, Antrim, North Ireland	University of Bristol; Queens University Belfast	Smith, GD (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	zetkin@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; s, hema/0000-0002-3440-9475				ABRAMOV LA, 1976, PSYCHOSOM MED, V38, P418, DOI 10.1097/00006842-197611000-00006; ACKER K, 1984, BLOOD GUTS HIGH SCH; Alter JS, 1997, MED ANTHROPOL Q, V11, P275, DOI 10.1525/maq.1997.11.3.275; Butler SM, 1996, J GERONTOL B-PSYCHOL, V51, pS201, DOI 10.1093/geronb/51B.4.S201; COHEN KN, 1984, PALEOPATHOLOGY ORIGI; Cohen L., 1963, FAVOURITE GAME; DAVIDSON JM, 1983, J CLIN ENDOCR METAB, V57, P71, DOI 10.1210/jcem-57-1-71; DAVISON C, 1991, SOCIOL HEALTH ILL, V13, P1, DOI 10.1111/1467-9566.ep11340301; DEMING W, 1995, PAUL MARRIAGE CELIBA; DRORY Y, 1995, AM J CARDIOL, V75, P835, DOI 10.1016/S0002-9149(99)80425-1; EASTON EB, 1988, AM PSYCHO; Ebrahim S, 1997, BMJ-BRIT MED J, V314, P1666, DOI 10.1136/bmj.314.7095.1666; ELWOOD PC, 1984, J EPIDEMIOL COMMUN H, V38, P259, DOI 10.1136/jech.38.3.259; FRANKEL S, 1991, BRIT J GEN PRACT, V41, P428; Frankel Stephen, 1986, HULI RESPONSE ILLNES; FRASER I, 1984, BRIT MED J, V288, P242, DOI 10.1136/bmj.288.6412.242-b; GREER G, 1968, FEMALE EUNUCH; HAIRE N, 1924, REJUVENATION; Joyce James, 1916, PORTRAIT ARTIST YOUN; KAPLAN SD, 1988, PREV MED, V17, P335, DOI 10.1016/0091-7435(88)90008-4; Knekt P, 1996, BRIT MED J, V312, P478, DOI 10.1136/bmj.312.7029.478; LOCK S, 1983, BRIT MED J, V287, P1964, DOI 10.1136/bmj.287.6409.1964; Muller JE, 1996, JAMA-J AM MED ASSOC, V275, P1405, DOI 10.1001/jama.275.18.1405; NYYSSONEN K, 1997, BMJ-BRIT MED J, V314, P6348; PALMORE EB, 1982, GERONTOLOGIST, V22, P513, DOI 10.1093/geront/22.6.513; PERSSON G, 1981, ACTA PSYCHIAT SCAND, V64, P244, DOI 10.1111/j.1600-0447.1981.tb00780.x; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; PURDY J, 1961, COLOR DARKNESS; SCHUTTE H, 1975, INVEST UROL, V12, P330; *SCUM AUX, 1983, OBSC IND CLASS; SHARP I, 1997, LEAST 5 DAY STRATEGI; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SMITH GD, 1992, LANCET, V340, P709; Solanas Valerie, 1971, SCUM MANIFESTO; Whiteman MC, 1997, LANCET, V350, P541, DOI 10.1016/S0140-6736(96)03141-8; YARNELL JWG, 1993, ARTERIOSCLER THROMB, V13, P517, DOI 10.1161/01.ATV.13.4.517; YARNELL JWG, 1994, BRIT HEART J, V71, P293	37	112	116	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 20	1997	315	7123					1641	1644		10.1136/bmj.315.7123.1641	http://dx.doi.org/10.1136/bmj.315.7123.1641			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YN263	9448525	Green Published			2022-12-24	WOS:000071149400007
J	Sharp, D				Sharp, D			Half-way at Kyoto - but to where?	LANCET			English	Editorial Material																		Bouma MJ, 1997, LANCET, V350, P1435, DOI 10.1016/S0140-6736(97)04509-1; Broecker WS, 1997, SCIENCE, V278, P1582, DOI 10.1126/science.278.5343.1582	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1646	1646		10.1016/S0140-6736(05)64271-7	http://dx.doi.org/10.1016/S0140-6736(05)64271-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400506				2022-12-24	WOS:A1997YK21100006
J	Morris, AD; Boyle, DIR; McMahon, AD; Greene, SA; MacDonald, TM; Newton, RW				Morris, AD; Boyle, DIR; McMahon, AD; Greene, SA; MacDonald, TM; Newton, RW			Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus	LANCET			English	Article							COMPLICATIONS; BEHAVIORS	Background Intensive insulin treatment effectively delays the onset and slows the progression of microvascular complications in insulin-dependent diabetes mellitus (IDDM). Variable adherence to insulin treatment is thought to contribute to poor glycaemic control, diabetic ketoacidosis, and brittle diabetes in adolescents and young adults with IDDM. We assessed the association between the prescribed insulin dose and the amount dispensed from all community pharmacies with the Diabetes Audit and Research in Tayside Scotland (DARTS) database. Methods We studied 89 patients, mean age 16 (SD 7) years, diabetes duration 8 (4) years, and glycosylated haemoglobin (HbA(1c)) 8.4 (1.9)%, who attended a teaching hospital paediatric or young-adult diabetes clinic in 1993 and 1994. The medically recommended insulin dose and cumulative volume of insulin prescriptions supplied were used to calculate the days of maximum possible insulin coverage per annum, expressed as the adherence index. Associations between glycaemic control (HbA(1c)), episodes of diabetic ketoacidosis, and all hospital admissions for acute complications and the adherence index were modelled. Findings Insulin was prescribed at 48 (19) IU/day and mean insulin collected from pharmacies was 58 (25) IU/day. 25 (28%) of the 89 patients obtained less insulin than their prescribed dose (mean deficit 115 [68; range 9-246] insulin days/annum). There was a significant inverse association between HbA(1c) and the adherence index (R-2=0.39; p<0.001). In the top quartile (HbA(1c)>10%), 14 (64%) of individuals had an adherence index suggestive of a missed dose of insulin (mean deficit 55 insulin days/annum). There were 36 admissions for complications related to diabetes. The adherence index was inversely related to hospital admissions for diabetic ketoacidosis (p<0.001) and all hospital admissions related to acute diabetes complications (p=0.008). The deterioration in glycaemic control observed in patients aged 10-20 years was associated with a significant reduction (p=0.01) in the adherence index. Interpretation We found direct evidence of poor compliance with insulin therapy in young patients with IDDM. We suggest that poor adherence to insulin treatment is the major factor that contributes to long-term poor glycaemic control and diabetic ketoacidosis in this age group.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, CTR DIABET, DUNDEE DD1 9SY, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, MED MONITORING UNIT, DUNDEE DD1 9SY, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT CHILD HLTH, DUNDEE DD1 9SY, SCOTLAND	University of Dundee; University of Dundee; University of Dundee	Morris, AD (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT MED, DUNDEE DD1 9SY, SCOTLAND.		Morris, Andrew D/C-2837-2009; McMahon, Alex D/C-4304-2008; Boyle, Douglas/B-9193-2017	Boyle, Douglas/0000-0002-4779-7083; MacDonald, Thomas/0000-0001-5189-6669	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Acerini CL, 1997, LANCET, V350, P1199, DOI 10.1016/S0140-6736(97)06467-2; BEARDON PHG, 1988, PHARM MED, V3, P185; CERKONEY KAB, 1980, DIABETES CARE, V3, P594, DOI 10.2337/diacare.3.5.594; CONOVER WJ, 1982, BIOMETRICS, V38, P715, DOI 10.2307/2530051; DeFronzo RA, 1994, DIABETES REV, V2, P209; DUNGER DB, 1995, PRACTICAL DIABETES I, V12, P63, DOI [10.1002/pdi.1960120205, DOI 10.1002/PDI.1960120205]; GILL GV, 1985, DIABETOLOGIA, V28, P579, DOI 10.1007/BF00281992; Gill GV, 1996, QJM-MON J ASSOC PHYS, V89, P839, DOI 10.1093/qjmed/89.11.839; GILL GV, 1991, BRIT MED J, V303, P285, DOI 10.1136/bmj.303.6797.285; GLASGOW RE, 1987, J CHRON DIS, V40, P399, DOI 10.1016/0021-9681(87)90173-1; Kurtz S M, 1990, Diabetes Educ, V16, P50, DOI 10.1177/014572179001600112; LEESE GP, 1992, DIABETIC MED, V9, P459, DOI 10.1111/j.1464-5491.1992.tb01817.x; MACDONALD TM, 1994, PHARMACOEPIDEM DR S, P245; McNabb WL, 1997, DIABETES CARE, V20, P215, DOI 10.2337/diacare.20.2.215; Morris AD, 1997, BMJ-BRIT MED J, V315, P524, DOI 10.1136/bmj.315.7107.524; POLONSKY WH, 1994, DIABETES CARE, V17, P1178, DOI 10.2337/diacare.17.10.1178; Pound N, 1996, DIABETIC MED, V13, P510, DOI 10.1002/(SICI)1096-9136(199606)13:6<510::AID-DIA122>3.0.CO;2-W; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; RODIN GM, 1986, INT J PSYCHIAT MED, V16, P49, DOI 10.2190/HULH-CTPR-4V17-383C; Rydall AC, 1997, NEW ENGL J MED, V336, P1849, DOI 10.1056/NEJM199706263362601; SCHAFER LC, 1986, DIABETES CARE, V9, P179, DOI 10.2337/diacare.9.2.179; SCOBIE IN, 1981, LANCET, V2, P521; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STEEL JM, 1994, LANCET, V344, P765, DOI 10.1016/S0140-6736(94)92333-7; THOMPSON CJ, 1995, DIABETIC MED, V12, P429, DOI 10.1111/j.1464-5491.1995.tb00508.x; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y	26	364	366	0	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1505	1510		10.1016/S0140-6736(97)06234-X	http://dx.doi.org/10.1016/S0140-6736(97)06234-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388398				2022-12-24	WOS:A1997YH11500009
J	RichEdwards, JW; Gillman, MW				RichEdwards, JW; Gillman, MW			A hypothesis challenged - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material							CORONARY HEART-DISEASE; BIRTH-WEIGHT; BREAST-CANCER; RISK		HARVARD PILGRIM CARE,BOSTON,MA 02215	Harvard Pilgrim Health Care	RichEdwards, JW (corresponding author), HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,126 BROOKLINE AVE,SUITE 200,BOSTON,MA 02215, USA.							ANTONOV AN, 1947, J PEDIATR, V30, P250, DOI 10.1016/S0022-3476(47)80160-X; Barker D. J. P., 1994, MOTHERS BABIES DIS L; Curhan GC, 1996, CIRCULATION, V94, P1310, DOI 10.1161/01.CIR.94.6.1310; Curhan GC, 1996, CIRCULATION, V94, P3246, DOI 10.1161/01.CIR.94.12.3246; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; Frankel S, 1996, LANCET, V348, P1478, DOI 10.1016/S0140-6736(96)03482-4; MCCANCE DR, 1994, BRIT MED J, V308, P945; Michels KB, 1996, LANCET, V348, P1542, DOI 10.1016/S0140-6736(96)03102-9; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; Rich-Edwards J. W., 1996, American Journal of Epidemiology, V143, pS39; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; Sanderson M, 1996, EPIDEMIOLOGY, V7, P34, DOI 10.1097/00001648-199601000-00007; SWERDLOW AJ, 1987, BRIT J CANCER, V55, P571, DOI 10.1038/bjc.1987.116; Trichopoulos D, 1990, Epidemiology, V1, P95; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157	15	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 22	1997	315	7119					1348	1349		10.1136/bmj.315.7119.1348	http://dx.doi.org/10.1136/bmj.315.7119.1348			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402776	Green Published			2022-12-24	WOS:A1997YJ21800023
J	Schuchat, A; Robinson, K; Wenger, JD; Harrison, LH; Farley, M; Reingold, AL; Lefkowitz, L; Perkins, BA				Schuchat, A; Robinson, K; Wenger, JD; Harrison, LH; Farley, M; Reingold, AL; Lefkowitz, L; Perkins, BA			Bacterial meningitis in the United States in 1995	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFLUENZAE TYPE-B; HAEMOPHILUS-INFLUENZAE; CONJUGATE VACCINE; HEMOPHILUS-INFLUENZAE; ANTIMICROBIAL RESISTANCE; MENINGOCOCCAL-DISEASE; RISK-FACTORS; CHILDREN; POLYSACCHARIDE; EMERGENCE	Background Before the introduction of the conjugate vaccines, Haemophilus influenzae type b was the major cause of bacterial meningitis in the United States, and meningitis was primarily a disease of infants and young children. We describe the epidemiologic features of bacterial meningitis five years after the H. influenzae type b conjugate vaccines were licensed for routine immunization of infants. Methods Data were collected from active, population-based surveillance for culture-confirmed meningitis and other invasive bacterial disease during 1995 in laboratories serving all the acute care hospitals in 22 counties of four states (total population, more than 10 million). The rates were compared with those for 1986 obtained by similar surveillance. Results On the basis of 248 cases of bacterial meningitis in the surveillance areas, the rates of meningitis (per 100,000) for the major pathogens in 1995 were Streptococcus pneumoniae, 1.1; Neisseria meningitidis, 0.6; group B streptococcus, 0.3; Listeria monocytogenes, 0.2; and H. influenzae, 0.2. Group B streptococcus was the predominant pathogen among newborns, N. meningitidis among children 2 to 18 years old, and S. pneumoniae among adults. Pneumococcal meningitis had the highest case fatality rate (21 percent) and in 36 percent of cases was caused by organisms that were not susceptible to penicillin. From these data, we estimate that 5755 cases of bacterial meningitis were caused by these five pathogens in the United States in 1995, as compared with 12,920 cases in 1986, a reduction of 55 percent. The median age of persons with bacterial meningitis increased greatly, from 15 months in 1986 to 25 years in 1995, largely as a result of a 94 percent reduction in the number of cases of ii. influenzae meningitis. Conclusions Because of the vaccine-related decline in meningitis due to H. influenzae type b, bacterial meningitis in the United Slates is now a disease predominantly of adults rather than of infants and young children. (C) 1997, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, SPECIAL PATHOGENS BRANCH, ATLANTA, GA 30333 USA; JOHNS HOPKINS SCH HYG & PUBL HLTH, BALTIMORE, MD USA; VET AFFAIRS MED CTR, ATLANTA, GA 30033 USA; EMORY UNIV, SCH MED, ATLANTA, GA USA; CALIF EMERGING INFECT PROGRAM, BERKELEY, CA USA; VANDERBILT UNIV, MED CTR, NASHVILLE, TN USA	Centers for Disease Control & Prevention - USA; Johns Hopkins University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Emory University; California Emerging Infections Program; Vanderbilt University	Schuchat, A (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, RESP DIS BRANCH, ATLANTA, GA 30333 USA.							ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S; Blumberg HM, 1996, J INFECT DIS, V173, P365, DOI 10.1093/infdis/173.2.365; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; COCHI SL, 1985, JAMA-J AM MED ASSOC, V253, P521, DOI 10.1001/jama.253.4.521; *COMM OBST PRACT, 1996, 173 ACOG COMM OBST P; DEMORAES C, 1992, LANCET, V340, P1554; DEMORAES JC, 1992, LANCET, V340, P1074; DOERN GV, 1986, DIAGN MICR INFEC DIS, V4, P95, DOI 10.1016/0732-8893(86)90143-4; FRASCH CE, 1989, CLIN MICROBIOL REV, V2, pS134, DOI 10.1128/CMR.2.Suppl.S134-S138.1989; FRASER DW, 1975, AM J EPIDEMIOL, V102, P394, DOI 10.1093/oxfordjournals.aje.a112178; FRASER DW, 1974, AM J EPIDEMIOL, V100, P29, DOI 10.1093/oxfordjournals.aje.a112005; FRASER DW, 1973, J INFECT DIS, V127, P271, DOI 10.1093/infdis/127.3.271; GOTSCHLICH EC, 1969, J EXP MED, V129, P1349, DOI 10.1084/jem.129.6.1349; Halsey NA, 1997, PEDIATRICS, V99, P489, DOI 10.1542/peds.99.3.489; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; JONSDOTTIR KE, 1992, LANCET, V340, P252, DOI 10.1016/0140-6736(92)90529-C; JORGENSEN JH, 1990, ANTIMICROB AGENTS CH, V34, P2075, DOI 10.1128/AAC.34.11.2075; Kaspar DL, 1996, J CLIN INVEST, V98, P2308, DOI 10.1172/JCI119042; MACLEOD CM, 1945, J EXP MED, V82, P445, DOI 10.1084/jem.82.6.445; MOHLEBOETANI JC, 1993, PEDIATR INFECT DIS J, V12, P589, DOI 10.1097/00006454-199307000-00009; MURPHY TV, 1993, J PEDIATR-US, V122, P517, DOI 10.1016/S0022-3476(05)83529-2; NCCLS, 1997, METH DIL ANT SUSC TE; Quagliarello VJ, 1997, NEW ENGL J MED, V336, P708, DOI 10.1056/NEJM199703063361007; RODRIGUES LP, 1971, J IMMUNOL, V107, P1071; Scheifele DW, 1996, CAN MED ASSOC J, V154, P1041; Scheifele DW, 1996, CAN MED ASSOC J, V154, P1319; SCHOENDORF KC, 1994, PEDIATRICS, V93, P663; SCHUCHAT A, 1992, JAMA-J AM MED ASSOC, V267, P2041, DOI 10.1001/jama.267.15.2041; SIERRA G V G, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P195; TAKALA AK, 1994, LARYNGOSCOPE, V104, P731; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982; TAPPERO JW, 1995, JAMA-J AM MED ASSOC, V273, P1118, DOI 10.1001/jama.273.14.1118; WARD J, 1994, VACCINES, P337; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WHALEN CM, 1995, JAMA-J AM MED ASSOC, V273, P390, DOI 10.1001/jama.273.5.390; 1996, MMWR-MORBID MORTAL W, V45, P853; 1996, MMWR-MORBID MORTAL W, V45, P1010	41	838	892	1	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 2	1997	337	14					970	976		10.1056/NEJM199710023371404	http://dx.doi.org/10.1056/NEJM199710023371404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY423	9395430	Bronze			2022-12-24	WOS:A1997XY42300004
J	Beitel, A				Beitel, A			A moment of clarity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	1998	279	4					256	256		10.1001/jama.279.4.256	http://dx.doi.org/10.1001/jama.279.4.256			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT472	9450692				2022-12-24	WOS:000071607000001
J	Jones, SM; Howell, KE; Henley, JR; Cao, H; McNiven, MA				Jones, SM; Howell, KE; Henley, JR; Cao, H; McNiven, MA			Role of dynamin in the formation of transport vesicles from the trans-Golgi network	SCIENCE			English	Article							TEMPERATURE-SENSITIVE MUTANT; GTP-BINDING PROTEINS; DROSOPHILA-MELANOGASTER; REVERSIBLE BLOCKAGE; MEMBRANE RETRIEVAL; ENDOCYTOSIS; SHIBIRE; MUTATIONS; FAMILY; FORMS	Dynamin guanosine triphosphatases support the scission of clathrin-coated vesicles from the plasmalemma during endocytosis. By fluorescence microscopy of cultured rat hepatocytes, a green fluorescent protein-dynamin II fusion protein localized with clathrin-coated vesicles at the Golgi complex. A cell-free assay was utilized to demonstrate the role of dynamin in vesicle formation at the trans-Golgi. Addition of peptide-specific anti-dynamin antibodies to the assay mixture inhibited both constitutive exocytic and clathrin-coated vesicle formation. Immunodepletion of dynamin proteins also inhibited vesicle formation, and budding efficiency was restored upon readdition of purified dynamin. These data suggest that dynamin participates in the formation of distinct transport vesicles from the trans-Golgi network.	Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Univ Colorado, Sch Med, Dept Cellular & Struct Biol, Denver, CO 80262 USA	Mayo Clinic; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	McNiven, MA (corresponding author), Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, 200 1st St SW, Rochester, MN 55905 USA.		Henley, John/D-7171-2011		NCI NIH HHS [P30 CA-46934] Funding Source: Medline; NIDDK NIH HHS [P30 DK-34914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAO H, UNPUB; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Cook T, 1996, J NEUROCHEM, V67, P927; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; GRIGLIATTI TA, 1973, MOL GEN GENET, V120, P107, DOI 10.1007/BF00267238; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; HENLEY JR, IN PRESS J CELL BIOL; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; JONES M, 1997, J CELL BIOL, V139, P339; JONES SM, 1997, CELL BIOL LAB HDB, V2, P12; JONES SM, UNPUB; KELLY RB, 1995, NATURE, V374, P116, DOI 10.1038/374116a0; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; Maier O, 1996, BIOCHEM BIOPH RES CO, V223, P229, DOI 10.1006/bbrc.1996.0876; NAKATA T, 1993, J CELL SCI, V105, P1; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; POODRY CA, 1990, DEV BIOL, V138, P464, DOI 10.1016/0012-1606(90)90212-2; Roos J, 1997, TRENDS CELL BIOL, V7, P257, DOI 10.1016/S0962-8924(97)01068-4; SALAMERO J, 1990, P NATL ACAD SCI USA, V87, P7717, DOI 10.1073/pnas.87.19.7717; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; SZTUL ES, 1985, J CELL BIOL, V100, P1255, DOI 10.1083/jcb.100.4.1255; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Taylor RS, 1997, MOL BIOL CELL, V8, P1911, DOI 10.1091/mbc.8.10.1911; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553	31	264	266	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					573	577		10.1126/science.279.5350.573	http://dx.doi.org/10.1126/science.279.5350.573			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438853				2022-12-24	WOS:000071616000050
J	Carr, MH; Belton, MJS; Chapman, CR; Davies, AS; Geissler, P; Greenberg, R; McEwen, AS; Tufts, BR; Greeley, R; Sullivan, R; Head, JW; Pappalardo, RT; Klaasen, KP; Johnson, TV; Kaufman, J; Senske, D; Moore, J; Neukum, G; Schubert, G; Burns, JA; Thomas, P; Veverka, J				Carr, MH; Belton, MJS; Chapman, CR; Davies, AS; Geissler, P; Greenberg, R; McEwen, AS; Tufts, BR; Greeley, R; Sullivan, R; Head, JW; Pappalardo, RT; Klaasen, KP; Johnson, TV; Kaufman, J; Senske, D; Moore, J; Neukum, G; Schubert, G; Burns, JA; Thomas, P; Veverka, J			Evidence for a subsurface ocean on Europa	NATURE			English	Article							GALILEAN SATELLITES; ICE SHELL	Ground-based spectroscopy of Jupiter's moon Europa, combined with gravity data, suggests that the satellite has an icy crust roughly 150 km thick and a rocky interior(1-4). In addition, images obtained by the voyager spacecraft revealed that Europa's surface is crossed by numerous intersecting ridges and dark bands (called lineae) and is sparsely cratered, indicating that the terrain is probably significantly younger than that of Ganymede and Callisto(5). It has been suggested that Europa's thin outer ice shell might be separated from the moon's silicate interior by a liquid water layer, delayed or prevented from freezing by tidal heating(6-10); in this model, the lineae could be explained by repetitive tidal deformation of the outer ice shell(11-13). However, observational confirmation of a subsurface ocean was largely frustrated by the low resolution (>2 km per pixel) of the Voyager images(14). Here we present high-resolution (54 m per pixel) Galileo spacecraft images of Europa, in which we find evidence for mobile 'icebergs'. The detailed morphology of the terrain strongly supports the presence of liquid water at shallow depths below the surface, either today or at some time in the past. Moreover, lower-resolution observations of much larger regions suggest that the phenomena reported here are widespread.	US Geol Survey, Menlo Pk, CA 94025 USA; Natl Opt Astron Observ, Tucson, AZ 85719 USA; SW Res Inst, Boulder, CO 80302 USA; Rand Corp, Santa Monica, CA 90406 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; Cornell Univ, Ithaca, NY 14853 USA; Brown Univ, Dept Geol, Providence, RI 02912 USA; Jet Prop Lab, Pasadena, CA 91909 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; DLR, Inst Planetenerkundung, D-12489 Berlin, Germany; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA	United States Department of the Interior; United States Geological Survey; National Optical Astronomy Observatory; RAND Corporation; University of Arizona; Arizona State University; Arizona State University-Tempe; Cornell University; Brown University; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Helmholtz Association; German Aerospace Centre (DLR); University of California System; University of California Los Angeles	Carr, MH (corresponding author), US Geol Survey, 345 Middlefield Rd, Menlo Pk, CA 94025 USA.	carr@astmnl.wr.usgs.gov	Pappalardo, Robert/AAP-8953-2021; Sullivan, Robert/AAR-8193-2020	Pappalardo, Robert/0000-0003-2571-4627; 				Anderson JD, 1997, SCIENCE, V276, P1236, DOI 10.1126/science.276.5316.1236; CASSEN P, 1980, GEOPHYS RES LETT, V7, P987, DOI 10.1029/GL007i011p00987; CASSEN P, 1979, GEOPHYS RES LETT, V6, P731, DOI 10.1029/GL006i009p00731; CHAPMAN C, 1997, LUNAR PLANET SCI C, V28, P217; GREELEY R, UNPUB; GREENBERG R, 1984, ICARUS, V58, P186, DOI 10.1016/0019-1035(84)90038-1; HELFENSTEIN P, 1985, ICARUS, V61, P175, DOI 10.1016/0019-1035(85)90099-5; KUIPER GP, 1961, PLANETS SATELLITES; Lucchitta B.K., 1982, SATELLITES JUPITER, P521; MCEWEN AS, 1986, NATURE, V321, P49, DOI 10.1038/321049a0; MOROZ VI, OSV ASTRON A J, V9, P999; MORRISON D, 1974, SPACE SCI REV, V15, P641, DOI 10.1007/BF00175241; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; Pappalardo R. T, 1996, P EUR OC C, P59; Pappalardo RT, 1996, ICARUS, V123, P557, DOI 10.1006/icar.1996.0178; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; PAPPALARDO RT, 1996, LUNAR PLANET SCI C, V27, P997; ROSS M, 1986, NATURE, V325, P13; SCHENK PM, 1989, ICARUS, V79, P75, DOI 10.1016/0019-1035(89)90109-7; SHOEMAKER EM, 1996, P EUR OC C, P65; SMITH BA, 1979, SCIENCE, V206, P927, DOI 10.1126/science.206.4421.927; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; SULLIVAN R, 1997, LUNAR PLANET SCI, V28, P1395; TUFTS RB, 1997, LUNAR PLANET SCI C, V28, P1455	24	378	386	1	162	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					363	365		10.1038/34857	http://dx.doi.org/10.1038/34857			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450749				2022-12-24	WOS:000071604200045
J	Cheng, EHY; Kirsch, DG; Clem, RJ; Ravi, R; Kastan, MB; Bedi, A; Ueno, K; Hardwick, JM				Cheng, EHY; Kirsch, DG; Clem, RJ; Ravi, R; Kastan, MB; Bedi, A; Ueno, K; Hardwick, JM			Conversion of Bcl-2 to a Bax-like death effector by caspases	SCIENCE			English	Article							CELL-DEATH; CONSERVED DOMAINS; APOPTOSIS; BCL-X(L); PROTEASE; DISTINCT; HETERODIMERIZATION; MODULATION; PATHWAYS; FODRIN	Caspases are a family of cysteine proteases implicated in the biochemical and morphological changes that occur during apoptosis (programmed cell death). The loop domain of Bcl-2 is cleaved at Asp(34) by caspase-3 (CPP32) in vitro, in cells overexpressing caspase-3, and after induction of apoptosis by Fas ligation and interleukin-3 withdrawal. The carboxyl-terminal Bcl-2 cleavage product triggered cell death and accelerated Sindbis virus-induced apoptosis, which was dependent on the BH3 homology and transmembrane domains of Bcl-2, Inhibitor studies indicated that cleavage of Bcl-2 may further activate downstream caspases and contribute to amplification of the caspase cascade. Cleavage-resistant mutants of Bcl-2 had increased protection from interleukin-3 withdrawal and Sindbis virus-induced apoptosis. Thus, cleavage of Bcl-2 by caspases may ensure the inevitability of cell death.	JOHNS HOPKINS SCH PUBL HLTH,DEPT MOL MICROBIOL & IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21205; KAGOSHIMA UNIV,FAC MED,KAGOSHIMA 890,JAPAN	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Kagoshima University				Clem, Rollie/0000-0002-2368-720X				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Haldar S, 1996, CANCER RES, V56, P1253; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hardwick J M, 1997, Adv Pharmacol, V41, P295, DOI 10.1016/S1054-3589(08)61063-7; HARDWICK JP, UNPUB; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; HUTNER JJ, 1996, MOL CELL BIOL, V16, P877; Irmler M, 1997, FEBS LETT, V406, P189, DOI 10.1016/S0014-5793(97)00271-8; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LEWIS LN, UNPUB; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Middleton G, 1996, DEVELOPMENT, V122, P695; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126	46	935	1041	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1966	1968		10.1126/science.278.5345.1966	http://dx.doi.org/10.1126/science.278.5345.1966			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395403				2022-12-24	WOS:A1997YL00200041
J	Keitel, T; Kramer, A; Wessner, H; Scholz, C; SchneiderMergener, J; Hohne, W				Keitel, T; Kramer, A; Wessner, H; Scholz, C; SchneiderMergener, J; Hohne, W			Crystallographic analysis of anti-p24 (HIV-1) monoclonal antibody cross-reactivity and polyspecificity	CELL			English	Article							ELECTRON-DENSITY MAPS; 3-DIMENSIONAL STRUCTURE; CAPSID PROTEIN; ANTIGEN INTERACTIONS; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; COMPLEX; BINDING; REARRANGEMENTS; CONFORMATIONS	The X-ray crystal structures of an anti-p24 (HIV-1) monoclonal antibody Fab fragment alone and in complexes with the epitope peptide GATPQDLNTnL (n = norleucine), an epitope-homologous peptide GATPED LNQKLAGN, as well as two unrelated peptides GLYEW GGARITNTD and efslkGpIIqwrsG (D-peptide), are presented to a maximum resolution of 2.6 Angstrom. The latter three peptides were identified from screening synthetic combinatorial peptide libraries. Although all peptides bind to the same antigen combining site, the nonhomologous peptides adopt different binding conformations and also form their critical contacts with different antibody residues. Only small readjustments are observed within the framework of the Fab fragment upon binding.	HUMBOLDT UNIV BERLIN, KLINIKUM CHARITE, INST BIOCHEM, D-10098 BERLIN, GERMANY; HUMBOLDT UNIV BERLIN, KLINIKUM CHARITE, INST MED IMMUNOL, D-10098 BERLIN, GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin				Kramer, Achim/0000-0001-9671-6078				ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; Abu-Shakra Mahmoud, 1996, P408, DOI 10.1016/B978-044482383-0/50063-7; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1992, X PLOR VERSION 3 0 S; Chacko S, 1996, PROTEINS, V26, P55, DOI 10.1002/(SICI)1097-0134(199609)26:1<55::AID-PROT5>3.0.CO;2-F; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; *COLL COMP PROJ NU, 1994, CCP4 SUIT PROGR PROT; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; Ehrhard B, 1996, BIOCHEMISTRY-US, V35, P9097, DOI 10.1021/bi9603534; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; GELIN BR, 1979, BIOCHEMISTRY-US, V18, P1256, DOI 10.1021/bi00574a022; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; Glaser RW, 1996, J IMMUNOL METHODS, V189, P1, DOI 10.1016/0022-1759(95)00221-9; GRUNOW R, 1990, Z KLIN MED, V45, P367; Hohne W E, 1993, Mol Immunol, V30, P1213, DOI 10.1016/0161-5890(93)90140-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE A, 1990, CRYSTALLOGRAPHIC COM, P110; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Padlan EA, 1996, ADV PROTEIN CHEM, V49, P57, DOI 10.1016/S0065-3233(08)60488-X; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; Rullmann J, 1996, AQUA COMPUTER PROGRA; SCHNEIDERMERGEN.J, 1996, COMBINATORIAL LIB, P53; SCHULZEGAHMEN U, 1993, J MOL BIOL, V234, P1098, DOI 10.1006/jmbi.1993.1663; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; Shirai H, 1996, FEBS LETT, V399, P1, DOI 10.1016/S0014-5793(96)01252-5; SHOHAM M, 1993, J MOL BIOL, V232, P1169, DOI 10.1006/jmbi.1993.1469; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; TORMO J, 1994, EMBO J, V13, P2247, DOI 10.1002/j.1460-2075.1994.tb06506.x; Wade H, 1997, ANNU REV BIOPH BIOM, V26, P461, DOI 10.1146/annurev.biophys.26.1.461; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WINKLER K, 1996, THESIS HUMBOLDT U BE	49	106	115	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 12	1997	91	6					811	820		10.1016/S0092-8674(00)80469-9	http://dx.doi.org/10.1016/S0092-8674(00)80469-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413990	Bronze			2022-12-24	WOS:A1997YL43900012
J	Lobel, HO; Kozarsky, PE				Lobel, HO; Kozarsky, PE			Update on prevention of malaria for travelers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT PLASMODIUM-VIVAX; MEFLOQUINE PROPHYLAXIS; FALCIPARUM-MALARIA; UNITED-STATES; ANTIMALARIAL-DRUGS; CHLOROQUINE; CHEMOPROPHYLAXIS; PREGNANCY; DOXYCYCLINE; REGIMENS	Individuals from industrialized nations frequently travel to countries with malaria, so health care providers need to be familiar with current recommendations for prevention of malaria, Changes in drug susceptibility of malaria parasites and evolving knowledge of how well drugs are tolerated necessitate periodic review of guidelines for prophylaxis of malaria, especially of chloroquine-resistant Plasmodium falciparum malaria, Mefloquine is the drug of choice for chemoprophylaxis for most travelers, with doxycycline and chloroquine being less effective alternatives. Mefloquine is well tolerated at prophylactic dosages, but anecdotal reports have raised concerns about its adverse effects, Resistance to this drug has emerged in parts of Southeast Asia and may spread to other regions of the world, The major disadvantages of doxycycline are the need for daily dosing, its contraindication for young children and pregnant women. and its adverse effects, Chloroquine is effective for prophylaxis only in Central America, the Caribbean, and parts of the Middle East. Few new drugs will be available in the near future because of reduced funding for antimalarial drug research and development; therefore, the usefulness of currently available drugs needs to be prolonged by rational use. Increased efforts should be made to ensure that alternative drugs will be available for prevention of malaria.	EMORY UNIV, SCH MED, DEPT MED, ATLANTA, GA 30322 USA	Emory University	Lobel, HO (corresponding author), CTR DIS CONTROL & PREVENT, MALARIA SECT, EPIDEMIOL BRANCH, DIV PARASIT DIS, NATL CTR INFECT DIS, ATLANTA, GA 30333 USA.							ARTHUR JD, 1990, LANCET, V335, P972, DOI 10.1016/0140-6736(90)91035-9; ARTHUR JD, 1990, AM J TROP MED HYG, V43, P608, DOI 10.4269/ajtmh.1990.43.608; BALOCCO R, 1992, LANCET, V340, P309, DOI 10.1016/0140-6736(92)92403-3; Barrett PJ, 1996, BRIT MED J, V313, P525, DOI 10.1136/bmj.313.7056.525; BEHRENS RH, 1993, BRIT MED BULL, V49, P363, DOI 10.1093/oxfordjournals.bmb.a072615; BERNARD KW, 1982, JAMA-J AM MED ASSOC, V248, P3136, DOI 10.1001/jama.248.23.3136; BOUDREAU E, 1993, TROP MED PARASITOL, V44, P257; BRASSEUR P, 1992, AM J TROP MED HYG, V46, P8, DOI 10.4269/ajtmh.1992.46.8; BRUCECHWATT LJ, 1950, BMJ-BRIT MED J, V2, P7, DOI 10.1136/bmj.2.4669.7; Buma APCCH, 1996, J INFECT DIS, V173, P1506, DOI 10.1093/infdis/173.6.1506; *CDCP, 1997, HLTH INF INT TRAV 19; Choo V, 1996, LANCET, V347, P891, DOI 10.1016/S0140-6736(96)91362-8; Collins WE, 1996, AM J TROP MED HYG, V55, P243, DOI 10.4269/ajtmh.1996.55.243; COOK GC, 1995, BRIT MED J, V311, P190, DOI 10.1136/bmj.311.6998.190b; CREAGH TH, 1992, NATO ADV SCI I A-LIF, V224, P53; Croft AMJ, 1996, LANCET, V347, P326, DOI 10.1016/S0140-6736(96)90500-0; Croft AMJ, 1997, T ROY SOC TROP MED H, V91, P199, DOI 10.1016/S0035-9203(97)90223-6; Davis TME, 1996, BRIT J CLIN PHARMACO, V42, P415, DOI 10.1111/j.1365-2125.1996.tb00003.x; DELANEY TJ, 1974, ACTA DERM-VENEREOL, V54, P487; FISH DR, 1988, BRIT MED J, V297, P526, DOI 10.1136/bmj.297.6647.526; GREENBERG AE, 1990, ANN INTERN MED, V113, P326, DOI 10.7326/0003-4819-113-4-326; HAUSER WA, 1983, EPILEPSY, P267; HELD TK, 1994, Q J MED, V87, P17; HOFFMAN SL, 1992, MED CLIN N AM, V76, P1327, DOI 10.1016/S0025-7125(16)30290-5; Huzly, 1996, J Travel Med, V3, P148, DOI 10.1111/j.1708-8305.1996.tb00729.x; Jaspers CAJJ, 1996, AM J TROP MED HYG, V55, P230, DOI 10.4269/ajtmh.1996.55.230; Keystone, 1994, J Travel Med, V1, P72, DOI 10.1111/j.1708-8305.1994.tb00566.x; LAMPE AS, 1994, EUR J CLIN MICROBIOL, V13, P332; Lobel H. O., 1986, Clinics in Tropical Medicine and Communicable Diseases, V1, P225; LOBEL HO, 1990, B WORLD HEALTH ORGAN, V68, P209; LOBEL HO, 1993, LANCET, V341, P848, DOI 10.1016/0140-6736(93)93058-9; LOBEL HO, IN PRESS AM J TROP M; LOBEL HO, 1993, 42 ANN M AM SOC TROP; LOVESTONE S, 1991, BRIT J PSYCHIAT, V159, P164, DOI 10.1192/bjp.159.1.164b; Luxemburger C, 1996, ANN TROP PAEDIATR, V16, P281, DOI 10.1080/02724936.1996.11747839; MACPHERSON D, 1997, 5 INT C TRAV MED MAR, P220; NOSTEN F, 1994, J INFECT DIS, V169, P595, DOI 10.1093/infdis/169.3.595; Ohrt C, 1997, ANN INTERN MED, V126, P963, DOI 10.7326/0003-4819-126-12-199706150-00006; PANG LW, 1987, LANCET, V1, P1161; PENNIE RA, 1993, T ROY SOC TROP MED H, V87, P459, DOI 10.1016/0035-9203(93)90036-P; PERAGALLO MS, 1997, 5 INT C TRAV MED MAR; PhillipsHoward PA, 1996, DRUG SAFETY, V14, P131, DOI 10.2165/00002018-199614030-00001; Regier Darrel, 1995, P135; Schlagenhauf P, 1997, AM J TROP MED HYG, V56, P235, DOI 10.4269/ajtmh.1997.56.235; SCHUURKAMP GJ, 1992, T ROY SOC TROP MED H, V86, P121, DOI 10.1016/0035-9203(92)90531-G; SCHWARTZ IK, 1991, NEW ENGL J MED, V324, P927; Shanks, 1994, J Travel Med, V1, P40, DOI 10.1111/j.1708-8305.1994.tb00554.x; SHANKS GD, 1994, MIL MED, V159, P275, DOI 10.1093/milmed/159.4.275; SINGHARAJ P, 1987, R THAI ARMY MED J, V40, P165; Smoak BL, 1997, J INFECT DIS, V176, P831, DOI 10.1086/517315; STEFFEN R, 1993, LANCET, V341, P1299, DOI 10.1016/0140-6736(93)90814-W; Steketee RW, 1996, AM J TROP MED HYG, V55, P50, DOI 10.4269/ajtmh.1996.55.50; Takeshima S., 1994, Japanese Journal of Tropical Medicine and Hygiene, V22, P185; THAN M, 1995, T R SOC TROP MED HYG, V89, P307; TSAI TF, 1992, SEMIN PEDIAT INFECT, V3, P62; VANHAUWERE B, IN PRESS AM J TROP M; Vuurman EFPM, 1996, EUR J CLIN PHARMACOL, V50, P475, DOI 10.1007/s002280050144; Wallace MR, 1996, AM J MED, V100, P49, DOI 10.1016/S0002-9343(96)90011-X; WATANASOOK C, 1989, Southeast Asian Journal of Tropical Medicine and Public Health, V20, P61; *WHO, 1997, INT TRAVEL HLTH VACC; Winstanley P, 1996, BRIT J CLIN PHARMACO, V42, P411, DOI 10.1111/j.1365-2125.1996.tb00002.x; WYLER DJ, 1993, NEW ENGL J MED, V329, P31, DOI 10.1056/NEJM199307013290107; 1988, LANCET, V2, P610	63	62	63	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1767	1771		10.1001/jama.278.21.1767	http://dx.doi.org/10.1001/jama.278.21.1767			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388154				2022-12-24	WOS:A1997YH98700032
J	Nichol, G; Walls, R; Goldman, L; Pearson, S; Hartley, LH; Antman, E; Stockman, M; Teich, JM; Cannon, CP; Johnson, PA; Kuntz, KM; Lee, TH				Nichol, G; Walls, R; Goldman, L; Pearson, S; Hartley, LH; Antman, E; Stockman, M; Teich, JM; Cannon, CP; Johnson, PA; Kuntz, KM; Lee, TH			A critical pathway for management of patients with acute chest pain who are at low risk for myocardial ischemia: Recommendations and potential impact	ANNALS OF INTERNAL MEDICINE			English	Article							CONTROLLED INTERVENTIONAL TRIAL; CORONARY-ARTERY DISEASE; CREATINE-KINASE MB; PRACTICE GUIDELINES; EMERGENCY ROOM; PREDICTIVE INSTRUMENT; MEDICAL-PRACTICE; OPINION LEADERS; EXERCISE TEST; INFARCTION	Background: Use of resources for patients with acute chest pain may be improved with clinical strategies that integrate research, Bayesian analysis, and expert opinion, Objectives: To 1) develop a critical pathway for management of patients with acute chest pain who are at low risk for complications of ischemic heart disease and 2) assess the potential effects of implementation of the pathway on patient safety and resource use. Design: Evidence-based consensus and prospective cohort study. Setting: Urban teaching hospital. Patients: Patients at least 30 years of age who were seen in the emergency department for chest pain and who did not have a history of trauma or abnormalities on radiologic study. Intervention: Physician-opinion leaders defined criteria for patient inclusion in the pathway and for remaining on the pathway after 6 or 12 hours of observation. Criteria were defined for appropriateness of direct admission, direct discharge, or 6 hours of observation followed by exercise treadmill testing. Measurements: Number of patients admitted to the hospital, number of days that patients were hospitalized, and clinical outcome. Results: 2898 of 4585 patients (63%) were admitted to the hospital; of the 2898, 1152 (40%) were classified as potentially eligible for the pathway and 1068 (93%) had a benign clinical course during the initial observation period. The 1068 patients had a mean length of stay of 2.8 +/- 4.8 days. If 47% of these patients had been discharged after observation and exercise testing, implementation of the pathway would have reduced the number of admissions by 505 (17%) and days of hospitalization by 1407 (11%). Conclusions: Retrospective analysis suggests that a critical pathway for patients with acute chest pain may substantially reduce resource use, Prospective study is needed to ensure increased efficiency without increased adverse outcomes.	HARVARD COMMUNITY HLTH PLAN, BOSTON, MA 02215 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT MED, BOSTON, MA 02115 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SCH MED, SAN FRANCISCO, CA 94143 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT EMERGENCY MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California San Francisco; Harvard University; Brigham & Women's Hospital; Harvard Medical School					AHRQ HHS [R01 HS06452] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAMS JE, 1993, CIRCULATION, V88, P101, DOI 10.1161/01.CIR.88.1.101; CANNON CP, 1994, J THROMB THROMBOLYS, V1, P27; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHO MK, 1994, JAMA-J AM MED ASSOC, V272, P101, DOI 10.1001/jama.272.2.101; Coffey R J, 1992, Qual Manag Health Care, V1, P45; *COLL PHYS SURG ON, 1988, POL DEEP VEIN THROMB; ELLRODT AG, 1995, ANN INTERN MED, V122, P277, DOI 10.7326/0003-4819-122-4-199502150-00007; Falconer J A, 1993, QRB Qual Rev Bull, V19, P8; FIELD D L, 1988, Journal of Emergency Medicine, V6, P363, DOI 10.1016/0736-4679(88)90002-9; FLEISCHMANN KE, 1994, J AM COLL CARDIOL, V23, P1390, DOI 10.1016/0735-1097(94)90382-4; GASPOZ JM, 1994, J AM COLL CARDIOL, V24, P1249, DOI 10.1016/0735-1097(94)90106-6; GIBLER WB, 1995, ANN EMERG MED, V25, P1, DOI 10.1016/S0196-0644(95)70347-0; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GRAFF L, 1992, ANN EMERG MED, V21, P967, DOI 10.1016/S0196-0644(05)82937-3; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HIGGINS GL, 1993, AM J EMERG MED, V11, P576, DOI 10.1016/0735-6757(93)90004-U; HILTON TC, 1994, J AM COLL CARDIOL, V23, P1016, DOI 10.1016/0735-1097(94)90584-3; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; KERNS JR, 1993, ANN EMERG MED, V22, P794, DOI 10.1016/S0196-0644(05)80793-0; LEE TH, 1992, AM J CARDIOL, V69, P145, DOI 10.1016/0002-9149(92)91294-E; LEE TH, 1995, ANN INTERN MED, V122, P434, DOI 10.7326/0003-4819-122-6-199503150-00006; LEE TH, 1985, ARCH INTERN MED, V145, P65, DOI 10.1001/archinte.145.1.65; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; LEWIS LM, 1995, ANN EMERG MED, V25, P9, DOI 10.1016/S0196-0644(95)70348-9; LEWIS WR, 1994, AM J CARDIOL, V74, P987, DOI 10.1016/0002-9149(94)90845-1; LIM R, 1994, BRIT HEART J, V71, P334; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; MARIN MM, 1992, AM HEART J, V123, P354, DOI 10.1016/0002-8703(92)90646-D; ODDERSON IR, 1993, STROKE, V24, P1823, DOI 10.1161/01.STR.24.12.1823; OGILVIEHARRIS DJ, 1993, J ORTHOP TRAUMA, V7, P428, DOI 10.1097/00005131-199310000-00005; Patton M D, 1995, Cancer Pract, V3, P286; PEARSON SD, 1995, ANN INTERN MED, V123, P941, DOI 10.7326/0003-4819-123-12-199512150-00008; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; RATNAIKE S, 1993, MED J AUSTRALIA, V159, P666, DOI 10.5694/j.1326-5377.1993.tb138081.x; RIBISL PM, 1992, ARCH INTERN MED, V152, P1618, DOI 10.1001/archinte.152.8.1618; RICHARDS JS, 1994, CLIN PATHS TOOLS OUT, P265; Schriefer J, 1995, Qual Manag Health Care, V3, P30; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; SHESSER R, 1994, ANN EMERG MED, V23, P334, DOI 10.1016/S0196-0644(94)70047-8; SOX HC, 1988, MED DECIS MAKING, P406; SPATH PL, 1994, CLIN PATHS TOOLS OUT, P265; STRATMANN HG, 1994, AM J CARDIOL, V73, P647, DOI 10.1016/0002-9149(94)90927-X; TUCKER JF, 1994, ANN EMERG MED, V24, P704, DOI 10.1016/S0196-0644(94)70282-9; TURLEY K, 1994, ANN THORAC SURG, V58, P57, DOI 10.1016/0003-4975(94)91072-3; *US DHHS, 1994, AHCPR PUBL; VARETTO T, 1993, J AM COLL CARDIOL, V22, P1804, DOI 10.1016/0735-1097(93)90761-O; WACHTEL T, 1986, MED DECIS MAKING, V6, P101, DOI 10.1177/0272989X8600600208; WEINER DA, 1984, J AM COLL CARDIOL, V3, P772, DOI 10.1016/S0735-1097(84)80254-5; WEINGARTEN S, 1993, AM J CARDIOL, V71, P259, DOI 10.1016/0002-9149(93)90787-D; WEINGARTEN S, 1990, ANN INTERN MED, V113, P283, DOI 10.7326/0003-4819-113-4-283; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; YOUNG GP, 1993, AM J EMERG MED, V11, P444, DOI 10.1016/0735-6757(93)90079-Q	56	72	73	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					996	1005		10.7326/0003-4819-127-11-199712010-00009	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412306				2022-12-24	WOS:A1997YJ08000007
J	Klenk, HP; Clayton, RA; Tomb, JF; White, O; Nelson, KE; Ketchum, KA; Dodson, RJ; Gwinn, M; Hickey, EK; Peterson, JD; Richardson, DL; Kerlavage, AR; Graham, DE; Kyrpides, NC; Fleischmann, RD; Quackenbush, J; Lee, NH; Sutton, GG; Gill, S; Kirkness, EF; Dougherty, BA; McKenney, K; Adams, MD; Loftus, B; Peterson, S; Reich, CI; McNeil, LK; Badger, JH; Glodek, A; Zhou, LX; Overbeek, R; Gocayne, JD; Weidman, JF; McDonald, L; Utterback, T; Cotton, MD; Spriggs, T; Artiach, P; Kaine, BP; Sykes, SM; Sadow, PW; DAndrea, KP; Bowman, C; Fujii, C; Garland, SA; Mason, TM; Olsen, GJ; Fraser, CM; Smith, HO; Woese, CR; Venter, JC				Klenk, HP; Clayton, RA; Tomb, JF; White, O; Nelson, KE; Ketchum, KA; Dodson, RJ; Gwinn, M; Hickey, EK; Peterson, JD; Richardson, DL; Kerlavage, AR; Graham, DE; Kyrpides, NC; Fleischmann, RD; Quackenbush, J; Lee, NH; Sutton, GG; Gill, S; Kirkness, EF; Dougherty, BA; McKenney, K; Adams, MD; Loftus, B; Peterson, S; Reich, CI; McNeil, LK; Badger, JH; Glodek, A; Zhou, LX; Overbeek, R; Gocayne, JD; Weidman, JF; McDonald, L; Utterback, T; Cotton, MD; Spriggs, T; Artiach, P; Kaine, BP; Sykes, SM; Sadow, PW; DAndrea, KP; Bowman, C; Fujii, C; Garland, SA; Mason, TM; Olsen, GJ; Fraser, CM; Smith, HO; Woese, CR; Venter, JC			The complete genome sequence of the hyperthermophilic, sulphate-reducing archaeon Archaeoglobus fulgidus	NATURE			English	Article							MONOXIDE DEHYDROGENASE PATHWAY; ARCHAEBACTERIA; OXIDOREDUCTASE; CO2; OXIDATION; BACTERIA; PROTEIN; ENZYME	Archaeoglobus fulgidus is the first sulphur-metabolizing organism to have its genome sequence determined. Its genome of 2,178,400 base pairs contains 2,436 open reading frames (ORFs). The Information processing systems and the biosynthetic pathways for essential components (nucleotides, amino acids and cofactors) have extensive correlation with their counterparts in the archaeon Methanococcus jannaschii. The genomes of these two Archaea indicate dramatic differences in the way these organisms sense their environment, perform regulatory and transport functions, and gain energy. In contrast to M. jannaschii, A. fulgidus has fewer restriction-modification systems, and none of its genes appears to contain inteins. A quarter (651 ORFs) of the A. fulgidus genome encodes functionally uncharacterized yet conserved proteins, two-thirds of which are shared with M. jannaschii (428 ORFs). Another quarter of the genome encodes new proteins indicating substantial archaeal gene diversity.	INST GENOM RES TIGR,ROCKVILLE,MD 20850; UNIV ILLINOIS,DEPT MICROBIOL,CHAMPAIGN,IL 61801; ARGONNE NATL LAB,DIV MATH & COMP SCI,ARGONNE,IL 60439	J. Craig Venter Institute; University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Energy (DOE); Argonne National Laboratory			Graham, David E/F-8578-2010; Kyrpides, Nikos C./A-6305-2014	Graham, David E/0000-0001-8968-7344; Kyrpides, Nikos C./0000-0002-6131-0462; Sykes, Sean/0000-0001-8344-5176; loftus, brendan/0000-0001-8871-8356; Fraser, Claire/0000-0003-1462-2428; Quackenbush, John/0000-0002-2702-5879; Kerlavage, Anthony/0000-0002-3954-9653				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Clark D. P., 1996, ESCHERICHIA COLI SAL, P343; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Cooling FB, 1996, APPL ENVIRON MICROB, V62, P2999, DOI 10.1128/AEM.62.8.2999-3004.1996; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; DAI YR, UNPUB ARCH MICROBIOL; Edgell DR, 1997, J BACTERIOL, V179, P2632, DOI 10.1128/jb.179.8.2632-2640.1997; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GORRIS LGM, 1991, BIOFACTORS, V3, P29; HUBER R, 1995, NATURE, V376, P57, DOI 10.1038/376057a0; IBBA M, UNPUB P NATL ACAD SC; KAGAWA HK, 1995, J MOL BIOL, V253, P712, DOI 10.1006/jmbi.1995.0585; Kletzin A, 1996, J BACTERIOL, V178, P248, DOI 10.1128/jb.178.1.248-257.1996; Kosa PF, 1997, P NATL ACAD SCI USA, V94, P6042, DOI 10.1073/pnas.94.12.6042; KUNOW J, 1994, EUR J BIOCHEM, V223, P503, DOI 10.1111/j.1432-1033.1994.tb19019.x; LaPaglia C, 1997, APPL ENVIRON MICROB, V63, P3158, DOI 10.1128/AEM.63.8.3158-3163.1997; MARSH TL, 1994, P NATL ACAD SCI USA, V91, P4180, DOI 10.1073/pnas.91.10.4180; MOLLERZINKHAN D, 1990, ARCH MICROBIOL, V153, P215, DOI 10.1007/BF00249070; NISHIHARA M, 1995, J BIOCHEM-TOKYO, V117, P933, DOI 10.1093/oxfordjournals.jbchem.a124822; NOLL KM, 1988, J BACTERIOL, V170, P4315, DOI 10.1128/jb.170.9.4315-4321.1988; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; SCHAUDER R, 1986, ARCH MICROBIOL, V145, P162, DOI 10.1007/BF00446775; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; SPEICH N, 1994, MICROBIOL-UK, V140, P1273, DOI 10.1099/00221287-140-6-1273; STETTER KO, 1995, ASM NEWS, V61, P285; STETTER KO, 1988, SYST APPL MICROBIOL, V10, P172, DOI 10.1016/S0723-2020(88)80032-8; STETTER KO, 1993, NATURE, V365, P743, DOI 10.1038/365743a0; STETTER KO, 1987, SCIENCE, V236, P822, DOI 10.1126/science.236.4803.822; STETTER KO, 1992, PROKARYOTES, P707; Sutton G. G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; Tersteegen A, 1997, EUR J BIOCHEM, V244, P862, DOI 10.1111/j.1432-1033.1997.00862.x; THAUER RK, 1995, BIOTECH HAN, V8, P33; THORNEBENE TG, 1979, SCIENCE, V203, P51; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; VORHOLT J, 1995, ARCH MICROBIOL, V163, P112, DOI 10.1007/s002030050179; WALDMANN T, 1995, HOPPESEYLERS BIOL CH, V376, P119; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; Yeliseev AA, 1997, P NATL ACAD SCI USA, V94, P5101, DOI 10.1073/pnas.94.10.5101; Zhang Q, 1996, J BIOCHEM-TOKYO, V120, P587	43	1183	2282	1	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					364	&		10.1038/37052	http://dx.doi.org/10.1038/37052			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389475	Bronze			2022-12-24	WOS:A1997YH54900052
J	Hordijk, PL; tenKlooster, JP; vanderKammen, RA; Michiels, F; Oomen, LCJM; Collard, JG				Hordijk, PL; tenKlooster, JP; vanderKammen, RA; Michiels, F; Oomen, LCJM; Collard, JG			Inhibition of invasion of epithelial cells by Tiam1-Rac signaling	SCIENCE			English	Article							E-CADHERIN; RAS TRANSFORMATION; ADHESION; GENE; IDENTIFICATION; PROTEIN; CATENIN; CDC42; RAC1; RHO	Tiam1 encodes an exchange factor for the Rho-like guanosine triphosphatase Rac. Both Tiam1 and activated RacV12 promote invasiveness of T lymphoma cells. In epithelial Madin-Darby canine kidney (MDCK) cells, Tiam1 localized to adherens junctions. Ectopic expression of Tiam1 or RacV12 inhibited hepatocyte growth factor-induced scattering by increasing E-cadherin-mediated cell-cell adhesion accompanied by actin polymerization at cell-cell contacts. In Ras-transformed MDCK cells, expression of Tiam1 or RacV12 restored E-cadherin-mediated adhesion, resulting in phenotypic reversion and loss of invasiveness. These data suggest an invasion-suppressor role for Tiam1 and Rac in epithelial cells.	NETHERLANDS CANC INST,DIV CELL BIOL,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				ten Klooster, Jean Paul/0000-0002-4979-7482; Hordijk, Peter/0000-0002-3348-078X				BECKER KF, 1994, CANCER RES, V54, P3845; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FURLONG RA, 1992, BIOESSAYS, V14, P613, DOI 10.1002/bies.950140908; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MICHIELS F, UNPUB; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIELDY AJ, 1995, MOL CELL BIOL, V15, P110; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Webb CP, 1996, J CELL SCI, V109, P2371	27	385	400	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1464	1466		10.1126/science.278.5342.1464	http://dx.doi.org/10.1126/science.278.5342.1464			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367959				2022-12-24	WOS:A1997YG85800045
J	Draper, GJ; Little, MP; Sorahan, T; Kinlen, LJ; Bunch, KJ; Conquest, AJ; Kendall, GM; Kneale, GW; Lancashire, RJ; Muirhead, CR; OConnor, CM; Vincent, TJ				Draper, GJ; Little, MP; Sorahan, T; Kinlen, LJ; Bunch, KJ; Conquest, AJ; Kendall, GM; Kneale, GW; Lancashire, RJ; Muirhead, CR; OConnor, CM; Vincent, TJ			Cancer in the offspring of radiation workers: a record linkage study	BRITISH MEDICAL JOURNAL			English	Article							NON-HODGKINS-LYMPHOMA; CHILDHOOD LEUKEMIA; PATERNAL EXPOSURE; WEST-BERKSHIRE; YOUNG-PEOPLE; NUCLEAR SITE; MICE; CHILDREN; IRRADIATION; SURVIVORS	Objectives: To test the ''Gardner hypothesis'' that childhood leukaemia and non-Hodgkin lymphoma can be caused by fathers' exposure to ionising radiation before the conception of the child, and, more generally, to investigate whether such radiation exposure of either parent is a cause of childhood cancer. Design: Case-control study. Setting: Great Britain. Subjects: 35 949 children diagnosed as having cancer, together with matched controls. Main outcome measures: Parental employment as radiation worker as defined by inclusion in the National Registry for Radiation Workers and being monitored for external radiation before conception of child; cumulative dose of external ionising radiation for various periods of employment before conception; dose during pregnancy. Results: After cases studied by Gardner and colleagues were excluded, fathers of children with leukaemia or non-Hodgkin lymphoma were significantly more likely than fathers of controls to have been radiation workers (relative risk 1.77, 95% confidence interval 1.05 to 3.03) but there was no dose-response relation for any of the exposure periods studied; indeed, the association was greatest for those with doses below the level of detection. No increased risk was found for fathers with a lifetime preconception dose of 100 mSv or more, or with a dose in the 6 months before conception of 10 mSv or more. There was no increased risk for the group of other childhood cancers. Mothers' radiation work was associated with a significant increase of childhood cancer (relative risk 5.00, 1.42 to 26.94; based on 15 cases and 3 controls). Only four of the case mothers and no controls were radiation workers during pregnancy. Conclusions: These results do not support the hypothesis that paternal preconception irradiation is a cause of childhood leukaemia and non-Hodgkin lymphoma; the observed associations may be chance findings or result from exposure to infective or other agents. If there is any increased risk for the children of fathers who are radiation workers, it is small in absolute terms: in Britain the average risk by age 15 years is 6.5 per 10 000; our best estimate, using all available data, is that the increase is 5.4 per 10 000. For mothers, the numbers are too small for reliable estimates of the risk, if any, to be made.	NATL RADIOL PROTECT BOARD,DIDCOT OX11 0RQ,OXON,ENGLAND; UNIV BIRMINGHAM,INST OCCUPAT HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV OXFORD,CRC,CANC EPIDEMIOL RES GRP,DEPT PUBL HLTH,OXFORD OX2 6HE,ENGLAND; UNIV BIRMINGHAM,DEPT PUBL HLTH & EPIDEMIOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham; University of Oxford; University of Birmingham	Draper, GJ (corresponding author), UNIV OXFORD,CHILDHOOD CANC RES GRP,S PARKS RD,OXFORD OX2 6HJ,ENGLAND.		Kendall, Gerald/AAW-5538-2021	Muirhead, Colin/0000-0001-5394-1267; Little, Mark/0000-0003-0980-7567				Alexander FE, 1997, BRIT J CANCER, V75, P457, DOI 10.1038/bjc.1997.77; ANDERSSON M, 1994, J NATL CANCER I, V86, P1866, DOI 10.1093/jnci/86.24.1866; BRESLOW N, 1982, IARC SCI PUBLICATION, V32; CATTANACH BM, 1995, INT J RADIAT BIOL, V67, P607, DOI 10.1080/09553009514550721; *COMM MED ASP RAD, 1996, 4 COMARE DEP HLTH; COSGROVE GE, 1993, MUTAT RES, V319, P71, DOI 10.1016/0165-1218(93)90032-9; *CYT SOFTW, 1993, LOGX TURB VERS 1 1; DOLL R, 1994, NATURE, V367, P678, DOI 10.1038/367678a0; DRAPER GJ, 1997, R298 NAT RAD PROT BO; DRAPER GJ, 1989, IARC SCI PUBL, V96, P275; GARDNER MJ, 1992, BRIT MED J, V305, P715, DOI 10.1136/bmj.305.6855.715; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GILMAN E A, 1988, Journal of Radiological Protection, V8, P3, DOI 10.1088/0952-4746/8/1/301; HAWKINS MM, 1995, BRIT J CANCER, V71, P1335, DOI 10.1038/bjc.1995.259; Health and Safety Executive, 1993, HSE INV LEUK OTH CAN; HOWE GR, 1981, COMPUT BIOMED RES, V14, P327, DOI 10.1016/0010-4809(81)90004-5; KENDALL GM, 1992, R251 NAT RAD PROT BO; KINLEN L, 1988, LANCET, V2, P1323; Kinlen L. J., 1997, Journal of Radiological Protection, V17, P63, DOI 10.1088/0952-4746/17/2/003; KINLEN LJ, 1993, BRIT MED J, V306, P1153, DOI 10.1136/bmj.306.6886.1153; KINLEN LJ, 1991, BRIT J CANCER, V64, P549, DOI 10.1038/bjc.1991.348; KINLEN LJ, 1993, BRIT MED J, V306, P743, DOI 10.1136/bmj.306.6880.743; KINLEN LJ, 1993, BRIT MED J, V306, P1718, DOI 10.1136/bmj.306.6894.1718; KINLEN LJ, 1995, BMJ-BRIT MED J, V310, P763, DOI 10.1136/bmj.310.6982.763; KINLEN LJ, 1995, CANCER CAUSE CONTROL, V6, P445, DOI 10.1007/BF00052185; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1; KOHN HI, 1965, RADIAT RES, V25, P423, DOI 10.2307/3571983; Little M. P., 1996, Journal of Radiological Protection, V16, P25, DOI 10.1088/0952-4746/16/1/004; Little M. P., 1994, Journal of Radiological Protection, V14, P187, DOI 10.1088/0952-4746/14/3/001; Little M. P., 1994, Journal of Radiological Protection, V14, P203, DOI 10.1088/0952-4746/14/3/002; Little M. P., 1993, Journal of Radiological Protection, V13, P161, DOI 10.1088/0952-4746/13/3/001; Little M. P., 1992, Journal of Radiological Protection, V12, P203, DOI 10.1088/0952-4746/12/4/001; LITTLE MP, 1993, J RADIOL PROTECT, V13, P295; MCLAUGHLIN JR, 1993, BRIT MED J, V307, P959, DOI 10.1136/bmj.307.6910.959; MCLAUGHLIN JR, 1993, BRIT MED J, V307, P1257; MCLAUGHLIN JR, 1993, BRIT MED J, V307, P1462; MICHAELIS J, 1994, ARBEITSMED SOZIALMED, V29, P324; MICHAELIS J, 1995, ARBEITSMED SOZIALMED, V30, P78; NOMURA T, 1991, J RADIAT RES, V32, P64, DOI 10.1269/jrr.32.SUPPLEMENT2_64; NOMURA T, 1982, NATURE, V296, P575, DOI 10.1038/296575a0; PARKER L, 1993, BRIT MED J, V307, P966, DOI 10.1136/bmj.307.6910.966; Petridou E, 1996, BRIT J CANCER, V73, P1278, DOI 10.1038/bjc.1996.245; Pobel D, 1997, BRIT MED J, V314, P101, DOI 10.1136/bmj.314.7074.101; PRESTON DL, 1996, EPICURE RELEASE 2 0; ROMAN E, 1993, BMJ-BRIT MED J, V306, P615, DOI 10.1136/bmj.306.6878.615; STEWART A, 1958, BRIT MED J, V1, P1495, DOI 10.1136/bmj.1.5086.1495; Stiller CA, 1996, BMJ-BRIT MED J, V313, P1297, DOI 10.1136/bmj.313.7068.1297; Stiller CA, 1995, EUR J CANCER, V31A, P2028, DOI 10.1016/0959-8049(95)00428-9; TAKAHASHI T, 1992, CANCER RES, V52, P1948; United Nations Scientific Committee on the Effects of Atomic Radiation Sources, 1982, ION RAD SOURC BIOL E; YOSHIMOTO Y, 1990, AM J HUM GENET, V46, P1041	51	85	88	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1181	1188		10.1136/bmj.315.7117.1181	http://dx.doi.org/10.1136/bmj.315.7117.1181			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393219	Green Published			2022-12-24	WOS:A1997YF25200015
J	Watkins, J				Watkins, J			Effectiveness of influenza vaccination policy at targeting patients at high risk of complications during winter 1994-5: cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article											Watkins, J (corresponding author), GWENT HLTH AUTHOR,PONTYPOOL NP4 OYP,GWENT,WALES.							CURWEN M, 1990, BRIT MED J, V300, P896; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; KURINCZUK JJ, 1989, BRIT MED J, V299, P367, DOI 10.1136/bmj.299.6695.367; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206	4	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1069	1070		10.1136/bmj.315.7115.1069	http://dx.doi.org/10.1136/bmj.315.7115.1069			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366738	Green Published			2022-12-24	WOS:A1997YD44500028
J	Ray, WA; Gigante, J; Mitchel, EF; Hickson, GB				Ray, WA; Gigante, J; Mitchel, EF; Hickson, GB			Perinatal outcomes following implementation of TennCare	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRENATAL-CARE; MEDICAID; TENNESSEE; ELIGIBILITY	Context.-The abrupt initiation of capitated Medicaid care in Tennessee (TennCare) in 1994 prompted many questions about changes in quality of care. Objective.-To evaluate the effect on perinatal outcomes of the transition to TennCare in 1994. Design.-Before and after retrospective cohort analysis. Setting and Population.-Births to women residing in Tennessee between 1990 and 1995 with complete demographic information on birth certificates, with a focus on women enrolled in Medicaid giving birth in 1993 (before TennCare) and 1995 (after TennCare). Outcome Measures.-Late prenatal care (after the fourth month of pregnancy) or inadequate prenatal visits, low and very low birth weight, and death in the first 60 days of life. Results.-Tennessee residents had 72 014 study births in 1993 and 72 278 in 1995, of which 37 543 (52.1%) and 35 707 (49.4%) were to women enrolled in Medicaid at delivery. For these Medicaid births, there were no changes after TennCare In the proportions with late prenatal care (16.2% in 1993 vs 15.8% in 1995), inadequate prenatal visits (5.9% vs 5.6%), low birth weight (9.4% vs 9.0%), very low birth weight (1.6% vs 1.5%), and death in the first 60 days (0.6% both years). These findings were unchanged in multivariate analysis, in analysis of high-risk subgroups, and in analysis of women with demographics characteristic of Medicaid women. Conclusion.-Study perinatal outcomes did not change among Medicaid births following the transition to TennCare.	Vanderbilt Univ, Dept Prevent Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pediat, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Ray, WA (corresponding author), Vanderbilt Univ, Dept Prevent Med, A-1124 MCN, Nashville, TN 37232 USA.				PHS HHS [18-C-90029] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Corrigan J M, 1993, Jt Comm J Qual Improv, V19, P566; IGLEHART JK, 1995, NEW ENGL J MED, V332, P1727, DOI 10.1056/NEJM199506223322525; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1414, DOI 10.2105/AJPH.84.9.1414; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; Meyer GS, 1996, JAMA-J AM MED ASSOC, V276, P672, DOI 10.1001/jama.276.9.672; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; PIPER JM, 1991, AM J PUBLIC HEALTH, V81, P1046, DOI 10.2105/AJPH.81.8.1046; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; PIPER JM, 1990, AM J EPIDEMIOL, V132, P561, DOI 10.1093/oxfordjournals.aje.a115692; PIPER JM, 1994, AM J PUBLIC HEALTH, V84, P1626, DOI 10.2105/AJPH.84.10.1626; PIPER JM, 1993, AM J EPIDEMIOL, V137, P758, DOI 10.1093/oxfordjournals.aje.a116736; Ray WA, 1997, AM J PREV MED, V13, P292, DOI 10.1016/S0749-3797(18)30178-8; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; SMITH T, 1996, TENNESSEAN      0921, pB6; *US BUR CENS, 1993, 1992 TECHN DOC PREP; *US BUR CENS, 1992, CENS POP HOUS 1990 S; *US BUR CENS, 1993, 1992 PREP BUR CENS; US Bureau of the Census, 1992, CENS POP HOUS SUMM S	18	33	33	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	1998	279	4					314	316		10.1001/jama.279.4.314	http://dx.doi.org/10.1001/jama.279.4.314			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT472	9450717				2022-12-24	WOS:000071607000040
J	Crair, MC; Gillespie, DC; Stryker, MP				Crair, MC; Gillespie, DC; Stryker, MP			The role of visual experience in the development of columns in cat visual cortex	SCIENCE			English	Article							BINOCULAR IMPULSE BLOCKADE; OCULAR DOMINANCE COLUMNS; ORIENTATION SELECTIVITY; MONOCULAR DEPRIVATION; POSTNATAL-DEVELOPMENT; SENSITIVE PERIOD; CORTICAL-CELLS; KITTENS; FERRET; CONNECTIONS	The role of experience in the development of the cerebral cortex has long been controversial. Patterned visual experience in the cat begins when the eyes open about a week after birth. Cortical maps for orientation and ocular dominance in the primary visual cortex of cats were found to be present by 2 weeks. Early pattern vision appeared unimportant because these cortical maps developed identically until nearly 3 weeks of age, whether or not the eyes were open. The naive maps were powerfully dominated by the contralateral eye, and experience was needed for responses to the other eye to become strong, a process unlikely to be strictly Hebbian, With continued visual deprivation, responses to both eyes deteriorated, with a time course parallel to the well-known critical period of cortical plasticity. The basic structure of cortical maps is therefore innate, but experience is essential for specific features of these maps, as well as for maintaining the responsiveness and selectivity of cortical neurons.	Univ Calif San Francisco, Dept Physiol, WM Keck Fdn Ctr Integrat Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Stryker, MP (corresponding author), Univ Calif San Francisco, Dept Physiol, WM Keck Fdn Ctr Integrat Neurosci, Box 0444, San Francisco, CA 94143 USA.			Stryker, Michael/0000-0003-1546-5831	NATIONAL EYE INSTITUTE [R37EY002874] Funding Source: NIH RePORTER; NEI NIH HHS [R37 EY002874, R37 EY002874-20, EY09760, EY02874] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBUS K, 1984, J PHYSIOL-LONDON, V348, P153, DOI 10.1113/jphysiol.1984.sp015104; ANTONINI A, 1993, J NEUROSCI, V13, P3549; Antonini A, 1996, J COMP NEUROL, V369, P64; BARLOW HB, 1971, J PHYSIOL-LONDON, V218, P98; BLAKEMORE C, 1973, NATURE, V241, P467, DOI 10.1038/241467a0; BLAKEMORE C, 1975, J PHYSIOL-LONDON, V248, P663, DOI 10.1113/jphysiol.1975.sp010995; BLAKEMORE C, 1974, J PHYSIOL-LONDON, V237, P195, DOI 10.1113/jphysiol.1974.sp010478; BONHOEFFER T, 1996, BRAIN MAPPING METHOD, P75; CHAPMAN B, 1993, J NEUROSCI, V13, P5251, DOI 10.1523/JNEUROSCI.13-12-05251.1993; Chapman B, 1996, J NEUROSCI, V16, P6443; Crair MC, 1997, NEURON, V19, P307, DOI 10.1016/S0896-6273(00)80941-1; Crair MC, 1997, J NEUROPHYSIOL, V77, P3381, DOI 10.1152/jn.1997.77.6.3381; CRAIR MC, UNPUB; FREGNAC Y, 1978, J PHYSIOL-LONDON, V278, P27, DOI 10.1113/jphysiol.1978.sp012290; Godecke I, 1997, EUR J NEUROSCI, V9, P1754; Godecke I, 1996, NATURE, V379, P251, DOI 10.1038/379251a0; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; HUBEL DH, 1963, J NEUROPHYSIOL, V26, P994, DOI 10.1152/jn.1963.26.6.994; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; IMBERT M, 1975, EXP BRAIN RES, V22, P25; Kohonen T., 1989, SELF ORG ASS MEMORY; KUHL PK, 1994, CURR OPIN NEUROBIOL, V4, P812, DOI 10.1016/0959-4388(94)90128-7; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; MCCORMICK DA, 1995, J NEUROSCI, V15, P5739; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; Movshon J.A., 1990, P155; MOVSHON JA, 1976, J PHYSIOL-LONDON, V261, P125, DOI 10.1113/jphysiol.1976.sp011551; OLSON CR, 1980, EXP BRAIN RES, V39, P17; PETTIGREW JD, 1974, J PHYSIOL-LONDON, V237, P49, DOI 10.1113/jphysiol.1974.sp010469; PRESTON KL, 1993, EARLY VISUAL DEV NOR, P80; Ruthazer ES, 1996, J NEUROSCI, V16, P7253; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHERK H, 1976, J NEUROPHYSIOL, V39, P63, DOI 10.1152/jn.1976.39.1.63; STRYKER MP, 1986, J NEUROSCI, V6, P2117; TORREALBA F, 1982, J COMP NEUROL, V211, P377, DOI 10.1002/cne.902110405; von der Malsburg C, 1979, Biol Cybern, V32, P49, DOI 10.1007/BF00337452; WIESEL TN, 1974, J COMP NEUROL, V158, P307, DOI 10.1002/cne.901580306; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0; WILLSHAW DJ, 1976, PROC R SOC SER B-BIO, V194, P431, DOI 10.1098/rspb.1976.0087; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8	40	436	447	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					566	570		10.1126/science.279.5350.566	http://dx.doi.org/10.1126/science.279.5350.566			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438851	Green Accepted			2022-12-24	WOS:000071616000048
J	Freedberg, KA; Scharfstein, JA; Seage, GR; Losina, E; Weinstein, MC; Craven, DE; Paltiel, AD				Freedberg, KA; Scharfstein, JA; Seage, GR; Losina, E; Weinstein, MC; Craven, DE; Paltiel, AD			The cost-effectiveness of preventing AIDS-related opportunistic infections	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; MYCOBACTERIUM-AVIUM COMPLEX; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; SECONDARY PROPHYLAXIS; RANDOMIZED TRIAL; CUBIC MILLIMETER; VIRUS INFECTION; RIFABUTIN; THERAPY; DISEASE	Context-Multiple options are now available for prophylaxis of opportunistic infections related to the acquired immunodeficiency syndrome (AIDS). However, because of differences in incidence rates as well as drug efficacy, toxicity, and costs, the role of different types of prophylaxis remains uncertain. Objective.-To determine the clinical impact, cost, and cost-effectiveness of strategies for preventing opportunistic infections in patients with advanced human immunodeficiency virus (HIV) disease. Design.-We developed a Markov simulation model to compare different strategies for prophylaxis of Pneumocystis carinii pneumonia (PCP), toxoplasmosis, Mycobacterium avium complex (MAC) infection, fungal infections, and cytomegalovirus (CMV) disease in HIV-infected patients. Data for the model were derived from the Multicenter AIDS Cohort Study, randomized controlled trials, and the national AIDS Cost and Services Utilization Survey. Main Outcome Measures.-Projected life expectancy, quality-adjusted life expectancy, total lifetime direct medical costs, and cost-effectiveness in dollars per quality-adjusted life-year (QALY) saved. Results.-For patients with CD4 cell counts of 0.200 to 0.300x10(9)/L (200-300/mu L) who receive no prophylaxis, we projected a quality-adjusted life expectancy of 39.08 months and average total lifetime costs of $40 288. Prophylaxis for PCP and toxoplasmosis with trimethoprim-sulfamethoxazole for patients with CD4 cell counts of 0.200x10(9)/L (200/mu L) or less increased quality-adjusted life expectancy to 42.56 months, implying an incremental cost of $16 000 per QALY saved. Prophylaxis for MAC for patients with CD4 cell counts of 0.050x10(9)/L (50/mu L) or less produced smaller gains in quality-adjusted life expectancy; incremental cost-effectiveness ratios were $35 000 per QALY saved for azithromycin and $74 000 per QALY saved for rifabutin. Oral ganciclovir for the prevention of CMV infection was the least cost-effective prophylaxis ($314 000 per QALY saved). Results were most sensitive to the risk of developing an opportunistic infection, the impact of opportunistic infection history on long-term survival, and the cost of prophylaxis. Conclusions.-The cost-effectiveness of prophylaxis against HIV-related opportunistic infections varies widely, but prophylaxis against PCP or toxoplasmosis and against MAC delivers the greatest comparative value. In an era of limited resources, these results can be used to set priorities and explore new alternatives for improving HIV patient care.	Boston Univ, Med Ctr, Dept Med, Clin Econ Res Unit, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Med, Gen Internal Med Sect, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Med, Clin AIDS Program, Boston, MA 02118 USA; Boston Univ, Med Ctr, Evans Med Fdn, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Dept Biostat & Epidemiol, Boston, MA USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Yale University	Freedberg, KA (corresponding author), Boston Univ, Med Ctr, Dept Med, Clin Econ Res Unit, 91E Concord St,Suite 200, Boston, MA 02118 USA.			Losina, ELENA/0000-0002-3424-0892; Paltiel, A. David/0000-0002-4861-3290	AHRQ HHS [1-RO1-HS07317-01A1] Funding Source: Medline; NIAMS NIH HHS [K24 AR057827] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K24AR057827] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		[Anonymous], 1997, MMWR Recomm Rep, V46, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BERK M, 1993, AHCPR PUBLICATION; BOZZETTE SA, 1995, NEW ENGL J MED, V332, P693, DOI 10.1056/NEJM199503163321101; BROSGART C, 1996, 11 INT C AIDS JUL 7; *BUR CENS, 1995, STAT ABSTR US; CANTOR SB, 1994, MED DECIS MAKING, V14, P259, DOI 10.1177/0272989X9401400308; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; CASTELLANO AR, 1991, JAMA-J AM MED ASSOC, V266, P820, DOI 10.1001/jama.266.6.820; *CDCP, 1993, HIV AIDS SURVEIL FEB, P7; DOYLE A, 1997, STATE AIDS DRUG ASSI; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; Finkelstein DM, 1996, J ACQ IMMUN DEF SYND, V12, P38, DOI 10.1097/00042560-199605010-00006; Freedberg KA, 1996, MED DECIS MAKING, V16, P29, DOI 10.1177/0272989X9601600110; FREEDBERG KA, 1991, J ACQ IMMUN DEF SYND, V4, P521; Freedberg KA, 1997, J ACQ IMMUN DEF SYND, V15, P275, DOI 10.1097/00042560-199708010-00005; GOLD MR, 1996, GOST EFFECTIVENESS H; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; Havlir DV, 1996, NEW ENGL J MED, V335, P392, DOI 10.1056/NEJM199608083350604; Ioannidis JPA, 1996, ARCH INTERN MED, V156, P177, DOI 10.1001/archinte.156.2.177; JACOBSON MA, 1997, 4 C RETR OPP INF JAN; KAPLAN JE, 1995, CLIN INFECT DIS    S, V21, P512; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KASPAR R, 1997, 4 C RETR OPP INF JAN; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; *MED EC, 1996, DRUG TOP RED BOOK; MIETTINEN OS, 1983, AM J EPIDEMIOL, V38, P963; MILLER DK, 1994, MED DECIS MAKING, V14, P52, DOI 10.1177/0272989X9401400107; Moore RD, 1996, ANN INTERN MED, V124, P633, DOI 10.7326/0003-4819-124-7-199604010-00003; *NAT PUBL HLTH HOS, 1991, HOSP AIDS HIV SURV; *NAT TECHN INF SER, 1994, AIDS COST SERV UT SU; *NAT TECHN INF SER, 1995, MULT AIDS COH STUD M; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; PALTIEL AD, IN PRESS INTERFACES; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; Pierce M, 1996, NEW ENGL J MED, V335, P384, DOI 10.1056/NEJM199608083350603; POWDERLY WG, 1995, NEW ENGL J MED, V332, P700, DOI 10.1056/NEJM199503163321102; ROBBINS GK, 1997, 4 C RETR OPP INF JAN; Rose DN, 1997, AIDS, V11, P883, DOI 10.1097/00002030-199707000-00007; SANDE MA, 1993, JAMA-J AM MED ASSOC, V270, P2583, DOI 10.1001/jama.270.21.2583; Scharfstein JA, 1997, MED DECIS MAKING, V17, P373, DOI 10.1177/0272989X9701700402; Spector SA, 1996, NEW ENGL J MED, V334, P1491, DOI 10.1056/NEJM199606063342302; TORRANCE GW, 1976, SOCIO ECON PLAN SCI, V10, P129, DOI 10.1016/0038-0121(76)90036-7; WALMSLEY S, 1997, 4 C RETR OPP INF JAN	48	167	169	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	1998	279	2					130	136		10.1001/jama.279.2.130	http://dx.doi.org/10.1001/jama.279.2.130			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ015	9440663	Bronze			2022-12-24	WOS:000071338900030
J	Hemminki, A; Markie, D; Tomlinson, I; Avizienyte, E; Roth, S; Loukola, A; Bignell, G; Warren, W; Aminoff, M; Hoglund, P; Jarvinen, H; Kristo, P; Pelin, K; Ridanpaa, M; Salovaara, R; Toro, T; Bodmer, W; Olschwang, S; Olsen, AS; Stratton, MR; de la Chapelle, A; Aaltonen, LA				Hemminki, A; Markie, D; Tomlinson, I; Avizienyte, E; Roth, S; Loukola, A; Bignell, G; Warren, W; Aminoff, M; Hoglund, P; Jarvinen, H; Kristo, P; Pelin, K; Ridanpaa, M; Salovaara, R; Toro, T; Bodmer, W; Olschwang, S; Olsen, AS; Stratton, MR; de la Chapelle, A; Aaltonen, LA			A serine/threonine kinase gene defective in Peutz-Jegheus syndrome	NATURE			English	Article							MUTATIONS; CANCER	Studies of hereditary cancer syndromes have contributed greatly to our understanding of molecular events involved in tumorigenesis. Here we investigate the molecular background of the Peutz-Jeghers syndrome(1,2) (PJS), a rare hereditary disease in which there is predisposition to benign and malignant tumours of many organ systems. A locus for this condition was recently assigned to chromosome 19p (ref. 3). We have identified truncating germline mutations in a gene residing on chromosome 19p in multiple individuals affected by PJS. This previously identified but unmapped gene, LKB1 (ref. 4), has strong homology to a cytoplasmic Xenopus serine/threonine protein kinase XEEK1 (ref. 5), and weaker similarity to many other protein kinases. Peutz-Jeghers syndrome is therefore the first cancer-susceptibility syndrome to be identified that is due to inactivating mutations in a protein kinase.	Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Dunedin Sch Med, Dept Pathol, Dunedin, New Zealand; Inst Canc Res, Haddow Labs, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Univ Helsinki, Cent Hosp, Dept Surg 2, FIN-00290 Helsinki, Finland; Folkhalsan Inst Genet, Helsinki 00280, Finland; John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund, Canc & Immunogenet Lab, Oxford OX3 9DS, England; Fdn Jean Dausset CEPH, INSERM, U434, F-75010 Paris, France; Univ Calif Lawrence Livermore Natl Lab, Ctr Human Genome, Livermore, CA 94550 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University of Helsinki; University of Helsinki; University of Otago; University of London; Institute of Cancer Research - UK; University of Oxford; University of Helsinki; Helsinki University Central Hospital; University of Oxford; Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Aaltonen, LA (corresponding author), Univ Helsinki, Haartman Inst, Dept Med Genet, POB 21 Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	Lauri.Aaltonen@Helsinki.Fi	Markie, David/I-7893-2019; Aaltonen, Lauri/A-5375-2010; Olschwang, Sylviane/G-2716-2013	Aaltonen, Lauri/0000-0001-6839-4286; Olschwang, Sylviane/0000-0001-7078-3029; Bodmer, Walter/0000-0001-6244-9792; Pelin, Katarina/0000-0002-7040-7266; Loukola, Anu-Maria/0000-0003-0542-5967; Markie, David/0000-0001-5452-9194				ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; FUTREAL PA, 1994, HUM MOL GENET, V3, P1359, DOI 10.1093/hmg/3.8.1359; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; JEGHERS H, 1949, NEW ENGL J MED, V241, P992; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KO MSH, SYSTEMATIC ANAL MOUS; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NEZU J, UNPUB MOL CLONING NO; Peutz JL, 1921, NEDERL MAANDSCHR GEN, V10, P134; PHILLIPS RK, 1994, FAMILIAL ADENOMATOUS; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Su JY, 1996, J BIOL CHEM, V271, P14430, DOI 10.1074/jbc.271.24.14430; TAGLE DA, 1993, NATURE, V361, P751, DOI 10.1038/361751a0; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	15	1165	1243	1	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 8	1998	391	6663					184	187		10.1038/34432	http://dx.doi.org/10.1038/34432			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428765				2022-12-24	WOS:000071380900053
J	Meulenberg, F				Meulenberg, F			The hidden delight of psoriasis	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Dutch Coll Gen Practitioners, NL-3511 AN Utrecht, Netherlands		Meulenberg, F (corresponding author), Dutch Coll Gen Practitioners, Oudegracht 16, NL-3511 AN Utrecht, Netherlands.							BENNETT P, 1991, PRACTITIONER, V235, P241; Boyd Brian, 1991, V NABOKOV AM YEARS; Boyd Brian, 1990, V NABOKOV RUSSIAN YE; FARBER EM, 1991, INT J DERMATOL, V30, P295, DOI 10.1111/j.1365-4362.1991.tb04644.x; Fuller Graham Fuller, 1993, POTTER POTTER; Gupta M A, 1990, Adv Dermatol, V5, P21; INGRAM JT, 1954, BMJ-BRIT MED J, V2, P823, DOI 10.1136/bmj.2.4892.823; Ishiguro Kazuo, 1995, UNCONSOLED; JOWETT S, 1985, SOC SCI MED, V20, P425, DOI 10.1016/0277-9536(85)90021-8; LANIGAN SW, 1991, BRIT J DERMATOL, V125, P340, DOI 10.1111/j.1365-2133.1991.tb14168.x; NABOKOV V, 1990, SELECTED LETT 1940 1, P25; Nabokov Vladimir, 1971, ADA ARDOR FAMILY CHR; Nabokov Vladimir, 1974, STRONG OPINIONS; PALMEN C, 1992, LAWS; Potter Dennis, 1986, SINGING DETECTIVE; POUER D, 1994, SEEING BLOSSOM 2 INT; RAMSAY B, 1988, BRIT J DERMATOL, V118, P195, DOI 10.1111/j.1365-2133.1988.tb01774.x; UPDIKE J, 1980, PROBLEMS OTHER STORI, P181; UPDIKE J, 1991, ODD JOBS ESSAYS CRIT, P865; UPDIKE J, 1963, CENTAUR; Updike John, 1989, SELF CONSCIOUSNESS M; WITTKOWER E, 1946, LANCET, V250, P566	22	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 20	1997	315	7123					1709	1711		10.1136/bmj.315.7123.1709	http://dx.doi.org/10.1136/bmj.315.7123.1709			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448549	Green Published			2022-12-24	WOS:000071149400041
J	Tugwell, P; Dennis, DT; Weinstein, A; Wells, G; Shea, B; Nichol, G; Hayward, R; Lightfoot, R; Baker, P; Steere, AC				Tugwell, P; Dennis, DT; Weinstein, A; Wells, G; Shea, B; Nichol, G; Hayward, R; Lightfoot, R; Baker, P; Steere, AC			Laboratory evaluation in the diagnosis of Lyme disease	ANNALS OF INTERNAL MEDICINE			English	Article							BORRELIA-BURGDORFERI DNA; CENTRAL-NERVOUS-SYSTEM; LINKED IMMUNOSORBENT-ASSAY; ERYTHEMA MIGRANS; ARTHRITIS; SERODIAGNOSIS; ANTIBODY; NEUROBORRELIOSIS; FIBROMYALGIA; EPIDEMIC	Purpose: To provide a quantitative and qualitative evaluation of the predictive value of the laboratory diagnosis of Lyme disease and to use the resultant data to formulate guidelines for clinical diagnosis. Data Sources: A MEDLINE search of English-language articles or articles with English-language abstracts published from 1982 to 1996. Data Extraction: Sensitivity, specificity, and likelihood ratios were calculated, and a random-effects model was used to combine the proportions from the eligible studies. Prespecified criteria were used to determine which studies were eligible for analysis. Data Synthesis: Laboratory testing in general is not clinically useful if the pretest probability of Lyme disease is less than 0.20 or greater than 0.80. When the pretest probability is 0.20 to 0.80, sequential testing with enzyme-linked immunosorbent assay and Western blot is the most accurate method for ruling in or ruling out the possibility of Lyme disease. Conclusions: Laboratory testing is recommended only in patients whose pretest probability of Lyme disease is 0.20 to 0.80. If the pretest probability is less than 0.20, testing will result in more false-positive results than true-positive results; a negative test result in this situation effectively rules out the disease.	Univ Ottawa, Dept Med, Ottawa, ON K1H 8L6, Canada; Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA; New York Med Coll, Div Rheumat Dis & Immunol, Valhalla, NY 10595 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; McMaster Univ, Med Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada	University of Ottawa; Centers for Disease Control & Prevention - USA; New York Medical College; Tufts Medical Center; McMaster University	Tugwell, P (corresponding author), Ottawa Gen Hosp, Dept Med, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.		Baker, Philip R A/J-1109-2012; Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556; Steere, Allen/0000-0002-5268-9853				ALPERT B, 1992, NEW YORK STATE J MED, V92, P5; BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; BERGER BW, 1992, J CLIN MICROBIOL, V30, P359, DOI 10.1128/JCM.30.2.359-361.1992; BERGER BW, 1983, AM J DERMATOPATH, V5, P111, DOI 10.1097/00000372-198304000-00008; BOWEN GS, 1984, AM J EPIDEMIOL, V120, P387; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P590; CIESIELSKI CA, 1988, ANN NY ACAD SCI, V539, P283, DOI 10.1111/j.1749-6632.1988.tb31862.x; Coyle BS, 1996, J INFECT DIS, V173, P1260, DOI 10.1093/infdis/173.5.1260; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; Dennis D. T., 1993, Lyme disease., P27; DENNIS DT, 1991, JAMA-J AM MED ASSOC, V266, P1269, DOI 10.1001/jama.266.9.1269; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; DRESSLER F, 1991, ANN INTERN MED, V115, P533, DOI 10.7326/0003-4819-115-7-533; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; FAWCETT PT, 1992, J RHEUMATOL, V19, P582; GOODMAN JL, 1991, INFECT IMMUN, V59, P269, DOI 10.1128/IAI.59.1.269-278.1991; HALPERIN JJ, 1991, NEUROLOGY, V41, P1571, DOI 10.1212/WNL.41.10.1571; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HANSEN K, 1988, J CLIN MICROBIOL, V26, P338, DOI 10.1128/JCM.26.2.338-346.1988; HEDBERG CW, 1987, J INFECT DIS, V155, P1325, DOI 10.1093/infdis/155.6.1325; HEDGES LV, 1985, STAT METHODS META AN; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; Johnson BJB, 1996, J INFECT DIS, V174, P346, DOI 10.1093/infdis/174.2.346; JOHNSTON YE, 1985, AM J PATHOL, V118, P26; JONES JM, 1991, ANN INTERN MED, V114, P1064, DOI 10.7326/0003-4819-114-12-1064_1; KELLER TL, 1992, NEUROLOGY, V42, P32, DOI 10.1212/WNL.42.1.32; KOWAL K, 1994, ARTHRITIS RHEUM-US, V37, P1206, DOI 10.1002/art.1780370815; KRAMER N, 1986, AM J MED, V81, P149, DOI 10.1016/0002-9343(86)90200-7; LASTAVICA CC, 1989, NEW ENGL J MED, V320, P133, DOI 10.1056/NEJM198901193200301; LIGHTFOOT RW, 1993, ANN INTERN MED, V119, P503, DOI 10.7326/0003-4819-119-6-199309150-00010; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V267, P1364, DOI 10.1001/jama.267.10.1364; LUGER SW, 1990, ARCH INTERN MED, V150, P761, DOI 10.1001/archinte.150.4.761; MAGNARELLI LA, 1984, J CLIN MICROBIOL, V20, P181, DOI 10.1128/JCM.20.2.181-184.1984; MALAWISTA SE, 1986, ADV INTERNAL MED, V31, P147; MARCUS LC, 1985, ANN INTERN MED, V103, P374, DOI 10.7326/0003-4819-103-3-374; MELCHERS W, 1991, J CLIN MICROBIOL, V29, P2401, DOI 10.1128/JCM.29.11.2401-2406.1991; MILLER GL, 1992, P 5 INT C LYM DIS AR; NADELMAN RB, 1990, AM J MED, V88, P21, DOI 10.1016/0002-9343(90)90122-T; NICHOL G, IN PRESS ANN INTERN; NOCTON JJ, 1994, NEW ENGL J MED, V330, P229, DOI 10.1056/NEJM199401273300401; PACHNER AR, 1992, NEUROLOGY, V42, P2185, DOI 10.1212/WNL.42.11.2185; PACHNER AR, 1989, ARCH NEUROL-CHICAGO, V46, P790, DOI 10.1001/archneur.1989.00520430086023; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SCHULZE TL, 1986, ZBL BAKT-INT J MED M, V263, P65; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; SNYDMAN DR, 1986, ANN INTERN MED, V104, P798, DOI 10.7326/0003-4819-104-6-798; SOX HC, 1997, MED DECISION MAKING; STEERE AC, 1990, J INFECT DIS, V161, P1203, DOI 10.1093/infdis/161.6.1203; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1977, ANN INTERN MED, V86, P685, DOI 10.7326/0003-4819-86-6-685; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; WEINSTEIN A, 1989, NEW YORK STATE J MED, V89, P566; Wharton M, 1990, MMWR Recomm Rep, V39, P1; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; WORMSER GP, 1992, JAMA-J AM MED ASSOC, V268, P1311, DOI 10.1001/jama.268.10.1311; ZOSCHKE DC, 1992, POSTGRAD MED, V91, P46; 1992, FED REG         0228, V57; 1995, MMWR MORB MORTAL WKL, V44, P459; 1996, MMWR MORB MORTAL WKL, V45, P481; 1994, MMWR MORB MORTAL WKL, V43, P564	66	174	182	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1109	1123		10.7326/0003-4819-127-12-199712150-00011	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00011			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412316				2022-12-24	WOS:000070936600010
J	Edwards, D; Johnson, NW; Cooper, D; Warnakulasuriya, KAAS				Edwards, D; Johnson, NW; Cooper, D; Warnakulasuriya, KAAS			Management of cancers of the head and neck in the United Kingdom: questionnaire survey of consultants	BRITISH MEDICAL JOURNAL			English	Article									Royal Coll Surg England, Dept Dent Sci, London SE5 9RW, England; Univ London Kings Coll, Sch Med & Dent, Sch Dent, Dept Oral Med & Pathol, London SE5 9RW, England; Univ London Kings Coll, Sch Med & Dent, Comp Informat Ctr, Western Educ Ctr, London SE5 9DJ, England	Royal College of Surgeons of England; University of London; King's College London; University of London; King's College London	Edwards, D (corresponding author), Bedfordshire Hlth Author, Charter House, Luton LU1 2PL, Beds, England.		Johnson, Newell W/D-8152-2019; , WARNAKULASURIYA/ABB-3793-2020	Johnson, Newell W/0000-0001-5866-262X; Warnakulasuriya, Saman/0000-0003-2103-0746				Birchall M, 1995, HEAD NECK CANC SERVI; EDWARDS D, 1997, FACE FACE HEAD NECK; *EXP ADV GROUP CAN, 1995, REP EXP ADV GROUP CA; LORE JM, 1987, ARCH OTOLARYNGOL, V113, P1165; RAPIDIS AD, 1980, ANN ROY COLL SURG, V62, P116	5	17	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 13	1997	315	7122					1589	1589		10.1136/bmj.315.7122.1589	http://dx.doi.org/10.1136/bmj.315.7122.1589			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437278	Green Published			2022-12-24	WOS:000071021900025
J	Folkner, WM; Yoder, CF; Yuan, DN; Standish, EM; Preston, RA				Folkner, WM; Yoder, CF; Yuan, DN; Standish, EM; Preston, RA			Interior structure and seasonal mass redistribution of Mars from radio tracking of Mars Pathfinder	SCIENCE			English	Article							INERTIA; OBLIQUITY; MOMENT; CYCLE	Doppler and range measurements to the Mars Pathfinder lander made using its radio communications system have been combined with similar measurements from the Viking landers to estimate improved values of the precession of Mars' pole of rotation and the variation in Mars' rotation rate. The observed precession of -7576 +/- 35 milliarc seconds of angle per year implies a dense core and constrains possible models of interior composition. The estimated annual variation in rotation is in good agreement with a model of seasonal mass exchange of carbon dioxide between the atmosphere and ice caps.			Folkner, WM (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.							BILLS BG, 1989, GEOPHYS RES LETT, V16, P385, DOI 10.1029/GL016i005p00385; CAZENAVE A, 1981, GEOPHYS RES LETT, V8, P245, DOI 10.1029/GL008i003p00245; CHAO BF, 1990, J GEOPHYS RES-SOLID, V95, P14755, DOI 10.1029/JB095iB09p14755; Davies M., 1996, CELESTIAL MECH, V63, P127, DOI DOI 10.1007/BF00693410; FOLKNER WM, 1994, ASTRON ASTROPHYS, V287, P279; Folkner WM, 1997, J GEOPHYS RES-PLANET, V102, P4057, DOI 10.1029/96JE02125; FRANCOIS LM, 1990, J GEOPHYS RES-SOLID, V95, P14761, DOI 10.1029/JB095iB09p14761; KAULA WM, 1979, GEOPHYS RES LETT, V6, P194, DOI 10.1029/GL006i003p00194; KONOPLIV AS, 1995, PUBLICATION JET PROP; LAUL JC, 1986, GEOCHIM COSMOCHIM AC, V50, P875, DOI 10.1016/0016-7037(86)90370-4; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; REASENBERG RD, 1977, J GEOPHYS RES, V82, P369, DOI 10.1029/JB082i002p00369; ROSEN RD, 1983, J GEOPHYS RES-OCEANS, V88, P5451, DOI 10.1029/JC088iC09p05451; Sears F.W., 1968, INTRO THEORY RELATIV; SMITH DE, 1993, J GEOPHYS RES-PLANET, V98, P20871, DOI 10.1029/93JE01839; Sohl F, 1997, J GEOPHYS RES-PLANET, V102, P1613, DOI 10.1029/96JE03419; TILLMAN JE, 1993, J GEOPHYS RES-PLANET, V98, P10963, DOI 10.1029/93JE01084; TOUMA J, 1993, SCIENCE, V259, P1294, DOI 10.1126/science.259.5099.1294; WARD WR, 1974, J GEOPHYS RES, V79, P3375, DOI 10.1029/JC079i024p03375; Yoder CF, 1997, J GEOPHYS RES-PLANET, V102, P4065, DOI 10.1029/96JE03642	20	232	242	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1749	1752		10.1126/science.278.5344.1749	http://dx.doi.org/10.1126/science.278.5344.1749			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388168				2022-12-24	WOS:A1997YJ90100034
J	Sheng, HZ; Moriyama, K; Yamashita, T; Li, H; Potter, SS; Mahon, KA; Westphal, H				Sheng, HZ; Moriyama, K; Yamashita, T; Li, H; Potter, SS; Mahon, KA; Westphal, H			Multistep control of pituitary organogenesis	SCIENCE			English	Article							HOMEOBOX GENE LHX3; HOMEODOMAIN FACTOR; PIT-1; LIM; EXPRESSION	Lhx3 and Lhx4 (Gsh4), two closely related LIM homeobox genes, determine formation of the pituitary gland in mice. Rathke's pouch is formed in two steps-first as a rudiment and later as a definitive pouch. Lhx3 and Lhx4 have redundant control over formation of the definitive pouch. Lhx3 controls a subsequent step of pituitary fate commitment. Thereafter, Lhx3 and Lhx4 together regulate proliferation and differentiation of pituitary-specific cell lineages. Thus, Lhx3 and Lhx4 dictate pituitary organ identity by controlling developmental decisions at multiple stages of organogenesis.	NICHHD,LAB MAMMALIAN GENES & DEV,NIH,BETHESDA,MD 20892; SHIMANE MED UNIV,DEPT ANAT,IZUMO,SHIMANE 693,JAPAN; ACAD SINICA,INST MOL BIOL,TAIPEI 11529,TAIWAN; UNIV CINCINNATI,COLL MED,CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Shimane University; Academia Sinica - Taiwan; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Baylor College of Medicine								BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; CAMPER SA, 1990, GENOMICS, V8, P586, DOI 10.1016/0888-7543(90)90050-5; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DIAKOKU S, 1982, DEV BIOL, V90, P198; ETKIN W, 1967, NEUROENDOCRINOLOGY, P261; FERRAND R, 1972, Archives de Biologie, V83, P297; KAUFMAN MH, 1992, ATLAS MOUSE DEVELOPM; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; RHODES SJ, 1994, CURR OPIN GENET DEV, V4, P709, DOI 10.1016/0959-437X(94)90138-S; ROBINSON GW, 1991, NEW BIOL, V3, P1183; Schwind JL, 1928, AM J ANAT, V41, P295, DOI 10.1002/aja.1000410206; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; Sornson MW, 1996, NATURE, V384, P327, DOI 10.1038/384327a0; Treier M, 1996, CURR OPIN CELL BIOL, V8, P833, DOI 10.1016/S0955-0674(96)80085-8; Yamashita T, 1997, GENOMICS, V44, P144, DOI 10.1006/geno.1997.4852; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405	18	295	295	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1809	1812		10.1126/science.278.5344.1809	http://dx.doi.org/10.1126/science.278.5344.1809			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388186				2022-12-24	WOS:A1997YJ90100052
J	Bao, WH; Srinivasan, SR; Valdez, R; Greenlund, KJ; Wattigney, WA; Berenson, GS				Bao, WH; Srinivasan, SR; Valdez, R; Greenlund, KJ; Wattigney, WA; Berenson, GS			Longitudinal changes in cardiovascular risk from childhood to young adulthood in offspring of parents with coronary artery disease - The Bogalusa Heart Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLLOW-UP; CHILDREN; OVERWEIGHT; OBESITY; CHOLESTEROL; HISTORY; ADOLESCENTS; TRENDS	Context.-Although the association between parental coronary artery disease (CAD) and its risk factors in the offspring is known, the timing and the course of development of risk factors from childhood to adulthood in the offspring is not known. Objective.-To examine the association between parental CAD and longitudinal changes in risk factor profile from childhood to young adulthood in offspring. Design.-Cohort study. Setting.-Bogalusa, La, a semirural, biracial community. Participants.-Individuals with clinically verified parental history of CAD (n = 271) vs those without such a history (n=1253) Mean age at first CAD event was 50 years for fathers and 52 years for mothers. Main Outcome Measures.-Body mass index, subscapular skinfolds, blood pressure, and triglyceride, cholesterol (total, very low-density lipoprotein [VLDL-C], low-density lipoprotein [LDL-C], and high-density lipoprotein [HDL-C] cholesterols), glucose, and insulin levels. Results.-The offspring of parents with CAD were consistently overweight beginning in childhood. Their levels of total serum cholesterol, LDL-C, plasma glucose, and insulin became significantly higher at older ages, because of a higher rate of increase in these risk factors over time. In adulthood, the offspring with a positive parental history had a higher prevalence of obesity (body mass index >85th percentile in the National Health and Nutrition Examination Survey I, 35% vs 26%, P=.01), elevated total cholesterol (>6.2 mmol/L [240 mg/dL], 8.4% vs 4.8%, P=.05) and LDL-C levels (>4.1 mmol/L [160 mg/dL], 12.4% vs 4.7%, P=.05), and hyperglycemia (glucose, >6.6 mmol/L, 2.7% vs 0.4%, P<.001), as well as a higher coexistence of these conditions (P=.01). Further, the prevalence of dyslipidemia, either involving only LDL-C or LDL-C in combination with HDL-C or triglycerides or both, was significantly higher in the adult offspring with parental CAD. Conclusions.-Offspring of parents with early CAD were overweight beginning in childhood and developed an adverse cardiovascular risk factor profile ai an increased rate. These observations have important implications for prevention and intervention.	TULANE UNIV,SCH PUBL HLTH & TROP MED,TULANE CTR CARDIOVASC HLTH,NEW ORLEANS,LA 70112	Tulane University				Valdez, Rodolfo/0000-0001-9979-3140	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032194] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038844, U01HL038844] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38844] Funding Source: Medline; NICHD NIH HHS [HD-32194] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; BAO WH, 1995, CIRCULATION, V91, P365, DOI 10.1161/01.CIR.91.2.365; BAO WH, 1994, ARCH INTERN MED, V154, P1842; Bao WH, 1996, ARCH INTERN MED, V156, P1315, DOI 10.1001/archinte.156.12.1315; *BECKM INSTR INC, 1976, BECKM GLUC AN OP MAN; BERENSON GS, 1992, AM J CARDIOL, V70, P851, DOI 10.1016/0002-9149(92)90726-F; BLONDE CV, 1981, PREV MED, V10, P25, DOI 10.1016/0091-7435(81)90003-7; BUCOLO G, 1973, CLIN CHEM, V19, P476; BURKE GL, 1991, CIRCULATION, V84, P1176, DOI 10.1161/01.CIR.84.3.1176; CRIQUI MH, 1980, PREV MED, V9, P525, DOI 10.1016/0091-7435(80)90047-X; *EXP PAN BLOOD CHO, 1992, PEDIATRICS S, V89, P529; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; GIDDING SS, 1995, J PEDIATR-US, V127, P868, DOI 10.1016/S0022-3476(95)70020-X; Greenlund KJ, 1997, AM J MED SCI, V313, P220, DOI 10.1097/00000441-199704000-00005; HARLAN WR, 1993, ANN NY ACAD SCI, V699, P1, DOI 10.1111/j.1749-6632.1993.tb18831.x; HIMES JH, 1994, AM J CLIN NUTR, V59, P307, DOI 10.1093/ajcn/59.2.307; HOFFMANS MDAF, 1988, J CLIN EPIDEMIOL, V41, P749, DOI 10.1016/0895-4356(88)90161-8; KANNEL WB, 1974, MED CLIN N AM, V58, P363, DOI 10.1016/S0025-7125(16)32163-0; KARIM MR, 1988, GEE ASAS MACRO LONGI; KHAW K, 1982, CIRCULATION, V74, P239; KHOURY P, 1980, AM J EPIDEMIOL, V112, P524, DOI 10.1093/oxfordjournals.aje.a113022; LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355; Lipid Research Clinics Program, 1974, DHEW PUBL; MOSSBERG HO, 1989, LANCET, V2, P491; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; MUST A, 1991, AM J CLIN NUTR, V53, P839, DOI 10.1093/ajcn/53.4.839; *NAT CHOL ED PROGR, 1993, JAMA-J AM MED ASSOC, V269, P3015; POLONSKY SM, 1993, PEDIATRICS, V91, P92; RISSANEN AM, 1977, BRIT HEART J, V39, P875, DOI 10.1136/hrt.39.8.875; ROSE G, 1964, BRIT J PREV SOC MED, V18, P75; ROSENMAN RH, 1975, JAMA-J AM MED ASSOC, V233, P872, DOI 10.1001/jama.233.8.872; *SAS I INC, 1989, SAS STAT 7 US GUID V; SHEAR CL, 1985, AM J EPIDEMIOL, V122, P762, DOI 10.1093/oxfordjournals.aje.a114159; SMOAK CG, 1987, AM J EPIDEMIOL, V125, P364, DOI 10.1093/oxfordjournals.aje.a114543; Srinivasan SR, 1996, METABOLISM, V45, P235, DOI 10.1016/S0026-0495(96)90060-8; Srinivasan SR., 1983, CRC HDB ELECTROPHORE, P185; TROIANO RP, 1995, ARCH PEDIAT ADOL MED, V149, P1085, DOI 10.1001/archpedi.1995.02170230039005; WEBBER LS, 1979, PREV MED, V8, P407, DOI 10.1016/0091-7435(79)90018-5; [No title captured]; 1990, JAMA-J AM MED ASSOC, V264, P3018	40	125	130	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1749	1754		10.1001/jama.278.21.1749	http://dx.doi.org/10.1001/jama.278.21.1749			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388151				2022-12-24	WOS:A1997YH98700029
J	Nightingale, SL				Nightingale, SL			New warning information for Rezulin labeling	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1728	1728						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388135				2022-12-24	WOS:A1997YH98700008
J	Boston, BA; Blaydon, KM; Varnerin, J; Cone, RD				Boston, BA; Blaydon, KM; Varnerin, J; Cone, RD			Independent and additive effects of central POMC and leptin pathways on murine obesity	SCIENCE			English	Article							AGOUTI GENE; ECTOPIC EXPRESSION; MICE; RECEPTOR; CLONING; PROTEIN	The lethal yellow (A(Y)/a) mouse has a defect in proopiomelanocortin (POMC) signaling in the brain that leads to obesity, and is resistant to the anorexigenic effects of the hormone leptin. It has been proposed that the weight-reducing effects of leptin are thus transmitted primarily by way of POMC neurons. However, the central effects of defective POMC signaling, and the absence of leptin, on weight gain in double-mutant lethal yellow (A(Y)/a) leptin-deficient (lep(ob)/lep(ob)) mice were shown to be independent and additive, Furthermore, deletion of the leptin gene restored leptin sensitivity to A(Y)/a mice. This result implies that in the A(Y)/a mouse, obesity is independent of leptin action, and resistance to leptin results from desensitization of leptin signaling.	OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PEDIAT,PORTLAND,OR 97201; MERCK RES LABS,DEPT GENET & MOL BIOL,RAHWAY,NJ 07065	Oregon Health & Science University; Oregon Health & Science University; Merck & Company					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002404] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33703] Funding Source: Medline; NIDDK NIH HHS [DK/AR517330, DK02404] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Cheung CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/en.138.10.4489; DICKIE MM, 1962, J HERED, V53, P4; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Friedman JM, 1997, NATURE, V385, P119, DOI 10.1038/385119a0; Graham M, 1997, NAT GENET, V17, P273, DOI 10.1038/ng1197-273; Gura T, 1997, SCIENCE, V275, P751, DOI 10.1126/science.275.5301.751; HALAAS JL, 1997, P NATL ACAD SCI USA, V944, P8878; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Kesterson RA, 1997, MOL ENDOCRINOL, V11, P630, DOI 10.1210/me.11.5.630; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; PLOCHER TA, 1976, METABOLISM, V25, P593, DOI 10.1016/0026-0495(76)90013-5; SEELY RJ, IN PRESS NATURE; SHIMIZU H, 1989, AM J PHYSIOL, V256, P494; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; WOLFF GL, 1963, GENETICS, V48, P1041; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	25	205	207	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1641	1644		10.1126/science.278.5343.1641	http://dx.doi.org/10.1126/science.278.5343.1641			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374468				2022-12-24	WOS:A1997YJ87400047
J	Thomas, SA; Palmiter, RD				Thomas, SA; Palmiter, RD			Impaired maternal behavior in mice lacking norepinephrine and epinephrine	CELL			English	Article							OLFACTORY-BULB; TARGETED DISRUPTION; RECEPTOR SUBTYPE; POSTPARTUM RATS; SHEEP; RECOGNITION; EXPERIENCE; PARTURITION; GENE; CYCLOHEXIMIDE	The roles of norepinephrine (NE) and epinephrine in behavior were investigated by targeted disruption of the dopamine beta-hydroxylase (Dbh) gene, thereby eliminating these compounds in vivo. Most heterozygous pups born to Dbh(-/-) females died within several days of birth and were often found scattered within the bedding. Potential causes including deficits in olfaction and lactation were not apparent. A deficit in maternal behavior was confirmed by the lack of pup retrieval exhibited by Dbh(-/-) virgin females. Restoration of NE shortly before but not after birth induced females that previously abandoned their litters to act maternally. Our results suggest that NE is responsible for longlasting changes that promote maternal behavior during both development and parturition in mice.	UNIV WASHINGTON,DEPT BIOCHEM,HOWARD HUGHES MED INST,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle					NICHD NIH HHS [HD09172] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009172, R37HD009172] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARNES CD, 1991, PROGR BRAIN RES, V88; BLASS EM, 1980, SCIENCE, V210, P15, DOI 10.1126/science.6997992; BRENNAN P, 1990, SCIENCE, V250, P1223, DOI 10.1126/science.2147078; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; CALAMANDREI G, 1994, BEHAV NEUROSCI, V108, P113, DOI 10.1037/0735-7044.108.1.113; CALAMANDREI G, 1992, PHYSIOL BEHAV, V52, P901, DOI 10.1016/0031-9384(92)90369-D; DICKINSON C, 1988, PHYSIOL BEHAV, V43, P313, DOI 10.1016/0031-9384(88)90193-X; FLEMING AS, 1974, J COMP PHYSIOL PSYCH, V86, P957, DOI 10.1037/h0036414; FLEMING AS, 1990, BEHAV NEURAL BIOL, V53, P64, DOI 10.1016/0163-1047(90)90814-M; GRANDELMAN R, 1970, SCIENCE, V171, P210; Holets V.R., 1990, PHARM NORADRENALINE, P1; KABA H, 1988, NEUROSCIENCE, V25, P1007, DOI 10.1016/0306-4522(88)90053-X; KENDRICK KM, 1992, SCIENCE, V256, P833, DOI 10.1126/science.1589766; KENDRICK KM, 1988, BRAIN RES, V439, P1, DOI 10.1016/0006-8993(88)91455-2; KEVERNE EB, 1982, NATURE, V296, P148, DOI 10.1038/296148a0; KEVERNE EB, 1983, TRENDS NEUROSCI, V6, P381, DOI 10.1016/0166-2236(83)90170-4; KEVERNE EB, 1988, PSYCHONEUROENDOCRINO, V13, P127, DOI 10.1016/0306-4530(88)90010-8; LEVIMONT.R, 1966, PHARMACOL REV, V18, P619; LEVY F, 1993, BEHAV NEUROSCI, V107, P662, DOI 10.1037/0735-7044.107.4.662; LEVY F, 1990, BEHAV NEUROSCI, V104, P464, DOI 10.1037/0735-7044.104.3.464; Link RE, 1996, SCIENCE, V273, P803, DOI 10.1126/science.273.5276.803; MacMillan LB, 1996, SCIENCE, V273, P801, DOI 10.1126/science.273.5276.801; MALENFANT SA, 1991, PHYSIOL BEHAV, V49, P289, DOI 10.1016/0031-9384(91)90045-P; MOLTZ H, 1975, NEUROENDOCRINOLOGY, V19, P252, DOI 10.1159/000122445; Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699; NUMAN M, 1988, BEHAV NEUROSCI, V102, P381, DOI 10.1037/0735-7044.102.3.381; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; PISSONNIER D, 1985, PHYSIOL BEHAV, V35, P361, DOI 10.1016/0031-9384(85)90309-9; Rohrer DK, 1996, P NATL ACAD SCI USA, V93, P7375, DOI 10.1073/pnas.93.14.7375; ROSENBERG P, 1977, PHARMACOL BIOCHEM BE, V6, P21, DOI 10.1016/0091-3057(77)90155-1; ROSENBERG P, 1976, PHARMACOL BIOCHEM BE, V4, P647, DOI 10.1016/0091-3057(76)90215-X; ROSENBLATT JS, 1967, SCIENCE, V156, P1512, DOI 10.1126/science.156.3781.1512; ROSSER AE, 1985, NEUROSCIENCE, V15, P1141, DOI 10.1016/0306-4522(85)90258-1; Sallinen J, 1997, MOL PHARMACOL, V51, P36, DOI 10.1124/mol.51.1.36; SMOTHERMAN WP, 1974, BEHAV BIOL, V12, P55, DOI 10.1016/S0091-6773(74)91026-8; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; Szabadi E, 1991, ADRENOCEPTORS STRUCT; Tafari AT, 1997, J NEUROSCI, V17, P4275; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; Thomas SA, 1997, BEHAV NEUROSCI, V111, P579, DOI 10.1037/0735-7044.111.3.579; Thomas SA, 1997, NATURE, V387, P94, DOI 10.1038/387094a0	41	133	133	2	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					583	592		10.1016/S0092-8674(00)80446-8	http://dx.doi.org/10.1016/S0092-8674(00)80446-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393852	Bronze			2022-12-24	WOS:A1997YH96000006
J	Iwahashi, H; Eguchi, Y; Yasuhara, N; Hanafusa, T; Matsuzawa, Y; Tsujimoto, Y				Iwahashi, H; Eguchi, Y; Yasuhara, N; Hanafusa, T; Matsuzawa, Y; Tsujimoto, Y			Synergistic anti-apoptotic activity between Bcl-2 and SMN implicated in spinal muscular atrophy	NATURE			English	Article							MOTOR-NEURON GENE; MITOCHONDRIAL-MEMBRANES; ENDOPLASMIC-RETICULUM; CELL-DEATH; SURVIVAL; PROTEIN; EXPRESSION; BCL-X(L); ADULT; BAD	Spinal muscular atrophy (SMA) is a motor neuron disease characterized by degeneration of the anterior horn cells of the spinal cord. It is a common fatal autosomal recessive disorder and linkage studies have identified two candidate genes, SMN (ref. 1) and NAIP (ref. 2), both on chromosome 5q13. Although NAIP protein is know to have an anti-apoptotic function(3), the function of SMN has been unclear and it shows no significant sequence similarity to any other protein. The SMN gene is deleted or interrupted on both chromosomes in nearly all SMA patients(1) Here we show that SMN interacts with Bcl-2, another anti-apoptotic that co-expression of SMN with Bcl-2 confers a synergistic preventive effect against Bar-induced or Fas-mediated apoptosis, although SMN itself has only a weak anti-apoptotic activity. SMNY272C, which carries a missense mutation and was found in an SMA patient who exceptionally retained SMN on one allele(1), exerts no synergism with Bcl-2. Furthermore, the product of a truncated transcript lacking exon 7, which was derived from an SMN gene carrying an intragenic mutation or from the SMN copy gene (C)BCD541 (ref. 1) retained in all SMA patients, had no synergistic activity but instead had a dominant-negative effect on full-length SMN. Our results indicate that an absent or decreased anti-apoptotic activity of SMN in concert with Bcl-2 underlies the pathogenesis of SMA.	OSAKA UNIV,SCH MED,DEPT MED GENET,BIOMED RES CTR,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT INTERNAL MED 2,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			Iwahashi, Hitoshi/S-1360-2019					AKAO Y, 1994, CANCER RES, V54, P2468; Burlet P, 1996, J MED GENET, V33, P281, DOI 10.1136/jmg.33.4.281; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GENNARELLI M, 1995, BIOCHEM BIOPH RES CO, V213, P342, DOI 10.1006/bbrc.1995.2135; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; MERRY DE, 1994, DEVELOPMENT, V120, P301; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5	17	170	173	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					413	417		10.1038/37144	http://dx.doi.org/10.1038/37144			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389483				2022-12-24	WOS:A1997YH54900067
J	Roubey, RAS; Hoffman, M				Roubey, RAS; Hoffman, M			From antiphospholipid syndrome to antibody-mediated thrombosis	LANCET			English	Editorial Material							SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTICARDIOLIPIN ANTIBODIES; PROCOAGULANT ACTIVITY; ANTICOAGULANT; BINDING; MEMBRANES; MONOCYTES; IGG		DUKE UNIV, DEPT PATHOL, DURHAM, NC 27706 USA	Duke University	Roubey, RAS (corresponding author), UNIV N CAROLINA, DIV RHEUMATOL & IMMUNOL, CHAPEL HILL, NC 27599 USA.		Hoffman, Maureane/D-1025-2009	Hoffman, Maureane/0000-0001-7123-0100				Cuadrado MJ, 1997, ARTHRITIS RHEUM-US, V40, P834, DOI 10.1002/art.1780400509; DELPAPA N, 1995, CLIN EXP RHEUMATOL, V13, P179; GINSBERG JS, 1993, BLOOD, V81, P2958; GINSBURG KS, 1992, ANN INTERN MED, V117, P997, DOI 10.7326/0003-4819-117-12-997; KITTNER SJ, 1992, STROKE, V23, pI19; KORNBERG A, 1994, J IMMUNOL, V153, P1328; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; Pradier O, 1996, BLOOD, V87, P3768, DOI 10.1182/blood.V87.9.3768.bloodjournal8793768; Rand JH, 1997, NEW ENGL J MED, V337, P154, DOI 10.1056/NEJM199707173370303; Rao LVM, 1996, BLOOD, V88, P4173; Roubey RAS, 1996, ARTHRITIS RHEUM-US, V39, P1444, DOI 10.1002/art.1780390903; SCHVED JF, 1992, AM J HEMATOL, V41, P92, DOI 10.1002/ajh.2830410205; SIMANTOV R, 1995, J CLIN INVEST, V96, P2211, DOI 10.1172/JCI118276; Takeya H, 1997, J CLIN INVEST, V99, P2260, DOI 10.1172/JCI119401; Willems GM, 1996, BIOCHEMISTRY-US, V35, P13833, DOI 10.1021/bi960657q	15	78	80	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1491	1493		10.1016/S0140-6736(05)63936-0	http://dx.doi.org/10.1016/S0140-6736(05)63936-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388393				2022-12-24	WOS:A1997YH11500004
J	Rosenberg, ES; Billingsley, JM; Caliendo, AM; Boswell, SL; Sax, PE; Kalams, SA; Walker, BD				Rosenberg, ES; Billingsley, JM; Caliendo, AM; Boswell, SL; Sax, PE; Kalams, SA; Walker, BD			Vigorous HIV-1-specific CD4(+) T cell responses associated with control of viremia	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 INFECTION; IN-VITRO; IMMUNE-RESPONSE; DEFICIENT MICE; LYMPHOCYTES; RECOGNITION; ANTIGEN; CYTOMEGALOVIRUS; IMMUNIZATION	Virus-specific CD4(+) T helper lymphocytes are critical to the maintenance of effective immunity in a number of chronic viral infections, but are characteristically undetectable in chronic human immunodeficiency virus-type 1 (HIV-1) infection. In individuals who control viremia in the absence of antiviral therapy, polyclonal, persistent, and vigorous HIV-1-specific CD4(+) T cell proliferative responses were present, resulting in the elaboration of interferon-gamma and antiviral beta chemokines. In persons with chronic infection, HIV-1-specific proliferative responses to p24 were inversely related to viral load. Strong HIV-1-specific proliferative responses were also detected following treatment of acutely infected persons with potent antiviral therapy. The HIV-1-specific helper cells are likely to be important in immunotherapeutic interventions and vaccine development.	MASSACHUSETTS GEN HOSP, PARTNERS AIDS RES CTR, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, INFECT DIS UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02114 USA; FENWAY COMMUNITY HLTH CTR, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV INFECT DIS, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital					NIAID NIH HHS [F32-AI09738, R01-AI28568] Funding Source: Medline; PHS HHS [R01-A136550] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028568, F32AI009738] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BATTEGAY M, 1994, J VIROL, V68, P4700, DOI 10.1128/JVI.68.7.4700-4704.1994; BERZOFSKY JA, 1988, NATURE, V334, P706, DOI 10.1038/334706a0; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CLERICI M, 1989, NATURE, V339, P383, DOI 10.1038/339383a0; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; DESTGROTH SF, 1982, J IMMUNOL METHODS, V49, pR11, DOI 10.1016/0022-1759(82)90269-1; DOLAN MJ, 1995, J INFECT DIS, V172, P79, DOI 10.1093/infdis/172.1.79; EPSTEIN JS, 1985, J INFECT DIS, V152, P727, DOI 10.1093/infdis/152.4.727; Harrer T, 1996, J IMMUNOL, V156, P2616; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; KALAMS S, UNPUB; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KROWKA JF, 1989, J CLIN INVEST, V83, P1198, DOI 10.1172/JCI114001; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LAURENCE J, 1989, J CLIN INVEST, V83, P1843, DOI 10.1172/JCI114090; Lekutis C, 1997, J IMMUNOL, V158, P4471; Lekutis C, 1997, J IMMUNOL, V159, P2049; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MURRAY HW, 1984, NEW ENGL J MED, V310, P883, DOI 10.1056/NEJM198404053101404; PANTALEO G, 1995, NEW ENGL J MED, V69, P5838; Planz O, 1997, P NATL ACAD SCI USA, V94, P6874, DOI 10.1073/pnas.94.13.6874; PONTESILLI O, 1994, AIDS RES HUM RETROV, V10, P113, DOI 10.1089/aid.1994.10.113; ROOS MTL, 1995, J INFECT DIS, V171, P531, DOI 10.1093/infdis/171.3.531; ROSENBERG E, UNPUB; Schnittman SM, 1997, AIDS RES HUM RETROV, V13, P815, DOI 10.1089/aid.1997.13.815; SCHRIER RD, 1989, J IMMUNOL, V142, P1166; SCHWARTZ D, 1994, AIDS RES HUM RETROV, V10, P1703, DOI 10.1089/aid.1994.10.1703; Stanley SK, 1996, NEW ENGL J MED, V334, P1222, DOI 10.1056/NEJM199605093341903; Thomsen AR, 1996, J IMMUNOL, V157, P3074; vonHerrath MG, 1996, J VIROL, V70, P1072, DOI 10.1128/JVI.70.2.1072-1079.1996; WAHREN B, 1987, J VIROL, V61, P2017, DOI 10.1128/JVI.61.6.2017-2023.1987; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Weissman D, 1996, J EXP MED, V183, P687, DOI 10.1084/jem.183.2.687	42	1572	1603	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 21	1997	278	5342					1447	1450		10.1126/science.278.5342.1447	http://dx.doi.org/10.1126/science.278.5342.1447			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367954				2022-12-24	WOS:A1997YG85800040
J	Naren, AP; Nelson, DJ; Xie, WW; Jovov, B; Pevsner, J; Bennett, MK; Benos, DJ; Quick, MW; Kirk, KL				Naren, AP; Nelson, DJ; Xie, WW; Jovov, B; Pevsner, J; Bennett, MK; Benos, DJ; Quick, MW; Kirk, KL			Regulation of CFTR chloride channels by syntaxin and Munc18 isoforms	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; N-TYPE; CALCIUM CHANNELS; EPITHELIAL-CELLS; PROTEIN-KINASE; CL CHANNEL; COMPLEX; PHOSPHORYLATION; TRANSPORT	The cystic fibrosis gene encodes a cyclic AMP-gated chloride channel (CFTR) that mediates electrolyte transport across the luminal surfaces of a variety of epithelial cells(1-4). The molecular mechanisms that modulate CFTR activity in epithelial tissues are poorly understood, Here we show that CFTR is regulated by an epithelially expressed syntaxin (syntaxin 1A), a membrane protein that also modulates neurosecretion(5-7) and calcium-channel gatings(8-11) in brain, Syntaxin 1A physically interacts with CFTR chloride channels and regulates CFTR-mediated currents both in Xenopus oocytes and in epithelial cells that normally express these proteins. The physical and functional interactions between syntaxin 1A and CFTR are blocked by a syntaxin-binding protein of the Munc18 protein family (also called n-Sec1; refs 12-14). Our results indicate that CFTR function in epithelial cells is regulated by an interplay between syntaxin and Munc18 isoforms.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,GREGORY FLEMING JAMES CYST FIBROSIS RES CTR,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT NEUROBIOL,BIRMINGHAM,AL 35294; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60037; UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60037; KENNEDY KRIEGER INST,DEPT NEUROSCI,BALTIMORE,MD 21250; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21250; UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Chicago; University of Chicago; Kennedy Krieger Institute; Johns Hopkins University; University of California System; University of California Berkeley								ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; CHAN HC, 1992, J BIOL CHEM, V267, P8411; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLIFF WH, 1992, AM J PHYSIOL, V262, pC1154, DOI 10.1152/ajpcell.1992.262.5.C1154; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; JOVOV B, 1995, J BIOL CHEM, V270, P29194, DOI 10.1074/jbc.270.49.29194; MCCARTY NA, 1993, J GEN PHYSIOL, V102, P1, DOI 10.1085/jgp.102.1.1; Meffert MK, 1996, NEURON, V16, P1229, DOI 10.1016/S0896-6273(00)80149-X; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WEBER E, 1994, J CELL BIOL, V125, P538; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Xie WW, 1996, J BIOL CHEM, V271, P14092, DOI 10.1074/jbc.271.24.14092	26	179	181	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					302	305		10.1038/36882	http://dx.doi.org/10.1038/36882			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384384				2022-12-24	WOS:A1997YG66700067
J	Rodvold, KA; Danziger, LH; Quinn, JP				Rodvold, KA; Danziger, LH; Quinn, JP			Single daily doses of aminoglycosides - Commentary	LANCET			English	Editorial Material									UNIV ILLINOIS,COLL MED,DEPT MED,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Rodvold, KA (corresponding author), UNIV ILLINOIS,COLL PHARM,DEPT PHARM PRACTICE,CHICAGO,IL 60612, USA.							Ali MZ, 1997, CLIN INFECT DIS, V24, P796, DOI 10.1093/clinids/24.5.796; Bailey TC, 1997, CLIN INFECT DIS, V24, P786, DOI 10.1093/clinids/24.5.786; Bertino JS, 1997, CLIN INFECT DIS, V24, P820, DOI 10.1093/clinids/24.5.820; Freeman CD, 1997, J ANTIMICROB CHEMOTH, V39, P677, DOI 10.1093/jac/39.6.677; GILBERT DN, 1997, CLIN INFECT DIS, V21, P816; Hatala R, 1997, CLIN INFECT DIS, V24, P810, DOI 10.1093/clinids/24.5.810; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; Urban A W, 1997, Curr Clin Top Infect Dis, V17, P236	8	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 15	1997	350	9089					1412	1412		10.1016/S0140-6736(97)22046-5	http://dx.doi.org/10.1016/S0140-6736(97)22046-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF953	9371159				2022-12-24	WOS:A1997YF95300002
J	Munoz, V; Thompson, PA; Hofrichter, J; Eaton, WA				Munoz, V; Thompson, PA; Hofrichter, J; Eaton, WA			Folding dynamics and mechanism of beta-hairpin formation	NATURE			English	Article							SHORT LINEAR PEPTIDE; AQUEOUS-SOLUTION; PROTEIN; STABILITY; DESIGN	Protein chains coil into alpha-helices and beta-sheet structures. Knowing the timescales and mechanism of formation of these basic structural elements is essential for understanding how proteins fold(1). For the past 40 years, alpha-helix formation has been extensively investigated in synthetic and natural peptides(2-5), including by nanosecond kinetic studies(6,7). In contrast, the mechanism of formation of beta structures has not been studied experimentally. The minimal beta-structure element is the beta-hairpin, which is also the basic component of antiparallel beta-sheets. Here we use a nanosecond laser temperature-jump apparatus to study the kinetics of folding a beta-hairpin consisting of 16 amino-acid residues. Folding of the hairpin occurs in 6 mu s at room temperature, which is about 30 times slower than the rate of alpha-helix formation(6,7). We have developed a simple statistical mechanical model that provides a structural explanation for this result, Our analysis also shows that folding of a beta-hairpin captures much of the basic physics of protein folding; including stabilization by hydrogen bonding and hydrophobic interactions, two-state behaviour, and a funnel-like, partially rugged energy landscape.			Munoz, V (corresponding author), NIDDK,PHYS CHEM LAB,NIH,BLDG 5,BETHESDA,MD 20892, USA.							BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BLANCO FJ, 1993, J AM CHEM SOC, V115, P5887, DOI 10.1021/ja00066a092; BLANCO FJ, 1994, NAT STRUCT BIOL, V1, P584, DOI 10.1038/nsb0994-584; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; deAlba E, 1996, FOLD DES, V1, P133, DOI 10.1016/S1359-0278(96)00022-3; Eaton WA, 1997, CURR OPIN STRUC BIOL, V7, P10, DOI 10.1016/S0959-440X(97)80003-6; Fersht AR, 1997, CURR OPIN STRUC BIOL, V7, P3, DOI 10.1016/S0959-440X(97)80002-4; GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600; GRUENEWALD B, 1979, BIOPHYS CHEM, V9, P137, DOI 10.1016/0301-4622(79)87008-8; Hagen SJ, 1996, P NATL ACAD SCI USA, V93, P11615, DOI 10.1073/pnas.93.21.11615; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; Klimov DK, 1997, PHYS REV LETT, V79, P317, DOI 10.1103/PhysRevLett.79.317; KOBAYASHI N, 1993, PEPTIDE CHEMISTRY 1992, P278; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; MUNOZ V, 1995, CURR OPIN BIOTECH, V6, P382, DOI 10.1016/0958-1669(95)80066-2; PHILLIPS CM, 1995, P NATL ACAD SCI USA, V92, P7292, DOI 10.1073/pnas.92.16.7292; RamirezAlvarado M, 1996, NAT STRUCT BIOL, V3, P604, DOI 10.1038/nsb0796-604; SEARLE MS, 1995, NAT STRUCT BIOL, V2, P999, DOI 10.1038/nsb1195-999; Sieber V, 1996, BIOCHEMISTRY-US, V35, P181, DOI 10.1021/bi950681o; Thompson PA, 1997, BIOCHEMISTRY-US, V36, P9200, DOI 10.1021/bi9704764; Thompson PA, 1997, TECH PROT CHEM, V8, P735, DOI 10.1016/S1080-8914(97)80072-5; Williams S, 1996, BIOCHEMISTRY-US, V35, P691, DOI 10.1021/bi952217p; ZIMM BH, 1959, P NATL ACAD SCI USA, V45, P1601, DOI 10.1073/pnas.45.11.1601	24	858	865	4	122	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					196	199		10.1038/36626	http://dx.doi.org/10.1038/36626			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367160				2022-12-24	WOS:A1997YF49400060
J	Pegoraro, A; Singh, A; Bakir, AA; Arruda, JAL; Dunea, G				Pegoraro, A; Singh, A; Bakir, AA; Arruda, JAL; Dunea, G			Simplified screening for microalbuminuria	ANNALS OF INTERNAL MEDICINE			English	Article							URINARY ALBUMIN EXCRETION; DIABETIC-PATIENTS; PREDICTOR	Background: Screening for microalbuminuria is increasingly advocated as a way to diagnose early renal involvement in diabetes and other diseases. It usually entails the use of a radioimmunoassay that is expensive and not always readily available. Objective: To assess the efficacy of three simple and inexpensive tests for ruling out microalbuminuria. Design: Cross-sectional study. Setting: Outpatient clinics. Patients: 221 patients from primary care clinics and a diabetes clinic. Measurements: Random urine specimens were tested for albumin by using Micral-Test immunoassay strips (Boehringer Mannheim, Mannheim, Germany) and for protein by using sulfosalicylic acid testing and impregnated dipsticks (Chemstrips, Boehringer Mannheim). Radioimmunoassay for albumin was used for all specimens as standard for comparison. Results: When less than 20 mg/L was considered the upper limit of normal for albumin concentration, Micral-Test, sulfosalicylic acid testing, and Chemstrips had negative predictive values of 99%, 95%, and 96%, respectively. Seventy-four specimens tested negative on both sulfosalicylic acid and Chemstrips; the negative predictive value of these two tests combined was 99%. Conclusions: The combination of sulfosalicylic acid testing and Chemstrips was as good as and less expensive than Micral-Test in ruling out microalbuminuria.	UNIV ILLINOIS, NEPHROL SECT, CHICAGO, IL 60612 USA; W SIDE VET ADM MED CTR, CHICAGO, IL USA; HEKTOEN INST MED RES, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Pegoraro, A (corresponding author), COOK CTY HOSP, NEPHROL SECT, 637 S WOOD ST, CHICAGO, IL 60612 USA.							BASHYAM MM, 1993, DIABETES CARE, V16, P634, DOI 10.2337/diacare.16.4.634; BORCHJOHNSEN K, 1993, BRIT MED J, V306, P1722, DOI 10.1136/bmj.306.6894.1722; COWELL CT, 1986, DIABETOLOGIA, V29, P97, DOI 10.1007/BF00456117; DEGRAUW WJC, 1995, DIABETIC MED, V12, P657; ESHOJ O, 1987, DIABETIC MED, V4, P531, DOI 10.1111/j.1464-5491.1987.tb00924.x; GYURE WL, 1977, CLIN CHEM, V23, P876; HASSLACHER C, 1993, CLIN BIOCHEM, V26, P283, DOI 10.1016/0009-9120(93)90126-Q; HUTCHISON AS, 1988, CLIN CHEM, V34, P2019; JOHNSTON J, 1993, BRIT MED J, V306, P493, DOI 10.1136/bmj.306.6876.493-a; KUTTER D, 1995, EUR J CLIN CHEM CLIN, V33, P243; LEFLOCH JP, 1994, DIABETIC MED, V11, P349; MARSHALL SM, 1992, CLIN CHEM, V38, P588; MEYER NL, 1994, AM J OBSTET GYNECOL, V170, P137; MOGENSEN CE, 1987, KIDNEY INT, V31, P673, DOI 10.1038/ki.1987.50; MOGENSEN CE, 1985, UREMIA INVEST, V9, P85, DOI 10.3109/08860228509088195; SILVER A, 1986, CLIN CHEM, V32, P1303; TAI J, 1990, DIABETES RES CLIN PR, V9, P137, DOI 10.1016/0168-8227(90)90105-3; TIU SC, 1993, DIABETES CARE, V16, P616, DOI 10.2337/diacare.16.4.616; WINOCOUR PH, 1992, BRIT MED J, V304, P1196, DOI 10.1136/bmj.304.6836.1196	19	20	20	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					817	819		10.7326/0003-4819-127-9-199711010-00007	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD898	9382403				2022-12-24	WOS:A1997YD89800006
J	Arioli, T; Peng, LC; Betzner, AS; Burn, J; Wittke, W; Herth, W; Camilleri, C; Hofte, H; Plazinski, J; Birch, R; Cork, A; Glover, J; Redmond, J; Williamson, RE				Arioli, T; Peng, LC; Betzner, AS; Burn, J; Wittke, W; Herth, W; Camilleri, C; Hofte, H; Plazinski, J; Birch, R; Cork, A; Glover, J; Redmond, J; Williamson, RE			Molecular analysis of cellulose biosynthesis in Arabidopsis	SCIENCE			English	Article							PLASMA-MEMBRANE ROSETTES; PLANT TRANSFORMATION; ACETOBACTER-XYLINUM; CATALYTIC SUBUNIT; THALIANA; SEQUENCE; SYNTHASE; GENE; GENOME; MAP	Cellulose, an abundant, crystalline polysaccharide, is central to plant morphogenesis and to many industries. Chemical and ultrastructural analyses together with map-based cloning indicate that the RSW1 locus of Arabidopsis encodes the catalytic subunit of cellulose synthase. The cloned gene complements the rsw1 mutant whose temperature-sensitive allele is changed in one amino acid. The mutant allele causes a specific reduction in cellulose synthesis, accumulation of noncrystalline beta-1,4-glucan, disassembly of cellulose synthase, and widespread morphological abnormalities. Microfibril crystallization may require proper assembly of the RSW1 gene product into synthase complexes whereas glucan biosynthesis per se does not.	Australian Natl Univ, Res Sch Biol Sci, Plant Cell Biol Grp, Glycobiol Unit, Canberra, ACT 2601, Australia; Australian Natl Univ, Cooperat Res Ctr Plant Sci, Res Sch Biol Sci, Canberra, ACT 2601, Australia; Grp Limagrain Pacific, Canberra, ACT 2601, Australia; Zellenlehre, D-69120 Heidelberg, Germany; INRA, Biol Cellulaire Lab, F-78026 Versailles, France	Australian National University; Australian National University; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Williamson, RE (corresponding author), Australian Natl Univ, Res Sch Biol Sci, Plant Cell Biol Grp, Glycobiol Unit, POB 475, Canberra, ACT 2601, Australia.	richard@rsbs.anu.edu.au						BASKIN TI, 1992, AUST J PLANT PHYSIOL, V19, P427, DOI 10.1071/PP9920427; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; CARPITA NC, 1989, ANAL CARBOHYDRATES G, P157; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; Cutler S, 1997, CURR BIOL, V7, pR108, DOI 10.1016/S0960-9822(06)00050-9; DELMER DP, 1995, PLANT CELL, V7, P987, DOI 10.1105/tpc.7.7.987; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOARES SH, 1991, CARBOHYD RES, V210, P311, DOI 10.1016/0008-6215(91)80131-6; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; HELM DR, 1991, PESTIC BIOCH PHYSL, V39, P93; HERTH W, 1985, PLANTA, V164, P12, DOI 10.1007/BF00391020; HERTH W, 1985, BOTANICAL MICROSCOPY, P285; HOFTE H, 1993, PLANT J, V4, P1051, DOI 10.1046/j.1365-313X.1993.04061051.x; Kawagoe Yasushi, 1997, Plant Physiology (Rockville), V114, P85; KONCZ C, 1992, METHODS ARABIDOPSISR; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; Kutish GF, 1996, VIROLOGY, V223, P303, DOI 10.1006/viro.1996.0482; MATTHYSSE AG, 1995, J BACTERIOL, V177, P1069, DOI 10.1128/jb.177.4.1069-1075.1995; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; NEEDS PW, 1993, PHYTOCHEM ANALYSIS, V4, P210, DOI 10.1002/pca.2800040504; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; Pear JR, 1996, P NATL ACAD SCI USA, V93, P12637, DOI 10.1073/pnas.93.22.12637; Saxena IM, 1997, CELLULOSE, V4, P33, DOI 10.1023/A:1018411101036; SAXENA IM, 1990, PLANT MOL BIOL, V15, P673, DOI 10.1007/BF00016118; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Schmidt R, 1996, PLANT J, V9, P755, DOI 10.1046/j.1365-313X.1996.9050755.x; SCHNEIDER B, 1986, PROTOPLASMA, V131, P142, DOI 10.1007/BF01285036; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; UPDEGRAFF DM, 1969, ANAL BIOCHEM, V32, P420, DOI 10.1016/S0003-2697(69)80009-6; WONG HC, 1990, P NATL ACAD SCI USA, V87, P8130, DOI 10.1073/pnas.87.20.8130	32	624	689	15	153	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	1998	279	5351					717	720		10.1126/science.279.5351.717	http://dx.doi.org/10.1126/science.279.5351.717			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445479				2022-12-24	WOS:000071731500040
J	Nimnual, AS; Yatsula, BA; Bar-Sagi, D				Nimnual, AS; Yatsula, BA; Bar-Sagi, D			Coupling of Ras and Rac guanosine triphosphatases through the Ras exchanger Sos	SCIENCE			English	Article							TRANSFORMATION; ACTIVATION; PROTEIN; PATHWAY; KINASE; DBL; PLECKSTRIN; EFFECTORS; SEVENLESS; DISTINCT	The Son of Sevenless (Sos) proteins control receptor-mediated activation of Ras by catalyzing the exchange of guanosine diphosphate for guanosine triphosphate on Ras. The NH2-terminal region of Sos contains a Dbl homology (DH) domain in tandem with a pleckstrin homology (PH) domain. In COS-1 cells, the DH domain of Sos stimulated guanine nucleotide exchange on Rac but not Cdc42 in vitro and in vivo. The tandem DH-PH domain of Sos (DH-PH-Sos) was defective in Rac activation but regained Rac stimulating activity when it was coexpressed with activated Ras, Ras-mediated activation of DH-PH-Sos did not require activation of mitogen-activated protein kinase but it was dependent on activation of phosphoinositide 3-kinase. These results reveal a potential mechanism for coupling of Ras and Rac signaling pathways.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bar-Sagi, D (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NCI NIH HHS [CA55360, CA09176, CA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA055360, P01CA028146, R01CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1994, TRENDS ENDOCRIN MET, V5, P165, DOI 10.1016/1043-2760(94)90014-0; BROEK D, COMMUNICATION; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NIMNUAL A, UNPUB; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAMEH LE, 1997, J BIOL CHEM, V272, P21999; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; YATSULA B, UNPUB; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	30	382	386	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					560	563		10.1126/science.279.5350.560	http://dx.doi.org/10.1126/science.279.5350.560			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438849				2022-12-24	WOS:000071616000046
J	Sullivan, R; Greeley, R; Homan, K; Klemaszewski, J; Belton, MJS; Carr, MH; Chapman, CR; Tufts, R; Head, JW; Pappalardo, R; Moore, J; Thomas, P				Sullivan, R; Greeley, R; Homan, K; Klemaszewski, J; Belton, MJS; Carr, MH; Chapman, CR; Tufts, R; Head, JW; Pappalardo, R; Moore, J; Thomas, P		Galileo Imaging Team	Episodic plate separation and fracture infill on the surface of Europa	NATURE			English	Article								Images obtained by the Voyager spacecraft revealed dark, wedge-shaped bands on Europa that were interpreted as evidence that surface plates, 50-100 km across, moved and rotated relative to each other(1). This implied that they may be mechanically decoupled from the interior by a layer of warm ice or Liquid water(2,3). Here we report similar features seen in higher resolution images (420 metres per pixel) obtained by the Galileo spacecraft that reveal new details of wedge-band formation. In particular, the interior of one dark band shows bilateral symmetry of parallel lineaments and pit complexes which indicates that plate separation occurred in discrete episodes from a central axis. The images also show that this style of tectonic activity involved plates < 10 km across. Although this tectonic style superficially resembles aspects of similar activity on Earth, such as sea-floor spreading and the formation of ice leads in polar seas, there are significant differences in the underlying physical mechanisms: the wedge-shaped bands on Europa most probably formed when lower material (ice or water) rose to fill the fractures that widened in response to regional surface stresses.	Cornell Univ, Ithaca, NY 14853 USA; Natl Opt Astron Observ, Tucson, AZ 85719 USA; US Geol Survey, Menlo Pk, CA 94025 USA; SW Res Inst, Boulder, CO 80302 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA	Cornell University; National Optical Astronomy Observatory; United States Department of the Interior; United States Geological Survey; University of Arizona; Brown University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Arizona State University; Arizona State University-Tempe	Sullivan, R (corresponding author), Cornell Univ, 308 Space Sci, Ithaca, NY 14853 USA.		Pappalardo, Robert/AAP-8953-2021; Sullivan, Robert/AAR-8193-2020	Pappalardo, Robert/0000-0003-2571-4627; 				Anderson JD, 1997, SCIENCE, V276, P1236, DOI 10.1126/science.276.5316.1236; Belton MJS, 1996, SCIENCE, V274, P377, DOI 10.1126/science.274.5286.377; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; FANALE FP, 1977, PLANETARY SATELLITES, P379; GOLOMBEK MP, 1990, ICARUS, V83, P441, DOI 10.1016/0019-1035(90)90078-N; Pappalardo RT, 1996, ICARUS, V123, P557, DOI 10.1006/icar.1996.0178; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; SCHENK PM, 1989, ICARUS, V79, P75, DOI 10.1016/0019-1035(89)90109-7; SCHENK PM, 1980, EOS T AM GEOPHYS UN, V61, P286; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; TUFTS BR, 1996, LUNAR PLANET SCI, V27, P1343; TUFTS BR, 1993, LUN PLANET SCI C, V24, P1445; TUFTS BR, 1997, LUNAR PLANET SCI C, V28, P1455	13	88	89	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					371	373		10.1038/34874	http://dx.doi.org/10.1038/34874			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450752				2022-12-24	WOS:000071604200048
J	Arap, W; Pasqualini, R; Ruoslahti, E				Arap, W; Pasqualini, R; Ruoslahti, E			Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model	SCIENCE			English	Article							PHAGE DISPLAY LIBRARY; INTEGRIN ALPHA(V)BETA(3); SOLID TUMORS; ANGIOGENESIS; PEPTIDE; THERAPY; ANTIBODIES; RECEPTOR; BINDING; LIGAND	In vivo selection of phage display libraries was used to isolate peptides that home specifically to tumor blood vessels. When coupled to the anticancer drug doxorubicin, two of these peptides-one containing an alpha(v) integrin-binding Arg-Gly-Asp motif and the other an Asn-Gly-Arg motif-enhanced the efficacy of the drug against human breast cancer xenografts in nude mice and also reduced its toxicity. These results indicate that it may be possible to develop targeted chemotherapy strategies that are based on selective expression of receptors in tumor vasculature.	Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Ruoslahti, E (corresponding author), Burnham Inst, Ctr Canc Res, N Torrey Pines Rd, La Jolla, CA 92037 USA.	ruoslahti@burnham-inst.org			NATIONAL CANCER INSTITUTE [R01CA074238, R01CA062042, P30CA030199] Funding Source: NIH RePORTER; NCI NIH HHS [CA74238-01, CA62042, CA30199] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAP W, UNPUB; Bauminger S, 1980, Methods Enzymol, V70, P151; Berger DP, 1991, NUDE MOUSE ONCOLOGY, P165; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BURROWS FJ, 1994, PHARMACOL THERAPEUT, V64, P155, DOI 10.1016/0163-7258(94)90037-X; DENEKAMP J, 1993, BRIT J RADIOL, V66, P181, DOI 10.1259/0007-1285-66-783-181; DVORAK HF, 1991, CANCER CELL-MON REV, V3, P77; Folkman J, 1997, NAT BIOTECHNOL, V15, P510, DOI 10.1038/nbt0697-510; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman Judah, 1997, P3075; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GETTER MR, 1973, NATURE, V246, P221; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HART SL, 1994, J BIOL CHEM, V269, P12468; HEALY JM, 1995, BIOCHEMISTRY-US, V34, P3948, DOI 10.1021/bi00012a012; JAIN RK, 1996, CANCER METAST REV, V9, P253; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; Max R, 1997, INT J CANCER, V71, P320, DOI 10.1002/(SICI)1097-0215(19970502)71:3<320::AID-IJC2>3.3.CO;2-3; Max R, 1997, INT J CANCER, V72, P706, DOI 10.1002/(SICI)1097-0215(19970807)72:4<706::AID-IJC25>3.0.CO;2-7; Nagy A, 1996, P NATL ACAD SCI USA, V93, P7269, DOI 10.1073/pnas.93.14.7269; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; RAJOTTE D, UNPUB; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SAKAMOTO M, UNPUB; SHOCKLEY TR, 1991, ANN NY ACAD SCI, V618, P367, DOI 10.1111/j.1749-6632.1991.tb27257.x; Steiner R, 1992, EXS, V61, P449	37	1732	1987	8	422	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	1998	279	5349					377	380		10.1126/science.279.5349.377	http://dx.doi.org/10.1126/science.279.5349.377			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430587				2022-12-24	WOS:000071570800045
J	Bada, JL; Glavin, DP; McDonald, GD; Becker, L				Bada, JL; Glavin, DP; McDonald, GD; Becker, L			A search for endogenous amino acids in martian meteorite ALH84001	SCIENCE			English	Article							MURCHISON METEORITE; GENERATION; HYDROLYSIS; MARS	Trace amounts of glycine, serine, and alanine were detected in the carbonate component of the martian meteorite ALH84001 by high-performance liquid chromatography. The detected amino acids were not uniformly distributed in the carbonate component and ranged in concentration from 0.1 to 7 parts per million. Although the detected alanine consists primarily of the L enantiomer, low concentrations (<0.1 parts per million) of endogenous D-alanine may be present in the ALH84001 carbonates. The amino acids present in this sample of ALH84001 appear to be terrestrial in origin and similar to those in Allan Hills ice, although the possibility cannot be ruled out that minute amounts of some amino acids such as D-alanine are preserved in the meteorite.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Hawaii, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Hawaii System	Bada, JL (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.	jbada@ucsd.edu	Glavin, Daniel P/D-6194-2012	Glavin, Daniel P/0000-0001-7779-7765				ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; BADA JL, 1995, NATURE, V374, P594, DOI 10.1038/374594a0; Bada JL, 1996, ANAL CHEM, V68, pA668, DOI 10.1021/ac9621231; BADA JL, 1983, NATURE, V301, P494, DOI 10.1038/301494a0; Bada JL, 1997, SCIENCE, V275, P942, DOI 10.1126/science.275.5302.942; Becker L, 1997, GEOCHIM COSMOCHIM AC, V61, P475, DOI 10.1016/S0016-7037(96)00400-0; Brinton KLF, 1996, GEOCHIM COSMOCHIM AC, V60, P349, DOI 10.1016/0016-7037(95)00404-1; BRINTON KLF, IN PRESS ORIGINS LIF; CLEMETT SJ, 1993, SCIENCE, V262, P721, DOI 10.1126/science.262.5134.721; Cronin J R, 1983, Adv Space Res, V3, P5, DOI 10.1016/0273-1177(83)90036-4; Cronin JR, 1997, SCIENCE, V275, P951, DOI 10.1126/science.275.5302.951; D'Hendecourt L., 1997, Astronomical Society of the Pacific Conference Series, V122, P129; ENGEL MH, 1982, NATURE, V296, P837, DOI 10.1038/296837a0; EVANS JCE, 1996, NATURE, V381, P644; GIBSON EK, 1980, P LUNAR PLANET SCI C, V12, P1223; GRADY MM, 1994, METEORITICS, V29, P469; HAHN JH, 1988, SCIENCE, V239, P1523, DOI 10.1126/science.239.4847.1523; Jull AJT, 1998, SCIENCE, V279, P366, DOI 10.1126/science.279.5349.366; Jull AJT, 1997, J GEOPHYS RES-PLANET, V102, P1663, DOI 10.1029/96JE03111; Kapitsa AP, 1996, NATURE, V381, P684, DOI 10.1038/381684a0; KEIL RG, 1991, MAR CHEM, V33, P243, DOI 10.1016/0304-4203(91)90070-D; KVENVOLDEN K, 1970, NATURE, V228, P923, DOI 10.1038/228923a0; KVENVOLDEN KA, 1971, P NATL ACAD SCI USA, V68, P486, DOI 10.1073/pnas.68.2.486; MACKENZIE AS, 1982, SCIENCE, V217, P491, DOI 10.1126/science.217.4559.491; MCDONALD GD, 1995, GEOCHIM COSMOCHIM AC, V59, P1179, DOI 10.1016/0016-7037(95)00033-V; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MITTLEFEHLDT DW, 1991, GEOCHIM COSMOCHIM AC, V55, P77, DOI 10.1016/0016-7037(91)90401-P; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; OSWALD GKA, 1973, NATURE, V245, P251, DOI 10.1038/245251a0; POLLOCK GE, 1975, GEOCHIM COSMOCHIM AC, V39, P1571, DOI 10.1016/0016-7037(75)90159-3; RAMDAHL T, 1983, NATURE, V306, P580, DOI 10.1038/306580a0; Scott ERD, 1997, NATURE, V387, P377, DOI 10.1038/387377a0; SIMONEIT BRT, 1990, APPL GEOCHEM, V5, P3, DOI 10.1016/0883-2927(90)90031-Y; TREIMAN AH, 1995, METEORITICS, V30, P294, DOI 10.1111/j.1945-5100.1995.tb01127.x; TSUGITA A, 1987, J BIOCHEM-TOKYO, V102, P1593, DOI 10.1093/oxfordjournals.jbchem.a122209; WRIGHT IP, 1989, NATURE, V340, P220, DOI 10.1038/340220a0; ZHAO MX, 1995, J CHROMATOGR A, V690, P55, DOI 10.1016/0021-9673(94)00927-2; ZHAO MX, 1989, NATURE, V339, P463, DOI 10.1038/339463a0	38	137	140	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					362	365		10.1126/science.279.5349.362	http://dx.doi.org/10.1126/science.279.5349.362			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430583				2022-12-24	WOS:000071570800041
J	Lledo, PM; Zhang, XY; Sudhof, TC; Malenka, RC; Nicoll, RA				Lledo, PM; Zhang, XY; Sudhof, TC; Malenka, RC; Nicoll, RA			Postsynaptic membrane fusion and long-term potentiation	SCIENCE			English	Article							CULTURED HIPPOCAMPAL-NEURONS; PROTEIN-PROTEIN INTERACTIONS; SYNAPTIC TRANSMISSION; NEUROMUSCULAR SYNAPSES; SILENT SYNAPSES; LTP; EXPRESSION; MECHANISM; ENDOSOMES; GLUTAMATE	The possibility that membrane fusion events in the postsynaptic cell may be required for the change in synaptic strength resulting from long-term potentiation (LTP) was examined. Introducing substances into the postsynaptic cell that block membrane fusion at a number of different steps reduced LTP. Introducing SNAP, a protein that promotes membrane fusion, into cells enhanced synaptic transmission, and this enhancement was significantly less when generated in synapses that expressed LTP. Thus, postsynaptic fusion events, which could be involved either in retrograde signaling or in regulating postsynaptic receptor function or both, contribute to LTP.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco	Nicoll, RA (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.							BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Calakos N, 1996, PHYSIOL REV, V76, P1; Cash S, 1996, NEURON, V16, P745, DOI 10.1016/S0896-6273(00)80095-1; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; Coorssen JR, 1996, EMBO J, V15, P3787, DOI 10.1002/j.1460-2075.1996.tb00752.x; Dan Yang, 1994, Current Opinion in Neurobiology, V4, P95, DOI 10.1016/0959-4388(94)90037-X; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; ESHHAR N, 1993, NEUROSCIENCE, V57, P943, DOI 10.1016/0306-4522(93)90040-M; FRANKI N, 1995, AM J PHYSIOL-CELL PH, V269, pC797, DOI 10.1152/ajpcell.1995.269.3.C797; GIROD R, 1995, J NEUROSCI, V15, P2826; Glitsch M, 1996, J PHYSIOL-LONDON, V497, P531, DOI 10.1113/jphysiol.1996.sp021786; Goda Y, 1997, P NATL ACAD SCI USA, V94, P769, DOI 10.1073/pnas.94.3.769; HENLEY JW, COMMUNICATION; HUTTNER WB, 1993, NATURE, V365, P104, DOI 10.1038/365104a0; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; JO IH, 1995, P NATL ACAD SCI USA, V92, P1876, DOI 10.1073/pnas.92.6.1876; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; LARKMAN AU, 1995, CURR OPIN NEUROBIOL, V5, P324, DOI 10.1016/0959-4388(95)80045-X; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; Maletic-Savatic M. M., 1995, Society for Neuroscience Abstracts, V21, P1743; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MCWILLIAMS JR, 1981, BRAIN RES, V211, P158; MUNDIGL O, 1993, J CELL BIOL, V122, P1207, DOI 10.1083/jcb.122.6.1207; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIAVO G, 1994, ANN NY ACAD SCI, V710, P65, DOI 10.1111/j.1749-6632.1994.tb26614.x; Spacek J, 1997, J NEUROSCI, V17, P190, DOI 10.1523/JNEUROSCI.17-01-00190.1997; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1993, CELL, V75, P1; TARRANT SB, 1977, TISSUE CELL, V9, P461, DOI 10.1016/0040-8166(77)90006-4; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; WESTRUM LE, 1962, J COMP NEUROL, V119, P281, DOI 10.1002/cne.901190303; ZIFF EB, COMMUNICATION	38	310	322	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					399	403		10.1126/science.279.5349.399	http://dx.doi.org/10.1126/science.279.5349.399			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430593				2022-12-24	WOS:000071570800051
J	Nogales, E; Wolf, SG; Downing, KH				Nogales, E; Wolf, SG; Downing, KH			Structure of the alpha beta tubulin dimer by electron crystallography	NATURE			English	Article							TAXOL-BINDING-SITE; COLCHICINE-BINDING; EXCHANGEABLE GTP; GUANOSINE TRIPHOSPHATE; BRAIN BETA-1-TUBULIN; AMINO-ACIDS; MICROTUBULE; HYDROLYSIS; LOCALIZATION; PHOTOLABELS	The alpha beta tubulin heterodimer is the structural subunit of microtubules, which are cytoskeletal elements that are essential for intracellular transport and cell division in all eukaryotes. Each tubulin monomer binds a guanine nucleotide, which is non-exchangeable when it is bound in the alpha subunit, or N site, and exchangeable when bound in the beta subunit, or E site. The alpha- and beta-tubulins share 40% amino-acid sequence identity, both exist in several isotype forms, and both undergo a variety of posttranslational modifications'. Limited sequence homology has been found with the proteins FtsZ(2) and Misato(3), which are involved in cell division in bacteria and Drosophila, respectively. Here we present an atomic model of the alpha beta tubulin dimer fitted to a 3.7-Angstrom density map obtained by electron crystallography of zinc-induced tubulin sheets. The structures of alpha- and beta-tubulin are basically identical: each monomer is formed by a core of two beta-sheets surrounded by alpha-helices. The monomer structure is very compact, but can be divided into three functional domains: the amino-terminal domain containing the nucleotide-binding region, an intermediate domain containing the Taxol-binding site, and the carboxy-terminal domain, which probably constitutes the binding surface for motor proteins.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Nogales, E (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.		WOLF, SHARON G/K-1768-2012	WOLF, SHARON G/0000-0002-5337-5063				ANDREU JM, 1993, CELL MOTIL CYTOSKEL, V26, P1, DOI 10.1002/cm.970260102; Bai RL, 1996, J BIOL CHEM, V271, P12639, DOI 10.1074/jbc.271.21.12639; BURNS RG, 1993, MICROTUBULES, P3; CAPLOW M, 1994, J CELL BIOL, V127, P779, DOI 10.1083/jcb.127.3.779; DAVIS A, 1994, SCIENCE, V264, P839, DOI 10.1126/science.8171338; DIAZ JF, 1994, J MOL BIOL, V238, P214, DOI 10.1006/jmbi.1994.1282; Fan J, 1996, J MOL BIOL, V259, P325, DOI 10.1006/jmbi.1996.0322; GUERITTEVOEGELEIN F, 1990, ACTA CRYSTALLOGR C, V46, P781, DOI 10.1107/S0108270189009376; HESSE J, 1987, J BIOL CHEM, V262, P15472; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; LINSE K, 1988, J BIOL CHEM, V263, P15205; LITTLE M, 1987, BIOCHIM BIOPHYS ACTA, V912, P28, DOI 10.1016/0167-4838(87)90243-3; LITTLE M, 1985, EMBO J, V4, P51, DOI 10.1002/j.1460-2075.1985.tb02316.x; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Ludvena R. F., 1998, INT REV CYTOL, V178, P207; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; Miklos GLG, 1997, P NATL ACAD SCI USA, V94, P5189, DOI 10.1073/pnas.94.10.5189; MITCHISON TJ, 1993, SCIENCE, V261, P1044, DOI 10.1126/science.8102497; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; Nogales E, 1997, J STRUCT BIOL, V118, P119, DOI 10.1006/jsbi.1997.3841; NOGALES E, 1995, NATURE, V375, P424, DOI 10.1038/375424a0; NOGALES E, 1995, J STRUCT BIOL, V115, P199, DOI 10.1006/jsbi.1995.1044; Ponstingl H, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 1, P191; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; SHEARWIN KE, 1994, BIOCHEMISTRY-US, V33, P894, DOI 10.1021/bi00170a007; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; UPPULURI S, 1993, P NATL ACAD SCI USA, V90, P11598, DOI 10.1073/pnas.90.24.11598; VALE RD, 1994, J BIOL CHEM, V269, P23769; Wolf SG, 1996, J MOL BIOL, V262, P485, DOI 10.1006/jmbi.1996.0530	30	1725	1791	5	229	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 8	1998	391	6663					199	203		10.1038/34465	http://dx.doi.org/10.1038/34465			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428769				2022-12-24	WOS:000071380900057
J	Miki, H; Sasaki, T; Takai, Y; Takenawa, T				Miki, H; Sasaki, T; Takai, Y; Takenawa, T			Induction of filopodium formation by a WASP-related actin-depolymerizing protein N-WASP	NATURE			English	Article							CDC42; KINASE; RAC; POLYMERIZATION; GTPASES; COFILIN; BRAIN	Cdc42 is a small GTPase of the Rho family which regulates the formation of actin filaments to generate filopodia(1,2). Although there are several proteins such as PAK(3), ACK(4) and WASP (Wiskott-Aldrich syndrome protein)(5) that bind Cdc42 directly, none of these can account for the filopodium formation induced by Cdc42. Here we demonstrate that before it can induce filopodium formation, Cdc42 must bind a WASP-related protein, N-WASP, that is richest in neural tissues(6) but is expressed ubiquitously. N-WASP induces extremely long actin microspikes only when coexpressed with active Cdc42, whereas WASP, which is expressed in haematopoietic cells, does not, despite the structural similarities between WASP and N-WASP. In a cell-free system, addition of active Cdc42 significantly stimulates the actin-depolymerizing activity of N-WASP, creating free barbed ends from which actin polymerization can then take place. This activation seems to be caused by exposure of N-WASP's actin-depolymerizing region induced by Cdc42 binding.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 108, Japan; Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Osaka 565, Japan	University of Tokyo; Osaka University	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Shirokanedai 4-6-1, Tokyo 108, Japan.							AIZAWA H, 1995, J BIOL CHEM, V270, P10923, DOI 10.1074/jbc.270.18.10923; ASPENSTROM P, 1996, CURR BIOL, V15, P5725; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; FUKUOKAM, 1997, GENE, V196, P43; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8	15	553	560	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					93	96		10.1038/34208	http://dx.doi.org/10.1038/34208			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422512				2022-12-24	WOS:000071326100056
J	Albrecht, U; Sun, ZS; Eichele, G; Lee, CC				Albrecht, U; Sun, ZS; Eichele, G; Lee, CC			A differential response of two putative mammalian circadian regulators, mper1 and mper2, to light	CELL			English	Article							SUPRACHIASMATIC NUCLEUS; DROSOPHILA PERIOD; BEHAVIORAL RHYTHMS; MESSENGER-RNA; CLOCK; PROTEIN; GENE; RAT; TIMELESS; DOMAIN	A mouse gene, mper1, having all the properties expected of a circadian clock gene, was reported recently. This gene is expressed in a circadian pattern in the suprachiasmatic nucleus (SCN). mper1 maintains this pattern of circadian expression in constant darkness and can be entrained to a new light/dark cycle. Here we report the isolation of a second mammalian gene, mper2, which also has these properties and greater homology to Drosophila period. Expression of mper1 and mper2 is overlapping but asynchronous by 4 hr. mper1, unlike period and mper2, is expressed rapidly after exposure to light at CT22. It appears that mper1 is the pacemaker component which responds to light and thus mediates photic entrainment.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA; Max Planck Inst Expt Endocrinol, D-30625 Hannover, Germany	Baylor College of Medicine; Baylor College of Medicine; Max Planck Society	Lee, CC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.		Sun, Zhongsheng/AAS-4883-2020; Albrecht, Urs/A-9831-2011; Jansen, Heiko T./A-5770-2008	Sun, Zhongsheng/0000-0002-7640-5026; Albrecht, Urs/0000-0002-0663-8676; Jansen, Heiko T./0000-0003-0178-396X				Albrecht U, 1997, MOL CELLULAR METHODS, P23; Albrecht U., 1998, HUMAN GENOME METHODS, P93; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; ASCHOFF J, 1969, AEROSPACE MED, V40, P844; BARGIELLO TA, 1984, NATURE, V312, P752, DOI 10.1038/312752a0; CARD JP, 1991, SUPRACHIASMATIC NUCL, P51; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; HALL JC, 1993, P NATL ACAD SCI USA, V90, P5382, DOI 10.1073/pnas.90.12.5382; Hall JC, 1996, NEURON, V17, P799, DOI 10.1016/S0896-6273(00)80211-1; HALL JC, 1990, ANNU REV GENET, V24, P659; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HASTINGS MH, 1995, CIBA F SYMP, V183, P175; HENDRICKSON AE, 1972, Z ZELLFORSCH MIK ANA, V135, P1, DOI 10.1007/BF00307084; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; JOHNSON RF, 1988, BRAIN RES, V462, P301, DOI 10.1016/0006-8993(88)90558-6; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MOORE RY, 1972, J COMP NEUROL, V146, P1, DOI 10.1002/cne.901460102; MOORE RY, 1995, CIBA F SYMP, V183, P88; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; REPPERT SM, 1995, NEURON, V15, P983, DOI 10.1016/0896-6273(95)90086-1; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SAUNDERS DS, 1994, J INSECT PHYSIOL, V40, P957, DOI 10.1016/0022-1910(94)90134-1; SCHWARTZ WJ, 1995, SEMIN NEUROSCI, V7, P53, DOI 10.1016/1044-5765(95)90017-9; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIWICKI KK, 1992, J NEUROGENET, V8, P33, DOI 10.3109/01677069209167270; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	44	708	723	1	30	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					1055	1064		10.1016/S0092-8674(00)80495-X	http://dx.doi.org/10.1016/S0092-8674(00)80495-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428527	Bronze			2022-12-24	WOS:000071281400021
J	Berckmans, P; Dawans, V; Schmets, G; Vandenbergh, D; Autier, P				Berckmans, P; Dawans, V; Schmets, G; Vandenbergh, D; Autier, P			Inappropriate drug-donation practices in Bosnia and Herzegovina, 1992 to 1996	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EARTHQUAKE		EUROPEAN ASSOC HLTH & DEV,B-1000 BRUSSELS,BELGIUM; EUROPEAN INST ONCOL,I-20141 MILAN,ITALY	IRCCS European Institute of Oncology (IEO)			Autier, Philippe/A-4402-2014	Autier, Philippe/0000-0003-1538-5321				ALI HM, 1988, LANCET, V333, P538; AUTIER P, 1990, LANCET, V335, P1388; BERCKMANS P, 1996, DRUG DONATION PRACTI; COHEN S, 1990, LANCET, V336, P745, DOI 10.1016/0140-6736(90)92233-8; GODLEE F, 1994, BRIT MED J, V309, P1424, DOI 10.1136/bmj.309.6966.1424; Hogerzeil HV, 1997, BRIT MED J, V314, P737, DOI 10.1136/bmj.314.7082.737; Michael M, 1996, JAMA-J AM MED ASSOC, V276, P364, DOI 10.1001/jama.276.5.364; OFFERHAUS L, 1992, LANCET, V339, P607; *RES MED DEV, 1996, ECH MED ENTR PAYS EU; SCHOUTEN E, 1995, BRIT MED J, V311, P684, DOI 10.1136/bmj.311.7006.684; *UN INF MED ETH DE, 1994, MED UT EUR REC DESTR; United Nations Environment Programme, 1989, BAS CONV CONTR TRANS; VANDERHEIDE B, 1995, BRIT MED J, V311, P684, DOI 10.1136/bmj.311.7006.684a; *WAR HLTH CROSS BR, 1996, EUR COR ANN REP 1995; *WEMOS PHARM PROJ, 1991, EXP DEADL EXP STOR E; *WHO, 1994, WHO MISS FORM YUG; *WHO, 1996, WHODAP962; *WHO, 1992, WHO TECH REP SER, V825, P1; *WHO, 1994, MED SUPPL DON GUID W; ZEBALLOS JL, 1986, DISASTERS, V10, P141, DOI 10.1111/j.1467-7717.1986.tb00579.x	20	24	26	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 18	1997	337	25					1842	1845		10.1056/NEJM199712183372512	http://dx.doi.org/10.1056/NEJM199712183372512			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL855	9400045				2022-12-24	WOS:A1997YL85500012
J	McNagny, SE; Wenger, NK; Frank, E				McNagny, SE; Wenger, NK; Frank, E			Personal use of postmenopausal hormone replacement therapy by women physicians in the United States	ANNALS OF INTERNAL MEDICINE			English	Article							PREVENT OSTEOPOROSIS; ESTROGEN REPLACEMENT; ATTITUDES; DISEASE	Background: Women physicians' use of postmenopausal hormone replacement therapy (HRT) is unknown. Objective: To study use of HRT by women physicians in the United States. Design: Stratified random-sample mail survey. Setting: United States. Participants: 1466 postmenopausal women U.S. physicians in the Women Physicians' Health Study. Measurements: Self-reported personal use of HRT and information on demographic, professional, and behavioral characteristics and medical history. Results: Overall, 47.4% of participants currently use HRT; the prevalence of use is 59.8% in women 40 to 49 years of age, 49.4% in women 50 to 59 years of age, and 36.4% in women 60 to 70 years of age (P < 0.001). In an adjusted logistic regression model, current users were significantly more likely to be gynecologists, to be younger, to be white, to be sexually active, to be previous users of oral contraceptives, to live in Pacific or Mountain states, to have had a hysterectomy, and to have no personal or family history of breast cancer. Conclusions: Women physicians have a higher rate of HRT use than that reported in cross-sectional U.S. surveys. This may presage greater use of HRT for U.S. women in the future.	Emory Univ, Sch Med, Div Gen Med, Atlanta, GA 30303 USA	Emory University	McNagny, SE (corresponding author), Emory Univ, Sch Med, Div Gen Med, 69 Butler St, Atlanta, GA 30303 USA.			Frank, Erica/0000-0001-7159-5417	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007034] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32-HL-07034] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barrett-Connor E., 1995, J WOMENS HEALTH, V4, P143; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; *COMM TECHN B AM C, 1992, ACOG TECHN B, V166, P1; Frank E, 1995, J Am Med Womens Assoc (1972), V50, P64; Frank E, 1997, WESTERN J MED, V166, P179; FRANK E, 1995, PREV MED, V24, P543, DOI 10.1006/pmed.1995.1086; FRANK E, IN PRESS ARCH INTERN; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREENDALE GA, 1990, J GEN INTERN MED, V5, P464, DOI 10.1007/BF02600870; GRISSO JA, 1990, J BONE MINER RES, V5, P213, DOI 10.1002/jbmr.5650050303; Handa VL, 1996, J AM GERIATR SOC, V44, P1; HEMMINKI E, 1991, DICP ANN PHARMAC, V25, P418, DOI 10.1177/106002809102500416; ISAACS AJ, 1995, BRIT MED J, V311, P1399, DOI 10.1136/bmj.311.7017.1399; NELSON DE, 1994, JAMA-J AM MED ASSOC, V271, P1273, DOI 10.1001/jama.271.16.1273; ODDENS BJ, 1992, MATURITAS, V15, P171, DOI 10.1016/0378-5122(92)90200-N; PILOTE L, 1995, AM HEART J, V129, P1237, DOI 10.1016/0002-8703(95)90426-3; *RES TRIANGL I, 1996, SUDAAN US MAN VERS 6; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F; [No title captured]	19	48	48	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1093	1096		10.7326/0003-4819-127-12-199712150-00007	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412312				2022-12-24	WOS:000070936600006
J	Mayne, S; Parker, JH; Harden, TA; Dodds, SD; Beale, JA				Mayne, S; Parker, JH; Harden, TA; Dodds, SD; Beale, JA			Rate of RhD sensitisation before and after implementation of a community based antenatal prophylaxis programme	BRITISH MEDICAL JOURNAL			English	Article									Derby City Gen Hosp, Blood Bank, Derby DE22 3NE, England	University of Nottingham	Mayne, S (corresponding author), Derby City Gen Hosp, Blood Bank, Derby DE22 3NE, England.							[Anonymous], 1991, PRESCRIBERS J, V1, P137; HUCHET J, 1987, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V16, P101; LETSKY EA, 1994, BRIT MED J, V309, P213, DOI 10.1136/bmj.309.6949.213; RAAFAT A, 1996, TRANSFUSION MED S2, V6, P26; TOVEY LAD, 1983, LANCET, V2, P244	5	39	39	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 13	1997	315	7122					1588	1588		10.1136/bmj.315.7122.1588	http://dx.doi.org/10.1136/bmj.315.7122.1588			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437277	Green Published			2022-12-24	WOS:000071021900024
J	Kim, JM; Mayfield, SP				Kim, JM; Mayfield, SP			Protein disulfide isomerase as a regulator of chloroplast translational activation	SCIENCE			English	Article							PSBA MESSENGER-RNA; CHLAMYDOMONAS-REINHARDTII; GENE-EXPRESSION; PHOTOSYSTEM-II; THIOREDOXIN REDUCTASE; NUCLEAR; BINDING; BIOGENESIS; BARLEY; MUTANT	Light-regulated translation of chloroplast messenger RNAs (mRNAs) requires transacting factors that interact with the 5' untranslated region (UTR) of these mRNAs, Chloroplast polyadenylate-binding protein (cPABP) specifically binds to the 5'-UTR of the psbA mRNA and is essential for translation of this mRNA, A protein disulfide isomerase that is localized to the chloroplast and copurifies with cPABP was shown to modulate the binding of cPABP to the 5'-UTR of the psbA mRNA by reversibly changing the redox status of cPABP through redox potential or adenosine 5'-diphosphate-dependent phosphorylation. This mechanism allows for a simple reversible switch regulating gene expression in the chloroplast.	Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	Kim, JM (corresponding author), SCRIPPS RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA.			Kim, Jungmook/0000-0003-1735-5564	NIGMS NIH HHS [GM54659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FROMM H, 1985, EMBO J, V4, P291, DOI 10.1002/j.1460-2075.1985.tb03628.x; GIRARDBASCOU J, 1992, CURR GENET, V22, P47, DOI 10.1007/BF00351741; Hauser CR, 1996, J BIOL CHEM, V271, P1486, DOI 10.1074/jbc.271.3.1486; JENSEN KH, 1986, J CELL BIOL, V103, P1315, DOI 10.1083/jcb.103.4.1315; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KLEIN RR, 1987, J BIOL CHEM, V262, P4341; KRUPINSKA K, 1989, MOL GEN GENET, V219, P467, DOI 10.1007/BF00259621; KUCHKA MR, 1988, EMBO J, V7, P319, DOI 10.1002/j.1460-2075.1988.tb02815.x; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; MALNOE P, 1988, J CELL BIOL, V106, P609, DOI 10.1083/jcb.106.3.609; MAYFIELD SP, 1994, J CELL BIOL, V127, P1537, DOI 10.1083/jcb.127.6.1537; MAYFIELD SP, 1995, ANNU REV PLANT PHYS, V46, P147, DOI 10.1146/annurev.pp.46.060195.001051; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NOIVA R, 1992, J BIOL CHEM, V267, P3553; Robinson C., 1994, V139, P273; ROCHAIX JD, 1989, EMBO J, V8, P1013, DOI 10.1002/j.1460-2075.1989.tb03468.x; Staples CR, 1996, BIOCHEMISTRY-US, V35, P11425, DOI 10.1021/bi961007p; Yohn CB, 1996, MOL CELL BIOL, V16, P3560; YOHN CB, UNPUB	25	190	203	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1954	1957		10.1126/science.278.5345.1954	http://dx.doi.org/10.1126/science.278.5345.1954			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395399				2022-12-24	WOS:A1997YL00200037
J	Rogan, MT; Staubli, UV; LeDoux, JE				Rogan, MT; Staubli, UV; LeDoux, JE			Fear conditioning induces associative long-term potentiation in the amygdala	NATURE			English	Article							NEURONAL TRANSMISSION; BRAIN TEMPERATURE; EVOKED-POTENTIALS; HIPPOCAMPUS; BEHAVIOR; NMDA; RAT; RECORDINGS; RESPONSES; RECEPTORS	Long-term potentiation (LTP) is an experience-dependent form of neural plasticity believed to involve mechanisms that underlie memory formation(1-3). Lip has been studied most extensively in the hippocampus, but the relation between hippocampal Lip and memory has been difficult to establish(4-6). Here we explore the relation between LTP and memory in fear conditioning, an amygdala-dependent form of learning in which an innocuous conditioned stimulus (CS) elicits fear responses after being associatively paired with an aversive unconditioned stimulus (US). We have previously shown that Lip induction in pathways that transmit auditory CS information to the lateral nucleus of the amygdala (LA) increases auditory-evoked field potentials in this nucleus(7). Now we show that fear conditioning alters auditory CS-evoked responses in LA in the same way as Lip induction, The changes parallel the acquisition of CS-elicited fear behaviour, are enduring, and do not occur if the CS and US remain unpaired. LTP-like associative processes thus occur during fear conditioning, and these may underlie the long-term associative plasticity that constitutes memory of the conditioning experience.			Rogan, MT (corresponding author), NYU,CTR NEURAL SCI,6 WASHINGTON PL,NEW YORK,NY 10003, USA.							BARNES CA, 1995, NEURON, V15, P751, DOI 10.1016/0896-6273(95)90166-3; BLANCHAR.RJ, 1969, J COMP PHYSIOL PSYCH, V68, P129, DOI 10.1037/h0027676; BLANCHARD RJ, 1969, J COMP PHYSIOL PSYCH, V67, P370, DOI 10.1037/h0026779; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLLES RC, 1980, BEHAV BRAIN SCI, V3, P291, DOI 10.1017/S0140525X0000491X; BOUTON ME, 1980, ANIM LEARN BEHAV, V8, P429, DOI 10.3758/BF03199629; BROWN TH, 1994, MODELS NEURAL NETWOR, V2, P287; BUZSAKI G, 1981, BRAIN RES, V225, P235, DOI 10.1016/0006-8993(81)90833-7; DEADWYLER SA, 1985, BEHAV NEURAL BIOL, V44, P201, DOI 10.1016/S0163-1047(85)90198-0; EICHENBAUM H, 1995, NATURE, V378, P131, DOI 10.1038/378131a0; Farb CR, 1997, SYNAPSE, V27, P106, DOI 10.1002/(SICI)1098-2396(199710)27:2<106::AID-SYN2>3.3.CO;2-F; Gewirtz JC, 1997, NATURE, V388, P471, DOI 10.1038/41325; Jeffery KJ, 1997, HIPPOCAMPUS, V7, P95; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LEUNG LS, 1980, BRAIN RES, V198, P95; LI XF, 1995, EXP BRAIN RES, V105, P87; Li XF, 1996, LEARN MEMORY, V3, P229, DOI 10.1101/lm.3.2-3.229; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; Maren S, 1996, BEHAV NEUROSCI, V110, P1365, DOI 10.1037/0735-7044.110.6.1365; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; MOSER E, 1993, SCIENCE, V259, P1324, DOI 10.1126/science.8446900; MOSER EI, 1994, LEARN MEMORY, V1, P55; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; QUIRK GJ, 1995, NEURON, V15, P1029, DOI 10.1016/0896-6273(95)90092-6; Rogan M. T., 1995, Society for Neuroscience Abstracts, V21, P1930; ROGAN MT, 1995, NEURON, V15, P127, DOI 10.1016/0896-6273(95)90070-5; Rogan MT, 1997, J NEUROSCI, V17, P5928; SKELTON RW, 1987, J NEUROSCI, V7, P3081; STAUBLI UV, 1995, BRAIN MEMORY MODULAT, P303; WINSON J, 1978, J NEUROPHYSIOL, V41, P716, DOI 10.1152/jn.1978.41.3.716	30	953	970	3	73	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					604	607		10.1038/37601	http://dx.doi.org/10.1038/37601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403688				2022-12-24	WOS:A1997YK85300048
J	Chiu, AY; Perez, PE; Parker, RN				Chiu, AY; Perez, PE; Parker, RN			Impact of banning alcohol on outpatient visits in Barrow, Alaska	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AVAILABILITY; DRINKING; IOWA	Context.-Community availability of alcohol affects alcohol consumption patterns and alcohol-related health and social problems. In Barrow, Alaska, an isolated community at the northernmost reaches of the United States, during a 33-month period, possession and importation of alcohol were legal, completely banned, made legal again, and then banned again. Objective.-To determine the impact of these public policy changes on alcohol-related outpatient visits at the area hospital. Design.-Retrospective review of outpatient records; time-series analysis of alcohol-related visits with respect to community alcohol policy. Main Outcome Measures.-Total monthly outpatient visits for alcohol-related problems. Results.-There was a substantial decrease in the number of alcohol-related outpatient visits when the ban on possession and importation was imposed compared with baseline. When the ban was lifted, outpatient visits increased; when the ban was reimposed, the number of outpatient visits again decreased. Interrupted time-series analyses confirm that the alcohol ban, its lifting, and its reimposition had a statistically significant and negative effect on the number of alcohol-related outpatient visits (P<.05). Conclusion.-In a geographically isolated community, the prohibition of alcohol can be an effective public health intervention, reducing the health problems associated with alcohol use.	N SLOPE BOROUGH PHYS SERV,BARROW,AK; SAMUEL SIMMONDS MEM HOSP PHYS SERV,BARROW,AK; PREVENT RES CTR,BERKELEY,CA	Pacific Institute for Research & Evaluation (PIRE)					NIAAA NIH HHS [AA09146] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009146] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALBRECHT E, 1984, CIRCUMPOLAR HLTH 84, P327; [Anonymous], 1976, TIME SERIES ANAL; BONDY S, 1995, JAMA-J AM MED ASSOC, V274, P1832, DOI 10.1001/jama.274.23.1832; BROWER CD, 1942, 50 YEARS ZERO, P137; CAMPBELL DT, 1966, EXPT QUASI-EXPT DESI; Gruenewald PJ, 1996, ADDICTION, V91, P967, DOI 10.1111/j.1360-0443.1996.tb03594.x; HILD CM, 1981, CIRCUMPOLAR HLTH, V81, P502; HOLDER HD, 1990, BRIT J ADDICT, V85, P1615; HOLDER HD, 1988, CONT DRUG PROBL, V15, P47; LOFTIN C, 1982, AM SOCIOL REV, V47, P393, DOI 10.2307/2094995; MCCLEARY R, 1988, APPLIED TIME SERIES; OMALLEY PM, 1991, J STUD ALCOHOL, V52, P478, DOI 10.15288/jsa.1991.52.478; PARKER RN, 1997, ANN M KETT BRUUN SOC; Parker Robert N., 1995, ALCOHOL HOMICIDE DEA; SKOG OJ, 1986, BRIT J ADDICT, V81, P365; VINGILIS ER, 1979, J CRIM JUST, V12, P161; WAGENAAR AC, 1991, J STUD ALCOHOL, V52, P162, DOI 10.15288/jsa.1991.52.162; WAGENAAR AC, 1983, ALCOHOL YOUNG DRIVER; WOOD JB, 1996, BARROW RECLAMATION	19	29	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1775	1777		10.1001/jama.278.21.1775	http://dx.doi.org/10.1001/jama.278.21.1775			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YH987	9388156				2022-12-24	WOS:A1997YH98700034
J	Elena, SF; Lenski, RE				Elena, SF; Lenski, RE			Test of synergistic interactions among deleterious mutations in bacteria	NATURE			English	Article							ESCHERICHIA-COLI; EVOLUTION; FITNESS; SEX; ADAPTATION; ADVANTAGE	Identifying the forces responsible for the origin and maintenance of sexuality remains one of the greatest unsolved problems in biology(1-6). The mutational deterministic hypothesis postulates that sex is an adaptation that allows deleterious mutations to be purged from the genome; it requires synergistic interactions, which means that two mutations would be more harmful together than expected from their separate effects(4,5), We generated 225 genotypes of Escherichia coli carrying one, two or three successive mutations and measured their fitness relative to an unmutated competitor. The relationship between mutation number and average fitness is nearly log-linear, We also constructed 27 recombinant genotypes having pairs of mutations whose separate and combined effects on fitness were determined. Several pairs exhibit significant interactions for fitness, but they are antagonistic as often as they are synergistic These results do not support the mutational deterministic hypothesis for the evolution of sex.			Elena, SF (corresponding author), MICHIGAN STATE UNIV, CTR MICROBIAL ECOL, E LANSING, MI 48824 USA.		Elena, Santiago F./A-4191-2011	Elena, Santiago F./0000-0001-8249-5593; Lenski, Richard/0000-0002-1064-8375				Bell G., 1982, MASTERPIECE NATURE; CHAO L, 1988, J THEOR BIOL, V133, P99, DOI 10.1016/S0022-5193(88)80027-4; CHARLESWORTH B, 1990, GENET RES, V55, P199, DOI 10.1017/S0016672300025532; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; DEVISSER JAG, IN PRESS EVOLUTION; deVisser JAGM, 1996, P ROY SOC B-BIOL SCI, V263, P193, DOI 10.1098/rspb.1996.0031; ELENA SF, IN PRESS GENETICA; HAIGH J, 1978, THEOR POPUL BIOL, V14, P251, DOI 10.1016/0040-5809(78)90027-8; Hurst Laurence D., 1996, Trends in Ecology and Evolution, V11, P46, DOI 10.1016/0169-5347(96)81041-X; Kibota TT, 1996, NATURE, V381, P694, DOI 10.1038/381694a0; KIMURA M, 1966, GENETICS, V54, P1337; KITIGAWA O, 1969, GENETICS, V57, P809; KLECKNER N, 1991, METHOD ENZYMOL, V204, P139; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1993, J HERED, V84, P372, DOI 10.1093/oxfordjournals.jhered.a111358; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; Maynard Smith J., 1978, EVOLUTION SEX; MUKAI T, 1969, GENETICS, V61, P749; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; Otto SP, 1997, THEOR POPUL BIOL, V51, P134, DOI 10.1006/tpbi.1997.1301; Redfield RJ, 1997, GENETICS, V146, P27; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; Sniegowski PD, 1997, NATURE, V387, P703, DOI 10.1038/42701; Sokal R. R, 1981, BIOMETRY; SPASSKY B, 1965, GENETICS, V52, P653; Williams G.C., 1975, Journal Cell Biol, VNo. 8, pi; WILLIS JH, 1993, EVOLUTION, V47, P864, DOI 10.1111/j.1558-5646.1993.tb01240.x; Zeyl C, 1997, NATURE, V388, P465, DOI 10.1038/41312; ZYSKIND J, 1989, RECOMBINANT DNA LAB	30	319	323	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 27	1997	390	6658					395	398		10.1038/37108	http://dx.doi.org/10.1038/37108			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389477				2022-12-24	WOS:A1997YH54900061
J	SchlagRey, M; Amador, N; Sanchez, H; Schlag, J				SchlagRey, M; Amador, N; Sanchez, H; Schlag, J			Antisaccade performance predicted by neuronal activity in the supplementary eye field	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; RHESUS-MONKEYS; MOVEMENTS; SACCADES; CONNECTIONS; INITIATION; FIXATION; LESIONS; SYSTEM; GOAL	The voluntary control of gaze implies the ability to make saccadic eye movements specified by abstract instructions, as well as the ability to repress unwanted orientating to sudden stimuli, Both of these abilities are challenged in the antisaccade task, because it requires subjects to look at an unmarked location opposite to a dashed stimulus, without glancing at it(1,2). Performance on this task depends on the frontal/prefrontal cortex and related structures(3-8), but the neuronal operations underlying antisaccades are not understood. It is not known, for example, how excited visual neurons that normally trigger a saccade to a target (a prosaccade) can activate oculomotor neurons directing gaze in the opposite direction, Visual neurons might, perhaps, alter their receptive fields depending on whether they receive a pro-or antisaccade instruction, If the receptive field is not altered, the antisaccade goal must be computed and imposed from the top down to the appropriate oculomotor neurons. Here we show, using recordings from the supplementary eye field (a frontal cortex oculomotor centre) in monkeys, that visual and movement neurons retain the same spatial selectivity across randomly mixed pro-and antisaccade trials, However, these neurons consistently fire more before antisaccades than prosaccades with the same trajectories, suggesting a mechanism through which voluntary antisaccade commands can override reflexive glances.	UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SchlagRey, M (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROBIOL,LOS ANGELES,CA 90095, USA.							BECKER W, 1979, VISION RES, V19, P967, DOI 10.1016/0042-6989(79)90222-0; Chen LTL, 1996, J NEUROSCI, V16, P3067; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; FISCHER B, 1992, EXP BRAIN RES, V89, P415; FUNAHASHI S, 1993, NATURE, V365, P753, DOI 10.1038/365753a0; Goldberg ME, 1989, NEUROBIOLOGY SACCADI, P283; GUITTON D, 1985, EXP BRAIN RES, V58, P455; HALLETT PE, 1978, VISION RES, V18, P1279, DOI 10.1016/0042-6989(78)90218-3; Hanes DP, 1996, SCIENCE, V274, P427, DOI 10.1126/science.274.5286.427; HUERTA MF, 1990, J COMP NEUROL, V293, P299, DOI 10.1002/cne.902930211; ODRISCOLL GA, 1995, P NATL ACAD SCI USA, V92, P925, DOI 10.1073/pnas.92.3.925; Passingham RE., 1993, FRONTAL LOBES VOLUNT; PIERROTDESEILLIGNY C, 1991, BRAIN, V114, P1473, DOI 10.1093/brain/114.3.1473; REMINGTON RW, 1992, PERCEPT PSYCHOPHYS, V51, P279, DOI 10.3758/BF03212254; RUGG MC, 1995, ELECTROPHYSIOLOGY MI; Russo GS, 1996, J NEUROPHYSIOL, V76, P825, DOI 10.1152/jn.1996.76.2.825; SALZMAN CD, 1994, SCIENCE, V264, P231, DOI 10.1126/science.8146653; SCHALL JD, 1991, J NEUROPHYSIOL, V66, P530, DOI 10.1152/jn.1991.66.2.530; SCHILLER PH, 1987, J NEUROPHYSIOL, V57, P1033, DOI 10.1152/jn.1987.57.4.1033; SCHLAG J, 1987, J NEUROPHYSIOL, V57, P179, DOI 10.1152/jn.1987.57.1.179; SCHLAG J, 1992, EXP BRAIN RES, V90, P302; Schlag J., 1993, Society for Neuroscience Abstracts, V19, P785; SCHLAG J, IN PRESS J NEUROPHYS; SCHLAGREY M, 1992, J NEUROPHYSIOL, V67, P1003, DOI 10.1152/jn.1992.67.4.1003; SEGRAVES MA, 1993, J NEUROPHYSIOL, V69, P1880, DOI 10.1152/jn.1993.69.6.1880; SHOOK BL, 1990, J COMP NEUROL, V301, P618, DOI 10.1002/cne.903010410; Sweeney JA, 1996, J NEUROPHYSIOL, V75, P454, DOI 10.1152/jn.1996.75.1.454; Thompson KG, 1996, J NEUROPHYSIOL, V76, P4040, DOI 10.1152/jn.1996.76.6.4040; TIAN JR, 1991, NEUROLOGY, V41, P875, DOI 10.1212/WNL.41.6.875; Weber H, 1995, PERCEPTION, V24, P1265, DOI 10.1068/p241265	30	279	282	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					398	401		10.1038/37114	http://dx.doi.org/10.1038/37114			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389478				2022-12-24	WOS:A1997YH54900062
J	Settles, AM; Yonetani, A; Baron, A; Bush, DR; Cline, K; Martienssen, R				Settles, AM; Yonetani, A; Baron, A; Bush, DR; Cline, K; Martienssen, R			Sec-independent protein translocation by the maize Hcf106 protein	SCIENCE			English	Article							ESCHERICHIA-COLI; THYLAKOID MEMBRANE; SIGNAL PEPTIDE; TRANSPORT; EXPORT; PATHWAY; MUTATIONS; HOMOLOG; NUCLEAR; BINDING	The bacterial Sec and signal recognition particle (ffh-dependent) protein translocation mechanisms are conserved between prokaryotes and higher plant chloroplasts. A third translocation mechanism in chloroplasts [the proton concentration difference (Delta pH) pathway] was previously thought to be unique. The hcf106 mutation of maize disrupts the localization of proteins transported through this Delta pH pathway in isolated chloroplasts. The Hcf106 gene encodes a receptor-like thylakoid membrane protein, which shows homology to open reading frames from all completely sequenced bacterial genomes, which suggests that the Delta pH pathway has been conserved since the endosymbiotic origin of chloroplasts. Thus, the third protein translocation pathway, of which HCF106 is a component, is found in both bacteria and plants.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; EMORY UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,ATLANTA,GA 30322; UNIV FLORIDA,DEPT HORT SCI,GAINESVILLE,FL 32611; USDA ARS,PHOTOSYNTHESIS RES UNIT,URBANA,IL 61801; UNIV ILLINOIS,DEPT PLANT BIOL,URBANA,IL 61801	Cold Spring Harbor Laboratory; Emory University; State University System of Florida; University of Florida; United States Department of Agriculture (USDA); University of Illinois System; University of Illinois Urbana-Champaign			Bush, Daniel R/AAG-8444-2019; Cline, Kenneth/J-6238-2013	Settles, A. Mark/0000-0002-5846-0996; Bush, Daniel/0000-0002-9160-5077				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARKAN A, 1986, EMBO J, V5, P1421, DOI 10.1002/j.1460-2075.1986.tb04378.x; BARKAN A, 1991, P NATL ACAD SCI USA, V88, P3502, DOI 10.1073/pnas.88.8.3502; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bogsch E, 1997, EMBO J, V16, P3851, DOI 10.1093/emboj/16.13.3851; BROCK IW, 1995, J BIOL CHEM, V270, P1657, DOI 10.1074/jbc.270.4.1657; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; CREIGHTON AM, 1995, J BIOL CHEM, V270, P1663, DOI 10.1074/jbc.270.4.1663; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DAS L, 1995, PLANT CELL, V7, P287, DOI 10.1105/tpc.7.3.287; ERNST F, 1994, J BIOL CHEM, V269, P12840; ETTINGER WF, 1992, PLANT PHYSIOL, V99, P791, DOI 10.1104/pp.99.2.791; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; KNOTT TG, 1994, J BIOL CHEM, V269, P4505; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; LEE JH, 1985, J BACTERIOL, V162, P344, DOI 10.1128/JB.162.1.344-352.1985; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; LUTZ S, 1991, MOL MICROBIOL, V5, P123, DOI 10.1111/j.1365-2958.1991.tb01833.x; MANT A, 1995, J BIOL CHEM, V270, P23275, DOI 10.1074/jbc.270.40.23275; MARTIENSSEN RA, 1989, EMBO J, V8, P1633, DOI 10.1002/j.1460-2075.1989.tb03553.x; MARTIENSSEN RA, 1987, PLANT MEMBRANES STRU, P181; NAKAI M, 1994, J BIOL CHEM, V269, P31338; NG DTW, 1994, CURR OPIN CELL BIOL, V6, P510, DOI 10.1016/0955-0674(94)90069-8; NIVIERE V, 1992, J GEN MICROBIOL, V138, P2173, DOI 10.1099/00221287-138-10-2173; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SMITH TA, 1994, J CELL BIOL, V126, P365, DOI 10.1083/jcb.126.2.365; VOELKER R, 1995, EMBO J, V14, P3905, DOI 10.1002/j.1460-2075.1995.tb00062.x; VOELKER R, 1997, GENETICS, V154, P467; YATES M, COMMUNICATION; YUAN J, 1994, J BIOL CHEM, V268, P18463; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633; [No title captured]	41	225	238	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1467	1470		10.1126/science.278.5342.1467	http://dx.doi.org/10.1126/science.278.5342.1467			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9367960				2022-12-24	WOS:A1997YG85800046
J	Mayho, P				Mayho, P			Multidrug resistant tuberculosis and HIV: a personal experience	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 15	1997	315	7118					1317	1317		10.1136/bmj.315.7118.1317	http://dx.doi.org/10.1136/bmj.315.7118.1317			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390087	Green Published			2022-12-24	WOS:A1997YG64500076
J	Kuusisto, J; Koivisto, K; Mykkanen, L; Helkala, EL; Vanhanen, M; Hanninen, T; Kervinen, K; Kesaniemi, YA; Riekkinen, PJ; Laakso, M				Kuusisto, J; Koivisto, K; Mykkanen, L; Helkala, EL; Vanhanen, M; Hanninen, T; Kervinen, K; Kesaniemi, YA; Riekkinen, PJ; Laakso, M			Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study	BRITISH MEDICAL JOURNAL			English	Article							DEMENTIA; RISK; HYPERINSULINEMIA; POLYMORPHISM; HYPERTENSION; DIAGNOSIS; LEVEL; BRAIN; AGE; SEX	Objective: To determine the association between features of the insulin resistance syndrome and Alzheimer's disease. Design: Cross sectional population based study. Subjects: 980 people aged 69 to 78 (349 men, 631 women). Setting: Population of Kuopio, eastern Finland. Main outcome measures: Presence of features of the insulin resistance syndrome and diagnosis of Alzheimer's disease by detailed neurological and neuropsychological evaluation. Results: 46 (4.7%) subjects were classified as having probable or possible Alzheimer's disease. In univariate analyses, apolipoprotein E4 phenotype (odds ratio; 95% confidence interval 3.24: 1.77 to 5.92), age (1.16; 1.05 to 1.29), low level of education (0.82; 0.72 to 0.93), low total cholesterol concentration (0.77; 0.59 to 1.00), high systolic blood pressure (1.01; 1.00 to 1.03), high fasting and 2 hour plasma glucose concentrations (1.11; 1.01 to 1.23 and 1.08; 1.03 to 1.13, respectively), high fasting and 2 hour insulin concentrations (1.05; 1.02 to 1.08 and 1.003; 1.00 to 1.01, respectively), and abnormal glucose tolerance (1.86; 1.23 to 2.80) were significantly associated with Alzheimer's disease. In multivariate analysis including apolipoprotein E4 phenotype, age, education, systolic blood pressure, total cholesterol concentration, fasting glucose concentration, and insulin concentration, apolipoprotein E4 phenotype, age, education, total cholesterol, and insulin were significantly associated with Alzheimer's disease. In 532 non-diabetic subjects without the e4 allele hyperinsulinaemia was associated with an increased risk for Alzheimer's disease (prevalence of disease 7.5% v 1.4% in normoinsulinaemic subjects, P = 0.0004). In contrast, in the 228 with the e4 allele hyperinsulinaemia had no effect on the risk of disease (7.0% v 7.1%, respectively). Conclusion: Features of the insulin resistance syndrome are associated with Alzheimer's disease independently of apolipoprotein E4 phenotype.	KUOPIO UNIV HOSP,DEPT MED,FIN-70211 KUOPIO,FINLAND; KUOPIO UNIV HOSP,DEPT NEUROL,FIN-70211 KUOPIO,FINLAND; OULU UNIV HOSP,DEPT INTERNAL MED,OULU,FINLAND; UNIV OULU,BIOCTR,OULU,FINLAND	Kuopio University Hospital; Kuopio University Hospital; University of Oulu; University of Oulu			Laakso, Mikko/AHB-7022-2022	Laakso, Mikko/0000-0003-1250-3425; Landin-Wilhelmsen, Kerstin/0000-0003-1998-5105				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BASKIN DG, 1987, ANNU REV PHYSIOL, V49, P335, DOI 10.1146/annurev.ph.49.030187.002003; BAURA GD, 1993, J CLIN INVEST, V92, P1824, DOI 10.1172/JCI116773; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; EHNHOLM C, 1986, J LIPID RES, V27, P227; GROBER E, 1988, NEUROLOGY, V38, P900, DOI 10.1212/WNL.38.6.900; HALES CN, 1963, BIOCHEM J, V88, P137, DOI 10.1042/bj0880137; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; KAMBOH MI, 1995, NAT GENET, V10, P486, DOI 10.1038/ng0895-486; KILANDER L, 1993, ACTA NEUROL SCAND, V87, P294, DOI 10.1111/j.1600-0404.1993.tb05511.x; Koivisto K, 1992, J Geriatr Psychiatry Neurol, V5, P162; KUUSISTO J, 1993, HYPERTENSION, V22, P771, DOI 10.1161/01.HYP.22.5.771; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; LAAKSO M, 1993, AM J EPIDEMIOL, V137, P959, DOI 10.1093/oxfordjournals.aje.a116768; LAAKSO M, 1991, ARTERIOSCLER THROMB, V11, P1068, DOI 10.1161/01.ATV.11.4.1068; LANDIN K, 1993, J INTERN MED, V233, P357, DOI 10.1111/j.1365-2796.1993.tb00684.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MENZEL HJ, 1986, ELECTROPHORESIS, V7, P492, DOI 10.1002/elps.1150071103; MYKKANEN L, 1990, DIABETES CARE, V13, P1099, DOI 10.2337/diacare.13.11.1099; Ott A, 1996, DIABETOLOGIA, V39, P1392, DOI 10.1007/s001250050588; PALOMAKI P, 1994, J CLIN EPIDEMIOL, V47, P659, DOI 10.1016/0895-4356(94)90213-5; PRINCE M, 1994, NEUROLOGY, V44, P97; Prineas R., 1982, MINNESOTA CODE MANUA; RAZAY G, 1994, AGE AGEING, V23, P396, DOI 10.1093/ageing/23.5.396; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; WARRINGTON EK, 1966, BRAIN, V89, P53, DOI 10.1093/brain/89.1.53; WEINFELD FD, 1981, STROKE S1, V12, P32; *WHO, 1982, MONICA MAN CVD MNC; *WHO, 1985, WHO TECH RECP SER, V727; *WHO, 1990, MONICA MAN CVD MNC	33	346	362	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1045	1049		10.1136/bmj.315.7115.1045	http://dx.doi.org/10.1136/bmj.315.7115.1045			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366728	Green Published			2022-12-24	WOS:A1997YD44500017
J	Pullen, N; Dennis, PB; Andjelkovic, M; Dufner, A; Kozma, SC; Hemmings, BA; Thomas, G				Pullen, N; Dennis, PB; Andjelkovic, M; Dufner, A; Kozma, SC; Hemmings, BA; Thomas, G			Phosphorylation and activation of p70(s6k) by PDK1	SCIENCE			English	Article							S6 KINASE; DOMAIN; SITE	Activation of the protein p70(s6k) by mitogens leads to increased translation of a family of messenger RNAs that encode essential components of the protein synthetic apparatus. Activation of the kinase requires hierarchical phosphorylation at multiple sites, culminating in the phosphorylation of the threonine in position 229 (Thr(229)), in the catalytic domain. The homologous site in protein kinase B (PKB), Thr(308), has been shown to be phosphorylated by the phosphoinositide-dependent protein kinase PDK1.A regulatory link between p70(s6k) and PKB was demonstrated, as PDK1 was found to selectively phosphorylate p70(s6k) at Thr(229). More importantly, PDK1 activated p70(s6k) in vitro and in vivo, whereas the catalytically inactive PDK1 blocked insulin-induced activation of p70(s6k).	Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hemmings, BA (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.		Thomas, George/K-9235-2014	Thomas, George/0000-0003-3518-8149; Pullen, Nicholas/0000-0002-4014-9278				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dennis P.B., UNPUB; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; HANKS SK, 1995, PROTEIN KINASE FACTS; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Meyuhas Oded, 1996, V30, P363; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744	17	718	732	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	1998	279	5351					707	710		10.1126/science.279.5351.707	http://dx.doi.org/10.1126/science.279.5351.707			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445476				2022-12-24	WOS:000071731500037
J	Krentz, AJ; Evans, AJ				Krentz, AJ; Evans, AJ			Selective imidazoline receptor agonists for metabolic syndrome	LANCET			English	Editorial Material							INSULIN-RESISTANCE; HYPERTENSION; ABNORMALITIES; DISEASE; SYSTEM		Southampton Gen Hosp, Dept Endocrinol & Diabet, Southampton SO16 6YD, Hants, England	University of Southampton	Krentz, AJ (corresponding author), Southampton Gen Hosp, Dept Endocrinol & Diabet, Southampton SO16 6YD, Hants, England.		Krentz, Andrew/AAD-2493-2019					CHRISP P, 1992, DRUGS, V44, P993, DOI 10.2165/00003495-199244060-00008; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; Ernsberger P, 1996, CARDIOVASC DRUG THER, V10, P275, DOI 10.1007/BF00120497; JULIUS S, 1991, J HYPERTENS, V9, P983, DOI 10.1097/00004872-199111000-00001; KAAN EC, 1995, CARDIOVASC RISK F S1, V5, P19; Landsberg Lewis, 1996, Blood Pressure, V5, P25; LITHELL H, 1997, EUR CARD SOC STOCKH; OGHIHARA T, 1995, AM J HYPERTENS, V8, P316; Reaven Gerald M., 1996, New England Journal of Medicine, V334, P374; Rosen P, 1997, J HYPERTENS, V15, pS31	11	18	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					152	153		10.1016/S0140-6736(98)22003-4	http://dx.doi.org/10.1016/S0140-6736(98)22003-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449863				2022-12-24	WOS:000071616300002
J	Quemeneur, E; Moutiez, M; Charbonnier, JB; Menez, A				Quemeneur, E; Moutiez, M; Charbonnier, JB; Menez, A			Engineering cyclophilin into a proline-specific endopeptidase	NATURE			English	Article							CIS-TRANS-ISOMERASE; ESCHERICHIA-COLI; ENZYME; ISOMERIZATION; HYDROLYSIS; MECHANISM; PROGRAM	Designing an enzyme requires, among a number of parameters, the appropriate positioning of catalytic machinery within a substrate-binding cleft. Using the structures of cyclophilin-peptide complexes(1-4), we have engineered a new catalytic activity into an Escherichia coli cyclophilin by mutating three amino acids, close to the peptide binding deft, to form a catalytic triad similar to that found in serine proteases. In conjunction with cyclophilin's specificity for proline-bearing peptides, this creates a unique endopeptidase, cyproase 1, which cleaves peptides on the amino-side of proline residues. When acting on an Ala-Pro dipeptide, cyproase 1 has an efficiency (k(cat)/K-m) of 0.7 x 10(4) M-1 s(-1) and enhances the rate of reaction (k(cat)/k(uncat)) 8 x 10(8)-fold. This activity depends upon a deprotonated histidine and is inhibited by nucleophile-specific reagents, as occurs in natural serine proteases. Cyproase 1 can hydrolyse a protein substrate with a proline-specific endoprotease activity.	CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Quemeneur, E (corresponding author), CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France.		Charbonnier, Jean-Baptiste/A-3868-2009; Moutiez, Mireille/T-7788-2019	Charbonnier, Jean-Baptiste/0000-0002-5219-1983; Moutiez, Mireille/0000-0002-0064-8291				BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CLUBB RT, 1994, BIOCHEMISTRY-US, V33, P2761, DOI 10.1021/bi00176a004; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Fersht A., 1985, ENZYME STRUCTURE MEC; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P69; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; KAHNE D, 1988, J AM CHEM SOC, V110, P7529, DOI 10.1021/ja00230a041; Kirby AJ, 1996, ANGEW CHEM INT EDIT, V35, P707; Konno M, 1996, J MOL BIOL, V256, P897, DOI 10.1006/jmbi.1996.0136; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; MAILLERE B, 1995, TOXICON, V33, P475, DOI 10.1016/0041-0101(94)00186-C; MATTHEWS BW, 1994, P NATL ACAD SCI USA, V91, P4103, DOI 10.1073/pnas.91.10.4103; MENEZ A, 1980, BIOCHEMISTRY-US, V19, P5202, DOI 10.1021/bi00564a008; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; PLUMMER TH, 1980, ANAL BIOCHEM, V108, P348, DOI 10.1016/0003-2697(80)90598-9; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; Segel IH., 1993, ENZYME KINETICS BEHA; STEIN RL, 1993, ADV PROTEIN CHEM, V44, P1, DOI 10.1016/S0065-3233(08)60562-8; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Zhao YD, 1996, BIOCHEMISTRY-US, V35, P7356, DOI 10.1021/bi9602775; Zhao YD, 1996, BIOCHEMISTRY-US, V35, P7362, DOI 10.1021/bi960278x	25	55	60	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					301	304		10.1038/34687	http://dx.doi.org/10.1038/34687			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440697				2022-12-24	WOS:000071484400056
J	Marsden, AFA; Wilkinson, B; Cortes, J; Dunster, NJ; Staunton, J; Leadlay, PF				Marsden, AFA; Wilkinson, B; Cortes, J; Dunster, NJ; Staunton, J; Leadlay, PF			Engineering broader specificity into an antibiotic-producing polyketide synthase	SCIENCE			English	Article							BIOSYNTHETIC GENE-CLUSTER; SACCHAROPOLYSPORA-ERYTHRAEA; STREPTOMYCES-HYGROSCOPICUS; ORGANIZATION; AVERMECTINS; RAPAMYCIN; DOMAIN; ACID; BACTERIA; SEQUENCE	The wide-specificity loading module for the avermectin-producing polyketide synthase was grafted onto the first multienzyme component (DEBS1) of the erythromycin-producing polyketide synthase in place of the normal loading module. Expression of this hybrid enzyme in the erythromycin producer Saccharopolyspora erythraea produced several novel antibiotic erythromycins derived from endogenous branched-chain acid starter units typical of natural avermectins. Because the avermectin polyketide synthase is known to accept more than 40 alternative carboxylic acids as starter units, this approach opens the way to facile production of novel analogs of antibiotic macrolides.	Univ Cambridge, Cambridge Ctr Mol Recognit, Cambridge CB2 1QW, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Univ Cambridge, Chem Lab, Cambridge CB2 1EW, England; Univ Cambridge, Cambridge Ctr Mol Recognit, Cambridge CB2 1EW, England	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge	Leadlay, PF (corresponding author), Univ Cambridge, Cambridge Ctr Mol Recognit, Tennis Court Rd, Cambridge CB2 1QW, England.			Cortes, Jesus/0000-0002-2475-6983; Leadlay, Peter/0000-0002-3247-509X				Aparicio JF, 1996, GENE, V169, P9, DOI 10.1016/0378-1119(95)00800-4; Bax RP, 1997, CLIN INFECT DIS, V24, pS151, DOI 10.1093/clinids/24.Supplement_1.S151; BEVITT DJ, 1992, EUR J BIOCHEM, V204, P39, DOI 10.1111/j.1432-1033.1992.tb16603.x; BROWN MJB, 1995, J CHEM SOC CHEM COMM, P1517, DOI 10.1039/c39950001517; CAFFREY P, 1992, FEBS LETT, V304, P225, DOI 10.1016/0014-5793(92)80624-P; CANE DE, 1983, J AM CHEM SOC, V105, P4110, DOI 10.1021/ja00350a070; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; CORTES J, 1995, SCIENCE, V268, P1487, DOI 10.1126/science.7770773; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; CUTTER A, UNPUB; Davies J, 1996, NATURE, V383, P219, DOI 10.1038/383219a0; DHILLON N, 1989, MOL MICROBIOL, V3, P1405, DOI 10.1111/j.1365-2958.1989.tb00123.x; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DUTTON CJ, 1991, J ANTIBIOT, V44, P357, DOI 10.7164/antibiotics.44.357; GRAMAJO HC, 1993, MOL MICROBIOL, V7, P837, DOI 10.1111/j.1365-2958.1993.tb01174.x; Hopwood D. A., 1985, GENETIC MANIPULATION; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; Jack DB, 1996, MOL MED TODAY, V2, P499, DOI 10.1016/S1357-4310(97)81453-0; Jacobsen JR, 1997, SCIENCE, V277, P367, DOI 10.1126/science.277.5324.367; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; Kim CG, 1996, J AM CHEM SOC, V118, P7486, DOI 10.1021/ja9601292; Kuhstoss S, 1996, GENE, V183, P231, DOI 10.1016/S0378-1119(96)00565-3; LAMBALOT RH, 1995, BIOCHEMISTRY-US, V34, P1858, DOI 10.1021/bi00006a006; Leadlay PF, 1997, CURR OPIN CHEM BIOL, V1, P162, DOI 10.1016/S1367-5931(97)80005-1; Lowden PAS, 1996, ANGEW CHEM INT EDIT, V35, P2249, DOI 10.1002/anie.199622491; MACNEIL DJ, 1992, GENE, V115, P119, DOI 10.1016/0378-1119(92)90549-5; MACNEIL DJ, 1994, ANN NY ACAD SCI, V721, P123, DOI 10.1111/j.1749-6632.1994.tb47384.x; MCARTHUR HAI, IN PRESS DEV IND MIC; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; Oliynyk M, 1996, CHEM BIOL, V3, P833, DOI 10.1016/S1074-5521(96)90069-1; PAIVA NL, 1993, J IND MICROBIOL, V12, P423, DOI 10.1007/BF01569676; PIEPER R, 1995, J AM CHEM SOC, V117, P11373, DOI 10.1021/ja00150a049; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; Staunton J, 1996, NAT STRUCT BIOL, V3, P188, DOI 10.1038/nsb0296-188; SWAN DG, 1994, MOL GEN GENET, V242, P358, DOI 10.1007/BF00280426; TRAEDER W, 1994, TIERARZTL UMSCHAU, V49, P465; Wallace KK, 1997, J BACTERIOL, V179, P3884, DOI 10.1128/jb.179.12.3884-3891.1997; WEBER JM, 1990, J BACTERIOL, V172, P2372, DOI 10.1128/jb.172.5.2372-2383.1990; WIESMANN KEH, 1995, CHEM BIOL, V2, P583, DOI 10.1016/1074-5521(95)90122-1; Williams DH, 1996, CHEMTECH, V26, P17	42	191	224	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					199	202		10.1126/science.279.5348.199	http://dx.doi.org/10.1126/science.279.5348.199			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422686				2022-12-24	WOS:000071408100033
J	Ekwall, K; Olsson, T; Turner, BM; Cranston, G; Allshire, RC				Ekwall, K; Olsson, T; Turner, BM; Cranston, G; Allshire, RC			Transient inhibition of histone deacetylation alters the structural and functional imprint at fission yeast centromeres	CELL			English	Article							POSITION-EFFECT VARIEGATION; INACTIVE X-CHROMOSOME; MATING-TYPE LOCI; SCHIZOSACCHAROMYCES-POMBE; CHROMATIN STRUCTURE; CPG ISLANDS; ACETYLATION; HETEROCHROMATIN; MUTATIONS; GENE	Histone acetylation may act to mark and maintain transcriptionally active or inactive chromosomal domains through the cell cycle and in different lineages. A novel role for histone acetylation in centromere regulation has been identified. Exposure of fission yeast cells to TSA, a specific inhibitor of histone deacetylase, interferes with repression of marker genes in centromeric heterochromatin, causes chromosome loss, and disrupts the localization of Swi6p, a component of centromeric heterochromatin. Transient TSA treatment induces a heritable hyperacetylated state in centromeric chromatin that is propagated in lineages in the absence of drug. This state is linked in cis to the treated centromere locus and correlates with inheritance of functionally defective centromeres and persistent chromosome segregation problems. Thus, assembly of fully functional centromeres is partly imprinted in the underacetylated or transcriptionally silent state of centromeric chromatin.	Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Gothenburg Univ, Dept Mol Biol, Lundberg Lab, S-41390 Gothenburg, Sweden; Univ Birmingham, Sch Med, Dept Anat, Chromatin & Gene Express Grp, Birmingham B15 2TT, W Midlands, England	University of Edinburgh; University of Gothenburg; University of Birmingham	Allshire, RC (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.			Allshire, Robin/0000-0002-8005-3625; Ekwall, Karl/0000-0002-3029-4041	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; ALLSHIRE RC, 1996, EPIGENETIC MECH GENE; Belyaev ND, 1996, HUM GENET, V97, P573; BICKMORE WA, 1995, J CELL SCI, V108, P2801; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; CRAIG JM, 1994, NAT GENET, V7, P376, DOI 10.1038/ng0794-376; DORN R, 1986, CHROMOSOMA, V93, P398, DOI 10.1007/BF00285820; duSart D, 1997, NAT GENET, V16, P144; EKWALL K, 1994, GENETICS, V136, P53; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; Ekwall K, 1996, J CELL SCI, V109, P2637; Grewal SIS, 1996, CELL, V86, P95, DOI 10.1016/S0092-8674(00)80080-X; Grewal SIS, 1997, GENETICS, V146, P1221; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; HOFFMAN CS, 1991, GENE DEV, V5, P561, DOI 10.1101/gad.5.4.561; Javerzat JP, 1996, NUCLEIC ACIDS RES, V24, P4676, DOI 10.1093/nar/24.23.4676; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KARPEN G, 1998, IN PRESS TRENDS GENE; KELLUM R, 1995, J CELL SCI, V108, P1419; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Shelby RD, 1997, J CELL BIOL, V136, P501, DOI 10.1083/jcb.136.3.501; STEINER NC, 1994, CELL, V79, P865, DOI 10.1016/0092-8674(94)90075-2; STEINER NC, 1993, MOL CELL BIOL, V13, P4578, DOI 10.1128/MCB.13.8.4578; SULLIVAN BA, 1995, HUM MOL GENET, V4, P2189, DOI 10.1093/hmg/4.12.2189; Sun XP, 1997, CELL, V91, P1007, DOI 10.1016/S0092-8674(00)80491-2; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; TENHAGEN KG, 1990, MOL CELL BIOL, V10, P6348, DOI 10.1128/MCB.10.12.6348; THON G, 1992, GENETICS, V131, P287; Thon G, 1997, GENETICS, V145, P685; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; Warburton PE, 1997, CURR BIOL, V7, P901, DOI 10.1016/S0960-9822(06)00382-4; WOLFFE AP, 1997, J BIOL CHEM, V387, P16	41	317	325	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	1997	91	7					1021	1032		10.1016/S0092-8674(00)80492-4	http://dx.doi.org/10.1016/S0092-8674(00)80492-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428524	Bronze			2022-12-24	WOS:000071281400018
J	Salpeter, SR; Sanders, GD; Salpeter, EE; Owens, DK				Salpeter, SR; Sanders, GD; Salpeter, EE; Owens, DK			Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: A risk-benefit and cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article							PREVENTIVE THERAPY; DECISION-ANALYSIS; UNITED-STATES; YOUNG-ADULTS; SKIN-TEST; CHEMOPROPHYLAXIS; HEPATITIS; LIVER; INFECTION; CHILDREN	Background: Isoniazid chemoprophylaxis effectively prevents the development of active infectious tuberculosis. Current guidelines recommend withholding this prophylaxis for low-risk tuberculin reactors older than 35 years of age because of the risk for fatal isoniazid-induced hepatitis. However, recent studies have shown that monitoring for hepatotoxicity can significantly reduce the risk for isoniazid-related death. Objective: To evaluate the effectiveness and cost-effectiveness of monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age. Design: A Markov model was used to compare the health and economic outcomes of prescribing or withholding a course of prophylaxis for low-risk reactors 35, 50, or 70 years of age. Subsequent analyses evaluated costs and benefits when the effect of transmission of Mycobacterium tuberculosis to contacts was included. Measurements: Probability of survival at 1 year, number needed to treat, life expectancy, and cost per year of life gained for individual persons and total population. Results: Isoniazid prophylaxis increased the probability of survival at 1 year and for all subsequent years. For 35-year-old, 50-year-old, and 70-year-old tuberculin reactors, life expectancy increased by 4.9 days, 4.7 days, and 3.1 days, respectively, and costs per person decreased by $101, $69, and $11, respectively. When the effect of secondary transmission to contacts was included, the gains in life expectancy per person receiving prophylaxis were 10.0 days for 35-year-old reactors, 9.0 days for 50-year-old reactors, and 6.0 days for 70-year-old reactors. Costs per person for these cohorts decreased by $259, $203, and $100, respectively. The magnitude of the benefit of isoniazid prophylaxis is moderately sensitive to the effect of isoniazid on quality of life. The hypothetical provision of isoniazid prophylaxis for all low-risk reactors older than 35 years of age in the U.S. population could prevent 35 176 deaths and save $2.11 billion. Conclusions: Monitored isoniazid prophylaxis reduces mortality rates and health care costs for low-risk tuberculin reactors older than 35 years of age, although reductions for individual patients are small. For the U.S. population, however, the potential health benefits and economic savings resulting from wider use of monitored isoniazid prophylaxis are substantial. We should consider expanding current recommendations to include prophylaxis for tuberculin reactors of all ages with no contraindications.	Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; Stanford Univ, Sch Med, Sect Med Informat, Stanford, CA 94305 USA; Cornell Univ, Ctr Radiophys & Space Res, Ithaca, NY USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA	Santa Clara Valley Medical Center; Stanford University; Cornell University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Salpeter, EE (corresponding author), Santa Clara Valley Med Ctr, 2400 Moorpark Ave,Suite 118, San Jose, CA 95128 USA.							ALCABES P, 1989, AM REV RESPIR DIS, V140, P1194, DOI 10.1164/ajrccm/140.5.1194; *AM MED ASS, 1995, PHYS CURR PROC TERM; *AM MED ASS, 1996, MED RBRVS PHYS GUID; BAILEY TC, 1995, ANN INTERN MED, V122, P580, DOI 10.7326/0003-4819-122-8-199504150-00004; BAILEY WC, 1983, AM REV RESPIR DIS, V127, P790; BAILEY WC, 1974, ANN INTERN MED, V81, P200, DOI 10.7326/0003-4819-81-2-200; BAILEY WC, 1973, AM REV RESPIR DIS, V107, P523, DOI 10.1164/arrd.1973.107.4.523; BAILEY WC, 1985, CHEST, V87, pS128; BARLOW PB, 1974, AM REV RESPIR DIS, V110, P371; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BARNES PF, 1993, ANN INTERN MED, V119, P400, DOI 10.7326/0003-4819-119-5-199309010-00009; BEAUDRY PH, 1974, AM REV RESPIR DIS, V110, P581; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BLACK M, 1975, GASTROENTEROLOGY, V69, P289; BLUM RN, 1993, CHEST, V103, P1670, DOI 10.1378/chest.103.6.1670; BROWN RE, 1995, ARCH INTERN MED, V155, P1595, DOI 10.1001/archinte.155.15.1595; BURRILL D, 1985, CAN MED ASSOC J, V132, P137; BYRD RB, 1979, JAMA-J AM MED ASSOC, V241, P1239, DOI 10.1001/jama.241.12.1239; BYRD RB, 1972, J AMER MED ASSOC, V220, P1471, DOI 10.1001/jama.1972.03200110051009; *CDC, 1994, COR CURR TUB, P13; *CDC, 1992, TUB US, P67; *CDC, 1991, TUB US, P14; *CDC PREV, 1996, REP TUB US 1995, P5; COLICE GL, 1990, ARCH INTERN MED, V150, P2517, DOI 10.1001/archinte.150.12.2517; COMSTOCK GW, 1976, PUBLIC HEALTH REP, V91, P276; COMSTOCK GW, 1967, AM REV RESPIR DIS, V95, P935; COMSTOCK GW, 1975, AM J EPIDEMIOL, V101, P363, DOI 10.1093/oxfordjournals.aje.a112105; COMSTOCK GW, 1974, AM REV RESPIR DIS, V110, P195; COMSTOCK GW, 1981, ANN INTERN MED, V94, P817, DOI 10.7326/0003-4819-94-6-817; COOPER JK, 1986, J AM GERIATR SOC, V34, P814, DOI 10.1111/j.1532-5415.1986.tb03988.x; CULLINAN P, 1991, THORAX, V46, P347, DOI 10.1136/thx.46.5.347; DASH LA, 1980, AM REV RESPIR DIS, V121, P1039; DICKINSON DS, 1981, J CLIN GASTROENTEROL, V3, P271, DOI 10.1097/00004836-198109000-00012; DOLAN JG, 1994, MED DECIS MAKING, V14, P1, DOI 10.1177/0272989X9401400101; FEREBEE SH, 1963, AM REV RESPIR DIS, V88, P161; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; FITZGERALD JM, 1990, AM REV RESPIR DIS, V142, P848, DOI 10.1164/ajrccm/142.4.848; FITZGERALD JM, 1990, AM REV RESPIR DIS, V1415, pA438; FRANKS AL, 1989, PUBLIC HEALTH REP, V104, P151; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; GARIBALDI RA, 1972, AM REV RESPIR DIS, V106, P357, DOI 10.1164/arrd.1972.106.3.357; GIRLING DJ, 1992, AM REV RESPIR DIS, V145, P36; GLASSROTH J, 1990, AM REV RESPIR DIS, V141, P1236, DOI 10.1164/ajrccm/141.5_Pt_1.1236; GOLD MR, 1996, COST EFFECTIVENESS H, P214; GRZYBOWSKI S, 1976, CAN MED ASSOC J, V114, P607; GRZYBOWSKI S, 1969, CAN MED ASSOC J, V101, P555; GURUMURTHY P, 1984, AM REV RESPIR DIS, V129, P58; HANSON ML, 1967, PUBLIC HEALTH REP, V82, P1045, DOI 10.2307/4593193; *HLTH CAR INV AN I, 1996, MED DRG HDB; HORWITZ O, 1969, B WORLD HEALTH ORGAN, V41, P95; HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P46, DOI 10.1080/00039896.1968.10665013; HSU KHK, 1974, JAMA-J AM MED ASSOC, V229, P528, DOI 10.1001/jama.229.5.528; Jordan T J, 1990, Bull Int Union Tuberc Lung Dis, V66 Suppl, P21; JORDAN TJ, 1991, AM REV RESPIR DIS, V144, P1357, DOI 10.1164/ajrccm/144.6.1357; KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991; KULLER LH, 1974, PREV MED, V3, P61, DOI 10.1016/0091-7435(74)90063-2; LEVIN ML, 1974, MARYLAND STATE MED J, V23, P64; LITT IF, 1976, J PEDIATR-US, V89, P133, DOI 10.1016/S0022-3476(76)80949-3; MACKAY AD, 1984, Q J MED, V53, P497; MADDREY WC, 1973, ANN INTERN MED, V79, P1, DOI 10.7326/0003-4819-79-1-1; *MED, 1997, FEE COD STAND; MEHTA JB, 1988, CHEST, V94, P138, DOI 10.1378/chest.94.1.138; Millard PS, 1996, WESTERN J MED, V164, P486; MITCHELL JR, 1975, CHEST, V68, P181, DOI 10.1378/chest.68.2.181; MOHLEBOETANI JC, 1995, JAMA-J AM MED ASSOC, V274, P613, DOI 10.1001/jama.274.8.613; MORI MA, 1992, ARCH INTERN MED, V152, P547, DOI 10.1001/archinte.152.3.547; NAKAJO MM, 1989, PEDIATR INFECT DIS J, V8, P649, DOI 10.1097/00006454-198909000-00019; *NAT CTR HLTH STAT, 1995, MONTHL VIT STAT REP; *NAT CTR HLTH STAT, 1991, VIT STAT US 1988 A, V2; NAZAR V, 1990, American Review of Respiratory Disease, V141, pA438; NOLAN CM, 1986, AM REV RESPIR DIS, V133, P431; OBRIEN RJ, 1990, AM REV RESPIR DIS, V141, P821, DOI 10.1164/ajrccm/141.4_Pt_1.821; Protection against viral hepatitis, 1990, MMWR RECOMM REP, V39, P1; Quillan S, 1990, J Am Coll Health, V38, P165; Rabindran E, 1991, Md Med J, V40, P793; RAPP RS, 1978, AM REV RESPIR DIS, V118, P794, DOI 10.1164/arrd.1978.118.4.794; ROSE DN, 1986, JAMA-J AM MED ASSOC, V256, P2709, DOI 10.1001/jama.256.19.2709; ROSENBERG T, 1993, AM REV RESPIR DIS, V148, P1537, DOI 10.1164/ajrccm/148.6_Pt_1.1537; SALPETER EE, IN PRESS AM J EPIDEM; SALPETER S, 1992, WESTERN J MED, V157, P421; SALPETER SR, 1993, WESTERN J MED, V159, P560; SCHARER L, 1969, ANN INTERN MED, V71, P1113, DOI 10.7326/0003-4819-71-6-1113; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; SPYRIDIS P, 1979, ARCH DIS CHILD, V54, P65, DOI 10.1136/adc.54.1.65; STEAD WW, 1987, ANN INTERN MED, V107, P843, DOI 10.7326/0003-4819-107-6-843; STERLING TR, 1995, ARCH INTERN MED, V155, P1622, DOI 10.1001/archinte.155.15.1622; TAYLOR WC, 1981, ANN INTERN MED, V94, P808, DOI 10.7326/0003-4819-94-6-808; THOMAS PA, 1979, ARCH SURG-CHICAGO, V114, P597; THOMPSON JE, 1978, MED J AUSTRALIA, V1, P165, DOI 10.5694/j.1326-5377.1978.tb107815.x; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; TRUMP DH, 1993, ARCH INTERN MED, V153, P211, DOI 10.1001/archinte.153.2.211; TSEVAT J, 1988, AM REV RESPIR DIS, V137, P215, DOI 10.1164/ajrccm/137.1.215; VADASZ I, 1974, Bulletin of the International Union Against Tuberculosis, V49, P294; WADHAWAN D, 1990, P ABSTR 6 INT C AIDS, V1, pA249; 1980, MMWR MORB MORTAL WKL, V29, P589; 1997, EC REPORT PRESIDENT; [No title captured]	97	86	87	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1051	1061		10.7326/0003-4819-127-12-199712150-00001	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00001			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412307				2022-12-24	WOS:000070936600001
J	Yaffe, MB; Schutkowski, M; Shen, MH; Zhou, XZ; Stukenberg, PT; Rahfeld, JU; Xu, J; Kuang, J; Kirschner, MW; Fischer, G; Cantley, LC; Lu, KP				Yaffe, MB; Schutkowski, M; Shen, MH; Zhou, XZ; Stukenberg, PT; Rahfeld, JU; Xu, J; Kuang, J; Kirschner, MW; Fischer, G; Cantley, LC; Lu, KP			Sequence-specific and phosphorylation-dependent proline isomerization: A potential mitotic regulatory mechanism	SCIENCE			English	Article							PROLYL CIS/TRANS ISOMERASES; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; CELL-CYCLE; M-PHASE; MITOSIS; FAMILY; ASSOCIATION; ANTIBODY; BINDING	Pin1 is an essential and conserved mitotic peptidyl-prolyl isomerase (PPlase) that is distinct from members of two other families of conventional PPlases, cyclophilins and FKBPs (FK-506 binding proteins). In response to their phosphorylation during mitosis, Pin1 binds and regulates members of a highly conserved set of protein; that overlaps with antigens recognized by the mitosis-specific monoclonal antibody MPM-2. Pin1 is here shown to be a phosphorylation-dependent PPlase that specifically recognizes the phosphoserine-proline or phosphothreonine-proline bonds present in mitotic phosphoproteins. Both Pin1 and MPM-2 selected similar phosphorylated serine-proline-containing peptides, providing the basis for the specific interaction between Pin1 and MPM-2 antigens. Pin1 preferentially isomerized proline residues preceded by phosphorylated serine or threonine with up to 1300-fold selectivity compared with unphosphorylated peptides. Pin1 may thus regulate mitotic progression by catalyzing sequence-specific and phosphorylation-dependent proline isomerization.	BETH ISRAEL DEACONESS MED CTR, DEPT MED, DIV HEMATOL ONCOL, CANC BIOL PROGRAM, BOSTON, MA 02215 USA; BETH ISRAEL DEACONESS MED CTR, DIV SIGNAL TRANSDUCT, DEPT MED, BOSTON, MA 02215 USA; BETH ISRAEL DEACONESS MED CTR, DEPT SURG, BOSTON, MA 02215 USA; MAX PLANCK RES UNIT ENZYMOL PROT FOLDING, D-06120 HALLE, GERMANY; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CLIN INVEST, HOUSTON, TX 77030 USA; HARVARD UNIV, SCH MED, DIV AGING, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Max Planck Society; Harvard University; Harvard Medical School; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Harvard Medical School			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Schutkowski, MIke/0000-0003-0919-7076; Stukenberg, Todd/0000-0002-6788-2111	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056230, R01GM056203] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056203, GM56230, GM56203] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BERNHARDT A, 1997, INT J PEPT PROT RES, V50, P143; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lu KP, 1996, NATURE, V380, P544; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; RAHFELD JU, 1994, FEBS LETT, V343, P65, DOI 10.1016/0014-5793(94)80608-X; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; RUDD KE, 1995, TRENDS BIOCHEM SCI, V20, P12, DOI 10.1016/S0968-0004(00)88940-9; SCHMID FX, 1995, CURR BIOL, V5, P993, DOI 10.1016/S0960-9822(95)00197-7; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHUTKOWSKI M, 1995, BIOCHEMISTRY-US, V34, P13016, DOI 10.1021/bi00040a012; SHEN M, UNPUB; TAAGEPERA S, 1994, MOL BIOL CELL, V5, P1243, DOI 10.1091/mbc.5.11.1243; VOLINIA S, UNPUB; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	671	700	2	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 12	1997	278	5345					1957	1960		10.1126/science.278.5345.1957	http://dx.doi.org/10.1126/science.278.5345.1957			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395400				2022-12-24	WOS:A1997YL00200038
J	Livesey, FJ; OBrien, JA; Li, M; Smith, AG; Murphy, LJ; Hunt, SP				Livesey, FJ; OBrien, JA; Li, M; Smith, AG; Murphy, LJ; Hunt, SP			A Schwann cell mitogen accompanying regeneration of motor neurons	NATURE			English	Article							PANCREATITIS-ASSOCIATED PROTEIN; SPINAL MOTONEURONS; SENSORY NEURONS; MESSENGER-RNA; EXPRESSION; RECEPTOR; RAT; IDENTIFICATION; SURVIVAL; AXOTOMY	Motor neurons are the only adult mammalian neurons of the central nervous system to regenerate following injury(1). This ability is dependent on the environment of the peripheral nerve and an intrinsic capacity of motor neurons for regrowth(2). We report here the identification, using a technique known as messenger RNA differential display(3), of an extracellular signalling molecule, previously described as the pancreatic secreted protein Reg-2 (ref. 4), that is expressed solely in regenerating and developing rat motor and sensory neurons. Axon-stimulated Schwann cell proliferation is necessary for successful regeneration(5,6), and we show that Reg-2 is a potent Schwann cell mitogen in vitro. In vivo, Reg-2 protein is transported along regrowing axons and inhibition of Reg-2 signalling significantly retards the regeneration of Reg-2-containing axons. During development, Reg-2 production by motor and sensory neurons is regulated by contact with peripheral targets. Strong candidates for peripheral factors regulating Reg-2 production are cytokines of the LIF/CNTF family, because Reg-2 is not exp,ressed in developing motor or sensory neurons of mice carrying a targeted disruption of the LIF receptor gene, a common component of the receptor complexes for all of the LIF/CNTF family(7).	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; UNIV EDINBURGH,CTR GENOME RES,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND; UNIV MANITOBA,DEPT INTERNAL MED,WINNIPEG,MB R3E 3J7,CANADA; UNIV MANITOBA,DEPT PHYSIOL,WINNIPEG,MB R3E 3J7,CANADA	MRC Laboratory Molecular Biology; University of Edinburgh; University of Manitoba; University of Manitoba			Li, Meng/I-6941-2013; HUNT, STEPHEN P/C-1646-2008	Smith, Austin/0000-0002-3029-4682; Livesey, Rick/0000-0001-6128-3372; Hunt, Stephen/0000-0001-9453-5505				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANNER LR, 1994, P NATL ACAD SCI USA, V91, P7109, DOI 10.1073/pnas.91.15.7109; Carroll SL, 1997, J NEUROSCI, V17, P1642; CHAKRABORTY C, 1995, J ENDOCRINOL, V145, P461, DOI 10.1677/joe.0.1450461; DEFELIPE C, 1994, J NEUROSCI, V14, P2911; DELAMONTE SM, 1990, J CLIN INVEST, V86, P1004, DOI 10.1172/JCI114762; DUMOULIN FL, 1991, EUR J NEUROSCI, V3, P338, DOI 10.1111/j.1460-9568.1991.tb00820.x; DUSETTI NJ, 1995, J BIOL CHEM, V270, P22417, DOI 10.1074/jbc.270.38.22417; ECCLESTON PA, 1992, EXP CELL RES, V199, P1, DOI 10.1016/0014-4827(92)90455-H; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; FRIGERIO JM, 1993, BIOCHIM BIOPHYS ACTA, V1216, P329, DOI 10.1016/0167-4781(93)90167-C; FRIGERIO JM, 1993, BIOCHEMISTRY-US, V32, P9236, DOI 10.1021/bi00086a032; Gassmann M, 1997, CURR OPIN NEUROBIOL, V7, P87, DOI 10.1016/S0959-4388(97)80125-0; Greensmith L, 1996, TRENDS NEUROSCI, V19, P450, DOI 10.1016/S0166-2236(96)20034-7; HALL SM, 1986, NEUROPATH APPL NEURO, V12, P401, DOI 10.1111/j.1365-2990.1986.tb00151.x; IOVANNA J, 1991, J BIOL CHEM, V266, P25664; JENKINS R, 1991, NEUROSCI LETT, V129, P107, DOI 10.1016/0304-3940(91)90731-8; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; Reynolds M L, 1993, Curr Opin Neurobiol, V3, P683, DOI 10.1016/0959-4388(93)90139-P; Scherer S.S., 1996, GLIAL CELL DEV, P165; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHMALBRUCH H, 1995, BRAIN RES, V700, P254, DOI 10.1016/0006-8993(95)00982-V; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; WEINMASTER G, 1990, EMBO J, V9, P915, DOI 10.1002/j.1460-2075.1990.tb08189.x; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0	30	155	157	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					614	618		10.1038/37615	http://dx.doi.org/10.1038/37615			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403691				2022-12-24	WOS:A1997YK85300051
J	McFadzean, J; Monson, JP; Watson, JD; Coakley, JH				McFadzean, J; Monson, JP; Watson, JD; Coakley, JH			Ethical debate - The dilemma of the incapacitated patient who has previously refused consent for surgery	BRITISH MEDICAL JOURNAL			English	Article								What should doctors do if a patient is critically ill and unable to give consent to a procedure that he or she has previously refused to consent to? Such a case is described below and discussed by a medicolegal specialist and by an ethicist.	ST BARTHOLOMEWS HOSP,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London									0	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1530	1531		10.1136/bmj.315.7121.1530	http://dx.doi.org/10.1136/bmj.315.7121.1530			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9420500	Green Published			2022-12-24	WOS:A1997YK98600032
J	Spitzer, WO				Spitzer, WO			Balanced view of risks of oral contraceptives	LANCET			English	Editorial Material											Spitzer, WO (corresponding author), STANFORD UNIV,SCH MED,DEPT MED,PALO ALTO,CA 94301, USA.							Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; Spitzer WO, 1997, HUM REPROD, V12, P2347, DOI 10.1093/humrep/12.11.2347; *WHO COLL STUD CAR, 1997, LANCET, V349, P1202	3	13	13	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1566	1567		10.1016/S0140-6736(05)64008-1	http://dx.doi.org/10.1016/S0140-6736(05)64008-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393332				2022-12-24	WOS:A1997YH98600004
J	Jamora, C; Takizawa, PA; Zaarour, RF; Denesvre, C; Faulkner, J; Malhotra, V				Jamora, C; Takizawa, PA; Zaarour, RF; Denesvre, C; Faulkner, J; Malhotra, V			Regulation of Golgi structure through heterotrimeric G proteins	CELL			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; TRIMERIC G-PROTEINS; ALPHA-SUBUNITS; MEMBRANES REQUIRES; GUANINE-NUCLEOTIDE; VESICLE FORMATION; COATED VESICLES; BREFELDIN-A; TRANSPORT	We have previously shown that ilimaquinone (IQ), a marine sponge metabolite, causes complete vesiculation of the Golgi stacks. By reconstituting the I-mediated vesiculation of the Golgi apparatus in permeabilized cells, we now demonstrate that this process does not require ARF and coatomers, which are necessary for the formation of Golgi-derived COPI vesicles. We find that IQ-mediated Golgi vesiculation is inhibited by G-alpha(s)-GDP and G-alpha(13)-GDP. Interestingly, adding beta-gamma subunits in the absence of IQ is sufficient to vesiculate Golgi stacks. Our findings reveal that I-mediated Golgi vesiculation occurs through activation of heterotrimeric G proteins and that it is the free beta-gamma, and not the activated alpha subunit, that triggers Golgi vesiculation.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Institution of Oceanography			Malhotra, Vivek/O-9811-2014	Malhotra, Vivek/0000-0001-6198-7943; Zaarour, Rania/0000-0001-9132-5940	NIGMS NIH HHS [GM46224] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; Benli M, 1996, EMBO J, V15, P6460, DOI 10.1002/j.1460-2075.1996.tb01037.x; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; GRABER SG, 1994, METHOD ENZYMOL, V237, P212; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HIDALGO J, 1995, J CELL SCI, V108, P1805; Jedd G, 1997, J CELL BIOL, V137, P563, DOI 10.1083/jcb.137.3.563; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; MAIER O, 1995, BIOCHEM BIOPH RES CO, V208, P135, DOI 10.1006/bbrc.1995.1315; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MALLABIABARRENA A, 1995, CELL, V83, P667, DOI 10.1016/0092-8674(95)90177-9; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Schekman R, 1997, CELL, V90, P197, DOI 10.1016/S0092-8674(00)80326-8; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TAKIZAWA PA, 1993, CELL, V75, P593, DOI 10.1016/0092-8674(93)90477-8; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; TAYLOR TC, 1994, MOL BIOL CELL, V5, P237, DOI 10.1091/mbc.5.2.237; VEIT B, 1993, J CELL BIOL, V122, P1197, DOI 10.1083/jcb.122.6.1197; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WILSON BS, 1994, J CELL BIOL, V125, P557, DOI 10.1083/jcb.125.3.557	40	99	99	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					617	626		10.1016/S0092-8674(00)80449-3	http://dx.doi.org/10.1016/S0092-8674(00)80449-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393855	Bronze			2022-12-24	WOS:A1997YH96000009
J	MacDonald, TM; Morant, SV; Robinson, GC; Shield, MJ; McGilchrist, MM; Murray, FE; McDevitt, DG				MacDonald, TM; Morant, SV; Robinson, GC; Shield, MJ; McGilchrist, MM; Murray, FE; McDevitt, DG			Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BLEEDING PEPTIC-ULCER; ELDERLY PERSONS; ASPIRIN; COMPLICATIONS; ANALGESICS; RISK	Objectives: To determine the profile of risk of upper gastrointestinal toxicity during continuous treatment with, and after cessation of, non-steroidal anti-inflammatory drugs. Design: Cohort study with a prospectively constructed, population based, record linkage database containing details of exposure to all community dispensed non-steroidal anti-inflammatory drugs and also all admissions to hospital for upper gastrointestinal diagnoses. Setting: The population of Tayside, Scotland. Subjects: 52 293 subjects aged 50 and over who received one or more non-steroidal anti-inflammatory between 1 January 1989 and 31 December 1991 and 73 792 subjects who did not receive one during the same period (controls). Main outcome measures: Admission to hospital for upper gastrointestinal bleeding and perforation, and admission for other upper gastrointestinal diagnoses. Results: About 2% of the non-steroidal anti-inflammatory cohort were admitted with an upper gastrointestinal event during the study period compared with 1.4% of controls. The risk of admission for upper gastrointestinal haemorrhage and perforation was constant during continuous non-steroidal anti-inflammatory exposure and carried over after the end of exposure. The results were similar for admissions for all upper gastrointestinal events. Conclusion: This study provides evidence that non-steroidal anti-inflammatory toxicity persists with continuous exposure. There seems to be carryover toxicity after the end of prescribing. These findings have implications for the management of patients requiring non-steroidal anti-inflammatory drugs.	SEARLE, HIGH WYCOMBE HP12 4HL, BUCKS, ENGLAND	Pfizer	MacDonald, TM (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, MED MONITORING UNIT, DEPT CLIN PHARMACOL, DUNDEE DD1 9SY, SCOTLAND.			MacDonald, Thomas/0000-0001-5189-6669; Morant, Steven/0000-0001-5674-3784				BEARD K, 1987, ARCH INTERN MED, V147, P1621, DOI 10.1001/archinte.147.9.1621; BEARDON PHG, 1993, BRIT MED J, V307, P846, DOI 10.1136/bmj.307.6908.846; BEARDON PHG, 1989, Q J MED, V71, P497; *BRIT MED ASS ROYA, 1994, BRIT NAT FORM, P34; CARSON JL, 1987, ARCH INTERN MED, V147, P1054, DOI 10.1001/archinte.147.6.1054; Dornan S, 1995, Health Bull (Edinb), V53, P274; FRIES JF, 1989, GASTROENTEROLOGY, V96, P647, DOI 10.1016/S0016-5085(89)80061-7; GRAHAM DY, 1988, GASTROENTEROLOGY, V95, P327, DOI 10.1016/0016-5085(88)90487-8; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HENRY D, 1993, GASTROENTEROLOGY, V105, P1078, DOI 10.1016/0016-5085(93)90952-9; HENRY DA, 1987, BRIT MED J, V295, P1227, DOI 10.1136/bmj.295.6608.1227; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; LEVY M, 1988, ARCH INTERN MED, V148, P281, DOI 10.1001/archinte.148.2.281; MACDONALD TM, 1994, PHARMACOEPIDEM DR S, P245; MCCULLAGH P, 1989, MONOGRAPHS STAT APPL, V37, P193; *OFF POP SENS SURV, 1990, TAB LIST CLASS SURG; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; SHORROCK CJ, 1990, GASTROENTEROLOGY, V99, P334, DOI 10.1016/0016-5085(90)91013-V; SOMERVILLE K, 1986, LANCET, V1, P462; World Health Organization, 1977, INT CLASS DIS; YOLA M, 1994, J CLIN EPIDEMIOL, V47, P731, DOI 10.1016/0895-4356(94)90170-8	23	236	246	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 22	1997	315	7119					1333	1337		10.1136/bmj.315.7119.1333	http://dx.doi.org/10.1136/bmj.315.7119.1333			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402773	Green Published			2022-12-24	WOS:A1997YJ21800020
J	Poole, CJM; Hill, DJ; Christie, JL; Birch, J				Poole, CJM; Hill, DJ; Christie, JL; Birch, J			Deficient colour vision and interpretation of histopathology slides: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							PATHOLOGISTS; BLINDNESS	Objective: To determine whether histopathologists with deficient colour vision make more errors in slide interpretation than those with normal colour vision. Design: Examination of projected transparencies of histopathological slides under standardised conditions by subjects whose colour discriminating ability was accurately assessed. Setting: Departments of histopathology in 45 hospitals in the United Kingdom. Subjects: 270 male histopathologists and medical laboratory scientific officers. Main outcome measures: Number of slides correctly identified by subjects whose colour vision was measured on the Ishihara, City University, and Farnsworth-Munsell 100 hue tests. Results: Mean (SD) scores (out of 10) for doctors with colour deficient vision were 9.4 (0.7) for 9.9 (0.4) for controls (P < 0.01) and 7.5 (1.6) v 9.4 (0.7) for scientific officers (P < 0.001). When subjects with colour deficient vision were categorised into severe, moderate, or mild, there was a significant trend towards those with severe deficiency making more mistakes (P < 0.001). Conclusions: Histopathologists and medical laboratory scientific officers should have their colour vision tested; if they are found to have a severe prolan or deutan deficiency, they should be advised to adopt a safe system of working.	DUDLEY GRP HOSP NHS TRUST,DEPT HISTOPATHOL,DUDLEY DY2 7BX,ENGLAND; CITY UNIV LONDON,DEPT OPTOMETRY & VISUAL SCI,LONDON EC1V 0HB,ENGLAND	City University London	Poole, CJM (corresponding author), DUDLEY PRIOR HLTH NHS TRUST,CENT CLIN,DEPT OCCUPAT HLTH,DUDLEY DY2 7BX,ENGLAND.							Birch J., 1993, DIAGNOSIS DEFECTIVE; BOGMAN MJJT, 1992, LANCET, V339, P185, DOI 10.1016/0140-6736(92)90255-2; CURRIER RD, 1994, ARCH NEUROL-CHICAGO, V51, P1090, DOI 10.1001/archneur.1994.00540230028008; LEACH C, 1979, INTRO STATISTICS NON; RIGBY HS, 1991, J CLIN PATHOL, V44, P745, DOI 10.1136/jcp.44.9.745; SPALDING JAB, 1993, BRIT J GEN PRACT, V43, P32; VORSTER BJ, 1979, LANCET, V2, P1295; 1991, LANCET, V338, P1302	8	34	34	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 15	1997	315	7118					1279	1281		10.1136/bmj.315.7118.1279	http://dx.doi.org/10.1136/bmj.315.7118.1279			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390055	Green Published			2022-12-24	WOS:A1997YG64500022
J	Cooper, RS; Osotimehin, B; Kaufman, JS; Forrester, T				Cooper, RS; Osotimehin, B; Kaufman, JS; Forrester, T			Disease burden in sub-Saharan Africa: what should we conclude in the absence of data?	LANCET			English	Editorial Material									Loyola Univ, Stritch Sch Med, Dept Epidemiol & Prevent Med, Maywood, IL 60153 USA; Univ Coll Ibadan Hosp, Ibadan, Nigeria; Trop Metab Res Unit, Mona, Jamaica	Loyola University Chicago	Cooper, RS (corresponding author), Loyola Univ, Stritch Sch Med, Dept Epidemiol & Prevent Med, 2160 S 1st Ave, Maywood, IL 60153 USA.		Swaibu, Ramadhani A/H-3164-2011	Kaufman, Jay/0000-0003-1606-401X				Akinkugbe OO, 1997, FINAL REPORT NATL SU; [Anonymous], 1996, GLOBAL BURDEN DIS CO; Asuzu M C, 1996, World Health Forum, V17, P373; Barker DJP, 1992, FETAL INFANT ORIGINS; Cooper R, 1997, AM J PUBLIC HEALTH, V87, P160, DOI 10.2105/AJPH.87.2.160; Cooper RS, 1996, TROP CARDIOL, V22, P69; Gwatkin DR, 1997, LANCET, V350, P141, DOI 10.1016/S0140-6736(97)26028-9; Jamison D.T., 1993, DIS CONTROL PRIORITI; Kaufman JS, 1996, J HUM HYPERTENS, V10, P461; MANTON K G, 1988, World Health Statistics Quarterly, V41, P255; MULLER AS, 1991, DIS MORTALITY SUBSAH, P267; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Murray CJL, 1992, HLTH ADULTS DEV WORL, P113; *NAT CTR HLTH STAT, 1995, HLTH US 1994; OWOAJE E, 1997, E AFR MED J, V74, P29; Patterson Orlando, 1982, SLAVERY SOCIAL DEATH; Tanner M., 1991, DIS MORTALITY SUBSAH	17	95	95	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					208	210		10.1016/S0140-6736(97)06512-4	http://dx.doi.org/10.1016/S0140-6736(97)06512-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449884				2022-12-24	WOS:000071616300043
J	Birdwell, BG; Raskob, GE; Whitsett, TL; Durica, SS; Comp, PC; George, JN; Tytle, TL; McKee, PA				Birdwell, BG; Raskob, GE; Whitsett, TL; Durica, SS; Comp, PC; George, JN; Tytle, TL; McKee, PA			The clinical validity of normal compression ultrasonography in outpatients suspected of raving deep venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article						ultrasonography; thrombophlebitis; thromboembolism; thrombolytic therapy; pulmonary embolism	PROXIMAL-VEIN-THROMBOSIS; SERIAL IMPEDANCE PLETHYSMOGRAPHY; PULMONARY-EMBOLISM; INITIAL TREATMENT; LOWER-EXTREMITY; DIAGNOSIS; LEG; MANAGEMENT; VENOGRAPHY; HEPARIN	Background: Ultrasonography using Vein compression accurately detects proximal deep Venous thrombosis in symptomatic outpatients. Repeated testing is required for patients with normal results at presentation, but the optimal management of such patients is uncertain. Objective: To test the safety of withholding anticoagulation in outpatients suspected of having first-episode deep venous thrombosis who have normal results on simplified compression ultrasonography at presentation and on a single repeated test done 5 to 7 days later. Design: Prospective cohort study. Setting: Noninvasive vascular laboratories at a university teaching hospital and a Veterans Administration medical center. Patients: 405 consecutive outpatients suspected of having first-episode deep Venous thrombosis. Intervention: Ultrasonography was performed at presentation. The common femoral and popliteal veins were assessed for compressibility. If the result was normal, anticoagulation was withheld and testing was repeated 5 to 7 days later. Anticoagulation was withheld from all patients whose results remained normal according to compression ultrasonography, regard less of their symptoms. The safety of this approach was tested by follow-up lasting 3 months. Measurements: Objective testing was done during follow-up in all patients with symptoms or signs of venous thromboembolism. The outcome measure was symptomatic Venous thrombosis or pulmonary embolism during follow-up, confirmed by objective testing. Results: Ultrasonography had normal results in 335 patients (83%) and abnormal results in 70 (17%). None of the patients with normal results died of pulmonary embolism. Venous thromboembolism occurred during follow-up in 2 patients with normal ultrasonographic results (0.6% [95% CI, 0.07% to 2.14%]) and in 4 patients with abnormal results (5.7% [CI, 1.58% to 13.99%]) (P = 0.009). Conclusions: It is safe to withhold anticoagulation in outpatients suspected of having first-episode deep venous thrombosis if results of simplified compression ultrasonography are normal at presentation and on a single repeated test done 5 to 7 days later.	Vet Adm Med Ctr, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Radiol Sci, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Warren Med Res Inst, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Birdwell, BG (corresponding author), Vet Adm Med Ctr, 151,921 NE 13th St, Oklahoma City, OK 73104 USA.				NHLBI NIH HHS [HL 08756, HL 08883] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008756, F32HL008883] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; APPELMAN PT, 1987, RADIOLOGY, V163, P743, DOI 10.1148/radiology.163.3.3554343; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; COGO A, 1993, ARCH INTERN MED, V153, P2777, DOI 10.1001/archinte.153.24.2777; CRANLEY JJ, 1976, ARCH SURG-CHICAGO, V111, P34; CRONAN JJ, 1987, RADIOLOGY, V162, P191, DOI 10.1148/radiology.162.1.3538148; DALEN JE, 1971, AM HEART J, V81, P175, DOI 10.1016/0002-8703(71)90128-1; DARKE SG, 1991, VENOUS DISORDERS, P227; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HILLNER BE, 1992, ARCH INTERN MED, V152, P165, DOI 10.1001/archinte.152.1.165; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUISMAN MV, 1989, ARCH INTERN MED, V149, P511, DOI 10.1001/archinte.149.3.511; HULL R, 1977, NEW ENGL J MED, V296, P1497, DOI 10.1056/NEJM197706302962604; HULL R, 1981, CIRCULATION, V64, P622, DOI 10.1161/01.CIR.64.3.622; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL R, 1976, CIRCULATION, V53, P696, DOI 10.1161/01.CIR.53.4.696; HULL R, 1978, CIRCULATION, V58, P898, DOI 10.1161/01.CIR.58.5.898; HULL R, 1981, ANN INTERN MED, V94, P12, DOI 10.7326/0003-4819-94-1-12; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1983, CIRCULATION, V67, P901, DOI 10.1161/01.CIR.67.4.901; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; KEARON C, 1994, THROMB HAEMOSTASIS, V72, P652; KOBAK M, 1954, AMA ARCH SURG, V68, P350, DOI 10.1001/archsurg.1954.01260050352011; Lensing Anthonie W. A., 1996, P115; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; ODONNELL TF, 1980, SURG GYNECOL OBSTET, V150, P69; Pezzullo JA, 1996, RADIOLOGY, V198, P67, DOI 10.1148/radiology.198.1.8539408; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; STRANDNESS DE, 1972, ARCH SURG-CHICAGO, V104, P180; SUMNER D, 1990, J VASC SURG, V11, P60; Sumner DS, 1993, VASCULAR DIAGNOSIS, P785; VOGEL P, 1987, RADIOLOGY, V163, P747, DOI 10.1148/radiology.163.3.3554344; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WHEELER HB, 1982, ARCH SURG-CHICAGO, V117, P1206; WILLIAMS SG, 1953, VENOUS DISORDERS, V97, P769	38	205	210	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					1	+		10.7326/0003-4819-128-1-199801010-00001	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424975				2022-12-24	WOS:000071158000001
J	Stevens, J; Cai, JW; Pamuk, ER; Williamson, DF; Thun, MJ; Wood, JL				Stevens, J; Cai, JW; Pamuk, ER; Williamson, DF; Thun, MJ; Wood, JL			The effect of age on the association between body-mass index and mortality	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WEIGHT; WOMEN; MEN	Background The effect of age on optimal body weight is controversial, and few studies have had adequate numbers of subjects to analyze mortality as a function of body-mass index across age groups. Methods We studied mortality over 12 years among white men and women who participated in the American Cancer Society's Cancer Prevention Study I (from 1960 through 1972). The 62,116 men and 262,019 women included in this analysis had never smoked cigarettes, had no history of heart disease, stroke, or cancer (other than skin cancer) at base line in 1959-1960, and had no history of recent unintentional weight loss. The date and cause of death for subjects who died were determined from death certificates. The associations between body-mass index (defined as the weight in kilograms divided by the square of the height in meters) and mortality were examined for six age groups in analyses in which we adjusted for age, educational level, physical activity, and alcohol consumption. Results Greater body-mass index was associated with higher mortality from all causes and from cardiovascular disease in men and women up to 75 years of age. However, the relative risk associated with greater body-mass index declined with age. For example, for mortality from cardiovascular disease, the relative risk associated with an increment of 1 in the body-mass index was 1.10 (95 percent confidence interval, 1.04 to 1.16) for 30-to-44-year-old men and 1.03 (95 percent confidence interval, 1.02 to 1.05) for 65-to-74-year-old men. For women, the corresponding relative risk estimates were 1.08 (95 percent confidence interval, 1.05 to 1.11) and 1.02 (95 percent confidence interval, 1.02 to 1.03). Conclusions Excess body weight increases the risk of death from any cause and from cardiovascular disease in adults between 30 and 74 years of age. The relative risk associated with greater body weight is higher among younger subjects. (C) 1998, Massachusetts Medical Society.	Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA; Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA; Amer Canc Soc, Atlanta, GA 30329 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA; American Cancer Society	Stevens, J (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Nutr, CB 7400, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050776] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK50776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISON DB, 1996, OBES RES S1, V4, pS12; [Anonymous], 1983, Stat Bull Metrop Life Found, V64, P3; Cox D. R., 1984, ANAL SURVIVAL DATA; *DIET GUID AM, 1990, DIET GUID AM PUBL; *DIET GUID AM, 1995, DIET GUID AM PUBL; GARFINKEL L, 1984, AM HEART J, V108, P802, DOI 10.1016/0002-8703(84)90675-6; GREENLAND S, 1988, AM J EPIDEMIOL, V128, P1185, DOI 10.1093/oxfordjournals.aje.a115073; LEW EA, 1985, ANN INTERN MED, V103, P1024, DOI 10.7326/0003-4819-103-6-1024; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; Lindsted KD, 1997, AM J EPIDEMIOL, V146, P1, DOI 10.1093/oxfordjournals.aje.a009185; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; PETERSON B, 1994, CONTROL CLIN TRIALS, V15, P326; PETERSON B, 1993, CONTROL CLIN TRIALS, V14, P511, DOI 10.1016/0197-2456(93)90031-8; PLANKEY MW, 1995, OBESITY RES S3, V3, pS386; RISSANEN A, 1989, J CLIN EPIDEMIOL, V42, P781, DOI 10.1016/0895-4356(89)90076-0; RISSANEN A, 1991, J CLIN EPIDEMIOL, V44, P787, DOI 10.1016/0895-4356(91)90131-R; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; *SOC ACT ASS LIF I, 1980, BUILD STUD 1979; SORKIN JD, 1996, OBES RES S1, V4, pS12; Steel R. G. D., 1980, Principles and procedures of statistics, a biometrical approach.; STEVENS J, 1990, AM J EPIDEMIOL, V132, P1156, DOI 10.1093/oxfordjournals.aje.a115758; WAALER HT, 1984, ACTA MED SCAND, P1; WILLIAMSON DF, 1991, AM J CLIN NUTR, V53, pS1515, DOI 10.1093/ajcn/53.6.1515S; World Health Organization (WHO), 1957, INT CLASS DIS	25	1034	1071	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 1	1998	338	1					1	7		10.1056/NEJM199801013380101	http://dx.doi.org/10.1056/NEJM199801013380101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN801	9414324	Green Published			2022-12-24	WOS:000071209200001
J	Xie, JW; Murone, M; Luoh, SM; Ryan, A; Gu, QM; Zhang, CH; Bonifas, JM; Lam, CW; Hynes, M; Goddard, A; Rosenthal, A; Epstein, EH; de Sauvage, FJ				Xie, JW; Murone, M; Luoh, SM; Ryan, A; Gu, QM; Zhang, CH; Bonifas, JM; Lam, CW; Hynes, M; Goddard, A; Rosenthal, A; Epstein, EH; de Sauvage, FJ			Activating Smoothened mutations in sporadic basal-cell carcinoma	NATURE			English	Article							HUMAN HOMOLOG; GENE; RECEPTOR; HEDGEHOG	Basal-cell carcinomas (BCCs) are the commonest human cancer(1). Insight into their genesis came from identification of mutations in the PATCHED gene (PTCH) in patients with the basal-cell nevus syndrome, a hereditary disease characterized by multiple BCCs and by developmental abnormalities(2-7). The binding of Sonic hedgehog (SHH) to its receptor, PTCH, is thought to prevent normal inhibition by PTCH of Smoothened (SMO), a seven-span transmembrane protein(8,9). According to this model, the inhibition of SMO signalling is relieved following mutational inactivation of PTCH in basal-cell nevus syndrome, We report here the identification of activating somatic missense mutations in the SMO gene itself in sporadic BCCs from three patients. Mutant SMO, unlike wild type, can cooperate with adenovirus E1A to transform rat embryonic fibroblast cells in culture, Furthermore, skin abnormalities similar to BCCs developed in transgenic murine skin overexpressing mutant SMO. These findings support the role of SMO as a signalling component of the SHH-receptor complex and provide direct evidence that mutated SMO can function as an oncogene in BCCs.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Dermatol, San Francisco, CA 94110 USA; Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Neurosci, S San Francisco, CA 94080 USA; Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Chinese University of Hong Kong; Prince of Wales Hospital	de Sauvage, FJ (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Dermatol, 1001 Potrero St,Rm 269,Bldg 100, San Francisco, CA 94110 USA.		de Sauvage, Frederic/ABE-8400-2020	de Sauvage, Frederic/0000-0002-5275-2584; Zhang, Chengfei/0000-0002-6016-9436; Hynes, Mary/0000-0001-6623-6727				BYME C, 1993, MOL CELL BIOL, V13, P3176; Chidambaram A, 1996, CANCER RES, V56, P4599; Fan H., 1997, Journal of Investigative Dermatology, V108, P544; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Raffel C, 1997, CANCER RES, V57, P842; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Unden AB, 1996, CANCER RES, V56, P4562; Unden Anne Birgitte, 1997, Journal of Investigative Dermatology, V108, P596; Wicking C, 1997, AM J HUM GENET, V60, P21; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Xie JW, 1997, CANCER RES, V57, P2369; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	21	1029	1091	1	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					90	92		10.1038/34201	http://dx.doi.org/10.1038/34201			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422511				2022-12-24	WOS:000071326100055
J	Chung, CD; Liao, JY; Liu, B; Rao, XP; Jay, P; Berta, P; Shuai, K				Chung, CD; Liao, JY; Liu, B; Rao, XP; Jay, P; Berta, P; Shuai, K			Specific inhibition of Stat3 signal transduction by PIAS3	SCIENCE			English	Article							TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; ACTIVATION; GENE; TRANSCRIPTION; PROTEINS; CLONING; PATHWAY; GAMMA; DNA	The signal transducer and activator of transcription-3 (Stat3) protein is activated by the interleukin 6 (IL-6) family of cytokines, epidermal growth factor, and leptin. A protein named PIAS3 (protein inhibitor of activated STAT) that binds to Stat3 was isolated and characterized. The association of PIAS3 with Stat3 in vivo was only observed in cells stimulated with ligands that cause the activation of Stat3. PIAS3 blocked the DNA-binding activity of Stat3 and inhibited Stat3-mediated gene activation. Although Stat1 is also phosphorylated in response to IL-6, PIAS3 did not interact with Stat1 or affect its DNA-binding or transcriptional activity. The results indicate that PIAS3 is a specific inhibitor of Stat3.	UNIV CALIF LOS ANGELES,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90095; CTR RECH BIOCHIM MACROMOL,F-34000 MONTPELLIER,FRANCE; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; Universite de Montpellier; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Jay, Philippe/ABD-9223-2020	Jay, Philippe/0000-0003-0156-5700	NATIONAL CANCER INSTITUTE [T32CA009056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039612] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09056] Funding Source: Medline; NIAID NIH HHS [AI39612] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chung C.-A., UNPUB; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Leveillard Thierry, 1993, Gene Expression, V3, P135; LIAO J, UNPUB, P63509; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	21	778	834	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1803	1805		10.1126/science.278.5344.1803	http://dx.doi.org/10.1126/science.278.5344.1803			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388184				2022-12-24	WOS:A1997YJ90100050
J	Deming, TJ				Deming, TJ			Facile synthesis of block copolypeptides of defined architecture	NATURE			English	Article							ANHYDRIDES; ACID	Many natural polymeric materials (particularly structural proteins) display a hierarchy of structure over several length scales. Block copolymers are able to self-assemble into ordered nanostructures(1,2), but the random-coiled nature of their polymer chains usually suppresses any further levels of organization. The use of components with regular structures, such as rigid-rod polymers, can increase the extent of spatial organization in self-assembling materials(3). But the synthesis of such polymeric components typically involves complicated reaction steps that are not suitable for large-scale production. Proteins form hierarchically organized structures in which the fundamental motifs are generally alpha-helical coils and beta-sheets(4). Attempts to synthesize polypeptides with well-defined amino-acid sequences, which might adopt similar organized structures, have been plagued by unwanted side reactions(5) that give rise to products with a wide range of molecular weights(6-10), hampering the formation of well-defined peptide block copolymers(11-17). Here I describe a polymerization strategy that overcomes these difficulties by using organonickel initiators which suppress chain-transfer and termination side reactions. This approach allows the facile synthesis of block copolypeptides with well-defined sequences, which might provide new peptide-based biomaterials with potential applications in tissue engineering, drug delivery and biomimetic composite formation.	UNIV CALIF SANTA BARBARA,DEPT CHEM,SANTA BARBARA,CA 93106	University of California System; University of California Santa Barbara	Deming, TJ (corresponding author), UNIV CALIF SANTA BARBARA,DEPT MAT,SANTA BARBARA,CA 93106, USA.		Deming, Timothy/I-5411-2013	Deming, Timothy/0000-0002-0594-5025				Bamford C.H.E.A., 1956, SYNTHETIC POLYPEPTID; BLOCK H, 1983, POLY GAMMA BENZYL LA; CARDINAUX F, 1977, BIOPOLYMERS, V16, P2005, DOI 10.1002/bip.1977.360160914; CASTANO AM, 1994, ORGANOMETALLICS, V13, P2262, DOI 10.1021/om00018a020; COLLMAN JP, 1987, PRINCIPLES APPLICATI; Deming TJ, 1997, J AM CHEM SOC, V119, P2759, DOI 10.1021/ja962625w; Deming TJ, 1997, ADV MATER, V9, P299, DOI 10.1002/adma.19970090404; Fetters L., 1987, ENCY POLYM SCI ENG, V10, P19; GRATZER WB, 1963, J AM CHEM SOC, V85, P1193, DOI 10.1021/ja00891a035; Hillmyer MA, 1996, SCIENCE, V271, P976, DOI 10.1126/science.271.5251.976; HOWARD JC, 1977, BIOPOLYMERS, V16, P2029, DOI 10.1002/bip.1977.360160915; IDELSON M, 1957, J AM CHEM SOC, V79, P3948, DOI 10.1021/ja01572a002; IDELSON M, 1958, J AM CHEM SOC, V80, P2387, DOI 10.1021/ja01543a012; INOUE K, 1994, J AM CHEM SOC, V116, P10783, DOI 10.1021/ja00102a053; Kricheldorf H. R., 1987, ALPHA AMINOACID N CA; Kricheldorf H. R., 1990, MODELS BIOPOLYMERS R; KUBOTA S, 1975, BIOPOLYMERS, V14, P305; LUNDBERG RD, 1957, J AM CHEM SOC, V79, P3961, DOI 10.1021/ja01572a004; Matsen MW, 1996, MACROMOLECULES, V29, P7641, DOI 10.1021/ma960744q; NOSHAY A, 1977, BLOCK COPOLYMERS; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SANO K, 1984, B CHEM SOC JPN, V57, P2741, DOI 10.1246/bcsj.57.2741; Stupp SI, 1997, SCIENCE, V276, P384, DOI 10.1126/science.276.5311.384; UHLIG E, 1980, Z ANORG ALLG CHEM, V465, P141, DOI 10.1002/zaac.19804650115; WEBSTER OW, 1991, SCIENCE, V251, P887, DOI 10.1126/science.251.4996.887	25	522	608	8	247	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					386	389		10.1038/37084	http://dx.doi.org/10.1038/37084			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389476				2022-12-24	WOS:A1997YH54900058
J	Hayward, RA; Manning, WG; Kaplan, SH; Wagner, EH; Greenfield, S				Hayward, RA; Manning, WG; Kaplan, SH; Wagner, EH; Greenfield, S			Starting insulin therapy in patients with type 2 diabetes - Effectiveness, complications, and resource utilization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POPULATION; MELLITUS; GLUCOSE; DISEASE; CARE; OUTCOMES; ILLNESS; IMPACT; TRIAL; BLOOD	Context.-Although experimental studies show that insulin therapy can be safe and efficacious in improving glycemic control in type 2 diabetes under optimal conditions (ie, using patient volunteers with close monitoring under strict study protocols), little is known about its effectiveness, complication rates, and associated resource utilization in actual clinical practice. Design.-Cohort study. Setting.-Large staff-model health maintenance organization. Participants.-A total of 8668 patients with type 2 diabetes cared for by generalist physicians from 1990 through 1993. Outcome Measures.-Resource use (hospitalizations, outpatient visits, laboratory testing, and home glucose monitoring) and glycemic control were evaluated using combined clinical, survey, and administrative information systems data. Detailed clinical case-mix data, including a newly validated case-mix method, the Total Illness Burden Index, were collected on a subsample of 1738 patients. Results.-Among patients starting insulin therapy, hemoglobin A(1c) (HbA(1c)) decreased by 0.9 percentage point (95% confidence interval, 0.7-1.0) at 1 year compared with those receiving stable medication regimens; however, 2 years after starting insulin therapy, 60% still had HbA(1c) levels of 8% or greater. There was no evidence that some primary care physicians achieved better results than other primary care physicians when starting insulin therapy in their patients. Patients with the poorest baseline glycemic control achieved substantially greater HbA(1c), reductions; those with a baseline HbA(1c) level of 13% had a 3-fold greater decline in HbA(1c) than those whose baseline HbA(1c) level was 9%, For a subset of all patients for whom detailed clinical case-mix data were obtained, those taking insulin had higher resource use than those taking sulfonylureas, independent of illness severity. After adjusting for age, sex, race, socioeconomic status, disease duration, and severity of diabetes and comorbidities, insulin: users had slightly more laboratory tests performed, 2.4 more outpatient visits per year, and almost 300 more fingersticks for home glucose testing per year compared with sulfonylurea users (all P<.01). Although 15% of patients receiving insulin therapy reported weekly symptoms of hypoglycemia, insulin therapy was not associated with an increase in emergency department visits (after case-mix adjustment) and resulted in only 0.5 hypoglycemia-related hospitalizations per 100 patient-years. Conclusions.-For patients with type 2 diabetes who were cared for by generalist physicians, starting insulin therapy was generally safe and effective in achieving moderate glycemic control in patients who initially had poor glycemic control. However, insulin therapy was associated with increases in resource use and was rarely effective in achieving tight glycemic control, even for those with moderate control.	ANN ARBOR VET AFFAIRS MED CTR, VET AFFAIRS CTR PRACTICE MANAGEMENT & OUTCOMES RE, ANN ARBOR, MI USA; UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MINNESOTA, SCH PUBL HLTH, DIV HLTH SERV RES & POLICY, MINNEAPOLIS, MN 55455 USA; TUFTS UNIV NEW ENGLAND MED CTR, PRIMARY CARE OUTCOMES RES INST, BOSTON, MA 02111 USA; GRP HLTH COOPERAT PUGET SOUND, CTR HLTH STUDIES, SEATTLE, WA 98101 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; University of Minnesota System; University of Minnesota Twin Cities; Tufts Medical Center; Group Health Cooperative				Kaplan, Sherrie/0000-0002-8644-5849; Greenfield, Sheldon/0000-0003-4628-1998	AHRQ HHS [HSO 666501] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABRAIRA C, 1995, DIABETES CARE, V18, P1113, DOI 10.2337/diacare.18.8.1113; ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; ALLEN BT, 1990, DIABETES CARE, V13, P1044, DOI 10.2337/diacare.13.10.1044; ANDERSON RM, 1988, DIABETES CARE, V11, P519, DOI 10.2337/diacare.11.7.519; [Anonymous], 1996, DIABETES CARE, V19, pS8; CAVE D, 1995, BENEFITS Q, V2, P6; Colwell JA, 1996, ANN INTERN MED, V124, P178, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00020; Colwell JA, 1996, DIABETES CARE, V19, P896, DOI 10.2337/diacare.19.8.896; DUAN N, 1983, J EC BUSINESS STATIS, V1, P115, DOI DOI 10.2307/1391852; GLAUBER HS, 1992, DIABETES CARE, V15, P870, DOI 10.2337/diacare.15.7.870; GREENFIELD S, 1994, DIABETES CARE, V17, P32; Greenfield S., 1995, JGIM, V10, P67; GREENFIELD S, 1993, MED CARE, V31, P141, DOI 10.1097/00005650-199302000-00005; GREENFIELD S, 1995, MED CARE, V33, pAS47; GREENFIELD S, 1994, AM J KIDNEY DIS, V24, P298, DOI 10.1016/S0272-6386(12)80195-8; KLEIN CE, 1993, J GEN INTERN MED, V8, P597, DOI 10.1007/BF02599711; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1987, AM J EPIDEMIOL, V126, P415, DOI 10.1093/oxfordjournals.aje.a114673; KrouselWood MA, 1996, J GEN INTERN MED, V11, P32, DOI 10.1007/BF02603483; LITTLE RR, 1991, CLIN CHEM, V37, P1725; Manning W. G., 1981, HLTH EC HLTH EC; MANNING WG, 1987, J ECONOMETRICS, V35, P59, DOI 10.1016/0304-4076(87)90081-9; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MCMAHON LF, 1989, ANN INTERN MED, V111, P318, DOI 10.7326/0003-4819-111-4-318; *MED EC CO INC, 1996, 1996 RED BOOK; NEWMAN WP, 1990, ARCH INTERN MED, V150, P107, DOI 10.1001/archinte.150.1.107; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Peters B.G., 1994, J EUROPEAN PUBLIC PO, V1, P9, DOI [10.1080/13501769408406945, DOI 10.1080/13501769408406945]; PREGIBON D, 1980, APPL STAT, V29, P115; RAMSEY JB, 1969, J ROY STAT SOC B, V31, P350; Rettig B A, 1985, Nebr Med J, V70, P370; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TUKEY JW, 1949, BIOMETRICS, V5, P232, DOI 10.2307/3001938; TURNER RC, 1991, DIABETOLOGIA, V34, P877; Vijan S, 1997, ANN INTERN MED, V127, P788, DOI 10.7326/0003-4819-127-9-199711010-00003; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; WEST KM, 1983, DIABETES CARE, V6, P361, DOI 10.2337/diacare.6.4.361	37	196	198	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	1997	278	20					1663	1669		10.1001/jama.278.20.1663	http://dx.doi.org/10.1001/jama.278.20.1663			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG859	9388085				2022-12-24	WOS:A1997YG85900027
J	Fukuda, M; Asano, S; Nakamura, T; Adachi, M; Yoshida, M; Yanagida, M; Nishida, E				Fukuda, M; Asano, S; Nakamura, T; Adachi, M; Yoshida, M; Yanagida, M; Nishida, E			CRM1 is responsible for intracellular transport mediated by the nuclear export signal	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ORDER CHROMOSOME STRUCTURE; CELL-CYCLE; PROTEIN; LOCALIZATION; REV; IDENTIFICATION; SEQUENCE; TRANSCRIPTION; NUCLEOPORIN	The discovery of nuclear export signals (NESs) in a number of proteins revealed the occurrence of signal-dependent transport of proteins from the nucleus to the cytoplasm(1-14). Although the consensus motif of the NESs has been shown to be a leucine-rich, short amino-acid sequence(2,6,7), its receptor has not been identified. A cytotoxin leptomycin B (LMB) has recently been suggested to inhibit the NES-mediated transport of Rev protein(15). Here we show that LMB is a potent and specific inhibitor of the NES-dependent nuclear export of proteins. Moreover, we have found a protein of relative molecular mass 110K (p110) in Xenopus oocyte extracts that binds to the intact NES but not to the mutated, non-functional NES. The binding of p110 to NES is inhibited by LMB. We show that p110 is CRM1, which is an evolutionarily conserved protein(16-18) originally found as an essential nuclear protein in fission yeas(16) and known as a likely target of LMB19. We also show that nuclear export of a fission yeast protein, Dsk1, which has a leucine-rich NES, is disrupted in wildtype yeast treated with LMB or in the crm1 mutant. These results indicate that CRM1 is an essential mediator of the NES-dependent nuclear export of proteins in eukaryotic cells.	KYOTO UNIV,GRAD SCH SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 60601,JAPAN; UNIV TOKYO,GRAD SCH AGR & LIFE SCI,DEPT BIOTECHNOL,BUNKYO KU,TOKYO 113,JAPAN	Kyoto University; University of Tokyo			Fukuda, Makoto/S-9748-2019; Yoshida, Minoru/C-8049-2014; Fukuda, Makoto/C-9745-2009; Fukuda, Makoto/I-7915-2014	Fukuda, Makoto/0000-0003-0112-9925; Yoshida, Minoru/0000-0002-4376-5674; Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925				ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FORMEROD M, 1997, EMBO J, V16, P807; Fornerod M, 1996, ONCOGENE, V13, P1801; FORNEROD M, 1997, CELL, V98, P1051; Fridell RA, 1996, EMBO J, V15, P5408, DOI 10.1002/j.1460-2075.1996.tb00924.x; Fridell RA, 1996, P NATL ACAD SCI USA, V93, P2936, DOI 10.1073/pnas.93.7.2936; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; Meyer BE, 1996, J VIROL, V70, P2350, DOI 10.1128/JVI.70.4.2350-2359.1996; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Richards SA, 1996, J CELL BIOL, V134, P1157, DOI 10.1083/jcb.134.5.1157; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STUZT F, 1995, CELL, V82, P495; TAKEUCHI M, 1993, MOL BIOL CELL, V4, P247, DOI 10.1091/mbc.4.3.247; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	29	1015	1029	1	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					308	311		10.1038/36894	http://dx.doi.org/10.1038/36894			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384386				2022-12-24	WOS:A1997YG66700069
J	Marrazzo, JM; White, CL; Krekeler, B; Celum, CL; Lafferty, WE; Stamm, WE; Handsfield, HH				Marrazzo, JM; White, CL; Krekeler, B; Celum, CL; Lafferty, WE; Stamm, WE; Handsfield, HH			Community-based urine screening for Chlamydia trachomatis with a ligase chain reaction assay	ANNALS OF INTERNAL MEDICINE			English	Article						Chlamydia trachomatis; urine; adolescence; polymerase chain reaction; ligase chain reaction	LEUKOCYTE ESTERASE TEST; SEXUALLY-TRANSMITTED DISEASE; PELVIC INFLAMMATORY DISEASE; FAMILY-PLANNING CLINICS; ADOLESCENT GIRLS; INFECTION; WOMEN; PREVALENCE; DIAGNOSIS; SPECIMENS	Background: Urine tests for Chlamydia trachomatis permit expansion of screening beyond traditional clinic environments. Prevention of infection in teenagers is a high priority. Objective: To define the prevalence of C. trachomatis among teenagers by using the ligase chain reaction assay on urine specimens and to evaluate leukocyte esterase testing of urine specimens as an indicator of infection. Design: Cross-sectional study. Setting: An adolescent clinic, a juvenile detention facility, seven school-based clinics, and three community-based youth organizations in Seattle, Washington. Participants: 10 118 sexually active teenagers and young adults. Measurements: Chlamydia trachomatis infection detected in urine specimens by ligase chain reaction assay and leukocyturia detected by leukocyte esterase testing. Results: The prevalence of chlamydial infection among female participants was 8.6% and declined with increasing age; among male participants, it was 5.4% and increased with increasing age. In female participants, independent predictors of infection were being 17 years of age or younger (odds ratio [OR], 1.49), having had two or more sex partners in the previous 2 months (OR, 1.61), and having genitourinary symptoms (OR, 1.46). In male participants, independent predictors were being of nonwhite race or ethnicity (OR, 2.00 to 3.08), having had two or more sex partners in the previous 2 months (OR, 1.57), and having used a condom during the most recent sexual encounter (OR, 0.67). For identifying infection in male participants, the sensitivity of leukocyte esterase testing was 58.9%, the specificity was 94.9%, the positive predictive value was 38.4%, and the negative predictive value was 97.7%. Conclusions: Chlamydial infection is common in teenagers and young adults in community settings. The urine ligase chain reaction assay will permit widespread screening for C. trachomatis, but leukocyte esterase testing had low sensitivity for selecting persons for screening with this assay. Indicators of chlamydial infection differed substantially in male and female participants.	UNIV WASHINGTON, HARBORVIEW MED CTR, SEXUALLY TRANSMITTED DIS CLIN, SEATTLE, WA 98104 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, DIV INFECT DIS, SEATTLE, WA 98104 USA; UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT HLTH SERV, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA USA; SEATTLE KING CTY DEPT PUBL HLTH, SEATTLE, WA USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Marrazzo, Jeanne/0000-0002-9277-7364	NIAID NIH HHS [T32 AI-07140, U19 AI/MH-31448] Funding Source: Medline; PHS HHS [R30/CCR011496] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007140, U19AI031448] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADDISS DG, 1990, SEX TRANSM DIS, V17, P138, DOI 10.1097/00007435-199007000-00006; ADDISS DG, 1993, SEX TRANSM DIS, V20, P28, DOI 10.1097/00007435-199301000-00006; ANESTAD G, 1995, J CLIN MICROBIOL, V33, P2483, DOI 10.1128/JCM.33.9.2483-2484.1995; BASS CA, 1993, J CLIN MICROBIOL, V31, P2648, DOI 10.1128/JCM.31.10.2648-2653.1993; BIRO FM, 1994, PEDIATRICS, V93, P476; BRITTON TF, 1992, AM J GYNECOL HLTH, V6, P24; CARPENTER WR, 1993, CLIN CHEM, V39, P1934; CATES W, 1991, AM J OBSTET GYNECOL, V164, P1771, DOI 10.1016/0002-9378(91)90559-A; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P375; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P193; DILLE BJ, 1993, J CLIN MICROBIOL, V31, P729, DOI 10.1128/JCM.31.3.729-731.1993; *DIV STD PREV, 1996, SEX TRANSM DIS SURV; GAYDOS CA, 1996, 1996 NAT STD PREV C; GENC M, 1993, JAMA-J AM MED ASSOC, V270, P2057, DOI 10.1001/jama.270.17.2057; Hadgu A, 1996, LANCET, V348, P592, DOI 10.1016/S0140-6736(96)05122-7; HANDSFIELD HH, 1986, JAMA-J AM MED ASSOC, V255, P1730, DOI 10.1001/jama.255.13.1730; HILLIS SD, 1995, FAM PLANN PERSPECT, V27, P108, DOI 10.2307/2136107; HUMPHREYS JT, 1992, SEX TRANSM DIS, V19, P47, DOI 10.1097/00007435-199201000-00010; Katz BP, 1996, SEX TRANSM DIS, V23, P226, DOI 10.1097/00007435-199605000-00011; KLAUSNER JD, 1996, 1996 NAT STD PREV C; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; LEONARDI GP, 1992, J CLIN MICROBIOL, V30, P2793, DOI 10.1128/JCM.30.11.2793-2796.1992; Males M, 1996, AM J PUBLIC HEALTH, V86, P565, DOI 10.2105/AJPH.86.4.565; Marrazzo JM, 1997, SEX TRANSM DIS, V24, P131, DOI 10.1097/00007435-199703000-00003; MCNAGNY SE, 1992, J INFECT DIS, V165, P573, DOI 10.1093/infdis/165.3.573; MORRIS RE, 1993, SEX TRANSM DIS, V20, P198, DOI 10.1097/00007435-199307000-00004; Mosure DJ, 1997, J ADOLESCENT HEALTH, V20, P6, DOI 10.1016/S1054-139X(96)00157-7; PATRICK DM, 1994, GENITOURIN MED, V70, P187; Ridgway GL, 1996, J CLIN PATHOL, V49, P116, DOI 10.1136/jcp.49.2.116; Rietmeijer CA, 1997, SEX TRANSM DIS, V24, P429, DOI 10.1097/00007435-199708000-00008; SADOF MD, 1987, JAMA-J AM MED ASSOC, V258, P1932, DOI 10.1001/jama.258.14.1932; SCHACHTER J, 1995, J INFECT DIS, V172, P1411, DOI 10.1093/infdis/172.5.1411; Schachter J, 1996, LANCET, V348, P1308, DOI 10.1016/S0140-6736(05)65783-2; SCHACHTER J, 1994, J CLIN MICROBIOL, V32, P2540, DOI 10.1128/JCM.32.10.2540-2543.1994; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; SHAFER MA, 1993, JAMA-J AM MED ASSOC, V270, P2065, DOI 10.1001/jama.270.17.2065; Stamm WE, 1990, SEXUALLY TRANSMITTED, P181; WASHINGTON AE, 1985, J ADOLESCENT HEALTH, V6, P298, DOI 10.1016/S0197-0070(85)80067-X; WEINSTOCK HS, 1992, AM J EPIDEMIOL, V135, P41, DOI 10.1093/oxfordjournals.aje.a116200; WERNER MJ, 1991, J ADOLESCENT HEALTH, V12, P326, DOI 10.1016/0197-0070(91)90008-A; WINTER L, 1990, SEX TRANSM DIS, V17, P30, DOI 10.1097/00007435-199017010-00007; WOOD DL, 1990, PEDIATRICS, V86, P666; 1996, MMWR-MORBID MORTAL W, V45, P883; 1994, MMWR-MORBID MORTAL W, V43, P366	44	107	108	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					796	+		10.7326/0003-4819-127-9-199711010-00004	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD898	9382400				2022-12-24	WOS:A1997YD89800003
J	Neven, P; Vergote, I				Neven, P; Vergote, I			Should tamoxifen users be screened for endometrial lesions?	LANCET			English	Editorial Material							BREAST-CANCER PATIENTS		Algemene Klin St Jan, Dept Obstet & Gynaecol, Brussels, Belgium; UZ Gasthuisberg, Dept Gynaecol Oncol, B-3000 Louvain, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; KU Leuven; University Hospital Leuven	Neven, P (corresponding author), Algemene Klin St Jan, Dept Obstet & Gynaecol, Brussels, Belgium.							ANDERSSON M, 1992, ACTA ONCOL, V31, P259, DOI 10.3109/02841869209088912; Carmichael PL, 1996, CANCER RES, V56, P1475; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; FORNANDER T, 1989, LANCET, V1, P117; Hemminki K, 1996, CANCER RES, V56, P4374; *INT AG RES CANC, 1996, IARC MON EV CARC RIS, V66; KAUFMANN M, 1995, BREAST, V4, P245; Langer RD, 1997, NEW ENGL J MED, V337, P1792, DOI 10.1056/NEJM199712183372502; Neven P, 1998, LANCET, V351, P36, DOI 10.1016/S0140-6736(05)78091-0; Peto R, 1996, J NATL CANCER I, V88, P1791, DOI 10.1093/jnci/88.24.1791; TIMMERMAN D, IN PRESS AM J OBSTET	12	41	41	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					155	157		10.1016/S0140-6736(05)78216-7	http://dx.doi.org/10.1016/S0140-6736(05)78216-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449866				2022-12-24	WOS:000071616300005
J	Huang, ZP; Willett, WC; Manson, JE; Rosner, B; Stampfer, MJ; Speizer, FE; Colditz, GA				Huang, ZP; Willett, WC; Manson, JE; Rosner, B; Stampfer, MJ; Speizer, FE; Colditz, GA			Body weight, weight change, and risk for hypertension in women	ANNALS OF INTERNAL MEDICINE			English	Article						body; weight; weight gain; hypertension; body index	HIGH BLOOD-PRESSURE; UNITED-STATES; NUTRITIONAL FACTORS; MILD HYPERTENSION; OBESITY; REDUCTION; INTERVENTION; OVERWEIGHT; DISEASE; PROGRAM	Background: Obesity increases the risk for hypertension, but the effects of modest long-term weight changes have not been precisely quantified. Objective: To investigate body mass index (BMI) and weight change in relation to risk for hypertension. Design: Cohort study. Setting: General community. Participants: Cohort of 82 473 U.S. female nurses 30 to 55 years of age followed every 2 years since 1976. The follow-up rate was 95%. Measurements: Primary risk factors examined were 1) BMI at age 18 years and midlife and 2) long-term and medium-term weight changes. The outcome was incident cases of hypertension. Results: By 1992, 16 395 incident cases of hypertension had been diagnosed. After adjustment for multiple covariates, BMI at 18 years of age and midlife were positively associated with occurrence of hypertension (P for trend < 0.001). Long-term weight loss after 18 years of age was related to a significantly lower risk for hypertension, and weight gain dramatically increased the risk for hypertension (compared with weight change less than or equal to 2 kg, multivariate relative risks were 0.85 for a loss of 5.0 to 9.9 kg, 0.74 for a loss greater than or equal to 10 kg, 1.74 for a gain of 5.0 to 9.9 kg, and 5.21 for a gain greater than or equal to 25.0 kg). Among women in the top tertile of baseline BMI at age 18 years, weight loss had a greater apparent benefit. The association between weight change and risk for hypertension was stronger in younger (<45 years of age) than older women (greater than or equal to 55 years of age). Medium-term weight changes after 1976 showed similar relations to risk for hypertension. Conclusions: Excess weight and even modest adult weight gain substantially increase risk for hypertension. Weight loss reduces the risk for hypertension.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med, Boston, MA 02215 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Huang, ZP (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NIDDK NIH HHS [DK 46200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475; Cassano Patricia A., 1990, Annals of Epidemiology, V1, P33; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; COX DR, 1972, J R STAT SOC B, V34, P187; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DAVIS BR, 1993, ARCH INTERN MED, V153, P1773, DOI 10.1001/archinte.153.15.1773; EPSTEIN FH, 1965, AM J EPIDEMIOL, V81, P307, DOI 10.1093/oxfordjournals.aje.a120517; FIEBACH NH, 1989, AM J EPIDEMIOL, V130, P646; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HAVLIK RJ, 1983, ANN INTERN MED, V98, P855, DOI 10.7326/0003-4819-98-5-855; Hebert Patricia R., 1995, Annals of Epidemiology, V5, P130, DOI 10.1016/1047-2797(94)00057-Z; HIGGINS MW, 1980, HYPERTENSION, V2, pI117, DOI 10.1161/01.HYP.2.4_Pt_2.I117; HSUEH WA, 1994, ENDOCRIN METAB CLIN, V23, P405, DOI 10.1016/S0889-8529(18)30105-1; HYPERTENSION DETECTION FOLLOW-UP, 1977, AM J EPIDEMIOL, V106, P351; Ikeda T, 1996, HYPERTENSION, V27, P1180, DOI 10.1161/01.HYP.27.5.1180; KANNEL WB, 1967, ANN INTERN MED, V67, P48, DOI 10.7326/0003-4819-67-1-48; KULLER LH, 1980, HYPERTENSION, V2, pI109, DOI 10.1161/01.HYP.2.4_Pt_2.I109; MACMAHON S, 1987, EUR HEART J, V8, P57, DOI 10.1093/eurheartj/8.suppl_B.57; MAKELA M, 1978, J CHRON DIS, V31, P587, DOI 10.1016/0021-9681(78)90019-X; MICOZZI MS, 1990, AM J PHYS ANTHROPOL, V81, P375, DOI 10.1002/ajpa.1330810307; REED D, 1982, HYPERTENSION, V4, P406, DOI 10.1161/01.HYP.4.3.406; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P35; SEVER PS, 1980, LANCET, V2, P60; STAMLER R, 1978, JAMA-J AM MED ASSOC, V240, P1607, DOI 10.1001/jama.240.15.1607; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; STEVENS VJ, 1993, ARCH INTERN MED, V153, P849, DOI 10.1001/archinte.153.7.849; TROY LM, 1995, INT J OBESITY, V19, P570; TUCK ML, 1981, NEW ENGL J MED, V304, P930, DOI 10.1056/NEJM198104163041602; *USDA, 1995, DIET GUID AM, P15; VANITALLIE TB, 1985, ANN INTERN MED, V103, P983, DOI 10.7326/0003-4819-103-6-983; WASSERTHEILSMOLLER S, 1992, ARCH INTERN MED, V152, P131, DOI 10.1001/archinte.152.1.131; WEINSTEIN MC, 1976, HYPERTENSION POLICY; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; Willett W., 2012, NUTR EPIDEMIOLOGY; WITTEMAN JCM, 1989, CIRCULATION, V80, P1320, DOI 10.1161/01.CIR.80.5.1320; YONG LC, 1993, AM J EPIDEMIOL, V138, P973, DOI 10.1093/oxfordjournals.aje.a116817	39	455	470	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1998	128	2					81	+		10.7326/0003-4819-128-2-199801150-00001	http://dx.doi.org/10.7326/0003-4819-128-2-199801150-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR200	9441586				2022-12-24	WOS:000071470800001
J	Sinclair, DA; Guarente, L				Sinclair, DA; Guarente, L			Extrachromosomal rDNA circles - A cause of aging in yeast	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; LIFE-SPAN; CAENORHABDITIS-ELEGANS; PODOSPORA-ANSERINA; MITOCHONDRIAL-DNA; SYNDROME GENE; LONGEVITY; TRANSCRIPTION; REPLICATION; SENESCENCE	Although many cellular and organismal changes have been described in aging individuals, a precise, molecular cause of aging has yet to be found. A prior study of aging yeast mother cells showed a progressive enlargement and fragmentation of the nucleolus. Here we show that these nucleolar changes are likely due to the accumulation of extrachromosomal rDNA circles (ERCs) in old cells and that, in fact, ERCs cause aging. Mutants for sgs1, the yeast homolog of the Werner's syndrome gene, accumulate ERCs more rapidly, leading to premature aging and a shorter life span. We speculate on the generality of this molecular cause of aging in higher species, including mammals.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Sinclair, David/0000-0002-9936-436X	NATIONAL INSTITUTE ON AGING [R37AG011119, R01AG011119] Funding Source: NIH RePORTER; NIA NIH HHS [AG11119] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; CHEN JB, 1990, MOL MICROBIOL, V4, P2081, DOI 10.1111/j.1365-2958.1990.tb00568.x; Childress AM, 1996, MICROBIOL-UK, V142, P2289, DOI 10.1099/13500872-142-8-2289; CLARKWALKER GD, 1980, NUCLEIC ACIDS RES, V8, P1009; CUMMINGS DJ, 1985, J MOL BIOL, V185, P659, DOI 10.1016/0022-2836(85)90052-X; DAMMANN R, 1993, NUCLEIC ACIDS RES, V21, P2331, DOI 10.1093/nar/21.10.2331; DMELLO NP, 1994, J BIOL CHEM, V269, P15451; DORMAN JB, 1995, GENETICS, V141, P1399; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EMILGEZ NK, 1989, J BACTERIOL, V171, P37; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GORDON CN, 1977, J CELL SCI, V24, P81; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Guarente L, 1997, GENE DEV, V11, P2449, DOI 10.1101/gad.11.19.2449; Guarente L, 1996, CELL, V86, P9, DOI 10.1016/S0092-8674(00)80072-0; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; HOLM C, 1982, CELL, V29, P585, DOI 10.1016/0092-8674(82)90174-X; HOROWITZ H, 1985, MOL CELL BIOL, V5, P2369, DOI 10.1128/MCB.5.9.2369; JAMETVIERNY C, 1980, CELL, V21, P189, DOI 10.1016/0092-8674(80)90126-9; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KENNEDY BK, 1994, J CELL BIOL, V127, P1985, DOI 10.1083/jcb.127.6.1985; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; Kim S, 1996, BIOCHEM BIOPH RES CO, V219, P370, DOI 10.1006/bbrc.1996.0240; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; LARIONOV V, 1984, GENE, V28, P229, DOI 10.1016/0378-1119(84)90260-9; LARIONOV VL, 1980, GENE, V12, P41, DOI 10.1016/0378-1119(80)90014-1; LARSEN PL, 1995, GENETICS, V139, P1567; LISKENS M, 1988, MOL CELL BIOL, V8, P4927; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MARTIN GM, 1985, ADV EXP MED BIOL, V190, P161; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MULLER I, 1985, A VAN LEEUW J MICROB, V51, P1, DOI 10.1007/BF00444223; MURRAY AW, 1983, CELL, V34, P961, DOI 10.1016/0092-8674(83)90553-6; Nierras CR, 1997, CHROMOSOMA, V105, P444; POHLEY HJ, 1987, MECH AGEING DEV, V38, P231, DOI 10.1016/0047-6374(87)90092-3; PRUSS GJ, 1985, J MOL BIOL, V185, P51, DOI 10.1016/0022-2836(85)90182-2; RINE J, 1987, GENETICS, V116, P9; ROBINOW CF, 1966, J CELL BIOL, V29, P129, DOI 10.1083/jcb.29.1.129; SALK D, 1981, CYTOGENET CELL GENET, V30, P108, DOI 10.1159/000131597; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Sherman F, 1979, METHODS YEAST GENETI; SHURE M, 1977, NUCLEIC ACIDS RES, V4, P1183, DOI 10.1093/nar/4.5.1183; SIKORSKI RS, 1989, GENETICS, V122, P19; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; STREHLER BL, 1986, EXP GERONTOL, V21, P283, DOI 10.1016/0531-5565(86)90038-0; SWEENEY R, 1989, GENETICS, V122, P749; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TTSUKAMOTO Y, 1997, NATURE, V388, P900; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WRIGHT RM, 1982, CELL, V29, P505, DOI 10.1016/0092-8674(82)90167-2; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	69	1112	1141	3	61	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					1033	1042		10.1016/S0092-8674(00)80493-6	http://dx.doi.org/10.1016/S0092-8674(00)80493-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428525	Bronze			2022-12-24	WOS:000071281400019
J	Cooke, F; Morse, R				Cooke, F; Morse, R			Do you know your chocolates? Recognition survey among medical staff of various grades	BRITISH MEDICAL JOURNAL			English	Article									Univ Wales Hosp, Dept Integrat Med, Cardiff CF4 4XW, S Glam, Wales; Royal Brompton Hosp, London SW3 6NP, England	Cardiff University; Royal Brompton Hospital	Morse, R (corresponding author), Univ Wales Hosp, Dept Integrat Med, Heath Pk, Cardiff CF4 4XW, S Glam, Wales.							SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P305	1	0	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1655	1656		10.1136/bmj.315.7123.1655	http://dx.doi.org/10.1136/bmj.315.7123.1655			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448530	Green Published			2022-12-24	WOS:000071149400013
J	Sawyer, LA; Hennessy, JM; Peixoto, AA; Rosato, E; Parkinson, H; Costa, R; Kyriacou, CP				Sawyer, LA; Hennessy, JM; Peixoto, AA; Rosato, E; Parkinson, H; Costa, R; Kyriacou, CP			Natural variation in a Drosophila clock gene and temperature compensation	SCIENCE			English	Article							PERIOD GENE; REPETITIVE REGION; MELANOGASTER; POLYMORPHISM; EVOLUTION; BEHAVIOR; SIMULANS; REPEAT	The threonine-glycine (Thr-Gly) encoding repeat within the clock gene period of Drosophila melanogaster is polymorphic in length. The two major variants (Thr-Gly)17 and (Thr-Gly)20 are distributed as a highly significant latitudinal dine in Europe and North Africa. Thr-Gly length variation from both wild-caught and transgenic individuals is related to the flies' ability to maintain a circadian period at different temperatures. This phenomenon provides a selective explanation for the geographical distribution of Thr-Gly lengths and gives a rare glimpse of the interplay between molecular polymorphism, behavior, population biology, and natural selection.	UNIV LEICESTER,DEPT GENET,LEICESTER LE1 7RH,LEICS,ENGLAND; UNIV PADUA,DIPARTIMENTO BIOL,I-35121 PADUA,ITALY	University of Leicester; University of Padua				Rosato, Ezio/0000-0001-7297-4697; Parkinson, Helen/0000-0003-3035-4195				AQUADRO CF, 1992, TRENDS GENET, V8, P355, DOI 10.1016/0168-9525(92)90281-8; CASTIGLIONEMORELLI MA, 1995, P ROY SOC B-BIOL SCI, V260, P155, DOI 10.1098/rspb.1995.0073; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COSTA R, 1991, J MOL EVOL, V32, P238, DOI 10.1007/BF02342746; COSTA R, 1992, P ROY SOC B-BIOL SCI, V250, P43, DOI 10.1098/rspb.1992.0128; DOWSE HB, 1989, J THEOR BIOL, V139, P487, DOI 10.1016/S0022-5193(89)80067-0; Hulme M, 1995, INT J CLIMATOL, V15, P1333, DOI 10.1002/joc.3370151204; KIMURA M, 1962, GENETICS, V47, P713; KLIMAN RM, 1993, GENETICS, V133, P375; KONOPKA RJ, 1997, J NEUROGENET, V11, P117; Kyriacou CP, 1996, SEMIN CELL DEV BIOL, V7, P803, DOI 10.1006/scdb.1996.0098; MINIS DH, 1972, P NATL ACAD SCI USA, V69, P1537; NIELSEN J, 1994, MOL BIOL EVOL, V11, P839; PEIXOTO AA, 1993, MOL BIOL EVOL, V10, P127; PEIXOTO AA, UNPUB; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; PITTENDRIGH CS, 1954, P NATL ACAD SCI USA, V40, P1018, DOI 10.1073/pnas.40.10.1018; Rosato E, 1997, GENET RES, V69, P89, DOI 10.1017/S001667239700267X; Rosato E, 1996, J MOL EVOL, V42, P392, DOI 10.1007/BF02498633; ROSATO E, 1994, GENETICS, V138, P693; ROSATO E, IN PRESS BIOESSAYS; SAWYER L, UNPUB; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; WHEELER DA, 1991, SCIENCE, V251, P1082, DOI 10.1126/science.1900131; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895; YU Q, 1987, NATURE, V326, P765, DOI 10.1038/326765a0	27	252	255	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2117	2120		10.1126/science.278.5346.2117	http://dx.doi.org/10.1126/science.278.5346.2117			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405346				2022-12-24	WOS:A1997YM23500051
J	Bloland, PB; Kazembe, PN; Watkins, WM; Doumbo, OK; Nwanyanwu, OC; Ruebush, TK				Bloland, PB; Kazembe, PN; Watkins, WM; Doumbo, OK; Nwanyanwu, OC; Ruebush, TK			Malarone-donation programme in Africa	LANCET			English	Editorial Material							PLASMODIUM-FALCIPARUM MALARIA; EFFICACY; CHLOROQUINE; RESISTANCE		LILONGWE CENT HOSP,LILONGWE,MALAWI; WELLCOME TRUST RES LABS,NAIROBI,KENYA; UNIV MALI,FAC MED & PHARM,DEPT EPIDEMIOL & PARASIT DIS,BAMAKO,MALI; US AGCY INT DEV,LILONGWE,MALAWI	University of Bamako; United States Agency for International Development (USAID)	Bloland, PB (corresponding author), CTR DIS CONTROL & PREVENT,MALARIA EPIDEMIOL SECT,DIV PARASIT DIS F22,NATL CTR INFECT DIS,ATLANTA,GA 30341, USA.							[Anonymous], 1986, CHEMOTHERAPY MALARIA; BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; Looareesuwan S, 1996, AM J TROP MED HYG, V54, P62, DOI 10.4269/ajtmh.1996.54.62; Nwanyanwu OC, 1996, TROP MED INT HEALTH, V1, P231; Plowe CV, 1996, AM J TROP MED HYG, V55, P467, DOI 10.4269/ajtmh.1996.55.467; Radloff PD, 1996, LANCET, V347, P1511, DOI 10.1016/S0140-6736(96)90671-6; Radloff PD, 1996, T ROY SOC TROP MED H, V90, P682, DOI 10.1016/S0035-9203(96)90435-6; SCHULTZ LJ, 1994, AM J TROP MED HYG, V51, P515, DOI 10.4269/ajtmh.1994.51.515; Trigg JK, 1997, ACTA TROP, V63, P185, DOI 10.1016/S0001-706X(96)00617-1; WHITE NJ, 1994, T ROY SOC TROP MED H, V88, P63, DOI 10.1016/0035-9203(94)90479-0; WHO, 1994, WHOMAL941067	11	18	18	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1624	1625		10.1016/S0140-6736(97)06082-0	http://dx.doi.org/10.1016/S0140-6736(97)06082-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393355				2022-12-24	WOS:A1997YH98600046
J	Solovey, A; Lin, Y; Browne, P; Choong, S; Wayner, E; Hebbel, RP				Solovey, A; Lin, Y; Browne, P; Choong, S; Wayner, E; Hebbel, RP			Circulating activated endothelial cells in sickle cell anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDITERRANEAN SPOTTED-FEVER; VASCULAR ENDOTHELIUM; MONOCLONAL-ANTIBODY; RICKETTSIA-CONORII; STEADY-STATE; WHOLE-BLOOD; EXPRESSION; INFARCTION; DISEASE; INJURY	Background The vascular wall participates in the pathogenesis of sickle cell disease. To determine whether the endothelium is activated in this disease, we studied the number, origin, and surface phenotype of circulating endothelial cells in patients with sickle cell anemia. Methods We used immunohistochemical examination of buffy-coat smears to enumerate circulating endothelial cells, and we evaluated the surface phenotype by applying immunofluorescence microscopy to preparations of circulating endothelial cells. A panel of antibodies was used, including a specific anti-endothelial-cell antibody, P1H12. Results Mean (+/-SD) numbers of circulating endothelial cells in normal blood donors, patients with sickle cell trait, and patients with hemolytic anemias not due to hemoglobin S were 2.6+/-1.6, 3.0+/-2.6, and 2.0+/-0.8 per milliliter of whole blood, respectively. Patients with sickle cell anemia who presented with acute painful episodes had 22.8+/-18.2 circulating endothelial cells per milliliter of blood (P<0.001 for the comparison with normal donors), and patients with no such events within one month before or after blood sampling had 13.2+/-11.8 circulating endothelial cells per milliliter of blood (P=0.002 for the comparison with normal donors and P=0.019 for the comparison with patients with acute events). Serial observations of three patients showed a tendency toward higher levels of circulating endothelial cells at the onset of acute painful crises. The average viability of circulating endothelial cells was 66+/-30 percent. In patients with sickle cell anemia, regardless of clinical status, the circulating endothelial cells were predominantly microvascular in origin (CD36-positive), and most of the cells expressed four markers of endothelial-cell activation: intercellular adhesion molecule 1, vascular-cell adhesion molecule 1, E-selectin, and P-selectin. Conclusions Our studies suggest that the vascular endothelium is activated in patients with sickle cell anemia, regardless of the patients' clinical status. Adhesion proteins on activated endothelial cells may have a role in the vascular pathology of sickle cell disease. (C) 1997, Massachusetts Medical Society.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center	Solovey, A (corresponding author), UNIV MINNESOTA,SCH MED,DEPT MED,MINNEAPOLIS,MN 55455, USA.		Lin, Yi/K-1510-2013	Browne, Paul/0000-0001-5310-1487; Lin, Yi/0000-0002-1556-6416	NHLBI NIH HHS [HL 55174, P01 HL055552] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055174, P01HL055552] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKINOLA NO, 1992, J CLIN PATHOL, V45, P902, DOI 10.1136/jcp.45.10.902; BLEI F, 1994, BLOOD, V84, pA409; Bouvier C., 1970, THROMB DIATH HAEMO, V40, P163; BRENNER BM, 1989, J CLIN INVEST, V84, P1373, DOI 10.1172/JCI114309; DRANCOURT M, 1992, J INFECT DIS, V166, P660, DOI 10.1093/infdis/166.3.660; Embury Stephen H., 1994, P311; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; FAVALORO EJ, 1993, IMMUNOL CELL BIOL, V71, P571, DOI 10.1038/icb.1993.63; GEORGE F, 1991, J IMMUNOL METHODS, V139, P65, DOI 10.1016/0022-1759(91)90352-G; GEORGE F, 1993, BLOOD, V82, P2109; GEORGE F, 1992, BLOOD S, V80, pA12; GERRITY RG, 1976, EXP MOL PATHOL, V24, P59, DOI 10.1016/0014-4800(76)90057-5; GREFTE A, 1993, J INFECT DIS, V167, P270, DOI 10.1093/infdis/167.2.270; Gupta K, 1997, EXP CELL RES, V230, P244, DOI 10.1006/excr.1996.3421; Hebbel RP, 1997, J LAB CLIN MED, V129, P288, DOI 10.1016/S0022-2143(97)90176-1; HLADOVEC J, 1978, KLIN WOCHENSCHR, V56, P1033, DOI 10.1007/BF01476669; KLUG PP, 1982, BLOOD CELLS, V8, P175; KNOWLES DM, 1984, J IMMUNOL, V132, P2170; PERCIVALLE E, 1993, J CLIN INVEST, V92, P663, DOI 10.1172/JCI116635; PETZELBAUER P, 1993, J IMMUNOL, V151, P5062; POBER JS, 1988, AM J PATHOL, V133, P426; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; RODGERS GM, 1988, FASEB J, V2, P116, DOI 10.1096/fasebj.2.2.3277885; ROTHMAN SM, 1986, ANN NEUROL, V20, P684, DOI 10.1002/ana.410200606; RUSSELL MO, 1984, BLOOD, V63, P162; SBARBATI R, 1991, BLOOD, V77, P764; SINGHAL A, 1993, LANCET, V341, P651, DOI 10.1016/0140-6736(93)90418-G; Solovey A., 1996, Blood, V88, p648A; SOWEMIMOCOKER SO, 1989, AM J HEMATOL, V31, P263, DOI 10.1002/ajh.2830310409; STOCKMAN JA, 1972, NEW ENGL J MED, V287, P846, DOI 10.1056/NEJM197210262871703; SUGIHARA K, 1992, BLOOD, V80, P2634; SWERLICK RA, 1992, J IMMUNOL, V148, P78	32	497	535	2	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 27	1997	337	22					1584	1590		10.1056/NEJM199711273372203	http://dx.doi.org/10.1056/NEJM199711273372203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH521	9371854				2022-12-24	WOS:A1997YH52100003
J	Joutel, A; Vahedi, K; Corpechot, C; Troesch, A; Chabriat, H; Vayssiere, C; Cruaud, C; Maciazek, J; Weissenbach, J; Bousser, MG; Bach, JF; TournierLasserve, E				Joutel, A; Vahedi, K; Corpechot, C; Troesch, A; Chabriat, H; Vayssiere, C; Cruaud, C; Maciazek, J; Weissenbach, J; Bousser, MG; Bach, JF; TournierLasserve, E			Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients	LANCET			English	Article							EPIDERMAL GROWTH-FACTOR; AUTOSOMAL-DOMINANT ARTERIOPATHY; MULTI-INFARCT DEMENTIA; SUBCORTICAL INFARCTS; LEUKOENCEPHALOPATHY; DROSOPHILA; RECEPTOR; GENE; ACTIVATION; SERRATE	Background CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy) is commonly overlooked or misdiagnosed owing to its recent identification and its variable mode of presentation. The defective gene in CADASIL is Notch3, which encodes a large transmembrane receptor. To set up a diagnostic test and to delineate the Notch3 domains involved in CADASIL, we undertook mutations analysis in this gene in a group of CADASIL patients. Methods 50 unrelated patients with CADASIL and 100 healthy controls were screened for mutations along the entire Notch3 sequence, by means of single-strand conformation polymorphism, heteroduplex, and sequence analysis. Findings Strongly stereotyped mis-sense mutations, located within the epidermal-growth-factor-like (EGF-like) repeats, in the extracellular domain of Notch3, were detected in 45 patients, Clustering of mutations within the two exons encoding the first five EGF-like repeats was observed (32 patients). All these mutations lead to toss or gain of a cysteine residue and therefore to an unpaired number of cysteine residues within a given EGF domain. None of these mutations was found in the 100 controls. Interpretation Because of the strong clustering and highly stereotyped nature of the pathogenetic mutations detected in CADASIL patients, an easy and reliable diagnostic test for CADASIL is feasible, The findings suggest that aberrant dimerisation of Notch3, due to abnormal disulphide bridging with another Notch3 molecule or with another protein, may be involved in the pathogenesis of this disorder.	UNIV PARIS 05, INSERM, U25, F-75730 PARIS, FRANCE; HOP LARIBOISIERE, F-75475 PARIS, FRANCE; BIOMERIEUX, LYON, FRANCE; GENETHON, EVRY, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; bioMerieux			Tournier-Lasserve, Elisabeth/N-7134-2017; Joutel, Anne/K-5601-2017; Chabriat, Hugues/G-5699-2010	Tournier-Lasserve, Elisabeth/0000-0002-3039-1677; Joutel, Anne/0000-0003-3963-3860; Cruaud, Corinne/0000-0002-4752-7278; Chabriat, Hugues/0000-0001-8436-6074				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BAUDRIMONT M, 1993, STROKE, V24, P122, DOI 10.1161/01.STR.24.1.122; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CHABRIAT H, 1995, LANCET, V346, P934, DOI 10.1016/S0140-6736(95)91557-5; DAVOUS P, 1991, REV NEUROL-FRANCE, V147, P376; DECELIS JF, 1991, P NATL ACAD SCI USA, V88, P632, DOI 10.1073/pnas.88.2.632; Ducros A, 1996, AM J HUM GENET, V58, P171; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; NYE JS, 1995, CURR BIOL, V5, P966, DOI 10.1016/S0960-9822(95)00189-8; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; RUCHOUX MM, 1995, ACTA NEUROPATHOL, V89, P500; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SONNINEN V, 1987, EUR NEUROL, V27, P209, DOI 10.1159/000116158; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; SOURANDER P, 1977, ACTA NEUROPATHOL, V39, P247, DOI 10.1007/BF00691704; STEVENS DL, 1977, LANCET, V1, P1364; TOURNIERLASSERVE E, 1991, STROKE, V22, P1297, DOI 10.1161/01.STR.22.10.1297; TOURNIERLASSERVE E, 1993, NAT GENET, V3, P256, DOI 10.1038/ng0393-256	24	507	531	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1511	1515		10.1016/S0140-6736(97)08083-5	http://dx.doi.org/10.1016/S0140-6736(97)08083-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388399				2022-12-24	WOS:A1997YH11500010
J	Misiani, R; Mantero, G; Bellavita, P; Mori, L; Vicari, O; Marchesi, D; Primi, D				Misiani, R; Mantero, G; Bellavita, P; Mori, L; Vicari, O; Marchesi, D; Primi, D			GB virus C infection in patients with type II mixed cryoglobulinemia	ANNALS OF INTERNAL MEDICINE			English	Article							HEPATITIS-G VIRUS; UNKNOWN ETIOLOGY; LONG-TERM; ASSOCIATION; THERAPY	Background: Hepatitis C virus (HCV) infection is present in most but not all patients with type II mixed cryoglobulinemia. Objective: To investigate the role of GB virus C (GBV-C) in type II mixed cryoglobulinemia. Design: Retrospective study of serum and cryoprecipitate samples. Setting: Tertiary care hospital in Bergamo, Italy. Patients: 58 cryoglobulinemic patients, 35 of whom were treated with interferon-alpha. Measurements: GB virus C RNA was determined by a reverse-transcription polymerase chain reaction assay done by using primers derived from the conserved GBV-C helicase region. Results: GB virus C RNA was detected in serum specimens from 23 of 58 cryoglobulinemic patients (40% [95% CI, 27% to 53%]) and 1 of 145 healthy blood donors (0.7%) (P < 0.001). Twenty of the 23 patients with GBV-C RNA were simultaneously infected with HCV. Unlike antibodies to HCV and HCV RNA, GBV-C RNA did not concentrate in cryoprecipitate in patients co-infected with GBV-C and HCV. Furthermore, the therapeutic effectiveness of interferon-alpha in patients with coinfection was related to the disappearance of HCV RNA but not GBV-C RNA from serum. None of 3 patients with GBV-C infection alone had detectable GBV-C RNA in cryoprecipitate. Conclusions: Infection with GBV-C, usually associated with HCV, is common in patients with type II mixed cryoglobulinemia but is unlikely to have a primary role in this disease.	OSPED RIUNITI BERGAMO, SERV IMMUNOEMATOL, I-24128 BERGAMO, ITALY; OSPED RIUNITI BERGAMO, DIV NEFROL & DIALISI, I-24128 BERGAMO, ITALY; SPEDALI CIVILI BRESCIA, CONSORZIO BIOTECHNOL, I-25123 BRESCIA, ITALY; OSPED RIUNITI BERGAMO, CTR TRASFUS, I-24128 BERGAMO, ITALY	Ospedali Riuniti di Bergamo; Ospedali Riuniti di Bergamo; Hospital Spedali Civili Brescia; Ospedali Riuniti di Bergamo								AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; BROUET JC, 1974, AM J MED, V57, P775, DOI 10.1016/0002-9343(74)90852-3; Byrnes JJ, 1996, LANCET, V348, P472, DOI 10.1016/S0140-6736(05)64562-X; CACOUB P, 1994, AM J MED, V96, P124, DOI 10.1016/0002-9343(94)90132-5; DAMMACCO F, 1994, BLOOD, V84, P3336, DOI 10.1182/blood.V84.10.3336.bloodjournal84103336; DiBisceglie AM, 1996, ANN INTERN MED, V125, P772, DOI 10.7326/0003-4819-125-9-199611010-00013; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P621; Fiordalisi G, 1996, J INFECT DIS, V174, P181, DOI 10.1093/infdis/174.1.181; GOREVIC PD, 1980, AM J MED, V69, P287, DOI 10.1016/0002-9343(80)90390-3; Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A; LEVEY JM, 1994, MEDICINE, V73, P53, DOI 10.1097/00005792-199401000-00005; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; MANTERO G, 1991, CLIN CHEM, V37, P422; Masuko K, 1996, NEW ENGL J MED, V334, P1485, DOI 10.1056/NEJM199606063342301; MELTZER M, 1966, AM J MED, V40, P837, DOI 10.1016/0002-9343(66)90200-2; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; MISIANI R, 1994, NEW ENGL J MED, V330, P751, DOI 10.1056/NEJM199403173301104; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; WEINER SM, 1996, 9 TRIENN INT S VIR H, P167; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7	20	18	18	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					891	894		10.7326/0003-4819-127-10-199711150-00005	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382367				2022-12-24	WOS:A1997YF54500005
J	Freund, CL; GregoryEvans, CY; Furukawa, T; Papaioannou, M; Looser, J; Ploder, L; Bellingham, J; Ng, D; Herbrick, JAS; Duncan, A; Scherer, SW; Tsui, LC; LoutradisAnagnostou, A; Jacobson, SG; Cepko, CL; Bhattacharya, SS; McInnes, RR				Freund, CL; GregoryEvans, CY; Furukawa, T; Papaioannou, M; Looser, J; Ploder, L; Bellingham, J; Ng, D; Herbrick, JAS; Duncan, A; Scherer, SW; Tsui, LC; LoutradisAnagnostou, A; Jacobson, SG; Cepko, CL; Bhattacharya, SS; McInnes, RR			Cone-rod dystrophy due to mutations in a novel photoreceptor-specific homeobox gene (CRX) essential for maintenance of the photoreceptor	CELL			English	Article							RETINITIS-PIGMENTOSA; RETINAL DYSTROPHY; CHROMOSOME 19Q; HUMAN GENOME; CONGENITAL AMAUROSIS; CRYSTAL-STRUCTURE; LINKAGE ANALYSIS; DNA; DIFFERENTIATION; HOMEODOMAIN	Genes associated with inherited retinal degeneration have been found to encode proteins required for phototransduction, metabolism, or structural support of photoreceptors. Here we show that mutations in a novel photoreceptor-specific homeodomain transcription factor gene (CRX) cause an autosomal dominant form of cone-rod dystrophy (adCRD) at the CORD2 locus on chromosome 19q13. In affected members of a CORD2-linked family, the highly conserved glutamic acid at the first position of the recognition helix is replaced by alanine (E80A). In another CRD family, a 1 bp deletion (E168 [Delta bp]) within a novel sequence, the WSP motif, predicts truncation of the C-terminal 132 residues of CRX. Mutations in the CRX gene cause adCRD either by haploinsufficiency or by a dominant negative effect and demonstrate that CRX is essential for the maintenance of mammalian photoreceptors.	HOSP SICK CHILDREN, RES INST, PROGRAM DEV BIOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, RES INST, DEPT GENET, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, RES INST, DEPT PEDIAT, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5G 1A8, CANADA; UCL, INST OPHTHALMOL, DEPT MOL GENET, LONDON EC1V 9EL, ENGLAND; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; CTR THALASSEMIA, UNIT PRENATAL DIAG, GR-11526 ATHENS, GREECE; QUEENS UNIV, DEPT PATHOL, KINGSTON, ON K7L 3N6, CANADA; UNIV PENN, SCHEIE EYE INST, PHILADELPHIA, PA 19104 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of London; University College London; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Queens University - Canada; University of Pennsylvania; Pennsylvania Medicine			Bhattacharya, Shom/N-2926-2016; Gregory-Evans, Cheryl Y/G-9550-2011; Tsui, Lap-chee/A-1081-2010; Bellingham, James/GVS-8955-2022; Scherer, Stephen W./B-3785-2013	Bhattacharya, Shom/0000-0002-1601-6344; Bellingham, James/0000-0003-3368-5221; Scherer, Stephen W./0000-0002-8326-1999; Jacobson, Samuel/0000-0003-2122-169X	NEI NIH HHS [R01 EY0 8064, EY05627] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008064, R01EY005627] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acampora D, 1996, NAT GENET, V14, P218, DOI 10.1038/ng1096-218; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; ALLIKMETS R, 1997, IN PRESS SCIENCE; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON DH, 1978, INVEST OPHTH VIS SCI, V17, P117; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BALCIUNIENE J, 1995, GENOMICS, V30, P281, DOI 10.1006/geno.1995.9876; BASCOM RA, 1995, HUM MOL GENET, V4, P1895, DOI 10.1093/hmg/4.10.1895; Berson EL, 1996, P NATL ACAD SCI USA, V93, P4526, DOI 10.1073/pnas.93.10.4526; BIRD AC, 1995, AM J OPHTHALMOL, V119, P543, DOI 10.1016/S0002-9394(14)70212-0; Burmeister M, 1996, NAT GENET, V12, P376, DOI 10.1038/ng0496-376; Cau E, 1997, DEVELOPMENT, V124, P1611; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; CHUMAKOV IM, 1995, NATURE, V377, P175; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; DUNCAN AMV, 1994, GENOMICS, V19, P400, DOI 10.1006/geno.1994.1084; EVANS K, 1994, NAT GENET, V6, P210, DOI 10.1038/ng0294-210; EVANS K, 1995, ARCH OPHTHALMOL-CHIC, V113, P195, DOI 10.1001/archopht.1995.01100020079033; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; Freund C, 1996, HUM MOL GENET, V5, P1471, DOI 10.1093/hmg/5.Supplement_1.1471; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; Fulton AB, 1996, ARCH OPHTHALMOL-CHIC, V114, P698, DOI 10.1001/archopht.1996.01100130690009; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1997, P NATL ACAD SCI USA, V94, P3088, DOI 10.1073/pnas.94.7.3088; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; Gal A, 1997, PROG RETIN EYE RES, V16, P51, DOI 10.1016/S1350-9462(96)00021-3; GREGORY CY, 1994, AM J HUM GENET, V55, P1061; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kelsell RE, 1997, HUM MOL GENET, V6, P597, DOI 10.1093/hmg/6.4.597; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLYSTRA JA, 1993, CAN J OPHTHALMOL, V28, P79; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNZLER P, 1995, BIOL CHEM H-S, V376, P201; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LIN CC, 1985, CYTOGENET CELL GENET, V39, P269, DOI 10.1159/000132156; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; MATSUO I, 1995, GENE DEV, V9, P2646, DOI 10.1101/gad.9.21.2646; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; Oliver G, 1997, TRENDS NEUROSCI, V20, P415, DOI 10.1016/S0166-2236(97)01082-5; PAPAIOANNOU M, 1997, IN PRESS J MED GENET; Perrault I, 1996, NAT GENET, V14, P461, DOI 10.1038/ng1296-461; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; SCHERER S, 1991, P33; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; SZYLYK JP, 1993, ARCH OPHTHALMOL-CHIC, V111, P781; TERWILLIGER JD, 1994, HDB HUMAN GENETIC LI; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; Tomita K, 1996, GENES CELLS, V1, P765, DOI 10.1111/j.1365-2443.1996.tb00016.x; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WARBURG M, 1991, AM J MED GENET, V39, P288, DOI 10.1002/ajmg.1320390309; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WU PX, 1997, DEVELOPMENT, V124, P219; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; YAGASAKI K, 1989, ARCH OPHTHALMOL-CHIC, V107, P701, DOI 10.1001/archopht.1989.01070010719034; Yokoyama M, 1996, DNA Res, V3, P311, DOI 10.1093/dnares/3.5.311; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700	66	429	445	0	18	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 14	1997	91	4					543	553		10.1016/S0092-8674(00)80440-7	http://dx.doi.org/10.1016/S0092-8674(00)80440-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390563	hybrid, Green Published			2022-12-24	WOS:A1997YG49200015
J	Sorensen, HT; Sabroe, S; Rothman, KJ; Gillman, M; Fischer, P; Sorensen, TIA				Sorensen, HT; Sabroe, S; Rothman, KJ; Gillman, M; Fischer, P; Sorensen, TIA			Relation between weight and length at birth and body mass index in young adulthood: cohort study	BRITISH MEDICAL JOURNAL			English	Article							OBESITY; GROWTH		AARHUS UNIV,DANISH EPIDEMIOL SCI CTR,DEPT EPIDEMIOL & SOCIAL MED,DK-8000 AARHUS,DENMARK; BOSTON UNIV,SCH MED,PREVENT MED & EPIDEMIOL SECT,BOSTON,MA 02118; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02215; HARVARD PILGRIM HLTH CARE,BOSTON,MA 02215; 5TH CONSCRIPT DIST,DK-9000 AALBORG,DENMARK; UNIV COPENHAGEN HOSP,DANISH EPIDEMIOL SCI CTR,INST PREVENT MED,DK-1399 COPENHAGEN K,DENMARK	Aarhus University; Boston University; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Aarhus University; University of Copenhagen	Sorensen, HT (corresponding author), AARHUS UNIV HOSP,DEPT INTERNAL MED 5,DK-8000 AARHUS,DENMARK.		Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040; Rothman, Kenneth/0000-0003-2398-1705				BINKIN NJ, 1988, PEDIATRICS, V82, P828; CHARNEY E, 1976, NEW ENGL J MED, V295, P6, DOI 10.1056/NEJM197607012950102; LAW CM, 1992, J EPIDEMIOL COMMUN H, V46, P184, DOI 10.1136/jech.46.3.184; PECKHAM CS, 1983, BMJ-BRIT MED J, V286, P1237, DOI 10.1136/bmj.286.6373.1237; SEIDMAN DS, 1991, AM J DIS CHILD, V145, P782	5	175	180	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 1	1997	315	7116					1137	1137						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE615	9374888	Green Published			2022-12-24	WOS:A1997YE61500027
J	Nee, S; May, RM				Nee, S; May, RM			Extinction and the loss of evolutionary history	SCIENCE			English	Article							GENETIC DIVERSITY; CONSERVATION; BIODIVERSITY; POPULATIONS; TAXONOMY	Extinction episodes, such as the anthropogenic one currently under way, result in a pruned tree of life. But what fraction of the underlying evolutionary history survives when k of n species in a taxon are lost? This is relevant both to how species loss has translated into a loss of evolutionary history and to assigning conservation priorities. Here it is shown that approximately 80 percent of the underlying tree of life can survive even when approximately 95 percent of species are lost, and that algorithms that maximize the amount of evolutionary history preserved are not much better than choosing the survivors at random. Given the political, economic, and social realities constraining conservation biology, these findings may be helpful.			Nee, S (corresponding author), UNIV OXFORD, DEPT ZOOL, S PARKS RD, OXFORD OX1 3PS, ENGLAND.							BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; Costanza R, 1997, NATURE, V387, P253, DOI 10.1038/387253a0; Courtillot V, 1996, NATURE, V381, P146, DOI 10.1038/381146a0; DONOGHUE MJ, 1985, BRYOLOGIST, V88, P172, DOI 10.2307/3243026; ERWIN DH, 1994, NATURE, V367, P231, DOI 10.1038/367231a0; ERWIN TL, 1991, SCIENCE, V253, P750, DOI 10.1126/science.253.5021.750; FAITH DP, 1994, BIOL CONSERV, V68, P69, DOI 10.1016/0006-3207(94)90548-7; GUYER C, 1993, EVOLUTION, V47, P253, DOI [10.2307/2410133, 10.1111/j.1558-5646.1993.tb01214.x]; HESSE H, 1987, GLASS BEARD GAME; HEY J, 1992, EVOLUTION, V46, P627, DOI [10.2307/2409633, 10.1111/j.1558-5646.1992.tb02071.x]; Hibbett DS, 1996, CONSERV BIOL, V10, P1321, DOI 10.1046/j.1523-1739.1996.10051321.x; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; KRAJEWSKI C, 1991, SCIENCE, V254, P918, DOI 10.1126/science.254.5034.918-a; Lawton J. H., 1995, EXTINCTION RATES; LAWTON JH, 1994, OIKOS, V71, P1; Lovelock J, 1997, PHILOS T ROY SOC B, V352, P143, DOI 10.1098/rstb.1997.0009; Martin G, 1996, NATURE, V380, P666, DOI 10.1038/380666a0; MAY RM, 1990, NATURE, V347, P129, DOI 10.1038/347129a0; Mooers AO, 1997, Q REV BIOL, V72, P31, DOI 10.1086/419657; MORITZ C, 1994, TRENDS ECOL EVOL, V9, P373, DOI 10.1016/0169-5347(94)90057-4; NEE S, 1995, PHILOS T ROY SOC B, V349, P25, DOI 10.1098/rstb.1995.0087; NEI M, 1975, EVOLUTION, V29, P1, DOI 10.2307/2407137; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; Pimm SL, 1997, NATURE, V387, P231, DOI 10.1038/387231a0; PURVIS A, 1995, P ROY SOC B-BIOL SCI, V260, P329, DOI 10.1098/rspb.1995.0100; RAUP DM, 1993, EXTINCTION; SLATKIN M, 1991, GENETICS, V129, P555; STANLEY SM, 1994, SCIENCE, V266, P1340, DOI 10.1126/science.266.5189.1340; STANLEY SM, 1987, EVOLUTION, V41, P1177; TAVARE S, 1984, THEOR POPUL BIOL, V26, P119, DOI 10.1016/0040-5809(84)90027-3; VANEWRIGHT RI, 1991, BIOL CONSERV, V55, P235, DOI 10.1016/0006-3207(91)90030-D; [No title captured]	32	216	223	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	1997	278	5338					692	694		10.1126/science.278.5338.692	http://dx.doi.org/10.1126/science.278.5338.692			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381180				2022-12-24	WOS:A1997YC32300056
J	Jones, AH				Jones, AH			Literature and medicine: Garcia Marquez' Love in the Time of Cholera	LANCET			English	Editorial Material											Jones, AH (corresponding author), UNIV TEXAS,MED BRANCH,INST MED HUMANITIES,ASHBEL SMITH BLDG SUITE 2-210,301 UNIV BLVD,GALVESTON,TX 77555, USA.							BELLVILLADA GH, 1990, G MARQUEZ MAN HIS WO, P192; BOOKER MK, 1993, LOVE TIME CHOLERA ST, V17, P181; CHARON R, 1995, ANN INTERN MED, V122, P599, DOI 10.7326/0003-4819-122-8-199504150-00008; COLUMBUS CK, 1992, TWENTIETH CENT LIT, V38, P89; CONTI MS, 1996, WORLD PRESS REV  OCT, P60; DICKEY J, 1969, EYE BEATERS BLOOD VI, P31; DOWNIE RS, 1991, J MED ETHICS, V17, P93, DOI 10.1136/jme.17.2.93; DOWNIE RS, 1991, J MED ETHICS, V17, P98; FIDDIAN R, 1987, GG MARQUEZ NEW READI, P192; Garcia Marquez G., 1988, LOVE TIME CHOLERA; HUNTER KM, 1995, ACAD MED, V70, P787, DOI 10.1097/00001888-199509000-00014; McLellan MF, 1996, LANCET, V348, P109, DOI 10.1016/S0140-6736(96)03521-0; Moore AR, 1978, MISSING MED TEXT HUM; RABUZZI KA, 1982, LIT MED, V1, P1; Tennyson Alfred, 1971, TENNYSONS POETRY, P54; Trautmann J., 1978, ROLE HUMANITIES MED, P32	16	3	6	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1169	1172		10.1016/S0140-6736(97)09249-0	http://dx.doi.org/10.1016/S0140-6736(97)09249-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	YB199	9379818				2022-12-24	WOS:A1997YB19900050
J	Enari, M; Sakahira, H; Yokoyama, H; Okawa, K; Iwamatsu, A; Nagata, S				Enari, M; Sakahira, H; Yokoyama, H; Okawa, K; Iwamatsu, A; Nagata, S			A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD	NATURE			English	Article							FAS-MEDIATED APOPTOSIS; NF-KAPPA-B; CELL-DEATH; ICE-LIKE; PROTEASE; PROTEINS; FAMILY; FRAGMENTATION; IDENTIFICATION; INVOLVEMENT	The homeostasis of animals is regulated not only by the growth and differentiation of cells, but also by cell death through a process known as apoptosis. Apoptosis is mediated by members of the caspase family of proteases, and eventually causes the degradation of chromosomal DNA. A caspase-activated deoxyribonuclease (CAD) and its inhibitor (ICAD) have now been identified in the cytoplasmic fraction of mouse lymphoma cells. CAD is a protein of 343 amino acids which carries a nuclear-localization signal; ICAD exists in a long and a short form. Recombinant ICAD specifically inhibits CAD-induced degradation of nuclear DMA and its DNase activity. When CAD is expressed with ICAD In COS cells or in a cell-free system, CAD is produced as a complex with ICAD: treatment with caspase 3 releases the DNase activity which causes DNA fragmentation in nuclei. ICAD therefore seems to function as a chaperone for CAD during its synthesis, remaining complexed with CAD to inhibit its DNase activity; caspases activated by apoptotic stimuli then cleave ICAD, allowing CAD to enter the nucleus and degrade chromosomal DNA.	Osaka Univ, Sch Med, Dept Genet, Osaka 565, Japan; Kirin Brewery Co Ltd, Cent Lab Key Technol, Kanagawa 236, Japan; Osaka Biosci Inst, Osaka 565, Japan	Osaka University; Kirin Brewery Company Limited	Nagata, S (corresponding author), Osaka Univ, Sch Med, Dept Genet, 2-2 Yamada Oka, Osaka 565, Japan.		Nagata, Shigekazu/AAG-3203-2019; Enari, Masato/E-5507-2014	Nagata, Shigekazu/0000-0001-9758-8426; Enari, Masato/0000-0003-4293-3848				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MOGIL RJ, 1994, J IMMUNOL, V152, P1674; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PETISCH MC, 1993, EMBO J, V12, P371; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Shiokawa D, 1997, ARCH BIOCHEM BIOPHYS, V346, P15, DOI 10.1006/abbi.1997.0275; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WALLIS R, 1992, EUR J BIOCHEM, V207, P687, DOI 10.1111/j.1432-1033.1992.tb17096.x; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; WYLLIE AH, 1984, J PATHOL, V142, P66; ZAKUT R, 1982, NATURE, V298, P857, DOI 10.1038/298857a0	44	2640	2808	2	137	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					43	50		10.1038/34112	http://dx.doi.org/10.1038/34112			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422506				2022-12-24	WOS:000071326100042
J	Davies, SJA; Fitch, MT; Memberg, SP; Hall, AK; Raisman, G; Silver, J				Davies, SJA; Fitch, MT; Memberg, SP; Hall, AK; Raisman, G; Silver, J			Regeneration of adult axons in white matter tracts of the central nervous system	NATURE			English	Article							DORSAL-ROOT GANGLION; NEURITE OUTGROWTH; SPINAL-CORD; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; OLIGODENDROCYTES; ASTROCYTES; INVITRO; PROTEOGLYCANS; INHIBITION	It is widely accepted that the adult mammalian central nervous system (CNS) is unable to regenerate axons(1), In addition to physical or molecular barriers presented by glial scarring at the lesion site(2-4), it has been suggested that the normal myelinated CNS environment contains potent growth inhibitors(5,6) or lacks growth-promoting molecules(1,7). Here we investigate whether adult CNS white matter can support long-distance regeneration of adult axons in the absence of glial scarring, by using a microtransplantation technique(8) that minimizes scarring(9) to inject minute volumes of dissociated adult rat dorsal root ganglia directly into adult rat CNS pathways. This atraumatic injection procedure allowed considerable numbers of regenerating adult axons immediate access to the host glial terrain, where we found that they rapidly extended for long distances in white matter, eventually invading grey matter. Abortive regeneration correlated precisely with increased levels of proteoglycans within the extracellular matrix at the transplant interface, whereas successfully regenerating transplants were associated with minimal upregulation of these molecules, Our results demonstrate, to our knowledge for the first time, that reactive glial extracellular matrix at the lesion site is directly associated with failure of axon regrowth in vivo, and that adult myelinated white matter tracts beyond the glial scar can be highly permissive for regeneration.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT NEUROSCI,CLEVELAND,OH 44106; NATL INST MED RES,DIV NEUROBIOL,NORMAN & SADIE LEE RES CTR,LONDON NW7 1AA,ENGLAND	Case Western Reserve University; MRC National Institute for Medical Research			Raisman, Geoffrey/B-3215-2009	Hall, Alison/0000-0002-7237-7945				ARD MD, 1991, GLIA, V4, P70, DOI 10.1002/glia.440040109; BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; BRITTIS PA, 1995, MOL CELL NEUROSCI, V6, P413, DOI 10.1006/mcne.1995.1031; CARLSTEDT T, 1987, NEUROSCI LETT, V74, P14, DOI 10.1016/0304-3940(87)90043-7; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; Davies SJA, 1996, EXP NEUROL, V142, P203, DOI 10.1006/exnr.1996.0192; DAVIES SJA, 1993, EUR J NEUROSCI, V5, P95, DOI 10.1111/j.1460-9568.1993.tb00474.x; DAVIES SJA, 1994, J NEUROSCI, V14, P1596, DOI 10.1523/JNEUROSCI.14-03-01596.1994; FAWCETT JW, 1995, J CELL SCI, V103; FITCH MT, IN PRESS EXP NEUROL; GIBSON SJ, 1984, J NEUROSCI, V4, P3101, DOI 10.1523/jneurosci.04-12-03101.1984; GIULIAN D, 1994, DEV NEUROSCI-BASEL, V16, P128, DOI 10.1159/000112099; Grill R, 1997, J NEUROSCI, V17, P5560; KOBAYASHI H, 1995, DEV BIOL, V168, P383, DOI 10.1006/dbio.1995.1088; Krekoski CA, 1996, J NEUROSCI RES, V43, P1, DOI 10.1002/jnr.490430102; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; PINDZOLA RR, 1993, DEV BIOL, V156, P34, DOI 10.1006/dbio.1993.1057; Ramon y, 1928, DEGENERATION REGENER; REIER PJ, 1983, SPINAL CORD RECONSTR, P163; ROHRER H, 1985, DEV BIOL, V111, P95, DOI 10.1016/0012-1606(85)90438-5; RUDGE JS, 1990, J NEUROSCI, V10, P3594; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; SMITHTHOMAS LC, 1994, J CELL SCI, V107, P1687; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; STEINDLER DA, 1990, EXP NEUROL, V109, P35, DOI 10.1016/S0014-4886(05)80007-X; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VAUDANO E, 1995, J NEUROSCI, V15, P3594; WICTORIN K, 1990, NATURE, V347, P556, DOI 10.1038/347556a0	30	628	653	0	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 25	1997	390	6661					680	683		10.1038/37776	http://dx.doi.org/10.1038/37776			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM508	9414159				2022-12-24	WOS:A1997YM50800030
J	Bonventre, JV; Huang, ZH; Taheri, MR; OLeary, E; Li, E; Moskowitz, MA; Sapirstein, A				Bonventre, JV; Huang, ZH; Taheri, MR; OLeary, E; Li, E; Moskowitz, MA; Sapirstein, A			Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A(2)	NATURE			English	Article							ARACHIDONIC-ACID; GERBIL BRAIN; ISCHEMIA; REPERFUSION; MITOCHONDRIAL; IMPLANTATION; DAMAGE; PLA(2); KIDNEY; FORMS	Phospholipase A(2) (PLA(2)) enzymes are critical regulators of prostaglandin and leukotriene synthesis and can directly modify the composition of cellular membranes(1,2). PLA(2) enzymes release fatty acids and lysophospholipids, including the precursor of platelet-activating factor, PAF, from phospholipids. Free fatty acids, eicosanoids, lysophospholipids and PAF are potent regulators of inflammation(1,3,4), reproduction(5-7) and neurotoxicity(1,8,9). The physiological roles of the various forms of PLA(2) are not well defined. The cytosolic form, cPLA(2), preferentially releases arachidonic acid from phospholipids and is regulated by changes in intracellular calcium concentration(10,11). We have now created 'knockout' (cPLA(2)(-/-)) mice that lack this enzyme, in order to evaluate its physiological importance. We find that cPLA(2)(-/-) mice develop normally, but that the females produce only small litters in which the pups are usually dead, Stimulated peritoneal macrophages from cPLA(2)(-/-) animals did not produce prostaglandin E-2 or leukotriene B-4 or C-4. After transient middle cerebral artery occlusion, cPLA(2)(-/-) mice had smaller infarcts and developed less brain oedema and fewer neurological deficits. Thus cPLA(2) is important for macrophage production of inflammatory mediators, fertility, and in the pathophysiology of neuronal death after transient focal cerebral ischaemia.	MASSACHUSETTS GEN HOSP, NEUROSURG SERV, DEPT MED, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, CARDIAC SERV, DEPT MED, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, ANESTHESIA SERV, DEPT MED, CHARLESTOWN, MA 02129 USA; HARVARD UNIV, SCH MED, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, MED SERV, DEPT NEUROSURG, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, NEUROSURG SERV, DEPT NEUROSURG, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, CARDIAC SERV, DEPT NEUROSURG, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, ANESTHESIA SERV, DEPT NEUROSURG, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, ANESTHESIA SERV, DEPT ANESTHESIA, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, MED SERV, DEPT ANESTHESIA, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, NEUROSURG SERV, DEPT ANESTHESIA, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, CARDIAC SERV, DEPT ANESTHESIA, CHARLESTOWN, MA 02129 USA; HARVARD MIT DIV HLTH SCI & TECHNOL, CHARLESTOWN, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University	Bonventre, JV (corresponding author), MASSACHUSETTS GEN HOSP, MED SERV, DEPT MED, 149 13TH ST, CHARLESTOWN, MA 02129 USA.		Moskowitz, Michael A/D-9916-2011					ABRAHAMSOHN PA, 1993, J EXP ZOOL, V266, P603, DOI 10.1002/jez.1402660610; Ausubel F.M., 1987, CURRENT PROTOCOLS MO; BAZAN NG, 1989, ANN NY ACAD SCI, V559, P1; BONVENTRE JV, 1993, J LIPID MEDIATOR, V6, P457; BONVENTRE JV, 1992, J AM SOC NEPHROL, V3, P128; Challis John R. G., 1994, P985; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Clemens JA, 1996, STROKE, V27, P527, DOI 10.1161/01.STR.27.3.527; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; GILBOE DD, 1991, J NEUROCHEM, V56, P311, DOI 10.1111/j.1471-4159.1991.tb02597.x; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; KIM DK, 1993, BIOCHEM J, V294, P261, DOI 10.1042/bj2940261; Kol S, 1997, ENDOCRINOLOGY, V138, P314, DOI 10.1210/en.138.1.314; MALIS CD, 1986, J BIOL CHEM, V261, P14201; MOSKOWITZ MA, 1984, SCIENCE, V224, P886, DOI 10.1126/science.6719118; Novaro V, 1996, PROSTAGLANDINS, V51, P363, DOI 10.1016/0090-6980(96)00043-3; RAJABI MR, 1995, AM J PHYSIOL-ENDOC M, V269, pE940, DOI 10.1152/ajpendo.1995.269.5.E940; Rice GE, 1995, REPROD FERT DEVELOP, V7, P1471, DOI 10.1071/RD9951471; RORDORF G, 1991, J NEUROSCI, V11, P1829; ROSS BM, 1995, J NEUROCHEM, V64, P2213; Sapirstein A, 1996, J BIOL CHEM, V271, P21505, DOI 10.1074/jbc.271.35.21505; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; Teslenko V, 1997, BBA-LIPID LIPID MET, V1344, P189, DOI 10.1016/S0005-2760(96)00137-3; vanderWeiden RMF, 1996, J REPROD FERTIL, V107, P161; VERITY MA, 1993, ANN NY ACAD SCI, V679, P110; WINKLER JD, 1997, BIOCHIM BIOPHYS ACTA, P173; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165	28	717	725	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 11	1997	390	6660					622	625		10.1038/37635	http://dx.doi.org/10.1038/37635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403693				2022-12-24	WOS:A1997YK85300053
J	Petricoin, EF; Ito, S; Williams, BL; Audet, S; Stancato, LF; Gamero, A; Clouse, K; Grimley, P; Weiss, A; Beeler, J; Finbloom, DS; Shores, EW; Abraham, R; Larner, AC				Petricoin, EF; Ito, S; Williams, BL; Audet, S; Stancato, LF; Gamero, A; Clouse, K; Grimley, P; Weiss, A; Beeler, J; Finbloom, DS; Shores, EW; Abraham, R; Larner, AC			Antiproliferative action of interferon-alpha requires components of T-cell-receptor signalling	NATURE			English	Article							ANTIGEN RECEPTOR; TYROSINE PHOSPHATASE; KINASE; TRANSDUCTION; EXPRESSION; PROTEINS; CD45	Signal transduction through both cytokine and lymphocyte antigen receptors shares some common pathways by which they initiate cellular responses, such as activation of mitogen-activated protein kinase(s)(1,2). However, other signalling components appear to be uniquely coupled to each receptor. For example, the interferon receptors transduce regulatory signals through the JAK/ STAT pathway, resulting in an inhibition of growth and of antiviral effects, whereas this pathway apparently plays no role in T-cell-receptor (TCR)-dependent gene expression(3,4). Conversely, signal transduction through the TCR requires the tyrosine kinases Lck and ZAP-70 and the tyrosine phosphatase CD45 (ref. 5). Here we show that, unexpectedly, transmission of growth-inhibitory signals by interferon-alpha (IFN-alpha) in T cells requires the expression and association of CD45, Lck and ZAP-70 with the IFN-alpha-receptor signalling complex.	US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892; MAYO CLIN & MAYO FDN,DEPT IMMUNOL & PHARMACOL,ROCHESTER,MN 55905; USUHS,DEPT PATHOL,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	US Food & Drug Administration (FDA); Mayo Clinic; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco								BEADLING C, 1994, EMBO J, V13; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS BL, UNPUB MOL CELL BIOL	10	137	140	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					629	632		10.1038/37648	http://dx.doi.org/10.1038/37648			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403695				2022-12-24	WOS:A1997YK85300055
J	Hess, RA; Bunick, D; Lee, KH; Bahr, J; Taylor, JA; Korach, KS; Lubahn, DB				Hess, RA; Bunick, D; Lee, KH; Bahr, J; Taylor, JA; Korach, KS; Lubahn, DB			A role for oestrogens in the male reproductive system	NATURE			English	Article							ESTROGEN-RECEPTOR GENE; DUCTULI-EFFERENTES; SPERM COUNTS; EPIDIDYMIS; TESTIS; MOUSE; RAT; DISRUPTION; SECRETION; ESTRADIOL	Oestrogen is considered to be the 'female' hormone, whereas testosterone is considered the 'male' hormone. However,both hormones are present in both sexes. Thus sexual distinctions are not qualitative differences, but rather result from quantitative divergence in hormone concentrations and differential expressions of steroid hormone receptors. In males, oestrogen is present in low concentrations in blood, but can be extraordinarily high in semen, and as high as 250 pg ml(-1) in rete testis fluids(1,2), which is higher than serum oestradiol in the female(3). It is well known that male reproductive tissues express oestrogen receptors(4-7), but the role of oestrogen in male reproduction has remained unclear. Here we provide evidence of a physiological role for oestrogen in male reproductive organs. We show that oestrogen regulates the reabsorption of luminal fluid in the head of the epididymis. Disruption of this essential function causes sperm to enter the epididymis diluted, rather than concentrated, resulting in infertility. This finding raises further concern over the potential direct effects of environmental oestrogens on male reproduction and reported declines in human sperm counts(8,9).	UNIV ILLINOIS,DEPT ANIM SCI,URBANA,IL 61801; UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65211; UNIV MISSOURI,DEPT CHILD HLTH,COLUMBIA,MO 65211; NIEHS,RES TRIANGLE PK,NC 27709	University of Illinois System; University of Illinois Urbana-Champaign; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Hess, RA (corresponding author), UNIV ILLINOIS,DEPT VET BIOSCI,2001 S LINCOLN AVE,URBANA,IL 61802, USA.			Hess, Rex/0000-0003-2649-3563; Korach, Kenneth/0000-0002-7765-418X	FIC NIH HHS [F06 TW002317] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F06TW002317] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; Carani C, 1997, NEW ENGL J MED, V337, P91, DOI 10.1056/NEJM199707103370204; CHAN HC, 1995, J CELL PHYSIOL, V164, P271, DOI 10.1002/jcp.1041640207; CLULOW J, 1994, EXP PHYSIOL, V79, P915, DOI 10.1113/expphysiol.1994.sp003817; COOKE PS, 1991, ENDOCRINOLOGY, V128, P2874, DOI 10.1210/endo-128-6-2874; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; Fisher JS, 1997, J ENDOCRINOL, V153, P485, DOI 10.1677/joe.0.1530485; FREE MJ, 1979, BIOL REPROD, V20, P269, DOI 10.1095/biolreprod20.2.269; GANJAM VK, 1976, ENDOCRINOLOGY, V99, P1618, DOI 10.1210/endo-99-6-1618; GRECO TL, 1993, ENDOCR REV, V14, P59, DOI 10.1210/er.14.1.59; Hess R.A., 1993, METHODS REPROD TOXIC, P52; HESS RA, 1991, FUND APPL TOXICOL, V17, P733, DOI 10.1016/0272-0590(91)90181-3; Hess RA, 1997, J ANDROL, V18, P602; ILIO KY, 1994, MICROSC RES TECHNIQ, V29, P432, DOI 10.1002/jemt.1070290604; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; KRAUSE W, 1992, INT J ANDROL, V15, P14, DOI 10.1111/j.1365-2605.1992.tb01110.x; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MORISHIMA A, 1995, J CLIN ENDOCR METAB, V80, P3689, DOI 10.1210/jc.80.12.3689; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Robaire B., 1988, P999; SCHLEICHER G, 1984, HISTOCHEMISTRY, V81, P139, DOI 10.1007/BF00490107; SHARPE RM, 1993, J ENDOCRINOL, V136, P357, DOI 10.1677/joe.0.1360357; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; SMITH EP, 1995, NEW ENGL J MED, V332, P131; SMITH GILLIAN, 1962, JOUR ENDOCRINOL, V23, P385, DOI 10.1677/joe.0.0230385; SMITH MS, 1975, ENDOCRINOLOGY, V96, P219, DOI 10.1210/endo-96-1-219; WAKELING AE, 1991, CANCER RES, V51, P3867; WEST NB, 1990, BIOL REPROD, V42, P533, DOI 10.1095/biolreprod42.3.533; YEUNG CH, 1991, AM J ANAT, V191, P261, DOI 10.1002/aja.1001910306	31	712	741	2	68	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					509	512		10.1038/37352	http://dx.doi.org/10.1038/37352			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9393999	Green Accepted			2022-12-24	WOS:A1997YJ86500051
J	Spanswick, D; Smith, MA; Groppi, VE; Logan, SD; Ashford, MLJ				Spanswick, D; Smith, MA; Groppi, VE; Logan, SD; Ashford, MLJ			Leptin inhibits hypothalamic neurons by activation of ATP-sensitive potassium channels	NATURE			English	Article							K+ CHANNELS; OBESE GENE; RAT FATTY; OB-R; RECEPTOR; IDENTIFICATION; EXPRESSION; CLONING; BRAIN; MICE	Leptin, the protein encoded by the obese (ob) gene, is secreted from adipose tissue and is thought to act in the central nervous system to regulate food intake and body weight(1,2). It has been proposed that leptin acts in the hypothalamus(3-5), the main control centre for satiety and energy expenditure(6). Mutations in leptin or the receptor isoform (Ob-R-L) present in hypothalamic neurons result in profound obesity and symptoms of non-insulin-dependent diabetes(7-10). Here we show that leptin hyperpolarizes glucose-receptive hypothalamic neurons of lean Sprague-Dawley and Zucker rats, but is ineffective on neurons of obese Zucker (fa/fa) rats. This hyperpolarization is due to the activation of a potassium current, and is not easily recovered on removal of leptin, but is reversed by applying the sulphonylurea, tolbutamide. Single-channel recordings demonstrate that leptin activates an ATP-sensitive potassium (K-ATP) channel. Our data indicate that the K-ATP channel may function as the molecular end-point of the pathway following leptin activation of the Ob-R-L receptor in hypothalamic neurons.	UNIV ABERDEEN,INST MED SCI,DEPT BIOMED SCI,ABERDEEN AB25 2ZD,SCOTLAND; PHARMACIA & UPJOHN INC,KALAMAZOO,MI 49001	University of Aberdeen; Pfizer			Smith, Mark/K-5792-2017	Smith, Mark/0000-0003-1474-5225; Ashford, Michael/0000-0002-0861-7676	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHFORD MLJ, 1990, PFLUG ARCH EUR J PHY, V415, P479, DOI 10.1007/BF00373626; ASHFORD MLJ, 1990, BRIT J PHARMACOL, V101, P531, DOI 10.1111/j.1476-5381.1990.tb14116.x; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Cusin I, 1996, DIABETES, V45, P1446, DOI 10.2337/diabetes.45.10.1446; Elmquist JK, 1997, ENDOCRINOLOGY, V138, P839, DOI 10.1210/en.138.2.839; Glaum SR, 1996, MOL PHARMACOL, V50, P230; Harvey J, 1997, J PHYSIOL-LONDON, V504, P527, DOI 10.1111/j.1469-7793.1997.527bd.x; KEIFFER TJ, 1997, DIABETES, V26, P1087; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LEE K, 1995, J PHYSIOL-LONDON, V488, P319, DOI 10.1113/jphysiol.1995.sp020969; LEVIN BE, 1996, AM J PHYSIOL-REG I, V40, pR491; Matson C.A., 1996, DIABETES REV, V4, P488; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; OOMURA Y, 1969, NATURE, V222, P282, DOI 10.1038/222282a0; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Rock FL, 1996, HORM METAB RES, V28, P748, DOI 10.1055/s-2007-979892; Rosenblum CI, 1996, ENDOCRINOLOGY, V137, P5178, DOI 10.1210/en.137.11.5178; Satoh N, 1997, NEUROSCI LETT, V224, P149, DOI 10.1016/S0304-3940(97)00163-8; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Seeley RJ, 1996, HORM METAB RES, V28, P664, DOI 10.1055/s-2007-979874; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; STREAMSON C, 1996, DIABETES, V45, P1141; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TREHERNE JM, 1991, J NEUROENDOCRINOL, V3, P323, DOI 10.1111/j.1365-2826.1991.tb00282.x; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Woods AJ, 1996, NATURE, V381, P745, DOI 10.1038/381745a0; Yamashita T, 1997, DIABETES, V46, P1077, DOI 10.2337/diabetes.46.6.1077; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	30	521	553	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					521	525		10.1038/37379	http://dx.doi.org/10.1038/37379			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394003				2022-12-24	WOS:A1997YJ86500055
J	Salzmann, P; Kerlikowske, K; Phillips, K				Salzmann, P; Kerlikowske, K; Phillips, K			Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age	ANNALS OF INTERNAL MEDICINE			English	Article							BREAST-CANCER; RECOMMENDATIONS; METAANALYSIS; STRATEGIES; MEDICINE; BENEFIT; YOUNGER; PROGRAM; TRIALS; HEALTH	Background: Screening mammography is recommended for women 50 to 69 years of age because of its proven efficacy and reasonable cost-effectiveness. Extending screening recommendations to include women 40 to 49 years of age remains controversial. Objective: To compare the cost-effectiveness of screening mammography in women of different age groups. Design: Cost-effectiveness analysis done using Markov and Monte Carlo models. Patients: General population of women 40 years of age and older. Interventions: Biennial screening from 50 to 69 years of age was compared with no screening. Screening done every 18 months from ages 40 to 49 years, followed by biennial screening from ages 50 to 69 years, was compared with biennial screening from ages 50 to 69 years. Measurements: Life-expectancy, costs, and incremental cost-effectiveness. Results: Screening women from 50 to 69 years of age improved life expectancy by 12 days at a cost of $704 per woman, resulting in a cost-effectiveness ratio of $21 400 per year of life saved. Extending screening to include women 40 to 49 years of age improved life expectancy by 2.5 days at a cost of $676 per woman. The incremental cost-effectiveness of screening women 40 to 49 years of age was $105 000 per year of life saved. On the basis of a multiway sensitivity analysis, there is a 75% chance that screening mammography in women 50 to 69 years of age costs less than $50 000 per year of life saved, compared with a 7% chance in women 40 to 49 years of age. Conclusion: The cost-effectiveness of screening mammography in women 40 to 49 years of age is almost five times that in older women. When breast cancer screening policies are being set, the incremental cost-effectiveness of extending mammographic screening to younger women should be considered.	VET AFFAIRS MED CTR, GEN INTERNAL MED SECT, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [P50CA058207, U01CA063740] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA58207, 1 U01 CA 63740] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		American College of Radiology, 1982, POL STAT GUID MAMM; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BLACK WC, 1995, J NATL CANCER I, V87, P720, DOI 10.1093/jnci/87.10.720; Black WC, 1996, JAMA-J AM MED ASSOC, V275, P111, DOI 10.1001/jama.1996.03530260025021; Boer R, 1996, JAMA-J AM MED ASSOC, V275, P111, DOI 10.1001/jama.1996.03530260025022; BROWN ML, 1995, AM J ROENTGENOL, V165, P1373, DOI 10.2214/ajr.165.6.7484568; BROWN ML, 1993, BREAST CANCER RES TR, V25, P113, DOI 10.1007/BF00662136; BROWN ML, 1995, RADIOLOGY, V195, P529, DOI 10.1148/radiology.195.2.7724778; DEKONING HJ, 1997, NIH CONS DEV C BREAS, P40; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; ELWOOD JM, 1993, ONLINE J CURR CLIN T, V2; FEIG SA, 1995, CANCER, V76, P2097, DOI 10.1002/1097-0142(19951115)76:10+<2097::AID-CNCR2820761332>3.0.CO;2-B; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; GLASZIOU PP, 1995, MED J AUSTRALIA, V162, P625, DOI 10.5694/j.1326-5377.1995.tb126047.x; HALL J, 1992, SOC SCI MED, V34, P993, DOI 10.1016/0277-9536(92)90130-I; HARRIS R, 1995, ANN INTERN MED, V122, P539, DOI 10.7326/0003-4819-122-7-199504010-00011; HARRIS RP, 1991, CANCER, V67, P2010, DOI 10.1002/1097-0142(19910401)67:7<2010::AID-CNCR2820670730>3.0.CO;2-8; KATTLOVE H, 1995, JAMA-J AM MED ASSOC, V273, P142, DOI 10.1001/jama.273.2.142; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; KERLIKOWSKE K, 1997, MONOGR NATL CANC I, V22, P105; KERLIKOWSKE K, 1997, MONOGR NATL CANC I, V22, P79; KOSARY CL, 1995, NIH PUBLICATION; Lee TT, 1997, ANN INTERN MED, V126, P337, DOI 10.7326/0003-4819-126-5-199703010-00001; LINDFORS KK, 1995, JAMA-J AM MED ASSOC, V274, P881, DOI 10.1001/jama.274.11.881; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; PEER PGM, 1994, J NATL CANCER I, V86, P436, DOI 10.1093/jnci/86.6.436; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; SHAPIRO S, 1994, AM J PUBLIC HEALTH, V84, P10, DOI 10.2105/AJPH.84.1.10; Shapiro S, 1988, PERIODIC SCREENING B; SICKLES EA, 1995, ANN INTERN MED, V122, P534, DOI 10.7326/0003-4819-122-7-199504010-00010; SICKLES EA, 1993, J NATL CANCER I, V85, P1621, DOI 10.1093/jnci/85.20.1621; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; SOX HC, 1995, ANN INTERN MED, V122, P550, DOI 10.7326/0003-4819-122-7-199504010-00013; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TAPLIN SH, 1995, J NATL CANCER I, V87, P417, DOI 10.1093/jnci/87.6.417; *TREEAG SOFTW, 1996, DATA 3 0; *US BUR CENS, 1991, STAT ABSTR US, P84; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; 1997, CANC LETT, V23, P4; 1986, CAN MED ASSOC J, V134, P724	43	193	193	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					955	965		10.7326/0003-4819-127-11-199712010-00001	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00001			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412300				2022-12-24	WOS:A1997YJ08000001
J	Coupland, RM				Coupland, RM			Abhorrent weapons and ''superfluous injury or unnecessary suffering'': from field surgery to law	BRITISH MEDICAL JOURNAL			English	Article											Coupland, RM (corresponding author), RED CROSS,INT COMM,HLTH OPERAT DIV,CH-1202 GENEVA,SWITZERLAND.							*INT COMM RED CROS, 1997, SIRUS PROJ DET WHICH	1	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1450	1452		10.1136/bmj.315.7120.1450	http://dx.doi.org/10.1136/bmj.315.7120.1450			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418099	Green Published			2022-12-24	WOS:A1997YJ67200035
J	Raskin, DM; deBoer, PAJ				Raskin, DM; deBoer, PAJ			The MinE ring: An FtsZ-independent cell structure required for selection of the correct division site in E-coli	CELL			English	Article							TOPOLOGICAL SPECIFICITY FACTOR; GREEN FLUORESCENT PROTEIN; ESCHERICHIA-COLI; SEPTUM PLACEMENT; BINDING-PROTEIN; MUTANTS; ENCODES; LOCUS; INHIBITORS; HOMOLOGS	E. coli cell division is mediated by the FtsZ ring and associated factors. Selection of the correct division site requires the combined action of an inhibitor of FtsZ ring formation (MinCD) and of a topological specificity factor that somehow prevents MinCD action at the middle of the cell (MinE). Here we show that a biologically active MinE-Gfp fusion accumulates in an annular structure near the middle of young cells. Formation of the MinE ring required MinD but was independent of MinC and continued in nondividing cells in which FtsZ function was inhibited. The results indicate that the MinE ring represents a novel cell structure, which allows FtsZ ring formation at midcell by suppressing MinCD activity at this site.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOL BIOL & MICROBIOL,CLEVELAND,OH 44106	Case Western Reserve University			Raskin, David/AAZ-5973-2021	Raskin, David/0000-0001-7421-7809; de Boer, Piet/0000-0002-5375-6317	NIGMS NIH HHS [T32GM08056] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008056] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Addinall SG, 1996, J BACTERIOL, V178, P7167, DOI 10.1128/jb.178.24.7167-7172.1996; Addinall SG, 1996, J BACTERIOL, V178, P3877, DOI 10.1128/jb.178.13.3877-3884.1996; ADLER HI, 1967, P NATL ACAD SCI USA, V57, P321, DOI 10.1073/pnas.57.2.321; Baumann P, 1996, P NATL ACAD SCI USA, V93, P6726, DOI 10.1073/pnas.93.13.6726; BI E, 1993, J BACTERIOL, V175, P1118, DOI 10.1128/JB.175.4.1118-1125.1993; BI E, 1990, J BACTERIOL, V172, P5610, DOI 10.1128/jb.172.10.5610-5616.1990; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; Cha JH, 1997, J BACTERIOL, V179, P1671, DOI 10.1128/jb.179.5.1671-1683.1997; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; DEBOER PAJ, 1991, EMBO J, V10, P4371, DOI 10.1002/j.1460-2075.1991.tb05015.x; DEBOER PAJ, 1992, J BACTERIOL, V174, P63, DOI 10.1128/jb.174.1.63-70.1992; DEBOER PAJ, 1990, P NATL ACAD SCI USA, V87, P1129, DOI 10.1073/pnas.87.3.1129; DEBOER PAJ, 1988, J BACTERIOL, V170, P2106, DOI 10.1128/jb.170.5.2106-2112.1988; Donachie WD, 1996, J BACTERIOL, V178, P5971, DOI 10.1128/jb.178.20.5971-5976.1996; Edwards DH, 1997, MOL MICROBIOL, V24, P905, DOI 10.1046/j.1365-2958.1997.3811764.x; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; Hale CA, 1997, CELL, V88, P175, DOI 10.1016/S0092-8674(00)81838-3; HIGASHITANI A, 1995, BIOCHEM BIOPH RES CO, V209, P198, DOI 10.1006/bbrc.1995.1489; HIRAGA S, 1989, J BACTERIOL, V171, P1496, DOI 10.1128/jb.171.3.1496-1505.1989; Huang J, 1996, J BACTERIOL, V178, P5080, DOI 10.1128/jb.178.17.5080-5085.1996; LEE SY, 1993, MOL MICROBIOL, V7, P601, DOI 10.1111/j.1365-2958.1993.tb01151.x; LEVIN PA, 1992, J BACTERIOL, V174, P6717, DOI 10.1128/JB.174.21.6717-6728.1992; LUTKENHAUS J, 1993, MOL MICROBIOL, V9, P403, DOI 10.1111/j.1365-2958.1993.tb01701.x; LUTKENHAUS J, 1996, ESCHERICHIA COLI SAL, P1615; Ma XL, 1996, P NATL ACAD SCI USA, V93, P12998, DOI 10.1073/pnas.93.23.12998; Margolin W, 1996, J BACTERIOL, V178, P1320, DOI 10.1128/jb.178.5.1320-1327.1996; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; PICHOFF S, 1995, MOL MICROBIOL, V18, P321, DOI 10.1111/j.1365-2958.1995.mmi_18020321.x; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; Rothfield LI, 1996, CELL, V84, P183, DOI 10.1016/S0092-8674(00)80971-X; Rothfield LI, 1997, CELL, V88, P581, DOI 10.1016/S0092-8674(00)81899-1; TEATHER RM, 1974, J BACTERIOL, V118, P407, DOI 10.1128/JB.118.2.407-413.1974; VARLEY AW, 1992, J BACTERIOL, V174, P6729, DOI 10.1128/JB.174.21.6729-6742.1992; WANG XD, 1991, EMBO J, V10, P3363, DOI 10.1002/j.1460-2075.1991.tb04900.x; WARD JE, 1985, CELL, V42, P941, DOI 10.1016/0092-8674(85)90290-9; ZHAO CR, 1995, P NATL ACAD SCI USA, V92, P4314	39	196	200	1	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					685	694		10.1016/S0092-8674(00)80455-9	http://dx.doi.org/10.1016/S0092-8674(00)80455-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393861	Bronze			2022-12-24	WOS:A1997YH96000015
J	Wang, JM; Hartling, JA; Flanagan, JM				Wang, JM; Hartling, JA; Flanagan, JM			The structure of ClpP at 2.3 angstrom resolution suggests a model for ATP-dependent proteolysis	CELL			English	Article							BACTERIAL CHAPERONIN GROEL; ESCHERICHIA-COLI CLPP; CRYSTAL-STRUCTURE; MOLECULAR CHAPERONES; SERINE PROTEASES; SUBSTRATE-SPECIFICITY; PROTEIN; DEGRADATION; COMPONENT; 2-COMPONENT	We have determined the crystal structure of the proteolytic component of the caseinolytic Clp protease (ClpP) from E. coli at 2.3 Angstrom resolution using an ab initio phasing procedure that exploits the internal 14-fold symmetry of the oligomer. The structure of a ClpP monomer has a distinct fold that defines a fifth structural family of serine proteases but a conserved catalytic apparatus. The active protease resembles a hollow, solid-walled cylinder composed of two 7-fold symmetric rings stacked back-to-back. Its 14 proteolytic active sites are located within a central, roughly spherical chamber similar to 51 Angstrom in diameter. Access to the proteolytic chamber is controlled by two axial pores, each having a minimum diameter of similar to 10 Angstrom. From the structural features of ClpP, we suggest a model for its action in degrading proteins.	BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973; YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520	United States Department of Energy (DOE); Brookhaven National Laboratory; Yale University					NIGMS NIH HHS [GM-22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; BLOW DM, 1970, ANN REV BIOCH, V39, P60; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRUNGER AT, 1992, X PLCR VERSION 3 1 S; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Chen P, 1996, CELL, V86, P835, DOI 10.1016/S0092-8674(00)80157-9; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Drenth J, 1994, PRINCIPLES PROTEIN X; FLANAGAN JM, 1995, BIOCHEMISTRY-US, V34, P10910, DOI 10.1021/bi00034a025; Goldberg A L, 1990, Semin Cell Biol, V1, P423; GOLDBERG AL, 1994, METHOD ENZYMOL, V244, P350; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HARADA Y, 1981, ACTA CRYSTALLOGR A, V37, P398, DOI 10.1107/S0567739481000867; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HORWICH AL, 1995, CURR BIOL, V5, P455, DOI 10.1016/S0960-9822(95)00089-3; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, CCP4 STUDY WEEKEND 1, P91; KANDROR O, 1994, J BIOL CHEM, V269, P23575; KATAYAMA Y, 1988, J BIOL CHEM, V263, P15226; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; KLUG A, 1972, QUANT BIOL, V36, P483; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOSTER AJ, 1995, MOL BIOL REP, V21, P1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1997, IN PRESS TRENDS BIOC; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MAURIZI MR, 1990, J BIOL CHEM, V265, P12546; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P315; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERONA JJ, 1995, PROTEIN SCI, V4, P337; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; SHANKLIN J, 1995, PLANT CELL, V7, P1713, DOI 10.1105/tpc.7.10.1713; Shin DH, 1996, J MOL BIOL, V262, P71, DOI 10.1006/jmbi.1996.0499; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; STEITZ TA, 1982, ANNU REV BIOPHYS BIO, V11, P419, DOI 10.1146/annurev.bb.11.060182.002223; THOMPSON MW, 1994, J BIOL CHEM, V269, P18201; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WOJTKOWIAK D, 1993, J BIOL CHEM, V268, P22609; WOO KM, 1989, J BIOL CHEM, V264, P2088	62	480	489	1	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					447	456		10.1016/S0092-8674(00)80431-6	http://dx.doi.org/10.1016/S0092-8674(00)80431-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390554	hybrid			2022-12-24	WOS:A1997YG49200006
J	McNamara, RL; Lima, JAC; Whelton, PK; Powe, NR				McNamara, RL; Lima, JAC; Whelton, PK; Powe, NR			Echocardiographic identification of cardiovascular sources of emboli to guide clinical management of stroke: A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article						cerebrovascular disorders; echocardiography, transesophageal; cost-benefit analysis; embolism and thrombosis; thrombolytic therapy	NONVALVULAR ATRIAL-FIBRILLATION; TRANSIENT ISCHEMIC ATTACKS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CEREBRAL-ISCHEMIA; DECISION-ANALYSIS; CARDIAC SOURCE; TRANSTHORACIC ECHOCARDIOGRAPHY; NATIONAL PERSPECTIVE; ARTERY DISEASE; BREAST-CANCER	Background: No consensus exists about the use of imaging strategies to identify potential cardiovascular sources of emboli in patients who have had strokes. Objective: To;determine the cost-effectiveness of various cardiac imaging strategies after stroke. Design: A Markov model decision analysis was used to evaluate the benefits and costs of nine diagnostic strategies, including transthoracic echocardiography, transesophageal echocardiography, sequential approaches, selective imaging, and no imaging. Setting: Simulated clinical practice in the United States. Patients: Hypothetical patients with a first stroke who were in normal sinus rhythm. Measurements: Echocardiographic detection rates of potential sources of emboli were ascertained by doing a systematic review of the literature. Values for event rates, anticoagulation effects, utilities, and costs were obtained from the literature and Medicare data. Results: When visualized left atrial thrombus was used as the only indication for anticoagulation, transesophageal echocardiography performed only in patients with a history of cardiac problems cost $9000 per quality-adjusted life-year; transesophageal echocardiography in all patients cost $13 000 per quality-adjusted life-year. Cost savings and decreased morbidity and mortality rates associated with reduction in preventable recurrent strokes substantially offset examination costs and risks of anticoagulation. These results were moderately sensitive to efficacy of anticoagulation and incidence of intracranial bleeding during anticoagulation and were mildly sensitive to prevalence of left atrial thrombus, rate of recurrent stroke in patients with thrombus, quality of life after stroke, cost of transesophageal echocardiography, and specificity of transesophageal echocardiography. Transthoracic echocardiography, alone or in sequence with transesophageal echocardiography, was not cost-effective compared with transesophageal echocardiography. Conclusion: Physicians should consider doing transesophageal echocardiography in all patients with new; onset stroke.	JOHNS HOPKINS MED INST, WELCH CTR PREVENT EPIDEMIOL & CLIN RES, BALTIMORE, MD 21250 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD USA; TULANE UNIV, MED CTR, SCH PUBL HLTH & TROP MED, NEW ORLEANS, LA 70112 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Tulane University					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K01AG000561] Funding Source: NIH RePORTER; NCRR NIH HHS [5M01RR00722] Funding Source: Medline; NHLBI NIH HHS [T32 HL07024-21] Funding Source: Medline; NIA NIH HHS [KO1 AG00561] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Amarenco P, 1996, NEW ENGL J MED, V334, P1216; AMARENCO P, 1992, NEW ENGL J MED, V326, P221, DOI 10.1056/NEJM199201233260402; [Anonymous], 1989, Arch Neurol, V46, P727; Ashraf T, 1996, AM J CARDIOL, V78, P409, DOI 10.1016/S0002-9149(96)00328-1; BOMBARDIER C, 1986, AM J MED, V81, P565, DOI 10.1016/0002-9343(86)90539-5; BOWEN J, 1994, NEUROLOGY, V44, P1961, DOI 10.1212/WNL.44.10.1961; COMESS KA, 1994, J AM COLL CARDIOL, V23, P1598, DOI 10.1016/0735-1097(94)90662-9; CUJEC B, 1991, STROKE, V22, P727, DOI 10.1161/01.STR.22.6.727; DAHL T, 1995, J INTERN MED, V237, P323, DOI 10.1111/j.1365-2796.1995.tb01182.x; DEBELDER MA, 1992, BRIT HEART J, V67, P297; DEROOK FA, 1992, ANN INTERN MED, V117, P922, DOI 10.7326/0003-4819-117-11-922; DESBIENS NA, 1992, J GEN INTERN MED, V7, P131, DOI 10.1007/BF02598001; DIENER HC, 1991, STROKE, V22, P1229; DOBKIN B, 1995, NEUROLOGY, V45, pS6; ECKMAN MH, 1992, CHEST, V102, pS538, DOI 10.1378/chest.102.4_Supplement.538S; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; Fatkin D, 1996, AM J CARDIOL, V77, P321, DOI 10.1016/S0002-9149(97)89406-4; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; GARDE A, 1983, STROKE, V14, P677, DOI 10.1161/01.STR.14.5.677; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; Gold MR, 1996, COST EFFECTIVENESS H; GUSTAFSSON C, 1992, BRIT MED J, V305, P1457, DOI 10.1136/bmj.305.6867.1457; HILLNER BE, 1992, JAMA-J AM MED ASSOC, V267, P2055, DOI 10.1001/jama.267.15.2055; HOFMANN T, 1990, LANCET, V336, P1421; JONES EF, 1993, AUST NZ J MED, V23, P477, DOI 10.1111/j.1445-5994.1993.tb01833.x; KESTLE J, 1989, CLIN RES, V37, pA316; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KUPERSMITH J, 1995, PROG CARDIOVASC DIS, V37, P307, DOI 10.1016/S0033-0620(05)80017-9; KUPERSMITH J, 1995, PROG CARDIOVASC DIS, V37, P243, DOI 10.1016/S0033-0620(05)80009-X; LABOVITZ AJ, 1993, AM J CARDIOL, V72, P1448, DOI 10.1016/0002-9149(93)90195-I; LANDEFELD CS, 1989, AM J MED, V87, P144; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; Lee AJ, 1996, MED CARE, V34, P811, DOI 10.1097/00005650-199608000-00008; LEUNG DY, 1995, STROKE, V26, P1820, DOI 10.1161/01.STR.26.10.1820; MAGAR DS, 1995, CANADIAN J CLIN PHAR, V2, P109; MANNING WJ, 1995, ANN INTERN MED, V123, P817, DOI 10.7326/0003-4819-123-11-199512010-00001; MATCHAR DB, 1994, ANN INTERN MED, V121, P41, DOI 10.7326/0003-4819-121-1-199407010-00008; MATCHAR DB, 1987, JAMA-J AM MED ASSOC, V258, P793, DOI 10.1001/jama.258.6.793; Matsumoto N, 1973, STROKE, V4, P20, DOI 10.1161/01.STR.4.1.20; MILLS E, 1978, NEW ENGL J MED, V299, P415, DOI 10.1056/NEJM197808242990810; NAGLIE IG, 1992, MED DECIS MAKING, V12, P239, DOI 10.1177/0272989X9201200401; OSTER G, 1994, STROKE, V25, P1149, DOI 10.1161/01.STR.25.6.1149; PEARSON AC, 1991, J AM COLL CARDIOL, V17, P66, DOI 10.1016/0735-1097(91)90705-E; Persson U, 1990, Int J Technol Assess Health Care, V6, P125; POP G, 1990, STROKE, V21, P560, DOI 10.1161/01.STR.21.4.560; SACCO RL, 1982, STROKE, V13, P290, DOI 10.1161/01.STR.13.3.290; SACCO RL, 1989, STROKE, V20, P983, DOI 10.1161/01.STR.20.8.983; SANSOY V, 1995, AM J CARDIOL, V75, P166, DOI 10.1016/S0002-9149(00)80068-5; Seto TB, 1997, J AM COLL CARDIOL, V29, P122, DOI 10.1016/S0735-1097(96)00448-2; SHYU KG, 1994, CARDIOLOGY, V85, P53, DOI 10.1159/000176646; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; TERENT A, 1994, STROKE, V25, P2363, DOI 10.1161/01.STR.25.12.2363; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; *US AG HLTH CAR PO, 1995, AHCPR PUBL; Whisnant JP, 1971, STROKE, V2, P11, DOI 10.1161/01.STR.2.1.11	57	74	77	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					775	+		10.7326/0003-4819-127-9-199711010-00001	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD898	9382398				2022-12-24	WOS:A1997YD89800001
J	Stephens, L; Anderson, K; Stokoe, D; Erdjument-Bromage, H; Painter, GF; Holmes, AB; Gaffney, PRJ; Reese, CB; McCormick, F; Tempst, P; Coadwell, J; Hawkins, PT				Stephens, L; Anderson, K; Stokoe, D; Erdjument-Bromage, H; Painter, GF; Holmes, AB; Gaffney, PRJ; Reese, CB; McCormick, F; Tempst, P; Coadwell, J; Hawkins, PT			Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B	SCIENCE			English	Article							3-KINASE; AKT; PHOSPHATIDYLINOSITOL(3,4,5)-TRISPHOSPHATE; EGF	Protein kinase B (PKB) is activated in response to phosphoinositide 3-kinases and their lipid products phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P-3] and PtdIns(3,4)P-2 in the signaling pathways used by a wide variety of growth factors, antigens, and inflammatory stimuli. PKB is a direct target of these lipids, but this regulation is complex. The lipids can bind to the pleckstrin homologqus domain of PKB, causing its translocation to the membrane, and also enable upstream, Thr(308)-directed kinases to phosphorylate and activate PKB. Four isoforms of these PKB kinases were purified from sheep brain. They bound PtdIns(3,4,5)P-3 and associated with lipid vesicles containing ii. These kinases contain an NH2-terminal catalytic domain and a COOH-terminal pleckstrin homologous domain, and their heterologous expression augments receptor activation of PKB, which suggests they are the primary signal transducers that enable PtdIns(3,4,5)P-3 or PtdIns(3,4)P-2 to activate PKB and hence to control signaling pathways regulating cell survival, glucose uptake, and glycogen metabolism.	Babraham Inst, Inositide Lab, Cambridge CB2 4AT, England; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ London Kings Coll, Dept Chem, London WC2R 2LS, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center; University of Cambridge; University of London; King's College London	Stephens, L (corresponding author), Babraham Inst, Inositide Lab, Cambridge CB2 4AT, England.	len.stephens@bbsrc.ac.uk		stephens, len/0000-0002-2771-3487; Hawkins, Phillip/0000-0002-6979-0464; Anderson, Karen/0000-0002-7394-6660; Erdjument-Bromage, Hediye/0000-0003-0224-3594	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANDERSON K, UNPUB; BALLACOSA A, 1993, ONCOGENE, V8, P745; BUNN TC, 1996, GENOME RES, V6, P525; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STEPHENS LR, UNPUB; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKER A, 1994, J BIOL CHEM, V269, P32358	25	899	941	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	1998	279	5351					710	714		10.1126/science.279.5351.710	http://dx.doi.org/10.1126/science.279.5351.710			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445477				2022-12-24	WOS:000071731500038
J	Weiss, RA				Weiss, RA			Transgenic pigs and virus adaptation	NATURE			English	Editorial Material							ACCELERATING FACTOR CD55; HUMAN-SERUM; CELLS; PROTEINS; RECEPTOR; CD46		Inst Canc Res, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Weiss, RA (corresponding author), Inst Canc Res, 237 Fulham Rd, London SW3 6JB, England.							BERGELSON JM, 1995, J VIROL, V69, P1903, DOI 10.1128/JVI.69.3.1903-1906.1995; Darrieussecq Marie, 1997, PIG TALES; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Dorling A, 1997, LANCET, V349, P867, DOI 10.1016/S0140-6736(96)09404-4; LeTissier P, 1997, NATURE, V389, P681, DOI 10.1038/39489; McMorrow IM, 1997, TRANSPLANTATION, V64, P501, DOI 10.1097/00007890-199708150-00021; Meng XJ, 1997, P NATL ACAD SCI USA, V94, P9860, DOI 10.1073/pnas.94.18.9860; MONTEFIORI DC, 1994, VIROLOGY, V205, P82, DOI 10.1006/viro.1994.1622; Murphy FA, 1996, SCIENCE, V273, P746, DOI 10.1126/science.273.5276.746; OSullivan JD, 1997, LANCET, V349, P93, DOI 10.1016/S0140-6736(96)06162-4; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; ROTHER RP, 1995, J EXP MED, V182, P1345, DOI 10.1084/jem.182.5.1345; SAIFUDDIN M, 1995, J EXP MED, V182, P501, DOI 10.1084/jem.182.2.501; Stoiber H, 1996, J EXP MED, V183, P307, DOI 10.1084/jem.183.1.307; Takeuchi Y, 1997, J VIROL, V71, P6174, DOI 10.1128/JVI.71.8.6174-6178.1997; Takeuchi Y, 1996, NATURE, V379, P85, DOI 10.1038/379085a0; VAUGHAN HA, 1994, TRANSPLANTATION, V58, P879, DOI 10.1097/00007890-199410270-00003; WARD T, 1994, EMBO J, V13, P5070, DOI 10.1002/j.1460-2075.1994.tb06836.x; WELSH RM, 1975, NATURE, V257, P612, DOI 10.1038/257612a0; White D, 1996, TRENDS BIOTECHNOL, V14, P3, DOI 10.1016/0167-7799(96)80906-1	20	139	142	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					327	328		10.1038/34772	http://dx.doi.org/10.1038/34772			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450739	Bronze			2022-12-24	WOS:000071604200022
J	Bais, C; Santomasso, B; Coso, O; Arvanitakis, L; Raaka, EG; Gutkind, JS; Asch, AS; Cesarman, E; Gerhengorn, MC; Mesri, EA				Bais, C; Santomasso, B; Coso, O; Arvanitakis, L; Raaka, EG; Gutkind, JS; Asch, AS; Cesarman, E; Gerhengorn, MC; Mesri, EA			G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; DNA-SEQUENCES; CELLS; EXPRESSION; VIRUS	The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8) is a gamma-2 herpesvirus(1-5) that is implicated in the pathogenesis of Kaposi's sarcoma(1,5) and of primary effusion B-cell lymphomas (PELs)(6). KSHV infects malignant and progenitor cells of Kaposi's sarcoma(7) and PEL2,6,8, it encodes putative oncogenes(4,5,9) and genes that may cause Kaposi's sarcoma pathogenesis by stimulating angiogenesis(4,5,9,10). The G-protein-coupled receptor encoded by an open reading frame (ORF 74) of KSHV9 is expressed in Kaposi's sarcoma lesions and in PEL9,11 and stimulates signalling pathways linked to cell proliferation(12) in a constitutive (agonist-independent) way(12). Here we show that signalling by this KSHV G-protein-coupled receptor leads to cell transformation and tumorigenicity, and induces a switch to an angiogenic phenotype(13) mediated by vascular endothelial growth factor(14), an angiogenesis(13,14) and Kaposi's-spindle-cell growth factor(15-17). We find that this receptor can activate two protein kinases, JNK/SAPK and p38MAPK, by triggering signalling cascades like those induced by inflammatory cytokines(18) that are angiogenesis activators(19) and mitogens for Kaposi's sarcoma cells(10) and B cells. We conclude that the KSHV G-protein-coupled receptor is a viral oncogene that can exploit cell signalling pathways to induce transformation and angiogenesis in KSHV-mediated oncogenesis.	Cornell Univ, Coll Med, Lab Viral Oncogenesis, New York, NY 10021 USA; Cornell Univ, Coll Med, Div Hematol Oncol, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Med, Div Mol Med, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Pathol, New York, NY 10021 USA; NIDR, Mol Signaling Unit, Cellular Dev & Oncol Lab, NIH, Bethesda, MD 20892 USA	Cornell University; Cornell University; Cornell University; Cornell University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Mesri, EA (corresponding author), Cornell Univ, Coll Med, Lab Viral Oncogenesis, New York, NY 10021 USA.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; Santomasso, Bianca/0000-0001-9423-4059				Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; ARVANITAKIS L, 1996, BLOOD, V86, P2708; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Boshoff C, 1997, CURR OPIN INFECT DIS, V10, P26, DOI 10.1097/00001432-199702000-00007; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Cornali E, 1996, AM J PATHOL, V149, P1851; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; Ferrara N, 1996, EUR J CANCER, V32A, P2413, DOI 10.1016/S0959-8049(96)00387-5; GOTO F, 1993, LAB INVEST, V69, P508; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HANAHAN D, 1996, CELL, V86, P356; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOLCH W, 1995, BREAST CANCER RES TR, V36, P139, DOI 10.1007/BF00666036; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; Mesri EA, 1996, J EXP MED, V183, P2385, DOI 10.1084/jem.183.5.2385; MESRI EA, 1995, CIRC RES, V76, P161, DOI 10.1161/01.RES.76.2.161; MONTESANO R, 1993, J CELL SCI, V105, P1013; Nakamura S, 1997, J IMMUNOL, V158, P4992; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RAAKA EG, UNPUB J EXP MED; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; RUSSO JJ, 1997, P NATL ACAD SCI USA, V93, P14862; SAMANIEGO F, 1995, J IMMUNOL, V154, P3582; VANSANDE J, 1995, J CLIN ENDOCR METAB, V80, P2577, DOI 10.1210/jc.80.9.2577	30	685	710	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					86	89		10.1038/34193	http://dx.doi.org/10.1038/34193			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422510				2022-12-24	WOS:000071326100054
J	Ricote, M; Li, AC; Willson, TM; Kelly, CJ; Glass, CK				Ricote, M; Li, AC; Willson, TM; Kelly, CJ; Glass, CK			The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation	NATURE			English	Article							INTERFERON-GAMMA; EXPRESSION; GENE; CELLS; METALLOPROTEINASES; LIPOPOLYSACCHARIDE; COLLAGENASE; LIGAND; J(2); AP-1	The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a member of the nuclear receptor superfamily of ligand-dependent transcription factors that is predominantly expressed in adipose tissue, adrenal gland and spleen(1-3). PPAR-gamma has been demonstrated to regulate adipocyte differentiation and glucose homeostasis in response to several structurally distinct compounds, including thiazolidinediones and fibrates(3-6). Naturally occurring compounds such as fatty acids and the prostaglandin D-2 metabolite 15-deoxy-Delta(12,14) prostaglandin J(2) (15d-PGJ(2)) bind to PPAR-gamma and stimulate transcription of target genes(7-10). Prostaglandin D-2 metabolites have not yet been identified in adipose tissue, but are major products of arachidonic-acid metabolism in macrophages(11), raising the possibility that they might serve as endogenous PPAR-gamma ligands in this cell type, Here we show that PPAR-gamma is markedly upregulated in activated macrophages and inhibits the expression of the inducible nitric oxide synthase, gelatinase B and scavenger receptor A genes in response to 15d-PGJ(2) and synthetic PPAR-gamma ligands, PPAR-gamma inhibits gene expression in part by antagonizing the activities of the transcription factors AP-1, STAT and NF-kappa B, These observations suggest that PPAR-gamma and locally produced prostaglandin D-2 metabolites are involved in the regulation of inflammatory responses, and raise the possibility that synthetic PPAR-gamma ligands may be of therapeutic value in human diseases such as atherosclerosis and rheumatoid arthritis in which activated macrophages exert pathogenic effects.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Glaxo Wellcome Inc, Res & Dev, Dept Med Chem, Res Triangle Pk, NC 27709 USA; San Diego Vet Affairs Med Ctr, Div Cellular & Mol Med, La Jolla, CA 92161 USA; San Diego Vet Affairs Med Ctr, Div Endocrinol & Metab, La Jolla, CA 92161 USA; San Diego Vet Affairs Med Ctr, Div Cardiol, La Jolla, CA 92161 USA; San Diego Vet Affairs Med Ctr, Div Nephrol, La Jolla, CA 92161 USA	University of California System; University of California San Diego; GlaxoSmithKline	Glass, CK (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Ricote, Mercedes/L-4615-2014; feinstein, doug/M-9414-2019; Glass, Christopher/AAI-3933-2021	Ricote, Mercedes/0000-0002-8090-8902; Glass, Christopher/0000-0003-4344-3592				AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Greene M. E., 1995, Gene Expression, V4, P281; Hawke RL, 1997, J LIPID RES, V38, P1189; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P8730; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; SATO H, 1993, ONCOGENE, V8, P395; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; URADE Y, 1989, J IMMUNOL, V143, P2982; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Zhu Y, 1996, MOL CELL BIOL, V16, P4808	27	3082	3243	4	172	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					79	82		10.1038/34178	http://dx.doi.org/10.1038/34178			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422508				2022-12-24	WOS:000071326100052
J	Nightingale, SL				Nightingale, SL			Final standards for mammography facilities issued	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1728	1728						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388135				2022-12-24	WOS:A1997YH98700009
J	Lambert, ML; Francois, I; Salort, C; Slypen, V; Bertrand, F; Tonglet, R				Lambert, ML; Francois, I; Salort, C; Slypen, V; Bertrand, F; Tonglet, R			Household survey of locomotor disability caused by poliomyelitis and landmines in Afghanistan	BRITISH MEDICAL JOURNAL			English	Article									HANDICAP INT BELGIUM,B-1040 BRUSSELS,BELGIUM; HANDICAP INT AFGHANISTAN,QUETTA,PAKISTAN		Lambert, ML (corresponding author), UNIV CATHOLIQUE LOUVAIN,SCH PUBL HLTH,EPIDEMIOL UNIT,CLOS CHAPELLE AUX CHAMPS 30,UCL 30-34,B-1200 BRUSSELS,BELGIUM.							ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; BERNIER R, 1984, EPIGEN843 WHO; KALSBEEK W, 1995, EPI INFO VERSON 6 WO; *MIN CLEAR PLANN A, 1993, REP NAT SURV MIN SIT; *WHO, 1992, EXP PROGR IMM EPI CO	5	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1424	1425		10.1136/bmj.315.7120.1424	http://dx.doi.org/10.1136/bmj.315.7120.1424			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418091	Green Published			2022-12-24	WOS:A1997YJ67200027
J	Cui, JQ; Shin, T; Kawano, T; Sato, H; Kondo, E; Toura, I; Kaneko, Y; Koseki, H; Kanno, M; Taniguchi, M				Cui, JQ; Shin, T; Kawano, T; Sato, H; Kondo, E; Toura, I; Kaneko, Y; Koseki, H; Kanno, M; Taniguchi, M			Requirement for V(alpha)14 NKT cells in IL-12-mediated rejection of tumors	SCIENCE			English	Article							RECEPTOR-ALPHA-CHAIN; LYMPHOCYTE MATURATION FACTOR; ANTI-MELANOMA ANTIBODY; IFN-GAMMA PRODUCTION; CLASS-I MOLECULES; BETA T-CELLS; HETERODIMERIC CYTOKINE; STIMULATORY FACTOR; LIVER METASTASIS; THYMOCYTES	A lymphocyte subpopulation, the V(alpha)14 natural killer T (NKT) cells, expresses both NK1.1 and a single invariant T cell receptor encoded by the V(alpha)14 and J(alpha)281 gene segments, Mice with a deletion of the J(alpha)281 gene segment were found to exclusively lack this subpopulation. The V(alpha)14 NKT cell-deficient mice could no longer mediate the interleukin-12 (IL-12)-induced rejection of tumors. Although the antitumor effect of IL-12 Was thought to be mediated through natural killer cells and T cells, V(alpha)14 NKT cells were found to be an essential target of IL-12, and they mediated their cytotoxicity by an NK-like effector mechanism after activation with IL-12.	CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV MOL IMMUNOL,CHUO KU,CHIBA 260,JAPAN; JAPAN SCI & TECHNOL CORP,CORE RES EVOL SCI & TECHNOL,TOKYO,JAPAN	Chiba University; Japan Science & Technology Agency (JST)			Taniguchi, Masaru/N-7932-2015; Koseki, Haruhiko/I-3825-2014	Taniguchi, Masaru/0000-0001-7821-7179; Koseki, Haruhiko/0000-0001-8424-5854; Kanno, masamoto/0000-0001-9169-3444				Akasaka T, 1996, DEVELOPMENT, V122, P1513; Ando K, 1997, J IMMUNOL, V158, P5283; BALLAS ZK, 1990, J IMMUNOL, V145, P1039; BARBERAGUILLEM E, 1989, CANCER RES, V49, P4003; BENDELAC A, 1994, SCIENCE, V263, P1774, DOI 10.1126/science.7907820; BIX M, 1993, J EXP MED, V178, P901, DOI 10.1084/jem.178.3.901; BRUNDA MJ, 1993, J EXP MED, V178, P1223, DOI 10.1084/jem.178.4.1223; BRUNDA MJ, 1984, INT J CANCER, V34, P421, DOI 10.1002/ijc.2910340321; BUDD RC, 1987, J EXP MED, V166, P577, DOI 10.1084/jem.166.2.577; CHEN LK, 1986, EUR J IMMUNOL, V16, P767, DOI 10.1002/eji.1830160709; FOWLKES BJ, 1987, NATURE, V329, P251, DOI 10.1038/329251a0; GATELY MK, 1991, J IMMUNOL, V147, P874; GUNJI Y, 1986, JPN J CANCER RES, V77, P595; HASHIMOTO W, 1995, J IMMUNOL, V154, P4333; IMAI K, 1986, P NATL ACAD SCI USA, V83, P8708, DOI 10.1073/pnas.83.22.8708; Kataoka T, 1996, J IMMUNOL, V156, P3678; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; KOPPER L, 1982, J CANCER RES CLIN, V103, P31, DOI 10.1007/BF00410303; KOSEKI H, 1990, P NATL ACAD SCI USA, V87, P5248, DOI 10.1073/pnas.87.14.5248; KOYASU S, 1992, J EXP MED, V175, P203, DOI 10.1084/jem.175.1.203; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; LEVITSKY HI, 1991, J IMMUNOL, V146, P1113; MAKINO Y, 1993, J EXP MED, V177, P1399, DOI 10.1084/jem.177.5.1399; MAKINO Y, 1995, INT IMMUNOL, V7, P1157, DOI 10.1093/intimm/7.7.1157; Makino Y, 1996, P NATL ACAD SCI USA, V93, P6516, DOI 10.1073/pnas.93.13.6516; MARASKOVSKY E, 1989, J IMMUNOL, V143, P1210; Masuda K, 1997, J IMMUNOL, V158, P2076; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NASTALA CL, 1994, J IMMUNOL, V153, P1697; NORES GA, 1987, J IMMUNOL, V139, P3171; OHTEKI T, 1994, J EXP MED, V180, P699, DOI 10.1084/jem.180.2.699; SCHOENHAUT DS, 1992, J IMMUNOL, V148, P3433; STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808; SYKES M, 1990, J IMMUNOL, V145, P3209; TAKAHAMA Y, 1991, J IMMUNOL, V146, P1134; Takahashi M, 1996, J IMMUNOL, V156, P2436; Taniguchi M, 1996, P NATL ACAD SCI USA, V93, P11025, DOI 10.1073/pnas.93.20.11025; Tardif M, 1996, INT J CANCER, V68, P97, DOI 10.1002/(SICI)1097-0215(19960927)68:1<97::AID-IJC17>3.0.CO;2-3; Teicher BA, 1996, INT J CANCER, V65, P80, DOI 10.1002/(SICI)1097-0215(19960103)65:1<80::AID-IJC14>3.0.CO;2-M; WAKABAYASHI S, 1981, NATURE, V294, P748, DOI 10.1038/294748a0; WAKABAYASHI S, 1984, JPN J CANCER RES, V75, P427; WEIGENT DA, 1983, BIOCHEM BIOPH RES CO, V111, P525, DOI 10.1016/0006-291X(83)90338-8; WOLF SF, 1991, J IMMUNOL, V146, P3074; ZOU JP, 1995, INT IMMUNOL, V7, P1135, DOI 10.1093/intimm/7.7.1135	45	1091	1128	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1623	1626		10.1126/science.278.5343.1623	http://dx.doi.org/10.1126/science.278.5343.1623			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374462				2022-12-24	WOS:A1997YJ87400041
J	Grassme, H; Gulbins, E; Brenner, B; Ferlinz, K; Sandhoff, K; Harzer, K; Lang, F; Meyer, TF				Grassme, H; Gulbins, E; Brenner, B; Ferlinz, K; Sandhoff, K; Harzer, K; Lang, F; Meyer, TF			Acidic sphingomyelinase mediates entry of N-gonorrhoeae into nonphagocytic cells	CELL			English	Article							HUMAN EPITHELIAL-CELLS; CULTURED-MAMMALIAN-CELLS; NEISSERIA-GONORRHOEAE; SIGNALING PATHWAY; HEPARAN-SULFATE; INDUCED APOPTOSIS; BACTERIAL ENTRY; TYROSINE PHOSPHORYLATION; SALMONELLA-TYPHIMURIUM; SHIGELLA-FLEXNERI	Invasion of human mucosal cells by N. gonorrhoeae via the binding to heparansulfate proteoglycan receptors is considered a crucial event of the infection. Using different human epithelial cells and primary fibroblasts, we show here an activation of the phosphatidylcholine-specific phospholipase C (PC-PLC) and acidic sphingomyelinase (ASM) by N. gonorrhoeae, resulting in the release of diacylglycerol and ceramide. Genetic and/or pharmacological blockade of ASM and PC-PLC cause inhibition of cellular invasion by N. gonorrhoeae. Complementation of ASM-deficient fibroblasts from Niemann-Pick disease patients restored N. gonorrhoeae-induced signaling and entry processes. The activation of PC-PLC and ASM, therefore, is an essential requirement for the entry of N. gonorrhoeae into distinct nonphagocytic human cell types including several epithelial cells and primary fibroblasts.	MAX PLANCK INST BIOL,INFEKT BIOL ABT,D-72076 TUBINGEN,GERMANY; MAX PLANCK INST INFEKT BIOL,MOL BIOL ABT,D-10117 BERLIN,GERMANY; UNIV TUBINGEN,INST PHYSIOL,D-72076 TUBINGEN,GERMANY; UNIV TUBINGEN,INST HIRNFORSCH,D-72070 TUBINGEN,GERMANY; UNIV BONN,D-53121 BONN,GERMANY	Max Planck Society; Max Planck Society; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; University of Bonn			Meyer, Thomas F. F/J-2485-2013; Gulbins, Erich/L-6989-2014	Meyer, Thomas F. F/0000-0002-6120-8679; Gulbins, Erich/0000-0002-3117-1342				Adam T, 1996, EMBO J, V15, P3315, DOI 10.1002/j.1460-2075.1996.tb00696.x; Apicella MA, 1996, J INFECT DIS, V173, P636, DOI 10.1093/infdis/173.3.636; BESSEN D, 1986, INFECT IMMUN, V54, P154, DOI 10.1128/IAI.54.1.154-160.1986; BHAT KS, 1991, MOL MICROBIOL, V6, P1073; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; Bos MP, 1997, INFECT IMMUN, V65, P2353, DOI 10.1128/IAI.65.6.2353-2361.1997; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; BRADY RO, 1966, P NATL ACAD SCI USA, V55, P366, DOI 10.1073/pnas.55.2.366; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; CHEN T, 1995, J EXP MED, V182, P511, DOI 10.1084/jem.182.2.511; Chen T, 1996, P NATL ACAD SCI USA, V93, P14851, DOI 10.1073/pnas.93.25.14851; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; COMPTON T, 1993, VIROLOGY, V193, P834, DOI 10.1006/viro.1993.1192; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; Duensing TD, 1997, INFECT IMMUN, V65, P964, DOI 10.1128/IAI.65.3.964-970.1997; Fussenegger M, 1996, MOL MICROBIOL, V19, P1357, DOI 10.1111/j.1365-2958.1996.tb02479.x; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; GomezDuarte OG, 1997, INFECT IMMUN, V65, P3857; GOTSCHLICH EC, 1987, P NATL ACAD SCI USA, V84, P8135, DOI 10.1073/pnas.84.22.8135; Grassme HUC, 1996, INFECT IMMUN, V64, P1621; GrayOwen SD, 1997, EMBO J, V16, P3435, DOI 10.1093/emboj/16.12.3435; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hedlund M, 1996, J EXP MED, V183, P1037, DOI 10.1084/jem.183.3.1037; Higuchi M, 1996, J IMMUNOL, V157, P297; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; HURWITZ R, 1994, BIOL CHEM H-S, V375, P447, DOI 10.1515/bchm3.1994.375.7.447; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISSACS RD, 1994, J CLIN INVEST, V93, P809; KISS Z, 1995, BBA-LIPID LIPID MET, V1259, P105, DOI 10.1016/0005-2760(95)00148-6; KUPSCH EM, 1993, EMBO J, V12, P641, DOI 10.1002/j.1460-2075.1993.tb05697.x; LAMBDEN PR, 1979, J GEN MICROBIOL, V114, P305, DOI 10.1099/00221287-114-2-305; LIANG OD, 1992, INFECT IMMUN, V60, P899, DOI 10.1128/IAI.60.3.899-906.1992; MAKINO S, 1991, EMBO J, V10, P1307, DOI 10.1002/j.1460-2075.1991.tb07649.x; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MCGEE ZA, 1983, REV INFECT DIS, V5, P708; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; PARUCHURI DK, 1990, P NATL ACAD SCI USA, V87, P333, DOI 10.1073/pnas.87.1.333; ROSENSHINE I, 1992, EMBO J, V11, P3551, DOI 10.1002/j.1460-2075.1992.tb05438.x; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; RUDEL T, 1992, MOL MICROBIOL, V6, P3439, DOI 10.1111/j.1365-2958.1992.tb02211.x; RUDEL T, 1995, NATURE, V373, P357, DOI 10.1038/373357a0; Rudel T, 1996, CELL, V85, P391, DOI 10.1016/S0092-8674(00)81117-4; SAUER G, 1984, P NATL ACAD SCI-BIOL, V81, P3263, DOI 10.1073/pnas.81.11.3263; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; STERN A, 1986, CELL, V47, P61, DOI 10.1016/0092-8674(86)90366-1; SWANSON J, 1988, J EXP MED, V168, P2121, DOI 10.1084/jem.168.6.2121; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; VANPUTTEN JPM, 1993, EMBO J, V12, P4043, DOI 10.1002/j.1460-2075.1993.tb06088.x; VANPUTTEN JPM, 1995, EMBO J, V14, P2144, DOI 10.1002/j.1460-2075.1995.tb07208.x; VANPUTTEN JPM, 1990, J MED MICROBIOL, V33, P35, DOI 10.1099/00222615-33-1-35; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Virji M, 1996, MOL MICROBIOL, V22, P941, DOI 10.1046/j.1365-2958.1996.01551.x; VIRJI M, 1984, J GEN MICROBIOL, V130, P1089; Watarai M, 1996, J EXP MED, V183, P991, DOI 10.1084/jem.183.3.991; WEEL JFL, 1991, J EXP MED, V174, P705, DOI 10.1084/jem.174.3.705; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; ZHANG JP, 1992, CELL, V69, P861, DOI 10.1016/0092-8674(92)90296-O	64	246	255	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					605	615		10.1016/S0092-8674(00)80448-1	http://dx.doi.org/10.1016/S0092-8674(00)80448-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393854	Green Published, Bronze			2022-12-24	WOS:A1997YH96000008
J	Plautz, JD; Kaneko, M; Hall, JC; Kay, SA				Plautz, JD; Kaneko, M; Hall, JC; Kay, SA			Independent photoreceptive circadian clocks throughout Drosophila	SCIENCE			English	Article							PERIOD GENE; BEHAVIORAL RHYTHMS; MELANOGASTER; EXPRESSION; SYSTEM; MUTANTS; CELLS; LIGHT; HEAD; TIME	Transgenic Drosophila that expressed either luciferase or green fluorescent protein driven From the promoter of the clock gene period were used lo monitor the circadian clock in explanted head, thorax, and abdominal tissues. The tissues (including sensory bristles in the leg and wing) showed rhythmic bioluminescence, and the rhythms could be reset by light, The photoreceptive properties of the explanted tissues indicate that unidentified photoreceptors are likely to contribute to photic signal transduction to the clock. These results show that autonomous circadian oscillators are present throughout the body, and they suggest that individual cells in Drosophila are capable of supporting their own independent clocks.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, NATL SCI FDN, CTR BIOL TIMING, LA JOLLA, CA 92037 USA; BRANDEIS UNIV, DEPT BIOL, WALTHAM, MA 02254 USA; BRANDEIS UNIV, NATL SCI FDN, CTR BIOL TIMING, WALTHAM, MA 02254 USA	Scripps Research Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Scripps Research Institute; Brandeis University; Brandeis University; National Science Foundation (NSF); NSF - Center for Biological Timing			Weydahl, Andi/C-6391-2008; Kay, Steve A/F-6025-2011	Kay, Steve A/0000-0002-0402-2878; Kaneko, Maki/0000-0002-2489-6185	NIMH NIH HHS [MH-51573] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051573] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARGAMASO SM, 1995, BIOPHYS CHEM, V56, P3, DOI 10.1016/0301-4622(95)00009-M; Brandes C, 1996, NEURON, V16, P687, DOI 10.1016/S0896-6273(00)80088-4; Emery IF, 1997, P NATL ACAD SCI USA, V94, P4092, DOI 10.1073/pnas.94.8.4092; EWER J, 1992, J NEUROSCI, V12, P3321; GIEBULTOWICZ JM, 1989, SCIENCE, V245, P1098, DOI 10.1126/science.245.4922.1098; Giebultowicz JM, 1997, NATURE, V386, P664, DOI 10.1038/386664a0; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HANDLER AM, 1979, NATURE, V279, P236, DOI 10.1038/279236a0; HARDIN PE, 1994, MOL CELL BIOL, V14, P7211, DOI 10.1128/MCB.14.11.7211; Hege DM, 1997, J BIOL RHYTHM, V12, P300, DOI 10.1177/074873049701200402; Ito K, 1997, CELL TISSUE RES, V290, P1, DOI 10.1007/s004410050901; JOHNSON RF, 1988, BRAIN RES, V460, P297, DOI 10.1016/0006-8993(88)90374-5; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LIU X, 1988, GENE DEV, V2, P228, DOI 10.1101/gad.2.2.228; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MARTINEZGOMEZ M, 1994, PHYSIOL BEHAV, V55, P651, DOI 10.1016/0031-9384(94)90040-X; MCMILLAN JP, 1975, J COMP PHYSIOL, V102, P251, DOI 10.1007/BF01464359; MENAKER M, 1996, CIRCADIAN ORG OSCILL, P39; OKEEFE LP, 1987, PHYSIOL BEHAV, V41, P193, DOI 10.1016/0031-9384(87)90353-2; Plautz JD, 1997, J BIOL RHYTHM, V12, P204, DOI 10.1177/074873049701200302; Plautz JD, 1996, GENE, V173, P83, DOI 10.1016/0378-1119(95)00700-8; POWER J, 1995, J NEUROGENET, V9, P227, DOI 10.3109/01677069509084159; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; Sehgal A, 1996, MOL CELL NEUROSCI, V7, P165, DOI 10.1006/mcne.1996.0013; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; Stanewsky R, 1997, EMBO J, V16, P5006, DOI 10.1093/emboj/16.16.5006; STOCKER RF, 1994, CELL TISSUE RES, V275, P3, DOI 10.1007/BF00305372; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAKAHASHI JS, 1982, J COMP PHYSIOL, V146, P245, DOI 10.1007/BF00610244; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TRUMAN JW, 1974, J COMP PHYSIOL, V95, P281, DOI 10.1007/BF00609702; TRUMAN JW, 1972, J COMP PHYSIOL, V81, P99, DOI 10.1007/BF00693553; VanGelder RN, 1995, CURR BIOL, V5, P1424, DOI 10.1016/S0960-9822(95)00280-6; VanGelder RN, 1996, EMBO J, V15, P1625, DOI 10.1002/j.1460-2075.1996.tb00507.x; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106	39	505	514	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1632	1635		10.1126/science.278.5343.1632	http://dx.doi.org/10.1126/science.278.5343.1632			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9374465				2022-12-24	WOS:A1997YJ87400044
J	Rao, PM; Rhea, JT; Novelline, RA; Mostafavi, AA; McCabe, CJ				Rao, PM; Rhea, JT; Novelline, RA; Mostafavi, AA; McCabe, CJ			Effect of computed tomography of the appendix on treatment of patients and use of hospital resources	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIAGNOSIS; EMERGENCY; CT; APPENDECTOMY; ACCURACY	Background In patients with clinically suspected appendicitis, computed tomography (CT) is diagnostically accurate. However, the effect of routine CT of the appendix on the treatment of such patients and the use of hospital resources is unknown. Method's We performed appendiceal CT on 100 consecutive patients in the emergency department who, on the basis of history, physical examination, and laboratory results, were to be hospitalized for observation for suspected appendicitis or for urgent appendectomy. Outcomes were determined at surgery and by pathological examination in 59 patients, and by clinical follow-up two months later in 41 patients. Treatment plans made before CT were compared with the patients' actual treatment, We also determined the costs of surgery that revealed no appendicitis (from data on 61 patients), one day of observation in the hospital (from data on 350 patient-days in patients with suspected appendicitis), and appendiceal CT (from data on all pelvic CT examinations in 1996). Results Fifty-three patients had appendicitis, and 47 did not. The interpretations of the appendiceal CT scans were 98 percent accurate. The results of CT led to changes in the treatment of 59 patients. These changes resulted in the prevention of unnecessary appendectomy in 13 patients, admission to the hospital for observation in 18 patients, admission to the hospital for observation before necessary appendectomy in 21 patients, and admission to the hospital for observation before the diagnosis of other conditions by CT in 11 patients. The effects of performing appendiceal CT on the use of hospital resources included the prevention of unnecessary appendectomy in 13 patients (for a savings of $47,281) and the prevention of unnecessary hospital admission for 50 patient-days (for a savings of $20,250). After the cost of 100 appendiceal CT studies ($22,800) was subtracted, the overall savings was $447 per patient. Conclusions Routine appendiceal CT performed in patients who present with suspected appendicitis improves patient care and reduces the use of hospital resources. (C) 1998, Massachusetts Medical Society.	Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Rao, PM (corresponding author), Massachusetts Gen Hosp, Dept Radiol, 32 Fruit St, Boston, MA 02114 USA.							ADDISS DG, 1990, AM J EPIDEMIOL, V132, P910, DOI 10.1093/oxfordjournals.aje.a115734; BALTHAZAR EJ, 1994, RADIOLOGY, V190, P31, DOI 10.1148/radiology.190.1.8259423; BALTHAZAR EJ, 1991, RADIOLOGY, V180, P21, DOI 10.1148/radiology.180.1.2052696; CALDER JDF, 1995, BRIT J HOSP MED, V54, P129; Cohen M M, 1993, J Laparoendosc Surg, V3, P93, DOI 10.1089/lps.1993.3.93; IZBICKI JR, 1992, EUR J SURG, V158, P227; JESS P, 1981, AM J SURG, V141, P232, DOI 10.1016/0002-9610(81)90164-1; Lane MJ, 1997, AM J ROENTGENOL, V168, P405, DOI 10.2214/ajr.168.2.9016216; LEWIS FR, 1975, ARCH SURG-CHICAGO, V110, P677; MALONE AJ, 1993, AM J ROENTGENOL, V160, P763, DOI 10.2214/ajr.160.4.8456661; MCCALLION J, 1987, AGE AGEING, V16, P256, DOI 10.1093/ageing/16.4.256; OHMANN C, 1995, EUR J SURG, V161, P273; Rao PM, 1997, RADIOLOGY, V202, P139, DOI 10.1148/radiology.202.1.8988203; Rao PM, 1997, AM J ROENTGENOL, V169, P1275, DOI 10.2214/ajr.169.5.9353441; Rao PM, 1997, J COMPUT ASSIST TOMO, V21, P686, DOI 10.1097/00004728-199709000-00002; REYNOLDS SL, 1993, PEDIATR EMERG CARE, V9, P1, DOI 10.1097/00006565-199302000-00002; Rhea JT, 1997, AM J ROENTGENOL, V169, P113, DOI 10.2214/ajr.169.1.9207509; ROTHROCK SG, 1991, ANN EMERG MED, V20, P45, DOI 10.1016/S0196-0644(05)81117-5; Rothrock Steven G., 1995, Journal of Emergency Medicine, V13, P1, DOI 10.1016/0736-4679(94)00104-9; SHUST N, 1993, PEDIATR RADIOL, V23, P289, DOI 10.1007/BF02010917; SIMMEN HP, 1991, HEPATO-GASTROENTEROL, V38, P279; TRAUTLEIN JJ, 1984, ANN EMERG MED, V13, P709, DOI 10.1016/S0196-0644(84)80733-7; VELANOVICH V, 1992, AM SURGEON, V58, P264; WADE DS, 1993, ARCH SURG-CHICAGO, V128, P1039	24	498	511	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 15	1998	338	3					141	146		10.1056/NEJM199801153380301	http://dx.doi.org/10.1056/NEJM199801153380301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ414	9428814				2022-12-24	WOS:000071384500001
J	Lebwohl, M; Tan, MH				Lebwohl, M; Tan, MH			Psoriasis and stress	LANCET			English	Editorial Material									Mt Sinai Med Ctr, Dept Dermatol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Lebwohl, M (corresponding author), Mt Sinai Med Ctr, Dept Dermatol, New York, NY 10029 USA.							FINLAY AY, 1990, BRIT J DERMATOL, V123, P751, DOI 10.1111/j.1365-2133.1990.tb04192.x; Fortune DG, 1997, BRIT J DERMATOL, V137, P755; Fortune DG, 1997, J PSYCHOSOM RES, V42, P467, DOI 10.1016/S0022-3999(97)00036-6; GINSBURG IH, 1993, INT J DERMATOL, V32, P587, DOI 10.1111/j.1365-4362.1993.tb05031.x; Savin J A, 1970, Trans St Johns Hosp Dermatol Soc, V56, P139; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	6	8	8	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					82	82		10.1016/S0140-6736(05)78153-8	http://dx.doi.org/10.1016/S0140-6736(05)78153-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YT341	9439490				2022-12-24	WOS:000071591900007
J	Kisker, C; Schindelin, H; Pacheco, A; Wehbi, WA; Garrett, RM; Rajagopalan, KV; Enemark, JH; Rees, DC				Kisker, C; Schindelin, H; Pacheco, A; Wehbi, WA; Garrett, RM; Rajagopalan, KV; Enemark, JH; Rees, DC			Molecular basis of sulfite oxidase deficiency from the structure of sulfite oxidase	CELL			English	Article							CRYSTAL-STRUCTURE; PROTEIN CRYSTALLOGRAPHY; NITRATE REDUCTASE; CHICKEN LIVER; MOLYBDENUM; DOMAINS; OXIDOREDUCTASE; CYSTEINE-207; PURIFICATION; RESOLUTION	The molybdenum-containing enzyme sulfite oxidase catalyzes the conversion of sulfite to sulfate, the terminal step in the oxidative degradation of cysteine and methionine. Deficiency of this enzyme in humans usually leads to major neurological abnormalities and early death. The crystal structure of chicken liver sulfite oxidase at 1.9 Angstrom resolution reveals that each monomer of the dimeric enzyme consists of three domains. At the active site, the Mo is penta-coordinated by three sulfur ligands, one oxo group, and one water/hydroxo. A sulfate molecule adjacent to the Mo identifies the substrate binding pocket. Four variants associated with sulfite oxidase deficiency have been identified: two mutations are near the sulfate binding site, while the other mutations occur within the domain mediating dimerization.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; Univ Arizona, Dept Chem, Tucson, AZ 85721 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; University of Arizona; Duke University	Kisker, C (corresponding author), CALTECH, Howard Hughes Med Inst, 147-75CH, Pasadena, CA 91125 USA.		Enemark, John/AAQ-4395-2020; Schindelin, Hermann/Q-2697-2019; Kisker, Caroline/T-1724-2019	Kisker, Caroline/0000-0002-0216-6026	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037773, R01GM050775] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37773, GM50775, GM00091] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; CRAMER SP, 1981, J AM CHEM SOC, V103, P7721, DOI 10.1021/ja00416a005; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GARRETT RM, 1994, J BIOL CHEM, V269, P272; GARRETT RM, 1995, BBA-GENE STRUCT EXPR, V1262, P147, DOI 10.1016/0167-4781(95)00068-R; Garrett RM, 1996, J BIOL CHEM, V271, P7387, DOI 10.1074/jbc.271.13.7387; Garton SD, 1997, J AM CHEM SOC, V119, P2590, DOI 10.1021/ja963931c; George GN, 1996, J AM CHEM SOC, V118, P8588, DOI 10.1021/ja961218h; GEORGE GN, 1909, BIOCHEMISTRY-US, V28, P5075; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; HILLE R, 1994, BBA-BIOENERGETICS, V1184, P143, DOI 10.1016/0005-2728(94)90220-8; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; JOHNSON JL, 1977, J BIOL CHEM, V252, P2017; Johnson JL, 1989, METABOLIC BASIS INHE, P1463; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KESSLER DL, 1972, J BIOL CHEM, V247, P6566; KIPKE CA, 1989, ARCH BIOCHEM BIOPHYS, V270, P383, DOI 10.1016/0003-9861(89)90041-6; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; KLEYWEGT GJ, 1994, CCP4 P, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBO Y, 1988, J BIOL CHEM, V263, P19684; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W., 1991, CCP4 STUDY WEEKEND, P80; MATHEWS FS, 1971, COLD SPRING HARB SYM, V36, P387, DOI 10.1101/SQB.1972.036.01.050; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVE C, 1995, RADIAT PHYS CHEM, V45, P483, DOI 10.1016/0969-806X(95)92800-E; Naylor CE, 1996, BLOOD, V87, P2974, DOI 10.1182/blood.V87.7.2974.bloodjournal8772974; NEAME PJ, 1989, J BIOL CHEM, V264, P20894; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1996, METHOD ENZYMOL, P307; RAPPE AK, 1982, J AM CHEM SOC, V104, P448, DOI 10.1021/ja00366a013; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; ROWLAND P, 1994, STRUCTURE, V2, P1073, DOI 10.1016/S0969-2126(94)00110-3; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SOUTHERLAND WM, 1978, J BIOL CHEM, V253, P8747; SULLIVAN EP, 1993, BIOCHEMISTRY-US, V32, P12465, DOI 10.1021/bi00097a026; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8	50	440	445	1	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	1997	91	7					973	983		10.1016/S0092-8674(00)80488-2	http://dx.doi.org/10.1016/S0092-8674(00)80488-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428520	Bronze			2022-12-24	WOS:000071281400014
J	Kozielski, F; Sack, S; Marx, A; Thormahlen, M; Schonbrunn, E; Biou, V; Thompson, A; Mandelkow, EM; Mandelkow, E				Kozielski, F; Sack, S; Marx, A; Thormahlen, M; Schonbrunn, E; Biou, V; Thompson, A; Mandelkow, EM; Mandelkow, E			Phe crystal structure of dimeric kinesin and implications for microtubule-dependent motility	CELL			English	Article							3-DIMENSIONAL STRUCTURE; MOTOR DOMAIN; BETA-TUBULIN; PROTEIN; COMPLEX; ACTIN; MYOSIN; HEAD; NCD; IDENTIFICATION	The dimeric form of the kinesin motor and neck domain from rat brain with bound ADP has been solved by X-ray crystallography. The two heads of the dimer are connected via a coiled-coil alpha-helical interaction of their necks. They are broadly similar to one another; differences are most apparent in the head-neck junction and in a moderate reorientation of the neck helices in order to adopt to the coiled-coil conformation. The heads show a rotational symmetry (similar to 120 degrees) about an axis close to that of the coiled-coil. This arrangement is unexpected since it is not compatible with the microtubule lattice. In this arrangement, the two heads of a kinesin dimer could not have equivalent interactions with microtubules.	DESY, Max Planck Unit Struct Mol Biol, D-22607 Hamburg, Germany; European Synchrotron Radiat Facil, F-38042 Grenoble, France	Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society; European Synchrotron Radiation Facility (ESRF)	Kozielski, F (corresponding author), Inst Biol Struct, 41 Av Martyrs, F-38027 Grenoble, France.			Schonbrunn, Ernst/0000-0002-3589-3510				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOCK SM, 1995, TRENDS CELL BIOL, V5, P169; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; CROSS RA, 1995, J MUSCLE RES CELL M, V16, P91, DOI 10.1007/BF00122526; Doublie S., 1992, CRYSTALLIZATION NUCL, P311; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; Hilgenfeld R, 1995, CURR OPIN STRUC BIOL, V5, P810, DOI 10.1016/0959-440X(95)80015-8; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOENGER A, 1995, NATURE, V376, P271, DOI 10.1038/376271a0; Holmes KC, 1997, CURR BIOL, V7, pR112, DOI 10.1016/S0960-9822(06)00051-0; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; HUNT AJ, 1993, P NATL ACAD SCI USA, V90, P11653, DOI 10.1073/pnas.90.24.11653; Inoue Y, 1997, P NATL ACAD SCI USA, V94, P7275, DOI 10.1073/pnas.94.14.7275; Jiang W, 1997, J BIOL CHEM, V272, P7626, DOI 10.1074/jbc.272.12.7626; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; Kozielski F, 1997, J STRUCT BIOL, V119, P28, DOI 10.1006/jsbi.1997.3872; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; Moyer ML, 1996, BIOCHEMISTRY-US, V35, P6321, DOI 10.1021/bi960017n; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; RAMENT I, 1996, STRUCTURE, V4, P501; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; Tripet B, 1997, J BIOL CHEM, V272, P8946; TTHORMAHLEN M, 1998, IN PRESS J MOL BIOL; TTUCKER C, 1997, J BIOL CHEM, V272, P9481; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; WALKER RA, 1995, P NATL ACAD SCI USA, V92, P5960, DOI 10.1073/pnas.92.13.5960; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0	48	341	350	1	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					985	994		10.1016/S0092-8674(00)80489-4	http://dx.doi.org/10.1016/S0092-8674(00)80489-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428521	Bronze			2022-12-24	WOS:000071281400015
J	Sun, XP; Wahlstrom, J; Karpen, G				Sun, XP; Wahlstrom, J; Karpen, G			Molecular structure of a functional Drosophila centromere	CELL			English	Article							HUMAN Y-CHROMOSOME; ALPHA-SATELLITE DNA; TRANSPOSABLE ELEMENTS; MELANOGASTER HETEROCHROMATIN; SCHIZOSACCHAROMYCES-POMBE; INSITU HYBRIDIZATION; MARKER CHROMOSOME; FISSION YEAST; CENP-C; SEQUENCES	Centromeres play a critical role in chromosome inheritance but are among the most difficult genomic components to analyze in multicellular eukaryotes. Here, we present a highly detailed molecular structure of a functional centromere in a multicellular organism. The centromere of the Drosophila minichromosome Dp1187 is contained within a 420 kb region of centric heterochromatin. We have used a new approach to characterize the detailed structure of this centromere and found that it is primarily composed of satellites and single, complete transposable elements. In the rest of the Drosophila genome, these satellites and transposable elements are neither unique to the centromeres nor present at all centromeres. We discuss the impact of these results on our understanding of heterochromatin structure and on the determinants of centromere identity and function.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	Salk Institute	Karpen, G (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054549] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABAD JP, 1992, P NATL ACAD SCI USA, V89, P4663, DOI 10.1073/pnas.89.10.4663; ALFENITO MR, 1993, GENETICS, V135, P589; AULT JG, 1988, CHROMOSOMA, V97, P71, DOI 10.1007/BF00331796; BONACCORSI S, 1990, CHROMOSOMA, V99, P260, DOI 10.1007/BF01731701; BROWN KE, 1994, HUM MOL GENET, V3, P1227, DOI 10.1093/hmg/3.8.1227; CARMENA M, 1995, CHROMOSOMA, V103, P676; CHARLESWORTH B, 1994, GENET RES, V64, P183, DOI 10.1017/S0016672300032845; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CHOO KH, 1991, NUCLEIC ACIDS RES, V19, P1179, DOI 10.1093/nar/19.6.1179; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE L, 1985, ANNU REV GENET, V19, P29, DOI 10.1146/annurev.genet.19.1.29; CLARKE L, 1990, TRENDS GENET, V6, P150, DOI 10.1016/0168-9525(90)90149-Z; CLARKE L, 1993, COLD SPRING HARB SYM, V58, P687, DOI 10.1101/SQB.1993.058.01.076; Cook KR, 1997, GENETICS, V145, P737; DANILEVSKAYA O, 1994, CHROMOSOMA, V103, P215, DOI 10.1007/s004120050027; Davis PS, 1995, DROSOPH INF SERV, V76, P134; Dernburg AF, 1996, GENETICS, V143, P1629; DEVLIN RH, 1990, GENETICS, V125, P129; DINOCERA PP, 1988, NUCLEIC ACIDS RES, V16, P4041; DINOCERA PP, 1983, J MOL BIOL, V168, P715; DINOCERA PP, 1987, P NATL ACAD SCI USA, V84, P5843; DUSART D, 1997, DNA CELL BIOL, V16, P144; EARNSHAW WC, 1985, CHROMOSOMA, V92, P290, DOI 10.1007/BF00329812; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; FINNEGAN DJ, 1985, INT REV CYTOL, V93, P281, DOI 10.1016/S0074-7696(08)61376-5; FISHEL B, 1988, MOL CELL BIOL, V8, P754, DOI 10.1128/MCB.8.2.754; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GATTI M, 1994, METHOD CELL BIOL, V44, P371, DOI 10.1016/S0091-679X(08)60924-3; GATTI M, 1992, ANNU REV GENET, V26, P239, DOI 10.1146/annurev.ge.26.120192.001323; HAAF T, 1992, CELL, V70, P681, DOI 10.1016/0092-8674(92)90436-G; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; Heller R, 1996, P NATL ACAD SCI USA, V93, P7125, DOI 10.1073/pnas.93.14.7125; HOCHSTENBACH R, 1993, CHROMOSOMA, V102, P526, DOI 10.1007/BF00368346; HSU TC, 1975, CYTOGENET CELL GENET, V15, P41, DOI 10.1159/000130497; KARPEN GH, 1992, GENETICS, V132, P737; KARPEN GH, 1990, CELL, V63, P97; Kurek R, 1996, CHROMOSOME RES, V4, P87, DOI 10.1007/BF02259701; KURENOVA EV, 1990, GENETIKA+, V26, P1701; LARIN Z, 1994, HUM MOL GENET, V3, P689, DOI 10.1093/hmg/3.5.689; LE MH, 1995, GENETICS, V141, P283; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOHE AR, 1986, P NATL ACAD SCI USA, V83, P696, DOI 10.1073/pnas.83.3.696; LOHE AR, 1993, GENETICS, V134, P1149; MITCHELL AR, 1985, CHROMOSOMA, V92, P369, DOI 10.1007/BF00327469; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MURPHY TD, 1995, CELL, V81, P139, DOI 10.1016/0092-8674(95)90378-X; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; OHARE K, 1991, MOL GEN GENET, V225, P17, DOI 10.1007/BF00282637; OHASHI H, 1994, AM J HUM GENET, V55, P1202; PAGE SL, 1995, HUM MOL GENET, V4, P289, DOI 10.1093/hmg/4.2.289; PARDUE ML, 1986, IN SITU HYBRIDIZATIO; PIMPINELLI S, 1995, P NATL ACAD SCI USA, V92, P3804, DOI 10.1073/pnas.92.9.3804; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; RATTNER JB, 1991, BIOESSAYS, V13, P51, DOI 10.1002/bies.950130202; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; RUSSO VEA, 1996, COLD SPRING HARBOR M, V32; Sacchi N, 1996, CYTOGENET CELL GENET, V73, P123, DOI 10.1159/000134322; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; SCHULMAN I, 1991, ANNU REV CELL BIOL, V7, P311, DOI 10.1146/annurev.cellbio.7.1.311; SHEVELYOV YY, 1993, MOL GEN GENET, V239, P205, DOI 10.1007/BF00281619; SNYDER MP, 1982, P NATL ACAD SCI-BIOL, V79, P7430, DOI 10.1073/pnas.79.23.7430; STEINER NC, 1994, CELL, V79, P865, DOI 10.1016/0092-8674(94)90075-2; SULLIVAN BA, 1995, HUM MOL GENET, V4, P2189, DOI 10.1093/hmg/4.12.2189; SUNKEL CE, 1995, CURR OPIN GENET DEV, V5, P756, DOI 10.1016/0959-437X(95)80008-S; TOWER J, 1993, GENETICS, V133, P347; TTALOR SS, 1996, CHROMOSOMA, V105, P70; TYLERSMITH C, 1993, NAT GENET, V5, P368, DOI 10.1038/ng1293-368; VIG BK, 1994, MUTAT RES-FUND MOL M, V309, P1, DOI 10.1016/0027-5107(94)90036-1; VOULLAIRE LE, 1993, AM J HUM GENET, V52, P1153; White M. J. D, 1973, ANIMAL CYTOLOGY EVOL; WILLIAMS B, 1998, IN PRESS NAT GENET; YUKI S, 1986, EUR J BIOCHEM, V158, P403, DOI 10.1111/j.1432-1033.1986.tb09767.x; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	75	209	223	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					1007	1019		10.1016/S0092-8674(00)80491-2	http://dx.doi.org/10.1016/S0092-8674(00)80491-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428523	Bronze, Green Accepted			2022-12-24	WOS:000071281400017
J	Madhani, HD; Styles, CA; Fink, GR				Madhani, HD; Styles, CA; Fink, GR			MAP kinases with distinct inhibitory functions impart signaling specificity during yeast differentiation	CELL			English	Article							PHEROMONE RESPONSE PATHWAY; SACCHAROMYCES-CEREVISIAE; FILAMENTOUS GROWTH; PROTEIN-KINASES; INVASIVE GROWTH; SHUTTLE VECTORS; FUS3; CASCADE; KSS1; TRANSDUCTION	Filamentous invasive growth of S. cerevisiae requires multiple elements of the mitogen-activated protein kinase (MAPK) signaling cascade that are also components of the mating pheromone response pathway. Here we show that, despite sharing several constituents, the two pathways use different MAP kinases. The Fus3 MAPK regulates mating, whereas the Kss1 MAPK regulates filamentation and invasion; Remarkably, in addition to their kinase-dependent activation functions, Kss1 and Fus3 each have a distinct kinase-independent inhibitory function. Kss1 inhibits the filamentation pathway by interacting with its target transcription factor Ste12. Fus3 has a different inhibitory activity that prevents the inappropriate activation of invasion by the pheromone response pathway. In the absence of Fus3, there is erroneous crosstalk in which mating pheromone now activates filamentation-specific gene expression using the Kss1 MAPK.			Madhani, HD (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Madhani, Hiten/0000-0001-7400-6657				Bardwell L, 1996, MOL CELL BIOL, V16, P3637; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHENEVERT J, 1994, GENETICS, V136, P1287; CHOI KY, 1994, CELL, V78, P499; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; Guthrie C, 1991, GUIDE YEAST GENETICS; HAGEN DC, 1991, MOL CELL BIOL, V11, P2952, DOI 10.1128/MCB.11.6.2952; Hall JP, 1996, MOL CELL BIOL, V16, P6715; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIGUCHI R, 1989, PCR TECHNOLOGY; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; HWANGSHUM JJ, 1991, MOL GEN GENET, V227, P197, DOI 10.1007/BF00259671; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MA D, 1995, MOL BIOL CELL, V6, P889, DOI 10.1091/mbc.6.7.889; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Mosch HU, 1997, GENETICS, V145, P671; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; PRINTEN JA, 1994, GENETICS, V138, P609; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Watanabe Y, 1997, MOL CELL BIOL, V17, P2615, DOI 10.1128/MCB.17.5.2615; YASHAR B, 1995, MOL CELL BIOL, V15, P6545; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	43	363	369	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 28	1997	91	5					673	684		10.1016/S0092-8674(00)80454-7	http://dx.doi.org/10.1016/S0092-8674(00)80454-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393860	Bronze			2022-12-24	WOS:A1997YH96000014
J	Palmeirim, I; Henrique, D; IshHorowicz, D; Pourquie, O				Palmeirim, I; Henrique, D; IshHorowicz, D; Pourquie, O			Avian hairy gene expression identifies a molecular clock linked to vertebrate segmentation and somitogenesis	CELL			English	Article							LOOP-HELIX REPRESSOR; CHICK-EMBRYO; SOMITE FORMATION; DROSOPHILA; EVOLUTION; PROTEINS; HOMOLOG; EMBRYOGENESIS; TRANSCRIPTION; NEUROGENESIS	We have identified and characterized c-hairy1, an avian homolog of the Drosophila segmentation gene, hairy. c-hairy1 is strongly expressed in the presomitic mesoderm, where its mRNA exhibits cyclic waves of expression whose temporal periodicity corresponds to the formation time of one somite (90 min). The apparent movement of these waves is due to coordinated pulses of c-hairy1 expression, not to cell displacement along the anteroposterior axis, nor to propagation of an activating signal. Rather, the rhythmic c-hairy mRNA expression is an autonomous property of the paraxial mesoderm. These results provide molecular evidence for a developmental clock linked to segmentation and somitogenesis of the paraxial mesoderm, and support the possibility that segmentation mechanisms used by invertebrates and vertebrates have been conserved.	DEV BIOL INST MARSEILLE IBDM,LGPD,CNRS,UMR 6545,F-13288 MARSEILLE 9,FRANCE; CNRS,INST EMBRYOL CELLULAIRE & MOL,F-94736 NOGENT SUR MARNE,FRANCE; COLL FRANCE,F-94736 NOGENT SUR MARNE,FRANCE; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; Cancer Research UK			Henrique, Domingos M/E-5460-2010; Pourquié, Olivier/CAJ-5443-2022; Palmeirim, Isabel/F-4522-2012	Henrique, Domingos M/0000-0001-8869-1894; Pourquié, Olivier/0000-0001-5189-1227; Ish-Horowicz, David/0000-0001-5684-7129; Palmeirim, Isabel/0000-0003-2282-7829				BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; CONLON RA, 1995, DEVELOPMENT, V121, P1533; COOKE J, 1976, J THEOR BIOL, V58, P455, DOI 10.1016/S0022-5193(76)80131-2; DAVIDSON D, 1988, DEVELOPMENT, V104, P221; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; DeRobertis EM, 1997, NATURE, V387, P25, DOI 10.1038/387025a0; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Holland LZ, 1997, DEVELOPMENT, V124, P1723; ISHHOROWICZ D, 1985, COLD SPRING HARB SYM, V50, P135, DOI 10.1101/SQB.1985.050.01.019; ISPIZUABELMONTE JC, 1993, CELL, V74, P645; Jimenez G, 1996, EMBO J, V15, P7088, DOI 10.1002/j.1460-2075.1996.tb01100.x; Johnston SH, 1997, DEVELOPMENT, V124, P2245; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; Kimmel CB, 1996, TRENDS GENET, V12, P329, DOI 10.1016/S0168-9525(96)80001-1; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MEIER S, 1984, CELL DIFFER DEV, V14, P235, DOI 10.1016/0045-6039(84)90012-5; MEINHARDT H, 1986, SOMITES DEV EMBRYOS, P179; MENKES B, 1977, BRIT SOC DEV BIOL S, V3, P405; Muller M, 1996, DEVELOPMENT, V122, P2071; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; OKA C, 1995, DEVELOPMENT, V121, P3291; PACKARD DS, 1976, DEV BIOL, V53, P36, DOI 10.1016/0012-1606(76)90207-4; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; PATEL NH, 1992, NATURE, V357, P339, DOI 10.1038/357339a0; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PRIMMETT DRN, 1989, DEVELOPMENT, V105, P119; SANDER K, 1988, DEVELOPMENT, V104, P112; SASSONECORSI P, 1994, CELL, V78, P361, DOI 10.1016/0092-8674(94)90415-4; STERN CD, 1988, DEVELOPMENT, V104, P231; TAM PPL, 1994, ANAT EMBRYOL, V189, P275; TAM PPL, 1986, SOMITES DEV EMBRYOS, P17; TAUTZ D, 1995, TRENDS GENET, V11, P23, DOI 10.1016/S0168-9525(00)88982-9; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; WEISBLAT DA, 1994, CURR TOP DEV BIOL, V29, P101, DOI 10.1016/S0070-2153(08)60548-7	42	703	720	2	39	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					639	648		10.1016/S0092-8674(00)80451-1	http://dx.doi.org/10.1016/S0092-8674(00)80451-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393857	Bronze			2022-12-24	WOS:A1997YH96000011
J	Paradise, JL				Paradise, JL			Short-course antimicrobial treatment for acute otitis media - Not best for infants and young children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CLINICAL-TRIAL; DOUBLE-BLIND; DECONGESTANT-ANTIHISTAMINE; PENICILLIN TREATMENT; AMOXICILLIN; EFFICACY; CEFTRIAXONE; THERAPY; EFFUSION; 3-DAY		UNIV PITTSBURGH, SCH MED, DEPT PEDIAT, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BAIN J, 1985, BRIT MED J, V291, P1243, DOI 10.1136/bmj.291.6504.1243; Barnett ED, 1997, PEDIATRICS, V99, P23, DOI 10.1542/peds.99.1.23; Bernstein J M, 1995, J RESP DIS, V16, P88; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; CANTEKIN EI, 1983, NEW ENGL J MED, V308, P297, DOI 10.1056/NEJM198302103080601; CARLIN SA, 1991, J PEDIATR-US, V118, P178, DOI 10.1016/S0022-3476(05)80479-2; CASSELBRANT ML, 1992, PEDIATR INFECT DIS J, V11, P278, DOI 10.1097/00006454-199204000-00004; CHAMBERLAIN JM, 1994, CLIN PEDIATR, V33, P642, DOI 10.1177/000992289403301101; CUNNINGHAM AS, 1994, CONT PEDIATR, V11, P17; DESAINTONGE DMC, 1982, BRIT MED J, V284, P1078; Gooch WM, 1996, PEDIATR INFECT DIS J, V15, P157, DOI 10.1097/00006454-199602000-00013; GREEN SM, 1993, PEDIATRICS, V91, P23; HARSTEN G, 1989, ACTA OTO-LARYNGOL, V108, P253, DOI 10.3109/00016488909125525; HATHAWAY TJ, 1994, PEDIATRICS, V94, P143; HENDRICKSE WA, 1988, PEDIATR INFECT DIS J, V7, P14, DOI 10.1097/00006454-198801000-00005; Hoberman A, 1996, PEDIATR INFECT DIS J, V15, P955, DOI 10.1097/00006454-199610000-00034; Hoberman A, 1997, PEDIATR INFECT DIS J, V16, P463, DOI 10.1097/00006454-199705000-00002; INGVARSSON L, 1982, ACTA OTO-LARYNGOL, V94, P283, DOI 10.3109/00016488209128915; JONES R, 1986, J ROY COLL GEN PRACT, V36, P356; KALEIDA PH, 1991, PEDIATRICS, V87, P466; MANDEL EM, 1987, NEW ENGL J MED, V316, P432, DOI 10.1056/NEJM198702193160803; MEISTRUPLARSEN KI, 1983, ACTA OTO-LARYNGOL, V96, P99, DOI 10.3109/00016488309132879; MURRAY BE, 1994, NEW ENGL J MED, V330, P1229, DOI 10.1056/NEJM199404283301710; NELSON CR, 1993, DRUG UTILIZATION OFF; NELSON WL, 1987, 27 INT C ANT AG CHEM; PARADISE JL, 1987, J PEDIATR-US, V111, P948, DOI 10.1016/S0022-3476(87)80226-3; Paradise JL, 1997, PEDIATRICS, V99, P318, DOI 10.1542/peds.99.3.318; PARADISE JL, 1995, PEDIATRICS, V96, P712; PARADISE JL, 1995, PEDIATR INFECT DIS J, V14, P429, DOI 10.1097/00006454-199505001-00005; PUCZYNSKI MS, 1987, LARYNGOSCOPE, V97, P16; SCHAPPERT SM, 1992, OFFICE VISITS OTITIS; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; VARSANO I, 1988, CHEMOTHERAPY, V34, P39, DOI 10.1159/000238646	35	53	54	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	1997	278	20					1640	1642		10.1001/jama.278.20.1640	http://dx.doi.org/10.1001/jama.278.20.1640			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG859	9388072				2022-12-24	WOS:A1997YG85900001
J	Zlokarnik, G; Negulescu, PA; Knapp, TE; Mere, L; Burres, N; Feng, LX; Whitney, M; Roemer, K; Tsien, RY				Zlokarnik, G; Negulescu, PA; Knapp, TE; Mere, L; Burres, N; Feng, LX; Whitney, M; Roemer, K; Tsien, RY			Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter	SCIENCE			English	Article							ESCHERICHIA-COLI; T-LYMPHOCYTES; GENE; PROTEINS; CEPHALOSPORIN; SECRETION; SEQUENCE; RECEPTOR; REAGENT; REVEALS	Gene expression was visualized in single living mammalian cells with beta-lactamase as a reporter that hydrolyzes a substrate loaded intracellularly as a membrane-permeant ester. Each enzyme molecule changed the fluorescence of many substrate molecules from green to blue by disrupting resonance energy transfer. This wavelength shift was detectable by eye or color film in individual cells containing less than 100 beta-lactamase molecules. The robust change in emission ratio reveals quantitative heterogeneity in real-time gene expression, enables clonal selection by flow cytometry, and forms a basis for high-throughput screening of pharmaceutical candidate drugs in living mammalian cells.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Saarland, D-66421 Homburg, Germany; Aurora Biosci, San Diego, CA 92121 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Saarland University	Tsien, RY (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA.				NINDS NIH HHS [NS27177] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027177, R01NS027177] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; CHRISTENSEN H, 1990, BIOCHEM J, V266, P853; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DIVIRGILIO F, 1988, J IMMUNOL, V140, P915; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; JONES RN, 1982, J CLIN MICROBIOL, V15, P677, DOI 10.1128/JCM.15.4.677-683.1982; JONES RN, 1982, J CLIN MICROBIOL, V15, P954, DOI 10.1128/JCM.15.5.954-958.1982; KADONAGA JT, 1984, J BIOL CHEM, V259, P2149; KARTTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972, DOI 10.1073/pnas.88.9.3972; Lakowicz J.R., 2006, PRINCIPLES FLUORESCE, P1, DOI 10.1007/978-0-387-46312-4/COVER; MATAGNE A, 1990, BIOCHEM J, V265, P131, DOI 10.1042/bj2650131; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; Moore JT, 1997, ANAL BIOCHEM, V247, P203, DOI 10.1006/abio.1997.2092; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; NISWENDER KD, 1995, J MICROSC-OXFORD, V180, P109, DOI 10.1111/j.1365-2818.1995.tb03665.x; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; PAGE MI, 1987, ADV PHYS ORG CHEM, V23, P165, DOI 10.1016/S0065-3160(08)60204-X; RAZ E, COMMUNICATION; SERAFINI AT, 1995, IMMUNITY, V3, P239, DOI 10.1016/1074-7613(95)90093-4; SUTCLIFFE JG, 1978, P NATL ACAD SCI USA, V75, P3737, DOI 10.1073/pnas.75.8.3737; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; TSIEN RY, 1996, Patent No. 30540; WEINTRAUB H, 1988, P NATL ACAD SCI USA, V85, P5819, DOI 10.1073/pnas.85.16.5819; WINGENDER E, 1982, ANAL BIOCHEM, V127, P351, DOI 10.1016/0003-2697(82)90186-5	26	538	632	3	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					84	88		10.1126/science.279.5347.84	http://dx.doi.org/10.1126/science.279.5347.84			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417030				2022-12-24	WOS:000071323900045
J	Pignoni, F; Hu, BR; Zavitz, KH; Xiao, JA; Garrity, PA; Zipursky, SL				Pignoni, F; Hu, BR; Zavitz, KH; Xiao, JA; Garrity, PA; Zipursky, SL			The eye-specification proteins so and eya form a complex and regulate multiple steps in Drosophila eye development	CELL			English	Article							HOMEOBOX-CONTAINING GENE; SINE OCULIS GENE; 2-HYBRID SYSTEM; NERVOUS-SYSTEM; VISUAL-SYSTEM; EYELESS GENE; EXPRESSION; FAMILY; ANIRIDIA; HOMOLOG	sine oculis (so) and eyes absent (eya) are required for Drosophila eye development and are founding members of the mammalian Six and Eya gene families. These genes have been proposed to act with eyeless (Pax6) to regulate eye development in vertebrates and invertebrates. so encodes a highly diverged homeobox transcription factor and eya encodes a novel nuclear protein. We demonstrate that So and Eya (1) regulate common steps in eye development including cell proliferation, patterning, and neuronal development; (2) synergize in inducing ectopic eyes; and (3) interact in yeast and in vitro through evolutionarily conserved domains. We propose that an So/Eya complex regulates multiple steps in eye development and functions within the context of a network of genes to specify eye tissue identity.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Zipursky, SL (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.			Zipursky, Stephen/0000-0001-5630-7181; Garrity, Paul/0000-0002-8274-6564				BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; Chanut F, 1997, DEVELOPMENT, V124, P559; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HAY BA, 1994, DEVELOPMENT, V120, P2121; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEBERLEIN U, 1995, NATURE, V373, P709, DOI 10.1038/373709a0; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Kawakami K, 1996, NUCLEIC ACIDS RES, V24, P303, DOI 10.1093/nar/24.2.303; Kawakami K, 1996, FEBS LETT, V393, P259, DOI 10.1016/0014-5793(96)00899-X; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MARDON G, 1994, DEVELOPMENT, V120, P3473; Oliver G, 1995, DEVELOPMENT, V121, P4045; OLIVER G, 1995, DEVELOPMENT, V121, P693; Pignoni F, 1997, DEVELOPMENT, V124, P271; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; SERIKAKU MA, 1994, GENETICS, V138, P1137; Shen WP, 1997, DEVELOPMENT, V124, P45; Smith Donald B., 1993, Methods in Molecular and Cellular Biology, V4, P220; Tio M, 1997, DEVELOPMENT, V124, P343; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; Wolff Tanya, 1993, P1277; Xu PX, 1997, P NATL ACAD SCI USA, V94, P11974, DOI 10.1073/pnas.94.22.11974; Xu PX, 1997, DEVELOPMENT, V124, P219; XU T, 1993, DEVELOPMENT, V117, P1223; Zimmerman JE, 1997, GENOME RES, V7, P128, DOI 10.1101/gr.7.2.128	40	471	479	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					881	891		10.1016/S0092-8674(00)80480-8	http://dx.doi.org/10.1016/S0092-8674(00)80480-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428512	Bronze			2022-12-24	WOS:000071281400006
J	Beckmann, R; Bubeck, D; Grassucci, R; Penczek, P; Verschoor, A; Blobel, G; Frank, J				Beckmann, R; Bubeck, D; Grassucci, R; Penczek, P; Verschoor, A; Blobel, G; Frank, J			Alignment of conduits for the nascent polypeptide chain in the Ribosome-Sec61 complex	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; CRYOELECTRON MICROSCOPY; ELECTRON-MICROSCOPY; SECRETORY PROTEINS; ENVIRONMENT; RESOLUTION; HOMOLOG; SEC61P	An oligomer of the Sec61 trimeric complex is thought to form the protein-conducting channel for protein transport across the endoplasmic reticulum. A purified yeast Sec61 complex bound to monomeric yeast ribosomes as an oligomer in a saturable fashion. Cryo-electron microscopy of the ribosome-Sec61 complex and a three-dimensional reconstruction showed that the Sec61 oligomer is attached to the large ribosomal subunit by a single connection. Moreover, a funnel-shaped pore in the Sec61 oligomer aligned with the exit of a tunnel traversing the large ribosomal subunit, strongly suggesting that both structures function together in the translocation of proteins across the endoplasmic reticulum membrane.	NEW YORK STATE DEPT HLTH,WADSWORTH CTR,ALBANY,NY 12201; SUNY ALBANY,DEPT BIOMED SCI,ALBANY,NY 12201	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Beckmann, R (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029169] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01 GM29169] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; BERNABEU C, 1983, J CELL BIOL, V96, P1471, DOI 10.1083/jcb.96.5.1471; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; LATA KR, 1995, ULTRAMICROSCOPY, V58, P381, DOI 10.1016/0304-3991(95)00002-I; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Penczek PA, 1996, ULTRAMICROSCOPY, V63, P205, DOI 10.1016/0304-3991(96)00037-X; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; STRAMBIODECASTILLIA C, 1995, J CELL BIOL, V131, P19, DOI 10.1083/jcb.131.1.19; Verschoor A, 1996, J CELL BIOL, V133, P495, DOI 10.1083/jcb.133.3.495; VERSCHOOR A, IN PRESS NUCL ACIDS; WAGENKNECHT T, 1988, J MOL BIOL, V199, P137, DOI 10.1016/0022-2836(88)90384-1	28	292	298	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2123	2126		10.1126/science.278.5346.2123	http://dx.doi.org/10.1126/science.278.5346.2123			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405348				2022-12-24	WOS:A1997YM23500053
J	Bollinger, RC; Brookmeyer, RS; Mehendale, SM; Paranjape, RS; Shepherd, ME; Gadkari, DA; Quinn, TC				Bollinger, RC; Brookmeyer, RS; Mehendale, SM; Paranjape, RS; Shepherd, ME; Gadkari, DA; Quinn, TC			Risk factors and clinical preservation of acute primary HIV infection in India	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; EPIDEMIC; VIREMIA	Context.-Most previous studies of clinical presentation and risk factors in early human immunodeficiency virus (HIV) infection have relied on retrospective analyses and referred seroconverters, and thus were subject to possible bias. Objectives.-To apply a method based on measurement of prevalent HIV-1 p24 antigenemia for identification of risk factors for newly acquired HIV infection and to describe the signs and symptoms of acute HIV infection. Design and Setting.-Nested case-control study in Pune, India. Participants.-HIV antibody-negative persons attending 2 sexually transmitted disease (STD) clinics between May 1993 and June 1996. Outcome Measures.-Prevalent p24 antigenemia, risk factors for HIV infection, and clinical symptoms of acute primary HIV infection. Results.-Of 3874 HIV antibody-negative persons tested, 58 (1.5%) were p24 antigen positive at initial presentation to the clinics. Unprotected sexual contact with a commercial sex worker (CSW) was reported by 39 (77%) of the 51 p24 antigenemic men, compared with 131 (51%) of 255 control men (adjusted odds ratio [AOR], 3.4; 95% confidence interval [CI], 1.2-9.6; P=.02). The presence of an active genital ulcer at the time of screening was found in 46 (79%) of the 58 p24 antigenemic men and women, compared with 137 (47%) of the 290 control subjects (AOR, 4.2; 95% CI, 2.0-9.0; P<.001). Signs and symptoms independently associated with p24 antigenemia in HIV antibody-seronegative persons included fever, which was reported by 28 (48%) of the 58 p24 antigenemic subjects, but only 52 (18%) of the 290 control subjects (AOR, 4.7; 95% CI, 2.4-9.0; P<.001). Joint pain was reported by 10% of subjects recently HIV infected, compared with 2% of the control subjects (AOR, 6.5; 95% CI, 1.7-24.8; P=.006), Night sweats were reported by 9% of the p24 antigenemic, but only 1% of the control subjects (AOR, 9.1; 95% CI, 1.7-47.6; P=.009), Overall, fever, joint pain, and/or night sweats were reported in 27 (47%) of the 58 subjects with recent HIV infection. Conclusions.-This systematic case-control study of p24 antigen screening in HIV-seronegative patients attending STD clinics in India identified unprotected sex with a CSW and a genital ulcer as independent risk factors associated with newly acquired HIV infection. In addition, p24 antigen positivity identified recent fever, night sweats, and arthralgias as symptoms that may be predictive of recent HIV infection, In a study of patients attending STD clinics in India, screening for p24 antigen in HIV antibody-negative persons was found to be a reliable and effective research method for determining recent risk behavior and identifying clinical signs of acute primary HIV infection.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DIV INFECT DIS,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21205; NATL AIDS RES INST,PUNE,MAHARASHTRA,INDIA; NIAID,NIH,BETHESDA,MD 20892	Johns Hopkins University; Johns Hopkins University; Indian Council of Medical Research (ICMR); ICMR - National AIDS Research Institute (NARI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Paranjape, Ramesh/0000-0003-2948-9148; Bollinger, Robert/0000-0002-6798-6834	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033879] Funding Source: NIH RePORTER; FIC NIH HHS [D43TW0000] Funding Source: Medline; NIAID NIH HHS [AI 33879-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOLLINGER RC, 1995, MEDICINE, V74, P97, DOI 10.1097/00005792-199503000-00005; BROOKMEYER R, 1995, AM J EPIDEMIOL, V142, P709, DOI 10.1093/oxfordjournals.aje.a117700; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P19; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; FOX R, 1987, AIDS, V1, P35; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; MEHENDALE SM, 1995, J INFECT DIS, V172, P1486, DOI 10.1093/infdis/172.6.1486; Mehendale SM, 1996, INDIAN J MED RES, V104, P327; RODRIGUES JJ, 1995, BRIT MED J, V311, P283, DOI 10.1136/bmj.311.7000.283; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SINICCO A, 1990, J ACQ IMMUN DEF SYND, V3, P260; VONSYDOW M, 1988, BMJ-BRIT MED J, V296, P238, DOI 10.1136/bmj.296.6617.238; 1996, 11 INT C AIDS JUL	15	87	88	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2085	2089		10.1001/jama.278.23.2085	http://dx.doi.org/10.1001/jama.278.23.2085			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403423				2022-12-24	WOS:A1997YK98700038
J	Brown, KE; Guest, SS; Smale, ST; Hahm, K; Merkenschlager, M; Fisher, AG				Brown, KE; Guest, SS; Smale, ST; Hahm, K; Merkenschlager, M; Fisher, AG			Association of transcriptionally silent genes with Ikaros complexes at centromeric heterochromatin	CELL			English	Article							TERMINAL TRANSFERASE GENE; CELL-CYCLE; INTERPHASE NUCLEI; TRANSGENIC MICE; GAGA FACTOR; HUNCHBACK; PROMOTER; DNA; ULTRABITHORAX; CHROMOSOME	Ikaros proteins are required for normal T, B, and NK cell development and are postulated to activate lymphocyte-specific gene expression. Here we examined Ikaros distribution in the nucleus of B lymphocytes using confocal microscopy and a novel immunofluorescence in situ hybridization (immune-FISH) approach. Unexpectedly, Ikaros localized to discrete heterochromatin-containing foci in interphase nuclei, which comprise clusters of centromeric DNA as defined by gamma-satellite sequences and the abundance of heterochromatin protein-1 (HP-1). Using locus-specific probes for CD2, CD4, CD8 alpha, CD19, CD45, and lambda 5 genes, we show that transcriptionally inactive but not transcriptionally active genes associate with Ikaros-heterochromatin foci. These findings support a model of organization of the nucleus in which repressed genes are selectively recruited into centromeric domains.	HAMMERSMITH HOSP, UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED,MRC, CLIN SCI CTR, LONDON W12 0NN, ENGLAND; UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	Imperial College London; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Merkenschlager, Matthias/0000-0003-2889-3288	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043726, R29DK043726] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43726] Funding Source: Medline; NIGMS NIH HHS [GM-07104] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Axcrona K, 1996, EUR J IMMUNOL, V26, P2203, DOI 10.1002/eji.1830260936; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; Boveri T., 1909, ARCH ZELLFORSCH, V3, P181; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN KE, 1994, HUM MOL GENET, V3, P1227, DOI 10.1093/hmg/3.8.1227; BROWN KE, 1995, THESIS U OXFORD OXFO; Buckle VJ, 1993, HUMAN GENETIC DISEAS, P59; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; COMINGS DE, 1968, AM J HUM GENET, V20, P440; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; EARNSHAW WC, 1994, FASEB J, V8, P947, DOI 10.1096/fasebj.8.12.8088460; Ernst P, 1996, MOL CELL BIOL, V16, P6121; ERNST P, 1993, MOL CELL BIOL, V13, P2982, DOI 10.1128/MCB.13.5.2982; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; FISHER AG, 1995, INT IMMUNOL, V7, P415, DOI 10.1093/intimm/7.3.415; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; GRANOK H, 1995, CURR BIOL, V5, P238, DOI 10.1016/S0960-9822(95)00048-0; HAAF T, 1989, HUM GENET, V81, P137, DOI 10.1007/BF00293889; HAAF T, 1991, EXP CELL RES, V192, P325, DOI 10.1016/0014-4827(91)90048-Y; HADLACZKY G, 1986, EXP CELL RES, V167, P1, DOI 10.1016/0014-4827(86)90199-0; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HENIKOFF S, 1996, GENOMES; Hostert A, 1997, J IMMUNOL, V158, P4270; HUANG S, 1992, P NATL ACAD SCI USA, V89, P305, DOI 10.1073/pnas.89.1.305; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; KIM KJ, 1979, J IMMUNOL, V122, P549; KLUG CA, 1997, IN PRESS P NATL ACAD; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; Marshall WF, 1997, CURR OPIN GENET DEV, V7, P259, DOI 10.1016/S0959-437X(97)80136-0; MCKENZIE EA, 1993, MOL GEN GENET, V240, P374, DOI 10.1007/BF00280389; Merkenschlager M, 1997, J EXP MED, V186, P1149, DOI 10.1084/jem.186.7.1149; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; MOORTHIBHAT K, 1996, DEVELOPMENT, V122, P1113; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; Poux S, 1996, EMBO J, V15, P4713, DOI 10.1002/j.1460-2075.1996.tb00848.x; Rabl C, 1885, MORPHOL JB, V10, P214; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; RALPH P, 1975, J IMMUNOL, V114, P898; RASKA I, 1991, EXP CELL RES, V195, P27, DOI 10.1016/0014-4827(91)90496-H; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; RODERICK TH, 1996, GENETIC VARIANTS STR, P926; ROLINK A, 1993, ADV IMMUNOL, V53, P123, DOI 10.1016/S0065-2776(08)60499-X; SAGA Y, 1988, MOL CELL BIOL, V8, P4889, DOI 10.1128/MCB.8.11.4889; SCHMID I, 1991, CYTOMETRY, V12, P279, DOI 10.1002/cyto.990120312; SPECTOR DL, 1986, EXP CELL RES, V163, P87, DOI 10.1016/0014-4827(86)90560-4; Strouboulis J, 1996, J CELL SCI, V109, P1991; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WHITE RAH, 1986, CELL, V47, P311, DOI 10.1016/0092-8674(86)90453-8; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; ZHANG CC, 1992, P NATL ACAD SCI USA, V89, P7511, DOI 10.1073/pnas.89.16.7511; ZHOU LJ, 1992, IMMUNOGENETICS, V35, P102, DOI 10.1007/BF00189519; Zirbel RM, 1993, CHROMOSOME RES, V1, P93, DOI 10.1007/BF00710032	67	644	661	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 12	1997	91	6					845	854		10.1016/S0092-8674(00)80472-9	http://dx.doi.org/10.1016/S0092-8674(00)80472-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413993	Bronze			2022-12-24	WOS:A1997YL43900015
J	Sunahara, RK; Tesmer, JJG; Gilman, AG; Sprang, SR				Sunahara, RK; Tesmer, JJG; Gilman, AG; Sprang, SR			Crystal structure of the adenylyl cyclase activator G(S alpha)	SCIENCE			English	Article							G-PROTEIN; GTP HYDROLYSIS; ALPHA-SUBUNITS; CHOLERA-TOXIN; BETA-GAMMA; TRANSDUCIN; MECHANISM; RECEPTORS; STIMULATION; EXPRESSION	The crystal structure of G(S alpha), the heterotrimeric G protein alpha subunit that stimulates adenylyl cyclase, was determined at 2.5 Angstrom in a complex with guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S). G(S alpha) is the prototypic member of a family of GTP-binding proteins that regulate the activities of effectors in a hormone-dependent manner. Comparison of the structure of G(S alpha).GTP gamma S with that of G(i alpha).GTP gamma S suggests that their effector specificity is primarily dictated by the shape of the binding surface formed by the switch II helix and the alpha 3-beta 5 loop, despite the high sequence homology of these elements. In contrast, sequence divergence explains the inability of regulators of G protein signaling to stimulate the GTPase activity of G(S alpha). The beta gamma binding surface of G(S alpha) is largely conserved in sequence ana structure to that of G(i alpha), whereas differences in the surface formed by the carboxyl-terminal helix and the alpha 4-beta 6 loop may mediate receptor specificity.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Sunahara, Roger/AAJ-8667-2020	Tesmer, John/0000-0003-1125-3727	NIDDK NIH HHS [DK46371] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENJAMIN DR, 1995, J MOL BIOL, V254, P681, DOI 10.1006/jmbi.1995.0647; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BERMAN DM, IN PRESS J BIOL CHEM; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, X PLOR VERSION 3 1; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Farfel Z, 1996, J BIOL CHEM, V271, P19653, DOI 10.1074/jbc.271.33.19653; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Grishina G, 1997, J BIOL CHEM, V272, P20619, DOI 10.1074/jbc.272.33.20619; Iiri T, 1997, P NATL ACAD SCI USA, V94, P5656, DOI 10.1073/pnas.94.11.5656; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; ITOH H, 1991, J BIOL CHEM, V266, P16226; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE E, 1994, METHOD ENZYMOL, V237, P146; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; VANDOP C, 1984, J BIOL CHEM, V259, P696; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1	42	247	255	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1943	1947		10.1126/science.278.5345.1943	http://dx.doi.org/10.1126/science.278.5345.1943			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395396				2022-12-24	WOS:A1997YL00200034
J	Hviid, SF; Madsen, MB; Gunnlaugsson, HP; Goetz, W; Knudsen, JM; Hargraves, RB; Smith, P; Britt, D; Dinesen, AR; Mogensen, CT; Olsen, M; Pedersen, CT; Vistisen, L				Hviid, SF; Madsen, MB; Gunnlaugsson, HP; Goetz, W; Knudsen, JM; Hargraves, RB; Smith, P; Britt, D; Dinesen, AR; Mogensen, CT; Olsen, M; Pedersen, CT; Vistisen, L			Magnetic properties experiments on the Mars Pathfinder lander: Preliminary results	SCIENCE			English	Article							SNC METEORITES; SOIL; CLUES; DUST	Many of the particles currently suspended in the martian atmosphere are magnetic, with an average saturation magnetization of about 4 A.m(2)/kg (amperes times square meters per kilogram). The particles appear to consist of claylike aggregates stained or cemented with ferric oxide (Fe2O3); at least some of the stain and cement is probably maghemite (gamma-Fe2O3). The presence of the gamma phase would imply that Fe2+ ions leached from the bedrock, passing through a state as free Fe2+ ions dissolved in liquid water. These particles could be a freeze-dried precipitate from ground water poured out on the surface. An alternative is that the magnetic particles are titanomagnetite occurring in palagonite and inherited directly from a basaltic precursor.	PRINCETON UNIV,DEPT GEOSCI,PRINCETON,NJ 08544; UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721	Princeton University; University of Arizona	Hviid, SF (corresponding author), UNIV COPENHAGEN,NIELS BOHR INST ASTRON PHYS & GEOPHYS,OERSTED LAB,COPENHAGEN,DENMARK.		Madsen, Morten Bo/D-2082-2011; Gunnlaugsson, Haraldur/L-6535-2016	Madsen, Morten Bo/0000-0001-8909-5111; Gunnlaugsson, Haraldur/0000-0002-8958-0245				ALT JC, 1988, MAR GEOL, V81, P227, DOI 10.1016/0025-3227(88)90029-1; BANIN A, 1993, J GEOPHYS RES-PLANET, V98, P20831, DOI 10.1029/93JE02500; BELL JF, 1990, J GEOPHYS RES-SOLID, V95, P14447, DOI 10.1029/JB095iB09p14447; BURNS RG, 1980, NATURE, V285, P647, DOI 10.1038/285647a0; BURNS RG, 1993, GEOCHIM COSMOCHIM AC, V57, P4555, DOI 10.1016/0016-7037(93)90182-V; Clark B. C.  III, 1977, Journal of Geophysical Research, V82, P4577, DOI 10.1029/JS082i028p04577; COEY JMD, 1990, J GEOPHYS RES-SOLID, V95, P14423, DOI 10.1029/JB095iB09p14423; GOODING JL, 1992, ICARUS, V99, P28, DOI 10.1016/0019-1035(92)90168-7; GUNNLAUGSSON HP, IN PRESS PLANET SPAC; HANEL R, 1972, ICARUS, V17, P423, DOI 10.1016/0019-1035(72)90009-7; Hapke B., 1993, THEORY REFLECTANCE E; Hargraves R. B., 1977, Journal of Geophysical Research, V82, P4547, DOI 10.1029/JS082i028p04547; HUNT GR, 1973, ICARUS, V18, P459, DOI 10.1016/0019-1035(73)90155-3; KOCH CB, 1995, PHYS CHEM MINER, V22, P333; MCSWEEN HY, 1985, REV GEOPHYS, V23, P391, DOI 10.1029/RG023i004p00391; MORRIS RV, 1989, J GEOPHYS RES-SOLID, V94, P2760, DOI 10.1029/JB094iB03p02760; MORRIS RV, 1990, J GEOPHYS RES-SOLID, V95, P14427, DOI 10.1029/JB095iB09p14427; Oyama V. I., 1977, Journal of Geophysical Research, V82, P4669, DOI 10.1029/JS082i028p04669; Pollack J. B., 1977, Journal of Geophysical Research, V82, P4479, DOI 10.1029/JS082i028p04479; POLLACK JB, 1995, J GEOPHYS RES-PLANET, V100, P5235, DOI 10.1029/94JE02640; Rieder R, 1997, SCIENCE, V278, P1771, DOI 10.1126/science.278.5344.1771; SINGER RB, 1984, B AM ASTRON SOC, V16, P679; Smith PH, 1997, SCIENCE, V278, P1758, DOI 10.1126/science.278.5344.1758; SMITH PH, 1997, J GEOPHYS RES, V102, P3953; Wendlandt W.W., 1966, REFLECTANCE SPECTROS; [No title captured]	26	88	90	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1768	1770		10.1126/science.278.5344.1768	http://dx.doi.org/10.1126/science.278.5344.1768			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388172				2022-12-24	WOS:A1997YJ90100038
J	Mayo, MW; Wang, CY; Cogswell, PC; RogersGraham, KS; Lowe, SW; Der, CJ; Baldwin, AS				Mayo, MW; Wang, CY; Cogswell, PC; RogersGraham, KS; Lowe, SW; Der, CJ; Baldwin, AS			Requirement of NF-kappa B activation to suppress p53-independent apoptosis induced by oncogenic Ras	SCIENCE			English	Article							UBIQUITIN-PROTEASOME PATHWAY; C-JUN; CELL-DEATH; ALPHA PROTEOLYSIS; CANCER-THERAPY; R-RAS; H-RAS; PHOSPHORYLATION; TRANSFORMATION; PROTEIN	The ras proto-oncogene is frequently mutated in human tumors and functions to chronically stimulate signal transduction cascades resulting in the synthesis or activation of specific transcription factors, including Ets, c-Myc, c-Jun, and nuclear factor kappa B (NF-kappa B). These Ras-responsive transcription factors are required for transformation, but the mechanisms by which these proteins facilitate oncogenesis have not been fully established. Oncogenic Ras was shown to initiate a p53-independent apoptotic response that was suppressed through the activation of NF-kappa B. These results provide an explanation for the requirement of NF-kappa B for Ras-mediated oncogenesis and provide evidence that Ras-transformed cells are susceptible to apoptosis even if they do not express the p53 tumor-suppressor gene product.	UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, SCH MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH DENT, CURRICULUM GENET & MOL BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH DENT, DEPT ENDODONT, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Cold Spring Harbor Laboratory; University of North Carolina; University of North Carolina Chapel Hill				Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA052072, R01CA072771, P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA52072, CA72771, CA13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; CHEN CY, 1995, ONCOGENE, V11, P1487; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Colman MS, 1996, NUCLEIC ACIDS RES, V24, P1971, DOI 10.1093/nar/24.10.1971; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1993, J BIOL CHEM, V268, P17676; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HOLMESMCNARY M, UNPUB; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LIN HJ, 1997, MOL CELL BIOL, V15, P4536; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MAYO MW, UNPUB; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUIN RG, 1995, NATURE, V374, P457; QUO ML, 1997, MOL CARCINOG, V18, P221; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Yang BS, 1996, MOL CELL BIOL, V16, P538	59	500	521	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 5	1997	278	5344					1812	1815		10.1126/science.278.5344.1812	http://dx.doi.org/10.1126/science.278.5344.1812			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388187	Green Submitted			2022-12-24	WOS:A1997YJ90100053
J	Smith, PH; Bell, JF; Bridges, NT; Britt, DT; Gaddis, L; Greeley, R; Keller, HU; Herkenhoff, KE; Jaumann, R; Johnson, JR; Kirk, RL; Lemmon, M; Maki, JN; Malin, MC; Murchie, SL; Oberst, J; Parker, TJ; Reid, RJ; Sablotny, R; Soderblom, LA; Stoker, C; Sullivan, R; Thomas, N; Tomasko, MG; Ward, W; Wegryn, E				Smith, PH; Bell, JF; Bridges, NT; Britt, DT; Gaddis, L; Greeley, R; Keller, HU; Herkenhoff, KE; Jaumann, R; Johnson, JR; Kirk, RL; Lemmon, M; Maki, JN; Malin, MC; Murchie, SL; Oberst, J; Parker, TJ; Reid, RJ; Sablotny, R; Soderblom, LA; Stoker, C; Sullivan, R; Thomas, N; Tomasko, MG; Ward, W; Wegryn, E			Results from the Mars Pathfinder camera	SCIENCE			English	Article							SPECTRAL REFLECTANCE; VIKING LANDERS; IRON-OXIDES; DUST; SPECTROSCOPY; MINERALOGY; HEMATITE; PYROXENE; SURFACE	Images of the martian surface returned by the Imager for Mars Pathfinder (IMP) show a complex surface of ridges and troughs covered by rocks that have been transported and modified by fluvial, aeolian, and impact processes. Analysis of the spectral signatures in the scene (at 440- to 1000-nanometer wavelength) reveal three types of rock and four classes of soil. Upward-looking IMP images of the predawn sky show thin, bluish clouds that probably represent water ice forming on local atmospheric haze (opacity similar to 0.5). Haze particles are about 1 micrometer in radius and the water vapor column abundance is about 10 precipitable micrometers.	CORNELL UNIV,ITHACA,NY 14853; CALTECH,JET PROP LAB,PASADENA,CA 91109; US GEOL SURVEY,FLAGSTAFF,AZ 86001; ARIZONA STATE UNIV,TEMPE,AZ 85287; MAX PLANCK INST AERON,KATHENBURG LINDAU,GERMANY; DLR,BERLIN,GERMANY; MALIN SPACE SCI SYST,SAN DIEGO,CA; JOHNS HOPKINS UNIV,APPL PHYS LAB,BALTIMORE,MD 21218; NASA,AMES RES CTR,MOFFETT FIELD,CA 94035	Cornell University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); United States Department of the Interior; United States Geological Survey; Arizona State University; Arizona State University-Tempe; Max Planck Society; Helmholtz Association; German Aerospace Centre (DLR); Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Smith, PH (corresponding author), UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721, USA.		Murchie, Scott L/E-8030-2015; Stoker, Carol/ABE-1381-2021; Lemmon, Mark/X-2333-2019; Johnson, Jeffrey R/F-3972-2015; Jaumann, Ralf/N-1001-2018; Lemmon, Mark T/E-9983-2010; Sullivan, Robert/AAR-8193-2020; Bridges, Nathan T/D-6341-2016; Thomas, Nicolas/G-4693-2015	Murchie, Scott L/0000-0002-1616-8751; Stoker, Carol/0000-0001-7265-292X; Lemmon, Mark/0000-0002-4504-5136; Johnson, Jeffrey R/0000-0002-5586-4901; Jaumann, Ralf/0000-0002-9759-6597; Lemmon, Mark T/0000-0002-4504-5136; Thomas, Nicolas/0000-0002-0146-0071				ADAMS JB, 1974, J GEOPHYS RES, V79, P4829, DOI 10.1029/JB079i032p04829; ARVIDSON RE, 1989, REV GEOPHYS, V27, P39, DOI 10.1029/RG027i001p00039; BAGNOLD RA, 1954, PHYSICS BLOWN SAND D; BELL JF, 1990, J GEOPHYS RES-SOLID, V95, P14447, DOI 10.1029/JB095iB09p14447; BELL JF, 1996, MINERAL SPECTROSCOPY, P359; BISHOP JL, 1993, GEOCHIM COSMOCHIM AC, V57, P4583, DOI 10.1016/0016-7037(93)90184-X; CLANCY T, 1997, COMMUNICATION; CLOUTIS EA, 1991, J GEOPHYS RES-PLANET, V96, P22809, DOI 10.1029/91JE02512; COSTA JE, 1983, GEOL SOC AM BULL, V94, P986, DOI 10.1130/0016-7606(1983)94<986:PROFPF>2.0.CO;2; FRENCH LM, 1988, ICARUS, V75, P127, DOI 10.1016/0019-1035(88)90131-5; Golombek MP, 1997, SCIENCE, V278, P1743, DOI 10.1126/science.278.5344.1743; GREELEY R, 1984, WIND GEOLOGICAL PROC; Greeley R., 1992, MARS, P730; Grundy WM, 1992, ASTEROIDS COMETS MET, P215; GUINNESS EA, 1987, J GEOPHYS RES-SOLID, V92, pE575, DOI 10.1029/JB092iB04p0E575; Hviid SF, 1997, SCIENCE, V278, P1768, DOI 10.1126/science.278.5344.1768; Jakosky B. M., 1992, MARS, P969; JAMES P, 1997, COMMUNICATION; KAHN R, 1981, J GEOPHYS RES-SPACE, V86, P5833, DOI 10.1029/JA086iA07p05833; KLASSEN KP, 1979, J GEOPHYS RES, V84, P8478; KOMAR PD, 1987, SEDIMENTOLOGY, V34, P1165, DOI 10.1111/j.1365-3091.1987.tb00599.x; KOMAR PD, 1989, FLOODS HYDROLOGICAL, P107; KOMAR PD, 1991, SEDIMENTOLOGY, V38; Komatsu G, 1997, J GEOPHYS RES-PLANET, V102, P4151, DOI 10.1029/96JE02564; Malin M. C., 1988, 4041 NASA, P502; MALIN MC, 1981, 84211 NASA, P272; MCCORD TB, 1977, ICARUS, V31, P25, DOI 10.1016/0019-1035(77)90069-0; MORRIS RV, 1995, J GEOPHYS RES-PLANET, V100, P5319, DOI 10.1029/94JE01500; MORRIS RV, 1985, J GEOPHYS RES-SOLID, V90, P3126, DOI 10.1029/JB090iB04p03126; MURCHIE S, 1993, ICARUS, V105, P454, DOI 10.1006/icar.1993.1141; MUSTARD JF, 1993, J GEOPHYS RES-PLANET, V98, P3387, DOI 10.1029/92JE02682; Mutch T. A., 1977, Journal of Geophysical Research, V82, P4452, DOI 10.1029/JS082i028p04452; MUTCH TA, 1976, SCIENCE, V194, P87, DOI 10.1126/science.194.4260.87; MUTCH TA, 1976, SCIENCE, V193, P791, DOI 10.1126/science.193.4255.791; OCONNOR JE, 1992, GEOL SOC AM BULL, V104, P267, DOI 10.1130/0016-7606(1992)104<0267:MAIOPD>2.3.CO;2; POLLACK JB, 1981, J ATMOS SCI, V38, P3, DOI 10.1175/1520-0469(1981)038<0003:AMGCEW>2.0.CO;2; POLLACK JB, 1995, J GEOPHYS RES-PLANET, V100, P5235, DOI 10.1029/94JE02640; POLLACK JB, 1980, J ATMOS SCI, V37, P868, DOI 10.1175/1520-0469(1980)037<0868:SBNPOS>2.0.CO;2; REID R, 1997, THESIS U ARIZONA; Rieder R, 1997, SCIENCE, V278, P1771, DOI 10.1126/science.278.5344.1771; RODDY DJ, 1977, IMPACT EXPLOSION CRA, P489; SCHOFIELD T, 1997, SCIENCE, V278, P1752; SHARP RP, 1984, GEOL SOC AM BULL, V95, P1398, DOI 10.1130/0016-7606(1984)95<1398:SGFVLO>2.0.CO;2; SHERMAN DM, 1982, J GEOPHYS RES, V87, P169, DOI 10.1029/JB087iB12p10169; SINGER RB, 1982, J GEOPHYS RES, V87, P159, DOI 10.1029/JB087iB12p10159; Smith PH, 1997, J GEOPHYS RES-PLANET, V102, P4003, DOI 10.1029/96JE03568; Zellner B., 1994, LUNAR PLANET SCI C, V25, P1541; ZUREK RW, 1982, ICARUS, V50, P288, DOI 10.1016/0019-1035(82)90127-0	48	215	216	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1758	1765		10.1126/science.278.5344.1758	http://dx.doi.org/10.1126/science.278.5344.1758			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388170				2022-12-24	WOS:A1997YJ90100036
J	Taipale, P; Hiilesmaa, V; Salonen, R; Ylostalo, P				Taipale, P; Hiilesmaa, V; Salonen, R; Ylostalo, P			Increased nuchal translucency as a marker for fetal chromosomal defects	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FIRST-TRIMESTER; TRANSVAGINAL SONOGRAPHY; CYSTIC HYGROMA; 1ST TRIMESTER; ALPHA-FETOPROTEIN; GESTATIONAL-AGE; DOWNS-SYNDROME; ULTRASOUND; THICKNESS; FETUSES	Background Screening for trisomy 21 (Down's syndrome) by measuring maternal serum alpha-fetoprotein, chorionic gonadotropin, and estriol concentrations and then performing chorionic-villus sampling or amniocentesis identifies approximately 60 percent of fetuses with this disorder. We used ultrasonography to detect increased nuchal translucency and cystic hygroma, which are characteristic features of fetuses with chromosomal defects. Methods We performed transvaginal ultrasonography in 10,010 unselected adolescents and women less than 40 years of age with live singleton fetuses at 10 to 15.9 weeks of gestation. Increased fetal nuchal translucency was defined as an area of translucency at least 3 mm in width, and cystic hygromas were defined as septated, fluid-filled sacs in the nuchal region. Subjects whose fetuses had these findings were offered fetal karyotyping. Information on pregnancies, deliveries, and neonates was subsequently obtained from hospital records and national birth and malformation registries. Results Nuchal translucency or cystic hygroma was seen in 76 fetuses (0.8 percent), of which 18 (24 percent) had an abnormal karyotype. The sensitivity for trisomies 21, 18, and 13 combined was 62 percent (13 of 21 fetuses), and the sensitivity for trisomy 21 alone was 54 percent (7 of 13 fetuses). Conclusions The use of transvaginal ultrasonography to detect increased nuchal translucency and cystic hygroma is a sensitive test for fetal aneuploidy. It can be done earlier in pregnancy than serum screening, and it decreases the subsequent need for chorionic-villus sampling or amniocentesis. (C) 1997, Massachusetts Medical Society.	JORVI HOSP,DEPT OBSTET & GYNECOL,SF-02740 ESPOO,FINLAND		Taipale, P (corresponding author), UNIV HELSINKI,CENT HOSP,DEPT OBSTET & GYNECOL,HAARTMANINKATU 2,SF-00290 HELSINKI,FINLAND.							BENACERRAF BR, 1992, RADIOLOGY, V184, P239, DOI 10.1148/radiology.184.1.1535162; BEWLEY S, 1995, BRIT J OBSTET GYNAEC, V102, P386, DOI 10.1111/j.1471-0528.1995.tb11290.x; BRAITHWAITE JM, 1995, BRIT J RADIOL, V68, P720, DOI 10.1259/0007-1285-68-811-720; BRONSHTEIN M, 1992, PRENATAL DIAG, V12, P587, DOI 10.1002/pd.1970120704; COMAS C, 1995, ULTRASOUND OBST GYN, V5, P26, DOI 10.1046/j.1469-0705.1995.05010026.x; CULLEN MT, 1990, PRENATAL DIAG, V10, P643, DOI 10.1002/pd.1970101004; DAYA S, 1993, AM J OBSTET GYNECOL, V168, P903, DOI 10.1016/S0002-9378(12)90842-X; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; HAFNER E, 1995, ULTRASOUND OBST GYN, V6, P330, DOI 10.1046/j.1469-0705.1995.06050330.x; JACKSON S, 1995, ULTRASOUND OBST GYN, V5, P55, DOI 10.1046/j.1469-0705.1995.05010055.x; MACGREGOR SN, 1987, OBSTET GYNECOL, V70, P344; MOONEY RA, 1994, OBSTET GYNECOL, V84, P298; NADEL A, 1993, OBSTET GYNECOL, V82, P43; NICOLAIDES KH, 1994, BRIT J OBSTET GYNAEC, V101, P782, DOI 10.1111/j.1471-0528.1994.tb11946.x; NICOLAIDES KH, 1992, BRIT MED J, V304, P867, DOI 10.1136/bmj.304.6831.867; Pandya PP, 1995, BRIT J OBSTET GYNAEC, V102, P957, DOI 10.1111/j.1471-0528.1995.tb10902.x; PANDYA PP, 1995, ULTRASOUND OBST GYN, V5, P334, DOI 10.1046/j.1469-0705.1995.05050334.x; PANDYA PP, 1994, OBSTET GYNECOL, V84, P420; PHILLIPS OP, 1992, OBSTET GYNECOL, V80, P353; SABBAGHA RE, 1994, DIAGNOSTIC ULTRASOUN, P155; Salonen R, 1997, ACTA OBSTET GYN SCAN, V76, P817, DOI 10.3109/00016349709024358; SALVESEN KA, 1995, ULTRASOUND OBST GYN, V6, P293, DOI 10.1046/j.1469-0705.1995.06040293.x; SANTOLAYA J, 1992, OBSTET GYNECOL, V79, P256; SHULMAN LP, 1992, OBSTET GYNECOL, V80, P80; SNIJDERS RJM, 1994, PRENATAL DIAG, V14, P543, DOI 10.1002/pd.1970140706; TIMORTRITSCH IE, 1993, OBSTET GYNECOL, V81, P742; VANZALENSPROCK RM, 1992, AM J OBSTET GYNECOL, V167, P94, DOI 10.1016/S0002-9378(11)91634-2; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WILSON RD, 1992, PRENATAL DIAG, V12, P755, DOI 10.1002/pd.1970120908	29	144	156	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 4	1997	337	23					1654	1658		10.1056/NEJM199712043372303	http://dx.doi.org/10.1056/NEJM199712043372303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ871	9385124	Bronze			2022-12-24	WOS:A1997YJ87100003
J	Boehm, T; Folkman, J; Browder, T; OReilly, MS				Boehm, T; Folkman, J; Browder, T; OReilly, MS			Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance	NATURE			English	Article							ANGIOGENESIS	Acquired drug resistance is a major problem in the treatment of cancer. Of the more than 500,000 annual deaths from cancer in the United States', many follow the development of resistance to chemotherapy. The emergence of resistance depends in part on the genetic instability, heterogeneity and high mutational rate of tumour cells'. In contrast, endothelial cells are genetically stable, homogenous and have a low mutational rate. Therefore, anti-angiogenic therapy directed against a tumour's endothelial cells should, in principle, induce little or no drug resistance, Endostatin(3), a potent angiogenesis inhibitor, was administered to mice bearing Lewis lung carcinoma, T241 fibrosarcoma or B16F10 melanoma. Treatment was stopped when tumours had regressed. Tumours were then allowed to re-grow and endostatin therapy was resumed. After 6, 4 or 2 treatment cycles, respectively, no tumours recurred after discontinuation of therapy, These experiments show that drug resistance does not develop in three tumour types treated with a potent angiogenesis inhibitor, An unexpected finding is that repeated cycles of antiangiogenic therapy are followed by prolonged tumour dormancy without further therapy.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC CTR,DEPT PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELLULAR BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Boehm, T (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT SURG,HUNNEWELL 103,300 LONGWOOD AVE,BOSTON,MA 02115, USA.							Brem Harold, 1994, Surgical Forum, V45, P674; Folkman J, 1996, NAT MED, V2, P167, DOI 10.1038/nm0296-167; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GOLDIN A, 1981, EUR J CANCER, V17, P129, DOI 10.1016/0014-2964(81)90027-X; Hill D. L., 1975, REV CYCLOPHOSPHAMIDE; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; KERBEL RS, 1991, BIOESSAYS, V13, P31, DOI 10.1002/bies.950130106; LI PL, 1993, CANC MED, V1, P322; MORROW CS, 1993, CANC MED, V1, P618; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; SINGH RK, 1995, P NATL ACAD SCI USA, V92, P4562, DOI 10.1073/pnas.92.10.4562	13	1449	1675	2	63	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					404	407		10.1038/37126	http://dx.doi.org/10.1038/37126			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389480				2022-12-24	WOS:A1997YH54900064
J	Anderson, DM; Maraskovsky, E; Billingsley, WL; Dougall, WC; Tometsko, ME; Roux, ER; Teepe, MC; DuBose, RF; Cosman, D; Galibert, L				Anderson, DM; Maraskovsky, E; Billingsley, WL; Dougall, WC; Tometsko, ME; Roux, ER; Teepe, MC; DuBose, RF; Cosman, D; Galibert, L			A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; BIOLOGICAL CHARACTERIZATION; INTERLEUKIN-4 RECEPTOR; SUPERFAMILY; ACTIVATION; MURINE; PROTEINS; CLONING; CD40; LYMPHOCYTES	Dendritic cells are rare haematopoietic cells that reside in a number of organs and tissues. By capturing, processing and presenting antigens to T cells, dendritic cells are essential for immune surveillance and the regulation of specific immunity(1-4) Several members of the tumour necrosis factor receptor (TNFR) superfamily are integral to the regulation of the immune response. These structurally related proteins modulate cellular functions ranging from proliferation and differentiation to inflammation and cell survival or death(5,6). The functional activity of dendritic cells is greatly increased by signalling through the TNFR family member CD40 (refs 7, 8). Here we report the characterization of RANK (for receptor activator of NF-kappa B), a new member of the TNFR family derived from dendritic cells, and the isolation of a RANK ligand (RANKL) by direct expression screening. RANKL augments the ability of dendritic cells to stimulate naive T-cell proliferation in a mixed lymphocyte reaction, and increases the survival of RANK(+) T cells generated with interleukin-4 and transforming growth factor (TGF)-beta. Thus RANK and RANKL seem to be important regulators of interactions between T cells and dendritic cells.	IMMUNEX RES & DEV CORP, DEPT IMMUNOBIOL, SEATTLE, WA 98101 USA; IMMUNEX RES & DEV CORP, DEPT BIOINFORMAT, SEATTLE, WA 98101 USA		Anderson, DM (corresponding author), IMMUNEX RES & DEV CORP, DEPT MOL BIOL, 51 UNIV ST, SEATTLE, WA 98101 USA.			Dougall, William/0000-0001-9487-251X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; Austyn JM, 1996, J EXP MED, V183, P1287, DOI 10.1084/jem.183.4.1287; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baker SJ, 1996, ONCOGENE, V12, P1; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; CAUX C, 1996, BLOOD CEL B, V7, P263; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; DEJONG R, 1994, INT IMMUNOL, V6, P631, DOI 10.1093/intimm/6.4.631; Dubois B, 1997, J EXP MED, V185, P941, DOI 10.1084/jem.185.5.941; Fukaura H, 1996, J CLIN INVEST, V98, P70, DOI 10.1172/JCI118779; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOODWIN RG, 1993, CELL, V73, P447, DOI 10.1016/0092-8674(93)90133-B; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; MADSEN M, 1980, J IMMUNOL METHODS, V33, P323, DOI 10.1016/0022-1759(80)90003-4; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; ROTHE M, 1995, SCIENCE, V269, P124; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5	30	1798	1942	4	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					175	179		10.1038/36593	http://dx.doi.org/10.1038/36593			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367155				2022-12-24	WOS:A1997YF49400055
J	BenArie, N; Bellen, HJ; Armstrong, DL; McCall, AE; Gordadze, PR; Guo, QX; Matzuk, MM; Zoghbi, HY				BenArie, N; Bellen, HJ; Armstrong, DL; McCall, AE; Gordadze, PR; Guo, QX; Matzuk, MM; Zoghbi, HY			Math1 is essential for genesis of cerebellar granule neurons	NATURE			English	Article							PRONEURAL GENE; NERVOUS-SYSTEM; MOUSE-BRAIN; MUTANT MICE; CELLS; EXPRESSION; PROTOONCOGENE; DELETION; PROTEIN; WNT-1	The cerebellum is essential for fine motor control of movement and posture, and its dysfunction disrupts balance and impairs control of speech, limb and eye movements. The developing cerebellum consists mainly of three types of neuronal cells: granule cells in the external germinal layer, Purkinje cells, and neurons of the deep nuclei(1). The molecular mechanisms that underlie the specific determination and the differentiation of each of these neuronal subtypes are unknown. Math1 (refs 2, 3), the mouse homologue of the Drosophila gene atonal(4), encodes a basic helix-loop-helix transcription factor that is specifically expressed in the precursors of the external germinal layer and their derivatives. Here we report that mice lacking Math1 fail to form granule cells and are born with a cerebellum that is devoid of an external germinal layer. To our knowledge, Math1 is the first gene to be shown to be required in vivo for the genesis of granule cells, and hence the predominant neuronal population in the cerebellum.	BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute			Ben-Arie, Nissim/K-4997-2012	Bellen, Hugo/0000-0001-5992-5989; Zoghbi, Huda/0000-0002-0700-3349				AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; ALBRECHT U, 1997, VISUALIZATION GENE E, P23; ALTMAN J, 1996, DEV CEREBELLAR SYSTE; BenArie N, 1996, HUM MOL GENET, V5, P1207, DOI 10.1093/hmg/5.9.1207; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; GOFFINET AM, 1984, BRAIN RES REV, V7, P261, DOI 10.1016/0165-0173(84)90013-4; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HALLONET MER, 1993, EUR J NEUROSCI, V5, P1145, DOI 10.1111/j.1460-9568.1993.tb00969.x; Hatten ME, 1997, CURR OPIN NEUROBIOL, V7, P40, DOI 10.1016/S0959-4388(97)80118-3; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; Heintz Nathaniel, 1993, V6, P19; His W., 1891, ABHANDLUNGEN KONI MP, V29, P1; JARMAN AP, 1995, DEVELOPMENT, V121, P2019; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MILLEN KJ, 1994, DEVELOPMENT, V120, P695; *MOUS GEN INF JACK, 1996, MOUS GEN DAT 3 1; REZAI Z, 1972, DEV BIOL, V29, P17, DOI 10.1016/0012-1606(72)90039-5; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SMEYNE RJ, 1989, J NEUROSCI, V9, P1608; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; THOMAS KR, 1990, NATURE, V346, P845; TOHYAMA T, 1992, LAB INVEST, V66, P303; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; WURST W, 1994, DEVELOPMENT, V120, P2065; Yang XW, 1996, DEVELOPMENT, V122, P555; 1997, FRONTIERS BIOSCIENCE	29	504	519	2	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 13	1997	390	6656					169	172		10.1038/36579	http://dx.doi.org/10.1038/36579			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367153				2022-12-24	WOS:A1997YF49400053
J	Inbal, B; Cohen, O; PolakCharcon, S; Kopolovic, J; Vadai, E; Eisenbach, L; Kimchi, A				Inbal, B; Cohen, O; PolakCharcon, S; Kopolovic, J; Vadai, E; Eisenbach, L; Kimchi, A			DAP kinase links the control of apoptosis to metastasis	NATURE			English	Article							LUNG-CARCINOMA; EXTRACELLULAR-MATRIX; CELLS; TUMORIGENESIS; SUPPRESSION; SELECTION; DEATH; GENE	DAP kinase is a new type of calcium/calmodulin-dependent enzyme that phosphorylates serine/threonine residues on proteins. Its structure contains ankyrin repeats and the 'death' domain, and it is associated with the cell cytoskeleton(1-3). The gene encoding DAP kinase was initially isolated as a positive mediator of apoptosis induced by interferon-gamma, by using a strategy of functional cloning(4). We have now tested whether this gene has tumour-suppressive activity We found that lung carcinoma clones, characterized by their highly aggressive metastatic behaviour and originating from two independent murine lung tumours, did not express DAP kinase, in contrast to their low-metastatic counterparts. Restoration of DAP kinase to physiological levels in high-metastatic Lewis carcinoma cells suppressed their ability to form lung metastases after intravenous injection into syngeneic mice, and delayed local tumour growth in a foreign 'microenvironment'. Conversely, in vivo selection of rare lung lesions following injection into syngeneic mice of low-metastatic Lewis carcinoma cells or of DAP kinase transfectants, was associated with loss of DAP kinase expression. In situ TUNEL staining of tumour sections revealed that DAP kinase expression from the transgene raised the incidence of apoptosis in vivo. DAP-kinase transfectants also showed increased sensitivity in vitro to apoptotic stimuli, of the sort encountered by metastasizing cells at different stages of malignancy. We propose that loss of DAP kinase expression provides a unique mechanism that links suppression of apoptosis to metastasis.	WEIZMANN INST SCI, DEPT MOL GENET, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT IMMUNOL, IL-76100 REHOVOT, ISRAEL; CHAIM SHEBA MED CTR, DEPT HISTOPATHOL, IL-52621 TEL HASHOMER, ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Chaim Sheba Medical Center				Eisenbach, Lea R/0000-0002-4816-1968				BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; EISENBACH L, 1983, INT J CANCER, V32, P113, DOI 10.1002/ijc.2910320118; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FIDLER IJ, 1987, CURR PROB SURG, V24, P137, DOI 10.1016/0011-3840(87)90002-5; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; Laird PW, 1997, MOL MED TODAY, V3, P223, DOI 10.1016/S1357-4310(97)01019-8; LAYTON MG, 1984, BRIT J CANCER, V49, P415, DOI 10.1038/bjc.1984.67; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nikiforov MA, 1996, ONCOGENE, V13, P1709; PLAKSIN D, 1988, P NATL ACAD SCI USA, V85, P4463, DOI 10.1073/pnas.85.12.4463; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WEISS L, 1992, CANCER METAST REV, V11, P227, DOI 10.1007/BF01307179; Xie KP, 1996, J LEUKOCYTE BIOL, V59, P797, DOI 10.1002/jlb.59.6.797; Yamauchi A, 1996, BLOOD, V87, P5127, DOI 10.1182/blood.V87.12.5127.bloodjournal87125127	30	341	362	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 13	1997	390	6656					180	184		10.1038/36599	http://dx.doi.org/10.1038/36599			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YF494	9367156				2022-12-24	WOS:A1997YF49400056
J	Turner, G; Robinson, H; Wake, S; Laing, S; Partington, M				Turner, G; Robinson, H; Wake, S; Laing, S; Partington, M			Case finding for the fragile X syndrome and its consequences	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; CARRIERS; ALLELES		SYDNEY CHILDRENS HOSP,FRAGILE X PROGRAM,SYDNEY,NSW,AUSTRALIA	University of Sydney	Turner, G (corresponding author), HUNTER GENET,FRAGILE X PROGRAM,POB 84,NEWCASTLE,NSW 2298,AUSTRALIA.							Kooy RF, 1996, AM J MED GENET, V64, P241, DOI 10.1002/(SICI)1096-8628(19960809)64:2<241::AID-AJMG1>3.0.CO;2-X; Partington MW, 1996, AM J MED GENET, V64, P370, DOI 10.1002/(SICI)1096-8628(19960809)64:2<370::AID-AJMG27>3.0.CO;2-B; Robinson H, 1996, AM J MED GENET, V64, P198, DOI 10.1002/(SICI)1096-8628(19960712)64:1<198::AID-AJMG36>3.0.CO;2-G; ROUSSEAU F, 1995, AM J HUM GENET, V57, P1006; SMITH RA, 1990, BRIT MED J, V300, P1112, DOI 10.1136/bmj.300.6732.1112; TURNER G, 1986, NEW ENGL J MED, V315, P607, DOI 10.1056/NEJM198609043151002; TURNER G, 1992, LANCET, V339, P1210, DOI 10.1016/0140-6736(92)91142-U; Turner G, 1996, AM J MED GENET, V64, P196, DOI 10.1002/(SICI)1096-8628(19960712)64:1<196::AID-AJMG35>3.0.CO;2-G; WEBB T, 1987, J MED GENET, V23, P396; Zhong N, 1996, AM J MED GENET, V64, P261, DOI 10.1002/(SICI)1096-8628(19960809)64:2<261::AID-AJMG5>3.0.CO;2-X	10	16	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1223	1226		10.1136/bmj.315.7117.1223	http://dx.doi.org/10.1136/bmj.315.7117.1223			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393231	Green Published			2022-12-24	WOS:A1997YF25200032
J	Hughes, JB; Daily, GC; Ehrlich, PR				Hughes, JB; Daily, GC; Ehrlich, PR			Population diversity: Its extent and extinction	SCIENCE			English	Article							GENE FLOW; BIODIVERSITY	Genetically distinct populations are an important component of biodiversity. This work estimates the number of populations per area of a sample of species from literature on population differentiation and the average range area of a species from a sample of distribution maps. This yields an estimate of about 220 populations per species, or 1.1 to 6.6 billion populations globally. Assuming that population extinction is a linear function of habitat loss, approximately 1800 populations per hour (16 million annually) are being destroyed in tropical forests alone.			Hughes, JB (corresponding author), STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA.		Martiny, Jennifer/AAB-9323-2019	Martiny, Jennifer/0000-0002-2415-1247				ALLEN TB, 1983, FIELD GUIDE BIRDS N; [Anonymous], 1994, RARITY; [Anonymous], 2013, THE FUTURE OF NATURE, DOI DOI 10.12987/9780300188479-039; BARROWCLOUGH GF, 1983, PERSPECTIVES ORNITHO; BROWN IL, 1980, OECOLOGIA, V47, P239, DOI 10.1007/BF00346827; Burt W., 1976, FIELD GUIDE MAMMALS, V3rd; Corbet G.B., 1992, P1; EHRLICH PR, 1992, AMBIO, V21, P219; EHRLICH PR, 1993, AMBIO, V22, P64; ERWIN T L, 1982, Coleopterists Bulletin, V36, P74; *FAO UN, 1990, FOR RES ASS TROP COU; FRANCE R, 1992, AM NAT, V139, P342, DOI 10.1086/285330; Hammond PM, 1995, GLOBAL BIODIVERSITY, P113; Hawksworth D. L, 1991, BIODIVERSITY MICROOR; KINGDON J, 1971, E AFRICAN MAMMALS A, V2; KINGDON J, 1971, E AFRICAN MAMMALS A, V3; LAVERY S, 1995, HEREDITY, V74, P531, DOI 10.1038/hdy.1995.75; Lawton J. H., 1995, EXTINCTION RATES; LEE D.S., 1980, ATLAS N AM FRESHWATE; Legge JT, 1996, CONSERV BIOL, V10, P85, DOI 10.1046/j.1523-1739.1996.10010085.x; MAC ARTHUR ROBERT H., 1967; MYERS N, 1984, PRIMARY SOURCE; PAGEL MD, 1991, AM NAT, V137, P791, DOI 10.1086/285194; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; PIMM SL, 1995, P NATL ACAD SCI USA, V92, P9343, DOI 10.1073/pnas.92.20.9343; RAPPORT EH, 1982, AEROGRAPHY GEOGRAPHI; RASMUSSEN IR, 1992, OECOLOGIA, V89, P277, DOI 10.1007/BF00317228; RAVEN PH, 1985, FUTURIST, V19, P8; RAVEN PH, 1983, B ESA            SPR, P4; Ridgely RS, 1989, BIRDS S AM, V1; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; SCOTT JA, 1986, BUTTERFLIES N AM; Sinnott E. W., 1950, PRINCIPLES GENETICS; Tsukada E, 1982, BUTTERFLIES S E ASIA, VI; TSUKADA E, 1982, BUTTERFLIES S E ASIA, V4; TSUKADA E, 1982, BUTTERFLIES S E ASIA, V3; TSUKADA E, 1982, BUTTERFLIES S E ASIA, V2; Webb, 1984, BUTTERFLIES DORSET; WILSON E O, 1992; [No title captured]	40	330	353	3	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 24	1997	278	5338					689	692		10.1126/science.278.5338.689	http://dx.doi.org/10.1126/science.278.5338.689			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381179				2022-12-24	WOS:A1997YC32300055
J	Boyers, SP; Gilbert, WM				Boyers, SP; Gilbert, WM			Elective repeat caesarean section versus trial of labour: the neonatologist's view	LANCET			English	Editorial Material							VAGINAL BIRTH		Univ Calif Davis, Sch Med, Dept Obstet & Gynecol, Sacramento, CA 95816 USA	University of California System; University of California Davis	Boyers, SP (corresponding author), Univ Calif Davis, Sch Med, Dept Obstet & Gynecol, Sacramento, CA 95816 USA.							American College of Obstetricians and Gynecologists Committee on Ethics, 1991, ACOG COMM OP; *CDC, 1993, MMWR-MORBID MORTAL W, V42, P285; *DEP HLTH HUM SERV, 1991, USDHHS PUBL, P378; FLAMM BL, 1994, OBSTET GYNECOL, V83, P927, DOI 10.1097/00006250-199406000-00005; Hook B, 1997, PEDIATRICS, V100, P348, DOI 10.1542/peds.100.3.348; MILLER DA, 1994, OBSTET GYNECOL, V84, P255; ROSEN MG, 1991, OBSTET GYNECOL, V77, P465; STAFFORD RS, 1990, JAMA-J AM MED ASSOC, V263, P683, DOI 10.1001/jama.263.5.683	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					155	155		10.1016/S0140-6736(05)78217-9	http://dx.doi.org/10.1016/S0140-6736(05)78217-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449865				2022-12-24	WOS:000071616300004
J	Ilver, D; Arnqvist, A; Ogren, J; Frick, IM; Kersulyte, D; Incecik, ET; Berg, DE; Covacci, A; Engstrand, L; Boren, T				Ilver, D; Arnqvist, A; Ogren, J; Frick, IM; Kersulyte, D; Incecik, ET; Berg, DE; Covacci, A; Engstrand, L; Boren, T			Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging	SCIENCE			English	Article							HUMAN GASTRIC EPITHELIUM; NEISSERIA-GONORRHOEAE; VIRULENCE FACTORS; HUMAN STOMACH; EXPRESSION; INFECTION; CYTOTOXIN; DISEASE; STRAINS; CLONING	The bacterium Helicobacter pylori is the causative agent for peptic ulcer disease. Bacterial adherence to the human gastric epithelial lining is mediated by the fucosylated Lewis b (Le(b)) histo-blood group antigen. The Le(b)-binding adhesin, BabA, was purified by receptor activity-directed affinity tagging. The bacterial Le(b)-binding phenotype was associated with the presence of the cag pathogenicity island among clinical isolates of H. pylori. A vaccine strategy based on the BabA adhesin might serve as a means to target the virulent type I strains of H. pylori.	Umea Univ, Dept Oral Biol, SE-90187 Umea, Sweden; Umea Univ, Dept Microbiol, SE-90187 Umea, Sweden; Univ Lund, Dept Cell & Mol Biol, SE-22100 Lund, Sweden; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Immunobiol Res Inst Siena, I-53100 Siena, Italy; Univ Hosp, Dept Clin Microbiol & Canc Epidemiol, SE-75185 Uppsala, Sweden	Umea University; Umea University; Lund University; Washington University (WUSTL); Uppsala University; Uppsala University Hospital	Boren, T (corresponding author), Umea Univ, Dept Oral Biol, SE-90187 Umea, Sweden.	thomas.boren@micro.umu.se		Ilver, Dag/0000-0002-3618-9496				Blaser M J, 1993, Trends Microbiol, V1, P255, DOI 10.1016/0966-842X(93)90047-U; Blaser MJ, 1997, LANCET, V349, P1020, DOI 10.1016/S0140-6736(96)09133-7; BLASER MJ, 1996, SCI AM, V274, P92; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; BOREN T, UNPUB; BOREN T, 1994, SCI MED, V1, P28; Brunner J, 1996, TRENDS CELL BIOL, V6, P154, DOI 10.1016/0962-8924(96)40001-0; BUKANOV NO, 1994, MOL MICROBIOL, V11, P509, DOI 10.1111/j.1365-2958.1994.tb00332.x; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; DUBOIS A, 1995, EMERG INFECT DIS, V1, P79, DOI 10.3201/eid0103.950302; FALK P, 1994, METHOD ENZYMOL, V236, P353; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; FALK P, 1994, METHOD CELL BIOL, V45, P161; HAAS R, 1986, CELL, V44, P107, DOI 10.1016/0092-8674(86)90489-7; HAGBLOM P, 1985, NATURE, V315, P156, DOI 10.1038/315156a0; Jiang Q, 1996, MOL MICROBIOL, V20, P833, DOI 10.1111/j.1365-2958.1996.tb02521.x; KIRSCHNER DE, 1995, J THEOR BIOL, V176, P281, DOI 10.1006/jtbi.1995.0198; Langermann S, 1997, SCIENCE, V276, P607, DOI 10.1126/science.276.5312.607; LOGAN RPH, 1994, LANCET, V344, P1078, DOI 10.1016/S0140-6736(94)91729-9; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MARSHALL B, 1983, LANCET, V1, P1273; Mol O, 1996, FEMS MICROBIOL REV, V19, P25, DOI 10.1016/0168-6445(96)00022-8; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P600; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TOMPKINS LS, 1995, SCIENCE, V267, P1621, DOI 10.1126/science.7886448; TUMMURU MKR, 1993, INFECT IMMUN, V61, P1799, DOI 10.1128/IAI.61.5.1799-1809.1993; WANG Y, 1990, GENE, V94, P23, DOI 10.1016/0378-1119(90)90463-2; WARREN JR, 1983, LANCET, V1, P1273; XIANG ZY, 1995, INFECT IMMUN, V63, P94, DOI 10.1128/IAI.63.1.94-98.1995	32	907	963	4	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					373	377		10.1126/science.279.5349.373	http://dx.doi.org/10.1126/science.279.5349.373			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430586				2022-12-24	WOS:000071570800044
J	Garkavtsev, I; Grigorian, IA; Ossovskaya, VS; Chernov, MV; Chumakov, PM; Gudkov, AV				Garkavtsev, I; Grigorian, IA; Ossovskaya, VS; Chernov, MV; Chumakov, PM; Gudkov, AV			The candidate tumour suppressor p33(ING1) cooperates with p53 in cell growth control	NATURE			English	Article							FIBROBLASTS	The candidate tumour-suppressor gene ING1 has been identified by using the genetic suppressor element (GSE) methodology(1). ING1 encodes a nuclear protein, p33(ING1), overexpression of which inhibits growth of different cell lines. The properties of p33(ING1) suggest its involvement in the negative regulation of cell proliferation and in the control of cellular ageing, anchorage dependence and apoptosis(1-3). These cellular functions depend largely on the activity of p53, a tumour-suppressor gene that determines the cellular response to various types of stress(4). Here we report that the biological effects of ING1 and p53 are interrelated and require the activity of both genes: neither of the two genes can, on its own, cause growth inhibition when the other one is suppressed. Furthermore, activation of transcription from the P21/WAF1 promoter, a key mechanism of p53-mediated growth control, depends on the expression of ING1. A physical association between p33(ING1) and p53 proteins has been detected by immunoprecipitation. These results indicate that p33(ING1) is a component of the p53 signalling pathway that cooperates with p53 in the negative regulation of cell proliferation by modulating p53-dependent transcriptional activation.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Univ Calgary, Dept Med Biochem, Calgary, AB T2N 4N1, Canada; Univ Calgary, So Alberta Canc Res Ctr, Calgary, AB T2N 4N1, Canada; VA Engelhardt Mol Biol Inst, Moscow 117984, Russia; Cleveland Clin Fdn, Cleveland, OH 44195 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Calgary; University of Calgary; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Cleveland Clinic Foundation	Gudkov, AV (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA.			Gudkov, Andrei/0000-0003-2548-0154; Chumakov, Peter/0000-0002-8078-2908				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1997, CYTOGENET CELL GENET, V76, P176, DOI 10.1159/000134539; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Helbing CC, 1997, CANCER RES, V57, P1255; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Kondratov R. V., 1996, Molekulyarnaya Biologiya (Moscow), V30, P613; KOPNIN BP, 1995, ONCOL RES, V7, P299; Maestro R, 1996, CANCER RES, V56, P1146; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; ZEREMSKI M, 1997, CELL MOL GENET, V23, P233	18	270	326	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					295	298		10.1038/34675	http://dx.doi.org/10.1038/34675			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440695				2022-12-24	WOS:000071484400054
J	Snow, TP; Le Page, V; Keheyan, Y; Bierbaum, VM				Snow, TP; Le Page, V; Keheyan, Y; Bierbaum, VM			The interstellar chemistry of PAH cations	NATURE			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; BANDS; MOLECULES; IONS; HYDROGEN; C10H8+; DUST	Diffuse interstellar bands (DIBs) are mysterious absorption lines in the optical spectra of stars, and have been known for 75 years(1). Although it is widely believes(2-4) that they arise from gas-phase organic molecules (rather than from dust grains) in the interstellar medium, no consensus has been reached regarding their precise cause. The realization that many emission features in astronomical infrared spectra probably arise from polycyclic aromatic hydrocarbons(5-8) (PAHs), which may themselves be very abundant in the interstellar medium, has led to the suggestion that ionized PAHs might be the source of the DIBs(9-12). Laboratory investigations have revealed that small, positively charged PAHs in matrices have absorption features that bear some resemblance to DIBs(13-15), but no clear identification of any DIB with any specific PAH cation has yet been made. Here we report a laboratory study of the chemical reactivity of PAH cations (C6H6+, C10H8+ and C16H10+) in the gas phase. We find that these PAH cations are very reactive, and are therefore unlikely to survive in high abundances in the interstellar medium. Rather, such molecules will react rapidly with hydrogen, and we therefore suggest that the resulting protonated PAH cations (and species derived from them) should become the focus of future searches for a correspondence between molecular absorption features and the DIBs.	Univ Colorado, Ctr Astrophys & Space Astron, Boulder, CO 80309 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; CNR, Ist Chim Nucl, I-00016 Rome, Italy	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; Consiglio Nazionale delle Ricerche (CNR)	Snow, TP (corresponding author), Univ Colorado, Ctr Astrophys & Space Astron, Campus Box 389, Boulder, CO 80309 USA.							ABOUELAZIZ H, 1993, J CHEM PHYS, V99, P237, DOI 10.1063/1.465801; ADAMSON AJ, 1991, MON NOT R ASTRON SOC, V252, P234, DOI 10.1093/mnras/252.2.234; Allain T, 1996, ASTRON ASTROPHYS, V305, P602; ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; ALLAMANDOLA LJ, 1985, ASTROPHYS J, V290, pL25, DOI 10.1086/184435; CRAWFORD MK, 1985, ASTROPHYS J, V293, pL45, DOI 10.1086/184488; DEPETRIS G, 1994, INT J MASS SPECTROM, V136, P155, DOI 10.1016/0168-1176(94)04022-2; GILES K, 1989, INT J MASS SPECTROM, V89, P303, DOI 10.1016/0168-1176(89)83066-6; Heger M. L, 1922, LICK OBSERVATORY B, V10, P146; HERBIG GH, 1995, ANNU REV ASTRON ASTR, V33, P19, DOI 10.1146/annurev.aa.33.090195.000315; HOWORKA F, 1978, J CHEM PHYS, V68, P804, DOI 10.1063/1.435866; LEGER A, 1985, ASTRON ASTROPHYS, V146, P81; LEGER A, 1995, ASTRON ASTROPHYS, V293, pL53; LEGER A, 1984, ASTRON ASTROPHYS, V137, pL5; LePage V, 1997, J AM CHEM SOC, V119, P8373, DOI 10.1021/ja971330v; LEPAGE V, UNPUB J AM CHEM SOC; OMONT A, 1986, ASTRON ASTROPHYS, V164, P159; PETRIE S, 1992, J AM CHEM SOC, V114, P9205, DOI 10.1021/ja00049a072; PUGET JL, 1989, ANNU REV ASTRON ASTR, V27, P161; SALAMA F, 1992, ASTROPHYS J, V395, P301, DOI 10.1086/171652; Salama F, 1996, ASTROPHYS J, V458, P621, DOI 10.1086/176844; SALAMA F, 1992, NATURE, V358, P42, DOI 10.1038/358042a0; Savage BD, 1996, ANNU REV ASTRON ASTR, V34, P279, DOI 10.1146/annurev.astro.34.1.279; Scott GBI, 1997, J PHYS CHEM A, V101, P4973, DOI 10.1021/jp9706947; SETSER DW, 1979, REACTIVE INTERMEDIAT; SNOW TP, 1995, ASTRON ASTROPHYS, V296, pL37; SNOW TP, 1995, SCIENCE, V270, P1455, DOI 10.1126/science.270.5241.1455; SNOW TP, 1997, STARDUST PLANETESIMA, P147; Tielens A. G. G. M., 1995, DIFFUSE INTERSTELLAR; TOSI P, 1984, J CHEM PHYS, V80, P1905, DOI 10.1063/1.446951; VANDERZWET GP, 1985, ASTRON ASTROPHYS, V146, P76; VANDOREN JM, 1987, INT J MASS SPECTROM, V81, P85, DOI 10.1016/0168-1176(87)80007-1	32	196	196	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					259	260		10.1038/34602	http://dx.doi.org/10.1038/34602			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440689				2022-12-24	WOS:000071484400041
J	Chiodini, PL				Chiodini, PL			Non-microscopic methods for diagnosis of malaria	LANCET			English	Editorial Material							PLASMODIUM-FALCIPARUM		Hosp Trop Dis, Dept Clin Parasitol, London NW1 0PE, England	University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine	Chiodini, PL (corresponding author), Hosp Trop Dis, Dept Clin Parasitol, London NW1 0PE, England.							Banchongaksorn T, 1996, B WORLD HEALTH ORGAN, V74, P47; BEADLE C, 1994, LANCET, V343, P564, DOI 10.1016/S0140-6736(94)91520-2; CHIODINI PL, 1996, MDA9633; Craig MH, 1997, T ROY SOC TROP MED H, V91, P279, DOI 10.1016/S0035-9203(97)90074-2; GILLES HM, 1993, BRUCECHWATTS ESSENTI, P1; Humar A, 1997, AM J TROP MED HYG, V56, P44, DOI 10.4269/ajtmh.1997.56.44; Laferi H, 1997, NEW ENGL J MED, V337, P1635, DOI 10.1056/NEJM199711273372219; MAKLER MT, 1993, AM J TROP MED HYG, V48, P205, DOI 10.4269/ajtmh.1993.48.205; Reilly JT, 1997, CLIN LAB HAEMATOL, V19, P165, DOI 10.1111/j.1365-2257.1997.tb00001.x; Singh N, 1997, T ROY SOC TROP MED H, V91, P396, DOI 10.1016/S0035-9203(97)90254-6	10	29	29	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					80	81		10.1016/S0140-6736(05)78155-1	http://dx.doi.org/10.1016/S0140-6736(05)78155-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439488				2022-12-24	WOS:000071591900005
J	Cramer, DW; Harlow, BL; Titus-Ernstoff, L; Bohlke, K; Welch, WR; Greenberg, ER				Cramer, DW; Harlow, BL; Titus-Ernstoff, L; Bohlke, K; Welch, WR; Greenberg, ER			Over-the-counter analgesics and risk of ovarian cancer	LANCET			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLORECTAL-CANCER; COLON-CANCER; ASPIRIN USE	Background Evidence that aspirin and other non-steroidal anti-inflammatory drugs reduce risk for colorectal cancer has prompted interest in their ability to prevent other cancers. We aimed to find out what effect over-the-counter analgesics have on risk of ovarian cancer. Methods In a case-control study we compared use of over-the-counter analgesics by 563 women from eastern Massachusetts and New Hampshire, USA, who had epithelial ovarian cancer with 523 women from the general population. We calculated exposure odds ratios to estimate the effect of over-the-counter analgesics on ovarian cancer risk. Use of over-the-counter analgesics was assessed through interviews and defined as use al least once a week continuously for at least 6 months. Findings The odds ratio for risk of ovarian cancer for aspirin use was 0.75 (95% CI 0.52-1.10), that for ibuprofen was 1.03 (0.64-1.64), and that for paracetamol was 0.52 (0.31-0.86), after adjusting for age, study centre, education, religion, parity, oral contraceptive use, and menstrual, arthritic, or headache pain. Relative to no use, the lower risk of ovarian cancer associated with paracetamol was more apparent for use on a daily basis, 0.39 (0.21-0.74), for more than 10 years of use, 0.40 (0.19-0.88), or for more than 20 tablet years defined as (tablets per dayXyears of use), 0.45 (0.20-0.99). Interpretation In our data, there was a statistically significant inverse association between paracetamol use and ovarian cancer risk. There was a modest but nonsignificant inverse association with aspirin use and ovarian cancer and no association with ibuprofen use. Experimental studies in rodents demonstrating uterine and ovarian atrophy at high doses of paracetamol and decreased ovarian-cyst formation at lower doses suggest a biological basis for our observations.	Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Obstet & Gynecol, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Dartmouth College; Norris Cotton Cancer Center	Cramer, DW (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Obstet & Gynecol, Obstet & Gynecol Epidemiol Ctr, 221 Longwood Ave, Boston, MA 02115 USA.			Harlow, Bernard/0000-0002-6735-8862	NCI NIH HHS [R01 CA 54419] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054419] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berkel HJ, 1996, EPIDEMIOL REV, V18, P205, DOI 10.1093/oxfordjournals.epirev.a017926; GOODWIN JS, 1981, MED CLIN N AM, V65, P829, DOI 10.1016/S0025-7125(16)31500-0; GREENBERG ER, 1996, IARC SCI PUBL, V139, P91; *INT AG RES CANC W, 1990, IARC MONOGRAPHS; ISENHOWER WD, 1986, BIOL RES PREG PERIN, V7, P6; LOGAN RF, 1993, BRIT MED J, V309, P285; MARNETT LJ, 1995, PREV MED, V24, P103, DOI 10.1006/pmed.1995.1017; MUSCAT JE, 1994, CANCER-AM CANCER SOC, V74, P1847, DOI 10.1002/1097-0142(19941001)74:7<1847::AID-CNCR2820740704>3.0.CO;2-#; *NAT TOX PROGR, 1993, NIH PUBL; PASHA KV, 1989, BRAIN RES BULL, V22, P617, DOI 10.1016/0361-9230(89)90079-8; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; SANTACOLOMA TA, 1991, BIOCHEM BIOPH RES CO, V176, P1256, DOI 10.1016/0006-291X(91)90421-3; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301	15	190	192	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					104	107		10.1016/S0140-6736(97)08064-1	http://dx.doi.org/10.1016/S0140-6736(97)08064-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439495				2022-12-24	WOS:000071591900012
J	Shigeyoshi, Y; Taguchi, K; Yamamoto, S; Takekida, S; Yan, L; Tei, H; Moriya, T; Shibata, S; Loros, JJ; Dunlap, JC; Okamura, H				Shigeyoshi, Y; Taguchi, K; Yamamoto, S; Takekida, S; Yan, L; Tei, H; Moriya, T; Shibata, S; Loros, JJ; Dunlap, JC; Okamura, H			Light-induced resetting of a mammalian circadian clock is associated with rapid induction of the mPer1 transcript	CELL			English	Article							RAT SUPRACHIASMATIC NUCLEUS; VASOACTIVE INTESTINAL POLYPEPTIDE; MESSENGER-RNA; CEREBROSPINAL-FLUID; VASOPRESSIN RHYTHM; PHOTIC REGULATION; GENE-EXPRESSION; FEEDBACK LOOP; TIMELESS; NEURONS	To understand how light might entrain a mammalian circadian clock, we examined the effects of light on mPer1, a sequence homolog of Drosophila per, that exhibits robust rhythmic expression in the SCN.mPer1 is rapidly induced by short duration exposure to light at levels sufficient to reset the clock, and dose-response curves reveal that mPer1 induction shows both reciprocity and a strong correlation with phase shifting of the overt rhythm. Thus, in both the phasing of dark expression and the response to light mPer1 is most similar to the Neurospora clock gene fro. Within the SCN there appears to be localization of the induction phenomenon, consistent with the localization of both light-sensitive and light-insensitive oscillators in this circadian center.	Kobe Univ, Sch Med, Dept Anat & Brain Sci, Chuo Ku, Kobe, Hyogo 650, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 108, Japan; Waseda Univ, Sch Human Sci, Dept Pharmacol & Brain Sci, Tokorozawa, Saitama 359, Japan; Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Kobe University; University of Tokyo; Waseda University; Dartmouth College	Okamura, H (corresponding author), Kobe Univ, Sch Med, Dept Anat & Brain Sci, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 650, Japan.		Dunlap, Jay/L-6232-2013; Loros, Jennifer/B-6293-2014; Jansen, Heiko T./A-5770-2008	Dunlap, Jay/0000-0003-1577-0457; Jansen, Heiko T./0000-0003-0178-396X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034985, R37GM034985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001186, R01MH044651] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34985] Funding Source: Medline; NIMH NIH HHS [MH44651, MH01186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARONIN N, 1991, SUPRACHIASMATIC NUCL, P445; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Aschoff J., 1981, BIOL RHYTHMS HDB BEH; Ban Y, 1997, J NEUROSCI, V17, P3920; BEST J, 1996, HOW QUICKLY DOES LIG, P105; COLWELL CS, 1992, J COMP NEUROL, V324, P135, DOI 10.1002/cne.903240202; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DAAN S, 1976, J COMP PHYSIOL, V106, P253, DOI 10.1007/BF01417857; Davisson M T, 1995, Trends Genet, P35; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; ELLIOT J, 1996, TIME COURSE HAMSTER, P105; FOSTER RG, 1991, J COMP PHYSIOL A, V169, P39, DOI 10.1007/BF00198171; Foulkes NS, 1996, P NATL ACAD SCI USA, V93, P14140, DOI 10.1073/pnas.93.24.14140; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; Gillette MU, 1996, PROG BRAIN RES, V111, P121, DOI 10.1016/S0079-6123(08)60404-5; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; Hall JC, 1996, NEURON, V17, P799, DOI 10.1016/S0896-6273(00)80211-1; Hall JC, 1997, CELL, V90, P9, DOI 10.1016/S0092-8674(00)80308-6; Hastings J.W., 1991, NEURAL INTEGRATIVE A, P435; HASTINGS JW, 1958, BIOL BULL, V115, P440, DOI 10.2307/1539108; Hastings MH, 1997, TRENDS NEUROSCI, V20, P459, DOI 10.1016/S0166-2236(97)01087-4; Hastings MH, 1996, PROG BRAIN RES, V111, P147, DOI 10.1016/S0079-6123(08)60406-9; HENDRICKSON AE, 1972, Z ZELLFORSCH MIK ANA, V135, P1, DOI 10.1007/BF00307084; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; INOUYE SIT, 1994, NEUROSCI RES, V20, P109, DOI 10.1016/0168-0102(94)90029-9; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; LOROS J, 1995, SEMIN NEUROSCI, V7, P3, DOI 10.1016/1044-5765(95)90012-8; Millar AJ, 1997, CURR BIOL, V7, pR474, DOI 10.1016/S0960-9822(06)00240-5; MOORE RY, 1973, BRAIN RES, V49, P403, DOI 10.1016/0006-8993(73)90431-9; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; OKAMURA H, 1987, BIOMED RES-TOKYO, V8, P253, DOI 10.2220/biomedres.8.253; OKAMURA H, 1995, MOL BRAIN RES, V29, P358, DOI 10.1016/0169-328X(94)00278-M; PITTENDRIGH CS, 1960, COLD SPRING HARB SYM, V25, P159, DOI 10.1101/SQB.1960.025.01.015; PITTENDRIGH CS, 1996, ANN REV PHYSL, V16, P4182; Qiu J, 1996, MOL CELL BIOL, V16, P4182; Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; Sauman I, 1996, NEURON, V17, P889, DOI 10.1016/S0896-6273(00)80220-2; SCHWARTZ WJ, 1983, BRAIN RES, V263, P105, DOI 10.1016/0006-8993(83)91205-2; SCHWARTZ WJ, 1985, J NEUROSCI, V5, P2771; SEHGAL A, 1995, SEMIN NEUROSCI, V7, P27, DOI 10.1016/1044-5765(95)90014-4; SHINOHARA K, 1994, NEUROSCI LETT, V170, P183, DOI 10.1016/0304-3940(94)90269-0; SHINOHARA K, 1993, J NEUROSCI, V13, P793; SUN S, 1997, CELL, V90, P1003; SWANSON LW, 1974, J COMP NEUROL, V156, P143, DOI 10.1002/cne.901560203; TAKAHASHI JS, 1984, NATURE, V308, P186, DOI 10.1038/308186a0; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; WINFREE A, 1976, MOL BASIS CIRCADIAN, P109; WINFREE AT, 1967, J THEOR BIOL, V16, P15, DOI 10.1016/0022-5193(67)90051-3; WINFREE AT, 1971, BIOCHRONOMETRY, P81; Young MW, 1996, COLD SPRING HARB SYM, V61, P279; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	57	704	719	1	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					1043	1053		10.1016/S0092-8674(00)80494-8	http://dx.doi.org/10.1016/S0092-8674(00)80494-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428526	hybrid			2022-12-24	WOS:000071281400020
J	Prendergast, BD				Prendergast, BD			La salle de garde: bastion of the French lunch hour for junior doctors	BRITISH MEDICAL JOURNAL			English	Article									Hop Lariboisiere, INSERM, Unite Rech Biol & Pathophysiol Syst Cardiovasc, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Prendergast, BD (corresponding author), Hop Lariboisiere, INSERM, Unite Rech Biol & Pathophysiol Syst Cardiovasc, 2 Rue Ambroise Pare, F-75010 Paris, France.							BALLOUL P, 1994, SALLE GARDE PLAISIR, V2, P78	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1708	1709		10.1136/bmj.315.7123.1708	http://dx.doi.org/10.1136/bmj.315.7123.1708			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448548	Green Published			2022-12-24	WOS:000071149400040
J	Gaal, T; Bartlett, MS; Ross, W; Turnbough, CL; Gourse, RL				Gaal, T; Bartlett, MS; Ross, W; Turnbough, CL; Gourse, RL			Transcription regulation by initiating NTP concentration: RRNA synthesis in bacteria	SCIENCE			English	Article							RIBOSOMAL-RNA TRANSCRIPTION; ESCHERICHIA-COLI K-12; NUCLEOTIDE-SENSITIVE SELECTION; FACTOR-INDEPENDENT ACTIVATION; RATE-DEPENDENT REGULATION; PYRBI OPERON EXPRESSION; GROWTH-RATE CONTROL; FEEDBACK-REGULATION; GUANOSINE TETRAPHOSPHATE; ALPHA-SUBUNIT	The sequence of a promoter determines not only the efficiency with which it forms a complex with RNA polymerase, but also the concentration of nucleoside triphosphate (NTP) required for initiating transcription. Escherichia coli ribosomal RNA (rrn PI) promoters required high initiating NTP concentrations for efficient transcription because they form unusually short-lived complexes with RNA polymerase; high initiating NTP concentrations [adenosine or guanosine triphosphate (ATP or GTP), depending on the rrn P1 promoter] are needed lo bind to and stabilize the open complex. ATP and GTP concentrations, and therefore rrn P1 promoter activity, increase with growth rate. Because ribosomal RNA transcription determines the rate of ribosome synthesis, the control of ribosomal RNA transcription by NTP concentration provides a molecular explanation for the growth rate-dependent control and homeostatic regulation of ribosome synthesis.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294	University of Wisconsin System; University of Wisconsin Madison; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037048, R01GM029466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37048, GM29466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER MD, 1978, J BACTERIOL, V133, P149, DOI 10.1128/JB.133.1.149-157.1978; Alper S, 1996, J MOL BIOL, V260, P165, DOI 10.1006/jmbi.1996.0390; APPLEMAN JA, 1983, GENE EXPRESSION, P65; APPLEMAN JA, UNPUB; Bachmann B.J., 1987, CELLULAR MOL BIOL, P1190; BAGNARA AS, 1973, EUR J BIOCHEM, V36, P422, DOI 10.1111/j.1432-1033.1973.tb02927.x; BALKE VL, 1987, J BACTERIOL, V169, P4499, DOI 10.1128/jb.169.10.4499-4506.1987; BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; BARTLETT MS, 1994, J BACTERIOL, V176, P5560, DOI 10.1128/JB.176.17.5560-5564.1994; BARTLETT MS, UNPUB; BECK C, 1973, J MOL BIOL, V78, P117, DOI 10.1016/0022-2836(73)90431-2; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; BOCK A, 1966, J BACTERIOL, V92, P470; Bokal AJ, 1997, EMBO J, V16, P154, DOI 10.1093/emboj/16.1.154; CASHEL M, 1968, J MOL BIOL, V34, P317, DOI 10.1016/0022-2836(68)90256-8; CASHEL M, 1996, CELLULAR MOL BIOL, P1458; COLE JR, 1987, J MOL BIOL, V198, P383, DOI 10.1016/0022-2836(87)90288-9; CONDON C, 1993, EMBO J, V12, P4305, DOI 10.1002/j.1460-2075.1993.tb06115.x; CONDON C, 1995, MICROBIOL REV, V59, P623, DOI 10.1128/MMBR.59.4.623-645.1995; de Boer H, 1979, J Biol Chem, V254, P5609; DONAHUE JP, 1994, J BIOL CHEM, V269, P18185; DONAHUE JP, 1990, J BIOL CHEM, V265, P19091; FRANZEN JS, 1961, J BIOL CHEM, V236, P515; GAAL T, 1990, P NATL ACAD SCI USA, V87, P5533, DOI 10.1073/pnas.87.14.5533; Gaal T, 1996, GENE DEV, V10, P16, DOI 10.1101/gad.10.1.16; GAAL T, UNPUB; GAFNY R, 1994, J MOL BIOL, V243, P152, DOI 10.1006/jmbi.1994.1641; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; Gourse RL, 1996, ANNU REV MICROBIOL, V50, P645, DOI 10.1146/annurev.micro.50.1.645; GOURSE RL, 1985, P NATL ACAD SCI USA, V82, P1069, DOI 10.1073/pnas.82.4.1069; GRUMMT I, 1976, CELL, V7, P447, DOI 10.1016/0092-8674(76)90175-6; HERNANDEZ VJ, 1990, J BIOL CHEM, V265, P11605; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; JENSEN KF, 1993, J BACTERIOL, V175, P3401, DOI 10.1128/jb.175.11.3401-3407.1993; JINKSROBERTSON S, 1983, CELL, V33, P865, DOI 10.1016/0092-8674(83)90029-6; JOSAITIS CA, 1995, P NATL ACAD SCI USA, V92, P117; KEENER J, 1996, CELLULAR MOL BIOL, P1417; KUPPER H, 1976, RNA POLYMERASE, P473; LEIRMO S, 1991, J MOL BIOL, V220, P555, DOI 10.1016/0022-2836(91)90100-K; LITTLE R, 1983, ANAL BIOCHEM, V126, P381; LIU CG, 1994, GENE DEV, V8, P2904, DOI 10.1101/gad.8.23.2904; LIU J, 1994, J BACTERIOL, V176, P2938, DOI 10.1128/JB.176.10.2938-2945.1994; LUND E, 1979, P NATL ACAD SCI USA, V76, P5480, DOI 10.1073/pnas.76.11.5480; LUND E, 1972, EUR J BIOCHEM, V28, P316, DOI 10.1111/j.1432-1033.1972.tb01916.x; MaalOe O, 1966, CONTROL MACROMOLECUL; MARR AG, 1991, MICROBIOL REV, V55, P316, DOI 10.1128/MMBR.55.2.316-333.1991; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; MCQUADE KL, UNPUB; MULLIGAN ME, 1985, J BIOL CHEM, V260, P3529; NEIDHARDT F, 1961, COLD SPRING HARB SYM, V26, P63, DOI 10.1101/SQB.1961.026.01.012; NEIDHARDT FC, 1996, CELLULAR MOL BIOL, pR11; Neidhardt FC, 1990, PHYSL BACTERIAL CELL; NEUHARD J, 1987, CELLULAR MOL BIOL, P445; NIERMAN WC, 1979, J BIOL CHEM, V254, P7921; NILSSON L, 1994, J BIOL CHEM, V269, P9460; NINFA A, 1996, CELLULAR MOL BIOL, P1246; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OHLSEN KL, 1992, J BIOL CHEM, V267, P19813; OHLSEN KL, 1992, J BACTERIOL, V174, P6071, DOI 10.1128/JB.174.19.6071-6075.1992; OHLSEN KL, 1992, MOL MICROBIOL, V6, P2243, DOI 10.1111/j.1365-2958.1992.tb01400.x; POULSEN P, 1987, MOL GEN GENET, V208, P152, DOI 10.1007/BF00330436; QI FX, 1995, J MOL BIOL, V254, P552, DOI 10.1006/jmbi.1995.0638; RAO L, 1994, J MOL BIOL, V235, P1421, DOI 10.1006/jmbi.1994.1098; RECORD MT, 1996, CELLULAR MOL BIOL, P792; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; ROSS W, UNPUB; ROWLEY KB, 1993, J BACTERIOL, V175, P1309, DOI 10.1128/JB.175.5.1309-1315.1993; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; SCHAECHTER M, 1958, J GEN MICROBIOL, V19, P592, DOI 10.1099/00221287-19-3-592; SHARROCK RA, 1985, P NATL ACAD SCI USA, V82, P5275, DOI 10.1073/pnas.82.16.5275; SHEN V, 1977, J BACTERIOL, V130, P1109, DOI 10.1128/JB.130.3.1109-1116.1977; SINGER M, 1991, J BACTERIOL, V173, P6249, DOI 10.1128/jb.173.19.6249-6257.1991; SMITH RC, 1964, BIOCHIM BIOPHYS ACTA, V86, P229, DOI 10.1016/0304-4165(64)90047-9; SQUIRES CL, 1993, P NATL ACAD SCI USA, V90, P970, DOI 10.1073/pnas.90.3.970; TRAVERS A, 1976, NATURE, V263, P641, DOI 10.1038/263641a0; Tu AHT, 1997, J BACTERIOL, V179, P6665, DOI 10.1128/jb.179.21.6665-6673.1997; TURNBOUGH CL, 1983, P NATL ACAD SCI-BIOL, V80, P368, DOI 10.1073/pnas.80.2.368; Villemain J, 1997, J MOL BIOL, V273, P958, DOI 10.1006/jmbi.1997.1358; VOGEL U, 1991, J BACTERIOL, V173, P1168, DOI 10.1128/jb.173.3.1168-1174.1991; WILSON HR, 1992, J BACTERIOL, V174, P514, DOI 10.1128/jb.174.2.514-524.1992; YAMAGISHI M, 1987, J MOL BIOL, V198, P547, DOI 10.1016/0022-2836(87)90299-3; ZENGEL JM, 1994, PROG NUCLEIC ACID RE, V47, P331, DOI 10.1016/S0079-6603(08)60256-1	84	289	292	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2092	2097		10.1126/science.278.5346.2092	http://dx.doi.org/10.1126/science.278.5346.2092			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405339				2022-12-24	WOS:A1997YM23500044
J	Bouma, MJ; Dye, C				Bouma, MJ; Dye, C			Cycles of malaria associated with El Nino in Venezuela	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SOUTHERN OSCILLATION; EPIDEMICS; MAIZE	Context.-Malaria has been increasing globally, and epidemics tend to occur when weather conditions favor this vector-borne disease, Long-term meteorologic forecasting using El Nino Southern Oscillation (ENSO) may assist in anticipating epidemics and targeting scarce resources. Objective.-To determine whether malaria epidemics in Venezuela are related to ENSO and rainfall and to determine whether such a relationship could be used to predict outbreaks. Design.-Retrospective analysis of national malaria morbidity (1975-1995) and mortality (1910-1935) data in the coastal zone and interior of Venezuela in relation to El Nino events and rainfall. Main Outcome Measure.-Correlation between malaria mortality and morbidity and sea surface temperatures (SSTs) in the Eastern Tropical Pacific, a parameter of ENSO. Results.-Malaria mortality and morbidity have increased by an average of 36.5% (95% confidence interval, 3.7%-69.3%; P=.004) in years following recognized El Nino events, A moderate correlation was found between Pacific tropical SST during a Nino event and malaria 1 year later (r=0.50, P<.001). Malaria mortality is more strongly related to drought in the year preceding outbreaks than to rainfall during epidemic years. Conclusions.-Historic and recent data from Venezuela demonstrate that malaria increases by an average of about one third in the year following a Nino event; change in malaria risk can be predicted from Pacific SSTs in the previous year, Therefore, the occurrence of an EI Nino event may help predict malaria epidemics in this part of South America.			Bouma, MJ (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.		Dye, Christopher/AIC-4659-2022	Dye, Christopher/0000-0002-2957-1793				[Anonymous], WHO TECHN REP SER; Bouma MJ, 1996, TROP MED INT HEALTH, V1, P86, DOI 10.1046/j.1365-3156.1996.d01-7.x; BOUMA MJ, 1994, LANCET, V343, P1440, DOI 10.1016/S0140-6736(94)92569-0; CANE MA, 1994, NATURE, V370, P204, DOI 10.1038/370204a0; CHRISTOPHERS R, 1911, SCI MEMOIRS OFFICERS; *DEP MET, 1978, B CLIM ANN; FONTAINE RE, 1961, AM J TROP MED HYG, V10, P795, DOI 10.4269/ajtmh.1961.10.795; GABALDON A., 1946, Tijeretazos sobre Malaria, V10, P191; GABALDON A, 1949, T ROY SOC TROP MED H, V43, P113, DOI 10.1016/0035-9203(49)90037-1; GABALDON A, 1949, MALARIOLOGY; GIGLIOLI G., 1939, Agric. J. Brit. Guiana, V10, P4; GONZALEZ PE, 1948, DATOS DETALLADOS CLI; Kiladis GN, 1989, J CLIMATE, V2, P1069, DOI 10.1175/1520-0442(1989)002<1069:GCAAWE>2.0.CO;2; MCDONALD G, 1953, TROP DIS B, V50, P871; MOLINEAUX L, 1988, MALARIA; NICHOLLS N, 1993, LANCET, V342, P1284, DOI 10.1016/0140-6736(93)92368-4; Nisbet RM, 1982, MODELLING FLUCTUATIN; PACKARD RM, 1984, J AFR HIST, V25, P189, DOI 10.1017/S0021853700022854; PARKER DE, 1994, J GEOPHYS RES, V99, P373; Ropelewski CF, 1989, J CLIMATE, V2, P268, DOI 10.1175/1520-0442(1989)002<0268:PPAWTH>2.0.CO;2; ROPELEWSKI CF, 1987, MON WEATHER REV, V115, P1606, DOI 10.1175/1520-0493(1987)115<1606:GARSPP>2.0.CO;2; *SMITHS I, 1961, WORLD WEATH REC; *SMITHS I, 1971, WORLD WEATH REC; SWELLENGREBEL NH, 1940, COLONIAL I AMSTERDAM, V16; *WHO, 1977, WKLY EPIDEMIOL REC; *WORLD MET ORG, 1992, CLIM SYST MON MON B; YACOB KBM, 1946, J MALAR I INDIA, V6, P273; Zurbrigg S., 1994, Parassitologia (Rome), V36, P121	28	130	143	0	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1772	1774		10.1001/jama.278.21.1772	http://dx.doi.org/10.1001/jama.278.21.1772			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388155				2022-12-24	WOS:A1997YH98700033
J	Donaldson, GC; Keatinge, WR				Donaldson, GC; Keatinge, WR			Mortality related to cold weather in elderly people in southeast England, 1979-94	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON QUEEN MARY & WESTFIELD COLL,DEPT PHYSIOL,LONDON E1 4NS,ENGLAND	University of London; Queen Mary University London			Donaldson, Gavin/M-7992-2017	Donaldson, Gavin/0000-0002-5538-4190				DONALDSON GC, IN PRESS J EPIDEMIOL; KEATINGE WR, 1989, INT J BIOMETEOROL, V33, P71, DOI 10.1007/BF01686280; McDowall M, 1981, POPUL TRENDS, V26, P16	3	39	39	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 25	1997	315	7115					1055	1056		10.1136/bmj.315.7115.1055	http://dx.doi.org/10.1136/bmj.315.7115.1055			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD445	9366732	Green Published			2022-12-24	WOS:A1997YD44500021
J	Hieter, P; Boguski, M				Hieter, P; Boguski, M			Functional genomics: It's all how you read it	SCIENCE			English	Editorial Material							GENE-EXPRESSION; STRATEGY		NIH,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	Hieter, P (corresponding author), UNIV BRITISH COLUMBIA,DEPT MED GENET,CTR MOL MED & THERAPEUT,VANCOUVER,BC V6T 124,CANADA.							DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1997, NAT GENET, V5, P325; FODOR SPA, 1993, NATURE, V364, P555, DOI 10.1038/364555a0; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Goodfellow P, 1997, NAT GENET, V16, P209, DOI 10.1038/ng0797-209; *HARV I HUM GEN, 1997, S GEN GEN THER MEAN; MCKUSICK V, IN PRESS GENOMICS; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; Oliver S, 1996, TRENDS GENET, V12, P241, DOI 10.1016/0168-9525(96)30053-X; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; SMITH V, 1995, P NATL ACAD SCI USA, V92, P6479, DOI 10.1073/pnas.92.14.6479; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	18	228	267	6	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 24	1997	278	5338					601	602		10.1126/science.278.5338.601	http://dx.doi.org/10.1126/science.278.5338.601			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC323	9381168				2022-12-24	WOS:A1997YC32300036
